An Update on Glomerulopathies by unknown
An Update on 
Glomerulopathies 
Edited by Sharma S. Prabhakar
Edited by Sharma S. Prabhakar
An Update on Glomerulopathies - Clinical and Treatment Aspects is a systemic 
overview of recent advances in clinical aspects and therapeutic options in major 
syndromes of glomerular pathology. The book contains twenty four chapters divided 
conveniently into five sections. The first section deals with primary glomerulopathies, 
and the second section is devoted to glomerulopathies complicating infectious 
conditions. The third section deals with systemic autoimmune disorders and 
vasculitides which constitute major causes of glomerular disease and often renal 
failure. The fourth section includes chapters discussing the glomerular involvement in 
some major metabolic and systemic conditions. The final section has chapters which 
relate to some general aspects of glomerular diseases. This book will form an excellent 
reference tool for practicing and academic nephrology community.
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Foreword 
The study of the fundamental and clinical aspects of glomerular disease has expanded 
exponentially over the last several decades. Fresh insights into old clinico-pathological 
entities emerge frequently and continuously. New disease entities also arise as the
sophistication of investigation expands. Novel disease-specific treatments are applied
often with impressive results while older, more empiric therapeutic strategies are in a
constant state of evaluation and re-evaluation. Thus a book dealing with recent 
advances in the field of glomerulopathies from both clinical and therapeutic aspects is
a welcome addition to our knowledge base. An Update on Glomerulopathies - Clinical and 
Treatment Aspects builds on the background provided by An Update on
Glomerulopathies - Etiology and Pathogenesis. 
In 24 concise, focused and well-formulated chapters the broad scope of clinical and 
therapeutic aspects of primary and secondary glomerular disease is reviewed and 
updated.  The Editor, Dr. Sharma Prabhakar has chosen both the topics and the 
authors wisely. The contributions will have great appeal and value to the practicing 
clinician who frequently must face diagnostic and management challenges in this
arena of medicine. While not exhaustive in coverage, the topics included embrace an 
impressive breadth of clinical experience in these disorders. The contributions also 
examine contemporary issues in sufficient detail to serve as an excellent guide for the 
clinician as well as trainees in nephrology. An Update on Glomerulopathies - Clinical and 
Treatment Aspects illustrates how far we have come in our understanding of clinical 
issues in glomerular disease, but also shows how much more needs to be understood. 
Richard J. Glassock, MD, MACP 
Laguna Niguel, California 
USA  
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As the complexities of pathobiology of the glomerular diseases continue to unfold, the 
resultant scientific knowledge has lent itself to development of novel therapeutic 
targets and innovative preventive and therapeutic strategies. This book is a sequel to a 
similar one devoted to Etiology and Pathogenesis, and a broad discussion of advances 
in the clinical and treatment aspects of various glomerular disorders is the focus of this 
book. While most individual chapters serve as updates of clinical and treatment 
aspects of the respective glomerulopathies, they are by no means comprehensive 
discussion of these clincal conditions. The reader is referred to currents textbooks for 
the basic background clinical information of glomerulopathies and to enrich such 
knowledge from this reference book. 
The book contains twenty four chapters divided conveniently into five sections. The 
first section deals with primary glomerulopathies and has six chapters. The first 
chapter is a rather comprehensive discussion on the clinical aspects of membranous 
nephropathy with a detailed review of the currently available treatment options. This 
is followed by a very exhaustive narrative of focal and segmental glomerulosclerosis 
with lucid illustrations. Membranoproliferative glomerulonephritis is a complex 
disorder which is also seen is several systemic conditions and is very elegantly 
discussed by Matthew Pickering et al. There are two chapters on IgA nephropathy, the 
most common glomerulopathy worldwide. Francois Berthoux et al. authored an 
excellent overall review of the clinical features and management of this condition, 
while Dimitrios Kirmizis et al. present a comprehensive review of the genetic 
determinants of IgA nephropathy. Finally, Maria Pia Rastaldi provides a crisp and 
clear discussion on the important subject of rapidly progressive glomerulonephritis 
with current management strategies. 
The second section is devoted to glomerulopathies complicating infectious conditions 
and includes six chapters. Gurmeet Singh authored a concise yet informative review 
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with current management strategies. 
The second section is devoted to glomerulopathies complicating infectious conditions 
and includes six chapters. Gurmeet Singh authored a concise yet informative review 
on the postinfectious glomerulonephritis. In addition, there is a separate chapter on 
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the renal and non-renal sequelae of S pyogenes infections by Luiza Guilherme et al., 
while W. Michael McShan et al. provided a focused overview on the genomics of post 
streptococcal glomerulonephritis. The atypical clinical features of poststreptococcal 
glomerulonephritis are discussed in a chapter written by Toru Watanabe. Finally, 
there are two chapters that provide recent insights into glomerular complications of 
Hepatitis C and HIV infections respectively. 
Systemic autoimmune disorders and vasculitides constitute major causes of 
glomerular disease and often renal failure. The third section deals with such 
conditions and includes six chapters. Marco Zaffanello provided an excellent overview 
of the clinical aspects and management of Henoch-Schönlein Purpura in children, 
while Chi Chiu Mok reviewed the glomerular involvement in systemic lupus 
erythematosis in an elaborate manner. There are two other chapters covering other 
autoimmune conditions leading to glomerular disease, namely anti-glomerular 
basement membrane disease with a detailed description of the clinical features and 
management (Kouichi Hirayama et al.) and autoimmune glomerulonephritis with 
special focus on mixed bone marrow chimerism in the treatment (Emiko Takeuchi). 
Two other chapters discuss pulmonary renal syndrome, with Martin Kimmel et al. 
discussing the differential diagnosis of the condition in a chapter, while Mitra Naseri 
describes in the chapter, the rapidly progressive glomerulonephritis specifically 
leading to pulmonary renal syndrome.  
The fourth section includes four chapters discussing the glomerular involvement in 
some major metabolic and systemic conditions. The first of these is diabetic 
glomerulopathy, which is the leading cause of renal failure resulting in end stage renal 
disease in the western hemisphere. This chapter is a very comprehensive review of 
pathogenesis and clinical features, besides being an exhaustive review of the currently 
available and emerging therapeutic options. Hequn Zou et al. wrote an excellent 
review on the glomerular involvement in a related disorder, the metabolic syndrome, 
a condition that is regarded by many as a distinct disease and is on the rapid rise to 
epidemic proportions. Daniel Fischman et al. authored a chapter on glomerular 
disease in cystic fibrosis, a systemic metabolic condition, while in another chapter, 
Han-Seung Yoon et al. reviewed milder forms of Alport syndrome, a hereditary 
glomerulopathy.  
The final section has two chapters which relate to some general aspects of glomerular 
diseases. Gertruida van Biljon reviewed in a special chapter, glomerular disease 
leading nephrosis in children in South Africa. Finally, Toshihiko Ishimitsu described 
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in a concise and clear manner the significance of and approaches to blood pressure 
control in the context of glomerular disease. 
In summary, An Update on Glomerulopathies - Clinical and Treatment Aspects is a systemic 
overview of recent advances in clinical aspects and therapeutic options in major 
syndromes of glomerular pathology. While by no means this book replaces currently 
available textbooks in nephrology, it is the expectation of the Editor that it will form an 
excellent reference tool for practicing and academic nephrology community. The 
Editor expresses deep and sincere gratitude to all the authors for their valuable 
contributions which facilitated the prompt compilation of this invaluable resource.  
 
Sharma S. Prabhakar MD MBA FACP FASN 
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Membranous Nephropathy  
         Abdelaziz Elsanjak and Sharma S. Prabhakar  
                  Department of Medicine, Texas Tech University Health Sciences Center 
USA 
1. Introduction 
Membranous nephropathy (MN), a very common cause of  nephrotic syndrome, is a 
glomerulopathy defined histopathologically by the presence of immune complexes on the 
extracapillary side of the glomerular basement membrane (GBM). Idiopathic membranous 
nephropathy (IMN) is an antibody-mediated glomerular disease with no defined etiology, 
histologically characterized by uniform thickening of glomerular basement membrane 
(GBM), caused by subepithelial immune complex deposits. Most cases of MN are idiopathic, 
for instance approximately 75% of the cases of MN in developed countries are idiopathic, or 
primary membranous nephropathy (IMN). MN can be secondary to a wide spectrum of 
infections, tumors, autoimmune diseases or exposure to drugs or toxic agents. Examples 
include systemic lupus erythematosus, hepatitis B antigenemia or other chronic infections, 
and historically graft vs. host disease, sickle cell anemia, a number of drugs and toxins such 
as therapeutic gold salts, penicillamine, tumors, and agents containing mercury 
Idiopathic MN is a glomerulus-specific autoimmune disease and second only to focal 
glomerulosclerosis, is a leading primary cause of the nephrotic syndrome in adults. The 
name, ‘membranous nephropathy’ reflects the pathological observation in light microscopy of  
thickening in the GBM between and around immune deposits that occur beneath the 
podocyte foot processes. The histological hallmarks of the disease were first described by 
Jones and Mellors and Ortega' over 60 years ago. These include "spikes," stained by 
methenamine silver, of normal GBM that extend between the immune deposits, a fine 
granular distribution of immunoglobulin (lg) G and the complement  component C3 in a 
capillary-loop pattern revealed by immunofluorescence, and the presence of electron-dense 
subepithelial immune deposits indicated by electron microscopy (EM). Idiopathic MN most 
commonly occurs in patients between the ages of 30 and 60 years, with men twice as likely 
to be affected as women. However, MN does occur in children as well as in the very elderly. 
Up to 70% of patients present with the nephrotic syndrome and the others garner clinical 
attention due to abnormalities in urine sediment such as proteinuria. Microscopic hematuria 
is observed in up to 50% of cases although red cell casts are rare. Hypertension and 
impaired renal function are uncommon at the outset of the disease and are more likely to 
occur with disease progression 
2. Pathogenesis 
Idiopathic membranous nephropathy (IMN) is an antibody-mediated glomerular disease 
that is histologically characterized by uniform thickening of glomerular basement 
membrane (GBM), caused by subepithelial immune complex deposits.  The immune 
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deposits consist of IgG, mainly IgG4 and IgG1 of antigens that have long escaped 
identification, and the membrane attack complex of complement C5b-9 (MAC). The 
formation of subepithelial immune deposits and complement activation are responsible for 
functional impairment of the glomerular capillary wall, causing proteinuria .Most data on 
the pathogenesis of MN comes from an animal model, the Heymann model of experimental 
MN in rats, which suggests that the podocyte is the target of injury. Studies show that there 
is in-situ binding of a circulating antibody to antigen in the subepithelial space. In the 
Heymann nephritis model, megalin was identified as the antigenic target. However, 
megalin, which is a member of the low-density lipoprotein receptor family and is expressed 
with clathrin at the base of podocyte foot processes (the site of immune complex formation) 
in rats, is an unlikely antigen for human MN. 
In Heymann nephritis model of MN, rats are immunized against an antigenic fraction 
derived from rat proximal tubular brush border and develop subepithelial deposits virtually 
identical to those observed in human disease. The target antigen is a large transmembrane 
endocytic receptor known as megalin. In the rat (but not in human beings) megalin is 
additionally present on the foot processes of podocytes, allowing circulating antimegalin 
antibodies to cross the GBM, bind megalin at the podocyte cell surface, and ultimately form 
subepithelial immune deposits in situ. Complement, activated by the immune deposits, 
leads to insertion of the terminal complement components C5b-9 (the membrane attack 
complex) into the podocyte cell membrane, causing cell injury, effacement of the foot 
processes, and proteinuria.  
In 2002, Debiec and Ronco identified neutral endopeptidase (NEP) as the responsible 
antigen in a rare subset of patients with alloimmune antenatal membranous nephropathy. 
This discovery supplied proof of concept that a human podocyte antigen could serve as a 
target for nephritogenic antibodies, as shown some 20 years earlier for the rat podocyte 
megalin in Heymann nephritis, the well established experimental model of membranous 
nephropathy.  
Debiec and Ronco studied the development of neonatal MN in infants born of mothers 
genetically lacking neutral endopeptidase (NEP), a membrane-associated podocyte antigen 
that digests peptides. Because the fetus did not lack NEP, fetomaternal alloimmunization 
occurred and anti-NEP antibodies (often in very high titers) developed in the mothers. 
These antibodies (often of the IgG4 or IgG1 subclasses, similar to human idiopathic MN) 
crossed the placental barrier and interacted with the NEP, heavily expressed on the normal 
fetal podocyte. In situ immune complexes (containing both IgG1 and IgG4) developed in the 
newborn infant (or soon after birth) and typical MN ensued, along with proteinuria and 
nephrotic syndrome. The finding of the C5b-C9 membrane attack complex in the deposits, 
suggesting that this spontaneous human alloimmune disease also might be complement-
dependent, was similar to what had been proposed for Heymann nephritis. 
In 2009 Beck and et al identified circulating autoantibodies reactive with the transmembrane 
glycoprotein M-type phospholipase A2 receptor (PLA2R) in the majority of cases of adult 
IMN.  This protein is expressed by the human podocyte, again suggesting a mechanism of 
disease that fits the paradigm established in Heymann nephritis. These anti-PLA2R 
autoantibodies were highly specific for IMN, and were not present in normal individuals, in 
patients with other causes of the nephrotic syndrome, or in cases of secondary MN.  Levels 
of circulating anti- PLA2R antibodies parallel the course of clinical disease, declining or 
disappearing before a partial or complete remission of proteinuria, and reappearing with 





T cells play a significant role in the pathogenesis. The presence of IgG4, which is a product 
of the type 2 response T helper cells (Th2) and an upregulation of cytokines, such as 
interleukins (IL) -4 and -10, suggest Th2 involvement. This CD4, T-cell dependent humoral 
response leads to subsequent Ig deposition and complement activation.   
More recently Stanescu et al (2011) performed independent genome-wide association 
studies of single-nucleotide polymorphisms (SNPs) in patients with idiopathic membranous 
nephropathy from three populations of white ancestry (75 French, 146 Dutch, and 335 
British patients). The patients were compared with racially matched control subjects; 
population stratification and quality controls were carried out according to standard criteria. 
In a joint analysis of data from the 556 patients studied (398 men), they identified significant 
alleles at two genomic loci associated with idiopathic membranous nephropathy. 
Chromosome 2q24 contains the gene encoding M-type phospholipase A2 receptor (PLA2R1) 
(SNP rs4664308, P=8.6×10−29), previously shown to be the target of an autoimmune 
response. Chromosome 6p21 contains the gene encoding HLA complex class II HLA-DQ 
alpha chain 1 (HLA-DQA1) (SNP rs2187668, P=8.0×10−93). The association with HLA-DQA1 
was significant in all three populations (P=1.8×10−9, P=5.6×10−27, and P=5.2×10−36 in the 
French, Dutch, and British groups, respectively). The odds ratio for idiopathic membranous 
nephropathy with homozygosity for both risk alleles was 78.5 (95% confidence interval, 34.6 
to 178.2). They concluded that an HLA-DQA1 allele on chromosome 6p21 is most closely 
associated with idiopathic membranous nephropathy in persons of white ancestry. This 
allele may facilitate an autoimmune response against targets such as variants of PLA2R1, 
findings which suggest a basis for understanding this disease and illuminate how adaptive 
immunity is regulated by HLA. 
2.1 Natural history and prognosis of idiopathic MN  
MN is a chronic disease, with spontaneous remission and relapses. In the United States and 
Europe, MN remains the second or third leading cause of ESRD among the primary 
glomerulonephritis types. Spontaneous remissions occur in up to 30% of cases and usually 
occur within the first 2 yrs after presentation. The percentage of patients going into 
spontaneous remission is much lower in patients with higher grades of proteinuria at 
presentation (e.g., proteinuria >8 g/24 h). The remaining two thirds are divided into those with 
persistent proteinuria who maintain renal function long term, or who progress to renal failure. 
In white patients with NS, 10-yr kidney survival of 70% has been reported. Although the 
percentage of the IMGN population that progresses to end-stage renal failure remains 
relatively small, the absolute numbers are large.  It affects people predominantly in their 30s 
and 40s, and has an enormous long-term impact on their quality of life and productivity.  
Because they have single-organ disease rather than multisystem organ failure (as is seen in 
diabetes), they survive longer on dialysis and after renal transplantation. However, even 
though these patients survive longer, they continue to function at a lower level in comparison 
with the age and gender matched normal population, and rarely returns to the same level of 
productivity or quality of life as their peers. Even in patients who do not progress to ESRD, 
complications often occur, including life-threatening thromboembolic phenomena and 
accelerated vascular disease. These may be due to an underlying specific defect in coagulation 
and/or tissue repair and/or the long-term sequelae of their prolonged nephrotic condition. 
Today, once the diagnosis is made, the management of edema, BP, and hyperlipidemia is 
effective in almost all IMGN patients. The impact of the control of these factors alone on the 
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natural history is expected to be positive but is currently unknown. This is partly due to the 
unusual phenomena of up to 30% of IMGN patients experiencing spontaneous remission. 
This wide variation in outcome is one of the factors that has led meta-analysis and 
systematic reviews of this disease to reach varying conclusions about the impact of 
immunosuppressive treatment on patient and renal survival and on proteinuria remission 
rates.  
Female gender and low grade proteinuria is associated with good prognosis and associated 
with spontaneous remission. End-stage renal disease occurs at a 2-3:1 male:female ratio.  
Also, Asians with IMN appear to have a more favorable long-term prognosis than their non-
Asian counterparts.    
The Toronto Glomerulonephritis Registry created a model for identifying patients at risk for 
progression of renal insufficiency, taking into account the initial creatinine clearance (CrCl), 
the slope of the CrCl, and the lowest amount of proteinuria during a 6-month period. 
According to this model, patients who present with a normal CrCl (proteinuria <4 g/24 h), 
and stable renal function over 6 months are considered to be at low risk for progression. On 
the other hand, patients with persistent proteinuria (>8 g/24 h) have a 66−80% probability 
of progression to ESRD within 10 years, independent of the degree of renal dysfunction.  
Other factors associated with poor prognosis include older age, tubular interstitial changes 
on kidney biopsy and a high degree of glomerulosclerosis. 
2.2 Clinical manifestations 
MN affects patients of all ages and races, but is generally more common in men than 
women. It most commonly occurs in middle age, with peak incidence between the ages of 
40-60. In contrast to primary MN, secondary forms of MN are most commonly encountered 
in young children and in individuals who are older than 60. At presentation, 60-70% of 
patients have nephrotic syndrome with the remaining 30-40% of patients presenting with 
subnephrotic range proteinuria (<3.5 g/24 h). 60 % of patients who present with 
subnephrotic range proteinuria will progress to full nephrotic syndrome in 1-2 years (Daniel 
Cattran 2006). Microscopic hematuria is common in MN (30 to 40%), but macroscopic 
hematuria and red cell casts are rare and should suggest other diagnoses .The majority of 
patients with MN are normotensive at presentation, however hypertension is present in 10-
20 % of patients.  Less than 20% present with renal insufficiency.  
Serologic evaluation of all patients with MN should include anti-nuclear antibody HbsAg 
and hepatitis C virus antibody studies.  Workup for malignancy is also warranted, to the 
extent that testing should be guided by the patient’s age and whether there is a history of 
tobacco use. 
2.3 Primary (idiopathic) vs. secondary forms of membraneous nephropathy 
In developed countries, MN is primarily idiopathic, implying that known secondary causes 
have been effectively ruled out. Secondary forms of MN have been linked to multiple 
different agents and conditions. MN occurring post-hematopoietic stem cell transplantation 
(HSCT) may be a humoral manifestation of chronic graft-versus-host disease; it is the most 
common cause of post-HSCT nephrotic syndrome, and like idiopathic, post-HSCT MN 
disproportionately affects males. MN may recur in up to 42% of renal allografts with slowly 
progressive proteinuria; it is also possible for de novo MN to occur, perhaps as an 





Finally, MN may briefly occur early in infancy as a result of feto-maternal alloimmunization. 
Idiopathic MN must be distinguished from the various secondary causes, since treating or 
eliminating those underlying conditions are often sufficient to cause nephrotic syndrome 
remission.  
The most common secondary form of MN in the United States (US) is membranous lupus 
nephritis (LN), designated class V LN by the International Society of Nephrology-Renal 
Pathology Society, and is seen in -10%-20% of LN cases (picture of LMN). The disease may 
occur in isolation and pre-date other symptoms or serological abnormalities suggestive of 
lupus. Thus, even in the absence of positive serological markers such as antinuclear 
antibodies (ANAs), membranous LN should remain a possibility in any young woman with 
a biopsy diagnosis of MN. Features that distinguish idiopathic MN from membranous LN 
and other secondary forms of MN include the glomerular location of the immune deposits, 
the predominance of a particular  IgG  subclass, and other pathological features. Clues to the 
diagnosis of membranous LN include the presence of subendothelial and mesangial 
deposits, in addition to the predominant subepithelial deposits, and a "full house" pattern of 
staining for IgG, IgA, IgM, C3, and Clq on immunofluorescence. In idiopathic MN the 
predominant IgG subclass found in the glomerular deposits is IgG4, whereas in many 
secondary forms, IgGl, IgG2, and IgG3 predorninate. Finally, an ultrastructural finding of 
tubuloreticular structures in the glomerular endothelium suggests lupus, although these 
structures can also be found in other non-idiopathic forms of MN.  
Currently, renal biopsy is the sole means for diagnosis of MN and distinguishing it from 
other causes of nephrotic syndrome. The results of routine serological studies, including 
complement levels, are all normal in idiopathic MN. Possibly, antibodies to the human 
phospholipase A2 receptor (PLA2R) found in many patients with idiopathic MN may allow 
a serological diagnosis of MN, but this test is only available in research settings. Secondary 
causes of MN may be suggested by the presence of ANA, hepatitis B virus (HBV)-
antigenemia, or concurrent infection with schistosomiasis or secondary syphilis. 
Hypocomplementemia may occur in lupus or HBV-associated MN, but normal complement 
levels do not rule out these diagnoses. Associations of MN with malignancy have been 
found in older individuals seemingly more frequent than chance. Therefore, in older 
individuals with newly diagnosed MN, tests to exclude malignancy is reasonable. 
A number of secondary processes can also cause MN that are clinically and histologically 
similar to IMN. Worldwide, chronic infections such as hepatitis B, malaria, syphilis, and 
schistosomiasis are the most important causes of secondary MN. Systemic lupus 
erythematosus can give rise to a membranous form of glomerular disease, classified as class 
V lupus nephritis. Other autoimmune diseases such as rheumatoid arthritis, autoimmune 
thyroid diseases, and Sjogren’s syndrome can all be associated with MN. Historically, 
certain medications used for the treatment of rheumatoid arthritis such as gold salts, 
penicillamine, and some NSAIDs were causally linked to MN. Solid tumors are associated 
with secondary MN more often than chance alone would predict, and on rare occasions 
remissions and relapses of the glomerular disease have been noted to occur with removal or 
relapse of the malignancy. 
Finally, MN can occur de novo after renal transplantation or allogeneic hematopoietic stem 
cell transplantation, perhaps reflecting alloimmunization to a minor histocompatibility 
antigen expressed in the glomerulus. Secondary forms of MN often exhibit histopathological 
clues that distinguish them from IMN, although this is not always the case. As opposed to 
the exclusively subepithelial and intra-membranous deposits seen in IMN, secondary forms, 
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especially membranous lupus nephritis, often have mesangial and subendothelial deposits. 
Tubuloreticular inclusions may also been seen within the glomerular endothelium on 
electron microscopy in lupus-associated MN. The IgG subclasses found within the 
glomerular deposits also differ. In contrast to the predominant IgG4 found in IMN, IgG2 
and IgG3 are typically most abundant in secondary (lupus- and malignancy-associated) 
forms of MN. Finally, the nature of the electron dense material itself may herald a secondary 
cause. A form of MN characterized by spherular structures within the subepithelial deposits 
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2.4 Post-transplantation membranous glomerulopathy 
Idiopathic MN recurs in 10–30% of patients after kidney transplantation. De novo MN, 
which is the most common de novo glomerulopathy in renal allografts, affects 2–9% of renal 
allografts. De novo MN occurs 2-3 years post-transplantation, while recurrent MN occurs 
after 1-2 years. The exact pathogenesis of de novo MN is unknown. Recurrence of 
membranous nephropathy is preceded by nephrotic range proteinuria. Recurrent 
membranous nephropathy usually presents sooner after transplantation (within 2 years) 
than de novo membranous nephropathy (after 2 years). Some data suggests that the actual 
risk of recurrence reaches 29% 3 years after transplantation. Half of the cases of recurrent 
membranous nephropathy progressed to end-stage renal disease within a decade. There is 
one case report in literature where the de novo MN was linked to antibody mediated 
rejection: the patient had donor specific antibody-DQ7. Remission of proteinuria was 
associated with a fall in the anti-DQ7 titer. This raised the possibility that de novo 
membranous nephropathy could be a particular manifestation of chronic antibody -
mediated rejection (Menon, Shina et al 2010) 
2.5 Histopathologic considerations of membranous nephropathy  
The subtle nature of the light microscopic findings in some cases of Membranous 
Glomerulonephritis (MGN) and presence of basement membrane thickening in other 
glomerular diseases lead to the uncertainty in the diagnosis of MGN in its earlier days of 
evolution as a pathologic entity (Heptinstall R ). Only after the development of electron 
microscopy and immunologic techniques MGN was distinguished with certainty from other 
causes of the nephrotic syndrome including minimal change disease and its variants and 
certain forms of chronic glomerulonephritis (Heptinstall).  
3. Light microscopy 
3.1 Glomeruli 
The characteristic changes of MGN are seen in glomerular capillary walls. The other 
compartments may have secondary changes but are usually minor until the advanced stages 
of disease. The light microscopic appearance may be subtle, especially in early cases; 
however, in these cases immunopathology and electron microscopy can easily establish the 
diagnosis. Capillary loops may appear round and rigid in more advanced stages on 
hematoxylin and eosin stain (Fig.1). 
The earliest sign by light microscopy is “moth-eaten” appearance of the GBM on silver 
stains (fig.2). 
3.2 Immunopathology 
The immunofluorescence characteristic of MGN is granular capillary wall staining for 
immunoglobulins and complement. IgG is present in almost all cases, and C3 staining is 
seen in approximately three quarter of cases (Fig. 3). The most important and invariable 
deposit is IgG, and even when other immunoglobulin or complement reactants are seen, 
they have a weaker staining and only segmental presence (Jenette JC 1983).  
Mesangial deposits are usually not seen. The presence of prominent mesangial deposits or 
full house positivity with other immunoglobulins or complements should suggest MGN 
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Fig. 1. Membranous glomerulonephropathy. Capillary loops may appear round and rigid in 
advanced cases. (H&E, 40X)  
 
 
Fig. 2. Membranous glomerulonephropathy. Linear projections or “spikes” protrude from 






Fig.3. Membranous glomerulonephropathy. IgG is positive (2+) by immunofluorescence.  
3.3 Electron microscopic findings 
Electron microscopy findings helped define MGN by demonstrating the subepithelial and 
intramembranous (depending on the stage) location of electron-dense deposits (Gartner HV 
1974). Electron-dense deposits are seen on the epithelial side of glomerular capillary loops 
(subepithelial). The location of electron-dense deposits at different levels in the GBM in the 
course of the disease led to the hypothesis that there is a sequence of changes in the GBM 
following initial subepithelial deposition (Ehrenreich T 1968). 
3.4 Tubules 
Tubular changes in MGN include progressive atrophy as the glomerular lesion progresses.  
3.5 Interstitium 
In uncomplicated cases, interstitial fibrosis may be seen without prominent inflammation or 
tubular atrophy. Development of interstitial fibrosis may reflect a progression of the 
glomerular lesion (Magill AB 1995).  
3.6 Differential diagnosis 
The light microscopic differential includes all glomerular diseases that have thickening of 
the glomerular basement membrane. In context of diseases associated with the nephrotic 
syndrome, the differential diagnosis includes minimal change disease, focal segmental 
glomerulosclerosis, membranoproliferative glomerulonephritis, diabetes mellitus and 
amyloidosis. In the past, before the development of electron microscopy and immunologic 
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techniques, many of these distinctions were made on clinical grounds or not at all. However, 
currently, characteristic histologic, immunopathologic, and ultrastructural findings can 
reliably distinguish it from other causes of nephrotic syndrome.  
 
 
Fig. 4. Electron-dense deposits are present in subepithelial location.  
3.7 Prognostic indicators 
Ehrenreich and Churg (5) described the stages of membranous transformation as the 
morphologic representations of progression of the disease. Favorable outcomes are 
generally related to early stages (I and II) of membranous transformation. However, several 
later studies (Wahrmann 1989) did not find a relation between glomerular stage and 
outcome. 
4. Natural history and prognosis of idiopathic MN 
Although spontaneous remission of nephrotic syndrome occurs in about a third of patients, 
end-stage renal failure is observed in about 40% of patients after 10 years. Predicting the 
clinical course of a patient with MN at disease presentation is impossible given the variable 
and fluctuating disease course. A widely appreciated yet oversimplified view is that one-
third of all patients will spontaneously remit without treatment, another third will remain 
proteinuric with preserved renal function and the final third will progress to end-stage renal 
disease (ESRD). Young females and those with subnephrotic levels of proteinuria are most 
likely to experience spontaneous remission, justifying several months of observation prior to 
any initiation of treatment in the absence of problematic clinical features. Baseline 
demographic differences in natural-history studies lead to a blurred prognostic picture. 
Several risk factors for MN progression have been proposed: older age at onset, male sex, 
nephrotic-range proteinuria (especially >8 g), and increased serum creatinine at 





tubulointerstitial disease on renal biopsy, and a tubulointerstitial disease score has been 
included as a prognostic variable in several studies. Although the rate of renal decline may 
not differ in comparison with MN patients having preserved renal function, patients with a 
higher serum creatinine or increased interstitial disease at presentation will reach ESRD in a 
shorter time; therefore, it is advisable to consider early treatment in these patients. Asians 
with IMN appear to have a more favorable long-term prognosis than their non-Asian 
counterparts.  
Achieving complete remission predicts an excellent long-term renal prognosis and those 
patients have nearly universal renal survival at 10 years, whereas the number falls to 90% 
with partial remission, and 45% with no remission. Cattran and  his colleagues (Cattran 
2005)  proposed a prognostic model dividing patients with into low-, moderate-, and high-
risk groups based on their degree of proteinuria and clinical course over 6 months of 
observation. Those with normal renal function and lower amounts of proteinuria <4 g daily) 
over 6 months constitute a group at low risk for developing progressive renal insufficiency 
from the disease. Intermediate levels of proteinuria (4-8 g daily) with stable renal function 
over 6 months define a group at moderate risk. The highest-risk patients are those with >8 g 
of daily proteinuria for 6 months, and/or reduced renal function at outset or deterioration of 
renal function over 6 months. The risk of further renal deterioration in this group is at least 
75%. 
A number of adult studies have allowed practitioners to characterize prognostic factors in 
adult patients with MN. Laluck et al. showed that low-grade, subnephrotic proteinuria and 
female gender were associated with spontaneous remission. Ideally, only patients unlikely 
to spontaneously remit and those at risk for significant renal deterioration should be treated. 
Male gender, age >50 years, persistent high-grade proteinuria, impaired renal function at 
onset, presence of segmental glomerular sclerosis, and tubulointerstitial damage on the 
kidney biopsy have been considered to be poor prognostic factors in adult idiopathic MN . 
The Toronto Glomerulonephritis Registry created a model for identifying patients at risk for 
progression of renal insufficiency, taking into account the initial creatinine clearance (CrCl), 
the slope of the CrCl, and the lowest amount of proteinuria during a 6-month period. 
According to this model, patients who present with a normal CrCl, proteinuria <4 g/24 h, 
and stable renal function over 6 months are considered to be at low risk for progression. On 
the other hand, patients with persistent proteinuria (>8 g/24 h) have a 66−80% probability 
of progression to ESRD within10 years, independent of the degree of renal dysfunction 
5. Treatment of idiopathic membranous nephropathy 
5.1 General outlines 
Treatment goals in  IMN are to prevent loss of renal function and to prevent the 
complications of the nephrotic syndrome (eg, hyperlipidemia, volume overload 
hypertension, and thrombophilia). Opinions vary on how best to obtain the desired results, 
and the literature concerning the treatment of IMN is still unclear. The relatively low 
incidence of MN hampers recruitment into clinical trials, and the variable natural history of 
the disease adds further treatment complications. In addition, substantial risks for treatment 
are associated with established immunosuppressive agents and newer, potentially less toxic 
agents (eg, mycophenolate or rituximab) have been introduced for the treatment of MN 
without the benefit of long-term clinical trials. A meta-analysis on 1025 patients with MN 
from 18 randomized clinical trials concluded that immunosuppressive treatment had no 
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benefits in patient or renal survival; however some data suggest that the treatment is 
warranted. Because of the high rate of spontaneous remission in MN, newly diagnosed 
patients with nephritic syndrome and normal renal function should initially receive 
conservative therapy with an ACE inhibitor or ARB, diuretics, salt restriction, and statins. If 
a patient remains proteinuric with normal renal function, such conservative treatment can 
be continued, but those patients who remain frankly nephrotic after 6 months or who 
initially present with (or develop) renal dysfunction should be treated with an 
immunosuppressive agent.  
The treatment of MN depends on patient presentation and disease progression after 
diagnosis is made by biopsy. The two leading immunomodulatory therapies used are 
alkylating agents (cyclophosphamide or chlorambucil) and calcineurin inhibitors 
(cyclosporine or tacrolimus), both typically given orally or intravenous  with corticosteroids 
. Given the limited efficacy, high rate of relapse, and toxicities of alkylating agents, 
calcineurin inhibitors, and corticosteroids, other therapies for MN are needed. Recently, 
rituximab has surfaced as a potential treatment option for MN. This monoclonal antibody 
directed against the B cell antigen CD20 may be beneficial in MN on the basis of 
experimental evidence that B cell activation is a key step in the pathogenesis of MN. 
Furthermore, rituximab is generally well tolerated with a limited short-term toxicity profile. 
A significant amount of literature is emerging on the benefits of rituximab in MN as primary 
treatment and as treatment for IMN refractory to other immunosuppressant regimens. 
The treatment of membranous nephropathy in patients with normal renal function remains 
controversial. However in patients with deteriorating renal function, a combination therapy 
with steroids and cytotoxic agents is considered beneficial . It remains unclear if therapy is 
effective in more advanced renal failure since there is no published data on such cases. 
There are some cases reported in literature   with near end-stage renal failure in whom 
treatment resulted in clinical improvement. Thus therapy is effective in patients with 
primary membranous nephropathy and advanced azotemia especially in those who had 
never been treated.( (Prabhakar S et al 1996) 
5.2 Alkylating agents 
Corticosteroids as monotherapy for treatment of IMN is not effective, instead, typical 
immunosuppressive regimens for idiopathic MN combine corticosteroids with alkylating 
agents for 6-12 months. Treatment with cyclophosphamide or chlorambucil in conjunction 
with corticosteroids is supported by randomized controlled trials (RCTs) cumulative data 
suggest that 30%-40% of those treated will achieve complete remission,  with 30%-50% 
attaining partial remission and only 10% developing progressive renal disease," Relapse 
occurs in approximately 25%- 30% within  5 years of discontinuing the alkylating agent, but 
often responds to a repeat course of immunosuppressive therapy  arm. A 6-month regimen 
consisting of alternating months of corticosteroids and alkylating agents has both short-term 
and long-term beneficial effects on proteinuria and renal survival. Ponticelli and colleagues 
found that this regimen increased remission rates at the final follow-up visit from 36% in 
untreated patients to 76%, and improved 10-year renal survival from 60% to 92%. The long-
term outcomes of a randomized, controlled trial from India (Jha et al) found the same result. 
Some studies indicated that a delay in therapy did not lead to differences in efficacy. Studies 
showed immunosuppressive therapy markedly lessened the decline in renal function. 
Despite the favorable results of alkylating agents in IMN, many physicians are reluctant to 





those with reduced GFR. Cancer risk is increased when alkylating agents are used for a long 
time. There are some reports of increased risk of wegener granulomatosis  with 
cyclophosphamide  when the dose is more than 36 gmr (equivalent to 100 mg daily for one 
year) were associated with a 9.5-fold increased risk of bladder cancer. Use of 
cyclophosphamide  for long time have also been associated with an increased risk of 
lympho-proliferative disorders. Relapses occur in 25–30% of patients within 5 years of 
discontinuation of therapy with alkylating agents. While this rate of relapse is lower than 
that observed after discontinuation of cyclosporine, it is still disconcerting since relapses 
generally necessitate increased immunosuppression. Despite reduction in proteinuria, these 
agents failed to show beneficial effects on overall mortality or risk of ESRD. 
5.3 The calcineurin inhibitors (CNls): Cyclosporine and tacrolimus 
Cyclosporine is an alternative, clinically validated immunosuppressive agent used in the 
treatment of IMN. In one randomized clinical trial (RCT), 51 patients with steroid-
resistant IMN, treatment with  cyclosporine plus steroids for 6 months with tapering over 
4 weeks resulted in a 75% complete or partial remission rate, versus only 22% in the 
placebo (steroids alone) group. Typically, many patients in cyclosporine based treatment 
regimens achieved partial remissions, and many relapsed after discontinuing treatment. 
Another similarly-sized trial compared 12 months of cyclosporine and corticosteroids to 
cyclosporine alone." Although both groups achieved -80% remission rates at 12 months, 
the relapse rate was lower in the group receiving adjunctive corticosteroids from the 
beginning. Longer courses of cyclosporine (1-2 years) with a slow taper may be necessary 
to avoid a high rate of relapse. Other investigators demonstrated that treatment with 
tacrolimus in heavily nephrotic patients resulted in higher remission rates compared with 
conservative treatment alone; however, nearly half of these patients had a nephritic 
relapse within several months of tapering tacrolimus. Cyclosporine reduces proteinuria 
and the rate of decline in renal function in patients with IMN. These effects have been 
demonstrated in patients with preserved renal function, in those with declining or 
impaired renal function and also in patients resistant to other immunosuppressants. In 
some studies almost 50% of patients who had achieved remission relapsed within 1 year 
of cyclosporine withdrawal, especially in the first 6 months. In high-risk patients with 
declining renal function a 12 month treatment of cyclosporine led to a 50% reduction in 
proteinuria in half of the patients, and slowed the rate of renal deterioration compared 
with placebo. Notably, no prospective, randomized, head-to-head comparisons of 
cyclosporine and alkylating agents have been conducted in IMN. 
On the basis of the available data, extended therapy seems to enhance the likelihood of 
remission. In one analysis, the majority of complete remissions occurred after at least 6 
months of therapy, and the number increased as treatment continued for more than 12 
months. Thereafter, the combination of low-dose cyclosporine (1.4–1.5 mg/kg per day; 
trough levels >100 ng/ml) and prednisolone (0.1 mg/kg per day) might be more beneficial 
than cyclosporin monotherapy for maintaining remission and preventing relapse.  
Several investigators have evaluated whether tacrolimus could provide similar efficacy to 
cyclosporine in IMN. Tacrolimus is considered to be more potent than cyclosporine, has a 
more favorable cardiovascular risk profile and leads to better long-term renal function after 
renal transplantation.  Studies showed the overall remission rate achieved with tacrolimus is 
similar to that reported with cyclosporine but the rate of complete remission is higher with 
tacrolimus. This difference might be, in part, related to the long duration of therapy used in 
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these studies (18 months, compared with 26 weeks in the study of cyclosporine by Cattran et 
al). The nephrotoxic effects of calcineurin inhibitors are of concern, particularly if long-term 
treatment is required as a result of relapses. Managing the use of these agents in patients 
with reduced GFR can be difficult. Due to this issue, Ponticelli and Villa recommend 
alternative agents in patients with impaired renal function (creatinine clearance <60 
ml/min), severe hypertension or severe interstitial fibrosis and tubular atrophy. Finally, the 
extent to which calcineurin inhibitors affect the underlying immune process rather than 
merely modifying disease expression is unclear. In view of the broad range of toxic effects 
and the high rates of relapse associated with the use of steroids, alkylating agents and 
calcineurin inhibitors, alternative treatments have been investigated 
6. Antimetabolites 
6.1 Mycophenolate mofetil 
Mycophenolate is another agent used for MN treatment with varying results. Initial studies 
suggested that mycophenolate could reduce proteinuria in patients with MN resistant to 
other conventional therapies. However, a recent RCT detected no effect of mycophenolate 
monotherapy in patients with normal renal function and nephrotic levels of proteinuria, 
when compared to conservative antiproteinuric therapy. Corticosteroid treatment with 
mycophenolate therapy achieved a 1-year cumulative remission rate of 66% in a group of 
MN patients with moderate renal dysfunction, but was inferior to alkalating agents and 
steroids in a historically treated control group and demonstrated a relapse rate of nearly 
40%. However, a small RCT revealed similar effects from 6 months of mycophenolate and 
steroids compared with chlorambucil and steroids at 15 months of follow-up. Given these 
small studies and lack of consistently demonstrated superior efficacy, mycophenolate is not 
a first-line agent for the treatment of MN, but may be considered with adjunctive 
corticosteroids, if standard therapies are not effective or cannot be tolerated. 
Clinical efficacy studies of mycophenolate mofetil (MMF) in IMN have produced mixed 
results in a multicenter study (Chan et al.) randomized 20 newly diagnosed patients with 
persistent proteinuria ≥3 g per day to undergo 6 months of treatment with either MMF  plus 
prednisolone or with a regimen of chlorambucil alternating monthly with corticosteroids. 
The groups achieved similar remission rates (65%) and experienced few relapses, which 
suggests that MMF in conjunction with steroids has similar efficacy to a modified Ponticelli 
regimen. An open-label trial in the Netherlands evaluated the efficacy of MMF in patients 
considered to be at high risk of disease progression. The outcomes of 32 patients treated for 
1 year with MMF 2 g per day and steroids were compared with those of historic matched 
controls treated with oral cyclophosphamide plus corticosteroids for 1 year. Patients in both 
groups had reduced GFR at baseline (median approximately 40 ml/min) and median 
proteinuria was >8 g/g creatinine. The two groups achieved similar remission rates 
(approximately 70%), but the relapse was higher in the MMF group such that by the end of 
follow-up, patients in the MMF arm were less likely to be in remission than those in the 
cyclophosphamide . Both treatments resulted in stabilization or improvement of renal 
function in the majority of patients, and infections and hospitalization occurred at a similar 
frequency in the two groups. Although the investigators concluded that MMF did not seem 
to be as effective as, or any better tolerated than cyclophosphamide, this study does suggest 
that a prolonged course of MMF might be of benefit even in patients with unfavorable 





In contrast to the above-mentioned studies, responses to MMF in other multicenter 
randomized controlled trials the have been poor. Firm recommendations regarding the use 
of this agent as initial therapy are difficult to make. MMF might be a reasonable option 
when the toxic effects of alkylating agents and high-dose steroids are of particular concern 
or when severe azotemia prohibits use of calcineurin inhibitors. Studies in large numbers of 
patients with prolonged follow-up are needed to determine the long-term effectiveness of 
MMF for maintenance of remission and preservation of renal function. Additional 
information is also needed to fully evaluate the adverse effect profile of MMF. MMF is also 
associated with pregnancy loss and congenital malformations and it can also increase the 
risk of lymphoma and infection. Cases of JC-virus-associated progressive multifocal 
leukoencephalopathy in patients with systemic lupus erythematosus receiving MMF have 
elicited concern. All these considerations must be weighed in the decision to use MMF in 
IMN, 
6.2 Azathioprine 
Before the use of MMF became widespread, azathioprine was tested as a treatment for IMN 
in several small studies, with mixed results. A combination of azathioprine and 
corticosteroids was reported to be beneficial in high-risk patients with declining renal 
function. Some patients experienced reduction in proteinuria and stabilization or 
improvement of renal function. However, these studies were case series with no control 
groups and the combined number of patients analyzed was small. In contrast to these 
favorable findings, a recent retrospective review indicated that azathioprine had no long-
term benefit in IMN. Due to the conflicting evidence regarding the efficacy of azathioprine 
in IMN and the popularity of MMF, azathioprine is unlikely to be tested in future 
randomized trials in this setting. 
7. Alternative agents 
Due to the often severe adverse or nephrotoxic effects associated with cyclophosphamide 
and cyclosporine, several newer and potentially less toxic agents are under evaluation for 
the treatment of MN. Several small studies indicate the potential efficacy of rituximab, 
mycophenolate, or synthetic adrenocorticotrophic hormone (ACTH) in MN; unfortunately, 
none are large RCTs nor do they provide long-term follow-up data                              
7.1 Rituximab 
Rituximab is a monoclonal anti-CD20 antibody that depletes B cells,  Its rationale for use is 
provided by the suggested pathophysiological basis for MN of autoantibodies targeting a 
suspected  glomerular antigen. Rituximab has been used in treatment of non-Hodgkin 
Lymphoma and others diseases. Although Rituximab appears to induce remission with an 
initial efficacy comparable to alkylating agents and corticosteroids, long-term data on 
dialysis-free survival have not been reported. In an open label trial of rituximab with a 
group of 15 high-risk idiopathic MN patients, there were 2 complete and 6 partial 
remissions at final follow-up. Others reported the effects of treatment with 4 weekly doses 
of rituximab on 50 consecutive patients with persistent nephrotic levels of proteinuria 
despite 6 months of conservative therapy," Ten patients achieved a full remission after 
treatment; however, they were more likely female and with lower baseline serum creatinine 
values, which is a population of high spontaneous remission. Recently, a small RCT study 
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conducted in Spain demonstrated that rituximab was of benefit in 13 Spanish patients with 
idiopathic MN and CNI dependence, allowing successful weaning of the nephrotoxic CN. A 
review of the published literature about rituximab describing the use of rituximab in MN 
highlights that, while promising, the existing literature consists of too few patients, 
heterogeneous populations, and insufficient follow-up to recommend the use of rituximab 
outside the research setting. 
There may be potentially fatal mucocutaneous reactions, such as stevens–Johnson syndrome 
and toxic epidermal necrolysis, can occur following rituximab exposure. Severe infections 
are infrequent, occurring in only 1–2% of patients. Of great concern, rare cases of 
progressive multifocal leukoencephalopathy have been reported with rituximab use, 
particularly as part of a multidrug immunosuppressive regimen. Physicians and patients 
need to be aware of the presenting features of this devastating demyelinating disease of the 
central nervous system, which include altered mental status, visual symptoms, motor 
deficits and ataxia. The preliminary results of rituximab treatment are encouraging, but 
concerns remain before this agent can be recommended for routine use in IMN. So far, no 
randomized, controlled trials have been conducted to clarify the role of rituximab in the 
treatment of IMN. Adequately powered, randomized, controlled trials with prolonged 
follow-up are needed to determine the long-term course of the disease following B-cell 
reconstitution; rates of relapse; subsequent redosing regimens; and effects on renal survival. 
Further studies must clarify whether rituximab should be used as monotherapy or in 
combination with other immunosuppressive drugs to achieve maximum anti proteinuric 
effect and durable remission. The preliminary small, uncontrolled study suggests that the 
addition of rituximab to tacrolimus can induce sustained remission of the nephrotic 
syndrome, allowing early tacrolimus withdrawal and thereby overcoming the issue of 
tacrolimus dependence. 
7.2 Adrenocorticotrophic hormone (ACTH) 
Several small, uncontrolled trials have reported beneficial effects of synthetic 
adrenocorticotropic hormone ACTH in patients with IMN. One small, randomized, 
controlled trial by Ponticelli et al. compared treatment with ACTH for 1 year to a 6-month 
regimen of methylprednisolone alternating monthly with a cytotoxic agent in 32 (mostly 
medium-risk) patients with IMN. The probability of complete or partial remission did not 
differ substantially between the groups (87% versus 93%), and the number of remissions, 
mean time to response and number of relapses were also comparable between the groups. 
The results suggest that prolonged ACTH treatment could be equivalent to the combined 
use of cytotoxic drugs and steroids. The side effects of ACTH include glucose intolerance, 
fluid retention, hypertension, diarrhea, bronze discoloration of the skin, dizziness and 
fatigue, all of which resolve after discontinuation of treatment. Extensive studies with long 
follow-up are needed to confirm the preliminary data on the use of ACTH in IMN. Further 
investigation is also required to find the mechanisms by which ACTH seems to decrease 
proteinuria and alter apolipoprotein metabolism. These effects are probably not entirely 
attributable to an increase in endogenous cortisol synthesis, since steroid monotherapy has 
not been shown to be effective in IMN. ACTH therapy can be effective in patients who are 
unresponsive to steroids. On the other hand, the endogenous cortisol liberated by the 







The role of sirolimus in IMN has been evaluated in two small pilot studies, with unfavorable 
results. No remissions occurred during therapy, but one patient achieved a partial remission 
after cessation of therapy. Severe adverse events, including pneumonitis, infection, 
persistent proteinuria and azotemia, necessitated discontinuation of the drug in the majority 
of cases. These trials were prematurely terminated owing to the unfavorable risk–benefit 
ratio. An open-label trial of sirolimus in 11 patients with a variety of chronic 
glomerulopathies and declining renal function, including three with membranous 
nephropathy, was associated with acute kidney injury in more than half of the patients; this 
event generally occurred within weeks of starting sirolimus. Thus, sirolimus does not seem 
to have a role in the treatment of IMN 
7.4 Eculizumab 
Eculizumab is a fully humanized monoclonal antibody directed against the complement 
protein C5, approved for the treatment of Paroxysmal Nocturnal Hematuria. Ecluzimab 
inhibit C5a and C5 b thus preventing complement activation. Treatment with eculizumab 
improves the quality of life and reduces the need of transfusions and the risk of thrombosis 
in patients with PNH. However, eculizumab can increase the risk of meningococcal 
infections perhaps due to the reduction in the levels of C5 activity. Patients should therefore 
be vaccinated or revaccinated with a meningococcal vaccine at least 2 weeks before 
receiving the first dose of eculizumab. Other side effects include headache, nasopharingitis, 
back pain and cough; nausea may occur in the period following injection. The mechanism of 
action of eculizumab renders this monoclonal antibody potentially attractive for treating 
patients with IMN, as the terminal components of the complement C5b--C9 play a 
prominent role in mediating the inflammation and the damage of podocytes and glomerular 
basement membrane. However, a RCT conducted in IMN failed to show any advantage 
over placebo of eculizumab 8 mg/kg every other week or every 4 weeks. Further trials are 
needed to establish whether a different dosage or more prolonged treatment may obtain 
therapeutic results in IMN  
8. Intravenous high-dose immunoglobulins [IVIG] 
IVIG have been used in high dose in treatment of IMN. IVIG interferes with complement-
mediated immune damage by binding to C3b and C4b,by this mechanism preventing 
glomerular injury. This mechanism may be involved in IMN, as suggested by a study in 
passive Heymann nephritis, in which treatment with systemic immunoglobulin obtained a 
decrease in proteinuria, associated with a decreased glomerular deposition of C3c and C5b--
9, without changes in the amount, size or distribution of the subepithelial immune 
complexes . A few anecdotal uncontrolled studies suggested a possible benefit of IVIG 
therapy in IMN.  
8.1 Anticoagulation 
Use of anticoagulation in nephrotic syndrome is controversial issue. Nephrotic syndrome 
(NS) is associated  with high  risk of  for thromboembolic complications, including deep 
venous thrombosis, renal vein thrombosis, and pulmonary embolism; this risk seems to be 
greater for IMN especially in patient with low albumin and previous history of thrombo-
embolic disease. Analyses showed that in patients with IMN the benefits of oral 
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anticoagulation outweigh the risks. However, before prescribing anticoagulants the 
physician should take into account the severity of the NS (as assessed by serum albumin 
concentration), pre-existing thrombotic states, and the overall likelihood of serious bleeding 
events consequent to oral anticoagulation  The optimal duration of prophylactic 
anticoagulation is unknown but should probably last for as long as NS persists (Ponticelli C 




[Cattran et al 2010]. 
9. Future directions 
If anti-PLA2R or other MN-specific autoantibodies can be demonstrated to be tightly 
associated with immunological disease activity in idiopathic MN, a serologic immunoassay 
would have several potential applications. it could use the anti- PLA2R as an initial assay for 
the diagnosis of idiopathic MN without kidney biopsy. Serial assays for the presence and 
titer of anti-PLA2R prior to therapeutic intervention in clinical trials could help reduce 
uncertainty as to whether rapid responders represent a true therapeutic effect or a 
spontaneous remission. Anti-PLA2R could also be followed during treatment to assess the 
efficacy of immunosuppressive therapy and to determine the length of treatment. It could 
also be useful in partial remission, when residual proteinuria could be caused either by 
ongoing but attenuated immune activity or by structural glomerular changes without 
immune activity. 
10. Summary 
Membranous Nephropathy is a common cause of nephrotic syndrome in adults of all races 
and ethnicities. Its molecular pathogenesis is increasingly well understood, and 





the disease course, and improved decision-making regarding necessity and duration of 
treatment. Treatment should be provided to those at high risk of progression to ESRD, 
including patients with persistent severe proteinuria or a documented loss of renal function. 
At present, alkylating agents and cyclosporine are the only clinically validated treatments 
with sufficient follow-up data; however, as the roles of tacrolimus, rituximab, 
mycophenolate, and ACTH grow, these agents may become the new treatments of choice for 
idiopathic MN. 
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treatment. Treatment should be provided to those at high risk of progression to ESRD, 
including patients with persistent severe proteinuria or a documented loss of renal function. 
At present, alkylating agents and cyclosporine are the only clinically validated treatments 
with sufficient follow-up data; however, as the roles of tacrolimus, rituximab, 
mycophenolate, and ACTH grow, these agents may become the new treatments of choice for 
idiopathic MN. 
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Focal Segmental Glomerulosclerosis 
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1. Introduction 
Focal segmental glomerulosclerosis (FSGS) as the name implies is a histopathological 
pattern of lesions, where the “focal” refers to, involving minority of glomeruli and the 
“segmental” refers to, involving a portion of the glomerular capillary tuft caused by injury 
to podocytes (Fig 1A). Clinically it manifests proteinuria which can progress to nephrotic 
syndrome and eventually to end stage renal failure. 
1.1 Historical aspects 
Karl T. Fahr, a German pathologist, described “Progressive lipoid nephrosis” in 1925 which 
is currently recognized as FSGS. Arnold Rich (1957) was the first to report segmental 
sclerosis in juxtamedullary glomeruli in autopsy cases of children with nephrosis and 
uremia. In this report, he hypothesized that the progression to end stage renal disease 
(ESRD) in a subset of children with idiopathic nephrotic syndrome was because of the 
development of glomerular sclerosis. Churg et al published histopathological classification 
of nephrotic syndrome in children for the International Study of Kidney Disease in Children 
(ISKDC) in 1970, and the disease entity of FSGS was emphasized as a clinicopathological 
entity separate from minimal change disease (MCD) by its marked resistance to steroids and 
progression to ESRD. Habib (1973) described clinical and histopathological features of this 
entity as a separate disease entity using the term ‘focal glomerular scleroses’. 
Brown et al (1978) reported the malignant form of FSGS, which is characterized by FSGS 
with rapid decline in renal function. Howie et al. (1984) described the glomerular tip lesion 
in FSGS, as glomeruli with segmental lesions at the outer 25% with adhesion or prominence 
of podocytes at the tubular neck. Patients with the glomerular tip lesion often develop 
nephrotic syndrome and have excellent response to steroids, favorable outcome, and their 
clinical course is similar to that of patients with MCD. Schwartz et al. (1985) reported 
another form of FSGS-related cellular lesion characterized by glomerular extracapillary 
epithelial hypercellularity and endocapillary hypercellularity with foam cells and 
infiltrating leukocytes, and this was considered to represent an early stage in the 
development of FSGS. Soon after a collapsing form of FSGS as a new clinic-pathological 
entity was described by Weiss et al. (1986), which is characterized by nephrotic syndrome 
with progressive irreversible ESRD and by glomerular collapse with epithelial 
hypercellularity. Subsequently, many cases of renal disease associated with HIV infection, 
(Rao TK et al 1984) termed as HIV-associated nephropathies, were reported with features 
similar to the collapsing form of FSGS..  
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Between 1980–2000, secondary FSGS (Rennke HG et al. 1989 & D’Agati V. 1994) was 
established as FSGS with recognized etiologic associations, including genetic mutations in 
podocyte-associated proteins, virus, drug toxicities, and structural–functional adaptations. 
Finally in 2004, the Columbia classification was proposed by D’ Agati, Fogo, Bruijn, and 
Jenette, as a working classification for FSGS as given in table 2. Lately some celebrity figures 
like Sean Elliott and Alonzo Mourning (National Basketball Association) have been 
diagnosed with FSGS which has further enhanced awareness of this disease in public. 
1.2 Epidemiology 
Focal segmental glomerulosclerosis (FSGS) currently is the leading cause of  
nephrotic syndrome in adults and children, particularly in the United States, Australia, 
Brazil, Canada, Kuwait, India and many other countries. (reference from: 
http://eng.hi138.com/?i295373_The-epidemiology-of-focal-segmental-glomerulosclerosis). 
Renal biopsy survey for idiopathic nephrotic syndrome in adults in United States between 
1995 to 1997, has revealed that FSGS is the most common cause of nephrotic syndrome, 
responsible for 35 percent of all cases and more than 50 percent of cases among black 
population, (67 percent of such cases in black adults were younger than 45 years of age). 
Idiopathic FSGS is now the most common cause of end stage renal disease (ESRD) caused by 
primary glomerular disease in the United States in both the black and white populations. 
The proportion of ESRD attributed to FSGS has increased 11-fold, from 0.2% in 1980 to 2.3% 
in 2000 (excluding patients with HIV). As per Kitiyakara C. et al (2004) the peak decade for 
FSGS ESRD incidence is 40 to 49 years among black patients as compared to, 70 to 79 years 
among white and Asian patients. Males have 1.5- to 2-fold greater risk than females. Recent 
incidence of end stage renal disease secondary to FSGS is five cases per million population 
in Caucasian US population and 30-40 cases per million population for African-American 
population (Hogg R. et al 2007).  
2. Etio-pathogenesis 
While majority of FSGS cases are still considered idiopathic, the etiologies and mechanisms 
involved in FSGS development continue to be elucidated. FSGS can be divided into primary 
or idiopathic and secondary depending upon if the etiology is unknown vs. known 
respectively. For FSGS to produce nephrotic range or non-nephrotic range proteinuria, 
alterations of normal glomerular structure and function has to occur. Normal glomerular 
function requires, that the three major components of glomerular filter, namely endothelial 
cells, podocytes, and glomerular basement membrane (GBM), be intact and are able to provide a 
permselective filtration barrier. Specialized tight junctions between podocyte foot processes 
create a slit diaphragm (SD) which is integral in preventing the loss of protein into 
Bowman’s space (Kimberly et al. 2007 & Asanma et al 2003) . Even though the clinical 
presentation of FSGS is often heterogeneous, a cardinal feature of the disease is proteinuria, 
which implies loss of this permselective barrier (Schnaper HW, 2003 & Fogo AB, 2003). 
Electron microscopic picture clearly reveals distortion of normal architecture (or effacement) 
of the foot processes of podocytes in FSGS 
(Fig 1B). 
A key factor in the pathogenesis of FSGS is damage and loss of podocytes. Asanuma K. et al. 
(2003) described that based on recent insights into the molecular pathology of podocyte 
injury, at least four major causes have been identified that lead to the uniform reaction of 
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pododcyte foot processes effacement and proteinuria: (1) interference with the slit 
diaphragm complex and its lipid rafts (2) direct interference with the actin cytoskeleton (3) 
interference with the GBM or with podocyte-GBM interaction, and (4) interference with 
negative surface charge of podocytes. Damage to podocytes triggers apoptosis and the 
detachment of podocytes from the glomerular basement membrane. The resulting reduction 
in podocyte number (podocytopenia) leaves the glomerular basement membrane to be 
exposed, (Fogo AB 2003) which leads to development of maladaptive interactions between 
the glomerular basement membrane and epithelial cells. This is followed by proliferation of 
epithelial, endothelial and mesangial cells. The combined reaction of cell proliferation and 
leakage of proteins into Bowman’s space results in deposition of the collagen. Eventually the 
capillary loop collapses and endothelial cells are lost and the affected part of the glomerular 
tuft heals by scarring causing a characteristic lesion of FSGS. Thus the lesions initially are 
limited to a few segments in the glomerulus (segmental) and in a few regions of the kidney 
(focal) but the disease ultimately progresses to involve the entire kidney leading to end 
stage renal disease (ESRD).        
The precise initial insult that leads to the above cascade of events is still unknown. A 
‘circulating permeability factor’ which leads to glomerular basement membrane injury has 
been proposed in the pathogenesis of FSGS (Shalhoub RJ, 1974). The following information 
favors the hypothesis of ‘circulating Permeability factor’ (1) frequent recurrence of 
proteinuria after renal transplant [Ingulli E. et al. 1991] (2) the efficacy of extracorporeal 
techniques such as plasmapheresis in reducing the post renal transplant proteinuria [Artero 
M. et al 1992 and 1994]. (3) the results of in vitro bioassay which detects permeability 
changes induced by FSGS serum on isolated glomeruli [Savin VJ et al in 1992 and 1996]. 
(4)Rea et al (2001) demonstrated that the main clinical feature of FSGS i.e. proteinuria, 
disappeared within one year after transplantation in two recipients of kidneys from a 
patient with FSGS. Not taking into account ethical and legal implications, good outcome of 
the FSGS allograft kidneys into non FSGS recipients is another good evidence for humoral 
genesis/circulating permeability factor, as a cause of the FSGS. (5) Kemper M. et al (2001) 
demonstrated transmission of glomerular permeability factor from the mother affected by 
FSGS to her infant during gestation. After birth, proteinuria in the child decreased and then 
disappeared, suggesting a strong correlation with some circulating factor transmitted from 
the mother to the child.  
At the molecular level, cytokines and vasoactive factors are believed to play a major role in 
the progression of FSGS. The overexpression of transforming growth factor β (TGFβ) or its 
downstream proteins, the ‘Smads’ lead to glomerulosclerosis in animal models. Activation 
of the renin-angiotensin system upregulates TGFβ, which is considered to cause further 
progression of the disease (Harris RC et al. 2006). Angiogenic factors, like platelet-derived 
growth factor (PDGF) and vascular endothelial growth factor (VEGF) seem to play a role in 
disease progression. This is based upon the rat remnant kidney model (RK model) 
experimental studies of progressive glomerulosclerosis. In this model, VEGF upregulation 
soon after the renal injury and later loss of VEGF expression correlates well with 
progression of the glomerulosclerosis (Kang DH et al. 2001). 
Mechanical stress is also believed to play a role in the progression of FSGS. (Hostetter TH. 
2003 & Kwoh C. et al 2006) The hyperfiltration due to the defects of the filtration barrier 
results in increased single nephron glomerular filtration rate (SNGFR), which results in 
hypertrophy of glomeruli. The hypertrophy exacerbates the mismatch between the 
glomerular basement membrane and the decreased numbers of podocytes, propagating the 
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Between 1980–2000, secondary FSGS (Rennke HG et al. 1989 & D’Agati V. 1994) was 
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like Sean Elliott and Alonzo Mourning (National Basketball Association) have been 
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1.2 Epidemiology 
Focal segmental glomerulosclerosis (FSGS) currently is the leading cause of  
nephrotic syndrome in adults and children, particularly in the United States, Australia, 
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of the renin-angiotensin system upregulates TGFβ, which is considered to cause further 
progression of the disease (Harris RC et al. 2006). Angiogenic factors, like platelet-derived 
growth factor (PDGF) and vascular endothelial growth factor (VEGF) seem to play a role in 
disease progression. This is based upon the rat remnant kidney model (RK model) 
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injury further. Another factor in the progression of FSGS is tubulointerstitial injury. 
Clinically, tubulointerstitial injury is a predictor of the loss of renal function in FSGS 
(D’Agati VD 2003 & Rodriguez-Iturbe B et al. 2005). The nonspecific entry of proteins into 
the tubular lumen is one potential source of damage to the tubulointerstitium. Indeed, 
persistence of nephrotic-range proteinuria is a negative prognostic factor for the progression 
of FSGS to ESRD (Walls J. 2001). Cytokines (such as TGFβ), when present in the tubules, will 
recruit monocytes, macrophage, and T-cells. This stimulates other cytokines, including 
interleukin-1, tumor necrosis factor alpha, and other chemokines. This inflammatory 
infiltrate leads to mesangial matrix deposition, promoting the collapse of glomeruli. The 
cellular infiltrate and cytokines also damage tubular epithelial cells, and some tubular 
epithelial cells may undergo transformation to mesenchymal cells. These mesenchymal cells, 
as well as recruited and stimulated fibroblasts, result in collagen matrix deposition and 
tubulointerstitial fibrosis 
(Harris RC et al. 2006). 
Regardless of the cause of podocyte injury, when the podocytes start dying, leakage of 
protein across the GBM leading to proteinuria and hypoalbuminemia ensues. At this time 
cholesterol levels start rising due to increased synthesis of cholesterol by the liver and loss of 
lipid regulating proteins in the urine, the underlying mechanism of these effects is not 
completely known yet. The beneficial effects of blocking the renin-angiotensin system may 
not be limited to their antiproteinuric or antihypertensive effects. As noted earlier, 
angiotensin stimulates TGFβ, in turn contributing to fibrosis. In addition, angiotensin affects 
intracellular calcium concentrations and the podocyte cytoskeleton (Harris RC et al. 2006). 
Inhibition of angiotensin may slow progression by these local mechanisms (Korbert SM, 
2003). 
With increasing incidence of FSGS, these pathways of podocyte injury and disease 
progression provide important targets for future intervention. Trials have already been 
initiated to antagonize cytokines, such as TGFβ (as discussed later in this chapter in 
treatment section). 
Genetic mutations seen in congenital forms of nephrotic syndrome and FSGS enabled 
researchers to identify specific gene mutations involved in podocyte damage (Tryggvason 
K. et al. 2006). Mutations of the nephrin gene, a podocyte-specific transmembrane 
component of the slit diaphragm, are found in congenital Finnish-type nephrotic syndrome, 
and may lead to loss of normal caliber slit diaphragms. (Kestila M. et al. 1998, Tryggvason 
K. et al. 2006, Kwoh et al. 2006). In mouse models, mutations of nephrin-like transmembrane 
genes (NEPH-1) which also localize to the slit diaphragm result in proteinuria and early 
death. Other proteins which are part of the slit diaphragm complex include: podocin, CD2-
associated protein (CD2AP), FAT, P-cadherin,ZO-1, LAP (leucine rich repeat and PDZ 
domain) protein. (Asanuma K et al 2003, Tryggvason K. et al. 2006). Mutations in podocin (a 
transmembrane protein that interacts with nephrin, NEPH-1 and CD2AP) have been 
identified in familial FSGS. Recently, mutations in CD2AP, an immunoglobulin-like protein 
that is involved in nephrin integration with podocyte cytoskeleton, have also been linked to 
genetic forms of FSGS (Shih NY. et al. 1999, Kim JM et al 2003, Tyggvason K. et al 2006). In 
mouse models, the loss of FAT1 and FAT2 (transmembrane proteins with cadherin-like 
repeats) results in the absence of slit diaphragms, proteinuria, and early death. Alpha-
actinin-4, an important structural component of the podocyte cytoskeleton, is mutated in 
some autosomal dominant forms of FSGS (Kaplan JM et al 2000, Yao J et al. 2004). In 
addition to the abnormal structural proteins mutations, some other mutations have been 
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identified in association with FSGS like TRPC6 (Transient receptor potential cation chanel, 
subfamily C, member 6) which is a cation-selective, ion-channel protein that mediates 
calcium signals (Winn MP et al. 2005). The role of the other components of the slit 
diaphragm in the pathophysiology of FSGS is not yet clear. 
In summary, these data suggest that mutations in the cytoskeleton and membrane 
proteins specific to podocytes are responsible for most inherited forms of disease. The 
frequency of spontaneous mutations in the general population who develop nephrotic 
syndromes or FSGS still needs to be assessed as it has diagnostic, prognostic and 
therapeutic implications in case of FSGS. For example, patients who possess genetically 
defective podocytes should be unresponsive to conventional steroid treatment. Similarly, 
these patients should not have recurrent FSGS when transplanted with a structurally 
normal kidney allograft. Furthermore, family members who are potential living donors 
could be genetically screened for mutations associated with the development of kidney 
disease and excluded as candidate donors. 
3. Secondary FSGS  
Secondary FSGS can be seen in a variety of conditions such as renal agenesis, obesity, or sickle 
cell disease etc where hyperfiltration is a characteristic abnormality. Glomerulomegaly is 
common in situations with hyperfiltration. Obesity-associated FSGS needs a definitive 
diagnosis with a renal biopsy to exclude the presence of concurrent early diabetic 
nephropathy. Secondary FSGS may also result from intravenous drug abuse and reflux 
disease. It has been reported that toxins, including lithium and pamidronate, and sirolimus are 
associated with the development of FSGS lesions. Among the viral infections, HIV is the most 
common cause. Rarer viral causes of secondary FSGS include persistent parvovirus B19, 
simian virus 40, and cytomegalovirus infection. 
4. Clinical presentation 
Primary FSGS more likely presents with sudden-onset nephrotic syndrome, whereas 
secondary FSGS presents more insidiously with subnephrotic range proteinuria and renal 
insufficiency. But the secondary FSGS from pamidronate toxicity though typically 
presents with full nephrotic syndrome and acute or subacute renal failure, with collapsing 
FSGS lesions on biopsy. Physical exam reveals elevated blood pressure and edema. Urine 
may be foamy and may have hematuria. The relative frequencies of these findings at 
presentation or biopsy based diagnosis in published series (Rydell JJ et al. 1995 & Chun 
MJ et al 2004) are as follows. Primary FSGS can present with nephrotic range proteinuria 
(60 to 75%), microscopic hematuria with variable degrees of proteinuria (30 to 50% ), 
hypertension (45 to 65 %), renal insufficiency (25 to 50 %) and with overlapping of these 
presentations. Children tend to present with more proteinuria whereas hypertension is 
more common in adults. A case of FSGS should be considered idiopathic only when other 
etiologies are thoroughly excluded. Uncommonly Muehrcke’s lines (white banding on the 
nails due to hypoalbuminaemia), xanthelasma and xanthomata (cholesterol deposits in 
skin) are associated with FSGS as well. Following risk factors need to be considered when 
doing history and physical examination on such patients: male gender, black race, 
positive family history, heroin abuse, use of known causative medications, chronic viral 
infection, a solitary kidney, and obesity. 
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injury further. Another factor in the progression of FSGS is tubulointerstitial injury. 
Clinically, tubulointerstitial injury is a predictor of the loss of renal function in FSGS 
(D’Agati VD 2003 & Rodriguez-Iturbe B et al. 2005). The nonspecific entry of proteins into 
the tubular lumen is one potential source of damage to the tubulointerstitium. Indeed, 
persistence of nephrotic-range proteinuria is a negative prognostic factor for the progression 
of FSGS to ESRD (Walls J. 2001). Cytokines (such as TGFβ), when present in the tubules, will 
recruit monocytes, macrophage, and T-cells. This stimulates other cytokines, including 
interleukin-1, tumor necrosis factor alpha, and other chemokines. This inflammatory 
infiltrate leads to mesangial matrix deposition, promoting the collapse of glomeruli. The 
cellular infiltrate and cytokines also damage tubular epithelial cells, and some tubular 
epithelial cells may undergo transformation to mesenchymal cells. These mesenchymal cells, 
as well as recruited and stimulated fibroblasts, result in collagen matrix deposition and 
tubulointerstitial fibrosis 
(Harris RC et al. 2006). 
Regardless of the cause of podocyte injury, when the podocytes start dying, leakage of 
protein across the GBM leading to proteinuria and hypoalbuminemia ensues. At this time 
cholesterol levels start rising due to increased synthesis of cholesterol by the liver and loss of 
lipid regulating proteins in the urine, the underlying mechanism of these effects is not 
completely known yet. The beneficial effects of blocking the renin-angiotensin system may 
not be limited to their antiproteinuric or antihypertensive effects. As noted earlier, 
angiotensin stimulates TGFβ, in turn contributing to fibrosis. In addition, angiotensin affects 
intracellular calcium concentrations and the podocyte cytoskeleton (Harris RC et al. 2006). 
Inhibition of angiotensin may slow progression by these local mechanisms (Korbert SM, 
2003). 
With increasing incidence of FSGS, these pathways of podocyte injury and disease 
progression provide important targets for future intervention. Trials have already been 
initiated to antagonize cytokines, such as TGFβ (as discussed later in this chapter in 
treatment section). 
Genetic mutations seen in congenital forms of nephrotic syndrome and FSGS enabled 
researchers to identify specific gene mutations involved in podocyte damage (Tryggvason 
K. et al. 2006). Mutations of the nephrin gene, a podocyte-specific transmembrane 
component of the slit diaphragm, are found in congenital Finnish-type nephrotic syndrome, 
and may lead to loss of normal caliber slit diaphragms. (Kestila M. et al. 1998, Tryggvason 
K. et al. 2006, Kwoh et al. 2006). In mouse models, mutations of nephrin-like transmembrane 
genes (NEPH-1) which also localize to the slit diaphragm result in proteinuria and early 
death. Other proteins which are part of the slit diaphragm complex include: podocin, CD2-
associated protein (CD2AP), FAT, P-cadherin,ZO-1, LAP (leucine rich repeat and PDZ 
domain) protein. (Asanuma K et al 2003, Tryggvason K. et al. 2006). Mutations in podocin (a 
transmembrane protein that interacts with nephrin, NEPH-1 and CD2AP) have been 
identified in familial FSGS. Recently, mutations in CD2AP, an immunoglobulin-like protein 
that is involved in nephrin integration with podocyte cytoskeleton, have also been linked to 
genetic forms of FSGS (Shih NY. et al. 1999, Kim JM et al 2003, Tyggvason K. et al 2006). In 
mouse models, the loss of FAT1 and FAT2 (transmembrane proteins with cadherin-like 
repeats) results in the absence of slit diaphragms, proteinuria, and early death. Alpha-
actinin-4, an important structural component of the podocyte cytoskeleton, is mutated in 
some autosomal dominant forms of FSGS (Kaplan JM et al 2000, Yao J et al. 2004). In 
addition to the abnormal structural proteins mutations, some other mutations have been 
 
Focal Segmental Glomerulosclerosis 
 
29 
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Primary or idiopathic FSGS: Refer to Table 2 
 
Secondary FSGS: 
1. Virus assoiated 
a. HIV associated nephropathy (HIVAN)  
b. Parvovirus B19 
c. SV40 
d. CMV 
2. Drug toxicity 
a. Pamidronate 
b. Lithium 
c. Interferon –alpha 
d. Heroin  
e. Sirolimus 
3.  Secondary FSGS mediated by adaptive structural-functional responses 
a. Reduced renal mass  
 Unilateral renal agenesis 
 Oligomeganephronia 
 Renal dysplasia 
 Reflux nephropathy 
 Sequela to cortical necrosis 
 Surgical renal ablation 
 Chronic allograft nephropathy 
 Any advanced renal disease with reduction in functioning nephrons 
b.  Initially normal renal mass 
 Obesity 
 Hypertension 
 Atheroembolic or other acute vaso-occlusive processes 
 Cyanotic congenital heart disease 
 Sickle cell anemia 
 Anabolic steroids 
4. Familial FSGS 
a. Autosomal recessive : 
 mutations in genes NPHS1 (coding for nephrin) ,NPHS2 (coding for podocin) and 
 PLCE1 (coding for PLC epsilon1) 
 LAMB2 (coding for Laminin beta 2 chain) 
b. Autosomal dominant 
 Mutations in genes ACTN1 (coding for alpha actinin4), TRPC6 (coding for TRPC6), 
 INF2 (coding for INF2) 
 WT1 (coding for WT1) 
_________________________________________________________________________________ 
 
Table 1. Etiologic Classification of Focal Segmental Glomerulosclerosis  
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Differences in clinical manifestations correlate with differences in pathologic phenotypes. 
Collapsing variant of FSGS often has more severe proteinuria and renal insufficiency but 
less hypertension than typical variant. Patients with collapsing FSGS frequently have 
extrarenal manifestations of the disease, a few weeks before the onset of the nephrosis e.g. 
episodes of upper respiratory infections, diarrhea that are usually ascribed to the viral or 
other infectious processes. However, the symptoms of fever, anorexia, aches and pains are 
present only in 20% of patients at the time of onset of nephrosis. Glomerular tip lesion 
variant (Fig 4) often presents with rapid onset of edema similar to minimal change disease. 
Glomerular tip lesion patients may develop reversible acute renal failure, at the times of 
initial presentation when the degree of proteinuria, edema, hypoalbuminemia are at their 
peak. This behaves like minimal change disease and this rarely happens in any other forms 
of FSGS. Patients with glomerular tip lesion FSGS tend to be older white males in 
comparison to younger black males predominance in collapsing variant FSGS. 
Distinguishing between primary and secondary FSGS is important, since secondary FSGS 
should not respond to immunosuppressive therapy. Instead, the inciting condition or toxin 
should be alleviated or stopped in secondary form FSGS if possible. Unfortunately, 
distinguishing between primary vs. secondary FSGS can be challenging, since focal sclerosis 
lesions may be present in a diverse assortment of glomerular, vascular, and tubular injuries, 
just as global sclerosis represents a common endpoint lesion for the end-stage renal disease. 
5. Laboratory findings 
Urine analysis may have wide range of findings starting from fatty casts to dysmorphic red 
blood cells and red blood cell casts. Proteinuria varies from less than 1 gm to 30g/day. 
Hypoproteinemia is common in patients with FSGS, with total serum protein reduced to 
varying extents. Hypoalbuminemia may drop as low as below 2 g/dL, especially in patients 
with the collapsing and glomerular tip variants of FSGS. Cholesterol levels are increased. 
Serum complement components are typically in normal range in FSGS. CD4 cell count and 
HIV test is essential in all patients with FSGS, especially those with the collapsing pattern. 
DNA/PCR for Parvo B19 and CMV test is an essential part of work up to rule out the rare 
forms of secondary FSGS. Finally renal biopsy is the final step to make the diagnosis of FSGS.  
6. Histopathology 
The diagnosis of FSGS is not an easy one to make, because the morphologic features of FSGS 
are nonspecific and can occur in a variety of other conditions or superimposed on other 
glomerular disease processes. Additionally, because the defining glomerular lesion is focal, 
it may not be adequately sampled in small needle biopsies. The diagnosis of FSGS is further 
complicated by the existence of a primary (or idiopathic) form and many secondary forms 
(Table 1). Before a diagnosis of primary FSGS can be made, secondary forms must be 
excluded. Idiopathic FSGS must be distinguished from human immunodeficiency virus 
(HIV) -associated nephropathy, heroin nephropathy and other large group of secondary 
FSGS caused by structural-functional adaptations mediated by intrarenal vasodilatation, 
and increased glomerular capillary pressures, (as listed in Table 1). The morphological types 
are not used to guide treatment but to provide useful prognostic information. Electron 
microscopy can be used to distinguish primary and secondary FSGS. In primary FSGS, foot 
process fusion is diffuse and occurs throughout the glomeruli. In secondary FSGS, foot 
process fusion is mostly limited to the sclerotic areas. 
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 Sequela to cortical necrosis 
 Surgical renal ablation 
 Chronic allograft nephropathy 
 Any advanced renal disease with reduction in functioning nephrons 
b.  Initially normal renal mass 
 Obesity 
 Hypertension 
 Atheroembolic or other acute vaso-occlusive processes 
 Cyanotic congenital heart disease 
 Sickle cell anemia 
 Anabolic steroids 
4. Familial FSGS 
a. Autosomal recessive : 
 mutations in genes NPHS1 (coding for nephrin) ,NPHS2 (coding for podocin) and 
 PLCE1 (coding for PLC epsilon1) 
 LAMB2 (coding for Laminin beta 2 chain) 
b. Autosomal dominant 
 Mutations in genes ACTN1 (coding for alpha actinin4), TRPC6 (coding for TRPC6), 
 INF2 (coding for INF2) 
 WT1 (coding for WT1) 
_________________________________________________________________________________ 
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Differences in clinical manifestations correlate with differences in pathologic phenotypes. 
Collapsing variant of FSGS often has more severe proteinuria and renal insufficiency but 
less hypertension than typical variant. Patients with collapsing FSGS frequently have 
extrarenal manifestations of the disease, a few weeks before the onset of the nephrosis e.g. 
episodes of upper respiratory infections, diarrhea that are usually ascribed to the viral or 
other infectious processes. However, the symptoms of fever, anorexia, aches and pains are 
present only in 20% of patients at the time of onset of nephrosis. Glomerular tip lesion 
variant (Fig 4) often presents with rapid onset of edema similar to minimal change disease. 
Glomerular tip lesion patients may develop reversible acute renal failure, at the times of 
initial presentation when the degree of proteinuria, edema, hypoalbuminemia are at their 
peak. This behaves like minimal change disease and this rarely happens in any other forms 
of FSGS. Patients with glomerular tip lesion FSGS tend to be older white males in 
comparison to younger black males predominance in collapsing variant FSGS. 
Distinguishing between primary and secondary FSGS is important, since secondary FSGS 
should not respond to immunosuppressive therapy. Instead, the inciting condition or toxin 
should be alleviated or stopped in secondary form FSGS if possible. Unfortunately, 
distinguishing between primary vs. secondary FSGS can be challenging, since focal sclerosis 
lesions may be present in a diverse assortment of glomerular, vascular, and tubular injuries, 
just as global sclerosis represents a common endpoint lesion for the end-stage renal disease. 
5. Laboratory findings 
Urine analysis may have wide range of findings starting from fatty casts to dysmorphic red 
blood cells and red blood cell casts. Proteinuria varies from less than 1 gm to 30g/day. 
Hypoproteinemia is common in patients with FSGS, with total serum protein reduced to 
varying extents. Hypoalbuminemia may drop as low as below 2 g/dL, especially in patients 
with the collapsing and glomerular tip variants of FSGS. Cholesterol levels are increased. 
Serum complement components are typically in normal range in FSGS. CD4 cell count and 
HIV test is essential in all patients with FSGS, especially those with the collapsing pattern. 
DNA/PCR for Parvo B19 and CMV test is an essential part of work up to rule out the rare 
forms of secondary FSGS. Finally renal biopsy is the final step to make the diagnosis of FSGS.  
6. Histopathology 
The diagnosis of FSGS is not an easy one to make, because the morphologic features of FSGS 
are nonspecific and can occur in a variety of other conditions or superimposed on other 
glomerular disease processes. Additionally, because the defining glomerular lesion is focal, 
it may not be adequately sampled in small needle biopsies. The diagnosis of FSGS is further 
complicated by the existence of a primary (or idiopathic) form and many secondary forms 
(Table 1). Before a diagnosis of primary FSGS can be made, secondary forms must be 
excluded. Idiopathic FSGS must be distinguished from human immunodeficiency virus 
(HIV) -associated nephropathy, heroin nephropathy and other large group of secondary 
FSGS caused by structural-functional adaptations mediated by intrarenal vasodilatation, 
and increased glomerular capillary pressures, (as listed in Table 1). The morphological types 
are not used to guide treatment but to provide useful prognostic information. Electron 
microscopy can be used to distinguish primary and secondary FSGS. In primary FSGS, foot 
process fusion is diffuse and occurs throughout the glomeruli. In secondary FSGS, foot 
process fusion is mostly limited to the sclerotic areas. 
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Five main light microscopic patterns of FSGS have been defined, as given below: 
 
 
Classified based upon the ‘Working Columbia Classification 2004’.  
Table 2. Morphological variants of FSGS 
Although appearance of the glomerular tuft differs in these forms, all share the common 
feature of podocyte alterations at the ultrastructural level. At present, it is unclear if these 
morphologic variants reflect pathogenetic differences or they are the consequence of 
different severities of podocyte injury or histopathologic evolution. Future studies are 
needed to address these questions.  
Classic Focal Segmental Glomerulosclerosis (Focal Segmental Glomerulosclerosis Not 
Otherwise Specified) : also called FSGS NOS, or typical FSGS. FSGS NOS requires exclusion of 
the other more specific subtypes described in the table 2. Light Micrscopic examination reveals 
accumulation of extracellular matrix which occlude glomerular capillaries, forming discrete 
segmental solidifications involving affected portion of the glomerular tuft. Also seen is 
plasmatic insudation of amorphous glassy material beneath the GBM, endocapillary foam 
cells, and wrinkling of the GBM. Adhesions to Bowman's capsule are common, and overlying 
visceral epithelial cells often appear swollen over the sclerosing segment. Non sclerotic 
glomerular lobules appear normal by light microscopy except for mild podocyte swelling. 
Immunofluorescence: focal and segmental granular deposition of IgM, and C3 is seen often, 
but C1 in the distribution of segmental glomerular sclerosis may also be seen. Nonsclerotic 
glomeruli may have weak mesangial staining for IgM and C3. By electron microscopic 
examination, segmental sclerotic lesions exhibit increased matrix, wrinkling and retraction 
of GBM. Accumulation of inframembranous hyaline material but no immune complex 
electron-dense deposits are seen. Overlying the segmental sclerosis, there is usually 
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effacement of foot processes (Fig 1.B)and podocyte hypertrophy. The adjacent nonsclerotic 
glomerular capillaries show only foot process effacement. 
 
   
Fig. 1. (A-left) Focal segmental distribution of glomerular lesions. The glomerulus at the top 
right of the picture is normal. The glomerulus at the bottom shows dense segmental scars 
with adhesion to Bowman's capsule. (Periodic acid methenamine silver, 20X). (B-Right) 
Patchy effacement of foot processes is present. No immune complex-type deposits are seen 
along the GBM. (Electron Microscopy).  
Perihilar Variant of Focal Segmental Glomerulosclerosis : This variant is defined as 
perihilar hyalinosis and sclerosis (Fig 2. A & B) which involves more than 50% of glomeruli 
with segmental lesions. This category requires that the cellular, tip, and collapsing variants 
be excluded. Podocyte hyperplasia is uncommon.  
 
   
Fig. 2. (A-left): Perihillar variant FSGS (B): Glomerulus with "Hyalinosis": homogeneous, 
eosinophilic material may be present at the periphery of sclerotic foci, or within the capillary 
subendothelial space (PAS, 40X). (Fig 2A-obtained from 
http://www.unckidneycenter.org/kidneyhealthlibrary/fsgs.html#causes) 
Immunofluorescence (IF) reveals segmental deposits of IgM and C3 in areas of sclerosis and 
hyalinosis.  
Electron microscopy (EM) demonstrates variable foot process effacement. The perihilar 
variant may occur in primary or secondary FSGS. It is more common in secondary forms of 
FSGS mediated by adaptive structural-functional responses, in which it is typically 
accompanied by glomerular hypertrophy. In this setting, the greater filtration pressures at 
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the proximal end of the glomerular capillary bed may favor the development of lesions at 
the vascular pole. 
Cellular Variant of Focal Segmental Glomerulosclerosis : This variant is characterized by 
focal and segmental endocapillary hypercellularity that may mimic a form of focal 
proliferative glomerulonephritis. Glomerular capillaries are segmentally occluded by 
endocapillary hypercellularity, including foam cells, infiltrating leukocytes, karyorrhectic 
debris, and hyaline. There is often hyperplasia of the visceral epithelial cells, which may 
appear swollen and crowded, sometimes forming pseudocrescents. This variant requires 
that tip lesions and collapsing lesions be excluded. 
IF shows focal and segmental glomerular positivity for IgM and C3 and EM reveals severe 
foot process effacement. 
Collapsing Variant of Focal Segmental Glomerulosclerosis: This variant is defined by at 
least one glomerulus with segmental or global collapse (Fig 3) and overlying hypertrophy 
and hyperplasia of visceral epithelial cells. There is occlusion of glomerular capillary lumina 
by implosive wrinkling and collapse of the GBMs. This lesion is more often global than 
segmental. Overlying podocytes display striking hypertrophy, hyperplasia and express 
proliferation markers. Podocytes often contain prominent intracytoplasmic protein 
resorption droplets and may fill Bowman's space, forming pseudocrescents . Although 
podocyte hyperplasia is found in both the collapsing and cellular variants of FSGS, 
collapsing glomerulopathy is distinguished by the absence of endocapillary 
hypercellularity. In collapsing FSGS, there is prominent tubulointerstitial disease, including 
tubular atrophy, interstitial fibrosis, interstitial edema, and inflammation. A distinctive 
feature is the presence of dilated tubules forming microcysts that contain loose 
proteinaceous casts. This pattern can occur both in primary FSGS and also in secondary 
FSGS due to HIV,parvovirus B12,pamidronate toxicity and interferon therapy. Endothelial 
tubuloreticular inclusions are identified in over 90% of patients with HIVinfection 
collapsing glomerulopathy and interferon therapy, whereas only in 10% cases with 
idiopathic collapsing glomerulopathy. Besides these conditions endothelial tubuloreticular 
inclusions are seen commonly in systemic lupus erythematosus nephritis.  
 
 
Fig. 3. A glomerulus displays collapsing variant of FSGS , glomerular capillaries show 
collapse with absent lumen (H&E, 40X).  
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IF microscopy of collapsing lesions often is positive for IgM and C3. EM reveals severe foot 
process effacement affecting both collapsed and noncollapsed glomeruli 
Tip Variant of Focal Segmental Glomerulosclerosis : 
This variant is defined by the presence of at least one segmental lesion involving the tip 
domain (i.e., the outer 25% of the tuft next to the origin of the proximal tubule). There is 
either adhesion (Fig 4) between the tuft and Bowman's capsule or confluence of swollen 
podocytes with parietal or tubular epithelial cells at the tubular lumen or neck. In some 
cases, the affected segment appears to herniate into the tubular lumen. The segmental 
lesions may be cellular or sclerosing type. Although initially peripherally located, these 
lesions may progress more centrally. The presence of perihilar sclerosis or collapsing 
sclerosis rules out the tip variant. 
IF microscopy reveals involved tip area positive for IgM and C3 and EM findings 
demonstrate foot process effacement. 
 
 
Fig. 4. Sclerotic glomerular segment with a small adhesion; "Glomerular tip lesion“ (Periodic 
acid methenamine silver, 40X) 
7. Treatment 
Typically the goals of treatment in FSGS include-(1) to reduce, eliminate or at least suppress 
the proteinuria and (2) to avoid or at least retard the progression to ESRD. Treatment of the 
FSGS can be arbitrarily divided into (1) Nonspecific; nutritional management (2)Non 
immunosuppressive therapy: diuretics and RAS interference. (3) Immunosuppressive 
treatment: which includes the use of steroids, steroid sparing medications like 
cyclophosphamide, cyclosporine A, tacrolimus and mycophenolic mofetil. (4)-Antifibrotic 
drugs:Pirfenidone, Rosiglitazone (FONT Phase 1 trial completed and now FONT phase II 
trial is ongoing) (5)-Monoclonal/polyclonal Antibodies: Adalimumab, Rituximab, 
Fresolmumab (6)-Plasmapheresis 
Nonspecific treatment: Nonspecific treatment goals in FSGS are like any other 
glomerulopathy associated with nephrotic syndrome, which include maintenance of 
adequate nutrition, minimization or elimination of proteinuria, and prevention of 
complications resulting from edema. The mainstay of treatment is reduction in daily salt 
intake to 2 g of sodium. A high level of protein intake may further aggravate proteinuria, 
adversely affecting renal function. Current recommendations call for an intake of 1to1.3 g of 
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high biologic value protein per kilogram of body weight and a reduction of fat intake. Lipid 
lowering is necessary to reduce cardiovascular risk and to possibly delay the progression of 
renal disease. 
7.1 Non-immunosuppressive drug treatment 
Symptomatic relief of edema helps the patient feel better. In most patients, loop diuretics are 
needed to promote diuresis. Patients with massive edema with impaired oral absorption 
may require intravenous administration of loop diuretics. In patients with refractory 
conditions, addition of other diuretics (eg, metolazone) and potassium-sparing agents (eg, 
spironolactone, triamterene) facilitates diuresis and prevents hypokalemia. Rarely, some 
patients (especially children) with intractable edema may need intravenous albumin and 
diuretics in a hospital setting to initiate diuresis. Protracted use of intravenous albumin 
should be discouraged; the regimen is expensive and ineffective, because most of the 
infused albumin is lost in the urine. Continuous IV drip of furosemide is preferred over 
large boluses of IV push to avoid side effects.  
Control of hypertension is one of the most important aspects of overall management in 
FSGS, like any other glomerular disease. Angiotensin-converting enzyme inhibitors (ACEIs) 
and angiotensin receptor blockers (ARBs) are nonspecific agents that reduce proteinuria 
because of their antihypertensive and intrarenal hemodynamic effects of reducing 
glomerular capillary pressure and resistance. ACEIs and ARBs are effective in reducing 
protein loss even in normotensive patients. These agents do have an effect in slowing down 
of the disease progression by downregulating the TGFβ by interfering with renin 
angiotensin system, regardless of any antihypertensive effects.These agents do not abolish 
proteinuria completely or reverse the primary glomerular disease process per se.  
As hypertension develops in most patients with FSGS which further causes deterioration of 
renal function, the control of blood pressure is an important part of the treatment of FSGS. 
Many patients, may require combination antihypertensive therapy to maintain blood 
pressure in the normal range. Lipid lowering therapy like statins is warranted to correct 
hyperlipidemia to reduce the risk of cardiovascular disease in this subset of patient 
population.  
7.2 Immunosuppressive treatment  
Idiopathic FSGS is a difficult disease to treat because of its highly variable clinical course. 
The specific treatment approach is still empirical, and no consensus has evolved because of a 
lack of prospective controlled trials. Current evidence is, mostly derived from retrospective 
analyses, and favors prolonged steroid therapy (6 months or longer) to induce remission in 
patients with idiopathic FSGS. 
Criteria for remission: (1) complete remission is considered when urinary protein excretion 
of less than 200-300 mg/day, and (2) partial response is considered when urinary protein 
excretion of 200-3500 mg/day, or a greater than 50% reduction in baseline proteinuria.  
Since long-term steroid therapy is not without serious toxicity, the patient counselling 
regarding the goals of the therapy, possible potential side affects and expected outcomes, is 
essential before starting such treatment. The current consensus is to initiate therapy with 
prednisone in a dose of 1 mg/kg (60-80 mg/d) for 2-6 months or longer, depending on 
patient’s response as assessed by presence or absence of edema, 24-hour urine protein 
excretions, creatinine clearance, serum creatinine, serum albumin, and lipid levels. 
Literature reveals that 30-60% of patients may undergo complete or partial remission with 
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this treatment regimen, and relapses are frequent when steroids are discontinued. Blacks 
and patients with collapsing FSGS are generally refractory to treatment and progress to 
renal failure. In steroid responsive patients, the goal is to titrate prednisone to the lowest 
dose needed to stop proteinuria and to prevent relapses. Use of steroids on alternate days 
can also reduce toxicity. The optimal duration of treatment is uncertain; some authorities 
recommend use of steroids indefinitely. If no remission after 4 months of corticosteroid 
treatment, disease is defined as being corticosteroid-resistant (Meyrier A.,2009). 
In patients who are refractory to 2-3 months of prednisone therapy, the recommendation is 
to reduce the steroid dose and to add cyclophosphamide (2.5 mg/kg [150-200 mg/day]), 
monitor patients for bone marrow suppression, and encourage adequate fluid intake to 
prevent hemorrhagic cystitis. Prolonged use of cyclophosphamide may lead to gonadal 
toxicity; therefore, persisting with cyclophosphamide beyond 3 months in patients who do 
not respond is unwise. Cyclosporine (3.5mg/kg/day) can induce remission and preserve 
renal function, although relapse occurs in 60% of patients when cyclosporine alone is used 
(Ponticelli C. et al. 1993 & Cattran DC et al. 1999). Continuing treatment with cyclosporine 
for 1 year after remission followed by a slow tapering of the dose results in a longer 
remission (Meyrier A 1994).  Low-dose cyclosporine in combination with low-dose 
prednisone (0.15mg/kg/day) in corticosteroid-resistant patients is more effective than 
cyclosporine alone (Cattaran DC. Et al 1999 & Meyrier A 2009). Rates of complete (Niaudet 
P. 1994 & Braun N et al 2008) and partial remission achieved with cyclosporine are greater if 
low-dose prednisone is given at the same time. Continuous use of cyclosporine for >12 
months is associated with a significant increase in tubulointerstitial fibrosis. Its use should, 
therefore, be limited to patients with creatinine clearance >60 ml/min/1.73 m2 
Isolated reports have suggested that patients who are refractory to steroids and 
cyclophosphamide, treatment with other immunosuppressive agents, such as tacrolimus 
and sirolimus, may be beneficial in inducing remission. However, studies using these agents 
were uncontrolled investigations that were limited to a few patients.  
7.3 Tacrolimus 
Few studies have reported the use of tacrolimus for Idiopathic FSGS. In the largest study, 25 
patients with nephrotic syndrome due to primary FSGS and known resistance to or 
dependence on cyclosporine (cyclosporine) were given tacrolimus plus prednisolone 
(prednisone) for 6 months. Seventeen patients had a reduced proteinuria to <3 g/day, and 
12 had complete or partial remission. Thirteen patients relapsed after discontinuing 
tacrolimus; reinstitution of therapy for 1 year resulted in complete remission (5 patients) and 
partial remission (4 patients). [Segarra A et al 2002]. 
7.4 Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is a reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH) in purine biosynthesis. MMF is selective for the de novo pathway 
critical to lymphocytic proliferation and activation. Because of favorable results in other 
glomerular diseases, mycophenolate mofetil has also been evaluated in FSGS. Although the 
experience is limited, the suggested dose is 750-1000 mg twice daily in patients who are 
refractory to corticosteroids and in whom calcineurin inhibitors may not be appropriate. 
However, adequate randomized studies supporting this approach are lacking (Cattran DC et 
al. 2004). If mycophenolate is being considered, cyclosporine should not be used concurrently. 
Mycophenolate can be either used alone or in combination with corticosteroids.  
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P. 1994 & Braun N et al 2008) and partial remission achieved with cyclosporine are greater if 
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patients with nephrotic syndrome due to primary FSGS and known resistance to or 
dependence on cyclosporine (cyclosporine) were given tacrolimus plus prednisolone 
(prednisone) for 6 months. Seventeen patients had a reduced proteinuria to <3 g/day, and 
12 had complete or partial remission. Thirteen patients relapsed after discontinuing 
tacrolimus; reinstitution of therapy for 1 year resulted in complete remission (5 patients) and 
partial remission (4 patients). [Segarra A et al 2002]. 
7.4 Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is a reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH) in purine biosynthesis. MMF is selective for the de novo pathway 
critical to lymphocytic proliferation and activation. Because of favorable results in other 
glomerular diseases, mycophenolate mofetil has also been evaluated in FSGS. Although the 
experience is limited, the suggested dose is 750-1000 mg twice daily in patients who are 
refractory to corticosteroids and in whom calcineurin inhibitors may not be appropriate. 
However, adequate randomized studies supporting this approach are lacking (Cattran DC et 
al. 2004). If mycophenolate is being considered, cyclosporine should not be used concurrently. 
Mycophenolate can be either used alone or in combination with corticosteroids.  
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7.5 Monoclonal antibody treatment 
Rituximab: Rituximab is an anti CD20 chimeric monoclonal antibody. Case reports have 
suggested rituximab may be effective in treating patients with minimal change nephropathy 
and FSGS. (Peters HP et al 2008). .Four patients with nephrotic syndrome due to minimal 
change nephropathy or FSGS were treated with rituximab because of failure of or 
intolerance to the standard immunosuppressive therapy. Other cases of FSGS reported in 
the literature (6 pediatric patients) that were successfully treated with rituximab were also 
included. Complete remission was reported within 1 month for a 7-year-old boy with FSGS 
during treatment with rituximab and concurrent treatment with mycophenolate, low-dose 
prednisolone (prednisone), and tacrolimus. Controlled trials are needed to further evaluate 
the efficacy of rituximab in FSGS.  
Fresolimumab: Recently a phase one trial (Trachtman H. et al 2011) has been completed 
which evaluated the safety and pharmacokinetics of single-dose infusions of fresolimumab, 
a human monoclonal antibody that inactivates all forms of transforming growth factor-beta 
(TGF-β), in a phase I open-label, dose-ranging study. Patients with biopsy-confirmed, 
treatment-resistant, primary FSGS with a minimum estimated glomerular filtration rate 
(eGFR) of 25 ml/min per 1.73m2, and a urine protein to creatinine ratio over 1.8mg/mg 
were enrolled. All 16 patients completed the study in which each received one of four 
single-dose levels of fresolimumab (up to 4mg/kg) and was followed for 112 days. 
Fresolimumab was well tolerated with pustular rash, the only adverse event, developing in 
two patients. Single-dose fresolimumab was well tolerated in patients with primary resistant 
FSGS. Additional evaluation in a larger dose-ranging study is necessary. 
7.6 Antifibrotic agents  
Pirfenidone has been shown to have therapeutic potential in fibrotic diseases, although the 
mechanism of action is not well understood. It has been shown to reduce transforming 
growth factor-β 1 production, antagonize TNF- signaling, and scavenge reactive oxygen 
species. It also reduces fibrosis and prevents loss of glomerular filtration in animal models 
of renal disease. An open-label trial evaluated the safety and efficacy of pirfenidone in 
patients with idiopathic and post adaptive FSGS. Pirfenidone had no effect on BP or 
proteinuria but it did preserve renal function. Controlled trials are needed to further 
evaluate the efficacy of pirfenidone in FSGS (Cho ME. et al 2007). 
Rosiglitazone: Renal mesangial cells express peroxisome proliferator-activated receptor 
(PPAR –gamma). PPAR-gamma activation, can exhibit anti-inflammatory effects. 
Weissgarten et al (2006) demonstrated that PPAR-gamma activation by rosiglitazone 
resulted in decreased manifestation of inflammatory hallmarks, including inhibition of 
mesangial cell proliferation, downregulation of apoptosis and blunted responsiveness to 
angiotensin II in animal models. FONT-I (a phase 1 clinical trial) showed that this agent was 
safe and well tolerated in 11 patients with biopsy-demonstrated FSGS. The results of further 
studies are awaited. 
Despite all attempts, some patients continue to deteriorate and progress to ESRD. Patients 
and their families should be counselled in detail regarding the treatment options for ESRD 
so that they can choose appropriate treatment tailored to their life style among maintenance 
hemodialysis, continuous ambulatory peritoneal dialysis, or renal transplantation. FSGS 
may recur in the transplanted kidney, but most centers do not consider this a 
contraindication for renal transplantation.  
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Secondary FSGS treatment management is directed toward the etiology or associated 
disorder. For example, discontinuing pamidronate in pamidronate induced FSGS, and in 
HIV-associated FSGS, HAART is associated with remission of proteinuria and preservation 
of renal function. In heroin-associated FSGS, discontinuation of the drug may result in 
remission of proteinuria and improvement in renal function.  
8. Prognosis 
Prognosis of idiopathic FSGS is variable. Important prognostic factors are, the amount of 
proteinuria, the level of plasma creatinine, the morphological subtype, and the response to 
therapy as listed in table 3. Korbet SM (1999) described that nephrotic patients with FSGS, 
particularly those with massive proteinuria, have a significantly poorer prognosis than non-
nephrotic patients, with 50% progressing to end-stage renal disease (ESRD) over 3-8 years as 
compared with a 10-year survival of >80%, respectively. In addition, the recurrence rate of 
this lesion is high in transplanted patients with primary FSGS. When clinical and 
histological features at presentation have been evaluated by multivariate analysis, the 
significant positive predictors of progression to ESRD have consistently been the serum 
creatinine (>1.3 mg/dl), amount of proteinuria and the presence of interstitial fibrosis (> or 
=20%). The one factor which is a significant negative predictor of progression to ESRD is the 
achievement of a remission in proteinuria. Unfortunately, spontaneous remissions are rare 




1. Clinical features at the time of biopsy 
a. Nephrotic range proteinuria or massive proteinuria 
b. Elevated serum creatinine 
c. Black race 
2. Histopathologic features at the time of biopsy 
a. Collapsing variant  
b. Tubulointerstitial fibrosis 
3. Clinical features during the course of the FSGS 
a. Failure to achieve partial or complete remission. 
_________________________________________________________________________________ 
Table 3. Risk factors for progressive loss of renal function in FSGS  
Thomas DB et al. (2006) described that the morphological subtype identified on renal biopsy 
also provided useful prognostic information. The collapsing variant, the main variant seen 
in HIV-induced FSGS, is associated with a worse prognosis than the other forms. The tip 
variant has a better prognosis than the other forms. 
9. Summary 
Focal segmental glomerulosclerosis is still largely an idiopathic disease but in the recent 
past, more genetic mutations and secondary causes have been described. As more and more 
pathogenetic mechanisms involved in idiopathic FSGS are coming into light and more 
secondary causes of FSGS are described, the occurrence of true idiopathic FSGS diagnosis is 
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pathogenetic mechanisms involved in idiopathic FSGS are coming into light and more 
secondary causes of FSGS are described, the occurrence of true idiopathic FSGS diagnosis is 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
40
decreasing and thus the frequency of the latter is often overstated. Other than the genetic 
and secondary causes of FSGS, the treatment strategies are still not based upon multiple 
large randomized controlled trials, and in fact are based upon predominantly anecdotal 
experiences. Still there are more questions than the answers for the pathogenesis, 
classification, treatment and prognosis of this an almost a century old disease. This 
clincopathologic entity still remains a challenge for the nephrologists and transplant 
physicians. 
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1. Introduction 
Membranoproliferative glomerulonephritis (MPGN) refers to glomerular pathology in 
which there is thickening of the capillary wall together with mesangial expansion. In this 
article we firstly review the pathological features of MPGN and discuss how advances in 
our understanding of the association between abnormalities in the regulation of 
complement and MPGN have revealed limitations in the historical pathological sub-division 
of MPGN. Secondly we review the clinical presentation of MPGN, its prognosis and 
therapeutic considerations. 
2. Pathological features of MPGN 
The name ‘membranoproliferative glomerulonephritis’ derives from the light microscopic 
glomerular histologic pattern. MPGN is synonymous with ‘mesangiocapillary 
glomerulonephritis’. The glomeruli are large and hypercellular. The hypercellularity is 
typically uniform though-out the glomeruli. Mesangial hypercellularity and expansion of 
the mesangial matrix can accentuate the appearance of discrete lobules within the glomeruli. 
In some cases the hypercellularity includes infiltration of the glomerulus with neutrophils 
[1] and in severe cases monocytes have been detected in the glomerulus [2]. The degree of 
leukocyte infiltration shows some correlation with the degree of C3d deposition, possibly 
due to the chemotactic effects of complement split products. In patients who have 
undergone two biopsies, for example, when the abundance of C3d decreased in the second 
biopsy fewer leukocytes were observed [3]. The basement membranes of glomerular 
capillaries in MPGN are thickened. A characteristic change in the capillary wall is splitting 
of the glomerular basement membrane (GBM), termed ‘tram-tracking’ or ‘double-contours’. 
This is due to the inter-position of the proliferated mesangial cells between the endothelial 
cells and the GBM.  The inter-positioned mesangial cells generate new basement membrane 
material between the endothelial and mesangial cells, a process that is readily identifiable on 
electron microscopy.  
Immunofluorescence studies of glomerular immunoglobulin and C3 in MPGN typically 
demonstrated granular deposition of these immune factors along the capillary loops. 
Staining for IgG is often fainter than it is for complement C3 and is sometimes absent [4 5]. 
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An early study described three immunofluorescence patterns in MPGN: glomerular 
deposition of both immunoglobulin and C3 (66%), predominant deposition of C3 (21%) and 
deposition of C3 only (13%) [4]. The finding of immunoglobulin and complement is 
characteristic of immune complex-mediated glomerular inflammation and suggests that the 
MPGN is secondary to systemic disorders in which there is a propensity for immune-
complexes to deposit or form within the kidney. The known conditions include diseases 
such as autoimmune disorders (e.g. systemic lupus erythematosus), malignancies and 
chronic infections. Hepatitis C, for example, is now recognized as a major cause of mixed 
cryoglobulinemia and MPGN [6]. Where a systemic disorder is identifiable the MPGN is 
referred to as secondary MPGN. In the absence of a clear aetiology MPGN is appropriately 
termed ‘idiopathic or primary MPGN’.  
The finding of glomerular complement deposition alone suggests activation of the 
complement system in the absence of immunoglobulin. This most commonly is a 
consequence of activation of the complement alternative pathway. Perhaps not surprisingly 
we now know that inherited and acquired disorders of the alternative pathway are 
associated with MPGN in which the histological features are characterized by predominant 
or isolated glomerular C3 deposition. The prototypic example of this is dense deposit 
disease. In the 1960s it was recognized that ribbon-like electron dense deposits are 
detectable within the lamina densa of the glomerular basement membrane in some patients 
with glomerulonephritis [7]. These intra-membranous deposits are the histological defining 
feature of dense deposit disease and this, rather than mesangial inter-positioning, produces 
thickening of the GBM. Dense deposit disease is rare: of children whose biopsies 
demonstrate an MPGN pattern by light microscopy, less than 20% have dense deposit 
disease [8 9]. Prominent C3 deposits are virtually always present in the glomeruli of patients 
with dense deposit disease. Granular C3 deposits are almost always present within the 
mesangium, although different patterns have also been observed [8], e.g. “ring-like” pattern 
of mesangial C3 staining. Glomerular C1q and/or immunoglobulins may be seen [10]. Our 
current understanding of dense deposit disease has recently been reviewed [11].  
Since the MPGN in dense deposit disease was associated with distinct immunofluorescence 
studies (predominant or isolated glomerular C3 deposition) and GBM ultrastructural 
appearances (striking linear electron dense transformation of the lamina densa) an MPGN 
classification emerged which sub-divided MPGN initially into two groups: MPGN type I 
and MPGN type II. MPGN type I was characterized by immunoglobulin and C3 deposition 
and sub-endothelial electron dense GBM deposits [5]. MPGN type I contained both primary 
and secondary types. MPGN type II was used to describe dense deposit disease. Hence in 
the literature dense deposit disease was renamed MPGN type II. A further group, MPGN 
type III was subsequently added to describe MPGN where there were prominent 
subepithelial GBM deposits, possibly caused by immune-complexes similar to those found 
in membranous disease [12]. As in membranous disease, the deposits are associated with 
spikes along the GBM that can be detected by silver stain. A further MPGN type III variant 
was characterized by the presence of basement membrane ruptures on electron microscopy 
[13]. C3 deposition is invariably present in the glomeruli of patients with MPGN type III 
whilst immunoglobulin deposition is variable [13]. The traditional classification of MPGN is 
depicted in figure 1.  
Subsequent studies have revealed limitations in this MPGN classification. Firstly, it is now 
recognized that patients with the dense deposit disease may present with many different 





include mesangial proliferative and crescentic lesions [10]. In fact more than half of the 
dense deposit disease biopsies did not show MPGN. The emerging consensus is that dense 
deposit disease is a distinct pathologic entity and should not be thought of as an MPGN 
variant [10 14]. Secondly, we now know that defects in complement regulation are strongly 
associated with glomerular inflammation in which there is isolated glomerular C3 
deposition irrespective of whether the glomerular lesion is MPGN. We discuss the intimate 
























Fig. 1. The traditional classification of MPGN. Dense deposit disease was renamed MPGN 
type II in this classification. Immunofluorescence refers to glomerular staining for 
complement C3 and IgG. GBM – glomerular basement membrane.  
3. Complement and MPGN 
The complement system is an integral component of immunity. Its principal role is 
concerned with host defence against pathogens and it forms an important component of 
innate immunity. Complement also acts as natural adjuvant enhancing the B cell response to 
antigen and more recent data implicates an important role for complement in T cell 
responses [15]. To understand the relationship between MPGN and complement it is 
important to understand how complement is activated. Binding of antibody to antigen 
forms an immune complex and immune complexes are the triggers of the complement 
classical pathway. In immune-complex associated MPGN the classical pathway is activated 
and contributes to glomerular inflammation. The complement alternative pathway is 
continuously activated i.e. requires no specific activating trigger. Unlike the classical 
pathway, the alternative pathway is antibody-independent and, through this pathway, the 
key effector molecules of the pathway (C3 and C5) can be deposited on surfaces in the 
absence of immunoglobulin. The key negative regulator of the alternative pathway is an 
abundant plasma protein called complement factor H (CFH). Early investigators studying 
MPGN hypothesized that MPGN lesions in which complement components such as C3 were 
present in the absence of immunoglobulin, were mediated by alternative pathway 
activation. We now know that both inherited and acquired causes of alternative pathway 
regulation are associated with this type of MPGN. Dense deposit disease, in which 
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glomerular C3 deposition is typically seen with little or no immunoglobulin, is associated 
with genetic and acquired factors that enhance alternative pathway activation (reviewed in 
[11]). C3 nephritic factor was associated with dense deposit disease decades ago [14] and the 
‘factor’ is now known to be an immunoglobulin which targets an enzyme complex within 
the alternative pathway. This autoantibody stabilizes the enzyme complex and enhances 
alternative pathway activation. Hence C3 nephritic factor is associated with over-activation 
of the alternative pathway. Consequently, through consumption, plasma C3 levels are 
typically low in individuals with C3 nephritic factor. Genetic factors include genetic 
deficiency of the alternative pathway regulatory protein, CFH (reviewed in [16]) and ‘gain 
of function’ mutations in the alternative pathway activation protein, complement C3 [17].   
Genetic deficiency of CFH in pigs and gene-targeted CFH-deficient mice also results in 
spontaneous MPGN [18 19]. Acquired dysregulation of the alternative pathway due to 
neutralizing autoantibodies against CFH [20] has also been described.  Recently, an 
autoantibody to factor B, an activation protein within the alternative pathway, has also been 
associated with MPGN [21]. In summary factors that increase alternative pathway activation 
have been associated with MPGN in which there is glomerular C3 with little or no 
immunoglobulin. It is clearly important to distinguish MPGN driven by these factors from 
MPGN associated with systemic immune complex disease or MPGN due to other 
aetiologies. Consequently, there has been much discussion on how to develop our current 
classification of MPGN.   
4. C3 glomerulopathy – moving away from the traditional classification of 
MPGN 
In order to identify individuals with inherited or acquired defects in complement 
regulation we proposed a classification called C3 glomerulopathy (Figure 2) [22]. C3 
glomerulopathy defines glomerular pathology characterized by isolated or predominant 
glomerular C3 deposition in the absence of immunoglobulin irrespective of both the 
glomerular light microscopic appearances and the ultrastructural appearance of the GBM 
[22]. Whilst many patients with isolated glomerular C3 deposition and complement 
abnormalities develop MPGN some do not [23 24]. For example, Servais and colleagues 
described 19 cases of primary glomerulonephritis cases with isolated deposition of C3 in 
the absence of morphological GBM changes of dense deposit disease [24]. Thirteen cases 
had an MPGN pattern by light microscopy whilst the remaining 6 did not [24]. They used 
the term ‘C3 glomerulonephritis’. Recently a familial C3 glomerulopathy associated with a 
mutation in a complement protein called complement factor H-related protein 5 (CFHR5) 
was characterised [23]. Affected individuals have renal biopsies consistent with C3 
glomerulonephritis. Biopsies show mesangial C3 deposition and variable degrees of 
mesangial hypercellularity. Mesangial and sub-endothelial GBM electron dense deposits 
are typical and some develop MPGN. These patients were identified and specifically 
investigated for complement disorders because renal biopsies demonstrated glomerular 
C3 deposition in the absence of immunoglobulin. The discovery of CFHR5 nephropathy is 
fascinating and we direct the interested reader to [25].  The impetus to propose the term 
C3 glomerulopathy was to enable the rapid identification of patients with glomerular 
disease who ought to be investigated for complement abnormalities and who may benefit 
from complement modulating therapeutic strategies. The relationship between C3 
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In summary the traditional MPGN classification has become outdated due to advances in 
our understanding of complement-mediated glomerular inflammation and our knowledge 
of the histopathological spectrum of dense deposit disease. Nevertheless, in reviewing 
historical studies the use of the traditional MPGN sub-groups is unavoidable. In the next 
sections we have used the traditional sub-groups acknowledging that the reader will now be 
aware of the limitations of this classification. The recent descriptions of C3 
glomerulonephritis and CFHR5 nephropathy are discussed separately.  
5. Clinical features of MPGN 
MPGN commonly presents with the nephritic syndrome (microscopic hematuria, non-
nephrotic proteinuria, and renal insufficiency). However, up to one third of the patients 
present with relatively preserved renal function and the nephrotic syndrome [27]. The 
spectrum of clinical findings is generally the same for all of the subgroups considered in this 
review, but some differences exist and are discussed under individual headings below. 
MPGN type I 
MPGN type I may be more common in children than in adults [28]. It typically presents as a 
renal limited disease, although many patients have hypertension at the time of diagnosis 
[29]. Hypertension may be less common in children [29], particularly when the disease is 
detected early through screening of asymptomatic individuals. The majority of patients 
have microscopic hematuria, and some have macroscopic haematuria [29]. Cameron 
reported that 75% of their patients with MPGN type I had normal C3 levels at the time of 
disease onset [29]. In an analysis of 9 patients with MPGN type I, however, Ooi and 
colleagues reported depressed C3 levels for all of the patients on at least one occasion [30]. 
Approximately 30% of patients have a C3 nephritic factor [29 30]. C4 levels were low for 
some of the patients.  
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review, but some differences exist and are discussed under individual headings below. 
MPGN type I 
MPGN type I may be more common in children than in adults [28]. It typically presents as a 
renal limited disease, although many patients have hypertension at the time of diagnosis 
[29]. Hypertension may be less common in children [29], particularly when the disease is 
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MPGN type II/Dense deposit disease 
Dense deposit disease usually presents in children between the ages of 5 and 15 [14], 
although a recent series included more patients diagnosed in adulthood than in childhood 
(12). There appears to be a slight female to male preponderance [31]. The clinical 
presentation is similar to that of MPGN type I. MPGN type II usually presents with the 
nephritic syndrome [28], but proteinuria is usually present and is in the nephrotic range 
in approximately 50% of patients [31]. Interestingly, the renal disease is often preceded by 
an infection [31]. More than 80% of patients with dense deposit disease have 
hypocomplementemia at some point [29], and 100% of children with the disease had 
depressed C3 levels in the report of Nasr et al. [31]. Approximately 80% of patients with 
dense deposit disease have detectable C3 nephritic factor [32]. As described above, dense 
deposit disease is strongly associated with defects in regulation of the alternative pathway 
of complement. This underlying defect probably explains the association of dense deposit 
disease with acquired partial lipodystrophy [33] and with retinal drusen (deposits within 
Bruch’s membrane of the retina) [34]. In acquired partial lipodystrophy, uncontrolled 
complement activation causes the loss of subcutaneous fat. The drusen resemble those 
seen in patients with age related macular degeneration and presumably also form as a 
result of defective complement regulation. However, only one patient with each of these 
co-morbidities was described in a recent report of 32 patients with dense deposit disease 
[31].  
MPGN type III 
MPGN type III usually presents with similar clinical findings to those seen in MPGN type I. 
The proportion of patients with hypocomplementaemia was comparable to that of MPGN 
type I [35].  
C3 glomerulonephritis 
C3 glomerulonephritis is a recently described entity so the full spectrum of its clinical 
manifestations is not yet known. Servais et al. reported a series of 19 patients [24]. Men and 
women were represented nearly equally, and the patients ranged in age from 7 years old to 
70. Sethi et al. recently reported three more cases of C3 glomerulopathy [36], all of whom 
were adult males (aged 38-73). Approximately 30% of the patients in the two reports had a 
creatinine clearance below 60 ml/min. Most of the patients had proteinuria (eight of the 22 
patients described had nephrotic range proteinuria) and 15 patients had hematuria [24 36]. 
A comprehensive evaluation of the complement system was performed in both reports. 
Nine of the 22 total patients had depressed C3 levels.  Six patients in the first series had C3 
nephritic factor, and one of the patients reported by Sethi et al. had C3 nephritic factor. 
Mutations in complement regulatory proteins were identified in six of the patients reported 
by Servais et al. [24]. The three patients reported by Sethi et al. all carried the Tyr402His allele 
of CFH which has been identified as a risk allele for dense deposit disease [36]. 
CFHR5 nephropathy 
CFHR5 nephropathy is a familial form of C3 glomerulopathy that has to date only been 
described among individuals with Cypriot ancestry. It was characterized only recently [23 
25]. Affected individuals all carry a mutation in CFHR5 and to date only heterozygous 
affected individuals have been identified. The biological role of CFHR5 is unknown 
although there is evidence that it interacts with complement deposited within the glomeruli 





internal duplication in exons 2 and 3 of the CFHR5 gene. This results in a secreted 
abnormally large CFHR5 protein. The clinical course of CFHR5 nephropathy has been 
described in a comprehensive review of 91 patients from 16 pedigrees [39]. Affected patients 
have continuous microscopic haematuria and often develop macroscopic haematuria during 
periods of infection. Hypertension, proteinuria and end-stage renal failure are more 
common in men. In this report of affected individuals aged over 50 years, 80% of affected 
men developed chronic renal failure whilst 21% of affected women developed chronic renal 
failure [39]. The condition recurs in the transplanted kidney [40].   
6. Prognostic considerations in MPGN 
As highlighted in the above discussion, many of the patients who were previously identified 
simply as having MPGN are now recognized as having distinct disease processes. 
Consequently, older data regarding the prognosis of MPGN may have combined patients 
who would now be categorized differently. For example, early studies of MPGN may well 
have included patients with dense deposit disease due to defective complement regulation 
or patients with secondary MPGN caused by hepatitis C associated cryoglobulinemia.  
MPGN type I 
Studies of patients with MPGN type I have reported fairly wide variation in the long-term 
prognosis of the disease. The 10-year renal survival for children has been reported to be  
60-80% [41 42]. The patients included in these studies were treated with corticosteroids  
and other immunosuppression. The prognosis may be improved by early detection, such  
as that afforded by screening of school children [43]. This improvement could be due to  
lead-time bias, however. Adverse prognostic features include nephrotic syndrome [32 44],  
an elevated creatinine at presentation or within the first year, and structural injury on the renal 
biopsy [44]. 
MPGN type II/Dense deposit disease 
The prognosis of dense deposit disease may be worse than that for MPGN type I [8 9 29], 
although the small numbers of patients with each disease make it difficult to control for 
other variables. Spontaneous remissions of dense deposit disease are rare, and 
approximately 50% of patients will reach end-stage renal disease within 10 years [29]. Of the 
27 patients in the report by Nasr et al. for whom follow-up was known, 25.9% had a 
complete response to therapy. There was no response in the remaining patients and 25.9% 
progressed to end-stage renal disease (duration of follow-up 2 months to 24 years) [31]. Age 
and the serum creatinine at biopsy were predictive of progression to end-stage renal disease. 
Only 7.1% of the adults had a complete response to therapy. Although uncontrolled 
complement activation is believed to be pathogenic in this disease, perturbations in C3 
levels do not appear to correlate with clinical outcomes [29 31]. Recurrence in renal 
allografts is common [31 45]. 
C3 glomerulonephritis 
During the period of follow-up (ranging from 0.4 – 34 years) in the series reported by 
Servais et al. [24], most of the patients had a decline in renal function. Three patients reached 
end stage renal disease, and another two patients had creatinine clearances below 15 
mL/min. The patients described by Sethi et al. did not show a decline in renal function 
during the short period of follow-up (6 months to 3 years) [36].  
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seen in patients with age related macular degeneration and presumably also form as a 
result of defective complement regulation. However, only one patient with each of these 
co-morbidities was described in a recent report of 32 patients with dense deposit disease 
[31].  
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The proportion of patients with hypocomplementaemia was comparable to that of MPGN 
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manifestations is not yet known. Servais et al. reported a series of 19 patients [24]. Men and 
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were adult males (aged 38-73). Approximately 30% of the patients in the two reports had a 
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A comprehensive evaluation of the complement system was performed in both reports. 
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or patients with secondary MPGN caused by hepatitis C associated cryoglobulinemia.  
MPGN type I 
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60-80% [41 42]. The patients included in these studies were treated with corticosteroids  
and other immunosuppression. The prognosis may be improved by early detection, such  
as that afforded by screening of school children [43]. This improvement could be due to  
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27 patients in the report by Nasr et al. for whom follow-up was known, 25.9% had a 
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progressed to end-stage renal disease (duration of follow-up 2 months to 24 years) [31]. Age 
and the serum creatinine at biopsy were predictive of progression to end-stage renal disease. 
Only 7.1% of the adults had a complete response to therapy. Although uncontrolled 
complement activation is believed to be pathogenic in this disease, perturbations in C3 
levels do not appear to correlate with clinical outcomes [29 31]. Recurrence in renal 
allografts is common [31 45]. 
C3 glomerulonephritis 
During the period of follow-up (ranging from 0.4 – 34 years) in the series reported by 
Servais et al. [24], most of the patients had a decline in renal function. Three patients reached 
end stage renal disease, and another two patients had creatinine clearances below 15 
mL/min. The patients described by Sethi et al. did not show a decline in renal function 
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As mentioned above the course of this condition is more severe in males. In affected 
individuals aged over 50 years the incidence of end-stage renal failure was 78% in men and 
22% in women [39]. 
7. Therapeutic approaches to MPGN 
Given the distinct mechanisms of glomerular injury between immune-complex-mediated 
MPGN and the primary complement-mediated MPGN groups, evidence of treatment 
efficacy in one group may not be applicable to the other. However, for both groups non-
specific therapies may be beneficial at slowing the progression of renal disease. The blood 
pressure should be rigorously controlled, and ACE inhibitors or angiotensin receptor 
blockers are probably agents of choice [46]. Complications of the nephrotic syndrome, such 
as hyperlipidemia, should be treated. 
MPGN type I 
As this is a disease of immune-complex deposition, there is a rationale for treating this disease 
with immunosuppression. Unfortunately, there is not conclusive evidence that any of the 
common treatments are effective.  Perhaps the best study to date was a randomized controlled 
trial of alternate day prednisone that included 41 children with MPGN type I [47]. The patients 
had high-grade proteinuria or renal impairment, and renal survival was better in the group 
that received steroids. Although this difference did not reach significance (P = 0.07), the 
authors concluded that this was due to the small number of patients. Other uncontrolled 
studies further support the finding that long-term treatment with corticosteroids may be 
effective at inducing disease remission [9 48 49]. One of these studies included patients with 
diffuse lesions on their biopsies, but who were detected early through school-based screening 
[49]. These patients were treated with alternate day steroids, and all of the patients but one 
was treated for at least four years. Of 19 patients evaluated, four patients had persistent mild 
proteinuria but only one patient had a disease relapse (successfully treated with a second 
course of steroids). Other case series have not shown improved outcomes in patients who 
received steroids. In one such study, however, the authors determined that patients who 
received steroids were more likely to have had the nephrotic syndrome [44]. They concluded, 
therefore, that steroids may, in fact, have been beneficial. After analyzing the available data, 
Levin concluded that corticosteroids are indicated for children with nephrotic syndrome or 
with renal insufficiency [50], but the optimal criteria by which patients should be stratified for 
treatment are still under debate [44].   
Similarly, some studies have suggested a benefit of treatment with anti-platelet agents [51 
52]. A randomized, controlled trial of aspirin and dipyridamole, for example, indicated that 
treatment with these agents was effective at preserving renal function [51]. However, a long-
term follow-up study that examined renal survival in these patients from the time of 
diagnosis (not from the start of treatment) did not see a sustained benefit [53]. Another 
randomized trial of patients demonstrated that aspirin plus dipyridamole was effective at 
reducing proteinuria at 36 months [54]. The serum creatinines in both groups were 
unchanged, however, so the effect of this treatment on the progression of renal disease 
remains uncertain. 
Several case series and case reports have described patients treated with other 





The patients treated with these agents are probably selected because they have concerning 
prognostic factors. Thus, it is difficult to determine the efficacy of these agents. Case reports 
have also described patients with steroid-resistant MPGN type I who responded to 
mycophenolate mofetil [57 58]. Certainly more data is needed, but given the relative safety of 
this medication it is a reasonable choice for patients who do not respond to steroids.  
Approximately 30-60% of patients with MPGN type I who undergo renal transplantation 
have a recurrence of the disease, and disease recurrence adversely affects graft survival [59 
60]. Although there are anecdotal reports that increasing immunosuppression may be 
beneficial, there is no well established therapy for recurrent disease [60].  
MPGN type II/Dense deposit disease 
No clinical trials have been conducted in patients with dense deposit disease. Based upon 
what is known about the pathophysiology of the disease, the complement inhibitor 
eculizumab may be beneficial, and a clinical trial of this agent in dense deposit disease is 
currently underway. Eculizumab is a monoclonal antibody that blocks C5 activation and is 
currently licensed for treatment of anemia in paroxysmal nocturnal haemoglobinuria. It has 
been used successfully to treat atypical haemolytic uraemic syndrome and is likely to be 
licensed for this indication soon. 
Plasma exchange may be effective at removing autoantibodies or dysfunctional complement 
components, while also enhancing CFH function through the infusion of plasma. Plasma 
exchange was reported to be effective in two affected sisters who had a factor H mutation 
and C3 nephritic factor [61].   
The role of immunosuppressive agents in dense deposit disease is uncertain. Theoretically, 
immunosuppressive drugs may be beneficial in patients with evidence of autoantibodies, 
yet corticosteroids are not of clear benefit in this disease [14]. The patients reported by Nasr 
et al. included 18 patients who received immunosuppression [31]. The immunosuppression 
regimens included steroids in all patients. Two patients were also treated with 
mycophenolate mofetil and three received calcineurin inhibitors. A trend towards a benefit 
was seen in patients treated with immunosuppression but this did not reach significance. 
The greatest benefit was seen in those who received immunosuppression and a renin-
angiotensin system inhibitor. Recently, a patient with fulminant disease was treated with 
high-dose corticosteroids, plasma exchange, and cyclophosphamide, and apparently 
responded to treatment [62]. This patient had a low C3 level, but did not have C3 nephritic 
factor or a complement mutation, so the mechanism by which the treatment benefited the 
patient is difficult to infer.  
Based on existing data, the optimal treatment of patients with dense deposit disease is 
uncertain. A treatment algorithm incorporating complement testing and the above 
treatment options has been proposed [63]. Treatment may need to be initiated before genetic 
testing can be performed, however, and the presence or absence of C3 nephritic factor is 
probably not sufficiently accurate to guide therapy. Thus, the decision to use plasma 
exchange, standard immunosuppressive drugs, and/or eculizumab must ultimately be 
made based on the clinical severity of the disease.  
Recurrence of MPGN type II is very common in patients who receive renal transplants, and 
some estimate the recurrence rate is 100% [60]. Graft survival at 5 years is approximately 
50%, and the most common cause of graft loss is recurrent disease [64]. The impact of more 
aggressive (e.g. peri-transplant plasma exchange) or newer therapies (e.g eculizumab) 
remain unknown.  
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licensed for this indication soon. 
Plasma exchange may be effective at removing autoantibodies or dysfunctional complement 
components, while also enhancing CFH function through the infusion of plasma. Plasma 
exchange was reported to be effective in two affected sisters who had a factor H mutation 
and C3 nephritic factor [61].   
The role of immunosuppressive agents in dense deposit disease is uncertain. Theoretically, 
immunosuppressive drugs may be beneficial in patients with evidence of autoantibodies, 
yet corticosteroids are not of clear benefit in this disease [14]. The patients reported by Nasr 
et al. included 18 patients who received immunosuppression [31]. The immunosuppression 
regimens included steroids in all patients. Two patients were also treated with 
mycophenolate mofetil and three received calcineurin inhibitors. A trend towards a benefit 
was seen in patients treated with immunosuppression but this did not reach significance. 
The greatest benefit was seen in those who received immunosuppression and a renin-
angiotensin system inhibitor. Recently, a patient with fulminant disease was treated with 
high-dose corticosteroids, plasma exchange, and cyclophosphamide, and apparently 
responded to treatment [62]. This patient had a low C3 level, but did not have C3 nephritic 
factor or a complement mutation, so the mechanism by which the treatment benefited the 
patient is difficult to infer.  
Based on existing data, the optimal treatment of patients with dense deposit disease is 
uncertain. A treatment algorithm incorporating complement testing and the above 
treatment options has been proposed [63]. Treatment may need to be initiated before genetic 
testing can be performed, however, and the presence or absence of C3 nephritic factor is 
probably not sufficiently accurate to guide therapy. Thus, the decision to use plasma 
exchange, standard immunosuppressive drugs, and/or eculizumab must ultimately be 
made based on the clinical severity of the disease.  
Recurrence of MPGN type II is very common in patients who receive renal transplants, and 
some estimate the recurrence rate is 100% [60]. Graft survival at 5 years is approximately 
50%, and the most common cause of graft loss is recurrent disease [64]. The impact of more 
aggressive (e.g. peri-transplant plasma exchange) or newer therapies (e.g eculizumab) 
remain unknown.  
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MPGN type III 
Patients with MPGN type III do not seem to respond as well to corticosteroids as do those 
with type I disease as assessed by disease relapse and estimated GFR [35]. Thus, other than 
non-specfic therapies there is scant evidence to guide the treatment of these patients.  
C3 glomerulonephritis 
In the series by Servais et al., five of the patients were treated with steroids [24]. The authors 
reported that there was no clear effect of treatment on the disease outcomes. The patients 
reported by Sethi et al. were treated conservatively (no patients received 
immunosuppression), and no deterioration in renal function was seen during the period of 
follow-up [36]. Thus, based upon the available data there is little evidence to support 
immunosuppression in these patients.  
CFHR5 nephropathy 
The optimum treatment for CFHR5 nephropathy presently remains unknown. There are 
theoretical grounds to investigate the utility of eculizumab in this condition e.g. during 
disease flares. The relationship between renal decline and infective episodes in CFHR5 
nephropathy implies that immunosuppressive strategies may be a potentially harmful 
approach.  
8. Conclusions 
MPGN is a fascinating glomerular pathology. We have made significant progress in 
understanding the role of complement in MPGN. There are limitations to the traditional 
histological classification. Dense deposit disease should not be referred to as MPGN type II 
since many patients with dense deposit disease do not have MPGN. C3 glomerulopathy is a 
new term which encompasses glomerular pathologies in which there is isolated or 
predominant deposition of glomerular C3. C3 glomerulopathy includes dense deposit 
disease and C3 glomerulonephritis. The most recent addition is CFHR5 nephropathy. 
Individuals with C3 glomerulopathy should be investigated for complement dysregulation 
and represent logical patient populations in which to explore the efficacy of complement 
modulating therapies.   
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1. Introduction 
IgA Nephropathy (IGAN) is also called mesangial IgA glomerulonephritis and was first 
described by Jean Berger, a French general pathologist, in 1968 in the journal d’Urologie-
Néphrologie [1, 2]. Many reviews have been written on the subject [3, 4, 5]. 
2. Definition [3, 4, 5] 
The definition is histopathologic with the characteristical deposition of the 
immunoglobulin A in the renal mesangium: these deposits are predominant (or 
codominant with other immunoglobulins, IgG and/or IgM), granular, coarse (with the “en 
mottes” aspect), generalized in the glomerulus and diffuse to all glomeruli. These deposits 
are evidenced usually by the technique of direct immunofluorescence on a semi-quantitative 
scale: traces (+/-), 1+, 2+, and ≥ 3+. There is a general agreement to accept at least 1+ IgA 
deposits for the definition. 
By contrast, the lesions observed by light microscopy are often segmental and focal. The main 
lesions concern the mesangium with increased matrix and hypercellularity with in addition 
endocapillary proliferation. The most severe lesions are represented by obsolescent glomeruli 
(“pains à cacheter”), focal and segmental glomerulosclerosis (FSGS) with capsular adhesions, 
and extracapillary proliferation with the formation of cellular/hyalinized crescents. 
3. The IgA nephritides [3, 4, 5] 
The deposition of mesangial IgA has been observed in different types of glomerulonephritis 
leading to the classification of Primary IgA nephropathy (Berger’s disease) versus the 
Secondary IgA nephropathies: associated to Schönlein-Henoch Purpura, to patent 
Alcoholic Liver Cirrhosis, to Systemic lupus Erythematosus, or to Ankylosing 
Spondylarthritis. Primary disease represents at least 80 % of the cases.  
4. Epidemiology [3, 4, 5] 
Primary IGAN is worldwide the most frequent glomerulonephritis; it accounts for about a 
quarter of the percutaneous renal biopsies performed on native kidneys. In France, the 
incidence is about 30 new cases per million inhabitants (pmp) and its prevalence is closed 
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to 1000 pmp according to the disease duration from onset to dialysis or to last follow-up 
(from few months to more than 5O years). All these numbers are of course dependent of the 
“politic” of renal biopsy: liberal indication or restricted to the most severe cases with already 
proteinuria over 1g/day or already some degree of renal insufficiency (Glomerular 
Filtration Rate <60 ml/mn/1.73 m² body surface area). 
The disease is more frequent in men than in women, about 70% males, in most continents 
except in Asia. Age at onset ranges from 5 years to 75 with a peak frequency in adolescents 
and young adults. 
 
 
Fig. 1. HistoPathology of IgA Nephropathy: 
(a) Light microscopy showing one glomerulus with segmental  increased in mesangial 
matrix and mild hypercellularity. 
(b) Immunofluorescent microscopy showing diffuse IgA deposits in all glomeruli. 
(c) Immunofluorescent microscopy showing generalized mesangial IgA deposits within all 
the glomerulus surface/volume. 
5. Mode of onset/initial presentation [3, 4, 5] 
The onset of the disease can be acute/subacute in about 30 to 35 % of the patients with the 
classical intra-infectious gross haematuria: at time of an infectious episode of various 
origin (pharyngitis, bronchitis, or even intestinal or urinary infection), the patient is 
urinating blood  with colored urine, more brown than red with a color of coffee or coca-
cola; this is a total haematuria (sometimes with loin pain) which lasts from few hours to 
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few days; there is no clot and the characteristics of this gross haematuria is nephrological 
with the presence on urine cytology of typical red blood cell casts. After such an episode, 
the patient is usually presenting microscopic haematuria or could be in total remission 
until the next episode. 
The discovery can be chance proteinuria or chance microscopic haematuria at time of 
systemic  urine control for medical check-up at school, at different institutions or at work; 
the time of onset is therefore imprecise and we should refer to the last negative control if 
any. 
The disease can be diagnosed later on with arterial hypertension (HT) and/or oedema 
and/or chronic kidney disease stage 3 or up (CKD-3+). 
6. Progression of the disease [6-12] 
Overall, IGAN is a progressive disease both clinically and pathologically. The clinical 
progression starts with urine abnormalities, followed by occurrence of HT, sometimes 
oedema related to massive proteinuria or nephrotic syndrome, and later on occurrence of 
CKD-3 through CKD-5 and ultimately renal death necessitating chronic dialysis. The 
progression is also pathological and this was demonstrated by repeated renal biopsies 5 
years later [6, 13]: it was shown that the global optical score (GOS) progressed in the 
majority of the patients with increased glomerular but also vascular and tubular/interstitial 
indices. 
We are taking as example our prospective cohort of primary IGAN patients [12] whose 
diagnostic biopsy was performed between January 1st 1990 and December 31st 1999 at our 
institution with loco-regional patients coming from the Saint-Etienne area, the IGAN-STET-
CO. This cohort is composed of 332 patients (237 men, 71.4 %) with a mean age of 35.9 at 
onset, 41.4 at diagnosis and 48.8 years at dialysis/death or at last follow-up visit. The total 
exposure time was about 13 years. Overall, 32 patients needed dialysis, 13 died before 
reaching dialysis, and 45 (13.6 %) reached the primary composite outcome while 99 (29.8 %) 
presented the secondary outcome (CKD-3+). 
7. Predictive risk factors and the absolute renal risk of dialysis/death: A new 
concept [12] 
One very important goal was to sort out the major and independent risk factors (RF), 
present at diagnosis, able to predict accurately the ultimate final prognosis (dialysis or death 
as primary end-point). From the literature, we already know that the amount of proteinuria 
(g per day), the occurrence/presence of HT, and the severity of renal lesions on the initial 
biopsy were associated with progression [6-11]. Many other risk factors were also described 
such as gender, overweight/obesity [14], metabolic syndrome, age at onset [15], 
hypertriglyceridemia/hyperuricemia [16], and also different immunogenetic markers (HLA 
antigens, different cytokines polymorphisms [17, 18],…) but they were not consistent or 
controversial in different published cohorts. We recently confirmed [12] that these 3 major 
risk factors were sufficient to cover the whole prediction in our cohort. These risk factors 
were simplified, dichotomized for easier use and shown to be independent predictors in a 
multivariate model of Cox regression: - the most important is the presence of HT (Yes or 
No) defined according to WHO (≥ 140/90); - the next is the presence of Proteinuria ≥ 1g/d 
(Yes or No); and - the last is the scoring of the renal lesions; we have used our own global 
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optical score (GOS) developed 20 years ago and integrating all elementary lesions 
(glomerular from 0 to 6, vascular from 0 to 5, tubular from 0 to 4, and interstitial from 0 to 5) 
with a GOS up to 20. We set up by ROC analysis that the best cut-off for predicting dialysis 
was the presence of GOS ≥ 8 (Yes or No). These 3 RF turned out to have a similar weight in 
the prediction of dialysis/death by the different accuracy parameters and also by the Cox 
regression (β/SE ratio of the same magnitude). 
In analogy to the absolute cardio-vascular risk (ACVR) of death or major CV events at 10 
years [19, 20], we proposed the Absolute Renal Risk of Dialysis/Death; this ARR is 
calculated at diagnosis and is very simply the number of these RF present: 0, 1, 2 or 3. By 
Kaplan-Meier survival curves, we could calculate the cumulative rate of primary event at 10 
and 20 years after onset (time zero); it was respectively 2 and 4 % for ARR=0; 2 and 9 % for 
ARR=1; 7 and 18 % for ARR=2; and 29 and 64% for ARR=3. 
In addition, this ARR integrates gender (less RF for women), age at diagnosis (more RF for 
older patients), and also body mass index (more RF in overweight/obese patients). We 
could also use it as prospective with time zero set-up at diagnosis and not at onset; the 
cumulative incidence of dialysis/death 10 years after diagnosis is 4% for ARR=0, 8% for 
ARR=1, 18% for ARR=2, and 68% for ARR=3. It is remarkable to underline the similarity of 
the values obtained 20 y after onset and 10y after diagnosis. 
Distribution of these Risk Factors at time of Diagnosis and at last follow-up (LFU): HT 
was present in 120 patients (36.1%) at diagnosis and in 164 (49.4%) at LFU; Proteinuria 
≥1g/d was present in 100 patients (30.1%) at diagnosis and in only 61 (18.4%) at LFU; and 
GOS ≥ 8 was present in 120 patients (36.1%) at time of diagnosis. The distribution of the 
ARR was as follows at time of diagnosis: 151 patients (45.5%) with ARR=0, 69 (20.8%) with 
ARR=1, 65 (19.6%) with ARR=2, and 47 patients (14.1%) with ARR=3. 
It should be stressed that this cohort is an adequately treated cohort with all RF targeted as 
soon as they were identified: perfect control of blood pressure (target <130/80) with all 
antihypertensive agents; persistent reduction of proteinuria with ACEI and ARBs; and 
prednisolone for severe renal lesions. 
8. Pathological classification of IgA nephropathy 
We have developed our own classification in 1990 [6, 13] with the Global Optical Score 
already described. During the past decades, the classifications of Haas [21] or Hass modified 
by Lee [22] were frequently used. The international Oxford classification was published in 
2009 [23, 24] and retained only 4 parameters with significant clinical prediction: - mesangial 
hypercellularity (M score= 0 or 1); - endocapillary hypercellurarity (E score= 0 or 1);  
- segmental glomerulosclerosis (S score= 0 or 1); and - tubular atrophy/interstitial fibrosis  
(T score= 0 or 1 or 2). Overall, the MEST score ranges from 0 to 5. One limitation is that 
patients were only included if proteinuria was ≥ 1g/d in adults and there was no patients  
with ARR=0 who are in fact the majority of the patients; in addition patients with 
extracapillary GN (≥ 50% crescents) were also excluded; the two tails of the IGAN cohorts 
were therefore lacking! 
9. Principles of treatment in IGAN 
The treatment should in fact target all major risk factors when present: hypertension, 
proteinuria, and severe renal lesions. 
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The permanent control of HT is a major step; the goal is to lower BP ≤ 130/80. Sodium 
chloride restriction is recommended with 24 h urinary sodium below 100 mmol/d 
corresponding to a maximum of 6 g daily sodium chloride. All antihypertensive agents can 
be used: diuretics, beta blockers, calcium blockers, central-acting, ACE inhibitors, 
angiotensin-2-receptor blockers (ARBs), and more recently renin inhibitors. However two 
classes have demonstrated a better protection and should be used alone or in association: 
ACEI and ARBs [25, 26]. In our prospective cohort [12], we have demonstrated that survival 
without dialysis/death improved in patients with adequately controlled BP on long term 
[27]. 
The significant reduction of proteinuria is another major step [28]; the reduction can be 
obtained with the use of ACEI and ARBs which have a significant antiproteinuric effect. It is 
recommended to start with either one of these drugs, to titrate the dose to the effect, and to 
use the association in case of resistant proteinuria; the goal is to bring proteinuria ≤ 1g/d  or 
ideally < 0.30 g/d. We have also demonstrated [12] that the permanent reduction of 
proteinuria is associated with a better survival on long-term. 
The treatment of severe renal lesions on the biopsy; this could be achieved by Prednisone 
or Prednisolone treatment [29-31] which should be in theory able to reduce hypercellularity 
and cellular infiltration within the glomeruli; however in the trial, there was no repeated 
biopsies at the end of the steroid therapy. For the most severe cases with extracapillary GN 
(>50 % crescents), the association of high dose steroids and immunosuppressive agents as 
already proposed might be a good option. 
The use of Fish Oil was limited with controversial results [32, 33]. 
We are still in the need of large randomized controlled trials with a long duration (5 years 
seems optimal) to draw definite conclusions on the treatment of IGAN. 
10. Pathogenesis and patho-physiology of primary IgA nephropathy 
Very significant progress has been made during the last decades. The key protein in this 
disease is the immunoglobulin A and more precisely the subgroup 1; in fact IgA1 is 
deposited in the mesangium but not IgA2 [34]. The major difference between IgA1 and IgA2 
is the presence of an hinge region in IgA1 composed of 23 aminoacids with usually five 
sugar side chains linked to threonin or serin. There is now a consensus [35-39] about the fact 
that the main difference between IgA1 in Controls and in IGAN patients is the hypo-
galactosylation of these  glycosylated side chains. The normal complete sugar chain is  
O-linked to threonine or serin and composed of one molecule of N-acetyl galactosamine 
(GalNac) and one molecule of Galactose; in addition a molecule of sialic acid can be  
bound in terminal to Galactose or in lateral to GalNac. In IGAN, more side chains are 
truncated with loss of terminal Galactose with its terminal sialic acid and is referred to the 
Galactose-deficient IgA1 (deGal-IgA1). This deGal-IgA1 represents the specific autoantigen 
in this disease and is present in the serum, within the circulating immune complexes and in 
the mesangial deposits [40]. This loss in terminal galactose is associated with a down-
regulation of the gene controlling the linkage of galactose to GalNac, C1GALT1 [41] and the 
description of specific polymorphism [42] raising the possibility of genetic predisposition 
[43]. 
The loss of terminal galactose unusually exposed the GalNac molecules, which become 
antigenic with elicitation of a specific antibody response [44, 45]: IgG and/or IgA anti O-
GalNac, the specific auto-antibodies. It is now possible to measure the amount of circulating 
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galactosylation of these  glycosylated side chains. The normal complete sugar chain is  
O-linked to threonine or serin and composed of one molecule of N-acetyl galactosamine 
(GalNac) and one molecule of Galactose; in addition a molecule of sialic acid can be  
bound in terminal to Galactose or in lateral to GalNac. In IGAN, more side chains are 
truncated with loss of terminal Galactose with its terminal sialic acid and is referred to the 
Galactose-deficient IgA1 (deGal-IgA1). This deGal-IgA1 represents the specific autoantigen 
in this disease and is present in the serum, within the circulating immune complexes and in 
the mesangial deposits [40]. This loss in terminal galactose is associated with a down-
regulation of the gene controlling the linkage of galactose to GalNac, C1GALT1 [41] and the 
description of specific polymorphism [42] raising the possibility of genetic predisposition 
[43]. 
The loss of terminal galactose unusually exposed the GalNac molecules, which become 
antigenic with elicitation of a specific antibody response [44, 45]: IgG and/or IgA anti O-
GalNac, the specific auto-antibodies. It is now possible to measure the amount of circulating 
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autoantigen and autoantibodies in patients sera and to discriminate between Controls and 
IGAN patients [46, 47]. 
The mesangial deposition of deGal-IgA1 is dependent on physical characteristics of this 
molecule (more sticky) and the presence of transferrin receptor (CD71) which is able to bind 
IgA1 variants [48]. After binding, the deGal-IgA1 and the deposited immune complexes are 
able to activate the different mediators of inflammation both cellular [49] and in fluid phase.  
There is also the CD89 system [50] that we personally consider as an amplification loop. This 
is a specific receptor for IgA1 variants, FcαRI, present on circulating monocytes but not in 
the mesangium; this receptor is able to bind immune complexes with further amplification 
and longer persistence in the circulation, and may play an additional pathogenic role. 
11. Renal transplantation in patients with biopsy-proven IGAN on native 
kidneys 
In cases which progressed to dialysis, renal transplantation should be a strong option and 
overall the results are similar to the other recipients matched for age and gender. However, 
there are two specific situations which have strong pathogenic implication.  
First, a silent IgA nephropathy can be present on grafted kidney from apparently normal 
donors leading to the discovery of mesangial IgA deposits on graft biopsies performed early 
after transplantation; it was demonstrated in few cases that these deposits can regress and 
disappear demonstrating a contrario that the disease has a systemic (blood) transmission. 
Second, the original disease may reappear (recurrence) on the normal grafted kidney after 
few years and despite immunosuppression [51-59]. The cumulative incidence of clinic-
pathological recurrence is high reaching 35 % or more at 10 years post-transplant [56] and 
may lead to graft losses in up to 17 % at 10 y [57]. The factors associated to recurrence are 
not well understood: living donors, better HLA matching, short duration of the original 
disease, etc. There is yet no specific treatment for the recurrent disease; however in a 
retrospective study [56] we demonstrated that induction treatment with ATG seems able to 
reduce the incidence of recurrence in comparison to no induction or to  induction with 
Basiliximab. A prospective randomized controlled trial comparing rabbit ATG to 
Basiliximab has already started, the PIRAT study: Prevention in IgA nephropathy recipients 
of full Recurrence After renal Transplantation according to induction immunosuppressive 
therapy: ATG versus Basiliximab. It seems now mandatory to carefully measure the serum 
levels of the auto-antigen and the auto-antibodies at time of grafting to check for any 
predicting value of these parameters for recurrence. 
12. Conclusions 
IgA nephropathy is a frequent disease whose individual prognosis can be totally different: 
no significant progression for 50 years versus progression to dialysis in few months or years. 
The clinical challenge is to accurately predict the long term individual prognosis at time of 
diagnosis (at time of the renal biopsy which is still mandatory for this purpose). We have 
made significant progress with our new concept: the Absolute Renal Risk of 
Dialysis/Death (ARR); it takes in account the presence or not of three independent, 
simplified and dichotomous risk factors: - arterial hypertension; - proteinuria ≥1g/d; and 
severe histopathological lesions appreciated by the Global Optical Score ≥ 8 (range from 0 
to 20). The cumulative incidence rate of primary event (dialysis or death) at 10 years post-
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diagnosis, is 4 % for ARR=0; 8 % for ARR=1; 18 % for ARR=2; and 68 % for ARR=3 in our 
prospective cohort adequately treated/managed on long term. 
The pathogenesis of the disease has also made significant progress: it is an auto-immune 
disease with a known auto-antigen, the Galactose-deficient IgA1, which can elicit a specific 
auto-antibody response, IgG and IgA anti-O-GalNac. There is formation of specific immune 
complexes which are circulating and then deposited in the mesangium with creation of the 
disease. These recent findings will have significant future applications in the diagnosis and 
in the treatment. 
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staining of kidney sections the disease is characterized by mesangial deposits of IgA, 
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complement factor C3, properdin and IgG. It is important however to realize that, although 
IgA mesangial deposits are necessary for the diagnosis of IgAN, the latter is not obligatory 
in every individual with mesangial IgA deposits. Thus, IgA deposits may also be seen in 
subjects with no evidence of renal disease [Suzuki et al, 2003; Waldherr et al, 1989] at an 
incidence that ranges from 3 to 16 percent. Furthermore, there are also a number of reports 
documenting IgA deposition in other forms of glomerulonephritis, particularly thin 
basement membrane disease, lupus nephritis, minimal change disease, and diabetic 
nephropathy, a finding which is most probably casual rather than causal. 
IgAN occurs at any age, but most commonly the age of onset is in the second or third 
decade of life. Males are more often affected than females, with a male:female ratio of  2:1. 
Most patients with IgAN present microscopic hematuria with or without mild proteinuria. 
About 40% of patients have episodes of macroscopic hematuria. This is sometimes preceded 
by infections, most commonly upper respiratory tract infections, a phenomenon known as 
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have also been reported to precede macroscopic hematuria. Proteinuria is common and can 
vary from mild proteinuria to nephrotic syndrome.  
IgAN has been considered a benign disease for a long time, but nowadays it is clear that 30-
40% of patients may develop renal failure with significant socioeconomical consequenses. In 
Western Europe and the United States of America 7-10% of the patients on renal 
replacement therapy suffer from IgAN. The severity of histological lesions, especially 
diffuse proliferative glomerulonephritis, marked capsular adhesions, fibrocellular crescents, 
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with poor renal outcome [Schena, 1998]. Next to the gravity of histological lesions, 
unfavourable outcome is associated with persistent hematuria and proteinuria of more than 
1g/day, decreased glomerular filtration rate (GFR) at the time of the diagnosis, and 
hypertension. Although several laboratory tests have been reported to correlate with clinical 
outcome, so far no reliable biomarker has been identified to predict outcome in IgAN. 
Recurrence of IgAN after renal transplantation is common. This finding, along with the 
observation that IgA depositions disappear from a kidney of an IgAN patient, after 
transplantation of this kidney to a non IgAN patient, are suggestive of a rather systemic 
disease.  
2. Genetics of IgAN 
The strongest evidence for the existence of genetic factors in the development and/or 
progression of IgAN comes from descriptions of familial IgAN, largely in white populations 
[Julian et al, 1985], and recent studies suggest that familial and sporadic IgAN may share a 
common pathogenic mechanism and similar outcomes [Izzi et al, 2006]. Τhe genetic 
predisposition may be independent of environmental factors and may reflect an inherited 
susceptibility to develop mesangial glomerulonephritis.  
IgAN does not exhibit classic single-gene Mendelian inheritance pattern [Frimat & Kessler, 
2002]. The complex genetic pattern of IgAN is reflected by the multiple pathways involved 
in its immunopathogenesis, namely multiple discrete immunologic abnormalities related to 
the abnormal overproduction and release of mucosal pIgA1 in the systemic compartment 
and possibly other protein functional abnormalities related to a propensity for mesangial 
deposition of pIgA1. It is therefore probable that the disease-associated genetic variations at 
identified IGAN loci, instead of occuring in the form of “classic” nonsense/missense/splice 
site mutations and deletions/insertions that affect protein structure and function, may be 
rather of the type specific single-nucleotide polymorphism (SNP) alleles in non-coding 
regions or synonymous SNPs in coding regions. The latter function as cis-acting elements 
that alter the transcriptional activity of a disease gene and/or messenger RNA stability and, 
therefore, the expression level of the encoded protein. It is interesting that recent studies 
indicate that 30% to 50% of human genes with coding SNPs can present allelic variation in 
gene expression [Hoogendoorn et al, 2003; Lo et al, 2003]. From this point of view, the most 
comprehensive theory is that several genetic loci contribute significantly to the disease 
susceptibility that underlie the primary immunologic defects observed in IgAN. Each locus 
may occur at a different prevalence rate in different racial/ethnic groups. Variations at these 
major genetic loci may not be sufficient for the development and progression of IgAN and 
the contribution from a potentially large number of modifying genes with modest genetic 
effects but high prevalence is probably needed as well. The various allelic combinations of 
these loci may underlie the different disease phenotypes (disease development and 
progression, nephritic vs. nephrotic clinical presentation, histopathologic subclass, severity 
of disease, responsiveness of proteinuria to angiotensin-converting enzyme [ACE] inhibitors 
and/or angiotensin II receptor blockers [ARBs], etc.) observed in IgAN.  For diseases with 
complex genetic pattern, it has been shown that the optimal analysis approach is the 
combination of linkage, association and sequence approaches. Until now, two basic 
approaches have been used in genetic studies of IgAN: a) genome-wide linkage analysis 
study, a methodology that has been used successfully to identify major 
disease/susceptibility loci, b) candidate-gene association study, mainly used to identify 
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altered genes with modest genetic effects but high prevalence. Recently, a genome-wide 
association study was carried out in cohorts of Chinese and European IgAN patients 
(A.G.Gharawi et al, 2011). Five loci (3 in the major histocompatibility complex at 
chromosome 6p21, a common deletion of CGHR1 and CFHR3 at chromosome 1q32 and one 
locus at chromosome 22q12) were identified. They explain 4-7% of the disease variance. 
2.1 Genome-wide linkage analysis studies 
Genome-wide linkage analysis is used successfully to identify major disease/susceptibility 
genes but has limited power to detect genes of modest effect. Linkage studies involve 
recruitment of families with multiple affected individuals. In a typical whole-genome 
linkage scan, up to 400 microsatellites, or equivalently approximately 10,000 SNP markers, 
equally spaced across the genome, are typed in families to interrogate marker cosegregation 
with a disease phenotype. The advantage of genome-wide linkage studies is that they do not 
require a priori assumption about disease pathogenesis. These studies are very sensitive to 
phenotype misspecification, however their power is limited to detecting rare genetic 
variants with a relatively large effect on the risk of disease.  
Linkage studies of IgAN are faced with multiple challenges. Familial forms of IgAN are 
frequently underrecognized because the associated urinary abnormalities in affected family 
members are often mild or intermittent. Moreover, once familial disease is documented, 
systematic screening by renal biopsy cannot be justified among asymptomatic at-risk 
relatives, necessitating reliance on less accurate phenotypes, such as microscopic hematuria, 
to diagnose affection. Additionally, IgAN has been observed to co-occur in families with 
thin basement membrane disease (TBMD), an autosomal dominant disease caused by 
heterozygous mutations in the collagen type IV genes (COL4A3/COL4A4) [Frasca et al, 
2004]. Short of kidney biopsy or direct sequencing of the very large collagen genes, TBMD 
cannot be reliably excluded among relatives of IgAN patients. Finally, because urinary 
abnormalities may manifest intermittently, one also cannot unequivocally classify at-risk 
relatives as unaffected, necessitating affected-only linkage analysis. The inability to classify 
affected and unaffected individuals accurately is commonly encountered in linkage studies 
of complex traits, leading to decreased study power. Increasing sample size by including 
additional families is also not necessarily helpful in these situations because the diagnosis of 
IgAN likely encompasses several disease subsets, such that expansion to larger sample size 
can paradoxically reduce analytic power due to increased heterogeneity [Durner et al, 1992; 
Cavalli-Sforza & King, 1986].  
To date, four genome-wide linkage studies of familial IgAN have been reported [Gharavi et 
al, 2000; Bisceglia et al, 2006; Paterson et al, 2007, Feehally et al, 2010]. Families in these 
studies have all been ascertained via at least two cases with biopsy-documented IgAN, with 
additional family members diagnosed as affected based on clinical evidence (renal failure or 
multiple documentation of hematuria/proteinuria). In the first study, 30 families with two 
or more affected members were examined [Gharavi et al, 2000]; multipoint linkage analysis 
under the assumption of genetic heterogeneity yielded a peak LOD score of 5.6 on 
chromosome 6q22-23 (locus named IGAN1), with 60% of families linked. The remainder of 
families linked to chromosome 3p24-23 with a suggestive LOD of 2.8. This study 
demonstrated that IgAN is genetically heterogeneous but argued for the existence of a single 
locus with a major effect in some families. In the second genome-wide linkage study 22 
Italian IgAN families were enrolled [Bisceglia et al, 2006] (see section 2.3). The third linkage 
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scan was based on a unique large pedigree with 14 affected relatives (two individuals with 
biopsy defined diagnosis and 12 with hematuria/proteinuria on urine dipstick) [Paterson et 
al, 2007]. Linkage to chromosome 2q36 was detected with a maximal multipoint LOD score 
of 3.47. Most reported linkage intervals did not contain obvious candidate genes, but the 
2q36 locus encompasses the COL4A3 and COL4A4 genes, which are mutated in TBMD. 
Together with the high penetrance of hematuria, this finding suggests that affected 
individuals in the 2q36-linked family may belong to an IgAN subtype that overlaps with 
TBMD. Finally, the fourth genome-wide analysis, carried out in a cohort of IgAN patients 
selected from the UK Glomerulonephritis DNA Bank, the region of the MHC (major 
histocompatibility complex). The strongest association signal included a combination of DQ 
loci and HLA-B. This study suggests that HLA region contains some alleles that predispose 
to the disease in the UK population. In conclusion, four genome-wide linkage studies, 
carried out in four different IgAN patient populations, demonstrate different chromosomal 
traits linked to the disease. 
None of the genes underlying these linkage loci has been identified until now. The 
underlying reasons are numerous, including the phenotyping difficulties discussed above; 
the presence of locus heterogeneity, which limits the ability to precisely map the disease 
interval and find additional linked families to refine loci; the contribution from non-coding 
susceptibility alleles (e.g. point mutations or structural genomic variants within intronic or 
promoter regions), which usually escape detection if mutational screening is confined to 
exonic regions. It is expected that the availability of inexpensive Next-Gen sequencing will 
enable comprehensive interrogation of linkage intervals, facilitating identification of 
disease-risk alleles.  
In addition, future studies of this kind that aim at dissection of increasingly genetically 
homogeneous cohorts must consider the importance of defining distinct clinical subtypes of 
IgAN that may exist within the single pathologic ascertainment criterion currently used to 
diagnose IgAN: light microscopic evidence of mesangial deposits of IgA by 
immunofluorescence. As with all family-based genetic studies, there is a high degree of 
dependency on access to sufficient numbers of clinically well-phenotyped and genetically 
informative cohorts. To address the paucity of cohorts with biopsy-proven IgAN available 
for the conduct of linkage-based, association-based, and sequence-based approaches, the 
European IgAN consortium has published the details of its IgAN Biobank resource [Schena 
et al, 2005]. 
2.2 Candidate-gene association studies 
Candidate-gene association studies examine polymorphisms in only specific genes that are 
selected based on a priori assumption about their involvement in the disease pathogenesis, 
and they are highly sensitive to population stratification, multiple testing, and reporting 
bias. As a result, most candidate-gene association studies in the literature have not been 
replicated [Ioannidis et al, 2001; Hsu SI et al, 2000; Hsu SI, 2001; Frimat & Kessler, 2002], an 
issue which questions the validity and the methodology used in these studies [Hsu & 
Feehally, 2008]. Not surprisingly, candidate-gene studies for IgAN have also been largely 
unrevealing. Many candidate genes have been proposed, but for most of them no solid a 
priori evidence for their involvement in IgAN existed, whereas most were studied in the 
context of IgAN progression rather than causality. Over the last 15 years, there were more 
than 120 candidate-gene association studies for IgAN published in the English literature and 
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indexed on PubMed (e.g., components of the renin-angiotensin-aldosterone pathway, 
mediators of inflammation and/or vascular tone, components of the mesangial matrix, and 
various receptors for polymeric IgA1 expressed in mesangial cells) [Kiryluk et al, 2010]. Of 
these, 39 (31%) studies examined genetic polymorphisms in association with susceptibility 
to IgAN, 40 (32%) examined an association with disease severity, progression, or 
complications, and 44 (35%) examined both susceptibility and risk of progression. Many 
candidate-gene association studies are lacking in functional genetics. 
Approximately one third of all studies involved polymorphisms in the renin-angiotensin-
aldosterone system (RAAS). A widely studied example of the dilemma of repeated non-
replication of results is represented by genetic case-control association studies of the 
angiotensin I–converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism in the 
development and/or progression of IgAN, as well as a whole host of common human 
diseases and conditions, including cardiovascular disease, complications of diabetes such as 
retinopathy and nephropathy, glomerular, tubulointerstitial, and renal cystic renal diseases, 
and even renal allograft survival [Hsu SI et al, 2000; Hsu SI, 2001; Schena et al, 2001]. The 
interest in studying the ACE I/D polymorphism is based on evidence for “biologic 
plausibility.” Rigat and colleagues reported in 1990 that the ACE I/D polymorphism in 
intron 16 of the human ACE gene accounts for half of the variation in serum ACE levels in a 
white study cohort [Rigat et al, 1990], and this is due to the presence of a transcriptional 
repressor element in the I allele [Hunley et al, 1996]. 
There have been numerous population-based studies that either support or refute an 
association between the D allele and progression of renal disease in these conditions [Hsu SI 
et al, 2000; Hsu SI, 2001]. Recent meta-analyses have concluded that the D allele is not 
associated with renal disease progression in patients with IgAN or diabetic nephropathy 
[Schena et al, 2001; Kunz et al, 1998]. Despite more than a dozen generally small genetic 
case-control studies of the ACE I/D polymorphism in both white and Asian IgAN cohorts 
have been done, no definite conclusions can be drawn from them regarding the association 
between the D allele or DD genotype and development and/or progression of IgAN. 
Population-based genetic association studies of other genes encoding proteins in the RAAS 
such as angiotensinogen (AGT) and the angiotensin II type 1 receptor (ATR1), as well as 
renin (REN) and aldosterone synthase (CYP11b2), have also generated conflicting results, as 
have similar studies of the “expanded” RAAS that includes 11b-hydroxysteroid 
dehydrogenase type 2 (11bHSD2) and the mineralocorticoid receptor (MLR) [Poch E et al, 
2001]. In general, the approach has been to genotype a single common polymorphism in 
each gene with the use of polymerase chain reaction/restriction fragment length 
polymorphism (PCR-RFLP). It is remarkable that to date, the role of the RAAS, whose 
components ACE and ATR1 are the targets of ACE inhibitors and angiotensin-II receptor 
blockers (ARB), respectively, has not been convincingly demonstrated by any genetic 
association study. 
In general, most of these studies were of poor quality and severely underpowered and, 
therefore, negative findings were almost universally inconclusive. Overall, the average size 
of case–control cohorts per study was 182 cases and 171 controls. Many studies used ad hoc 
controls derived from unscreened blood donors who were poorly matched to the cases in 
terms of ancestry and geography. The potential impact of confounding by population 
stratification was ignored by the majority of studies, despite the fact that the tools for 
quantification of this problem have been developed. An additional matter of concern is the 
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scan was based on a unique large pedigree with 14 affected relatives (two individuals with 
biopsy defined diagnosis and 12 with hematuria/proteinuria on urine dipstick) [Paterson et 
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issue which questions the validity and the methodology used in these studies [Hsu & 
Feehally, 2008]. Not surprisingly, candidate-gene studies for IgAN have also been largely 
unrevealing. Many candidate genes have been proposed, but for most of them no solid a 
priori evidence for their involvement in IgAN existed, whereas most were studied in the 
context of IgAN progression rather than causality. Over the last 15 years, there were more 
than 120 candidate-gene association studies for IgAN published in the English literature and 
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lack of adequate correction (permutation testing) for multiple, non-independent tests which 
would be anticipated as long as several of these studies tested several hypotheses (multiple 
polymorphisms, multiple phenotypes, or multiple genetic models). Other major problems 
included inadequate or variable SNP coverage of candidate genomic areas, with several 
studies examining only a single polymorphism. Thus far, only one group attempted to 
survey the entire genome, yet the results have not been replicated, are inconclusive and 
difficult to interpret, as long as an underpowered cohort was studied with inadequate 
coverage of ~80,000 SNPs [Obara et al, 2003; Ohtsubo et al, 2005]. Moreover, 77% of all 
published candidate-gene studies reported positive findings, an observation that is likely 
explained by a combination of high rate of false positives and a strong publication bias, 
whereas the statistical effect of the study of the same patient cohorts for multiple 
polymorphisms has never been accounted for in the literature [Kiryluk et al, 2010]. Most 
findings were not reproduced in other populations. None of the above problems is unique 
to the field of IgAN and for these reasons, new general guidelines aimed at improving the 
design and execution of genetic association studies have recently been formulated [von Elm 
et al, 2007; Little et al, 2009]. 
In the post-genomic era, there has been a renewed interest in conducting genetic association 
studies, especially SNP-based, whole-genome association studies, to identify genetic 
variations associated with the development and/or progression of a number of common 
human diseases. This renewed interest reflects the important finding that linkage 
disequilibrium (LD), the phenomenon that particular alleles at nearby sites can co-occur on 
the same haplotype more often than expected by chance [Goldstein, 2001; Wahl et al, 2003] 
is highly structured into discrete blocks separated by hotspots for recombination. The 
haplotype block model for LD has important implications for the way in which genetic 
association studies should now be conducted, and may explain at least in part the problem 
of repeated non-replication of results that has plagued such studies in the past. Based on the 
haplotype block model of LD, the ACE I/D polymorphism is a single marker variant in the 
ACE gene, whereas in unknown yet whether the D allele defines a simple population of 
subjects at risk for disease or not. The lumping of subgroups defined by haplotypes that 
share the D allele may explain at least in part the basis for discrepant reports of genetic 
association with disease. 
Nowadays the common SNP haplotype block model is considered essential for the 
credibility of a study [Couser, 2003] and genetic association studies, especially family based, 
that employ one or more methodologically valid approaches and satisfy the minimum 
rigorous conditions for a reliable genetic association study are viewed as studies with solid 
documentation. These include mainly studies employing biologic plausibility, haplotype 
relative risk analysis to identify statistically significant “at-risk haplotype[s]” associated 
with small P values, use of family-based methodologies, such as the transmission 
equilibrium test (TDT/sib-TDT) or the family-based association test (FBAT) to directly study 
trios/sib-trios and extended families or to verify the absence of significant population 
stratification bias (admixture) inherent in population-based case-control association studies, 
and the study of moderately large i.e., adequately powered] cohorts. To date, very few 
studies examining candidate genes have employed the family-based TDT study 
methodology and/or analysis of “at-risk” haplotypes, reflecting the emergence of the first 
studies to attempt to satisfy minimum criteria for a valid association study.  
A family- and haplotype-based association study employing the TDT methodology has 
shown that 2093C and 2180T SNP variants in the 3’-untranslated region of the Megsin gene 
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were significantly more frequently transmitted from heterozygous parents to patients than 
expected in the extended TDT analysis (increased co-transmission in 232 Chinese families,  
P < 0.001). In addition, haplotype relative risk (HRR) analyses showed that these same SNP 
alleles were more often transmitted to patients (HRR = 1.568, P < 0.014 for the 2093C allele; 
HRR = 2.114, P < 0.001 for the 2180T allele) [Li YJ et al, 2004]. The same group using a 
similar approach recently reported that the Megsin 23167G SNP variant is associated with 
both susceptibility and progression of IgAN in 435 Chinese patients and their family 
members using TDT and HRR analyses [Takei et al, 2006]. The GG genotype was found to 
be associated with severe histologic lesions and disease progression. Megsin is a member of 
the serpin (serine proteinase inhibitor) superfamily that is upregulated in the context of 
mesangial proliferation and extracellular matrix expansion in IgAN, and therefore 
represents a strong candidate gene for susceptibility to IgAN. Lately, the gene encoding 
Cosmc, a C1Gal-T1 chaperone protein which also mediates IgA O-galactosylation was 
studied as a candidate gene involved in the pathogenesis of IgAN but no evidence for a role 
for Cosmc mutations was reported [Malycha et al, 2009].  
2.3 IgAN consortium 
The IgAN Biobank, coordinated by F.P. Schena, contains at minimum 72 multiplex 
extended pedigrees, 159 trios, and 1,068 cases and 1,040 matched controls. All subjects 
enrolled are white and belong to various geographic areas from Germany, Italy, and 
Greece [Schena et al, 2005]. Aiming at a genome wide linkage study, which has been 
considered the most promising approach to identify IgAN susceptibility genes, a group of 
investigators constituted the European IgAN Consortium which was initially funded by 
the European Union. DNA samples of IgAN patients and relatives belonging to 74 
multiple extended pedigrees were collected. Moreover, 166 trios (affected sons or 
daughters and their healthy parents), 1,085 patients with biopsy-proven IgAN and 1,125 
healthy subjects were included in the Biobank. In combination with linkage analysis, 
family based candidate gene association studies were also applied in an efford to discover 
responsible genes and overcome obstacles inherent the genetic analysis of complex traits 
such as IgAN.  
Linkage Analysis Studies – The European IgAN Consortium performed the first genome-wide 
scan involving 22 Italian multiplex IgAN families [Bisceglia L et al, 2006]. A total of 186 
individuals (59 affected and 127 unaffected) were genotyped and included in a two-stage 
linkage analysis. The regions 4q26–31 and 17q12–22 exhibited the strongest evidence of 
linkage by non-parametric analysis (best p values of 0.0025 and 0.0045, respectively). These 
localizations were also supported by multipoint parametric analysis where a peak LOD 
score of 1.83 (α=0.50) and of 2.56 (α=0.65), respectively, were obtained using the affected 
only dominant model, and by allowing for the presence of genetic heterogeneity. These 
regions became the second (IGAN2) and third (IGAN3) genetic locus candidates to contain 
causative and/or susceptibility genes for familial IgAN. Other regions did not reach the 
threshold of a suggestive or significant LOD score; however, the enrolment of additional 
IgAN families means that these chromosomal regions may be explored in the near future. 
The above results provide further evidence for genetic heterogeneity among IgAN families. 
Evidence of linkage to multiple chromosomal regions is consistent with both an 
oligo/polygenic and a multiple susceptibility gene model for familial IgAN with 
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small/moderate effects in determining the pathological phenotype. The analysis of the 
known genes located in these two novel loci (positional information procedure), carried out 
consulting the National Center for Biotechnology Information, identified some potential 
candidate genes such as the transient receptor potential channel 3 (TRPC3) gene, the 
interleukin-2 (IL-2) gene, and the IL-21 gene located in 4q26–31, which could be largely 
involved in the unbalanced Th1/Th2 immune response reported in IgAN patients. In 
addition, the histone deacetylase 5 (HD5) gene and the granulin (GRN) gene located on the 
17q12–22 region, which could be involved in the immune-response deregulation, will also 
considered. Family-based association studies, evaluating the distribution of these candidate 
gene polymorphisms, are in progress.  
Microarray Studies – Different high-throughput gene analysis techniques can be used for 
obtaining transcriptome profiling of renal diseases. Microarray analysis represents the best 
and the latest approach to gain information on global gene expression. Genome-wide 
linkage analyses have identified at least three locus candidates containing IgAN 
susceptibility genes, although no specific gene(s) have been discovered. Microarrays are 
now in use to fingerprint the pathological process. 
A published study postulated that changes in gene expression patterns in circulating 
leukocytes of IgAN patients may correlate with renal disease activity [Preston et al, 2004]. 
The investigators identified 14 upregulated genes. The BTG2, NCUBE1, FLJ2948, SRPK1, 
LYZ, GIG2 and IL-8 genes correlated with serum creatinine levels and the PMAIP1, SRPK1, 
SSI-3, LYZ and PTGS2 genes correlated with higher values of creatinine clearance, thus 
implying that the latter group of genes may provide a protective effect, while the 
overexpression of other genes such as B3GNT5, AXUD1 and GIG-2 indicated a worse 
prognosis. This gene signature reflected kidney function and did not correlate with 
hematuria or proteinuria. The authors concluded that studies carried out on large 
populations of IgAN patients will be necessary to confirm that the leukocyte gene 
expression profile can be used as a marker for diagnosis and for predicting outcome. The 
European IgAN Consortium has recently organized a protocol for studying gene expression 
in peripheral blood mononuclear cells (PBMC) and their subpopulations from IgAN patients 
with different clinical and histological patterns. Cox et al [2010] conducted a whole-genome 
expression study to identify genes and pathways differently modulated in peripheral blood 
leukocytes of IgAN patients. Gene expression of leukocytes demonstrated the hyperactivity 
of two important pathways as the canonical WNT- catenin and the PI3k/Akt pathways. 
The abnormal WNT signalling was also confirmed in IgAN patient’s monocytes and to a 
less extent in B lymphocytes. Low gene expression of inversion and phosphatase and tensin 
homolog (PTEN) are responsible for the hyperactivation of these two pathways that enhance 
cell proliferation through lymphoid enhancer factor-1 (LEF-1) of which the gene is located 
within our previous described region 4q26-31 linked to IgAN [Bisceglia et al, 2006]. Finally, 
the hyperactivation of the PJ3k/Akt pathway is in linkage with the upregulation of the 
immunoproteasome in peripheral blood mononuclear cells of IgAN patients, reported by 
Coppo et al, [2009]. 
Expression profiling using serial analysis of gene expression (SAGE) and microarray 
techniques allows global description of expressed genes present in renal tissue. This is a 
high throughput genomics technology which enables the simultaneous determination of a 
large number of genes from tissue samples. Preston et al identified 13 upregulated genes in 
IgAN renal biopsy samples. The cluster analysis identified 3 clusters with 7, 12 and 1 
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involved gene, respectively [Preston et al, 2004]. The expression levels of these genes were 
then examined on expanded RNA samples from other renal biopsies, leukocyte samples and 
cultured primary cells. Data demonstrated the involvement of the genes GABP and STAT3 
in cluster I, and gp330 (megalin), MBP45K, MEF2, Oct1 and GABX in cluster II. The use of 
laser-capture microdissection applied to renal biopsy samples in combination with 
differential gene expression analysis is expected to provide novel knowledge in the search 
for IgAN candidate genes. 
Candidate genes association studies – The IgAN Consortium takes care of the collection of 
biological samples from large homogeneous cohorts of IgAN patients, their parents and 
their first degree relatives, and family-based association studies are preferred to analyze the 
role of some candidate genes. A family-based association study, including 53 patients, 45 
complete trios, 4 incomplete trios and 36 discordant siblings, evaluated the impact of some 
Th1/Th2/Th3/TR-type lymphocyte and monocyte/macrophage cytokines on IgAN 
susceptibility [Schena FP et al, 2006]. Cytokine gene polymorphisms with a potential 
regulatory role on their production were investigated using the family-based association test 
(FBAT): IFN intron-1 CA-repeat at position 1349–1373; IL-13 –1055C/T; TGF 915G/C; IL-
10 5’-proximal and distal microsatellites; TNF –308G/A, –238G/A. The FBAT multi-allelic 
analysis showed an association between IFN polymorphism and susceptibility to IgAN 
(p=0.03). The bi-allelic analysis showed that the 13-CA repeat allele was preferentially 
transmitted to the affected individuals (p=0.006; Bonferroni p=0.04). The direct sequencing 
of IFN amplicons showed a strict association between the 13-CA repeat allele and the A 
variant of the +874T/A SNP (rs2430561) directly adjacent to the 5’ end of the microsatellite. 
The in vitro production of IFN evaluated in PBMC from 10 genotyped patients 
demonstrated a correlation between the +874A allele and a lower production of IFNγ 
(p=0.028). Notably, the +874A variant was associated with transcriptional downregulation 
of INFγ gene promoter activity, consistent with the known role of NF-κB in the 
transcriptional regulation of the INFγ gene. 
The occurrence of the +874A variant is responsible for the low production of IFNγ and 
predisposes to a preferential Th2-mediated immune response. The predominance of this 
variant in individuals with IgAN may be responsible for the onset of the disease. This 
unbalanced Th2 cytokine production in response to upper respiratory tract infections may 
be a significant pathogenic factor in human IgAN. The prevalence of Th2 cytokines may 
also explain the abnormality in IgA1 glycosylation occurring in IgAN patients and the 
concomitant formation of circulating IgA1-IgG immune complexes. Hyperfunction of Th2 
cells and cytokine polarity are linked to a more nephritogenic pattern of IgA1 
glycosylation in the animal model, and the decreased glycosylation of IgA1 elicited by 
Th2 cytokines is blunted in vitro by the addition of IFNγ [Ebihara et al, 2008]. The core 1 
β1,3-galactosyltransferase (C1Gal-T1) is suspected to be involved in the abnormal 
glycosylation process of IgA1 in IgAN. With the genetic characterization of the enzymes 
responsible for O-glycosylation of IgA1, it has been possible to study changes in the O-
glycosylation of IgA1 at a genetic level. Most recently two groups [Pirulli et al, 2009; Li GS 
et al, 2007] have independently found that SNPs in the C1Gal-T1 gene are associated with 
a genetic susceptibility to IgAN in Chinese and Italian populations, albeit it is not clear 
how these polymorphisms relate to changes in the functional activity of C1Gal-T1. The 
C1Gal-T1 gene complete sequence analysis was performed in 284 IgAN patients and 234 
healthy controls. A statistically significant association of the genotype 1365G/G with 
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small/moderate effects in determining the pathological phenotype. The analysis of the 
known genes located in these two novel loci (positional information procedure), carried out 
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addition, the histone deacetylase 5 (HD5) gene and the granulin (GRN) gene located on the 
17q12–22 region, which could be involved in the immune-response deregulation, will also 
considered. Family-based association studies, evaluating the distribution of these candidate 
gene polymorphisms, are in progress.  
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involved gene, respectively [Preston et al, 2004]. The expression levels of these genes were 
then examined on expanded RNA samples from other renal biopsies, leukocyte samples and 
cultured primary cells. Data demonstrated the involvement of the genes GABP and STAT3 
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laser-capture microdissection applied to renal biopsy samples in combination with 
differential gene expression analysis is expected to provide novel knowledge in the search 
for IgAN candidate genes. 
Candidate genes association studies – The IgAN Consortium takes care of the collection of 
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transcriptional regulation of the INFγ gene. 
The occurrence of the +874A variant is responsible for the low production of IFNγ and 
predisposes to a preferential Th2-mediated immune response. The predominance of this 
variant in individuals with IgAN may be responsible for the onset of the disease. This 
unbalanced Th2 cytokine production in response to upper respiratory tract infections may 
be a significant pathogenic factor in human IgAN. The prevalence of Th2 cytokines may 
also explain the abnormality in IgA1 glycosylation occurring in IgAN patients and the 
concomitant formation of circulating IgA1-IgG immune complexes. Hyperfunction of Th2 
cells and cytokine polarity are linked to a more nephritogenic pattern of IgA1 
glycosylation in the animal model, and the decreased glycosylation of IgA1 elicited by 
Th2 cytokines is blunted in vitro by the addition of IFNγ [Ebihara et al, 2008]. The core 1 
β1,3-galactosyltransferase (C1Gal-T1) is suspected to be involved in the abnormal 
glycosylation process of IgA1 in IgAN. With the genetic characterization of the enzymes 
responsible for O-glycosylation of IgA1, it has been possible to study changes in the O-
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et al, 2007] have independently found that SNPs in the C1Gal-T1 gene are associated with 
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C1Gal-T1 gene complete sequence analysis was performed in 284 IgAN patients and 234 
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susceptibility to IgAN (χ2=17.58, p<0.0001, odds ratio 2.57 [95% CI: 1.64–4.04]), but not 
with the progression of the disease, was found [Pirulli et al, 2009]. The latter case-control 
association study demonstrates that the low expression of C1Gal-T1 seems to confer 
susceptibility to IgAN. 
In conclusion, to date the Consortium has identified two loci (located on chromosomes 
4q26–31 and 17q12–22), in addition to a previous study which described the first IgAN locus 
on chromosome 6q22–23. The functional mapping of genes involved in the disease proceeds 
from the identification of susceptibility loci identified by linkage analysis (step 1) to the 
isolation of candidate genes within gene disease-susceptibility loci, after obtaining 
information by microarray analysis carried out on peripheral leukocytes and renal tissue 
samples (step 2). Next steps will be the design of RNA interference agents against selected 
genes (step 3) and the application of systematically tested effect of RNA agents on functional 
cellular assay (step 4). The above combined high-throughput technologies will give 
information on the pathogenic mechanisms of IgAN. In addition, these data may indicate 
potential targets for screening, prevention and early diagnosis of the disease and more 
appropriate and effective treatment. 
3. Treatment of IgAN   
Treatment strategy for IgAN remains a controversial issue, even more as published 
randomized controlled trials (RCTs) on this topic are few and most studies are 
underpowered to provide definitive information. Furthermore, the disease heterogeneity, its 
clinical course along with the slow rate of GFR decline (1 to 3 mL/min per year) seen in 
many patients hinders the ability to perform adequate studies. An additional obstacle is the 
fact that a significant percentage of the patients have only minimal clinical presentation, 
such as isolated microhematuria, no or minimal proteinuria and normal GFR, and are often 
not biopsied or even identified. Still no treatment is known to modify mesangial deposition 
of IgA, which obviously reflects our incomplete knowledge of immunopathogenesis of 
IgAN [Barratt et al, 2007], and available treatment options are directed mostly at 
downstream immune and inflammatory events that may lead on to renal scarring. 
Therefore, as more pathogenetic details, the genetic substrate and heterogeneity of IgAN 
become increasingly understood, novel treatment strategies with solid therapeutic targets 
are anticipated, as long as the traditional therapies used until today seem symptomatic 
rather than etiologic. The discovery and establishment of novel biomarkers associated with 
the disease activity and outcome will provide the prognostic and therapeutic tool for more 
accurate and clear therapeutic targeting.  
However, there seems to be a consensus regarding patient selection for the different 
therapeutic approaches. Patient selection for therapy is based in part upon the perceived 
risk of progressive kidney disease: 
 Patients with isolated hematuria, no or minimal proteinuria (<500mg/day), a normal 
GFR and no signs of progressive disease, such as increasing proteinuria, blood pressure, 
and/or serum creatinine, are typically not treated. 
 Patients with persistent proteinuria (>500 mg/day), normal or only slightly reduced 
GFR (>50mL/min) that is not declining rapidly, and only mild to moderate histologic 
findings on renal biopsy are managed with general interventions to slow progression 
with ACE-inhibitors or angiotensin receptor blockers (ARB) or with combination 
therapy of corticosteroid (6 months) and ACE-inhibitors forever.   
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 Patients with more severe or rapidly progressive disease (eg, proteinuria > 1g or 
proteinuria persisting despite ACE inhibitor/ARB therapy, rising serum creatinine, 
and/or renal biopsy with more severe histologic findings, but no significant chronic 
changes) may benefit from immunosuppressive therapy in addition to non-
immunosuppressive interventions to slow disease progression.  
 In the future, the Oxford histologic classification system, once validated, is anticipated 
to become a useful prognostic tool that could lead in the future our therapeutic choices 
[Working Group of the International IgAN Network and the Renal Pathology Society, 
2010].  
3.1 Monitoring disease activity 
Up to date, there are no specific markers to identify continued immunologic activity. 
Instead, the clinical parameters typically used as the main therapeutic criterion are the urine 
sediment, protein excretion and the serum creatinine concentration. Persistent hematuria is 
generally a marker of persistent immunologic activity, but not necessarily of progressive 
disease. This finding may be a sign of a "smoldering" segmental necrotizing lesion, 
suggestive of "capillaritis." Hematuria alone does not require any form of therapy. 
Proteinuria, rather than hematuria alone, is a marker of more severe disease [Donadio et al, 
2002]. Increasing proteinuria may be due to one of two factors: ongoing active disease; and 
secondary glomerular injury due to non-immunologic progression. It is often not possible to 
distinguish between these two possibilities, except for a rapid increase in protein excretion 
which is only seen with active disease. Protein excretion most often falls with ACE 
inhibitor/ARB therapy and the degree of proteinuria is, as described below, one of the end 
points of such therapy. Protein excretion also may fall spontaneously, particularly during 
recovery from an acute episode and perhaps in children, and following effective 
immunosuppressive therapy. Finally, serum creatinine, unless it is rapidly rising, permits an 
estimation of the GFR. As noted above, most patients with chronic IgAN have stable or 
slowly progressive disease. The rate of GFR decline is often as low as 1 to 3 mL/min per 
year, a change that will not detectably raise the serum creatinine above normal levels for 
many years [Rekola et al, 1991]. Thus, a stable and even normal serum creatinine does not 
necessarily indicate stable disease. 
The establishment of accurate biomarkers is necessary for the optimal categorization and 
treatment of patients with IgAN. Over the last few years specific urine biomolecules have 
been proposed as probable biomarkers to be used in the prognosis and therapeutic strategy 
in patients with IgAN. Two recent studies identified urine epidermal growth factor and 
monocyte chemoattractant protein-1 as strong independent predictors of renal outcome in 
patients with IgAN [Torres et al, 2008; Stangou et al, 2009]. These and other biomolecules 
are being validated as probable biomarkers of IgAN in studies underway. 
3.2 Non-immunosuppressive therapies 
Three main non-immunosuppressive therapies are in use in IgAN [Barratt & Feehally, 2006; 
Appel & Waldman, 2006]: 
 ACE inhibitors or ARB, to control blood pressure and to slow down progression of the 
renal disease. 
 Statin therapy, for lipid-lowering in selected patients, to lower cardiovascular risk and 
possibly reduce disease progression. 
 Fish oil (omega-3 fatty acids) may also be beneficial in certain cases.  
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[Working Group of the International IgAN Network and the Renal Pathology Society, 
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Up to date, there are no specific markers to identify continued immunologic activity. 
Instead, the clinical parameters typically used as the main therapeutic criterion are the urine 
sediment, protein excretion and the serum creatinine concentration. Persistent hematuria is 
generally a marker of persistent immunologic activity, but not necessarily of progressive 
disease. This finding may be a sign of a "smoldering" segmental necrotizing lesion, 
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treatment of patients with IgAN. Over the last few years specific urine biomolecules have 
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in patients with IgAN. Two recent studies identified urine epidermal growth factor and 
monocyte chemoattractant protein-1 as strong independent predictors of renal outcome in 
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are being validated as probable biomarkers of IgAN in studies underway. 
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3.2.1 Angiotensin inhibition 
The progression of IgAN may be slowed by anti-hypertensive and anti-proteinuric therapy 
that can minimize secondary glomerular injury [Kanno et al, 2000]. The treatment goals with 
angiotensin inhibition are the same as those in other forms of proteinuric chronic kidney 
disease as described in the K/DOQI guidelines [K/DOQI, 2004]. ACE inhibitors and ARBs 
act by reducing the intraglomerular pressure and by directly improving the size-selective 
properties of the glomerular capillary wall, both of which contribute to reducing protein 
excretion [Remuzzi et al, 1991; Maschio et al, 1994]. 
Both observational studies [Cattran et al, 1994; Kanno et al, 2005] and small randomized 
trials [Maschio et al, 1994; Praga et al, 2003; Li PK et al, 2006] have provided suggestive 
evidence that ACE inhibitors or ARBs are more effective than other antihypertensive drugs 
in slowing the progressive decline in GFR in IgAN as they are in other forms of chronic 
proteinuric kidney disease. Praga et al in their randomized trial in 44 IgAN patients with 
proteinuria (≥0.5 g/day, mean 1.9 g/day) and a serum creatinine concentration ≤1.5 mg/dL 
at baseline, found a significant decrease in proteinuria in the enalapril group (1.9 g/day at 
baseline to 0.9 g/day at the last visit) and a significantly higher renal survival, defined as 
less than a 50 percent increase in the serum creatinine concentration, at 6 years of follow up 
[Praga et al, 2003]. More recently, Li et al in their double-blind randomized placebo-
controlled HKVIN trial in 109 Chinese patients with protein excretion ≥1 g/day (mean ~2.0 
g/day), found a better renal survival, defined as doubling of serum creatinine or ESRD, a 
significant improvement in proteinuria (33 % reduction in proteinuria) and a slower rate of 
decline in GFR (4.6 versus 6.9 mL/min per year) in the valsartan group compared to placebo 
[Li PK et al, 2006]. Similarly, the IgACE trial in 65 young patients with moderate proteinuria 
(between 1 and 3.5 grams/day per 1.73 m2) and creatinine clearance >50 mL/min per  
1.73 m2 revealed a better renal survival (fewer patients with >30% decline in renal function) 
and significant improvement in proteinuria at 38 months of follow-up in the benazepril 
group compared to the placebo group [Coppo, 2007].  
Normotensive patients who excrete less than 500 mg of protein per day are not typically 
treated with angiotensin inhibition. However, because most patients progress slowly over 
time, monitoring of the serum creatinine and protein excretion at yearly intervals is 
recommended. Angiotensin inhibition should be started if there is evidence of progressive 
disease and protein excretion above 500 mg/day. 
The addition of an ARB to an ACE inhibitor in patients with IgAN seems to exert a further 
antiproteinuric effect [Russo et al, 1999, 2001], albeit there are no randomized trials 
showing that this regimen improves renal outcomes. This finding is consistent with meta-
analyses of trials in different glomerular diseases, the largest of which found a significant 
18 to 25% greater reduction in proteinuria with combined ACE inhibitors and ARBs 
compared to monotherapy [Kunz et al, 2008; Catapano et al, 2008]. The rationale for this 
combination therapy is the assumption that ARBs would counteract theAT1-mediated 
effect of residual angiotensin II formation by non-ACE enzymes like chymase, whereas 
ACE inhibitors would additionally increase the level of kinins. Furthermore, ACE 
inhibitors as well as ARBs would synergistically elevate the levels of angiotensin, which 
also might promote vasodilation. Finally, combining both drug classes might simply 
provide a higher degree of blockade of the classic renin-angiotensin system pathways 
[Alexopoulos, 2004].  However, any anticipated benefits from this combination should be 
weighted against possible adverse effects in individual patients; this is important 
especially given the findings from the ONTARGET trial in 25,620 patients with vascular 
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disease or diabetes, where an increase in adverse side effects (including a possible 
increase in mortality) in patients who received combination therapy with an ACE 
inhibitor and ARB was shown, compared to those who received monotherapy 
[ONTARGET Investigators, 2008; Mann et al, 2008].  
3.2.2 Lipid-lowering therapy 
Chronic kidney disease is associated with a marked increase in cardiovascular risk, and is 
now considered a coronary artery disease risk equivalent. Furthermore, lipid-lowering with 
statins has been associated with a slower rate of loss of GFR in patients in some patients 
with mild to moderate CKD, and there are indications for such a beneficial effect of statins 
in patients with IgAN as well [Kano et al, 2003]. Therefore, it seems rational that all patients 
with decreased kidney function and/or hypercholesterolemia should receive lipid-lowering 
therapy with a statin, with treatment goals similar to that in patients with underlying 
coronary heart disease.  
3.2.3 Fish oil 
The rationale for using fish oil (omega-3 fatty acids) in IgAN is based on the premise that 
they may limit the production or action of cytokines and eicosanoids evoked by the initial or 
by repeated immunologic renal injury, and the resulting production of mediators involved 
in renal damage [Donadio, 1991]. Randomized controlled trials evaluating fish oil in patients 
with IgAN have reported conflicting results [Donadio et al, 1994; Alexopoulos et al, 2004; 
Donadio et al, 1999, 2001; Bennett et al, 1989; Pettersson et al, 1994; Hogg et al, 2006; Ferraro 
et al, 2009]. In the largest and most well documented and conducted randomized trial in 106 
patients with baseline creatinine clearance 80 mL/min and protein excretion of 2.5 to  
3 g/day, Donadio et al found better patient and renal outcomes at 4 years, extended also at 
>6 years, in patients having received 12g of fish oil for 2 years, compared to patients having 
received a similar amount of olive oil [Donadio et al, 1994, 1999]. Similarly, in a controlled 
study of 14 IgAN patients and 14 controls, a low dose of fish oil (0.85 g eicosapentaenoic 
acid and 0.57 g phytohemaglutinin) was found effective in slowing renal progression in 
high-risk patients with IgAN and particularly those with advanced renal disease 
[Alexopoulos et al, 2004]. On the other hand, in the randomized controlled trial by the 
Southwest Pediatric Nephrology Study Group in 96 patients with IgAN, mean GFR >100 
mL/min per 1.73 m2 and proteinuria 1.4 to 2.2 g/day, no significant benefit in the renal 
outcome was found in patients assigned to omega-3 fatty acids (4 g/day) for two years 
compared to the patients assigned to either alternate day prednisone or placebo [Hogg et al, 
2006]. On the basis of the existing data, fish oil can be tried in addition to ACE inhibitors or 
ARBs in patients with protein excretion >500 to 1000 mg/day, a gradual reduction in GFR, 
and mild to moderate histologic lesions [Alexopoulos E, 2004]. 
3.3 Immunosuppressive therapy 
The optimal role of immunosuppressive therapy in IgAN is uncertain [Barratt & Feehally, 
2006; Appel & Waldman, 2006]. A variety of regimens have been used, mostly consisting of 
corticosteroids alone or with other immunosuppressive drugs. The available studies are not 
conclusive since most are relatively small and have limited follow-up, and the results are 
sometimes conflicting [D'Amico, 1992; Alamartine et al, 1991; Alexopoulos, 2004; Strippoli et 
al, 2003; Laville & Alamartine, 2004; Ballardie, 2004; Julian, 2000; Dillon, 2001]. There is 
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disease or diabetes, where an increase in adverse side effects (including a possible 
increase in mortality) in patients who received combination therapy with an ACE 
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rather consensus that mild, stable, or very slowly progressive IgAN should not be treated 
with corticosteroids or other immunosuppressive therapies, given the limited evidence of 
benefit and their known toxicity from chronic use [Floege & Eitner, 2005; Locatelli et al, 
1999]. Corticosteroid or other immunosuppressive therapy should only be attempted in 
patients with clinical and histologic evidence of active inflammation (eg, hematuria and/or 
proliferative or necrotizing glomerular changes). Patients with chronic kidney disease with 
significant tubulointerstitial fibrosis and glomerulosclerosis are not likely to benefit from 
such therapy and are likely to be harmed from the side effects.  
3.3.1 Corticosteroids 
Current evidence regarding the potential benefit of corticosteroid therapy in IgAN are 
rather limited, as long as most of the studies performed are uncontrolled retrospective 
observations; moreover, the few available randomized controlled trials are rather small and 
in most of them the standard recommendations for proteinuria and blood pressure goals 
were not followed, limiting thus the applicability of the findings to current practice.  
Whatsoever, these studies point towards a beneficial effect of corticosteroid therapy 
(administered for 6 up to >24 months) in proteinuria and perhaps in renal survival [Floege 
& Eitner, 2005; Nolin & Courteau, 1999; Kobayashi Y et al, 1989, 1996; Pozzi et al, 1999, 2004; 
Tamoura et al, 2001; Katafuchi et al, 2003; Hotta et al, 2001; Moriyama et al, 2004; Lv et al, 
2009, Manno et al, 2009], probably preferentially in individuals with preserved kidney 
function (eg, creatinine clearance above 50 mL/min) [Kobayashi et al, 1989, 1996; Pozzi et al, 
1999, 2004].  Two randomised clinical trials demonstrated the benefit of the combination 
therapy with corticosteroids and ACE inhibitors on long-term follow-up in proteinuric 
IgAN patients. Lv et al (2009) evaluated the efficacy of the combination therapy versus ACE-
inhibitors alone in a small number of IgAN patients with mild or moderate histologic lesions 
and with a follow-up period that was too short to evaluate the renal survival. Data 
demonstrated that the combination therapy reduced better the urinary protein excretion 
than the administration of ACE-inhibitors alone.  
Even more, Manno et al enrolled 97 IgAN patients with moderate histologic lesion (see 
IgAN classification of F.P. Schena in Manno et al., 2007) daily proteinuria more than 1.0g 
and estimated GFR more than 50 ml/min/1.73m2. Patients were randomly allocated to 
receive a 6-month course of oral prednisone plus ramipril or ramipril alone for the total 
duration of the follow-up (96 months). The combination of corticosteroids and ramipril 
provided less probability of renal disease progression because induced the decline of GFR 
and daily proteinuria. In an interesting recent meta-analysis of randomized and quasi-
randomized controlled trials of corticosteroid treatment in IgAN against treatment without 
steroids, Zhou et al found that steroid therapy, especially long-term, is associated with a 
significant benefit in proteinuria and renal survival [Zhou et al, 2011].  
In addition, the IgAN patients seemingly to benefit from prednisone therapy are those with 
nephrotic syndrome, little or no hematuria, preserved kidney function, minimal glomerular 
changes on light microscopy, and diffuse fusion of glomerular epithelial cell foot processes 
on electron microscopy. These histologic findings are characteristic of minimal change 
disease, and these patients behave accordingly, frequently developing a remission with 
corticosteroids and occasionally requiring cytotoxics for frequently relapsing proteinuria 
[Mustonen et al, 1983; Lai KN et al, 1986; Cheng et al, 1989]. Mesangial IgA deposits in these 
patients often disappear or are greatly reduced following steroid-induced remission [Cheng 
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et al, 1989].  Nephrotic syndrome can also occur with severe chronic IgAN and relatively 
advanced disease on renal biopsy. These patients do not seem to benefit from corticosteroid 
therapy alone [Mustonen et al, 1983; Lai KN et al, 1986]. 
3.3.2 Combined immunosuppressive therapy  
Combined immunosuppressive therapy should only be attempted in patients with more 
severe active disease as defined by a more rapidly progressive clinical course and/or 
histologic evidence of severe active inflammation (eg, crescent formation). Early therapy is 
important because improvement is rare when the baseline serum creatinine concentration is 
greater than 3.0 mg/dL in the absence of crescentic glomerulonephritis [Alexopoulos E, 
2004].  
Corticosteroids plus azathioprine — Whether the addition of azathioprine provide any benefit 
to that of corticosteroids is still debatable. In a multicenter randomized trial by Pozzi et al in 
207 patients with plasma creatinine ≤ 2.0 mg/dL and protein excretion >1.0 g/day, at a 
median follow-up of 4.9 years, there was no difference neither in renal survival time, 
defined as the time to 50% increase in plasma creatinine from baseline, nor in the decrease in 
proteinuria between patients who received corticosteroids alone or along with azathioprine 
(1.5 mg/kg /day for six months) [Pozzi et al, 2010]. However, in the above study, only a 
rather small percentage of patients were receiving either ACE inhibitors or ARBs, and even 
fewer patients were receiving statins. Most recently, Stangou et al published a randomized, 
yet underpowered study in 22 patients with IgAN and eGRF≥30mL/min, urine protein 
≥1g/day, blood pressure <130/80mmHg, who failed to respond to previous treatment with 
renin-angiotensin system inhibitors and poly-unsaturated fatty acids administered for at 
least 6 months. During the 5th year after the diagnosis was made, the patients were 
randomized to receive either methylprednisolone alone, or methyl-prednisolone in 
combination with azathioprine, for 12months, while treatment with renin-angiotensin 
system inhibitors and poly-unsaturated fatty acids continued unchanged in both groups. 
Both, steroid treatment alone, or steroids in combination with azathioprine were found to be 
equally effective in reducing the severity of proteinuria and stabilizing renal function 
[Stangou et al, 2011].  
Corticosteroids plus cyclophosphamide— There are evidence suggesting that patients with 
severe or progressive disease (eg, rising creatinine, nephrotic range proteinuria, and/or 
marked proliferation without crescents) who do not have significant chronic damage on 
kidney biopsy may benefit from combined immunosuppressive therapy with 
prednisone and cyclophosphamide. This regimen was evaluated in a study of Ballardie et al 
in 38 patients with IgAN and initially impaired renal function (baseline serum creatinine 
between 1.5 and 2.8 mg/dL, mean baseline protein excretion 4.0 to 4.5 g/day, no crescents 
on biopsy) that was declining at a relatively moderate rate (by at least 15% per year). 
Compared with the control group, the patients treated with combination therapy 
(prednisolone 40mg/day tapered to 10mg/day by two years plus low-dose 
cyclophosphamide for 3 months followed by low-dose azathioprine for at least 2 years) had 
a significant reduction in protein excretion during the first six months of therapy that 
persisted during follow-up (eg, reached 1.8 g/day in treatment group versus unchanged at 
4.4 g/day in controls at one year). Renal survival was significantly higher in the treatment 
group at two (82 versus 68 percent) and five years (72 versus 6 percent). [Ballardie et al, 
2002]. 
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Uncontrolled reports in patients with crescentic, rapidly progressive glomerulonephritis 
suggest possible benefit from regimens similar to those used in idiopathic crescentic 
glomerulonephritis: intravenous pulse methylprednisolone followed by oral prednisone, 
intravenous or oral cyclophosphamide, and/or plasmapheresis [Welch et al, 1988; Lai KN et 
al, 1987a; Rocatello et al, 1995; McIntyre et al, 2001; Tumlin et al, 2003]. Corticosteroids may 
act in this setting by diminishing acute inflammatory injury rather than by correcting the 
abnormality in IgA production [Galla, 1995]. In a study by Rocatello et al, although a 
substantial clinical improvement was found with the administration of aggressive 
combination therapy (including pulse methylprednisolone, oral cyclophosphamide, and 
plasmapheresis) for 2 months in six patients with crescentic glomerulonephritis due to IgAN 
[Rocatello et al, 1995], yet cellular crescents failed to remit in repeat renal biopsy, whereas 
the disease continued to progress in half of the patients after therapy was discontinued. 
Limited data for a more prolonged course of aggressive immunosuppressive therapy (pulse 
methylprednisolone 15mg/kg/day for 3 days, followed by oral prednisolone 1 mg/kg/ day 
for 60 days gradually tapered, along with monthly iv cyclophosphamide (0.5 g/m2) for 6 
months) point towards a significant improvement in the serum creatinine and in protein 
excretion along with a significant reversion of cellular crescents and endocapillary 
proliferation [Tumlin et al, 2003].  
These limited data suggest that patients with active crescentic glomerulonephritis who do 
not have significant chronic damage on kidney biopsy may benefit from therapy that 
initially includes intravenous cyclophosphamide. This is consistent with the benefit noted 
with a similar regimen in other forms of crescentic glomerulonephritis.  
3.3.3 Other immunosuppressive agents 
Cyclosporine — Cyclosporine has been investigated in small studies, and resulted in reduced 
proteinuria. In a recent study, Shin et al reported a significant benefit of cyclosporine 
therapy in proteinuria reduction and renal pathology regression in 14 children with IgAN 
and near normal creatinine clearance [Shin et al, 2010]. However, there are important issues 
of concern regarding its use in IgAN treatment, with most important the associated 
nephrotoxicity, which can lead to harmful effects on renal function [Lai KN et al, 1987b; 
Cattran, 1991], as well as the rapid disease relapse after drug discontinuation. 
Mycophenolate mofetil — Small, prospective placebo-controlled randomized trials of 
mycophenolate mofetil (MMF) in which the patients were also treated with ACE inhibitors, 
have produced conflicting results, ranging from no benefit [Maes et al, 2004; Frisch et al, 
2005] to a reduction in proteinuria and decrease in rate of decline of GFR [Tang et al, 2010]. 
A short course (< 6 months) of MMF in patients with persistent proteinuria (>1.5 g/day) and 
well-maintained renal function (serum creatinine <1.5 mg/dL) in addition to ACE 
inhibitor/ARB therapy may be considered in patients with well-preserved renal histology 
on biopsy. Current evidence does not support the use of MMF in patients with advanced 
disease (serum creatinine >2.5 to 3 mg/dL) [Cattran & Appel, 2011]. 
3.4 Other possible interventions 
Tonsillectomy — Several retrospective studies have suggested that tonsillectomy, usually in 
combination with some immunosuppressive therapy, is associated with improved renal 
survival among patients with relatively mild renal injury [Hotta et al, 2001; Xie et al, 2003; 
Komatsu et al, 2008]. These non-randomized studies provide some evidence that 
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tonsillectomy may be effective in inducing remission of proteinuria and hematuria in 
patients with IgAN (ie, proteinuria >500 mg/day). However, there are no randomized trials 
of tonsillectomy in IgAN, the design of the above studies precludes any definitive 
conclusions regarding the overall efficacy of tonsillectomy in IgAN, while other studies 
reported negative results [Rasche et al, 1999].  
Low antigen diet — The rationale for using a low antigen diet in IgAN, ie diet free of gluten, 
dairy products, eggs, and most meats, is that dietary macromolecules may be responsible for 
activating the mucosal IgA system. When given to 21 consecutive patients with IgAN, 
protein excretion fell markedly in all 12 patients whose baseline rate was more than 1g/day. 
In addition, repeat renal biopsy showed significant reductions in mesangial IgA and 
complement deposition and mesangial cellularity [Ferri et al, 1993]. However, the benefits in 
the above study have not been confirmed and a report using a gluten-free diet alone for 
several years was unable to document improvement in either proteinuria or renal function 
despite a reduction in the level of circulating IgA-containing immune complexes [Coppo et 
al, 1990]. 
Intravenous immune globulin — At least part of the rationale for intravenous immune 
globulin (IVIG) therapy in IgAN comes from the observation that a partial IgG deficiency, 
which could be corrected with IVIG, may predispose to infections that trigger flare-ups of 
the renal disease [Rostoker et al, 1989, 1994]. Despite the promising findings from two small 
studies with the administration of high-dose IVIG in severe IgAN, characterized by heavy 
proteinuria and a relatively rapid decline in GFR (reduction in protein excretion, prevention 
of GFR decline, decreased inflammatory activity and IgA deposition on repeat renal biopsy) 
[Rostoker et al, 1994; Rasche et al, 2006], these findings need to be confirmed by larger 
studies.  
4. Conclusion 
Genetic susceptibility for IgAN exhibits a complex genetic pattern. To date  various groups 
and the European IgAN Consortium have identified several loci. The extensive genetic 
studies under way with the use of delicate, high-throughput technologies will give 
information on the pathogenic mechanisms of IgAN. In addition, these data may indicate 
potential targets for screening, prevention and early diagnosis of the disease and more 
appropriate and effective treatment. 
Summarizing the most updated data, following are concise treatment guidelines: 
 Patients with isolated hematuria, no or minimal proteinuria (<0.5g/day), and a normal 
GFR need no treatment. Such patients should be periodically monitored at 6 to 12 
month intervals to assess disease progression that might warrant therapy. 
 Patients with persistent proteinuria (>0.5 or >1 g/day), should be treated with 
angiotensin inhibition (ACE inhibitor or ARB), with a target of a minimum reduction in 
protein excretion of at least 50 to 60% from baseline values and a goal protein excretion 
of <0.5 or <1 g/day.  
 All patients who meet criteria for angiotensin inhibition may also be considered as 
candidates to receive fish oil.  
 Patients with persistent nephrotic syndrome and/or chronic kidney disease who have 
dyslipidemia should be treated with a statin, primarily for cardiovascular protection.  
 Corticosteroid therapy for at least  6 months is indicated in the following cases: 
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protein excretion fell markedly in all 12 patients whose baseline rate was more than 1g/day. 
In addition, repeat renal biopsy showed significant reductions in mesangial IgA and 
complement deposition and mesangial cellularity [Ferri et al, 1993]. However, the benefits in 
the above study have not been confirmed and a report using a gluten-free diet alone for 
several years was unable to document improvement in either proteinuria or renal function 
despite a reduction in the level of circulating IgA-containing immune complexes [Coppo et 
al, 1990]. 
Intravenous immune globulin — At least part of the rationale for intravenous immune 
globulin (IVIG) therapy in IgAN comes from the observation that a partial IgG deficiency, 
which could be corrected with IVIG, may predispose to infections that trigger flare-ups of 
the renal disease [Rostoker et al, 1989, 1994]. Despite the promising findings from two small 
studies with the administration of high-dose IVIG in severe IgAN, characterized by heavy 
proteinuria and a relatively rapid decline in GFR (reduction in protein excretion, prevention 
of GFR decline, decreased inflammatory activity and IgA deposition on repeat renal biopsy) 
[Rostoker et al, 1994; Rasche et al, 2006], these findings need to be confirmed by larger 
studies.  
4. Conclusion 
Genetic susceptibility for IgAN exhibits a complex genetic pattern. To date  various groups 
and the European IgAN Consortium have identified several loci. The extensive genetic 
studies under way with the use of delicate, high-throughput technologies will give 
information on the pathogenic mechanisms of IgAN. In addition, these data may indicate 
potential targets for screening, prevention and early diagnosis of the disease and more 
appropriate and effective treatment. 
Summarizing the most updated data, following are concise treatment guidelines: 
 Patients with isolated hematuria, no or minimal proteinuria (<0.5g/day), and a normal 
GFR need no treatment. Such patients should be periodically monitored at 6 to 12 
month intervals to assess disease progression that might warrant therapy. 
 Patients with persistent proteinuria (>0.5 or >1 g/day), should be treated with 
angiotensin inhibition (ACE inhibitor or ARB), with a target of a minimum reduction in 
protein excretion of at least 50 to 60% from baseline values and a goal protein excretion 
of <0.5 or <1 g/day.  
 All patients who meet criteria for angiotensin inhibition may also be considered as 
candidates to receive fish oil.  
 Patients with persistent nephrotic syndrome and/or chronic kidney disease who have 
dyslipidemia should be treated with a statin, primarily for cardiovascular protection.  
 Corticosteroid therapy for at least  6 months is indicated in the following cases: 
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a. In patients with acute onset of nephrotic syndrome and minimal changes beyond 
mesangial IgA deposits on renal biopsy (as in patients with minimal change 
disease). 
b. In patients with moderate renal lesions (eg, hematuria with persistent proteinuria 
>1 g/day and/or GFR>50ml/min) in association with ACE inhibitors or ARBs.  
 For patients with severe disease at baseline (defined as initial serum creatinine >1.5 
mg/dL) or progressive disease (eg, increasing serum creatinine and/or protein 
excretion) who do not have significant chronic damage on kidney biopsy, therapy with 
oral prednisone and cyclophosphamide is recommended.  
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1. Introduction 
Rapidly Progressive Glomerulonephritis are a group of renal diseases which are still posing 
serious threat to human health and survival. They are all characterised by acute and rapid 
deterioration of renal function. Renal biopsy reveals extracapillary glomerulonephritis, most 
frequently circumferential and diffuse, and immunofluorescence findings continue to 
represent the most important clue toward precise diagnosis. In the last years, with the 
development of new technologies and more targeted animal models, several discoveries 
have been made, that can help in better understanding the pathogenesis and perspectively 
defining new molecular targets for novel therapies, which are still required to improve the 
prognosis of these patients.  
2. Definition 
Introduced for the first time by Ellis in 1942 (Ellis, 1942), the term Rapidly Progressive 
Glomerulonephritis (RPGN) clinically describes a heterogeneous group of 
glomerulonephritis characterised by worsening of kidney function that, if not adequately 
and timely treated, rapidly progresses to end stage renal disease. From the pathological 
point of view, these diseases are classified as extracapillary or crescentic glomerulonephritis, 
generally showing extracapillary proliferation in more than 50% of glomeruli. Besides renal 
biopsy, which is mandatory to make the diagnosis and guide therapeutic decisions, clinical 
symptoms, biochemical exams, and the observation of the urinary sediment are relevant to 
the diagnostic process.  
Observation of the urinary sediment in the acute phase of disease allows to detect in the vast 
majority of cases marked erythrocytic cylindruria, mild to moderate leukocyturia, presence 
of tubular epithelial cells and tubular epithelial cell casts. Fatty casts and leukocyte casts can 
be detected in about one third of cases (Fogazzi, 2009). Progressive disappearance of these 
features follows successful therapeutic intervention, and their reappearance frequently 
precedes disease relapses, making the urinary sediment an important exam not only at 
diagnosis but also during the patient’s follow-up. 
Despite the amelioration of prognosis obtained with introduction of high doses of steroids, 
immunosuppressive agents, and plasma exchange, these diseases are still life-threatening 
and a high percentage of subjects have a poor renal outcome. 
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Along the years, different schemes for classifying RPGN have been proposed. Among them, 
the classification which is still largely accepted and mostly utilised was proposed by Couser 
(Couser, 1988), and defines disease groups on the basis of immunofluorescent findings. 
Clinical features and haematological exams are as well very important in reaching a precise 
diagnosis (Table 1).  
 
Light microscopy Necrotising extracapillary or pure extracapillary glomerulonephritis 
Immuno-
fluorescence Linear IgG staining
None or minimal 



































Other primary GN 
Table 1. Classification of RPGN according to immunofluorescence findings 
Linear deposition of IgG along the glomerular basement membrane associated to circulating 
anti-GBM antibodies allow the diagnosis of anti-GBM disease. If pulmonary haemorrhage is 
present, the diagnosis becomes of Goodpasture’s Syndrome.  
When immunofluorescence on renal biopsy material demonstrates absence of immune 
deposits or scanty immune deposition in the glomerulus, in association to the presence of 
circulating ANCA antibodies, a diagnosis of pauci-immune ANCA-associated renal 
vasculitis is made. In these cases, necrotising crescentic GN can be associated to clinical 
symptoms of systemic vasculitis. A prevalent involvement of the upper respiratory tract is 
highly suggestive for a diagnosis of Wegener’s Granulomatosis, whereas the presence of 
only general systemic symptoms, such as fever, is highly suggestive of Renal Limited 
Vasculitis. Rarely presenting as RPGN, Churg-Strauss syndrome is diagnosed when asthma 
and increased circulating eosinophils are present.  
Importantly, there is a percentage (10-30%, according to the literature) (Chen, 2009) of renal 
vasculitis which are negative for ANCA antibodies. A part from subjects with circulating 
AECA (anti-endothelial cell antibodies), that according to a recent study may be present in 
about 50% of cases (Cong, 2008), diagnosis is mainly based on clinical and biopsy findings 
and exclusion of other causes. 
Among cases of RPGN with granular immune deposition in glomeruli, the most frequent 
are Post-Streptococcal/post-infectious nephritis and extracapillary GN observed in cases of 
Lupus Nephritis. In these diseases, besides clinical symptoms, diagnosis is made thanks to 
the presence of autoantibodies (ASLO and anti-DNAseB in PSGN, and ANA in SLE).  
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RPGN can also complicate any primary form of GN, most frequently MPGN and IgA 
nephropathy. A part from the immunofluorescence findings, diagnosis is also guided by 
clinical and biochemical exams, such as the evaluation of complement components for the 
diagnosis of MPGN, and the presence of purpura in cases of Henoch-Schoenlein syndrome.  
It remains to be said, as a word of caution, that it is not infrequent to find a completely 
negative immunofluorescence or immunofluorescence findings particularly difficult to 
interpret in cases with very severe extracapillary proliferation or necrotic lesions, because of 
the consequent compression or destruction of the glomerular tuft.  
4. Morphological findings 
Though the common element characterising this group of diseases is the presence of 
extracapillary proliferation, morphological findings can be very diverse, according to the 
stage of the disease and also to the underlying disease, likely reflecting the different 
pathogenesis of glomerular lesions.  
4.1 Anti-GBM nephritis and Goodpasture’s Syndrome 
By light microscopy, variable degrees of necrotising extracapillary lesions can be observed, 
which range from focal and segmental to global and diffuse (Fig 1).  
 
 
Fig. 1. Anti-GBM nephritis. A large area of necrosis of the glomerular tuft is surrounded by 
a circumferential crescent. Inflammatory cells surround the glomerulus.  
Extracapillary lesions are composed by monocytes, epithelioid macrophages and epithelial 
cells. Glomeruli not involved by these lesions and the parts of the glomerulus not affected 
by necrosis can present normal features, but more commonly they show mild to moderate 
mesangial proliferation, some degree of mesangial matrix expansion, and increased 
leukocyte infiltration. Intraglomerular inflammatory cells are mostly monocyte-
macrophages with variable numbers of T-lymphocytes (Ferrario, 1985; Bolton, 1987). 
In about 50% of cases, multinucleated giant cells can be detected either in the crescent or in 
the periglomerular inflammatory infiltrate, forming the so-called granuloma-like lesions.  
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Generally well corresponding to the degree of glomerular damage, the tubulointerstitium 
shows variable extents of tubular atrophy, oedema, and interstitial inflammation. If the 
biopsy is timely performed, no interstitial fibrosis is observed.  
Vascular lesions are not common, though necrotising arteritis and thrombotic 
microangiopathy have been reported occasionally in the literature (Dean, 1991; Stave, 1984). 
Immunofluorescence is diagnostic, with the linear deposition of IgG along the glomerular 
basement membrane. This aspect can be best appreciated in glomeruli not particularly 
damaged, whereas it is more difficult to be seen when the glomerular capillary is largely 
destroyed by necrosis or compressed by extensive cellular crescents. 
A combination of IgG and C3 can also be found, as well as a linear deposition of IgA or IgM 
(Gris, 1991; Peto, 2011) has been reported. 
Linear IgG staining can be also detected along the Bowman’s capsule, and along the tubular 
basement membranes. Additionally, the fibrinogen antiserum strongly stains the areas of 
necrosis in the tuft and within the crescents. 
4.2 ANCA-associated renal vasculitis 
Irrespective of diagnosis, identical renal microscopy features can be observed in Wegener’s 
granulomatosis, microscopic polyangiitis, and renal limited vasculitis. Necrotising 
glomerulonephritis and extracapillary proliferation are the renal hallmark of these diseases, 
and can be found with variable degrees of association. Necrosis can be present alone in cases 
when renal biopsy is early performed, but more commonly is associated with segmental 
areas of extracapillary proliferation. Particularly compromised glomeruli show instead large 
areas of necrosis of the tuft and circumferential crescents, with frequent rupture of the 
Bowman’s capsule and intense periglomerular leukocyte infiltration, so that the limit of the 




Fig. 2. ANCA-associated vasculitis. A large rupture of the Bowman’s capsule can be 
observed.  
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Extracapillary and granuloma-like lesions are mainly made by inflammatory cells, mostly 
acutely activated monocyte-macrophages (Fig. 3, Fig 4) (Rastaldi, 1996; Rastaldi, 2000), 
whose entrance into the glomerulus seems to be facilitated by the de novo expression of the 
adhesion molecule VCAM-1 (Fig 5).  
 
 
Fig. 3. ANCA-associated vasculitis. Glomerular damage and periglomerular granuloma-like 
reaction are mainly composed by monocyte-macrophages, as witnessed by the positivity for 
the marker CD68. 
 
 
Fig. 4. ANCA-associated vasculitis. A vast glomerular granuloma-like reaction is strongly 
positive for the marker of acutely activated monocyte-macrophages 27E10.  
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The acute activation of cells composing the glomerular granuloma-like reaction 
differentiates this type of alteration from other kind of tissue granulomas, where acute 
macrophages have not been found (Bhardwaj, 1992). 
Differently from those observed in other diseases, monocyte-macrophages present in renal 
vasculitis are proliferating cells, as we have shown by staining with antibodies against 
PCNA (Fig 6) and Ki67 (Rastaldi, 2000). 
 
 




Fig. 6. ANCA-associated vasculitis. PCNA labels numerous cells in and around the 
glomerulus. 
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Depending on the timing of renal biopsy, glomeruli can be affected by active lesions or by 
more sclerotic alterations. It is not infrequent to observe both types of lesions in the same 
renal biopsy and even in the same glomerulus (Fig 7). 
 
 
Fig. 7. ANCA-associated vasculitis. The glomerulus shows evident necrotic damage in the 
upper part of the crescent, whereas the lower part is already fibrous. 
Besides periglomerular infiltrates, focal perivascular inflammatory cells are frequently 
detected in the interstitium, and a diffuse interstitial leukocyte infiltration is also present, 
whose degree well corresponds to the extent of glomerular damage. Interstitial cells are 
mainly monocyte-macrophages and T-lymphocytes. 
Prevalence of eosinophils, in association to the clinical symptoms of asthma, and 
increased numbers of circulating eosinophils, stand for a diagnosis of Churg-Strauss 
syndrome. 
By definition, in ANCA-associated renal vasculitis immune deposits are absent or few and 
scattered, hence the term pauci-immune glomerulonephritis. Instead, the fibrinogen 
antiserum strongly stains areas of necrosis of the tuft and fibrin deposits into the 
crescents. 
4.3 Post-infectious glomerulonephritis 
Either post-streptococcal and other post-infectious glomerulonephritis can present with a 
rapidly progressive course, which is indicative of a poor prognosis. 
Several systemic infections, especially occult, such as infective endocarditis, infected atrio-
ventricular shunts, visceral abscesses, and infected vascular prostheses, can be at the origin 
of RPGN. Blood levels of complement can be reduced. 
By light microscopy necrotising lesions, but more frequently extracapillary damage without 
necrosis of the tuft are observed.  
Especially in case of streptococcal infections, the presence of numerous intraglomerular 
granulocytes (so-called glomerular exudative lesions) (Fig 8) is useful for diagnostic 
purposes. 
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In post-streptococcal GN, granular IgG and C3 deposits are the most common finding. IgG, 
C3, and IgM deposits can be observed in other post-infectious GN, at various locations, but 
primarily subendothelial and mesangial.  
 
 
Fig. 8. Post-streptococcal GN. Numerous granulocytes can be observed in the glomerular 
tuft and in the crescent.  
4.4 RPGN complicating primary and secondary glomerular diseases 
Though rarely, any primary or secondary glomerular diseases can be complicated by a 
rapidly progressive course and display necrotising crescentic glomerulonephritis at light 
microscopy. Very recently, a report has shown for the first time the appearance of RPGN 
complicating the course of AL amyloidosis (Crosthwaite, 2010). Cases of association of 
primary or secondary glomerulonephritis and anti-GBM disease or renal vasculitis have 
also been published, as well as cases of association of anti-GBM disease and ANCA-
positive renal vasculitis (Curioni, 2002; O’Connor, 2010). Diagnosis in these patients 
requires skilful and careful analysis of clinical features, renal biopsy findings, and 
hematochemical exams.  
4.4.1 IgA nephropathy and Henoch-Schonlein purpura 
Less than 10% of patients with primary IgA nephropathy or Henoch-Schonlein syndrome 
have been reported with a truly rapidly progressive course (Ferrario, 1997).  
Clinical features of cutaneous purpura or abdominal and joint pain, accompanied by the 
finding of a small vessel leukocytoclastic vasculitis, most frequently detected in skin 
biopsies, help in making a diagnosis of systemic disease.  
Focal segmental or global and diffuse necrotising and extracapillary lesions of the 
glomerulus can be found, or extracapillary lesions can be present without necrosis of the 
glomerular tuft (Fig 9), which always presents variable degrees of mesangial proliferation 
and expansion of the mesangial matrix.  
Immunofluorescence shows prevailing IgA mesangial deposits, possibly in combination 
with IgG and C3 deposition, especially in the systemic disease. 
 




Fig. 9. Primary IgA nephropathy. A circumferential crescent surrounds a glomerulus 
affected by mesangial proliferation and mesangial expansion.  
4.4.2 Systemic lupus erythematosus 
Among the histological classes of SLE nephritis (Weening, 2004), RPGN is more frequently 
observed in classes III and IV. In these cases the occurrence of antineutrophil cytoplasmic 
antibodies is not uncommon and is thought to contribute to the development of necrotising 
and crescentic glomerular lesions (Sen, 2003). 
Extensive extracapillary proliferation has been rarely reported (Fig 10), whereas segmental 
necrotising extracapillary alterations are a rather common finding, but not always translate 
in a RPGN clinical phenotype. 
 
 
Fig. 10. Rapidly progressive class IV SLE nephritis. A circumferential crescent surrounds a 
glomerulus affected by intense intracapillary proliferation, mesangial expansion, and 
leukocyte infiltration. 
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Immunofluorescence has the typical findings of lupus nephritis, according to the class of 
disease, with frequent “full house” deposition, and fibrinogen positivity in necrotic areas 
and crescents. 
5. Pathogenesis and experimental models 
In recent years, thanks to the possibilities offered by molecular modelling, genetic studies, 
and the generation of novel animal models better reproducing human disease features, 
important advances have been made in understanding pathogenetic mechanisms 
underlying certain forms of RPGN, especially anti-GBM nephritis and ANCA-associated 
renal vasculitis.  
Instead, it continues to be less clear why a rapidly progressive course can complicate 
virtually any type of primary and secondary glomerulonephritis.  
5.1 Anti-GBM nephritis and Goodpasture’s disease 
The seminal discovery in understanding the pathogenesis of the disease was the 
identification of the antigen that causes production of pathogenic autoantibodies (Saus, 
1988).  
Thereafter, injection of the recombinant antigen, i.e. the noncollagenous domain (NC1) of 
the alpha3chain of collagen type IV, was shown to induce a severe glomerulonephritis in 
Wistar-Kyoto rats (Sado, 1998), hence proving a direct relationship between the self-antigen 
sustaining autoantibody production and the disease.  
More recently, a second class of autoantibodies has been described, which are specific for 
the alpha5NC1 domain, occur in 70% of affected patients, and seem to be associated with a 
worse renal prognosis (Pedchenko, 2010).  
In the normal glomerular basement membrane, the NC1 domain is assembled in 
alpha345NC1 hexamers, whose quaternary organisation has been shown in a three-
dimensional model (Vanacore, 2008) as an ellipsoid-shaped structure composed by two NC1 
trimers joined at the base by hydrophobic and hydrophilic interactions and reinforced by 
sulfilimine bonds. This crosslinked alpha345NC1 hexamer is inert to antibody binding. Anti-
GBM antibodies in fact can bind only to dissociated monomer and dimer subunits that form 
after alteration of the hexamer and expose pathogenic neoepitopes. This explains why 
passive transfer of antibodies to the mouse, where hexamers in the GBM are completely 
crosslinked, does not result in glomerulonephritis (Luo, 2010). 
The major epitopes within the alpha3 and alpha5 subunits have been identified as well, and 
named EA-alpha3, EA-alpha5, and EB-alpha3 (Netzer, 1999; Hellmark, 1999; Pedchenko, 
2010).  
Several questions, primarily regarding the causes of hexamer alteration that induce epitope 
exposure and antibody production, need to be answered. At present, the most accredited 
hypothesis is that environmental factors act in genetically predisposed subjects, leading to 
epitope alteration and antibody formation.  
As for genetic predisposition, positive and negative associations with HLA molecules have 
been found, especially with the MHC class II HLA-DRB1*1501 allele (Yang, 2009), which is 
strongly associated to anti-GBM disease. 
A number of experimental data are in favour of a role played by FcR gene and the 
complement system, though their precise role in humans is still unclear.  
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Instead, several experimental models implicate T-cell mediated immunity in the 
pathogenesis of anti-GBM disease, which is based on the following findings. In rats, anti-
GBM disease can be induced by injecting alpha3(IV)NC1-specific CD4+Tcells (Wu, 2002). 
Anti-CD8 monoclonal antibodies reduce disease severity and antigen-specific CD8+Tcell 
clones have been found in diseased patients (Reynolds, 2002). Invariant natural killer cells 
(iNKT) could have a role as well, because the disease has a worse course in iNKT cell-
deficient mice (Mesnard, 2009). Finally, mice deficient in IL-23, which is important for the 
maintenance of Th17 cells, the CD4+Tcell subset producing IL17, are protected from anti-
GBM disease (Ooi, 2009). 
5.2 ANCA-associated renal vasculitis 
The discovery of ANCAs (Falk, 1988) radically changed not only the diagnosis of small 
vessel vasculitis, but also introduced an important element for the study of the etiology and 
pathogenesis of this group of diseases. Major ANCA autoantigens are two proteins 
contained in azurophil granules of neutrophil granulocytes, MPO and PR3, which are 
mainly expressed during neutrophil development at the myeloblast and promyelocytic 
stage (Cowland, 1999). They are aberrantly expressed in mature neutrophils of ANCA 
patients, whereas are silenced in mature neutrophils of healthy subjects (Yang, 2004).  
In vivo first evidence for a pathogenetic role of ANCA was demonstrated by injection of 
anti-MPO antibodies or anti-MPO lymphocytes, causing a pauci-immune focal necrotising 
extracapillary glomerulonephritis (Xiao, 2002). Subsequent research then showed that in this 
model neutrophil granulocytes are required, because mice depleted of neutrophils do not 
develop the disease, and disease worsening is obtained by priming neutrophils using a pro-
inflammatory stimulus (Xiao, 2005). The model has been also useful in investigating the role 
of the alternative complement pathway, because the disease does not occur in C5 or Factor B 
null mice, but it fully develops in C4-KO animals (Xiao, 2007). 
In an additional model, MPO-KO mice were first immunised with mouse MPO, determining 
production of anti-MPO antibodies. These mice having circulating anti-MPO antibodies 
were then irradiated and subsequently transplanted with MPO-wild type or MPO-KO bone 
marrow cells. A pauci-immune necrotising-crescentic glomerulonephritis developed only in 
mice engrafted with MPO-wild type cells, indicating the requirement for bone marrow 
derived cells in disease development (Schreiber, 2006). 
5.3 Cells involved in crescent formation 
Along the years, composition of glomerular extracapillary proliferation has been, and still 
remains, the object of intense investigation and discussion.  
Though the exact mechanism/s of crescent formation remain elusive, novel animal models 
have recently added important information, that will lead to further clarification of the 
molecular pathways involved and the potential identification of possible novel therapeutic 
targets. 
A word has first to be spent in stating that, morphologically speaking, extracapillary 
proliferation is a heterogeneous phenomenon. It has been shown by several investigators 
that presence or absence of necrosis of the glomerular capillary is relevant to the type of 
crescent. When necrosis is present, the crescent is more inflammatory, and mainly formed 
by monocyte-macrophages. In absence of tuft necrosis, the crescent has more epithelial and 
less inflammatory features. 
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If the presence of inflammatory cells and epithelioid macrophages has never been 
questioned either in animal models and in human disease, opposite data have been obtained 
when attempting to define the epithelial cell composition. 
Until some years ago, both experimental and human studies aiming to study the cells 
contained in the crescents were mostly based on morphological findings and 
immunostaining. The conflicting results produced by these studies were due not only to the 
specific type of experimental model or of human disease under analysis, but especially to a 
dysregulated phenotype with loss of specific markers. In fact, both podocytes and parietal 
epithelial cells are likely to change their original resting phenotype once they start 
proliferating and filling the Bowman’s space.  
The advent of novel experimental models, though not generating unifying and conclusive 
data, is providing more convincing proofs of the participation of either podocytes or parietal 
epithelial cells, based on tagged expression of specific molecules. 
Convincing evidence of podocyte contribution to crescent formation has been shown in a 
podocyte specific mouse model of Vhlh gene knockout (Ding, 2006). These mice showed 
rapidly progressive glomerulonephritis by 4 weeks of age and died by terminal renal failure 
after 3-4 weeks. Histology displayed a crescentic glomerulonephritis, and podocytes 
expressing tagged-ZO1 were found into the crescents. A part from showing podocyte 
participation in crescent formation, the model also identified a novel pathway potentially 
operating in extracapillary glomerulonephritis; deletion of Vhlh in fact resulted in 
stabilisation of hypoxia inducible factor-aplha (HIF1alpha) and consequent upregulation of 
target genes, among them the chemokine receptor CXCR4. Further, podocyte-specific 
expression of CXCR4 was sufficient to induce podocyte proliferation and crescent 
formation, and CXCR4 positivity was observed in glomeruli of human biopsies with 
necrotising extracapillary lesions, suggesting that the VHLH-HIF-CXCR4 pathway may 
have functional relevance also in humans. 
The contribution of parietal epithelial cells to crescent formation has been recently shown in 
a mouse model where a construct containing 3 kb of the human podocalyxin (hPODXL1) 5′ 
flanking region and 0.3 kb of the rabbit Podxl1 5′ untranslated region were used to drive 
expression of rabbit podocalyxin, and transgene expression was detected exclusively within 
PECs but not in podocytes. In this model, injection of nephrotoxic serum caused 
extracapillary glomerulonephritis and cells within crescents could be clearly identified as of 
parietal origin (Smeets, 2009, a). 
As a final consideration, recent work has demonstrated that the Bowman’s capsule contains 
renal progenitors mainly located at the urinary pole of the glomerulus (Ronconi, 2009). If it 
is true that these cells are able to regenerate either tubular cells and podocytes, then their 
participation to crescent formation can be viewed as the pathological consequence of a 
tentative to repair glomerular damage in the course of inflammatory conditions (Smeets, 
2009, b). 
6. Conclusion  
RPGN still constitute a threat for human health and survival. Despite numerous 
improvements in understanding the pathogenesis of these diseases, numerous questions 
still remain unanswered and will need clarification before providing targeted, pathway-
based, novel therapeutics.  
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1. Introduction 
This chapter will provide a comprehensive review of post-infectious glomerulonephritis 
focusing in particular on the changing epidemiology and long term outcome. 
The immunological response of the kidney to an insult results in glomerulonephritis. The 
insult can result from a large number of conditions, both infectious and non-infectious. 
Regardless of the initial insult, the outcome is similar in terms of pathology and clinical 
symptoms. The most common and most-studied cause is post streptococcal 
Glomerulonephritis (PSGN). A list of causes is presented in Table 1.  
 
INFECTIOUS 
Bacterial: Streptococcal (PSGN), methicillin-resistant Staphylococcus aureus (MRSA), 
pneumococcal pneumonia, typhoid, secondary syphilis, meningococcemia, infective 
endocarditis, shunt nephritis, sepsis 
Viral: Hepatitis B, infectious mononucleosis, mumps, measles, varicella, vaccinia, 





Primary glomerular diseases: Membranoproliferative GN (MPGN), IgA nephropathy, 
mesangial proliferative GN 
Multisystem systemic diseases: Systemic lupus erythematosus, vasculitis, Henoch-Schönlein 
purpura, Goodpasture syndrome, Wegener granulomatosis  
Miscellaneous: Gullian-barre syndrome, pertussis-tetanus vaccine, serum sickness 
Table 1. Causes of post-Infectious Glomerulonephritis 
2. Burden of disease and changing epidemiology 
Of all the bacterial pathogens, group A streptococcus (GAS) causes the widest range of 
illness in humans. These illnesses range from local infections of the skin and throat 
(impetigo and pharyngitis respectively) to invasive infections as well as the significant post-
infectious immunological sequelae such as the well documented acute rheumatic fever and 
acute post-streptococcal glomerulonephritis and the lesser known PANDAS (Paediatric 
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infectious immunological sequelae such as the well documented acute rheumatic fever and 
acute post-streptococcal glomerulonephritis and the lesser known PANDAS (Paediatric 
Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) [1]. 
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While global estimates of the burden of disease due to GAS infections are difficult to get, 
some estimates have been reported which are based on published population studies. The 
estimate of 500 000 deaths per year due to GAS makes it a major human Pathogen [2]. This 
minimal estimate places GAS infections as less common than HIV, Mycobacterium 
tuberculosis, Plasmodium falciparum and Streptococcus pneumonia but as common as rotavirus, 
measles, Haemophilus influenzae type b and hepatitis B as a cause of global mortality [2]. In 
addition there is the long-term morbidity associated with GAS infections.  
The global burden of severe group A streptococcal disease is concentrated largely in 
developing countries and within disadvantaged populations living in developed countries 
such as Aboriginal Australians. The review of population based studies estimated the 
prevalence of severe GAS disease at a minimum of 18·1 million cases, with 1·78 million new 
cases each year [2]. The greatest burden was due to rheumatic heart disease, with a 
prevalence of at least 15·6 million cases, with 282 000 new cases and 233 000 deaths each 
year. The burden of invasive GAS diseases was found to be unexpectedly high, with at least 
663 000 new cases and 163 000 deaths each year. In addition, there were more than 111 
million prevalent cases of GAS pyoderma, and over 616 million incident cases per year of 
GAS pharyngitis [2]. The review estimated that over 470 000 cases of acute post-
streptococcal glomerulonephritis occur annually, with approximately 5000 deaths (1% of 
total cases), 97% of which were in less developed countries [2]. 
The global incidence of acute PSGN was estimated at 472,000 cases per year, of which 
456,000 ( 96.6%) occurred in less developed countries [3, 4]. A similar distribution of higher 
incident cases in less developed countries is also reported in a review of population based 
studies [2]. A review of 11 population-based studies documenting the incidence of acute 
PSGN in children from less developed countries or those that included substantial minority 
populations in more developed countries, estimated 24·3 cases per 100,000 person as the 
median PSGN incident rate [2]. The same review estimated an incidence in adults of 2 cases 
per 100,000 person-years for developing countries and 0.3 per 100,000 person-years in 
developed countries [2]. Due to the paucity of data in adults with PSGN, the estimate for 
developing countries was based on data from Kuwait and for developed countries on data 
from Italian Biopsy Registry and the most conservative estimates were reported [2]. Another 
recent study described a slightly higher incidence of 9.5-28.5 cases per 100,000 person-years 
in developing countries [5]. These rates represent only the clinical cases. When 
asymptomatic cases are screened for in household contacts and family members, 
asymptomatic disease is reported to be 4-19 times greater [5-7].  
PSGN can occur sporadically or epidemically. The changing pattern of PSGN over the last 
few decades has been described in studies from Florida [8] and Singapore [9]. The overall 
incidence of PSGN has decreased over the last few decades [10]. The reasons for this 
decline have not been clearly delineated but possible reasons are the widespread use of 
antibiotics, changes in etiological pathogens, altered susceptibility of the host, better 
health care delivery and improved socioeconomic and nutritional conditions [8-10]. 
Nevertheless, epidemics and clusters of cases continue to appear in several regions of the 
world and sporadic cases of PSGN account for 21% (4.6–51.6%) of children admitted to the 
hospital with acute renal failure in developing countries [5]. Although epidemic PSGN 
has decreased dramatically and is almost unknown in the developed world, epidemics of 
PSGN continue to occur in the developing world, mainly in Africa, West Indies and the 
Middle East, as well as in Indigenous people living in the developed world [11]. 





dwellings or areas with poor hygienic conditions, both urban and rural. These conditions 
are especially prevalent in Aboriginal peoples of Australia living in remote communities, 
in settings with a high burden of infectious disease and overcrowding [11, 12]. Sporadic 
cases of PSGN occur in the Northern Territory of Australia each year with outbreaks 
every 5-7 years [13]. PSGN in New Zealand occurs mostly in children of Pacific Island and 
Maori heritage (>85% of cases) [14]. Sporadic cases of PSGN also continue to be reported 
from all over the world.  
The rates are higher in children than in adults, and PANDAS is described solely in the 
paediatric age group. PSGN primarily affects children, aged 2-12 years, with clinically 
detectable cases estimated to be 10% of children with pharyngitis and up to 25% of children 
with impetigo during epidemics [15, 16]. Children account for 50-90% of epidemic cases, 
with 5-10% occurring in people > 40 years and 10% in those below 2 years of age [5]. PSGN 
is uncommon below 3 years of age and rarely seen below 2 years [17]. This low incidence of 
PSGN is likely to be due to the decreased immunogenicity of children below 2 years of age, 
for although GAS pharyngitis is uncommon in children of this age, GAS skin infections are 
common. Decreased immunogenicity likely results in less robust immune complex 
formation thus leading to less PSGN [18]. 
Males have more symptomatic disease, but this difference is no longer present when 
symptomatic and asymptomatic cases are considered together [19]. Spontaneous recovery 
occurs in almost all patients, including those who develop renal insufficiency during the 
acute phase [16], with 1% of all paediatric patients developing renal insufficiency.  
There are no large scale published studies of bacterial infections associated with GN other 
than streptococcal infection. These are limited to small cases series and individual cases 
reports. The most common of these are related to staphylococcal infections, both methicillin 
sensitive [20] and methicillin resistant [21, 22]. A case series of 10 cases, age range 21-65 
years, of MRSA-associated glomerulonephritis reported polyclonal increases of IgA and IgG 
and massive T cell activation and suggested the role of the enterotoxin as a bacterial super-
antigen initiating the immunological response leading to the glomerulonephritis [22]. The 
histopathologic findings on immunofluorescence in the patients with MRSA infection with 
nephritis resemble those seen in IgA nephropathy [22]. Nephritis associated with 
endocarditis and ventricular shunts is associated with staphylococcal infection [22]. A 
number of infections can cause nephritis as listed in table 1. Most have been reported as case 
reports, such as a report of nephritis following malaria due to falciparum vivax infection in a 
7 year old girl [23], and a report of nephritis following pneumococcal pneumonia in an adult 
male [24].  
Hepatitis-B-associated glomerulonephritis (HBGN) is a distinct entity occurring frequently 
in hepatitis-B-prevalent areas of the world. The disease affects both adults and children who 
are chronic hepatitis-B-virus (HBV) carriers with or without a history of overt liver disease. 
The diagnosis is established by serologic evidence of HBV antigens/antibodies, presence of 
an immune complex glomerulonephritis, immunohistochemical localization of 1 or more 
HBV antigens and pertinent clinical history [25]. With the high incidence of hepatitis B in 
Asia, this entity assumes a greater public health importance. A study from China reported 
205 cases from a single hospital from September 1995 to November 2008 [26]. In this series, 
the peak incidence of HBV-GN was between 20 -40 years of age, with a 3:1 predominance of 
males. The most common clinic manifestation was nephrotic syndrome and the most 
common pathology was membranous nephropathy. Decreased renal function was present in 
10% of cases. The degree of albuminuria correlated with the viral load [26]. 
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While global estimates of the burden of disease due to GAS infections are difficult to get, 
some estimates have been reported which are based on published population studies. The 
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minimal estimate places GAS infections as less common than HIV, Mycobacterium 
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Renal disease is not uncommon in those infected with HIV. The most common 
manifestation of HIV in the kidney is HIV-associated nephropathy (HIVAN). 
Immunotactoid glomerulonephritis is a rare disorder found in 0.06% of renal biopsies 
characterized by organized tubular immune complex deposits. This is seen more commonly 
Caucasians and tends to occur in an older age group. There are 6 reported cases of HIV 
associated immunotactoid glomerulonephritis [27]. 
3. Pathogenesis 
The kidney has a limited number of ways of responding to injury. Similar pathological signs 
may be the end result of different processes, produced by different initiating mechanisms 
and different molecular pathways may perpetuate the injury process. The initiation and 
development of the inflammatory response of the kidney to infection are still poorly 
understood.  
The pathognomonic feature of PSGN is the deposition of immune complexes in the 
glomerular basement membrane. A proposed sequence of events is that a nephritogenic 
antigen(s) leads to the activation of the complement pathway and/or activates plasmin or 
production of the circulating immune-complexes. These then lead to increased permeability 
of the glomerular basement membrane, which allows deposition of the immune complexes, 
and leakage of the protein and red blood cells. The nephritogenic antigen is responsible for 
the C3 deposition, the recruitment of immune cells, tissue destruction and IgG deposition 
which further aggravates tissue injury. Complement activation leads to the release of 
cytokines, such as C5a, which attracts phagocytes, and proliferation of intrinsic cells and 
formation of a membrane attack complex which also aggravate the process. The definitive 
nephritogenic antigen has not yet been defined, although a large number of streptococcal 
factors (M proteins) have been proposed as the triggering factor. M proteins are present on 
the pili of the organism and more than 100 have been identified so far. Nephritogenic M 
proteins are types 1, 2, 4, 3, 25, 49, and 12 following skin infections and types 47, 49, 55, 2, 60, 
and 57 following throat infections [28]. Infections with nephritogenic streptococci have 
considerable variability in their ability to cause nephritis. The reason for this variability is 
not known. 
Pathology shows typical glomerular changes which include proliferation of mesangial, 
endothelial and epithelial cells, inflammatory exudate and deposition of C3 early in the 
disease process followed by deposition of IgG. This immune deposition has been classified 
into 3 patterns [29]. The “starry sky” pattern represents an irregular and finely granular 
deposit of C3 and IgG along the glomerular capillary walls and in the mesangium. This 
occurs early in the course of the disease and is also seen in subclinical cases [28, 29]. The 
“mesangial pattern” has mainly C3 and some IgG in the mesangium. The “garland pattern” 
shows dense deposits along the capillary walls, is commonly associated with severe 
proteinuria and a poor prognosis [28, 29].  
The immunological response of the kidney to an insult results in glomerulonephritis. The 
causal factors that underlie acute GN can be broadly divided into infectious and 
noninfectious groups. The most common infectious cause of acute GN is infection by 
Streptococcus species (ie, group A, beta-hemolytic). Nonstreptococcal postinfectious GN may 
also result from infection by other bacteria, viruses, parasites, or fungi. Bacteria besides 
group A streptococci that can cause acute GN include diplococci, other streptococci, 
staphylococci, and mycobacteria. Salmonella typhosa, Brucella suis, Treponema pallidum, 





In the absence of evidence of a recent group A beta-hemolytic streptococcal infection, 
infections with Cytomegalovirus (CMV), coxsackievirus, Epstein-Barr virus (EBV), hepatitis 
B virus (HBV) [30], rubella, rickettsiae (as in scrub typhus), and mumps virus may be 
accepted as causal organisms. Similarly, attributing glomerulonephritis to a parasitic or 
fungal etiology requires the exclusion of a streptococcal infection. Possible organisms are 
Coccidioides immiti, Plasmodium malariae, Plasmodium falciparum, Schistosoma mansoni, 
Toxoplasma gondii, filariasis, trichinosis, and trypanosomes. While hepatitis B infection has 
been well documented as a cause of renal involvement and glomerulonephritis [25, 26], 
acute GN is as a rare complication of hepatitis A [31]. 
Noninfectious causes of acute GN may be divided into primary renal diseases, systemic 
diseases, and miscellaneous conditions or agents. The primary renal diseases are 
membranoproliferative glomerulonephritis (MPGN), IgA nephropathy and mesangial 
proliferative glomerulonephritis. Multisystem systemic diseases that can cause acute GN are 
vasculitis such as Wegener granulomatosis, polyarteritis nodosa and hypersensitivity 
vasculitis, collagen-vascular diseases like systemic lupus erythematosus (SLE) which causes 
glomerulonephritis through renal deposition of immune complexes, Henoch-Schönlein 
purpura and Goodpasture syndrome. Miscellaneous noninfectious causes are Guillain-Barré 
syndrome, Diphtheria-pertussis-tetanus (DPT) vaccine and serum sickness. These are 
summarised in table 1.  
It is important to identify the exact aetiology of the glomerulonephritis as the prognosis 
differs widely depending on the underlying cause. There are a number of clinical and 
laboratory features that may help to differentiate between or even point to a particular cause 
of glomerulonephritis. The latent period between infection and nephritis is helpful in 
differentiating PSGN from IgA nephropathy. In contrast to the latent period of 2-3 weeks 
seen in PSGN, the nephritis of IGA nephropathy may occur either at the same time or just 1-
2 days after an upper respiratory infection. Similarly, patients with nephritis of chronic 
infection have an active infection at the time nephritis becomes evident. Despite the chronic 
nature of the underlying infection, the associated nephritis can present acutely. Circulating 
immune complexes play an important role in the pathogenesis of acute GN in these 
diseases.  
The failure of the C3 levels to return to normal should prompt consideration of the 
possibility of MPGN or SLE as the underlying cause. MPGN is a chronic disease which can 
manifest with an acute nephritic picture. Gross haematuria is unusual in lupus nephritis. 
Other associated systemic findings may identify the underlying systemic disease, for 
example, vasculitic lesions of the lower extremities point to an underlying vasculitis as the 
cause of glomerulonephritis.  
4. Clinical presentation 
The typical presentation is the abrupt onset of acute nephritis occurring 1-3 weeks after a 
streptococcal throat infection and 3-6 weeks after skin infection [28]. The nephritis is 
characterised by the triad of oedema, gross haematuria, and hypertension. The classical 
presenting feature is the presence of “coca-cola” coloured urine which is characteristic of 
homogenous gross haematuria [32]. Other common features are facial puffiness and 
hypertension secondary to fluid overload and urinary abnormalities such as albuminuria 
and the presence of red cell casts. General features like malaise, weakness, and anorexia may 
occur in about half the patients and a minority complain of nausea and vomiting. Within a 
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infection have an active infection at the time nephritis becomes evident. Despite the chronic 
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immune complexes play an important role in the pathogenesis of acute GN in these 
diseases.  
The failure of the C3 levels to return to normal should prompt consideration of the 
possibility of MPGN or SLE as the underlying cause. MPGN is a chronic disease which can 
manifest with an acute nephritic picture. Gross haematuria is unusual in lupus nephritis. 
Other associated systemic findings may identify the underlying systemic disease, for 
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week or so from onset of symptoms, most patients with PSGN begin to experience 
spontaneous resolution of fluid retention and hypertension and the urine abnormalities 
begin to subside. The low C3 levels begin to rise and normalise by 8 weeks. Normal urine 
findings are found by 12 weeks.  
Microscopic haematuria is universally present. Of the triad of features, oedema is seen in 
85% of cases and is often the presenting symptom, gross haematuria in 40% of cases (range 
30-50%) and hypertension in 50-95% of hospitalised cases. Approximately 95% of clinical 
cases have at least 2 manifestations, and 40% have the full-blown acute nephritic syndrome. 
The puffiness of the face or eyelids is sudden, usually prominent upon awakening and tends 
to subside at the end of the day if the patient is active. The oedema is a result of a defect in 
renal excretion of salt and water leading to fluid overload. The severity of edema does not 
correlate well with the degree of renal impairment. 
In most cases, urinary abnormalities clear by 12 weeks, although proteinuria may persist for 
6 months to 3 years and microscopic haematuria from 1 year to 4 years after the onset of 
nephritis [33]. In some cases, generalized edema and other features of circulatory 
congestion, such as dyspnea, may be present. 
Accompanying this clinical picture is laboratory evidence of streptococcal infection, 
typically increasing antistreptolysin-O titers (ASOT) or streptozyme titres following throat 
infections and anti-DNase B titers following skin infections. Complement levels are 
decreased; low C3 levels are found in almost all patients with acute PSGN and C4 levels 
may be slightly low. These low levels of C3 usually normalize within 8 weeks after the first 
sign of PSGN [34], although up to 12 weeks has been reported [33]. The typical 
accompanying histopathology is one of diffuse cellular proliferation in the glomerulus, an 
exudate containing neutrophils and monocytes and variable degrees of complement and 
immunoglobulin deposition. In most cases, hypertension subsides, renal function returns to 
normal and all urinary abnormalities eventually disappear [33]. 
There is, however, a wide variation in the clinical presentation as well in the histopathology 
associated with PSGN. At the severe end of the spectrum is a rapidly rising azotemia with a 
rapidly progressive nephritic picture associated with severe cell proliferation, massive 
exudates and crescent formation in biopsy specimens. This is seen in <5% of PSGN cases 
[19]. The severity of renal failure tends to be directly related to the degree of proliferation 
and crescent formation, and about 50% of these patients recover renal function [35]. This 
type of presentation is more common in the elderly. The mild end of the spectrum, 
represented by subclinical or asymptomatic glomerulonephritis, is more common. Diligent 
examination of people with acute, trivial or self-limited infections caused by a range of 
organisms including various bacteria, parasites or viruses reveal subclinical infection in the 
form of microscopic hematuria, proteinuria and pyuria. Histopathology reveals mesangial 
proliferation with mesangial deposits of C3 and IgG deposits [19]. Asymptomatic household 
contacts of PSGN cases show sub-clinical disease 4-5 times more commonly than the acute 
classical presentation [6, 36]. An older study puts the ratio of asymptomatic cases as high as 
19:1 [7].  
5. Typical findings on investigations  
Urinalysis reveals haematuria in all patients and proteinuria (from trace to 2+ on dipstick 





associated with more severe disease. Red blood cell casts are pathognomonic of acute 
glomerulonephritis. Occasionally other cellular casts and pyuria are present.  
Serological evidence of an antecedent streptococcal infection is present in the form of raised 
ASOT (> 200 IU/ml) and increased anti-DNAse B (which is a better serological marker of 
preceding streptococcal skin infection). Bacteriological evidence of streptococcal disease 
may be present in throat or skin swabs.  
Complement levels especially C3 are low at the onset of symptoms. C4 is usually within 
normal limits in post-streptococcal GN. Causes of nephritis with low complement besides 
PSGN are MPGN, SLE, cryoglobulinemia, Diabetes Mellitus and Hepatitis C Virus. These 
diseases should be screened for in case of either an atypical presentation or atypical clinical 
course of the glomerulonephritis.  
Renal function tests, blood urea, sodium, potassium and serum creatinine may be elevated 
in the acute phase and reflect the decrease in the glomerular filtration rate that occurs at this 
time. These elevations are usually transient. Failure of renal function tests to normalize 
within several weeks or months suggests that the patient may not have PSGN and indicates 
the need to seek an alternative diagnosis by further investigation. The full blood count may 
show anaemia which is usually dilutional and will return to normal once the fluid overload 
resolves.  
Renal ultrasound is not required to make a diagnosis of glomerulonephririts. Renal 
ultrasound images usually reveal normal-sized kidneys bilaterally. Renal imaging is often 
done to confirm that there are two kidneys and that they are structurally normal. It may be 
done as a prelude to a renal biopsy. PSGN is a clinical diagnosis and requires the detection 
of glomerulonephritis and evidence of preceding streptococcal infection. A renal biopsy is 
indicated in cases with an atypical presentation, an atypical course, persistence of clinical 
features, or a persisting low level of complement (C3) or abnormal renal function tests. 
Features that suggest a diagnosis other than PSGN in the early stages may also indicate a 
need for a biopsy. These include the absence of the latent period between streptococcal 
infection and acute glomerulonephritis, anuria, rapidly deteriorating renal function, normal 
serum complement levels, lack of rise in antistreptococcal antibodies, general symptoms of 
systemic disease and either persistent hypertension or lack of improvement in glomerular 
filtration rate for more than 2 weeks. In the recovery phase, persistent low C3 beyond 8 and 
definitely beyond 12 weeks from the onset of illness would indicate a need to look for 
alternate causes and for a renal biospsy.  
6. Treatment  
Treatment of PSGN remains largely supportive. Complete recovery occurs in over 90% of 
children, but only 60% of adults fully recover. The rest develop hypertension or renal 
impairment. 
Treatment is directed towards monitoring the signs and symptoms, in particular facial 
puffiness and hypertension, the main cause of which is fluid overload. Treatment when it is 
required, is mainly directed towards managing the fluid overload, which is responsive to 
diuresis and sodium restriction. Effective diuresis reduces cardiac congestion and controls 
hypertension and in most cases no further treatment is required. Strict input-output 
monitoring is recommended during the acute phase.  
As the hypertension is caused by fluid overload, loop diuretics are the first line treatment 
and may be adequate for control of hypertension. Furosemide in a dose of 40 mg either 
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85% of cases and is often the presenting symptom, gross haematuria in 40% of cases (range 
30-50%) and hypertension in 50-95% of hospitalised cases. Approximately 95% of clinical 
cases have at least 2 manifestations, and 40% have the full-blown acute nephritic syndrome. 
The puffiness of the face or eyelids is sudden, usually prominent upon awakening and tends 
to subside at the end of the day if the patient is active. The oedema is a result of a defect in 
renal excretion of salt and water leading to fluid overload. The severity of edema does not 
correlate well with the degree of renal impairment. 
In most cases, urinary abnormalities clear by 12 weeks, although proteinuria may persist for 
6 months to 3 years and microscopic haematuria from 1 year to 4 years after the onset of 
nephritis [33]. In some cases, generalized edema and other features of circulatory 
congestion, such as dyspnea, may be present. 
Accompanying this clinical picture is laboratory evidence of streptococcal infection, 
typically increasing antistreptolysin-O titers (ASOT) or streptozyme titres following throat 
infections and anti-DNase B titers following skin infections. Complement levels are 
decreased; low C3 levels are found in almost all patients with acute PSGN and C4 levels 
may be slightly low. These low levels of C3 usually normalize within 8 weeks after the first 
sign of PSGN [34], although up to 12 weeks has been reported [33]. The typical 
accompanying histopathology is one of diffuse cellular proliferation in the glomerulus, an 
exudate containing neutrophils and monocytes and variable degrees of complement and 
immunoglobulin deposition. In most cases, hypertension subsides, renal function returns to 
normal and all urinary abnormalities eventually disappear [33]. 
There is, however, a wide variation in the clinical presentation as well in the histopathology 
associated with PSGN. At the severe end of the spectrum is a rapidly rising azotemia with a 
rapidly progressive nephritic picture associated with severe cell proliferation, massive 
exudates and crescent formation in biopsy specimens. This is seen in <5% of PSGN cases 
[19]. The severity of renal failure tends to be directly related to the degree of proliferation 
and crescent formation, and about 50% of these patients recover renal function [35]. This 
type of presentation is more common in the elderly. The mild end of the spectrum, 
represented by subclinical or asymptomatic glomerulonephritis, is more common. Diligent 
examination of people with acute, trivial or self-limited infections caused by a range of 
organisms including various bacteria, parasites or viruses reveal subclinical infection in the 
form of microscopic hematuria, proteinuria and pyuria. Histopathology reveals mesangial 
proliferation with mesangial deposits of C3 and IgG deposits [19]. Asymptomatic household 
contacts of PSGN cases show sub-clinical disease 4-5 times more commonly than the acute 
classical presentation [6, 36]. An older study puts the ratio of asymptomatic cases as high as 
19:1 [7].  
5. Typical findings on investigations  
Urinalysis reveals haematuria in all patients and proteinuria (from trace to 2+ on dipstick 





associated with more severe disease. Red blood cell casts are pathognomonic of acute 
glomerulonephritis. Occasionally other cellular casts and pyuria are present.  
Serological evidence of an antecedent streptococcal infection is present in the form of raised 
ASOT (> 200 IU/ml) and increased anti-DNAse B (which is a better serological marker of 
preceding streptococcal skin infection). Bacteriological evidence of streptococcal disease 
may be present in throat or skin swabs.  
Complement levels especially C3 are low at the onset of symptoms. C4 is usually within 
normal limits in post-streptococcal GN. Causes of nephritis with low complement besides 
PSGN are MPGN, SLE, cryoglobulinemia, Diabetes Mellitus and Hepatitis C Virus. These 
diseases should be screened for in case of either an atypical presentation or atypical clinical 
course of the glomerulonephritis.  
Renal function tests, blood urea, sodium, potassium and serum creatinine may be elevated 
in the acute phase and reflect the decrease in the glomerular filtration rate that occurs at this 
time. These elevations are usually transient. Failure of renal function tests to normalize 
within several weeks or months suggests that the patient may not have PSGN and indicates 
the need to seek an alternative diagnosis by further investigation. The full blood count may 
show anaemia which is usually dilutional and will return to normal once the fluid overload 
resolves.  
Renal ultrasound is not required to make a diagnosis of glomerulonephririts. Renal 
ultrasound images usually reveal normal-sized kidneys bilaterally. Renal imaging is often 
done to confirm that there are two kidneys and that they are structurally normal. It may be 
done as a prelude to a renal biopsy. PSGN is a clinical diagnosis and requires the detection 
of glomerulonephritis and evidence of preceding streptococcal infection. A renal biopsy is 
indicated in cases with an atypical presentation, an atypical course, persistence of clinical 
features, or a persisting low level of complement (C3) or abnormal renal function tests. 
Features that suggest a diagnosis other than PSGN in the early stages may also indicate a 
need for a biopsy. These include the absence of the latent period between streptococcal 
infection and acute glomerulonephritis, anuria, rapidly deteriorating renal function, normal 
serum complement levels, lack of rise in antistreptococcal antibodies, general symptoms of 
systemic disease and either persistent hypertension or lack of improvement in glomerular 
filtration rate for more than 2 weeks. In the recovery phase, persistent low C3 beyond 8 and 
definitely beyond 12 weeks from the onset of illness would indicate a need to look for 
alternate causes and for a renal biospsy.  
6. Treatment  
Treatment of PSGN remains largely supportive. Complete recovery occurs in over 90% of 
children, but only 60% of adults fully recover. The rest develop hypertension or renal 
impairment. 
Treatment is directed towards monitoring the signs and symptoms, in particular facial 
puffiness and hypertension, the main cause of which is fluid overload. Treatment when it is 
required, is mainly directed towards managing the fluid overload, which is responsive to 
diuresis and sodium restriction. Effective diuresis reduces cardiac congestion and controls 
hypertension and in most cases no further treatment is required. Strict input-output 
monitoring is recommended during the acute phase.  
As the hypertension is caused by fluid overload, loop diuretics are the first line treatment 
and may be adequate for control of hypertension. Furosemide in a dose of 40 mg either 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
120 
orally or intravenously is given 12 hourly. Usually treatment is required for less than 48 
hours. Sometimes other anti-hypertensive agents may be needed, especially when the blood 
pressure is very high and it is unsafe to wait for the effect of diuretic therapy. Nifedipine is 
then given every 4-6 hours in doses of 5-10 mg. Rarely parenteral hydralazine may be 
required. Captopril has shown to be effective [37, 38] but should be used in caution in the 
presence of renal failure and hyperkalemia. Occasionally acute renal failure requires 
dialysis. Pulmonary oedema may be complication of severe fluid overload and needs urgent 
treatment. 
It is important to check serum complement levels 6-8 weeks after initial testing to make sure 
they have returned to normal. Blood pressure should be monitored every month for 6 
months and then 6 monthly. Renal function tests and serum creatinine levels repeated every 
3 months after the acute phase for 1 year and then yearly after that. Urine should be checked 
for hematuria and proteinuria every 3-6 months. 
Aggressive therapy using pulse methyprednisolone has been used in adults with poor 
prognostic factors such as nephritic range proteinuria, cellular crescents on biopsy and renal 
insufficiency [39]. Plasmapharesis and pulse methyprednisolone was successfully used in a 
6 year old girl with garland pattern PSGN [40]. Whether this would benefit all patients with 
poor prognosis has not been studied.  
Penicillin treatment is given to treat any persisting streptococcal infection [41]. Methicillin 
resistant staphylococcus should be treated with appropriate antibiotics. Specific infections 
require treatment with specific antibiotics or antiviral agents. Treatment of the underlying 
infection may resolve the glomerulonephritis as well. A review of six trials (a total of 159 
patients) of which five were specified as hepatitis B virus-associated membranous 
glomerulonephritis (HBV-MN) showed that antiviral therapy for hepatitis B infections 
including IFN and lamivudine is effective in leading to remission of proteinuria, HBeAg 
clearance, and HBV-DNA reduction in both children and adults [42]. 
7. Preventing spread  
A case of PSGN has 2 or more of the following clinical manifestations: oedema, macroscopic 
hematuria or dipstick hematuria of ≥ 2, or diastolic blood pressure of >80mmHg if ≤ 13 
years of age and >90 mmHg if >13 years of age, in the presence of a reduced complement 
level (C3) and evidence of streptococcal infection by either elevated ASO or anti-DNAse B 
titres or positive cultures of GAS from skin, if sores are present, or from the throat in the 
absence of skin sores.  
There is evidence that outbreaks can be halted by treating all children with any evidence of 
skin sores with intra-muscular (IM) benzathine penicillin to stop the transmission of the 
bacteria in the community [43]. In experimental PSGN, the nephritic process is prevented if 
penicillin is given within 3 days of the streptococcal infection [41]. Prevention of epidemics 
requires the control of spread of skin sores and infected scabies [44]. Following the 
identification of a case(s), family and household members are screened for the presence of 
skin sores and scabies and tested for urinary abnormalities. Those with skin manifestations 
are treated with penicillin. Those with urinary abnormalities undergo complete 
investigation for PSGN including urea, electrolytes, C3, ASO, anti-DNAse B and cultures for 
streptococcal infection.  
Prevention of epidemics of PSGN requires a community level control of skin sores and 





Improvement in housing, especially reduction in overcrowding, will hinder spread of 
infectious disease. The significant decline in PSGN in Singapore children is attributed to an 
improvement in the socioeconomic status, the health care system and urbanization of the 
country [9]. 
Although research into the development of a vaccine is advanced and 3 GAS vaccines have 
been approved for phase 1 human trials [45], it is unlikely to be available in the near future. 
8. Prognosis  
In keeping with the clinico-pathological picture, the prognosis of PSGN is also extremely 
variable, and largely influenced by clinical presentation and histopathology. An episode of 
PSGN may result in complete recovery, progression of symptoms or progression to renal 
failure. Persistence of symptoms may represent either a slow recovery, limited injury 
without further progression or progression to renal failure.  
The immediate prognosis is generally good. In general, children are believed to have an 
excellent prognosis with the majority showing complete recovery [5]. Fewer than 1% of 
children have elevated serum creatinine values after 10-15 years of follow-up. Adults have a 
poorer prognosis overall. Early mortality can be as high as 25% in the elderly who have 
congestive cardiac failure or azotemia in the early phase. In adults approximately 25% will 
progress to chronic renal failure. These are usually those with massive proteinuria which 
suggests a worse prognosis and often signifies the garland pattern of immune deposits on 
pathology.  
It is difficult to predict the prognosis in an individual case particularly early in the disease. 
While a typical presentation and clinical course indicates a good prognosis and an atypical 
presentation, severe persistent hypertension and abnormal renal function tests, massive 
proteinuria and older age group suggest a poor prognosis, there is a lack of a clinical or 
biochemical marker that might differentiate those with a good prognosis from those with a 
poorer outcome. Neutrophil gelatinase-associated lipocalin (NGAL), is emerging as a 
promising biomarker of acute kidney injury [46, 47], but has not yet been evaluated in PSGN.  
However, some studies have reported persistent urinary abnormalities [8, 11, 19, 48, 49] and 
subtle abnormalities in renal function, as defined by reduction in renal functional reserve, in 
patients who had recovered from PSGN without apparent sequelae [50]  
Epidemic cases have a better prognosis than sporadic cases [14, 51, 52], but not always. An 
outbreak of PSGN in Brazil following an epidemic of Streptococcus equi zooepidemicus 
resulted in a high prevalence of renal abnormalities at a mean follow-up of 5.4 years [53, 54]. 
These were, however, mainly adult patients. A study of Iranian children has shown that 
even mild PSGN may result in impaired renal function and that a rising diastolic blood 
pressure may be an early sign of worsening renal function [55].  
Elderly people have poorer outcomes as do those with co-morbidities, including diabetes, 
cardiovascular and liver diseases [5, 28]. In an Aboriginal population with high rates of 
ESRD, follow-up of children 6-18 years (mean 14.6 years) after epidemic PSGN showed that 
risk of overt proteinuria was 6 times ( 95% CI 2.2-16.9) greater than in healthy controls after 
adjustment of age, sex and birth weight [11, 56]. The Australian Aboriginal population is at 
considerably higher risk than the general Australian population of developing chronic 
diseases such as diabetes mellitus, cardiovascular and renal diseases. There is also a greater 
burden of infectious disease and adverse early life factors such as low birth and infant 
weights. It is proposed that in this high risk population with multiple adverse renal 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
120 
orally or intravenously is given 12 hourly. Usually treatment is required for less than 48 
hours. Sometimes other anti-hypertensive agents may be needed, especially when the blood 
pressure is very high and it is unsafe to wait for the effect of diuretic therapy. Nifedipine is 
then given every 4-6 hours in doses of 5-10 mg. Rarely parenteral hydralazine may be 
required. Captopril has shown to be effective [37, 38] but should be used in caution in the 
presence of renal failure and hyperkalemia. Occasionally acute renal failure requires 
dialysis. Pulmonary oedema may be complication of severe fluid overload and needs urgent 
treatment. 
It is important to check serum complement levels 6-8 weeks after initial testing to make sure 
they have returned to normal. Blood pressure should be monitored every month for 6 
months and then 6 monthly. Renal function tests and serum creatinine levels repeated every 
3 months after the acute phase for 1 year and then yearly after that. Urine should be checked 
for hematuria and proteinuria every 3-6 months. 
Aggressive therapy using pulse methyprednisolone has been used in adults with poor 
prognostic factors such as nephritic range proteinuria, cellular crescents on biopsy and renal 
insufficiency [39]. Plasmapharesis and pulse methyprednisolone was successfully used in a 
6 year old girl with garland pattern PSGN [40]. Whether this would benefit all patients with 
poor prognosis has not been studied.  
Penicillin treatment is given to treat any persisting streptococcal infection [41]. Methicillin 
resistant staphylococcus should be treated with appropriate antibiotics. Specific infections 
require treatment with specific antibiotics or antiviral agents. Treatment of the underlying 
infection may resolve the glomerulonephritis as well. A review of six trials (a total of 159 
patients) of which five were specified as hepatitis B virus-associated membranous 
glomerulonephritis (HBV-MN) showed that antiviral therapy for hepatitis B infections 
including IFN and lamivudine is effective in leading to remission of proteinuria, HBeAg 
clearance, and HBV-DNA reduction in both children and adults [42]. 
7. Preventing spread  
A case of PSGN has 2 or more of the following clinical manifestations: oedema, macroscopic 
hematuria or dipstick hematuria of ≥ 2, or diastolic blood pressure of >80mmHg if ≤ 13 
years of age and >90 mmHg if >13 years of age, in the presence of a reduced complement 
level (C3) and evidence of streptococcal infection by either elevated ASO or anti-DNAse B 
titres or positive cultures of GAS from skin, if sores are present, or from the throat in the 
absence of skin sores.  
There is evidence that outbreaks can be halted by treating all children with any evidence of 
skin sores with intra-muscular (IM) benzathine penicillin to stop the transmission of the 
bacteria in the community [43]. In experimental PSGN, the nephritic process is prevented if 
penicillin is given within 3 days of the streptococcal infection [41]. Prevention of epidemics 
requires the control of spread of skin sores and infected scabies [44]. Following the 
identification of a case(s), family and household members are screened for the presence of 
skin sores and scabies and tested for urinary abnormalities. Those with skin manifestations 
are treated with penicillin. Those with urinary abnormalities undergo complete 
investigation for PSGN including urea, electrolytes, C3, ASO, anti-DNAse B and cultures for 
streptococcal infection.  
Prevention of epidemics of PSGN requires a community level control of skin sores and 





Improvement in housing, especially reduction in overcrowding, will hinder spread of 
infectious disease. The significant decline in PSGN in Singapore children is attributed to an 
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country [9]. 
Although research into the development of a vaccine is advanced and 3 GAS vaccines have 
been approved for phase 1 human trials [45], it is unlikely to be available in the near future. 
8. Prognosis  
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biochemical marker that might differentiate those with a good prognosis from those with a 
poorer outcome. Neutrophil gelatinase-associated lipocalin (NGAL), is emerging as a 
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However, some studies have reported persistent urinary abnormalities [8, 11, 19, 48, 49] and 
subtle abnormalities in renal function, as defined by reduction in renal functional reserve, in 
patients who had recovered from PSGN without apparent sequelae [50]  
Epidemic cases have a better prognosis than sporadic cases [14, 51, 52], but not always. An 
outbreak of PSGN in Brazil following an epidemic of Streptococcus equi zooepidemicus 
resulted in a high prevalence of renal abnormalities at a mean follow-up of 5.4 years [53, 54]. 
These were, however, mainly adult patients. A study of Iranian children has shown that 
even mild PSGN may result in impaired renal function and that a rising diastolic blood 
pressure may be an early sign of worsening renal function [55].  
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diseases such as diabetes mellitus, cardiovascular and renal diseases. There is also a greater 
burden of infectious disease and adverse early life factors such as low birth and infant 
weights. It is proposed that in this high risk population with multiple adverse renal 
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influences, childhood PSGN might be a more important risk factor for ESRD than it would 
be in lower risk populations [11, 44, 57].  
9. References  
[1] Kurlan, R., D. Johnson, and E.L. Kaplan, Streptococcal infection and exacerbations of 
childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. 
Pediatrics, 2008. 121(6): p. 1188-97. 
[2] Carapetis, J.R., et al., The global burden of group A streptococcal diseases. Lancet Infect Dis, 
2005. 5(11): p. 685-94. 
[3] Steer, A.C., M.H. Danchin, and J.R. Carapetis, Group A streptococcal infections in children. J 
Paediatr Child Health, 2007. 43(4): p. 203-13. 
[4] Jackson, S.J., A.C. Steer, and H. Campbell, Systematic Review: Estimation of global burden of 
non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-
streptococcal glomerulonephritis. Trop Med Int Health, 2011. 16(1): p. 2-11. 
[5] Rodriguez-Iturbe, B. and J.M. Musser, The current state of poststreptococcal 
glomerulonephritis. J Am Soc Nephrol, 2008. 19(10): p. 1855-64. 
[6] Rodriguez-Iturbe, B., L. Rubio, and R. Garcia, Attack rate of poststreptococcal nephritis in 
families. A prospective study. Lancet, 1981. 1(8217): p. 401-3. 
[7] Sagel, I., et al., Occurrence and nature of glomerular lesions after group A streptococci infections 
in children. Ann Intern Med, 1973. 79(4): p. 492-9. 
[8] Ilyas, M. and A. Tolaymat, Changing epidemiology of acute post-streptococcal 
glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol, 2008. 
23(7): p. 1101-6. 
[9] Yap, H.K., et al., Acute glomerulonephritis--changing patterns in Singapore children. Pediatr 
Nephrol, 1990. 4(5): p. 482-4. 
[10] Markowitz, M., Changing epidemiology of group A streptococcal infections. Pediatr Infect Dis 
J, 1994. 13(6): p. 557-60. 
[11] White, A.V., W.E. Hoy, and D.A. McCredie, Childhood post-streptococcal glomerulonephritis 
as a risk factor for chronic renal disease in later life. Med J Aust, 2001. 174(10): p. 492-6. 
[12] Streeton, C.L., et al., An epidemic of acute post-streptococcal glomerulonephritis among 
aboriginal children. J Paediatr Child Health, 1995. 31(3): p. 245-8. 
[13] Communicable Diseases Surveillance System. 2002, Centre for Communicable Diseases: 
Darwin, NT. 
[14] Wong, W., M.C. Morris, and J. Zwi, Outcome of severe acute post-streptococcal 
glomerulonephritis in New Zealand children. Pediatr Nephrol, 2009. 24(5): p. 1021-6. 
[15] Stetson, C.A., et al., Epidemic acute nephritis: studies on etiology, natural history and 
prevention. Medicine (Baltimore), 1955. 34(4): p. 431-50. 
[16] Tejani, A. and E. Ingulli, Poststreptococcal glomerulonephritis. Current clinical and pathologic 
concepts. Nephron, 1990. 55(1): p. 1-5. 
[17] Bingler, M.A., D. Ellis, and M.L. Moritz, Acute post-streptococcal glomerulonephritis in a 14-
month-old boy: why is this uncommon? Pediatr Nephrol, 2007. 22(3): p. 448-50. 
[18] Shet, A., et al., Immune response to group A streptococcal C5a peptidase in children: 
implications for vaccine development. J Infect Dis, 2003. 188(6): p. 809-17. 
[19] Kanjanabuch, T., W. Kittikowit, and S. Eiam-Ong, An update on acute postinfectious 





[20] Handa, T., et al., Glomerulonephritis induced by methicillin-sensitive Staphylococcus aureus 
infection. Clin Exp Nephrol, 2003. 7(3): p. 247-9. 
[21] Kobayashi, M. and A. Koyama, Methicillin-resistant Staphylococcus aureus (MRSA) 
infection in glomerulonephritis--a novel hazard emerging on the horizon. Nephrol Dial 
Transplant, 1998. 13(12): p. 2999-3001. 
[22] Koyama, A., et al., Glomerulonephritis associated with MRSA infection: a possible role of 
bacterial superantigen. Kidney Int, 1995. 47(1): p. 207-16. 
[23] Zaki, S.A. and P. Shanbag, Acute glomerulonephritis: an unusual manifestation of 
Plasmodium vivax malaria. Ann Trop Paediatr, 2011. 31(2): p. 181-4. 
[24] Kaehny, W.D., et al., Acute nephritis and pulmonary alveolitis following pneumococcal 
pneumonia. Arch Intern Med, 1978. 138(5): p. 806-8. 
[25] Venkataseshan, V.S., et al., Hepatitis-B-associated glomerulonephritis: pathology, 
pathogenesis, and clinical course. Medicine (Baltimore), 1990. 69(4): p. 200-16. 
[26] Wei, R.B., et al., [Clinicopathological analysis on hepatitis B virus-associated 
glomerulonephritis in 205 patients]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue 
Za Zhi, 2010. 24(6): p. 464-7. 
[27] Chen, Y.M., et al., An unusual cause of membranous glomerulonephritis in a patient with HIV. 
Int Urol Nephrol, 2011. 
[28] Nordstrand, A., M. Norgren, and S.E. Holm, Pathogenic Mechanism of Acute Post-
Streptococcal Glomerulonephritis. Scandinavian Journal of Infectious Diseases, 1999. 
31(6): p. 523-537. 
[29] Sorger, K., et al., Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and 
pathological features. Clin Nephrol, 1982. 17(3): p. 114-28. 
[30] Safadi, R., et al., Glomerulonephritis associated with acute hepatitis B. Am J Gastroenterol, 
1996. 91(1): p. 138-9. 
[31] Aggarwal, A., D. Kumar, and R. Kumar, Acute glomerulonephritis in hepatitis A virus 
infection: a rare presentation. Trop Doct, 2009. 39(3): p. 186-7. 
[32] Pan, C.G., Evaluation of gross hematuria. Pediatr Clin North Am, 2006. 53(3): p. 401-12, vi. 
[33] Yoshizawa, N., Acute glomerulonephritis. Intern Med, 2000. 39(9): p. 687-94. 
[34] Pan, C.G., Glomerulonephritis in childhood. Curr Opin Pediatr, 1997. 9(2): p. 154-9. 
[35] El-Husseini, A.A., et al., Acute postinfectious crescentic glomerulonephritis: clinicopathologic 
presentation and risk factors. Int Urol Nephrol, 2005. 37(3): p. 603-9. 
[36] Tasic, V. and M. Polenakovic, Occurrence of subclinical post-streptococcal glomerulonephritis 
in family contacts. J Paediatr Child Health, 2003. 39(3): p. 177-9. 
[37] Morsi, M.R., et al., Evaluation of captopril versus reserpine and frusemide in treating 
hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr, 
1992. 81(2): p. 145-9. 
[38] Parra, G., et al., Short-term treatment with captopril in hypertension due to acute 
glomerulonephritis. Clin Nephrol, 1988. 29(2): p. 58-62. 
[39] Raff, A., et al., Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the 
adult: is aggressive therapy warranted? Clin Nephrol, 2005. 63(5): p. 375-80. 
[40] Suyama, K., Y. Kawasaki, and H. Suzuki, Girl with garland-pattern poststreptococcal acute 
glomerulonephritis presenting with renal failure and nephrotic syndrome. Pediatr Int, 
2007. 49(1): p. 115-7. 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
122 
influences, childhood PSGN might be a more important risk factor for ESRD than it would 
be in lower risk populations [11, 44, 57].  
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1. Introduction 
Suppurative streptococcal infections of the throat and the skin generate stimuli that lead 
Rheumatic fever (RF) in 1 to 5% of susceptible children. The disease manifests initially as 
polyarthritis, carditis/valvulitis, Sydenham`s chorea, erythema marginatum and/or 
subcutaneous nodules. Chronic renal disease can also occur.  
RF occurs at an early phase of life (3 to 19 years of age); thus, heart damage (carditis) can 
appear in very young children. Rheumatic carditis usually presents as pancarditis, affecting 
the endocardium, myocardium and pericardium. Recurrent acute cardiac lesions frequently 
evolve into chronic rheumatic heart disease (RHD), of which valvular deformities are the 
most important sequelae; these deformities lead to mitral and aortic regurgitation and/or 
stenosis. Valve replacement surgery is usually the only treatment for chronic RHD patients 
and incurs high costs for both public and private health systems.  
Here, we will present three cases of young RHD patients who underwent valve replacement 
and the autoimmune reactivity that triggered the heart-tissue rheumatic lesions. 
Post-streptococcal glomerulonephritis (PSGN) is another immune sequelae that presents a 
latency period of one to three weeks after scarlet fever, streptococcal pharyngitis and 
purulent skin infections. 
PSGN has become a rare disease, especially in adults in developed countries, due to an 
improved standard of living, earlier treatment of pharyngeal infections and widespread use 
of antibiotics (Rodriguez-Iturbe & Musser, 2008). Despite decades of research, the 
pathogenesis of PSGN remains obscure. It is still unclear whether or to what extent 
autoimmune reactions are involved, but several studies have shown that different 
streptococcal antigens are detectable by immunohistology in the diseased kidneys 
(Rodriguez-Iturbe & Batsford, 2007). These data are in favor of direct contributions of 
streptococcal nephritogenic factors to PSGN pathogenesis, although intact bacteria have 
never been found in affected kidneys. Two PSGN cases will also be presented. 
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1. Introduction 
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most important sequelae; these deformities lead to mitral and aortic regurgitation and/or 
stenosis. Valve replacement surgery is usually the only treatment for chronic RHD patients 
and incurs high costs for both public and private health systems.  
Here, we will present three cases of young RHD patients who underwent valve replacement 
and the autoimmune reactivity that triggered the heart-tissue rheumatic lesions. 
Post-streptococcal glomerulonephritis (PSGN) is another immune sequelae that presents a 
latency period of one to three weeks after scarlet fever, streptococcal pharyngitis and 
purulent skin infections. 
PSGN has become a rare disease, especially in adults in developed countries, due to an 
improved standard of living, earlier treatment of pharyngeal infections and widespread use 
of antibiotics (Rodriguez-Iturbe & Musser, 2008). Despite decades of research, the 
pathogenesis of PSGN remains obscure. It is still unclear whether or to what extent 
autoimmune reactions are involved, but several studies have shown that different 
streptococcal antigens are detectable by immunohistology in the diseased kidneys 
(Rodriguez-Iturbe & Batsford, 2007). These data are in favor of direct contributions of 
streptococcal nephritogenic factors to PSGN pathogenesis, although intact bacteria have 
never been found in affected kidneys. Two PSGN cases will also be presented. 
 




2.1 Acute rheumatic fever 
The incidence of ARF in some developing countries exceeds 50 cases per 100,000 children 
(Carapetis et al., 2005). The worldwide incidence of RHD is at least 15.6 million cases and is 
responsible for around 233,000 deaths / year. However, these estimates are based on 
conservative assumptions, so the true disease burden is probably substantially higher 
(Carapetis et al., 2005). The incidence of ARF can vary from 0.7 to 508 per 100,000 children 
per year in different populations from several countries (Carapetis et al., 2005). In Brazil, 
according to the WHO epidemiological model and data from IBGE (Brazilian Institute of 
Geography and Statistics), the number of Streptococcal pharyngitis infections is around 10 
million cases, which could lead to 30,000 new cases of RF, of which around 15,000 could 
develop cardiac lesions (Barbosa et al.,2009). 
2.2 Post-streptococcal glomerulonephritis (PSGN) 
PSGN has become a rare disease, especially in adults in developed countries, due to an 
improved standard of living, earlier treatment of pharyngeal infections and widespread use 
of antibiotics (Rodriguez-Iturbe & Musser, 2008). However, the occurrence of acute post-
infection glomerulonephritis (APIGN) has emerged as a major risk in diabetic patients all 
over the world (Nars et al., 2008). 
The global incidence of acute PSGN was estimated at 472,000 cases per year, of which 
456,000 occurred in less-developed countries (Carapetis, 2005). In agreement with these 
data, the incidence of PSGN ranges from 9.5 to 28.5 new cases per 100,000 individuals per 
year in developing countries (Rodríguez-Iturbe, 2008).  
3. Autoimmunity is the major mechanism leading to both diseases 
3.1 Rheumatic fever and rheumatic heart disease  
The autoimmune reactions in RF and RHD are controlled by several genes related to both the 
innate and adaptive immune responses (Guilherme et al., 2011). Briefly, in the last 50 years, 
several genetic markers from different populations have been studied, and the susceptibility of 
developing RF/RHD was first associated with some alleles of HLA (human leukocytes 
antigens) class II genes (DRB1, DQB and DQA), which are located on human chromosome 6. 
HLA alleles are involved in antigen recognition by T lymphocytes through the T cell receptor 
(TCR). Later, some studies showed that the TNF-α gene, located in the same region of this 
chromosome was also associated with the disease. The TNF-α gene encodes the inflammatory 
TNF alpha protein, which is involved in the inflammatory process mediating heart-tissue 
lesions in RHD. Several other associations have been established based on gene variability by 
studying single nucleotide polymorphisms (SNPs). These genes code for other proteins also 
involved with the immune response (innate and adaptive pathways) (see Diagram 1) 
(Guilherme et al., 2011). 
3.1.1 Molecular mimicry 
Molecular mimicry mediates cross-reactivity between streptococcal antigens and human 
proteins. Several autoantigens have been identified, including cardiac myosin epitopes, 
vimentin and other intracellular proteins. 
Several streptococcal and human cross-reactive antibodies have been found in the sera of RF 
patients and immunized rabbits and mice over the last 50 years and have been recently 
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reviewed. Briefly, antibodies against N-acetyl β-D-glucosamine, a polysaccharide present in 
both the streptococcal cell wall and heart valvular tissue displayed cross reactivity against 
laminin, an extracellular matrix alpha-helical coiled-coil protein that surrounds heart cells 
and is also present in the valves (Cunningham, 2000; Guilherme et al., 2005).  
Among human proteins, cardiac myosin and vimentin seem to be the major target antigens. 
By using affinity-purified anti-myosin antibodies, Cunningham´s group identified a five 
amino acid residue (Gln-Lys-Ser-Lys-Gln) epitope of the N-terminal M5 and M6 proteins as 
cross-reactive with cardiac myosin (Cunningham et al., 1989). 
Cunningham´s group found that streptococcal and human cross-reactive antibodies 
upregulate the adhesion molecule VCAM-1 after binding to the endothelial surface, leading to 
inflammation, cellular infiltration and valve scarring (Gavin et al., 2000, Roberts et al, 2001). 
These data established the role of the heart–tissue cross-reactive antibodies (anti-cardiac 
myosin and laminin) in the early stages of inflammation and T cell infiltration in RHD lesions. 
Studies performed in the last 25 years showed that CD4+ cells are the major effectors of 
autoimmune reactions in the heart tissue in RHD patients (Raizada et al., 1984; Kemeny et 
al.,1989; Guilherme et al., 1995). However, the role of T cells in the pathogenesis of RF and 
RHD was demonstrated through the analysis of heart-tissue infiltrating T cell clones 
(Guilherme et al., 1995). Immunodominant peptides of the M5 protein (residues 81-96 and 
83-103) displayed cross-reactivity with valvular proteins and cardiac myosin peptides by 
molecular mimicry (Faé et al., 2006; Yoshinaga et al., 1995; Guilherme et al, 1995). These M5 
epitopes were also preferentially recognized by peripheral T lymphocytes from RHD 
patients when compared with normal individuals, mainly in the context of HLA-DR7 
(Guilherme et al., 2001). Analysis of the T cell receptors (TCR) of peripheral and intralesional 
T cells from RHD patients showed several antigen-driven oligoclonal T cell expansions at 
the site of heart-tissue lesions (Guilherme et al, 2000). These autoreactive cells are CD4+ and 
produce inflammatory cytokines (TNF and IFNγ). IL-4+ cells are found in the 
myocardium; however, these cells are very scarce in the valve lesions of RHD patients. IL-4 
is a Th2-type cytokine and plays a regulatory role in the inflammatory response mediated 
by Th1 cytokines. These findings indicate that the Th1/Th2 cytokine balance has a role in 
healing myocarditis, while the low numbers of IL-4-producing cells in the valves probably 
induced progressive and permanent valve damage (Guilherme et al, 2004).  
Three cases of RHD patients (clinical, surgical data) will be presented. Histological and 
immunological data obtained from peripheral blood and T-cell lines and T cell clones derived 
from heart-tissue infiltrating T cells of these patients are summarized in Tables 1 and 2. 
 
Patients 




Neovasc Fibrosis Calcification Inflammation Rheumatic Activity 
Case 1 (++) AB-PR(+) VER(+) (+) (+) () AB-PR (+) (+) 
Case 2- (+) () () (++) () () () 
Case 3- 
1st surgery 
     (+) AB() 
2nd surgery (+)     (+) () 
LA-left atrium; AB-PR- Achoff Bodies in proliferative phase; Ver- verrucae, (-) negative;(+) mild;  
(++) moderate  
Table 1. Histological data of Rheumatic Heart Disease patients 
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from heart-tissue infiltrating T cells of these patients are summarized in Tables 1 and 2. 
 
Patients 




Neovasc Fibrosis Calcification Inflammation Rheumatic Activity 
Case 1 (++) AB-PR(+) VER(+) (+) (+) () AB-PR (+) (+) 
Case 2- (+) () () (++) () () () 
Case 3- 
1st surgery 
     (+) AB() 
2nd surgery (+)     (+) () 
LA-left atrium; AB-PR- Achoff Bodies in proliferative phase; Ver- verrucae, (-) negative;(+) mild;  
(++) moderate  
Table 1. Histological data of Rheumatic Heart Disease patients 
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Amino acid sequences of M5 protein were based on sequence published by Philips et al, 1981 and 
Manjula et al, 1985. M5 (81-96)-DKLKQQRDTLSTQKET; M5 (83-103)-LKQQRDTLSTQKETLEREVQN; 
M5-(163-177) ETIGTLKKILDETVK; cardiac myosin beta chain sequences published by Diederich et al, 
1989: LMM 10 (1413-1430) CSSLEKTKHRLQNEIEDL; LMM12 (1439-1456) AAAAALDKKRNFDKILA; 
LMM25 (1607-1624) RSRNEALRVKKKMEGDLN, (Guilherme et al, 1995, Faé et al, 2006). 
Table 2. T cells from heart-tissue of Rheumatic Heart Disease patients recognize 
streptococcal peptides and cardiac proteins.  
Case # 1 
Male 4 years old, presented mitral, aortic and tricuspid regurgitation, left ventricular 
diastolic diameter of 51 mm and systolic diameter of 34 mm, ejection fraction (LVEF) of 78%, 
left atrium (LA) of 40 mm, thickened pericardium.  
At surgery, mitral valve prolapse was observed with very long strings and small tears of 
rope. Mitral annulus was dilated. A mitral valve replacement was done. Heart biopsy 
showed chronic valvulitis with areas of mucoid collagen degeneration and papillary 
muscles with Aschoff nodules in the granulomatous stage (Table 1). 
Case # 2 
Male 6 years old, presented clinical features of fever, polyarthritis and carditis with mitral 
valve involvement. On this occasion, patient showed evidence of inflammatory activity; 
Gallium 67 positive scintigraphy; endomyocardial biopsy suggestive of rheumatic carditis. 
A left ventricular diastolic diameter of 59 mm, left ventricular systolic diameter of 39 mm, 
ejection fraction (LVEF) of 71% and left atrium (LA) of 52 mm were observed. Two valve 
correction surgeries were performed. Pathological examination of the mitral valve showed 
sequelae of chronic valvulitis with intense fibrosis and mucoid degeneration. 
Case #3 
Male 10 years old, presented clinical features of fever, polyarthritis and carditis with 
progressive cardiac heart failure and mitral and aortic shortcomings as well as relapses of 
acute outbreak by irregular use of secondary prophylaxis with benzathine penicillin and 
progression to chronic atrial fibrillation, culminating in death at 18 years of life. Increased 
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left ventricular diastolic diameter (67/43 mm) and left atrial diameter of 62 mm, significant 
mitral regurgitation, aortic insufficiency and moderate impact tricuspid regurgitation with 
mild rebound were found. Subjected to two surgeries, first for mitral valve repair and 
prosthetic aortic and tricuspid valves, then for exchange of the mitral and aortic 
bioprostheses, and tricuspid valve repair. 
3.2 Post Streptococcal Glomerulonephritis (PSGN) 
Acute glomerulonephritis can occur sporadically or endemically as a result of infections of 
both the upper airways and skin by group A streptococcus strains.  
Genetic susceptibility factors are likely involved with the development of the disease. HLA 
class II alleles (DR4 and DRB1* 03011) have been found to be associated with PSGN 
compared to healthy controls. Genetic association with endothelial nitric oxide synthase 
intron 4 a/b (eNOSa/b) defined by variable numbers of tandem repeats (VNTR) 
polymorphism was also described (Ahn & Ingulli, 2008). 
The disease is mediated by immune complexes and complement pathway activation. 
Several theories seek to explain the formation of immune complexes in glomeruli. The most 
accepted one is that a streptococcal antigen, with affinity for the glomerular structures, can 
be deposited in the glomerulus, activating the host immune response and initiating 
development of immune complexes in situ (Rodriguez-Iturbe &  Bastford, 2007).  
Apparently, molecular mimicry between streptococcal antigens and glomerular proteins 
leads to tissue damage. Two antigens have been investigated as potential causes of PSGN: 
the plasmin receptor linked to nephritis (NAPlr), identified as glyceraldehyde 3-phosphate 
dehydrogenase, and a protein known as streptococcal pyrogenic exotoxin B (SpeB). Both are 
present in renal biopsies of patients with PSGN and are capable of activating the alternative 
pathway of the complement system. In addition, they are capable of promoting enhanced 
expression of adhesion molecules, facilitating inflammatory reactions mediated by cytokines 
(IL-6, TNF α, IL-8 and TGF ß). It seems that the nephritogenic properties of NAPlr and SpeB 
are related to the binding ability of plasmin, which facilitates the deposition of immune 
complexes (IgG and C3, properdin and C5) in the glomeruli and subsequent inflammation 
(Rodriguez-Iturbe & Bastford, 2007; Rodriguez-Iturbe & Musser, 2008). 
Molecular mimicry, as mentioned above, leads to the recognition of streptococcal antigens 
and laminin, collagen and glomerular basement membrane (GBM). Sub-epithelial 
localization of immune complexes and complement factors in the injured glomeruli points 
towards a crucial role of the host immune system in tissue destruction.  
As mentioned before, renal inflammation may result from a myriad of insults and is often 
characterized by the presence of infiltrating inflammatory leukocytes within the glomerulus 
or tubular interstitium. Accumulating evidence indicates that infiltrating leukocytes are the 
key to the induction of renal injury. 
Two cases of PSGN are presented in which anti-streptolysin O (ASO) was positive, 
indicating a previous infection by S. pyogenes.  
Case #1  
Male 6 years old, presented swollen eyes followed by bilateral periorbital edema followed by 
progression of lower limb edema and increased abdominal size, decreased urine volume and 
urine darkness. Lab tests detected hematuria, increased serum levels of urea (63.0 mg/dl) and 
creatinine (1.2 mg/dl). Decreased levels of complement (16.1 mg/dl) and fractions C3 and C4 
(both 11.7 mg/dl) were found. The patient also presented increased levels of ASO (1055 IU). 
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Several theories seek to explain the formation of immune complexes in glomeruli. The most 
accepted one is that a streptococcal antigen, with affinity for the glomerular structures, can 
be deposited in the glomerulus, activating the host immune response and initiating 
development of immune complexes in situ (Rodriguez-Iturbe &  Bastford, 2007).  
Apparently, molecular mimicry between streptococcal antigens and glomerular proteins 
leads to tissue damage. Two antigens have been investigated as potential causes of PSGN: 
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and laminin, collagen and glomerular basement membrane (GBM). Sub-epithelial 
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towards a crucial role of the host immune system in tissue destruction.  
As mentioned before, renal inflammation may result from a myriad of insults and is often 
characterized by the presence of infiltrating inflammatory leukocytes within the glomerulus 
or tubular interstitium. Accumulating evidence indicates that infiltrating leukocytes are the 
key to the induction of renal injury. 
Two cases of PSGN are presented in which anti-streptolysin O (ASO) was positive, 
indicating a previous infection by S. pyogenes.  
Case #1  
Male 6 years old, presented swollen eyes followed by bilateral periorbital edema followed by 
progression of lower limb edema and increased abdominal size, decreased urine volume and 
urine darkness. Lab tests detected hematuria, increased serum levels of urea (63.0 mg/dl) and 
creatinine (1.2 mg/dl). Decreased levels of complement (16.1 mg/dl) and fractions C3 and C4 
(both 11.7 mg/dl) were found. The patient also presented increased levels of ASO (1055 IU). 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
130 
Case # 2  
Male 15 years old, presented edema, hypertension, and gross hematuria and reported a skin 
abscess in the left leg 20 days before hospital admission. No previous signs of disease or 
significant co-morbidities were identified. Physical examination showed a 2+ lower edema, 
with no signs of current skin infections. Laboratory tests revealed 24 hr urine protein 2.4 
g/day, serum creatinine 2.9 mg/dl, hematuria, and positive ASO (> 200 IU). Renal 
ultrasound showed normal kidneys. After introducing antibiotic and controlling edema and 
hypertension with diuretics and anti-hypertensive drugs, the patient was subjected to a 
renal biopsy that showed a diffuse proliferative pattern, with focal endocapillary and 
mesangial proliferation with no cellular crescents.  
4. Frequencies of S. pyogenes strains collected at Clinical Hospital of the 
School of Medicine of the University of Sao Paulo 
Diverse S. pyogenes strains are related with the development of RF/RHD or PSGN and are 
considered as rheumatogenic and nephritogenic, respectively.  
We analyzed 177 samples obtained from diverse biological sources. Most samples were 
recovered from blood, throat and wound (Table 3).  
 
Source nº of cases
Strains identified 
emm1 emm87 emm22 emm12 emm77 emm6 emm75 emm89 st2904 others 
Throat 30 6 - 5 1 - 2 1 - 2 13 
Blood 58 10 6 3 7 5 3 2 1 - 21 
Wound 15 3 2 - - - - - 1 2 7 
Sputum 8 2 - 1 - 2 1 - - - 2 
Surgical 
wound 5 - - 1 1 1 - - - - 2 
Ascitis 3 - - - - - - 1 - - 2 
Catheter 3 - - 1 - - - - - - 2 
Lymph  
node 3 1 2 - - - - - - - - 
Ocular 
discharge 3 2 - - - - - - - - 1 
Synovial 
fluid 2 2 - - - - - - - - - 
Liquor 2 1 - - - - - - 1 - - 
Others 11 3 2 - - 1 - 1 1 - 3 
Table 3. Distribution of emm types according to biological source. 
The M1 type was more frequently observed. Figure 1 shows the frequencies of all strains 
analyzed.  Our results are similar to those previously published (Table 4). It is interesting to 
note that studies done by Schulman et al., 2004 and Ma et al., 2009 showed variability of 
frequencies for some streptococcus strains over different periods, probably due to seasonal 
influence. 
 




Fig. 1. Prevalence of the M types in a sample from São Paulo 
Beta-hemolytic samples (177) obtained from diverse biological sites  at the Clinical Hospital, 
University of Sao Paulo during the period of 2001-2008. 
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2010 
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Two studies were reported for North America and China. 
Table 4. Distribution of emm types around the world 
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Diagram 1. Major events leading autoimmune reactions on both RHD and Glomerulonephritis 
5. Prospective vaccines against S. pyogenes 
Many studies have focused on developing a vaccine against S. pyogenes in order to prevent 
infection and its complications. There are four anti-group A streptococci (GAS) vaccine 
candidates based on the M protein and eight more candidates based on other streptococcal 
antigens, including group A CHO, C5a peptidase (SCPA), cysteine protease (Spe B), binding 
proteins similar to fibronectin, opacity factor, lipoproteins, Spes (super antigens) and 
streptococcal pili (Steer et al, 2009). 
We developed a vaccine epitope (StreptInCor) composed of 55 amino acid residues of the C-
terminal portion of the M protein that encompasses both T and B cell protective epitopes 
Peripheral Blood
 Streptococcal and human proteins: cross-reactions mediated by both antibodies and 
CD4+T cells  
 Inflammatory cytokines: IL-1, IL-6, IL-10, TNF- , IFN- γ 
 Circulating immune complexes  
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Genetic Susceptible Untreated Children and Teenagers 
Genetic markers Role 
 MBL, TLR2, FCN2, Fcγ RIIA alleles  Innate immunity 
 HLA class II alleles  Adaptive immune response 
 Cytokines genes: TNF-α, TGF ß1, IL-
1Ra, IL-10  
Mediators of inflammatory reactions  
(agonist or antagonist) 
Heart Tissue (RHD)
 Anti-laminin and/or cardiac myosin antibodies upregulate the VCAM-1 molecule 
in the endothelium surface leading to inflammation, cellular infiltration and valve 
scarring 
 Infiltrating T cells are predominantly CD4+ (~80%) 
 Antigen-driven oligoclonal T cells are expanded in the myocardium and valves 
 Intralesional T cell clones recognize streptococcal M peptides and heart-tissue 
proteins and cardiac myosin peptides (LMM) 
 High numbers of TNF- and IFN-γ secreting mononuclear cells are mediators of 
myocardium and valvular inflammation 
 Low numbers of mononuclear cells IL-4+ in the valves probably lead to permanent 
and progressive valvular damage 
 
Kidney (Glomerulonephritis)  
 Streptococcal anti – SpeB  crossreactive antibodies recognize  NAPlr,  laminin,  
collagen and the glomerular basement membrane (GBM) antigens 
 Sub-epithelial deposition of immune complex and complement factors
 
S. pyogenes Infections and Its Sequelae 
 
133 
(Guilherme et al, 2006). The structural, chemical and biological properties of this peptide 
were evaluated, and we have shown that StreptInCor is a very stable molecule, an important 
property for a vaccine candidate (Guilherme et al, 2011). Furthermore, experiments with 
mice showed that this construct is immunogenic and safe (Guilherme et al, 2011). 
6. Conclusions 
The knowledge acquired in the last 25 years pointed out the molecular mimicry mechanism 
as one of the most important leading autoimmune reactions in RHD and PSGN. Although 
both diseases are triggered by S. pyogenes, RHD is mediated by both antibodies and T cells 
while PSGN is mainly due to immune complex deposition in the glomeruli. 
Several streptococcal cross reactive autoantigens were identified in both diseases. 
Many proteins and cardiac myosin epitopes were identified as putative cross-reactive 
autoantigens in RHD and collagen, glomerular basement membrane in PSGN. Laminin, 
another autoantigen is also involved in the cross reactivity in both diseases.  
Diagram 1 illustrates the major events leading to RHDand PSGN. 
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 Cytokines genes: TNF-α, TGF ß1, IL-
1Ra, IL-10  
Mediators of inflammatory reactions  
(agonist or antagonist) 
Heart Tissue (RHD)
 Anti-laminin and/or cardiac myosin antibodies upregulate the VCAM-1 molecule 
in the endothelium surface leading to inflammation, cellular infiltration and valve 
scarring 
 Infiltrating T cells are predominantly CD4+ (~80%) 
 Antigen-driven oligoclonal T cells are expanded in the myocardium and valves 
 Intralesional T cell clones recognize streptococcal M peptides and heart-tissue 
proteins and cardiac myosin peptides (LMM) 
 High numbers of TNF- and IFN-γ secreting mononuclear cells are mediators of 
myocardium and valvular inflammation 
 Low numbers of mononuclear cells IL-4+ in the valves probably lead to permanent 
and progressive valvular damage 
 
Kidney (Glomerulonephritis)  
 Streptococcal anti – SpeB  crossreactive antibodies recognize  NAPlr,  laminin,  
collagen and the glomerular basement membrane (GBM) antigens 
 Sub-epithelial deposition of immune complex and complement factors
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(Guilherme et al, 2006). The structural, chemical and biological properties of this peptide 
were evaluated, and we have shown that StreptInCor is a very stable molecule, an important 
property for a vaccine candidate (Guilherme et al, 2011). Furthermore, experiments with 
mice showed that this construct is immunogenic and safe (Guilherme et al, 2011). 
6. Conclusions 
The knowledge acquired in the last 25 years pointed out the molecular mimicry mechanism 
as one of the most important leading autoimmune reactions in RHD and PSGN. Although 
both diseases are triggered by S. pyogenes, RHD is mediated by both antibodies and T cells 
while PSGN is mainly due to immune complex deposition in the glomeruli. 
Several streptococcal cross reactive autoantigens were identified in both diseases. 
Many proteins and cardiac myosin epitopes were identified as putative cross-reactive 
autoantigens in RHD and collagen, glomerular basement membrane in PSGN. Laminin, 
another autoantigen is also involved in the cross reactivity in both diseases.  
Diagram 1 illustrates the major events leading to RHDand PSGN. 
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Streptococcal Glomerulonephritis  
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USA 
1. Introduction 
Acute post-streptococcal glomerulonephritis (APSGN) is one of the nonsuppurative 
sequelae that can occur following a group A streptococcal infection, the other common post-
infection sequelae being rheumatic heart disease. Worldwide, it is estimated that 
approximately 470,000 cases of APSGN occur annually. Children and young adults most 
commonly are affected with males having twice the incidence as females.  By the middle of 
the twentieth century, evidence was found that streptococcal skin infections were associated 
with APSGN, and these infections usually did not cause rheumatic fever, leading to the 
hypothesis that certain GAS strains were “rheumatogenic” while others were 
“nephritogenic.”  In contrast to the molecular and immunological details that have brought 
considerable insight into the pathogenesis of rheumatic heart disease, the bacterial and host 
factors that contribute to ASPGN remain poorly defined and at times controversial.  Modern 
bacterial genome sequencing projects have now provided a rich genetic resource that 
includes complete sequences of nephritogenic group A streptococcus strain NZ131 (McShan 
et al., 2008) and nephritogenic group C streptococcus strain MGCS10565 (Beres et al., 2008) 
as well as other group A and C strains associated with rheumatic heart disease and other 
syndromes.  A metagenomic analysis is presented and considers the contribution of genes 
previously associated with APSGN strains (such as streptokinase, protease SpeB, and M 
protein) as well as other potential genetic factors that may be found uniquely in these 
genomes including genes acquired by horizontal transfer and via mobile genetic elements.  
This analysis provides complementary information to the many published studies using 
nephritogenic S. pyogenes strain NZ131 and places them in a broader context, shedding light 
upon the genetic basis for the human disease caused by this and related streptococci. 
2. Acute post-streptococcal glomerulonephritis 
Streptococcus pyogenes (group A streptococcus) is a common bacterial pathogen of humans, 
causing a wide range of disease from uncomplicated pharyngitis to severe life-threatening 
infections like toxic shock syndrome or necrotizing fasciitis.  Acute post-streptococcal 
glomerulonephritis (APSGN) is one of the two major post-infection sequelae that can follow 
acute streptococcal infections, the other being rheumatic heart disease.  The typical causative 
agent of APSGN is the group A streptococcus although other Lancefield groups may 
occasionally trigger this disease.  Worldwide, it is estimated that approximately 470,000 
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approximately 470,000 cases of APSGN occur annually. Children and young adults most 
commonly are affected with males having twice the incidence as females.  By the middle of 
the twentieth century, evidence was found that streptococcal skin infections were associated 
with APSGN, and these infections usually did not cause rheumatic fever, leading to the 
hypothesis that certain GAS strains were “rheumatogenic” while others were 
“nephritogenic.”  In contrast to the molecular and immunological details that have brought 
considerable insight into the pathogenesis of rheumatic heart disease, the bacterial and host 
factors that contribute to ASPGN remain poorly defined and at times controversial.  Modern 
bacterial genome sequencing projects have now provided a rich genetic resource that 
includes complete sequences of nephritogenic group A streptococcus strain NZ131 (McShan 
et al., 2008) and nephritogenic group C streptococcus strain MGCS10565 (Beres et al., 2008) 
as well as other group A and C strains associated with rheumatic heart disease and other 
syndromes.  A metagenomic analysis is presented and considers the contribution of genes 
previously associated with APSGN strains (such as streptokinase, protease SpeB, and M 
protein) as well as other potential genetic factors that may be found uniquely in these 
genomes including genes acquired by horizontal transfer and via mobile genetic elements.  
This analysis provides complementary information to the many published studies using 
nephritogenic S. pyogenes strain NZ131 and places them in a broader context, shedding light 
upon the genetic basis for the human disease caused by this and related streptococci. 
2. Acute post-streptococcal glomerulonephritis 
Streptococcus pyogenes (group A streptococcus) is a common bacterial pathogen of humans, 
causing a wide range of disease from uncomplicated pharyngitis to severe life-threatening 
infections like toxic shock syndrome or necrotizing fasciitis.  Acute post-streptococcal 
glomerulonephritis (APSGN) is one of the two major post-infection sequelae that can follow 
acute streptococcal infections, the other being rheumatic heart disease.  The typical causative 
agent of APSGN is the group A streptococcus although other Lancefield groups may 
occasionally trigger this disease.  Worldwide, it is estimated that approximately 470,000 
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cases of APSGN occur annually (Carapetis et al., 2005).  Children and young adults are the 
group that is most commonly presents with APSGN, and males have twice the incidence as 
females (Silva, 1998).   
The link between group A streptococcal infections and the onset of nephritis was considered 
as early as 1917 by Ophuls (Ophuls, 1917).  By the 1940s, a link had been found between 
streptococcal skin infections and the onset of APSGN, and since the associated strains usually 
did not cause rheumatic fever, the hypothesis was developed that certain S. pyogenes strains 
were “rheumatogenic” while others were “nephritogenic” (Futcher, 1940; Osman et al., 1933; 
Seegal and Earle, 1941).  Additionally, it was observed that there were divergent seasonal 
patterns of peak incidence separating nephritogenic and rheumatogenic GAS, with skin 
infections and APSGN cases peaking in the late summer while throat infections and rheumatic 
fever had the highest incidence in October (Bisno et al., 1970).  Cases of rheumatic fever were 
rare during the summer APSGN outbreaks, peaking instead during the autumn season.  These 
observations lead to the development of the hypothesis that subpopulations of GAS exist that 
were adapted for colonization and infection of either the throat or the skin.  These “throat 
specialists” and “skin specialists” were proposed to have specific sets of virulence factors that 
lead to the post-streptococcal sequelae of rheumatic heart disease or APSGN, respectively.  
This hypothesis has been refined over time to now define throat specialists, skin specialists and 
generalists using a classification scheme that relates the Mga regulon, the gene complement 
surrounding the major antiphagocytic protein M gene (emm), to preferred anatomical site of 
infection (Bessen et al., 1997; Enright et al., 2001; McGregor et al., 2004).   
3. Comparative genomics of nephritogenic streptococcal strains 
3.1 The nephritogenic streptococcal genomes 
The role of streptococcal induced autoimmunity as the basis for the development of rheumatic 
heart disease has been supported by a number of detailed studies (Cunningham, 2000a; 
Cunningham et al., 1989; Ellis et al., 2010; Krisher and Cunningham, 1985).  It is reasonable 
therefore to expect that a similar underlying source of antigenic cross-reactivity might be 
responsible for the development of APSGN, especially since the time of onset roughly follows 
the time required for the adaptive immune response.  However, to date no definitive link has 
been found although a number of candidate streptococcal proteins have been proposed over 
the years, including streptokinase, protease SpeB, and the antiphagocytic M protein (reviewed 
by Cunningham (Cunningham, 2000b)).  One of the goal’s for genome sequencing of multiple 
streptococcal strains associated with different diseases was to use comparative genomics to 
gain insight into the genetic variations that underlie virulence.  Several nephritogenic 
streptococcal isolates now have had their genome sequences determined, and this information 
will be crucial in understanding the pathogenic mechanisms underlying APSGN.   
3.2 Physical chromosome characteristics 
The genomes of nephritis-associated streptococcal isolates S. pyogenes NZ131 (group A) and S. 
equi subsp. zooepidemicus MGCS10565 (group C) were completely sequenced in independent 
efforts in 2008 (Beres et al., 2008; McShan et al., 2008).  Both of these isolates were originally 
isolated from cases of human glomerulonephritis (Beres et al., 2008; McShan et al., 2008); 
additionally, NZ131 has been also studied intensively in over thirty published studies 
(McShan et al., 2008).  Both genomes are single circular molecules of 1,815,783 bp and 2,024,171 
bp for NZ131 and MGCS10565, respectively.  Neither strain has been found to have naturally 
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occurring plasmids or other episomes.  Strain NZ131 has 1,699 predicted open reading frames 
(ORFs) that use 1,548,919 bases so that 85.3% of the genomic DNA is used as coding sequences.  
The base composition of the ORFs is 39.18% G+C while the composition of the total genome is 
38.57%; both values are similar to the composition seen in the other completed GAS genomes 
(McShan et al., 2008). The MGCS10565 genome has a 42.59% G+C content, and its genome has 
1,961 predicted ORFs, which require 85% of the genome (Beres et al., 2008).  The physical 
parameters of both genomes are typical for the family streptococcaceae.   
3.3 Prophages and mobile genetic elements 
Strikingly, strain NZ131 carries three prophages in its genome while MGCS10565 carries none.  
Prophages are always prominent features in the group A streptococcal genomes, sometimes 
accounting for 10% of the total DNA, and are well-known as vectors for carrying virulence 
genes such as superantigens or other bioactive proteins.  While MGCS10565 has genes that are 
homologous to prophage integrases or regulatory proteins as well as virulence factors that are 
often associated with prophages (two DNases and a phospholipase A2), no organized 
prophage genome exists (Beres et al., 2008).  This lack of prophages is in contrast to the S. equi 
subsp. zooepidemicus animal pathogen strain NC_012470 that was recently described as having 
four endogenous prophages (Holden et al., 2009).   
The naturally competent streptococci have the comCDE operon that is thought to be 
essential in genetic transformation (Cvitkovitch, 2001).  Although a previous study had not 
found this operon in S. equi subsp. zooepidemicus strain NCTC 4676 (Havarstein et al., 1997), 
it is present in MGSA10565 (Beres et al., 2008).  The genomes of the naturally competent 
streptococci (including S. pneumoniae and S. mutans (Ajdic et al., 2002; Hoskins et al., 2001; 
Tettelin et al., 2001)) contain comCDE and lack prophages, and it is often suggested that 
frequent DNA transformation events may disrupt the genomes of prophages; thus, their 
typical absence.  The presence of comCDE in MGCS10565 suggests that this isolate also may 
be naturally competent for DNA transformation, and this phenotype may be responsible for 
the absence of prophages (Beres et al., 2008).  Balancing that viewpoint is the fact that these 
genes appear in the genome of S. equi subsp. zooepidemicus strain NC_120470, which does 
carry prophages.  Thus, there may be other factors controlling competence in this species. 
The prophages of NZ131 carry the virulence genes streptococcal pyrogenic exotoxin H (speH), 
a streptodornase (spd3) and the paratox gene (McShan et al., 2008). Prophage-associated 
virulence factors have not been linked to APSGN in the literature, and comparison of these 
two genomes would tend to confirm that non-association.  Rather, it would seem that if a 
common genetic trait exists that leads to APSGN, it would be found among the bacterial genes.  
Further, the absence of prophages in MGCS10565 and its potential to be competent suggests 
that if it has acquired genetic material from group A streptococci, it may have occurred via 
uptake of DNA from the environment rather by bacteriophage mediated transduction.  This 
scenario suggests that genetic transfer may be somewhat of a one-way street, flowing from S. 
pyogenes to this and similar S. zooepidemicus strains since group A streptococci have not been 
demonstrated to be naturally competent.  Therefore, the lack of prophages in MGCS10565 
argues that group A streptococci, which probably use transduction as a means for horizontal 
transfer, would be somewhat genetically isolated from these group C streptococcal strains. 
3.4 The nephritogenic strains and diversity 
The NZ131 and MGCS10565 genomes are not collinear with respect to gene order, but a 
great number of genes are shared between the two.  The genome map of NZ131 is shown in 
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Fig. 1 with gene homology comparisons to strains MGCS10565 (circle 6) and MGAS2096 
(circle 5).  Strain MGAS2096 is a group A streptococcus M12 serotype strain that was also 
isolated from a case of APSGN (Beres et al., 2006) and provides an inter-species reference. 
 
 
Fig. 1. The genome map of M49 S. pyogenes strain NZ131.  The NZ131 genome map is 
shown with comparisons to the other two sequenced nephritogenic streptococcal genomes, 
S. pyogenes strain MGAS2096 and S. equi subsp. zooepidemicus strain MGCS10565.  The outer 
circle and circle 4 indicate the positions of the three endogenous prophages in strain NZ131.  
The two circles they enclose (circles 2 and 3) show the location of the predicted NZ131 ORFs 
encoded by the two strands of DNA.  The open reading frames were extracted from S. 
pyogenes strain MGAS2096 and S. equi subsp. zooepidemicus strain MGCS10565 and were 
compared to the genome of NZ131 using tblastx (circles 5 and 6).  Circle 7 shows the specific 
tblastx hits of surface exposed proteins from MGCS10565.  The innermost circles show the 
total G+C percentage of the NZ131 genomic DNA and the %G+C skew.  The ribosomal 
RNA (rRNA) and tRNA (tRNA) genes were not included in the tblastx comparison.  The 
figure was created using the online tools available at http://stothard.afns.ualberta.ca/ 
cgview_server/index.html. 
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Overall, the main regions of divergence between the two S. pyogenes strains are in the 
endogenous prophages and other mobile genetic elements (MGE) carried by each (Fig. 1, 
circles 1 and 4), the genetic structures of the M protein gene region (Mga regulon) and 
streptococcal pilus region (circle 5), and by the presence the novel M49 and M82 specific 
NUDIX hydrolase operon in NZ131 (circle 5 (McShan et al., 2008)).  NZ131 prophage 
NZ131.2 shares significant homology with a prophage from MGAS2096 (circle 5) but not 
including the crucial lysogeny module or virulence genes.  Additionally, MGAS2096 has a 
deletion of a cluster of genes required for citrate metabolism (circle 5, about 925 kb on the 
map).  To date, little evidence has been found to suggest that genes found on prophages 
or other MGE play a role in APSGN, and the lack of homology in these elements from the 
two group A streptococcal strains strengthens this idea.  Thus, if a common mechanism 
for triggering APSGN exists, one would predict that bacterially encoded genes would be 
responsible, either in the form of unique nephritis-associated genes or gene alleles.  A 
number of streptococcal proteins have been investigated as potential triggers of APSGN, 
and many of targets remain still largely unexplored.  For example, circles 6 and 7 show 
the homology of MGCS10565 total genes and predicted membrane associated genes, 
respectively, to NZ131.  While the homology is not as complete as was for the inter-
species strain, many genes and particularly genes encoding cell-surface proteins are 
present in this intra-species streptococcus.  Most of these proteins have not had their 
function or their potential immunogenicity identified.  Thus, if genome comparisons tell 
us anything, it is that that many targets for future investigations remain.  However, 
several genes have been considered to play a role in APSGN in previous work, and it is 
worthwhile to examine the variants found in each of these nephritogenic strains for 
possible shared features.   
4. Genes associated with post-streptococcal glomerulonephritis 
4.1 Streptokinase  
Streptokinase is a plasminogen activator that is released as an extracellular protein by 
groups A, C, and G streptococci.  It generates plasmin, which may promote bacterial spread 
through fibrinolysis and degradation of the extracellular matrix as well as induce 
inflammation via complement activation.  This latter event may play a role in post-infection 
sequelae like APSGN (Nordstrand et al., 1999).  It has been proposed that structural 
differences between alleles of streptokinase may be associated with diverse pathogenic 
outcomes, particularly in the variable eta-domain (Lizano and Johnston, 2005).  The role of 
streptokinase in the pathogenesis of APSGN has been supported by the use of a mouse 
model and derivatives of strain NZ131 with either nephritis- or non-nephritis-associated 
alleles of streptokinase (Nordstrand et al., 2000; Nordstrand et al., 1998).   
The streptococcal streptokinase is composed of three domains, which are the highly 
conserved alpha and gamma domains and the variable eta domain (Wang et al., 1998).  The 
alpha and eta domains are associated with plasminogen activation while the variable eta 
domain is not required for this enzymatic activity (Lizano and Johnston, 2005).  However, in 
the mouse model used by Nordstrand and her co-workers, the alleles that caused the onset 
of nephritis mapped their variations to the eta domain (Nordstrand et al., 2000; Nordstrand 
et al., 1998).  These studies, along with clinical observations (Johnston et al., 1992), have lead 
to a proposed role for streptokinase in APSGN, possibly in mediating complement 
deposition in the kidney.   
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One of the striking observations from the genome of the nephritis-associated group C 
MGCS10565 strain is the divergence of the encoded streptokinase when compared to those 
encoded by other group C and group A strains, whether nephritis-associated or not.  Figure 2 
shows a clustalw alignment of the amino acids from the streptokinase eta regions from the 
group A genome strains M1, M2, M3, M4, M6, M12, M18, M28, and M49 as well as the group 
C strains H46 and GGS 124 (S. dysgalactiae subsp. equisimilis) and H70 and MGCS10565 (S. equi 
subsp. zooepidemicus).  The eta region from the two zooepidemicus strains is quite divergent 
from the other streptokinase proteins from both groups A and C subsp. equisimilis strains.  
Considerable divergence is also observed in the alpha and gamma domains (not shown).  The 
eta domain is required for docking to plasminogen via a kringle binding hairpin loop (Dhar 
et al., 2002; Wang et al., 1998), and the variation seen in this region suggests that a number of 
primary sequences are able to generate the needed secondary and tertiary protein structures. 
 
 
Fig. 2. Analysis of the streptokinase gene ska eta-region.  The variable eta-region  
from the ska genes from GAS genome strains (NZ131 (M49, APSGN), MGAS10750 (M4), 
MGAS2096 (M12, APSGN), MGAS6180 (M28), MGAS10270 (M2), SF370 (M1), MGAS315 
(M3), MGAS10394 (M6), and MGAS8232 (M18)) and GCS strains (S. equisimilis H46a,  
S. equisimilis GGS124, MGCS10565 (APSGN), and the non-nephritogenic S. zooepidemicus 
H70) was aligned using CLUSTALW (Thompson et al., 1994) and the resulting consensus 
analyzed using WebLogo (Crooks et al., 2004).  The non-nephritogenic M12 S. pyogenes 
strain MGAS9429 was omitted from this analysis since its sequence is 100% identical  
to that of the nephritis-associated M12 strain MGAS2096. The primary descriptions of 
each of these genomes are found in the literature (Banks et al., 2004; Beres et al., 2006; 
Beres et al., 2008; Beres et al., 2002; Ferretti et al., 2001; Green et al., 2005; Holden et al., 
2009; Holden et al., 2007; McShan et al., 2008; Shimomura et al., 2011; Smoot et al.,  
2002) 
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Further, it should be noted that a number of conserved neutral amino acid residues are 
positioned in the eta domain, suggesting an essential contribution to function.  Inspection 
of the primary sequence of the streptokinase proteins in this group shows additional 
conserved sequences in the two nephritogenic group A streptococcal isolates (NZ131 and 
MGAS2096) but not found in the nephritogenic group C strain.  Protein folding of this 
domain may create similar structures in both groups that might contribute to APSGN, but 
such information is not available yet.  Interestingly, the streptokinase gene from the non-
nephritis M12 serotype strain MGAS9429 is 100% identical to the nephritogenic M12 strain.  
It is also possible that the mechanisms of pathogenesis that trigger nephritis following 
group A or group C infection may be different.  Clearly, more detailed studies need to be 
done to address the possible role of streptokinase in APSGN. 
4.2 Protease SpeB 
Zabriskie and co-workers first observed that strains were associated with APSGN produced an 
extracellular protein not seen in non-nephritis strains, which was subsequently found to be 
bound to plasmin (Poon-King et al., 1993; Villarreal et al., 1979).  This plasmin binding protein 
was discovered to be the major extracellular protease SpeB, and analysis of patient sera 
showed significantly higher levers of anti-SpeB antibodies in APSGN patients as compared to 
rheumatic fever patients or controls (Cu et al., 1998; Poon-King et al., 1993).  Recent studies 
using a mouse tissue cage model have demonstrated that SpeB expression is inhibited in S. 
pyogenes strains that are maintained in the animal for extended periods, and this inhibition is 
inversely related to the increased expression of phage-encoded pyogenic exotoxins and 
DNases (Aziz et al., 2004).  The strains studied were not associated with nephritis, suggesting 
that group A streptococci which cause APSGN may differentially express this protein when 
compared to non-nephritogenic strains.  The lack of an identifiable homolog to SpeB in the 
group C strain MGCS10565 argues against the necessity of it in either the onset or progression 
of APSGN.  However, the molecular mechanisms that underlie APSGN in the group C species 
may be different in some aspects from group A nephritogenic strains, and thus the absence of 
this protein in MGCS10565 may not be informative about group A APSGN disease.  Further 
studies on this problem are clearly warranted.   
4.3 Surface associated proteins   
4.3.1 The Mga regulon genes 
The molecular mimicry that underlies the onset of rheumatic heart disease results from the 
immune response to a prominent surface antigen of group A streptococci, the M protein.  
Therefore, such immunological cross-reactivity may be expected to contribute to APSGN, 
especially considering the time course of onset of symptoms.  Particular M protein serotypes 
have been associated with APSGN, with M types 2, 49, 42, 56, 57, and 60 being associated 
with skin infections and APSGN while M types 1, 4, 12, and 25 being associated with throat 
infections and APSGN (Bessen et al., 1997; Bessen et al., 1996; Bisno, 1995; Enright et al., 
2001; Kalia et al., 2002; Silva, 1998).  As reported in the original description of the 
MGCS10565 genome, this group C contains a major deletion in much of the Mga regulon, 
including the genes for protease SpeB and the serum opacity factor (sof), although orthologs 
of many of these proteins including the M protein gene (emm) are found elsewhere in this 
genome (Beres et al., 2008).  The genome of MGCS10565 revealed a large number of 
predicted extracellular collagen-like proteins, but none of these provided direct evidence of 
linkage to the nephritis-associated group A streptococcal serotypes.  The linkage of serotype 
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One of the striking observations from the genome of the nephritis-associated group C 
MGCS10565 strain is the divergence of the encoded streptokinase when compared to those 
encoded by other group C and group A strains, whether nephritis-associated or not.  Figure 2 
shows a clustalw alignment of the amino acids from the streptokinase eta regions from the 
group A genome strains M1, M2, M3, M4, M6, M12, M18, M28, and M49 as well as the group 
C strains H46 and GGS 124 (S. dysgalactiae subsp. equisimilis) and H70 and MGCS10565 (S. equi 
subsp. zooepidemicus).  The eta region from the two zooepidemicus strains is quite divergent 
from the other streptokinase proteins from both groups A and C subsp. equisimilis strains.  
Considerable divergence is also observed in the alpha and gamma domains (not shown).  The 
eta domain is required for docking to plasminogen via a kringle binding hairpin loop (Dhar 
et al., 2002; Wang et al., 1998), and the variation seen in this region suggests that a number of 
primary sequences are able to generate the needed secondary and tertiary protein structures. 
 
 
Fig. 2. Analysis of the streptokinase gene ska eta-region.  The variable eta-region  
from the ska genes from GAS genome strains (NZ131 (M49, APSGN), MGAS10750 (M4), 
MGAS2096 (M12, APSGN), MGAS6180 (M28), MGAS10270 (M2), SF370 (M1), MGAS315 
(M3), MGAS10394 (M6), and MGAS8232 (M18)) and GCS strains (S. equisimilis H46a,  
S. equisimilis GGS124, MGCS10565 (APSGN), and the non-nephritogenic S. zooepidemicus 
H70) was aligned using CLUSTALW (Thompson et al., 1994) and the resulting consensus 
analyzed using WebLogo (Crooks et al., 2004).  The non-nephritogenic M12 S. pyogenes 
strain MGAS9429 was omitted from this analysis since its sequence is 100% identical  
to that of the nephritis-associated M12 strain MGAS2096. The primary descriptions of 
each of these genomes are found in the literature (Banks et al., 2004; Beres et al., 2006; 
Beres et al., 2008; Beres et al., 2002; Ferretti et al., 2001; Green et al., 2005; Holden et al., 
2009; Holden et al., 2007; McShan et al., 2008; Shimomura et al., 2011; Smoot et al.,  
2002) 
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and disease in the streptococcal, while clearly observed, remains somewhat unclear from the 
genetic level in terms of gene linkage or evolutionary co-selection.   
4.3.2 Glyceraldehyde phosphate dehydrogenase (GAPDH) 
Surface associated glyceraldehyde phosphate dehydrogenase (GAPDH) from nephritogenic 
strains of group A streptococci have been implicated in APSGN, with the molecule often 
detected in renal biopsies and patient sera having elevated anti-GAPDH antibody titers 
(Lange et al., 1976; Yamakami et al., 2000; Yoshizawa et al., 1992; Yoshizawa et al., 2004).  
This protein, which also has been referred to in the literature as the nephritis associated 
plasmin receptor, shows >85% homology between S. zooepidemicus MGCS10565 and the 
group A genome strains, which are virtually identical in amino acid sequence (Beres et al., 
2008).  Thus, it seems that if GAPDH plays a role in APSGN it is not a specific trigger for the 
disease.  Indeed, other investigators have failed to find an association between GAPDH and 
APSGN (Batsford et al., 2005), so its role remains somewhat in question.  
4.3.3 Enolase 
Another S. pyogenes surface associated protein that has been implicated in APSGN is 
enolase, which is a major plasminogen binding protein and may be involved in triggering 
APSGN (Fontan et al., 2000).  The phylogenetic analysis of the enolase genes from the S. 
pyogenes, S. zooepidemicus, S. equisimilis subsp. dysgalactiae, S. pneumoniae, and S. mutans 
genomes is presented in Fig. 3.  The two S. zooepidemicus genes form a separate branch that is 
quite distinct from the S. pyogenes genes and encode proteins that are 100% identical.  
 
 
Fig. 3. Phylogenetic analysis of streptococcal enolase genes.  The enolase genes from the 
group A streptococcal genomes (see Fig. 2 legend), now including the non-nephritogenic 
M12 strain MGAS2096, along with the genes from S. zooepidemicus strains MGCS10565 
(nephritogenic) and NC_012470 (non-nephritogenic), S. dysgalactiae subsp. equisimilis 
GGS_124, S. pneumoniae TIGR4, and S. mutans UA159 were compared and a phylogenetic 
tree constructed using Geneious (Drummond et al., 2010).    
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Interestingly, the two nephritogenic group A streptococcal strains, NZ131 and MGAS2096, 
occupy a separate branch from the other S. pyogenes strains.  However, this branch also 
includes the other M12 genome strain (MGAS9429) that was not nephritis associated.  It may 
be that these closely related alleles of enolase play a role in the onset or development of 
APSGN in S. pyogenes, but the presence a non-nephritogenic strain argues that other factors 
must be required.  Further, it would seem that enolase is probably not a common factor 
between groups A and C streptococci in the onset of APSGN. 
4.3.4 Streptococcal pilus genes 
Recent studies have demonstrated that group A streptococci and other Gram positive 
bacteria produce long, pili-like appendages that mediate binding to human fibronectin or 
collagen (Kang et al., 2007; Mora et al., 2005).  These regions are identified by the presence of 
the genes encoding the pilus subunit proteins and their associated C sortases. A 
transcriptional regulator is included in the gene cluster of group A streptococci, and strains 
may be subdivided into two groups based upon whether the pilus region carries rofA or nra 
regulator genes.  A recent classification scheme has described this region in S. pyogenes as 
belonging to one of six FCT groups (Kratovac et al., 2007). Strain NZ131 is a member of the 
nra group (FCT-3) that also includes the M3, M5, and M18 genome strains. 
 
 
Fig. 4. Phylogeny of the streptococcus pili regions.  The phylogenetic tree of the 
streptococcal pilus (fibronectin binding) regions from the S. pyogenes genome strains (see 
Fig. 2 legend) and from MGCS10565 is shown.  The regions from the S. pyogenes genomes 
are indicated by the M protein serotype, and the nephritogenic group A streptococcal strains 
(NZ131 and MGCS2096) and group C strain (MGCS10565) are shaded.  
Group C strain has three potential pilus (fibronectin binding protein) regions (Beres et al., 
2008), which is in contrast to the one pilus (T antigen) cluster found in the group A 
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streptococci (McShan et al., 2008).  Two of the group C pilus regions have homology to the 
pilus regions from the M2 and M6 genomes but little match that genome location in either 
the NZ131 or MGAS2096 chromosomes.  Sortases are Gram-positive transpeptidases that 
anchor pili and other surface proteins to the cell wall (Hae Joo Kang and Baker, 2011; 
Janulczyk and Rasmussen, 2001).  Strain NZ131 encodes an alternate sortase in this region 
(srcC2, Spy49_0116).  Interestingly, the rofA gene in MGCS10565 is not included in this gene 
cluster, being encoded elsewhere on the genome.  When a phylogenetic tree of the pilus 
regions from the S. pyogenes and S. equi subsp. zooepidemicus genomes is constructed (Figure 
4), the three pili regions (FimI – FimIII) form a distinct out-group from the S. pyogenes 
regions.  The regions from the two nephritogenic group A streptococcal strains, NZ131 and 
MGAS2096, also are not closely related to each other, and the diversity of this region again 
argues that this is not the genetic location where are located unique factors that define 
nephritogenic strains of streptococci.  
5. Conclusions   
Comparison of the genomes of nephritogenic strain NZ131 and MGCS10565 reveals many 
similarities and differences that reflect related genera but distinct species.  It is difficult, 
however, to make a convincing argument that an obvious shared trait is responsible for 
APSGN in both strains; rather, it is the differences that seem the most obvious when 
comparing potential virulence mechanisms.   
One striking finding from genome comparison is the level of diversity between the group A 
streptococcal genomes and the genome of MGCS10565.  Indeed, no common link to APSGN 
is immediately evident from the examination of the potential genetic sources from previous 
studies to the genomes.  Beres et al. (Beres et al., 2008), after considering the diversity 
between the group A and group C genomes, tended to discount potential roles for 
streptokinase and protease SpeB in APSGN.  Indeed, these proteins may not be key in the 
onset or progression of the disease although there are a number of studies supporting both.  
However, this conclusion presumes that the mechanism of pathogenesis of APSGN is the 
same in both species, which it well may not be.  Many diarrheal diseases present with 
similar symptoms even though the underlying bacterial infection may be quite different, 
and it is possible that streptococcal nephritis caused by different species may result from a 
different series of molecular events.  Further, even if there is a common molecular trigger for 
APSGN, it may be also true that for some bacterial factors that may amplify or promote the 
disease the phenotype may be more important through their enzymatic activity than their 
antigenicity.  Thus, the important message from genomics at this time is that many aspects 
of APSGN remain to be explored so to uncover the roles played by virulence factors both 
known and yet to be characterized.  Additional genome sequences from nephritogenic 
streptococci would help increase our understanding.  The genomic information that is 
already available provides a rich resource for future studies as well as providing a 
framework for understanding the previous efforts in this field of investigation.  
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1. Introduction 
Acute poststreptococcal glomerulonephritis (APSGN) is one of the most common and 
important renal diseases resulting from a prior infection with group A β-hemolytic 
streptococcus (GAS) (Ash and Ingulli, 2008). Typical clinical features of the disease include 
an acute onset with gross hematuria, edema, hypertension and moderate proteinuria (acute 
nephritic syndrome) 1 to 2 weeks after an antecedent streptococcal pharyngitis or 3 to 6 
weeks after a streptococcal pyoderma (Ahn & Ingulli 2008; Rodriguez-Iturbe & Mezzano, 
2009). Gross hematuria usually disappears after a few days, while edema and hypertension 
subside in 5 to 10 days (Rodriguez-Iturbe & Mezzano, 2009). Although the incidence of 
APSGN appears to be decreasing in industrialized countries, more than 472,000 cases with 
APSGN are estimated to occur each year worldwide, with 97% of them occurring in 
developing countries (Carapetis et al., 2005; Eison et al., 2010).  
APSGN occurs most commonly in children, 5 to 12 years old (Ahn & Ingulli, 2008), although 
5 to 10 percent of the patients are more than 40 years old (Yoshizawa, 2000). The immediate 
and long-term prognoses of APSGN are excellent for children, assuming it is diagnosed in a 
timely fashion (Kasahara et al., 2001, Rodriguez-Iturbe & Musser, 2008). In contrast, adult 
patients with APSGN show markedly worse prognoses both in the acute phase and in the 
long-term (Rodriguez-Iturbe & Musser, 2008).  
The most popular theory of the pathogenic mechanism of APSGN has been the immune-
complex theory, which involves the glomerular deposition of nephritogenic streptococcal 
antigen and subsequent formation of immune complexes in situ and/or the deposition of 
circulating antigen-antibody complexes (Oda et al., 2010). Two antigens have been 
actively investigated as the potential causes of APSGN (Rodriguez-Iturbe & Musser, 
2008): the nephritis-associated plasmin receptor (NAPlr) also known as streptococcal 
glyceraldehyde-3-phosphate dehydrogenase (Yamakami et al., 2000; Yoshizawa et al., 
2004), and a cationic cysteine proteinase known as streptococcal pyogenic exotoxin B 
(SPEB) (Batsford et al., 2005).  
Patients with APSGN sometimes exhibit atypical or unusual clinical manifestations, which 
may lead to diagnostic delay or misdiagnosis of the disorder (Eison et al. 2011; Pais et al. 
2008). Recognition of these unusual manifestations in cases of APSGN is important in order 
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1. Introduction 
Acute poststreptococcal glomerulonephritis (APSGN) is one of the most common and 
important renal diseases resulting from a prior infection with group A β-hemolytic 
streptococcus (GAS) (Ash and Ingulli, 2008). Typical clinical features of the disease include 
an acute onset with gross hematuria, edema, hypertension and moderate proteinuria (acute 
nephritic syndrome) 1 to 2 weeks after an antecedent streptococcal pharyngitis or 3 to 6 
weeks after a streptococcal pyoderma (Ahn & Ingulli 2008; Rodriguez-Iturbe & Mezzano, 
2009). Gross hematuria usually disappears after a few days, while edema and hypertension 
subside in 5 to 10 days (Rodriguez-Iturbe & Mezzano, 2009). Although the incidence of 
APSGN appears to be decreasing in industrialized countries, more than 472,000 cases with 
APSGN are estimated to occur each year worldwide, with 97% of them occurring in 
developing countries (Carapetis et al., 2005; Eison et al., 2010).  
APSGN occurs most commonly in children, 5 to 12 years old (Ahn & Ingulli, 2008), although 
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timely fashion (Kasahara et al., 2001, Rodriguez-Iturbe & Musser, 2008). In contrast, adult 
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long-term (Rodriguez-Iturbe & Musser, 2008).  
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circulating antigen-antibody complexes (Oda et al., 2010). Two antigens have been 
actively investigated as the potential causes of APSGN (Rodriguez-Iturbe & Musser, 
2008): the nephritis-associated plasmin receptor (NAPlr) also known as streptococcal 
glyceraldehyde-3-phosphate dehydrogenase (Yamakami et al., 2000; Yoshizawa et al., 
2004), and a cationic cysteine proteinase known as streptococcal pyogenic exotoxin B 
(SPEB) (Batsford et al., 2005).  
Patients with APSGN sometimes exhibit atypical or unusual clinical manifestations, which 
may lead to diagnostic delay or misdiagnosis of the disorder (Eison et al. 2011; Pais et al. 
2008). Recognition of these unusual manifestations in cases of APSGN is important in order 
to assure that the patient receives adequate treatment. In this chapter, I review the atypical 
clinical manifestations of APSGN. 
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2. Atypical manifestations of APSGN 
Atypical manifestations of APSGN can be classified as the following: co-occurrence of 
immune-mediated diseases; non immune-mediated complications; and unusual clinical 
presentations or courses (Table 1). 
 
Immune-mediated diseases 
     Acute rheumatic fever (ARF)  
     Poststreptococcal reactive arthritis (PSRA) 
     Vasculitis 
     Immune thrombocytopenic purpura (ITP) 
     Autoimmune hemolytic anemia (AIHA) 
     Diffuse alveolar hemorrhage (DAH) 
     Uveitis 
 
Non immune-mediated complications 
     Posterior reversible encephalopathy syndrome (PRES)  
     Thrombotic microangiopathy (TMA) 
     Gallbladder wall thickening 
 
Unusual clinical presentations or courses 
     Minimal urinary abnormalities 
     Recurrence 
Table 1. Atypical manifestations of acute poststreptococcal glomerulonephritis 
2.1 Immune-mediated diseases 
Immune-mediated diseases most likely result from immune-complex formation between 
streptococcal antigens and their associated antibodies, and include acute rheumatic fever, 
poststreptococcal reactive arthritis, vasculitis, immune thrombocytopenic purpura, 
autoimmune hemolytic anemia, diffuse alveolar hemorrhage and uveitis. 
2.1.1 Acute rheumatic fever 
Acute rheumatic fever (ARF) is an autoimmune disease that follows infection by GAS and is 
characterized by inflammation of several tissues that gives rise to typical clinical characteristics 
(the so-called Jones criteria) including carditis/valvulitis, arthritis, chorea, erythema 
marginatum, and subcutaneous nodules (Steer & Carapetis, 2009). ARF is rare in developed 
countries, but it remains common in developing countries and some poor, mainly indigenous 
populations of wealthy countries (Steer & Carapetis, 2009; Carapetis et al., 2005). 
Although both ARF and APSGN develop following GAS infection, the two diseases have 
different epidemiology, immunology and bacteriology, and simultaneous occurrence of 
them in the same patient is rare (Lin et al., 2007). Since Gibney et al. first reported a patient 
with co-occurrence of ARF and histologically proven APSGN (Gibney et al., 1981), 
seventeen patients with concurrent ARF and APSGN have been reported (Akasheh et al., 
1995; Ben-Dov et al., 1985; Castillejos et al., 1985; Imanaka et al., 1995; Kakkera et al., 1998; 
Kujala et al., 1989; Kula et al., 2003; Kwong et al., 1987; Lin et al., 2003; Mastell et al., 1990; 
Öner, et al., 1993; Said et al., 1986; Sieck et al., 1992; Sinha et al., 2007).  
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Fourteen patients were children and ten were male. Eight patients initially presented with 
ARF preceding APSGN, 3 patients suffered from ARF following the development of APSGN 
and both ARF and APSGN simultaneously occurred in 6 patients. Although many patients 
showed carditis (16 out of 17 patients) and polyarthritis (13 out of 17 patients), the 
remaining characteristics (erythema marginatum, chorea and subcutaneous nodules) 
developed in only 4 patients, 1 patient and 1 patient, respectively. 
Although it remains unclear why simultaneous occurrence of APSGN and ARF is so rare, 
one explanation may be that only few streptococcal strains have both nephritogenic and 
rheumatogenic antigenic features (Lin et al., 2003). 
2.1.2 Poststreptococcal reactive arthritis 
Poststreptococcal reactive arthritis (PSRA) is defined as acute arthritis of more than 1 joint 
following an episode of GAS infection in a patient whose illness does not fulfill the Jones 
criteria for the diagnosis of ARF (Barash et al., 2008; Gerber M, 2007). It remains 
controversial whether or not PRSA and ARF are distinct entities or not (Gerber M, 2007). 
Mackie and Keat reviewed 188 published cases of PSRA and concluded that PSRA was a 
heterogenous group of clinical entities (Mackie & Keat, 2004). However, two recent studies 
suggested that PSRA and ARF were separate disease entities on the basis of the differences 
in clinical presentation and disease course (Barash et al., 2008; van der Helm-van Mil, 2010). 
Compared to patients with ARF, patients with PSRA are older, respond poorer to salicylates 
and have non-migratory and persistent arthritis (Tokura et al., 2008; van der Helm-van Mil, 
2010). The precise pathogenic mechanism underlying the development of PSRA is unclear, 
production of antistreptococcal antibodies that cross-react with human epitopes causing 
inflammation and tissue damage is a likely pathogenic mechanism for PSRA, as has been 
proposed for ARF (Niewold & Ghosh, 2003). 
Simultaneous occurrence of PSRA and APSGN is rare, with only 3 cases having been reported 
(Niewold & Ghosh, 2003; Sugimoto et al., 2008; Tokura et al., 2008). Niewold & Ghosh 
described a 44-year-old man who developed severe PSRA and APSGN after a subclinical 
streptococcal infection (Niewold & Ghosh, 2003). Tokura et al. reported a 16-year-old man who 
presented with simultaneous occurrence of APSGN and PSRA with symmetric persistent 
tenosynovitis in hands and feet (Tokura et al., 2008). Sugimoto et al. described a 61-year-old 
man who exhibited PSRA and APSGN with marked renal interstitial inflammation after 
bacterial endophthalmitis due to Streptococcus pyogenes (Sugimoto et al., 2008). Arthritis of all 
the patients improved with corticosteroid therapies without any sequellae.  
2.1.3 Vasculitis  
Vasculitis is not a well-recognized condition associated with GAS infection, but there have 
been several reports of Henoch-Schönlein purpura (HSP) (al-Sheyyab et al., 1999) or 
Henoch-Schönlein purpura with nephritis (HSPN) (Masuda et al., 2003), cutaneous 
leukocytoclastic vasculitis (Chalkias et al, 2010), vasculitic neuropathy (Traverso et al., 1997), 
polyarteritis nodosa (PN) (David et al., 1993) and unclassified systemic vasculitis (Lucas & 
Moxham, 1978). Although the precise pathogenic role of GAS infection contributing to the 
development of vasculitis remains unclear, an immune complex-mediated mechanism 
triggered by GAS infection has been postulated (Ritt M. et al., 2006).  
Vasculitides including cutaneous vasculitis mimicking HSP, cerebral vasculitis, PN, 
necrotizing vasculitis and Wegener’s granulomatosis have been described to occur in 
patients with APSGN.  
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HSP is an IgA immune complex-mediated systemic leukocytoclastic vasculitis of small 
vessels that primarily affects the skin, gastrointestinal tract, joints and kidney (Dedeoglu & 
Sundel, 2007; Robson & Leung , 1994). Respiratory infections with GAS preceding the onset 
of HSP have been reported in up to one-third of cases (Dedeoglu & Sundel, 2007). APSGN 
patients simultaneously presenting with HSP or vasculitis mimicking HSP are rare and only 
five patients have been reported. Goodyer et al. described two boys with histologically 
proven APSGN, in whom cutaneous vasculitis and abdominal symptoms mimicked HSP 
(Goody et al., 1978). Onisawa et al. reported a patient with concurrent APSGN and 
cutaneous leukocytoclastic vasculitis without IgA deposition (Onisawa et al., 1989). 
Maruyama et al. presented a patient with congenital complement 9 deficiency exhibiting 
biopsy-proven APSGN and clinical symptoms mimicking HSP (Maruyama et al., 1995). 
Matsukura et al. also described a 20-month-old girl with biopsy-proven APSGN, who 
presented with cutaneous vasculitis mimicking HSP (Matsukura et al., 2003). All patients 
recovered completely without any sequellae.  
Central nervous system abnormalities of APSGN are usually secondary to acute severe 
hypertension, electrolyte disturbances or uremia, but can also be attributed to cerebral 
vasculitis (Dursun et al., 2008; Ritt et al., 2006). To date, five cases of cerebral vasculitis 
associated with APSGN have been reported (Dursun et al., 2008; Kaplan et al., 1993; Ritt et 
al., 2006; Rovang et al., 1997; Wong & Morris, 2001), in which 4 patients were children. 
Clinical features of cerebral vasculitis in APSGN include severe headache with nausea and 
vomiting, transient focal neurological signs, visual disturbances, and seizures. Although the 
computed tomography of the brain may not detect abnormalities, the magnetic resonance 
imaging of the brain often demonstrated multiple supratentorial areas of abnormal signal 
intensity in the white and adjacent grey matter (Dursun et al., 2008). All patients underwent 
corticosteroid therapy (three of them commenced on methylprednisolone pulse therapy) 
and recovered without any neurological sequellae. 
PN is a necrotizing vasculitis affecting the medium-sized muscular arteries (Dillon et al., 2010). 
Five patients with co-occurrence with PN and APSGN have been described. Fordham et al. 
reported three young adult patients with both PN and APSGN, two of whom died secondary 
to multi-system organ failure (Fordham et al., 1964). Blau et al. described two children with PN 
who also had serological and clinical evidence of APSGN (Blau et al., 1977).  
Although extremely rare, necrotizing vasculitis other than PN (Bodaghi et al., 1987; 
Ingelfinger et al., 1977) and Wegener’s granulomatosis (Garrett et al., 1993) has also been 
reported in patients with APSGN.   
2.1.4 Immune thrombocytopenic purpura 
Immune thrombocytopenic purpura (ITP) is an immune-mediated acquired disorder in which 
antiplatelet antibodies cause accelerated destruction of platelets, resulting in 
thrombocytopenia and an increase risk of bleeding (Psaila & Bussel, 2007). Childhood ITP 
often occurs following an infection with viruses such as varicella zoster, rubella, Epstein-Barr, 
influenza, or human immunodeficiency virus (Tasic & Polenakovic, 2003), but may also be 
preceded by a bacterial infection (Muguruma et al., 2000). Recently, a number of studies have 
suggested an association between Helicobacter pylori and ITP (Cooper & Bussel, 2006).  
Since Kaplan and Esseltine first reported ITP in two patients with APSGN (Kaplan & 
Esseltine, 1978), five cases of ITP in patients with APSGN have been reported (Muguruma et 
al., 2000; Rizkallah et al., 1984; Tasic & Polenakov, 2003). All patients were children (4 to 7 
years of age) who underwent corticosteroid therapy and fully recovered from APSGN and 
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ITP. One patient exhibited a marked increase in platelet-associated immunoglobulin G level 
(Muguruma et al., 2000). Although the precise pathogenic mechanism for the development 
of ITP in patients with APSGN is unclear, Muguruma et al. speculated about the 
pathogenesis of associated diseases through production of autoantibodies cross-reactive 
against GAS and against platelets (Muguruma et al., 2000). 
2.1.5 Autoimmune hemolytic anemia 
Anemia is common in APSGN and traditionally it has been attributed solely to volume 
overload (Eison et al., 2011). However, autoimmune hemolytic anemia (AIHA) has recently 
been reported in patients with APSGN. AIHA is a clinical condition in which IgG and/or 
IgM antibodies bind to red blood cells (RBC) surface antigens and initiate RBC destruction 
via the complement system and the reticuloendothelial system (Gehrs & Friedberg, 2002). 
Subtypes include warm AIHA, cold AIHA, mixed-type AIHA and drug-induced immune 
hemolytic anemia. Furthermore, cold AIHA has been categorized into cold agglutinin 
syndrome (CAS) and paroxysmal cold hemoglobinuria (PCH). Infectious agents associated 
with CAS or PCH include Mycoplasma pneumonia, Epstein-Barr virus, adenovirus, 
cytomegalovirus, influenza viruses, human immunodeficiency virus, measles, mumps, 
Escherichia coli, Listeria monocytogenes, Haemophilus influenza and Treponema pallidum (Gehrs & 
Friedberg, 2002).  
Greenbaum et al. described three children with both APSGN and cold AIHA, two of whom 
had an anti-I autoantibody and thereby were diagnosed with CAS (Greenbaum et al., 2003). 
Two patients were transfused and all patients recovered from AIHA and APSGN. Cachat et 
al. presented a 10-year-old child with concurrent cold AIHA and APSGN, who developed 
anuric acute renal failure and profound anemia (Cachat et al., 2003). The patient responded 
well to corticosteroid therapy and had a full renal and hematological recovery. 
2.1.6 Diffuse alveolar hemorrhage 
Diffuse alveolar hemorrhage (DAH) is sometimes accompanied by glomerulonephritis, and 
is often referred to as pulmonary-renal syndrome (Papiris et al., 2007). Pulmonary-renal 
syndromes include Goodpasture’s syndrome, antineutrophil cytoplasmic antibody-
associated vasculitis, immune complex-associated glomerulopathy and thrombotic 
microangiopathy (Papiris et al., 2007). 
DAH associated with APSGN is extremely rare and only three patients have been reported. 
Chugh et al. described a 38-year-old-male with concurrent DAH and crescentic APSGN who 
progressed to end-stage renal failure (Chugh et al., 1981). Gilboa et al. reported a 12-year-old 
girl who exhibited a noncrescentic APSGN and DAH (Gilboa et al., 1993). Sung et al. 
recently described a 59-year-old-woman with APSGN and DAH (Sung et al., 2007). DAH in 
all three patients subsided after intravenous corticosteroid therapies. The pathogenic 
mechanism of DAH in APSGN remains unclear. 
2.1.7 Uveitis 
Uveitis is believed to be an immunological response to exogenous and endogenous antigens 
(Leiba et al., 1998) and can occur following GAS infection, so-called “poststreptococcal 
uveitis”. Since Cokingtin & Han reported the first case of poststreptococcal uveitis in 1991 
(Cokingtin & Han, 1991), several patient reports and case series with poststreptococcal 
uveitis have been presented (Leiba et al., 1998, Ur Rehman et al., 2006).  
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Feldon et al. recently reported the first case of a child with concomitant APSGN and uveitis, 
whose uveitis subsided within a few days with topical corticosteroid and mydriatic 
treatment (Feldon et al., 2010).  
2.2 Non immune-mediated complications 
Non immune-mediated complications of APSGN include posterior reversible 
encephalopathy syndrome, thrombotic microangiopathy and gallbladder wall thickening. 
2.2.1 Posterior reversible encephalopathy syndrome 
Posterior reversible encephalopathy syndrome (PRES), also known as reversible posterior 
leukoencephalopathy syndrome (RPLS), is a recently described brain disorder associated 
with findings on neuroimaging that suggest white-matter edema, mostly in the posterior 
parietal-temporal-occipital regions of the brain (Hinchey et al., 1996). However, radiological 
lesions in PRES are rarely isolated to these areas, and often involve the cortex, frontal lobes, 
basal ganglia and brainstem (Fugate et al., 2010) (Fig. 1).  
 
 
Fig. 1. Magnetic resonance images (MRI) of the brain (T2-weighted image) showing 
increased intensity in the cortex and subcortical white matter of left occipital (a), bilateral 
parietal and right frontal lobes (b), consistent with PRES. 
The clinical characteristics of the disease include headache, decreased alertness, altered 
mental functioning, seizures, and visual loss including cortical blindness (Hinchey et al., 
1996). The syndrome has been associated with acute hypertension, preeclampsia or 
eclampsia, glomerulonephritis, sepsis, autoimmune disorders and immunosuppressive or 
chemotherapeutic treatments (Bartynski, 2008a; Hinchey et al., 1996). Although the 
underlying pathophysiology of PRES remains elusive, three theories have been proposed: 1) 
hypertension-induced breakdown in cerebral auto-regulation; 2) cerebrovascular 
endothelial dysfunction and; 3) vasoconstriction and hypoperfusion with subsequent 
ischemia and vasogenic edema (Bartynski, 2008b; Fugate et al., 2010). The preferential 
involvement of the posterior brain in PRES may be caused by its relative paucity of 
sympathetic innervation in comparison to the anterior circulation (Froehlich et al., 1999). 
The outcome of PRES is generally favorable, but delay in initiating the appropriate 
treatment may result in permanent damage to the brain (Fux et al., 2006; Garg, 2001). 
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While it is estimated that PRES occurs in 5% to 10% of children hospitalized with acute 
glomerulonephritis of all etiologies, the prevalence of PRES associated with APSGN  
is unknown (Froehlich et al., 1999). PRES caused by hypertension has been reported  
in 7 children (from 7 to 15 years of age) with APSGN (Froehlich et al., 1999; Fux et al., 
2006; Guputa et al., 2010; Nordby, 1997; Özcakar et al., 2004; Soylu et al., 2001). Six 
patients complained of headache, 5 exhibited decreased alertness and seizures, and 3 had 
altered mental functioning and visual loss. All patients exhibited abnormal findings of the 
brain MRI or CT in the white matter of the parietal and occipital lobes, and recovered 
without any neurological sequellae following adequate treatment of the associated 
hypertension.  
One patient with APSGN suffered from PRES without severe hypertension (Nordby, 1997). 
The most important factor in development of pediatric hypertensive PRES is the rapidity of 
blood pressure elevation and the degree of elevation relative to the patient’s baseline 
pressure (Froehlich et al., 1999). It has been suggested that blood pressures more than 30% 
above normal for age should alert clinicians to the possibility of hypertensive PRES 
(Nordby, 1997). 
2.2.2 Thrombotic microangiopathy 
Thrombotic microangiopathy (TMA) is a pathological term used to describe occlusive 
microvascular thrombus formation and is most commonly associated with hemolytic uremic 
syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) (Keir & Coward, 2010). 
Pathological features of TMA include vessel wall thickening, swelling and detachment of 
the endothelial cell from the basement membrane, accumulation of material in the 
subendothelial space, intraluminal platelet thrombosis, partial or complete vessel luminal 
obstruction and fragmentation of red blood cells (Keir & Coward, 2010). HUS is defined as 
the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury 
(Copelovitch & Kaplan, 2008). TTP is characterized by the pentad of microangiopathic 
hemolytic anemia, thrombocytopenia, fever, acute renal injury, and neurological 
abnormalities (Copelovitch & Kaplan, 2008).   
TMA has been reported in 8 patients with APSGN, consisting of 5 children and 3 adults 
(Duvic et al., 2000; Izumi, et al., 2005; Laube, et al., 2001; Medani et al., 1987; Proesmans, 
1996; Siebels et al., 1995; Tan et al., 1998). All patients exhibited severe hypertension. 
Hemodialysis or peritoneal dialysis was required in 2 patients. Renal biopsy showed 
histological features of both APSGN and TMA in 3 patients, and revealed characteristics 
of APSGN without features of TMA in 5 patients. The outcome in all patients was 
excellent.  
The precise pathogenesis of TMA in patients with APSGN is unclear, although two causes 
have been postulated: severe hypertension and streptococcal neuraminidase (Duvic et al., 
2000; Laube et al., 2001; Izumi et al., 2005). HUS has been reported as a complication of 
severe hypertension, regardless of the cause (Broyer, 1995). If severe hypertension is 
transient, histological lesions of TMA are absent. When hypertension becomes malignant, 
renal histological lesions show features of TMA (Duvic et al., 2000). Another possible cause 
of TMA in APSGN is alteration of vascular endothelial cells by streptococcal neuraminidase. 
Circulating neuraminidase causes exposure of the cryptic T-antigen on cell surfaces, to 
which most people possess a naturally occurring antibody. Therefore antigen-antibody 
interaction may damage the vascular endothelial cells leading to the clinical manifestations 
of HUS (Izumi et al., 2005).  
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
156 
Feldon et al. recently reported the first case of a child with concomitant APSGN and uveitis, 
whose uveitis subsided within a few days with topical corticosteroid and mydriatic 
treatment (Feldon et al., 2010).  
2.2 Non immune-mediated complications 
Non immune-mediated complications of APSGN include posterior reversible 
encephalopathy syndrome, thrombotic microangiopathy and gallbladder wall thickening. 
2.2.1 Posterior reversible encephalopathy syndrome 
Posterior reversible encephalopathy syndrome (PRES), also known as reversible posterior 
leukoencephalopathy syndrome (RPLS), is a recently described brain disorder associated 
with findings on neuroimaging that suggest white-matter edema, mostly in the posterior 
parietal-temporal-occipital regions of the brain (Hinchey et al., 1996). However, radiological 
lesions in PRES are rarely isolated to these areas, and often involve the cortex, frontal lobes, 
basal ganglia and brainstem (Fugate et al., 2010) (Fig. 1).  
 
 
Fig. 1. Magnetic resonance images (MRI) of the brain (T2-weighted image) showing 
increased intensity in the cortex and subcortical white matter of left occipital (a), bilateral 
parietal and right frontal lobes (b), consistent with PRES. 
The clinical characteristics of the disease include headache, decreased alertness, altered 
mental functioning, seizures, and visual loss including cortical blindness (Hinchey et al., 
1996). The syndrome has been associated with acute hypertension, preeclampsia or 
eclampsia, glomerulonephritis, sepsis, autoimmune disorders and immunosuppressive or 
chemotherapeutic treatments (Bartynski, 2008a; Hinchey et al., 1996). Although the 
underlying pathophysiology of PRES remains elusive, three theories have been proposed: 1) 
hypertension-induced breakdown in cerebral auto-regulation; 2) cerebrovascular 
endothelial dysfunction and; 3) vasoconstriction and hypoperfusion with subsequent 
ischemia and vasogenic edema (Bartynski, 2008b; Fugate et al., 2010). The preferential 
involvement of the posterior brain in PRES may be caused by its relative paucity of 
sympathetic innervation in comparison to the anterior circulation (Froehlich et al., 1999). 
The outcome of PRES is generally favorable, but delay in initiating the appropriate 
treatment may result in permanent damage to the brain (Fux et al., 2006; Garg, 2001). 
 
Atypical Clinical Manifestations of Acute Poststreptococcal Glomerulonephritis 
 
157 
While it is estimated that PRES occurs in 5% to 10% of children hospitalized with acute 
glomerulonephritis of all etiologies, the prevalence of PRES associated with APSGN  
is unknown (Froehlich et al., 1999). PRES caused by hypertension has been reported  
in 7 children (from 7 to 15 years of age) with APSGN (Froehlich et al., 1999; Fux et al., 
2006; Guputa et al., 2010; Nordby, 1997; Özcakar et al., 2004; Soylu et al., 2001). Six 
patients complained of headache, 5 exhibited decreased alertness and seizures, and 3 had 
altered mental functioning and visual loss. All patients exhibited abnormal findings of the 
brain MRI or CT in the white matter of the parietal and occipital lobes, and recovered 
without any neurological sequellae following adequate treatment of the associated 
hypertension.  
One patient with APSGN suffered from PRES without severe hypertension (Nordby, 1997). 
The most important factor in development of pediatric hypertensive PRES is the rapidity of 
blood pressure elevation and the degree of elevation relative to the patient’s baseline 
pressure (Froehlich et al., 1999). It has been suggested that blood pressures more than 30% 
above normal for age should alert clinicians to the possibility of hypertensive PRES 
(Nordby, 1997). 
2.2.2 Thrombotic microangiopathy 
Thrombotic microangiopathy (TMA) is a pathological term used to describe occlusive 
microvascular thrombus formation and is most commonly associated with hemolytic uremic 
syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) (Keir & Coward, 2010). 
Pathological features of TMA include vessel wall thickening, swelling and detachment of 
the endothelial cell from the basement membrane, accumulation of material in the 
subendothelial space, intraluminal platelet thrombosis, partial or complete vessel luminal 
obstruction and fragmentation of red blood cells (Keir & Coward, 2010). HUS is defined as 
the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury 
(Copelovitch & Kaplan, 2008). TTP is characterized by the pentad of microangiopathic 
hemolytic anemia, thrombocytopenia, fever, acute renal injury, and neurological 
abnormalities (Copelovitch & Kaplan, 2008).   
TMA has been reported in 8 patients with APSGN, consisting of 5 children and 3 adults 
(Duvic et al., 2000; Izumi, et al., 2005; Laube, et al., 2001; Medani et al., 1987; Proesmans, 
1996; Siebels et al., 1995; Tan et al., 1998). All patients exhibited severe hypertension. 
Hemodialysis or peritoneal dialysis was required in 2 patients. Renal biopsy showed 
histological features of both APSGN and TMA in 3 patients, and revealed characteristics 
of APSGN without features of TMA in 5 patients. The outcome in all patients was 
excellent.  
The precise pathogenesis of TMA in patients with APSGN is unclear, although two causes 
have been postulated: severe hypertension and streptococcal neuraminidase (Duvic et al., 
2000; Laube et al., 2001; Izumi et al., 2005). HUS has been reported as a complication of 
severe hypertension, regardless of the cause (Broyer, 1995). If severe hypertension is 
transient, histological lesions of TMA are absent. When hypertension becomes malignant, 
renal histological lesions show features of TMA (Duvic et al., 2000). Another possible cause 
of TMA in APSGN is alteration of vascular endothelial cells by streptococcal neuraminidase. 
Circulating neuraminidase causes exposure of the cryptic T-antigen on cell surfaces, to 
which most people possess a naturally occurring antibody. Therefore antigen-antibody 
interaction may damage the vascular endothelial cells leading to the clinical manifestations 
of HUS (Izumi et al., 2005).  
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
158 
2.2.3 Gallbladder wall thickening 
Thickening of the gallbladder wall is the most common findings in acute cholecystitis, but it 
has also been reported in patients with kidney diseases including pyelonephritis (Talarico & 
Rubens, 1990) and chronic kidney failure (van Breda Vriesman et al., 2007). Only one child 
with APSGN and gallbladder wall thickening has been reported (Watanabe & Baba, 2009). 
Although the pathogenesis of this complication is unclear, elevated systemic venous 
pressure or subclinical vasculitis may have caused edema of the gallbladder wall (Watanabe 
& Baba, 2009). 
2.3 Unusual clinical presentations or courses 
Unusual clinical presentations or courses of APSGN include acute nephritic syndrome with 
minimal urinary abnormalities, and recurrence of the disease. 
2.3.1 Minimal urinary abnormalities 
Patients with APSGN usually exhibit hematuria and proteinuria. However, Blumberg and 
Feldman first reported two children with biopsy-proven APSGN without any urinary 
abnormalities (Blumberg & Feldman, 1962). Thereafter, several authors described biopsy-
proven APSGN patients with minimal or no urinary abnormalities including 13 children 
and 4 adult patients (Albert et al., 1966; Cohen & Levitt, 1963; Dunn, 1967; Fujinaga et al., 
2007; Goorno et al., 1967; Grossman et al., 1973; Hoyer et al., 1967; Kandall et al., 1969; 
Kobayashi et al., 1971). All patients exhibited edema and hypertension, and seven showed 
pulmonary edema or congestion. Hypertensive encephalopathy occurred in one patient 
(Hoyer et al., 1967) and acute rheumatic fever developed in another patient (Cohen & Levitt, 
1963). All patients recovered completely without any sequellae. The mechanism for the 
elaboration on normal or minimal urinary abnormalities during the course of APSGN is 
unclear (Fujinaga et al., 2007; Kandall et al., 1969).  
2.3.2 Recurrence 
Recurrence of APSGN is a well-recognized, but relatively rare phenomenon, probably due 
to the relatively limited number of nephritogenic strains of streptococci and the acquisition 
of protective immunity against a nephritogenic streptococcal antigen after an initial episode 
of APSGN (Watanabe & Yoshizawa, 2001). Ramberg first mentioned this condition and 
reported eleven patients with the recurrent attacks out of 152 patients with APSGN 
(Ramberg, 1947). Thereafter, several clinical studies of APSGN have suggested an incidence 
of recurrent APSGN that ranges from 0.7% to 7.0% (Baldwin D et al., 1974; Bernstein et al., 
1960; Dodge W. et al., 1968; Sanjad et al., 1977; Roy et al., 1969). In addition, a few case 
reports of recurrent APSGN have been described (Casquero et al., 2006; Derakhshan 2002; 
Kim et al., 1979; Rosenberg et al., 1984; Velhote et al., 1986; Watanabe & Yoshizawa, 2001). 
Clinical features and outcomes were well-described in 35 patients including 22 children. 
Most patients suffered from one recurrent episode, but one patient exhibited 2 recurrent 
attacks of APSGN (Velhote et al., 1986). Twenty-nine patients recovered completely, whilst 4 
patients continued to have some urinary abnormalities and two patients progressed to end-
stage renal failure. 
Although the exact mechanism leading to recurrence of APSGN has not yet been 
determined, three possible explanations have been postulated: the suppression of immune 
response against nephritogenic streptococcal strains due to early antibiotic therapy (Roy et 
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al., 1969; Sanjad et al., 1977); an absence of natural immune responses against nephritogenic 
streptococcal components without antibiotic therapy (Watanabe & Yoshizawa, 2001), and; a 
failure to exclude microbial agents through the digestive and respiratory tract due to IgA 
deficiency (Casquero et al., 2006).  
Sanjado et al. suggested that reinfection with the same type of Streptococcus would occur if 
the patient lacked antibodies against that particular type, and penicillin therapy given in the 
first ten days after a streptococcal infection suppressed the formation of type-specific 
immunity conferring antibodies, which might increase the chances of re-infection with the 
same nephritogenic strain responsible for the initial episode of APSGN (Sanjad et al., 1977). 
Recently, Yoshizawa et al. identified a new nephritogenic streptococcal antigen and termed 
it nephritis-associated plasmin receptor (NAPlr) (Yamakami et al., 2000; Yoshizawa et al., 
2004). They demonstrated that most patients with APSGN had high titers of long-lasting 
antibody against NAPlr and that it was present in glomeruli in 100% of patients with 
APSGN early in the disease (Yoshizawa et al., 2004). Watanabe and Yoshizawa described an 
8-year-old boy with recurrent ASPGN who did not have serum antibodies against NAPlr, 
even though NAPlr was detected in glomeruli of an early kidney biopsy specimen from the 
patient during the second attack of APSGN. These results indicated that recurrence of 
APSGN in some patients might be caused by an absence of a natural immune response to 
NAPlr (Watanabe & Yoshizawa, 2001). 
Recently, Casquero et al. published a patient with selective IgA deficiency who experienced 
two episodes of APSGN (Casquero et al., 2006), suggesting that a failure of IgA defenses 
might also predispose to streptococcal re-infection and cause recurrent APSGN. 
3. Conclusions 
Patients with APSGN sometimes exhibit atypical or unusual clinical manifestations, which 
are divided into 3 categories: immune-mediated diseases (ARF, PSRA, vasculitis, ITP, 
AIHA, DAH and uveitis), non-immune mediated conditions (PRES, TMA and gallbladder 
wall thickening), and unusual clinical presentations or courses (minimal urinary 
abnormalities and recurrence).  
Immune-mediated diseases seem to result from immune-complex formation between 
streptococcal antigens and their associated antibodies. Hypertension contributes to the 
development of PRES and TMA, while fluid retention results in PRES and gallbladder wall 
thickening. Recurrence of APSGN may be the consequence of suppressed immune 
responses against nephritogenic streptococcal strains caused by early antibiotic therapy, by 
the absence of natural immune responses against NAPlr, or by selective IgA deficiency.  
Because atypical or unusual manifestations of APSGN may lead to diagnostic delays or 
misdiagnosis of the disorder, recognition of them is important in order to assure that the 
patient receives adequate treatment. 
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1. Introduction 
Approximately 170 million persons worldwide are infected with the hepatitis C (HCV) 
virus. The incidence of glomerulonephritis in HCV-infected patients is unknown due to a 
lack of large-scale cross sectional surveys however subclinical renal involvement is believed 
to be highly prevalent among patients with HCV hepatitis. The most common HCV-
associated glomerulonephritis is membranoproliferative glomerulonephritis (MPGN) type 1 
with or without cryoglobulinaemia. MPGN typically presents several years, and often 
decades, after initial infection with HCV. Most patients have laboratory evidence of 
hypocomplementaemia, circulating rheumatoid factors, and cryoglobulinaemia. Other 
uncommon forms of glomerular disease that have been reported to be associated with HCV 
infection include membranous nephropathy, IgA nephropathy, focal segmental 
glomerulosclerosis, fibrillary glomerulonephritis/immunotactoid glomerulopathy, pauci-
immune glomerulonephritis, and thrombotic microangiopathy.  
The principal clinical manifestations of glomerular disease in HCV patients are the presence 
of proteinuria and microscopic haematuria with or without impaired kidney function. The 
clinical course of these HCV-associated glomerulopathies is generally characterised by 
remission and relapsing phases. The overall prognosis for HCV-associated 
glomerulonephritis remains poor, not only because of renal disease progression but because 
of the high incidence of cardiovascular disease, infection and hepatic failure.  
The exact pathogenic sequence of injury that results in glomerulonephritis is not known. 
The prevailing theory is that glomerular injury results from deposition of circulating 
immune complexes that contain HCV antigens and anti-HCV antibody. Involvement of the 
innate immune system in HCV-associated MPGN has been suggested with demonstration of 
upregulation of Toll-like receptor 3.  
In establishing a link between HCV infection and the immune response targeting the 
glomerulus, antiviral, plasma exchange and immunosuppressive therapies have been used 
in patients. The use of antiviral therapy in HCV-positive patients with glomerulonephritis is 
targeted at eliminating the virus and reducing the generation of HCV-related antibodies and 
immune complexes. The data to support antiviral treatment for HCV-associated 
glomerulonephritis is limited, however interferon therapy may be superior to 
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immunosuppressive agents in HCV-associated cryoglobulinaemic glomerulonephritis in 
lowering proteinuria. Agents such as rituximab have also been shown to be efficacious in 
the treatment of HCV-associated cryoglobulinaemic glomerulonephritis.  
This chapter provides the reader with an overview of hepatitis C-associated 
glomerulonephritis that covers epidemiology, clinical manifestations, natural history, 
immunopathophysiology, and a review of the evidence underpinning current therapeutic 
approaches.  
Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the world. The World 
Health Organization estimates that there are 170 million individuals with HCV infection 
and an incidence of 3–4 million new cases per year (WHO, 2000).  HCV infection leads to 
chronic liver disease, but also to extra-hepatic manifestations. These include mixed 
cryoglobulinaemia, lymphoproliferative disorders and renal disease. HCV infection has 
been reported in association with distinct histological patterns of glomerulonephritis.  
In this review, we will canvass the epidemiology, clinical manifestations, natural history, 
immunopathophysiology, and current therapies of HCV-associated glomerulonephritis, as 
well as cover issues around renal transplantation.  
2. Immunopathogenesis 
HCV is a single-stranded enveloped RNA virus. Its genome codes for a nucleocapsid core 
protein, envelope proteins, and a number of non-structural proteins. Glomerular injury due 
to HCV occurs as a result of the direct interaction of viral RNA and proteins with 
glomerular cells, as well as indirectly through immunological mediators such as immune 
complex deposition. 
The adaptive immune response to HCV infection includes both cellular and humoral 
pathways. Unlike the overt cytotoxic cellular T-cell response to infected hepatocytes in the 
liver, the mechanism of injury in glomerulonephritis appears predominantly due to 
circulating immune complex deposition. This humoral response to HCV infection 
includes the production of various antibodies against HCV protein antigens. To evade 
this, HCV displays antigenic variability resulting from lack of proofreading activity in the 
HCV RNA polymerase. Hypervariable regions are present particularly in the envelope 
protein E2 sequence. Combined with a high replication rate, this antigenic variability 
allows mutant virus strains to escape antibody binding. Thus in chronic HCV infection, 
HCV RNA persists in serum despite the presence of anti-HCV antibodies. The chronic 
simultaneous presence of both HCV antigens and anti-HCV antibodies is a fertile setting 
for the formation of circulating immune complexes. In addition, HCV-induced liver injury 
decreases the hepatic clearance of circulating immune complexes, prolonging their 
survival in the circulation. 
Often the anti-HCV antibodies have the properties of cryoglobulins, that is they precipitate 
at low temperatures. Serum cryoglobulins are present at low levels in up to 50% of chronic 
HCV infected patients, however symptomatic cryoglobulinaemia occurs in 1% or less of 
patients and usually only after years of chronic infection (Meyers et al., 2003). In HCV 
infection, the cryoglobulins are almost always of mixed type, with type 2 (monoclonal 
rheumatoid factor usually IgM kappa) more common than type 3 (polyclonal rheumatoid 
factor) (Miller and Howell, 2000). Possibly, IgM directed against epitopes of the HCV 
envelope cross-reacts with IgG, forming the rheumatoid factor (Alpers and Kowalewska, 
2007). Thus, the cryoglobulins in HCV infection are composed of HCV RNA and/or 
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proteins, complexed with anti-HCV IgG, in turn complexed to IgM rheumatoid factor. The 
concentration of HCV RNA in cryoprecipitates has been found to be around 1,000 times 
higher than in serum (Kamar et al., 2008). While symptomatic cryoglobulinaemia is 
relatively rare in HCV infected patients, conversely the vast majority (over 80%) of patients 
with mixed cryoglobulins have evidence of HCV infection (Kamar et al., 2008). 
Circulating immune complexes, including cryoglobulins, deposit in glomeruli along the 
capillary walls and in the mesangium. IgM kappa rheumatoid factor has a particular affinity 
for cellular fibronectin in the mesangial matrix (Perico et al., 2009). While immunoglobulins 
are readily and routinely identified in glomerular tissues, the demonstration of HCV 
antigens in glomeruli is controversial and limited to relatively small numbers of studies. For 
example, Sansonno and colleagues (2005) used laser capture microdissection combined with 
PCR to identify HCV RNA in glomeruli, as well as immunohistochemistry to identify HCV 
core protein in glomeruli. Virus-like particles have been identified by electron microscopy in 
renal biopsies of patients with HCV infection (Sabry, 2002). 
While much work has focused on humoral immunity and immune complex deposition, 
there has also been research on the innate immune response of the glomerulus to HCV. This 
innate immune response to microbes involves Toll-like receptors (TLRs), transmembrane 
proteins that recognise microbial antigens. Dolganiuc and colleagues (2004), using a variety 
of human and mouse cell types, found that HCV core protein and HCV non-structural 
protein 3 act via Toll-like receptor 2 (TLR2) to trigger inflammatory pathways. In the kidney, 
it is also hypothesized that HCV RNA is recognised by Toll-like receptor 3 (TLR3) expressed 
on mesangial cells. Using a microdissection technique, increased TLR3 mRNA expression 
has been demonstrated in glomeruli with HCV-associated glomerulonephritis, compared to 
glomeruli with non-HCV-associated glomerulonephritis (Wornle et al., 2006). Recognition of 
HCV by TLR3 with subsequent intracellular signalling activates mesangial cells to produce 
pro-inflammatory cytokines and growth factors. The cytokines involved include TNFalpha 
and the chemokine IP-10 (interferon gamma inducible protein-10), both of which are 
upregulated in HCV-associated glomerulonephritis (Merkle et al., 2011). 
The innate immune response, together with the trapping and deposition of immune 
complexes, both contribute to generate activation of local inflammatory and complement 
cascades in glomeruli. These cascades induce glomerular cell proliferation and matrix 
production as well as the recruitment of inflammatory cells, which can be seen 
morphologically as the characteristic histological patterns of glomerulonephritis. While 
some morphological patterns are characteristic of HCV, none is specific, and the diagnosis of 
HCV-associated glomerulonephritis relies on correlation with clinical findings as well as the 
presence of serum anti-HCV antibody and HCV RNA. Evidence of HCV RNA and/or core 
protein in glomeruli has been identified irrespective of the histological pattern of 
glomerulonephritis (Sansonno et al., 2005). 
Membranoproliferative glomerulonephritis (MPGN) type 1 with or without 
cryoglobulinaemia is the most characteristic pattern, comprising the large majority (roughly 
80%) of all HCV-associated glomerulonephritis. Conversely, HCV is perhaps the most 
important cause of secondary MPGN. Histologically, the glomeruli have a 
membranoproliferative pattern with accentuated lobularity, mesangial hypercellularity, and 
mesangial interpositioning causing double contouring of the capillary walls. The glomeruli 
may have prominent inflammatory cell infiltration, particularly of monocytes (Alpers and 
Kowaleska, 2007).  See Figure 1 
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Fig. 1a. Membranoproliferative glomerulonephritis in a HCV-infected patient, with 
accentuated lobularity, mesangial hypercellularity and intracapillary mononuclear 
inflammatory cells (H&E, 400x). 
 
 
Fig. 1b. Double contouring of the capillary basement membranes is more evident on silver 
staining (Modified Wilder's silver stain, 400x). 
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Immunofluorescence staining highlights granular deposits of C3 and immunoglobulins 
(usually IgG and IgM) along capillary walls and in the mesangium, and electron microscopy 
confirms electron-dense immune complex deposits in subendothelial and mesangial locations. 
Cryoglobulin deposits themselves also produce a membranoproliferative pattern of injury. 
In these cases with cryoglobulinaemia, the deposits themselves may be seen histologically as 
eosinophilic glomerular capillary ‘hyaline thrombi’.  See Figure 2 
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reported as small series and case reports, with varying degrees of strength in their association 
with HCV. Of these relatively uncommon forms of HCV-associated glomerulonephritis, 
membranous nephropathy is the most often quoted. In a study by Yamabe and colleagues 
(1995), 2 of 24 patients (8.3%) with membranous nephropathy had evidence of HCV infection. 
A separate Japanese study of 2 patients with membranous nephropathy demonstrated 
pathogenic linkage to HCV by detecting HCV core protein in the affected glomeruli using 
immunofluorescence (Okada et al., 1996). In contrast to HCV-associated MPGN, HCV-
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associated membranous nephropathy does not appear associated with cryoglobulinaemia, 





Fig. 3. (3a above and 3b below). Cryoglobulin deposits classically show organised 
substructure such as microtubular aggregates (EM; photos courtesy of Mr Paul Kirwan, EM 
unit Concord Repatriation General Hospital Sydney Australia). 
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A case series from the University of Alabama at Birmingham examined the kidney biopsies 
of 30 patients receiving liver transplants for HCV-induced cirrhosis at the time of liver 
engraftment (McGuire et al., 2006). Three types of disease were observed: 
membranoproliferative glomerulonephritis type 1, IgA nephropathy, and “mesangial 
glomerulonephritis”. Cryoglobulins were not detected, even in rheumatoid factor-positive 
patients with urinary abnormalities.  
Other rare, somewhat speculative, reported associations with HCV include focal segmental 
glomerulosclerosis (Stehman-Breen et al., 1999), fibrillary glomerulonephritis/immunotactoid 
glomerulopathy (Markowitz et al., 1998), pauci-immune glomerulonephritis (Usalan et al., 
1998), and thrombotic microangiopathy (Herzenberg et al., 1998). 
Lastly, it should be noted that the development of de novo immune complex 
glomerulonephritis in the transplanted kidney is one mechanism leading to the increased 
graft failure seen in HCV-infected renal transplant recipients (Scott et al., 2010). 
3. Clinical manifestations 
Glomerulonephritis can develop several years or even decades after initial infection with 
HCV. As described previously the principal renal manifestation of HCV infection is 
membranoproliferative glomerulonephritis (MPGN). This is usually accompanied by 
cryoglobulinaemia. Classically, HCV-associated MPGN is found in persons with long-
standing infection and patients most often display mild subclinical liver disease. MPGN is 
rarely found in children. Clinically, patients may exhibit symptoms of cryoglobulinaemia, 
including palpable purpura, arthralgias, myalgias, neuropathy, and fatigue. The triad of 
purpura, peripheral neuropathy and arthralgia is evident in nearly 30% of cases (Monti et 
al., 1995). The majority of cryoglobulinaemic HCV-infected patients however have either no 
symptoms or nonspecific clinical manifestations. Cryoglobulins, or immunoglobulins (Igs) 
that precipitate at cold temperature, are detected in approximately 50–70% of patients. 
Cryoglobulinaemic vasculitis, predominantly involving the small vessels, is observed in less 
than 10% of patients (Lamprecht et al., 1999). The most frequently affected tissues/organs 
are skin, nerves, and kidney. Renal involvement has been reported in about one-third of 
cryoglobulinaemic patients (Meyers et al., 2003), but the predilection for renal involvement 
in certain patients is unclear. Renal signs of cryoglobulinaemia include nephrotic or non-
nephrotic proteinuria and microscopic haematuria with mild to moderate renal insufficiency 
(Baid et al., 2000; Johnson et al., 1993; Markowitz et al., 1998). Glomerular disease may 
manifest acutely as oliguric acute renal failure in 5% of cases (Meyers et al., 2003). Around 
80% of patients develop hypertension (Tarantino et al., 1995) which can be severe and 
difficult to control.  
Usually, the diagnosis of HCV-associated MPGN is made by positive tests for serum HCV 
antibodies and HCV RNA. However patients with HCV-associated glomerulonephritis in 
whom HCV RNA were not detected in the blood have been reported (Yamabe et al., 2010).  
Serum aminotransferase levels are increased in the majority of patients and often low serum 
concentrations of complement components (C1q, C4, and C3) are found (Meyers et al., 2003). 
Elevated levels of serum cryoglobulins can be divided by the Brouet classification into three 
types (Brouet et al., 1974). Type 2 and 3 cryoglobulins which are strongly associated with 
hepatitis C, have rheumatoid factor activity and bind to polyclonal immunoglobulins (Ferri 
et al., 2002). These two types are known as mixed cryoglobulinaemia.  
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4. Natural history  
A large prospective cohort study conducted in Northern Norway on 1010 HCV-positive 
patients found elevated alanine aminotransferases in 27.4%, decompensated liver disease in 
2.9%, hepatocellular carcinoma in 0.4% but only 2 patients (or 0.2%) with end-stage renal 
failure caused by membranoproliferative glomerulonephritis (Kristiansen et al., 2010). The 
median observation period from estimated acquisition of the disease to follow-up in these 
patients was 26 years.  
The long-term outcome of HCV-associated nephropathies is nebulous. A retrospective 
cohort study of 474,369 adult veterans in the United States (Tsui et al., 2007) found that 
patients with HCV infection were more likely to develop end-stage renal disease (4.3 per 
1000 person year) than HCV-seronegative patients (3.1 per 1000 person year). For patients 
aged 18 to 70 years with an estimated glomerular filtration rate of at least 30 mL/min per 
1.73 m2, HCV seropositivity was associated with a nearly threefold higher risk of 
developing ESRD (adjusted hazard rate, 2.80; 95% confidence interval, 2.43-3.23). 
Another cross-sectional study (Dalrymple et al., 2007) showed that HCV-positive veterans 
after adjustment for age, race, gender, diabetes and hypertension, had 40% higher odds for 
renal insufficiency (odds ratio 1.40; 95% confidence interval 1.11 to 1.76) as compared with 
HCV-negative veterans.  
An early literature review of patients with essential mixed cryoglobulinaemia (Ponticelli et 
al., 1986) found that of 11 patients with nephrotic syndrome and renal dysfunction who 
received supportive treatment alone, 4 patients (36%) died or exhibited progressive renal 
failure, 2 patients (18%) had stable renal disease, and spontaneous improvement occurred in 
the other 5 patients (45%).  
Finally Tarantino and colleagues (1995) reported the overall poor clinical outcome of 105 
essential mixed cryoglobulinaemia patients with renal involvement collected throughout 25 
years in three renal units in Milan. Patient survival was 49% at 10 years after renal biopsy. 
Forty-two patients died primarily from cardiovascular disease, liver disease or infection, 
whereas 15 patients developed chronic renal failure. Two patients had a complete remission 
of the disease while 15 had a remission only of renal manifestations. Thirty-one patients 
were alive at the end of the study with persistent renal and extrarenal manifestations. Thus 
only a minority of patients eventually developed renal failure because most patients died 
from cardiovascular disease, liver disease or infection.  
5. Therapy 
5.1 Renoprotective therapies 
As hypertension, proteinuria, and progressive renal failure are the main clinical 
manifestations of HCV-associated chronic renal disease, it is essential that renoprotective 
therapies be instituted. Diuretics, renin–angiotensin system inhibitors (angiotensin-
converting enzyme inhibitors or angiotensin II receptor blockers), and lipid-lowering agents, 
have been proven to be beneficial in HCV patients with chronic renal disease (Chadban and 
Atkins, 2005; Ruggenenti et al., 2001; Ruggenenti et al., 2004). 
5.2 Immunosuppressive therapy  
High-dose methylprednisolone has been used to treat exacerbations of mixed 
cryoglobulinaemia for over 30 years (Tarantino et al., 1981; De Vecchi et al., 1983). In one of 
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the earlier studies (De Vecchi et al., 1983), 3 pulses of intravenous methylprednisolone (0.5-1 
gm each) was given for 3 consecutive days during episodes of acute renal function 
deterioration in 16 patients with essential mixed cryoglobulinaemia. The intravenous 
administration was followed by oral prednisone 0.5 mg/kg per day with a slow taper until 
withdrawal of steroids after 4-6 months. Intravenous methylprednisolone pulse therapy did 
have a dramatic effect on renal function with cumulative mean plasma creatinine values 
decreasing from 3.3  1.3 mg/dL to 2.2  0.7 mg/dL (p<0.001). Proteinuria levels were not 
found to be significantly changed as a result of therapy. The basal cryocrit level decreased 
after pulse therapy, however again this was not found to be significant.  
In one case report of rapidly progressive MPGN type 1 with HCV and nephritic syndrome, 
intravenous pulsed methylprednisolone appeared to be useful in establishing rapid 
remission but as antiviral therapy was used concurrently it is impossible to ascertain the 
effect of methylprednisolone alone (Ahmed et al., 2008). 
Unlike intravenous pulse steroid therapy, oral steroids however have not been found to be 
effective in the acute setting. Ponticelli and colleagues (1986) reported 27 patients with 
mixed cryoglobulinaemia and acute renal disease that were treated with oral corticosteroids 
alone or in combination with other cytotoxic agents. 10 patients (37%) died or showed 
progressively worsening renal function, 4 patients continued to have stable renal disease, 
and the other 13 patients (48%) had improved renal function. This does not appear to differ 
markedly from their reporting of the natural outcomes of such patients with supportive 
treatments alone.  
Indeed there are conflicting results on the use of oral steroids for HCV-associated MPGN. A 
Japanese study (Komatsuda et al., 1996) found that only 2 out of 6 patients with MPGN 
responded to steroids but paradoxically found that the serum titre of HCV RNA decreased 
in 5 out of 7 treated patients.  
Other studies have subsequently confirmed that HCV RNA levels increase with steroid 
exposure (Fong et al., 1994; Lake, 2003; McHutchinson et al., 1993).  
Cyclophosphamide has been used successfully in the treatment of HCV-infected patients 
with cryoglobulinaemia and progressive loss of kidney function due to MPGN. In one case 
report a patient with HCV-associated MPGN and progressive renal failure displayed 
disappearance of serum cryoglobulins and a marked improvement in creatinine clearance 
with the institution of cyclophosphamide (Quigg et al., 1995). However cyclophosphamide 
treatment similar to steroids produces a rise in HCV RNA levels.  
It is generally agreed that immunosuppressive medications do increase HCV RNA levels 
but their selective use does not appear to worsen the underlying hepatic disease (D’Amico 
and Fornaserieri, 2003). A review by D’Amico (1998) reported no evidence of acute liver 
damage in more than 100 treatment courses (steroids, cyclophosphamide, plasma exchange) 
in Italian patients with HCV-associated cryoglobulinaemic glomerulonephritis. 
The expert consensus currently is that in patients with HCV-associated renal disease, 
treatment of acute flares does require immunosuppressive therapy to preserve renal 
function however prolonged therapy does not confer any additional benefit (Campise and 
Tarantino, 1999).  
5.3 Antiviral therapy 
Antiviral therapy in the form of alpha interferon was first used in a small pilot study of 7 
patients with cryoglobulinaemic vasculitis in 1987, before the discovery of the critical role of 
HCV in its pathogenesis (Bonomo et al., 1987).  
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After a link was established between HCV infection and the occurrence of 
cryoglobulinaemic MPGN, a number of studies have examined the efficacy of antiviral 
treatment to achieve both sustained virological response (clearance of HCV from the serum 
for at least 6 months after completing an antiviral course) and to improve renal injury. The 
use of antiviral therapy in HCV-positive patients with glomerulonephritis is targeted at 
eliminating the virus and reducing the generation of HCV-related antibodies and immune 
complexes. 
In the early 1990s, standard recombinant alpha interferon (-IFN) was used by itself. The 
first prospective randomised controlled trial by Misiani and colleagues (1994) reported that 
15 out of 25 patients with HCV-associated type II cryoglobulinaemia receiving recombinant 
alpha-interferon had a complete clearance of hepatitis C viral RNA and that all these 
patients reported improvements in cutaneous vasculitis and renal function. There was no 
effect on proteinuria. Unfortunately after treatment with interferon alpha-2a was 
discontinued, viraemia and cryoglobulinaemia recurred in all 15 HCV RNA-negative 
patients. 
Johnson and colleagues (1994) reported the results of a prospective uncontrolled trial of 
fourteen patients receiving interferon alpha for 6 to 12 months. There was a significant 
reduction in proteinuria but no improvement in renal function. Although a good clinical 
response correlated with disappearance of HCV RNA from the serum during treatment, 
relapse of viraemia and renal disease was common after the completion of therapy.  
It was clear at this stage that alpha-interferon was useful but the optimal treatment strategy 
was yet to be defined.  
An advance came with the discovery that ribavirin played a synergistic role with an 
interferon-based regimen to increase the possibility that an on-treatment responder would 
become a sustained responder. Ribavirin monotherapy itself was found to be disappointing 
(Pham et al., 1998) although one case report referenced a patient with refractory nephritic 
syndrome secondary to HCV-associated membranous nephropathy who had a complete 
remission following the initiation of ribavirin monotherapy (Hu and Jaber, 2005).  
Small scale studies examined the combination of standard interferon plus ribavirin for HCV-
associated cryoglobulinaemic glomerulonephritis. Rossi and colleagues (2003) treated 3 
patients with HCV-associated cryoglobulinaemic glomerulonephritis with standard 
interferon and ribavirin for 12 months and showed that all had sustained virological 
response, with reductions in daily proteinuria and rheumatoid factor at the end of follow-
up. Brucheld and colleagues (2003) treated 7 patients with HCV and renal insufficiency (2 
patients with cryoglobulinaemic vasculitis, 4 patients with MPGN, 1 patient with focal 
segmental glomerulosclerosis) with a combination of interferon and ribavirin. 4 of the 7 
patients had maintained virological and renal remission. The frequency of haematuria and 
amount of proteinuria decreased after the course of antiviral treatment.   
The next important clinical breakthrough was the introduction of a polyethylene glycol side 
chain (pegylation) to the interferon to give it a much longer bioavailability, allowing for 
weekly injections rather than three injections per week. Pegylated interferon was shown to 
double the sustained viral response rate in hepatitis C treatment (Lindsay et al., 2001).  
Saadoun and colleagues (2006) carried out a study on 72 consecutive patients with HCV-
associated mixed cryoglobulinaemic vasculitis receiving recombinant interferon or 
pegylated interferon, both in combination with oral ribavirin. A complete clinical response 
of the cryoglobulinaemic vasculitis occurred in 45 patients, a sustained virologic response 
occurred in 42 patients, and cryoglobulins cleared in 33 patients. Compared with patients 
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treated with IFN alpha-2b plus ribavirin, those receiving PEG-IFN alpha-2b plus ribavirin 
had a higher sustained clinical (67.5% versus 56.3%), virologic (62.5% versus 53.1%), and 
immunologic (57.5% versus 31.3%) response, regardless of HCV genotype and viral load. 
Fabrizi and colleagues (2007) then undertook a meta-analysis looking at clinical controlled 
trials of the 2 treatments (antiviral versus immunosuppressive) for HCV-associated 
glomerulonephritis. Six studies involving 145 patients with HCV-associated 
glomerulonephritis were identified (Alric et al., 2004; Beddhu et al., 2002; Johnson et al., 
1994; Komatsuda et al., 1996; Mazzaro et al., 2000; Misiani et al., 1994). The primary 
endpoint was the frequency of patients with significant reduction in proteinuria (return of 
proteinuria to normal or decrease of >50%) at the conclusion of therapy. It was shown that 
standard interferon alpha therapy was more effective than immunosuppressive therapy in 
lowering proteinuria of patients with HCV-associated glomerulonephritis (OR 3.86, 95% CI 
1.44-10.33; P=0.007). However renal dysfunction was not significantly improved with either 
therapy (Fabrizi et al., 2007).   
This meta-analysis was methodologically flawed by the inclusion of studies where patients 
received immunosuppressive agents during antiviral treatment, making it difficult to 
ascertain the effect of each treatment alone.  
A later meta-analysis (Feng et al., 2011) examined the results before and after stable 
regimens of antiviral therapy in subjects with HCV-associated glomerulonephritis and 
compared the results of those subjects who achieved sustained virological response (SVR) to 
those that did not. Improvement of proteinuria and serum creatinine levels after antiviral 
therapy were taken as the end points of interest. Eleven clinical trials involving 225 patients 
were included in the meta-analysis. At the end of antiviral therapy, the mean decrease in 
proteinuria was 2.71 g/24 h [95% confidence interval (CI) 1.38-4.04, P < 0.0001]. The pooled 
decrease in mean serum creatinine levels was 0.23 mg/dL (95% CI 0.02-0.44, P = 0.03). 
Comparison of nonsustained virological response (nonSVR) to SVR groups demonstrated a 
significant mean difference of proteinuria decrease in the SVR group of 1.04 g/24 h (95% CI 
0.20-1.89, P = 0.02) but the serum creatinine decrease of 0.05 mg/dL was not significant (95% 
CI -0.33 to 0.43, P = 0.80).  
A limitation of this meta-analysis is the small number of study subjects making it difficult to 
perform subgroup analysis on the basis of cryoglobulinaemia or baseline proteinuria. 
Another weakness is the lack of randomized controlled trials (RCTs) of interferon alpha-
based therapy in HCV-associated glomerulonephritis. Indeed only 1 of the 11 studies in this 
analysis was an RCT (Misiani et al., 1994). 
Thus antiviral therapy based on interferon alpha can significantly decrease proteinuria and 
hence should be undertaken in patients with HCV-associated glomerulonephritis.  
It should be acknowledged that currently there are no long-term follow-up studies of 
antiviral therapy on HCV-associated glomerulonephritis patients. It is important to ascertain 
whether interferon alpha-based treatments can delay or halt the progression of chronic renal 
disease in the long term. This will require investment in large RCTs with longer durations of 
follow-up.  
5.4 Rituximab 
Treatment with interferon alpha in combination with ribavirin can suppress HCV RNA in 
50-60% of patients with a subsequent decrease in cryoglobulins. Many patients however fail 
to respond to interferon therapy and half the responders relapse.  
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
178 
After a link was established between HCV infection and the occurrence of 
cryoglobulinaemic MPGN, a number of studies have examined the efficacy of antiviral 
treatment to achieve both sustained virological response (clearance of HCV from the serum 
for at least 6 months after completing an antiviral course) and to improve renal injury. The 
use of antiviral therapy in HCV-positive patients with glomerulonephritis is targeted at 
eliminating the virus and reducing the generation of HCV-related antibodies and immune 
complexes. 
In the early 1990s, standard recombinant alpha interferon (-IFN) was used by itself. The 
first prospective randomised controlled trial by Misiani and colleagues (1994) reported that 
15 out of 25 patients with HCV-associated type II cryoglobulinaemia receiving recombinant 
alpha-interferon had a complete clearance of hepatitis C viral RNA and that all these 
patients reported improvements in cutaneous vasculitis and renal function. There was no 
effect on proteinuria. Unfortunately after treatment with interferon alpha-2a was 
discontinued, viraemia and cryoglobulinaemia recurred in all 15 HCV RNA-negative 
patients. 
Johnson and colleagues (1994) reported the results of a prospective uncontrolled trial of 
fourteen patients receiving interferon alpha for 6 to 12 months. There was a significant 
reduction in proteinuria but no improvement in renal function. Although a good clinical 
response correlated with disappearance of HCV RNA from the serum during treatment, 
relapse of viraemia and renal disease was common after the completion of therapy.  
It was clear at this stage that alpha-interferon was useful but the optimal treatment strategy 
was yet to be defined.  
An advance came with the discovery that ribavirin played a synergistic role with an 
interferon-based regimen to increase the possibility that an on-treatment responder would 
become a sustained responder. Ribavirin monotherapy itself was found to be disappointing 
(Pham et al., 1998) although one case report referenced a patient with refractory nephritic 
syndrome secondary to HCV-associated membranous nephropathy who had a complete 
remission following the initiation of ribavirin monotherapy (Hu and Jaber, 2005).  
Small scale studies examined the combination of standard interferon plus ribavirin for HCV-
associated cryoglobulinaemic glomerulonephritis. Rossi and colleagues (2003) treated 3 
patients with HCV-associated cryoglobulinaemic glomerulonephritis with standard 
interferon and ribavirin for 12 months and showed that all had sustained virological 
response, with reductions in daily proteinuria and rheumatoid factor at the end of follow-
up. Brucheld and colleagues (2003) treated 7 patients with HCV and renal insufficiency (2 
patients with cryoglobulinaemic vasculitis, 4 patients with MPGN, 1 patient with focal 
segmental glomerulosclerosis) with a combination of interferon and ribavirin. 4 of the 7 
patients had maintained virological and renal remission. The frequency of haematuria and 
amount of proteinuria decreased after the course of antiviral treatment.   
The next important clinical breakthrough was the introduction of a polyethylene glycol side 
chain (pegylation) to the interferon to give it a much longer bioavailability, allowing for 
weekly injections rather than three injections per week. Pegylated interferon was shown to 
double the sustained viral response rate in hepatitis C treatment (Lindsay et al., 2001).  
Saadoun and colleagues (2006) carried out a study on 72 consecutive patients with HCV-
associated mixed cryoglobulinaemic vasculitis receiving recombinant interferon or 
pegylated interferon, both in combination with oral ribavirin. A complete clinical response 
of the cryoglobulinaemic vasculitis occurred in 45 patients, a sustained virologic response 
occurred in 42 patients, and cryoglobulins cleared in 33 patients. Compared with patients 
 
Hepatitis C Virus Associated Glomerulonephritis 
 
179 
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Rituximab is a monoclonal antibody against the CD20 antigen on the cell surface of B 
lymphocytes. Rituximab can thus reduce rheumatoid factor-producing B lymphocytes, 
resulting in a reduction in cryoglobulin production. In recent years the concept of anti-CD20 
for mixed-type cryoglobulinaemia has emerged as an effective and safe treatment, inducing 
a rapid remission of disease activity (Sansonno et al., 2003; Zaja et al., 2003).  
One study examined 20 HCV-positive patients with mixed-type cryoglobulinaemia (who 
were refractory to interferon therapy) that were treated with rituximab 375 mg/m² weekly 
for 4 weeks (Sansonno et al., 2003). Patients had a follow-up period of 12 months. Sixteen 
patients (80%) had a complete response defined as a 75% or greater reduction in 
cryoglobulins and resolution of at least 2 major clinical signs and symptoms. In these 
patients, rituximab treatment resulted in a reduction in both the IgM and IgG components of 
the cryoglobulin. Only 1 of the 20 patients had nephritis that did not respond to treatment.  
Another study looked at the treatment of 15 patients with rituximab with a follow-up period 
of 9 to 31 months (Zaja et al., 2003). 12 patients were HCV-infected and 3 patients had mixed 
cryoglobulinaemia unrelated to HCV. All patients had early improvement in their 
cutaneous manifestations with rituximab however only 1 patient had complete resolution of 
the cryoglobulin at 6 months and only 3 lost their rheumatoid factor. It is worthwhile noting 
that in 7 of 8 patients, maintenance corticosteroids were successfully withdrawn by the 
second post-treatment month.  
Quartuccio and colleagues (2006) carried out a study where 5 patients with HCV-
associated mixed cryoglobulinaemia were treated with 4 weekly infusions of rituximab 
375mg/m² without accompanying steroids. Renal function improved within 2 months in 
all 5 cases treated. There were no relevant short-term or delayed side effects reported. 
However 3 out of 5 patients showed a recurrence of disease at 5, 7 and 12 months. A 
repeated cycle of rituximab infusion induced rapid remission of disease activity in 2 of 
these patients. Only one patient achieved persistent remission after a single cycle and thus 
the results of the study suggest the need for repeated rituximab administrations for 
adequate control of nephritis. The optimal dosage and frequency of rituximab 
administrations in HCV-associated mixed cryoglobulinaemia remains unclear as all 
studies to date have been based on the rituximab prescribing regimen used in non-
Hodgkin lymphoma (Coiffier et al., 1998).  
6. Renal transplantation and HCV-related renal disease  
It should be recognised that the most common cause of proteinuria and renal insufficiency 
after kidney transplantation in HCV-positive patients is not HCV-related damage but 
chronic allograft nephropathy (Cosio et al., 1996; Nampoory et al., 2001). Renal diseases that 
have been reported in HCV-infected patients after kidney transplantation include recurrent 
or de novo MPGN, membranous nephropathy, minimal change disease, thrombotic 
microangiopathy, acute transplant glomerulopathy, and chronic transplant glomerulopathy 
(Baid et al., 2000; Cruzado et al., 2001; Gallay et al., 1995; Gloor et al., 2007; Hammoud et al., 
1996; Morales et al., 1997; Roth et al., 1995).  
MPGN is the most commonly reported, with an incidence as high as 54% in HCV-positive 
renal transplant recipients (Cruzado et al., 2001; Hammoud et al., 1996; Roth et al., 1995). In 
these patients proteinuria or nephrotic syndrome is the commonest clinical presentation 
(Cruzado et al., 2001; Nampoory et al., 2001; Virgilio et al., 2001).  Serum cryoglobulins are 
very often detected (Roth et al., 1995).   
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Early studies on patient and graft survival in HCV-positive renal transplant recipients have 
concentrated on recurrent liver disease as causes of morbidity and mortality rather than 
examining recurrent renal disease or graft loss (Batty et al., 2001; Meier-Kriesche, 2001; 
Pereira and Levy, 1997). Small single centre studies have shown that both graft and patient 
survival are lower for HCV-positive than HCV-negative patients (Batty et al., 2001; Pereira 
and Levy, 1997).  
More recently two large population based studies have published long term results of 
patient and graft survival (Morales et al., 2010; Scott et al., 2010).  
The outcomes of a large cohort of renal transplant patients was reviewed recently using 
the Australian and New Zealand Dialysis and Transplant registry (Scott et al., 2010). 
Survival outcomes, causes of mortality, and causes of graft failure were examined. 140 
(1.8%) patients were HCV antibody positive. Patient survival among HCV antibody 
positive and HCV antibody negative groups was 77% versus 90% and 50% versus 79% at 5 
and 10 years respectively. The adjusted hazard ratio for patient death was 2.38 (95% CI 
1.69-3.37). Higher rates of death due to cardiovascular disease (adjusted hazard ratio 
2.74), malignancy (adjusted hazard ratio 2.52) and hepatic failure (adjusted hazard ratio 
22.1) were observed. 
A large national study in Spain used data on 4304 renal transplant recipients, 587 of them 
with HCV antibody collected over a long period (1990-2002), to estimate graft and patient 
survival at 4 years (Morales et al., 2010). 4-year graft survival was found to be significantly 
better in HCV-negative versus HCV-positive patients (94.4% versus 89.5%, P < 0.005). 
Patient survival was 96.3% in the entire group with a demonstrable difference between 
HCV-negative and HCV-positive patients (96.6% vs 94.5%, P < 0.05). HCV-positive patients 
were characterised as having more episodes of acute rejection, a higher degree of 
proteinuria with impaired renal function and a greater need for renal graft biopsies. In 
particular de novo glomerulonephritis and transplant glomerulopathy rates in HCV-positive 
and HCV-negative renal graft biopsies was 9.3% versus 5.2% and 11.4% versus 5.0% 
respectively.  
6.1 Hepatitis C treatment implications in renal transplantation 
A meta-analysis of 12 trials of interferon alpha-based therapy in 102 kidney transplant 
patients showed that sustained virological response is extremely variable ranging from 0-
50% with a variable and often extremely high drop-out rate (0% to 100%) (Fabrizi et al., 
2006). HCV genotype is an important determinant of sustained virological response with 
genotype 1 being the most resistant (Lock et al., 1999). Any conferred benefit on the 
underlying disease is mitigated by a 15-60% increased risk of acute cellular or vascular 
rejection (Baid et al., 2003; Fabrizi et al., 2006; Weclawiack et al., 2008).  Unfortunately graft 
rejection is often severe and resistant to steroid therapy (Fabrizi et al., 2006).  
Cessation of standard interferon therapy leads to a surge in hepatitis C viral load (104,105). 
Avoidance of interferon in HCV-positive renal transplant patients has been recommended 
because of the potential to precipitate acute graft rejection. However combined therapy with 
ribavirin and pegylated interferon achieved sustained virological response in 5 out of 8 
patients (62%) without unduly affecting renal function (Montalbano et al., 2007; Mukherjee 
and Ariyarantha, 2007; Schmitz et al., 2007). This suggests a therapeutic role in certain 
settings albeit with an appreciable risk of graft dysfunction.  
Rituximab appeared to be safe in one study of 7 HCV RNA-positive kidney transplant 
patients with de novo cryoglobulinaemia-related MPGN. HCV infection remained stable 
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during and after rituximab therapy (Kamar et al., 2007). Larger long-term studies will be 
necessary to establish efficacy.   
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1. Introduction 
The course and prognosis of patients infected with the human immunodeficiency virus 
(HIV) is changing dramatically following the introduction of highly active antiretroviral 
therapy (HAART), with increased patient survival and decreased morbidity (Mocroft et al, 
1998). 
Current therapy offers patients increased survival by making it more susceptible to certain 
comorbidities (Fang et al, 2007). Cardiovascular and renal diseases are the prototype of 
diseases whose prevalence increases progressively with the prolonged survival and aging 
(Braithwaite et al, 2005). On the other hand, besides specifically associated nephropathy or 
HIV coinfection with hepatitis C virus (HCV) with prolonged survival of the HIV-infected 
population, the spectrum of kidney disease in patients with HIV also reflects the growing 
burden of comorbid diabetes and hypertension and development chronic renal disease 
(Wyatt et al, 2007; Mocroft et al 2007; Szczech, 2004). 
The prevalence of chronic kidney disease in HIV patients may be between 5 to 15% 
depending on the series. However, it has been manifested as albuminuria or proteinuria 
may be present up to 30% in some cohorts of HIV-infected patients (Szczech et al, 2002). 
The prevalence of renal histological involvement has ranged from 1-15% depending on 
the different autopsy series (Shahinian et al, 2000). Patients with HIV infection may 
develop different types of glomerular diseases, vascular lesions and tubulointerstitial 
nephritis related in some cases with the virus itself or other co-infections (Williams et al, 
1998). 
In this chapter we will review at different types of glomerular diseases found in patients 
with HIV infection, highlighting its etipopatogenia, clinical presentation, diagnosis and 
therapeutic alternatives. 
2. Glomerular diseases in patients with HIV infection  
Association between HIV infection and renal disease was first described in 1984, shortly 
after isolation of the virus (Rao et al, 1984). The glomerular diseases are relatively common 
complication in patients infected with HIV, with a wide range of clinical presentations and 
with a poor prognosis in most cases. Although HIV-associated nephropathy (HIVAN) has 
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been considered the most frequent and most representative glomerular disease, after the 
generalized treatment of HIV-infected patients with HAART therapy has allowed the 
emergence of other glomerular diseases with a higher incidence than the general 




 HIV-Associated glomerulonephritis. Immune complex glomerulonephritis 
 Membranoproliferative glomerulonephritis 
 Membranous nephropathy 
 Mesangial glomerulonephritis (IgA) 
 Focal segmental glomerulosclerosis non-collapsing 
 Lupus-like glomerulonephritis 
 Postinfectious glomerulonephritis 
 Other nephropathies 
 Thrombotic Microangiopathy 
 Malignant hypertension 
 Amyloidosis 
 
Table 1. Glomerular diseases in patients with HIV infection 
2.1 HIV-associated nephropathy  
This type of glomerular disease is HIV-associated nephropathy best described (Rao et al, 
1987). The disease affects mostly males, intravenous drugs users and black patients (D’Agati 
& Appel, 1997). U.S. is the third leading cause of end-stage renal disease (ESRD) in African 
Americans between 20 and 64 years of age and the most common cause of ESRD in HIV-1 
seropositive patients (Eggers & Kimmel, 2004; Shahinian et al, 2000). Prevalence is variable, 
ranging from 4% in clinical studies and 10% in autopsy (Mazbar et al, 1989). Although these 
renal findings can be seen in patients with asymptomatic or primary HIV infection, most of 
patients have low CD4 cells count and advanced disease. 
Among the specific mechanisms involved, in addition to genetic susceptibility (several 
polymorphisms that influence susceptibility to HIV infection), the virus can be seen in 
glomerular epithelial cells (Kimmel et al, 1993; Röling et al, 2006). Transgenic mice were crated 
with HIV-DNA construct inserted into the genome and developed a histological picture and 
clinical presentation very similar to that of humans (Bruggeman et al, 1997). The viral genome 
is detected in different renal structures (tubular cells, podocytes, glomerular parietal epithelial 
cells), even in cases without renal involvement, indicating that the presence in the renal tissue 
is not sufficient to cause nephropathy (Lu & Ross, 2005; Mikulak & Singhal, 2010). There are 
many mediators and the expression of nonstructural viral proteins, cytokines and growth 
factors can modulate and amplify renal injury. The mechanism of viral entry into renal 
epithelial cell is still unknown. CCR5 and CXCR4 are coreceptors to CD4 that mediate HIV-1 
entry into lymphocytes. These receptors have not been demonstrated on renal epithelial cells 
in vivo (Eitner et al, 2000). Recently, have been described the DEC-205 receptor, which 
facilitates the entry of the virus in renal tubular cells (Hatsukari et al 2007). 
HIVAN is a characterized by a constellation of pathologic findings involving glomerular, 
tubular and interstitial compartments. Glomerular pathologic findings include a collapsing 
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focal segmental glomerulonephritis, with a marked retraction of glomerular capillary loops, 
and occlusion of the lumen (D’Agati & Appel, 1998). Podocytes show intense hypertrophy 
and hyperplasia, which is associated with decrease expression of podocyte maturity 
markers and accumulations of protein in their cytoplasm. On the other hand, there is a 
characteristic intense tubulointerstitial involvement, which gives it a matter of some 
exclusivity over other nephrotic syndromes. These changes consist of dilatation of the renal 
tubules, which sometimes are proliferative microcyst, and large proteinaceous cylinders in 
light, cell infiltrates and areas of fibrosis (D’Agati & Appel, 1998; Klotman, 1999). 
Immunofluorescence usually shows mesangial deposits of IgM and C3 and electron 
microscopy, are frequently observed tubuloreticular inclusions in the cytoplasm of 
endothelial cells. These structures are synthesized by the stimulation of alpha-interferon, as 
in the cases of patients with lupus nephritis. The histological differential diagnoses of focal 
segmental glomerulosclerosis are the collapsing nephropathy heroin abuse, caused by 
bisphosphonates, interferon or parvovirus (Klotman, 1999). 
Main manifestation of HIV-associated nephropathy is a nephrotic syndrome (Herman & 
Klotman, 1998). However, although the proteinuric can be massive in many cases (more 
than 8-10 g/24 h), most patients with HIVAN do not have significant peripheral edema. 
Moreover, patients with HIVAN are usually not hypertensive, a remarkable finding 
considering that more than 90% of black patients with renal insufficiency of other causes 
exhibit hypertension. The kidneys are usually normal in size or larger. Most patients also 
have advanced renal failure at the time of diagnosis.  
Evolution without HAART is poor, with rapid development of renal failure requiring 
dialysis within the first year of diagnosis, and with a high mortality (Winston et al, 1998). 
The beneficial effects of HAART on HIVAN have been shown in individual clinical 
observations. There are reports of resolution of renal disease with the administration of 
HAART, with a recurrence of renal disease after stopping treatment (Scialla et al, 2007). 
Although no controlled clinical trials have demonstrated the effectiveness of any therapeutic 
measure in the HIVAN, it is recognized that HAART prevents or reduces the risk of 
developing HIVAN and if this occurs, the patients may have a slower course and lower 
mortality than in untreated patients (Lucas et al, 2004). Another treatment option is 
recommended in these patients using drugs that blocker renin-angiotensin-aldosterone 
system (BRAAS). These drugs are a part like any other chronic proteinuric nephropathy 
(Wei et al, 2003). Some studies have shown a decrease in proteinuria and a trend towards 
stabilization of renal damage in patients with HIVAN treated with corticosteroids. 
However, this treatment was not without significant side effects (Smith et al, 1994), so it 
should be limited to cases in which treatment with HAART have not produced any 
improvement and if we rule out opportunistic infections. Finally, we can find some curious 
case of spontaneous improvement of the glomerular pathology (Morales et al, 2002). The 
indications for renal replacement therapy with dialysis or transplantation in patients with 
HIVAN are similar to those followed in other chronic renal disease in the general 
population. 
2.2 Immune-mediated glomerulonephritis 
Patients with HIV infection have a higher incidence of other glomerulonephritis whose 
pathogenesis is generally attributed to glomerular deposition of immune complexes (Balow, 
2005; Nochy et al, 1993), see Table 2.  
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Types of Glomerular 
diseases Ref 
Williams DI 
et al London 17 
13 M,  
4 F  
47% blacks    53% 
caucasians 
HIVAN 41%, MN 23%, 
HUS 12%, others 24 % 9 
Rao TKS  
et al. Nueva York 55 
49 M,   
6 F  100% blacks 
HIVAN 90%, Mesangial 
GN 10% 11 
Mazbar SA 
et al. San Francisco 27 
26 M,   
1 F  
63% blacks    37% 
caucasians 
HIVAN 27%, MPGN 27%, 
Interstitial nephritis 9%, 
immune complex GN 




et al. Paris 60 
51 M,   
9 F  
48% blacks    52% 
caucasians 
43 % HIVAN, Immune 
complex GN 37%, lupus 




et al. Italy 26 
21 M,   
5 F  100% caucasians
Immune complex GN 
65.5%, MPGN 15.5%, 
lupus like nephritis 




et al. London 34 
25 M,   
9 F  
55.8% blacks 
41.1%caucasians
50 % HIVAN,  
14.5 % MN,  
6% MPGN, 12 % HUS, 3% 
Immune complex GN, 
14.5 % others 
53 
Shahinian V 
et al. Texas 389 
362 M, 
27 F  
54 % blacks   35% 
caucasians 
26%  unknown,  
7 % HIVAN,  
7% immune complex GN, 
17 % ATN,  




et al. EEUU 89 
73 M,  
16 F  
88% blacks   12% 
others 
47% HIVAN,  
53 % non-HIVAN 6 
Cheng JT  
et al. EEUU 14 
8 M,     
6 F 100 
93% blacks     7% 
caucasians 79% MPGN, 21% MN 36 
Stokes MB 
et al. EEUU 12 
11 M,   
1 F 100 
58% blacks   42% 
caucasians 
41% MPGN,  
41 % mesangial GN, 8% 
MN, 8 % HIVAN 
37 
Gutiérrez  




89%   caucasians
29.6% MPGN, 25.9% Non-
collapsing FSGS, 22.2% 
mesangial GN, 14.8% 
HIVAN. 
45 
Table 2. Different studies with renal disease in HIV patients 
In Europe, especially in Caucasians, glomerular immune complex glomerular diseases are 
more common than HIVAN and may take several forms. The immune-mediated 
glomerulonephritis would be the counterpart among the white population to what is 
represented by the HIVAN in the black (Casanova et al, 1995).  
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The pathogenesis of these types of glomerulonephritis remains largely unknown; there is 
a local formation or glomerular deposition of circulating immune complexes that may 
contain HIV antigens and polyclonal antibodies. We can not rule out the involvement of 
an immune response against associated viral infections. The clinical features are very 
striking (gross hematuria, edema, acute renal failure, and hypertension), although cases of 
more subtle presentation and are diagnosed incidentally, see Table 3. 
Hypergammaglobulinemia is common, reflecting a polyclonal B cell activation. However, 
the role of some viral co-infections very frequent among HIV patients, such hepatitis C 
(HCV) and hepatitis B virus (HBV), appears to be decisive, particularly in MPGN and 
NM.  
Very limited information is presently available regarding treatment and clinical outcomes in 
patients with immune-mediated GN in patients with HIV infection. Until now we have not 
information about the therapeutic interventions used in patients without HIV infection 
(steroids, immunosuppressants, calcineurin inhibitors) can change the course of immune-
complex glomerulonephritis. 
 
 HIVAN MPGN IgAN FSGS-NC MN PIGN
Lupus-
like Amyloidosis MAT 
Nephrotic 
syndrome 4 3 0 3 4 1 4 4 1 
Macroscopic 
hematuria 0 2 4 0 0 3 2 0 2 




1 1 3 1 1 1 1 0 3 
Hypo-
complementemia 0 3 0 0 0 4 1 0 0 
Cryglobulins (+) 0 3 0 0 0 1 1 0 0 
Coinfection 

























HIVAN: HIV-associated nephropathy; MPGN: membranoproliferative GN; IgAN: IgA nephropathy; 
FSGS-NC: Not collapsing forms of FSG; MN: membranous nephropathy; PIGN: Postinfectious GN; 
MAT: Thrombotic microangiopathy; HAART: Highly active antiretroviral therapy; BSRAA: Blockers of 
the system renin-angiotensin-aldosterone; S: steroids; INF: interferon; RBV: ribavirin; RTX: rituximab; 
P:Plasmapheresis. Degrees: (0-4): (Never-Always) 
Table 3. Most common presentations and laboratory markers in glomerular diseases in 
patients with HIV infection 
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2.2.1 Membranoproliferative glomerulonephritis 
The most common clinical presentation is nephrotic syndrome with macroscopic 
hematuria or microhematuria and normal renal function or mild renal function 
impairment. Up to 90% of cases there are co-infected with HCV (Morales et al, 1997; 
Cheng et al, 1999). Cryoglobulins are detected in most cases with elevated rheumatoid 
factor and decrease of complement, especially C4. The clinical and serological profile is 
very similar to the membranoproliferative GN associated with HCV patients without HIV 
infection. For all these reasons it is considered that this is a pathogenetically GN induced 
by HCV, without the concomitant presence of HIV play a prominent role (Stokes et al, 
1997). 
In some cases the extrarenal manifestations of cryoglobulinemia include clinical 
presentation, with vasculitis cutaneous, and even gastrointestinal manifestations alveolar 
hemorrhage. In these cases we can find an acute renal failure with hematuria and 
proteinuria, and characteristic histological finding of membranoproliferative GN with 
deposits of cryoglobulins in glomerular capillary lumens. Cryoglobulins are usually of a 
mixed IgG-IgM. 
The safety and efficacy of HCV treatment with interferon and ribavirin in patients 
coinfected with HIV has been evaluated in numerous series in the literature (Kadan & Talal, 
2007). There are series of cases in which an effective antiviral treatment correlated with 
improvement in renal manifestations (Kamar et al, 2006). However, we find cases in which 
there is no negativity of cryoglobulins despite the negativity of HCV-RNA, and can even 
clinical manifestations (Morales et al, 2007). There are cases in which clinical aggressiveness 
may be amenable to immunosuppressive treatment. High-dose steroids and plasmapheresis 
may improve the clinical course, although has increased HCV replication and risk of 
worsening liver disease. Rituximab is an anti-CD20 monoclonal antibody that has produced 
a prolonged improvement of renal manifestations in cases that can not be eradicated HCV 
(Kamar et al, 2006).  
In cases of membranoproliferative GN is not associated with HCV; the experience is limited 
and can recommend the use of drugs that block the RAAS, since its effect antiproteinuric, 
renoprotective and antihypertensive. 
2.2.2 IgA nephropathy 
Series have described several cases of IgA nephropathy in patients infected with HIV. The 
actual incidence is unknown, but in a study of 116 autopsies in patients with HIV infection 
were detected IgA glomerular deposits by 7.7% (Beaufils et al, 1995).  
Patients infected with HIV develop IgA antibodies against specific HIV antigens and this 
seems to be the pathogenic basis of this nephropathy. On the other hand, can produce 
idiotype IgA antibodies against other antibodies IgG and IgM directed against viral 
antigens. Renal lesions may result from HIV antigen-specific immune complexes that are 
derived from the circulation and from in situ complex formation (Kimmel et al, 1992). 
Clinical presentation is similar to that of idiopathic IgA nephropathy: microhematuria with 
occasional episode of gross hematuria after infection mainly located in the upper respiratory 
tract and different proteinuria degrees. The long-term prognosis depends mainly on the 
amount of the proteinuria. In addition to these developments chronic, slowly progressive, 
characteristic of IgA nephropathy, patients may also develop acute complications similar to 
those of the IgA idiopathic acute renal failure that is associated with macroscopic hematuria 
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is a widely known complication (Gutierrez et al, 2007) and development of hypertension 
malignant (MHT) (Chen et al, 2005). In episodes of gross hematuria may develop acute 
tubular necrosis, tubular abnormalities consist in a high proportion of tubules that are filled 
by red blood cells (RBC) casts and signs of tubular necrosis that are more evident in tubules 
that are occupied by RBC casts, see Figure 1. 
 
 
Fig. 1. Tubules filled by red blood cells, showing diminished number of lining epithelial 
cells and nuclear pyknosis.  
Regarding the MHT, is observed in a significant percentage (5% -7%) of cases of idiopathic 
IgA, but some series indicate that its incidence may be even higher in HIV-associated IgA 
nephropathy. In our experience, most of the cases with HIV-infection and IgA nephropathy 
presented malignant hypertension (Gutierrez et al, 2007). The prognosis is poor and many 
cases progress to irreversible end-stage renal failure, see Figure 2. However, in some 
patients the effective control of blood pressure drug type inhibitors of angiotensin 
converting enzyme (ACE) inhibitors and / or antagonists of the angiotensin receptor (ARB) 
manages to partially reverse renal failure. 
In some patients with HIV infection, as also in Idiopathic IgA renal manifestations may be 
associated with systemic manifestations of the type of vasculitis cutaneous, arthritis and 
various digestive disorders, all components of the Schönlein-Henoch syndrome. 
At the present there is a little information about the treatment and outcomes of patients with 
HIV infection. Therefore, according to the recommendations in idiopathic IgA, it is 
recommended to treat all patients who develop significant proteinuria (>0.5-1 g / day) or 
hypertension, with ACE inhibitors or ARB, since the antiproteinuric and renoprotective 
effect of these drugs, also tested with IgA nephropathy (Praga et al, 2003). 
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Fig. 2. Renal survival of patients with mesangial IgA nephropathy and MHT and mesangial 
nephropathy patients without MHT. 
2.2.3 Focal segmental glomerulosclerosis non-collapsing 
Among the different histological forms of focal glomerulosclerosis, have also been reported 
not collapsing glomerulosclerosis in patients with HIV (Haas et al, 2005). The pathogenesis 
and the exact relationship of these GN may have HIV or other pathogens have not been 
investigated.  
Very limited information is available about the real incidence, clinical and developmental 
characteristics and therapeutic possibilities of this entity. In our experience, this type of 
glomerular disease is the second most common presentation in our HIV-infected patients 
(Gutierrez et al, 2007). The most common clinical presentation was proteinuria, and 
nephrotic syndrome was observed in 72% of cases. All patients were treated with HAART 
and BSRAA; at the end of treatment no patient need dialysis and 60% had renal 
insufficiency (Gutierrez et al, 2007).  
In idiopathic forms, not associated with HIV, proteinuria and nephrotic syndrome are 
common manifestations. Some cases progress rapidly to ESRD. Corticosteroids administered 
for a long time for months and calcineurin inhibitors drugs are treatment options supported by 
experience. However, given the absence of data on HIV-infected patients and the susceptibility 
of these patients to infections, careful observational studies are needed before recommending 
these options. The optimization of antihypertensive and antiproteinuric drugs (ACEI/ARB) 
can exert a favorable effect, as in idiopathic less aggressive forms. 
2.2.4 Membranous nephropathy 
Membranous nephropathy (MN) is a typical example of glomerular disease mediated by 
deposition of immune complexes. MN is a recognized complication of renal malignancies 
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and infections. Among these, HBV and HCV have been associated with the development of 
MN and syphilis, and various parasitic diseases. 
In this context, the frequent presence of HBV and HCV co-infection and the increasing 
incidence of syphilis and other infectious processes suggests that there may be a 
predisposition of patients with HIV infection to the development of MN, although not 
known actual incidence and its outcome. 
The characteristic clinical presentation is nephrotic syndrome, although minorities of cases 
show no nephrotic range proteinuria. In forms idiopathic, there are two therapeutic 
strategies that have proven effective in controlled prospective studies, immunosuppression 
with steroids plus cyclophosphamide or chlorambucil, and calcineurin inhibitors drugs 
(cyclosporine, tacrolimus) (Praga, 2008). However, consider that a high percentage (up to 
50% in some series) have spontaneous remission within the first years of the disease 
(Polanco et al, 2010) for this reason may be preferable initially attitude conservative in 
patients with HIV-infection. All chronic proteinuric nephropathies may be beneficial to use 
renin-angiotensin-aldosterone system blockers (ACEI/ARB). If we can identify an infectious 
agent as pathogenic factor, the treatment could potentially resolve the kidney problem. 
2.2.5 Postinfectious glomerulonephritis 
Although the descriptions are limited (Enriquez et al, 2004), patients with HIV infection 
could be theoretically exposed to the development of postinfectious GN due to its higher 
rate of infection. The clinical picture is generally abrupt, with hypertension difficult to 
control, often gross hematuria and mild and transient impairment of renal function 
frequently. There are typical red blood cell casts present in urinary sediment and 
hypocomplementemia. Renal biopsy shows a diffuse endocapillary GN with proliferation of 
mesangial and endothelial cells, Glomerular and interstitial infiltration of monocytes and 
lymphocytes is present. Glomerular accumulation of neutrophils is common and is termed 
“exudative”. Ultrastructural studies demonstrate the subepithelial “humps” which are 
typical although not pathognomonic of postinfectious GN.  
The history of an infection, usually 1-2 weeks, followed by a short asymptomatic period and 
the typical abrupt onset of nephritic syndrome for the diagnosis in many cases, along with 
the study of the sediment and the detection of hypocomplementemia. The majority of cases 
have benign course with conservative treatment of the infectious process and complications 
(hypertension, edema). The descriptions of acute postinfectious GN in patients with 
endocarditis or localized infections are characteristic, although they have published very 
few cases among HIV-infected patients. 
2.2.6 Lupus-like glomerulonephritis 
Lupus-like glomerulonephritis, defined by the presence of a “full house” of glomerular 
immunoglobulin and complement deposits on immunofluorescence in the absence of 
serologic evidence of systemic lupus erythematosus (SLE). There is presently little 
information known about the etiology, its treatment, or its long-term outcome. 
Its main histological features are cell proliferation and mesangial matrix, the presence of 
hyaline thrombi and massive deposit of immune complexes in capillary walls, which reach 
mimic the "wire loops" typical of lupus nephritis and are the origin of name ("lupus-like") 
that has been proposed for these cases. In immunofluorescence, as occurs in lupus nephritis, 
deposit detects all types of immunoglobulins (IgG, IgA, IgM) and various fractions of 
 

























Fig. 2. Renal survival of patients with mesangial IgA nephropathy and MHT and mesangial 
nephropathy patients without MHT. 
2.2.3 Focal segmental glomerulosclerosis non-collapsing 
Among the different histological forms of focal glomerulosclerosis, have also been reported 
not collapsing glomerulosclerosis in patients with HIV (Haas et al, 2005). The pathogenesis 
and the exact relationship of these GN may have HIV or other pathogens have not been 
investigated.  
Very limited information is available about the real incidence, clinical and developmental 
characteristics and therapeutic possibilities of this entity. In our experience, this type of 
glomerular disease is the second most common presentation in our HIV-infected patients 
(Gutierrez et al, 2007). The most common clinical presentation was proteinuria, and 
nephrotic syndrome was observed in 72% of cases. All patients were treated with HAART 
and BSRAA; at the end of treatment no patient need dialysis and 60% had renal 
insufficiency (Gutierrez et al, 2007).  
In idiopathic forms, not associated with HIV, proteinuria and nephrotic syndrome are 
common manifestations. Some cases progress rapidly to ESRD. Corticosteroids administered 
for a long time for months and calcineurin inhibitors drugs are treatment options supported by 
experience. However, given the absence of data on HIV-infected patients and the susceptibility 
of these patients to infections, careful observational studies are needed before recommending 
these options. The optimization of antihypertensive and antiproteinuric drugs (ACEI/ARB) 
can exert a favorable effect, as in idiopathic less aggressive forms. 
2.2.4 Membranous nephropathy 
Membranous nephropathy (MN) is a typical example of glomerular disease mediated by 
deposition of immune complexes. MN is a recognized complication of renal malignancies 
 
Glomerular Pathology in Patients with HIV Infection 
 
197 
and infections. Among these, HBV and HCV have been associated with the development of 
MN and syphilis, and various parasitic diseases. 
In this context, the frequent presence of HBV and HCV co-infection and the increasing 
incidence of syphilis and other infectious processes suggests that there may be a 
predisposition of patients with HIV infection to the development of MN, although not 
known actual incidence and its outcome. 
The characteristic clinical presentation is nephrotic syndrome, although minorities of cases 
show no nephrotic range proteinuria. In forms idiopathic, there are two therapeutic 
strategies that have proven effective in controlled prospective studies, immunosuppression 
with steroids plus cyclophosphamide or chlorambucil, and calcineurin inhibitors drugs 
(cyclosporine, tacrolimus) (Praga, 2008). However, consider that a high percentage (up to 
50% in some series) have spontaneous remission within the first years of the disease 
(Polanco et al, 2010) for this reason may be preferable initially attitude conservative in 
patients with HIV-infection. All chronic proteinuric nephropathies may be beneficial to use 
renin-angiotensin-aldosterone system blockers (ACEI/ARB). If we can identify an infectious 
agent as pathogenic factor, the treatment could potentially resolve the kidney problem. 
2.2.5 Postinfectious glomerulonephritis 
Although the descriptions are limited (Enriquez et al, 2004), patients with HIV infection 
could be theoretically exposed to the development of postinfectious GN due to its higher 
rate of infection. The clinical picture is generally abrupt, with hypertension difficult to 
control, often gross hematuria and mild and transient impairment of renal function 
frequently. There are typical red blood cell casts present in urinary sediment and 
hypocomplementemia. Renal biopsy shows a diffuse endocapillary GN with proliferation of 
mesangial and endothelial cells, Glomerular and interstitial infiltration of monocytes and 
lymphocytes is present. Glomerular accumulation of neutrophils is common and is termed 
“exudative”. Ultrastructural studies demonstrate the subepithelial “humps” which are 
typical although not pathognomonic of postinfectious GN.  
The history of an infection, usually 1-2 weeks, followed by a short asymptomatic period and 
the typical abrupt onset of nephritic syndrome for the diagnosis in many cases, along with 
the study of the sediment and the detection of hypocomplementemia. The majority of cases 
have benign course with conservative treatment of the infectious process and complications 
(hypertension, edema). The descriptions of acute postinfectious GN in patients with 
endocarditis or localized infections are characteristic, although they have published very 
few cases among HIV-infected patients. 
2.2.6 Lupus-like glomerulonephritis 
Lupus-like glomerulonephritis, defined by the presence of a “full house” of glomerular 
immunoglobulin and complement deposits on immunofluorescence in the absence of 
serologic evidence of systemic lupus erythematosus (SLE). There is presently little 
information known about the etiology, its treatment, or its long-term outcome. 
Its main histological features are cell proliferation and mesangial matrix, the presence of 
hyaline thrombi and massive deposit of immune complexes in capillary walls, which reach 
mimic the "wire loops" typical of lupus nephritis and are the origin of name ("lupus-like") 
that has been proposed for these cases. In immunofluorescence, as occurs in lupus nephritis, 
deposit detects all types of immunoglobulins (IgG, IgA, IgM) and various fractions of 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
198 
complement (Haas et al, 2005; Weiner et al, 2003). However, the term may be misleading, 
because the similarities end with lupus in the histological aspects of renal biopsy. There are 
no systemic symptoms similar to lupus flares and serology (ANA and anti-DNA, 
hypocomplementemia) is negative. 
Most reported cases present with nephrotic syndrome and progressive deterioration of 
renal function. No information about the natural history of this process and whether or 
not modify therapeutic interventions. Regarding the pathogenesis, there are only 
speculations. It is proposed that, in addition to frequent infections with HBV, HCV and 
other infectious agents, HIV itself through several of its proteins (p24, gp41, gp120) can 
induce a systemic response of immunoglobulin, causing a large amount of circulating 
immune complexes that would be trapped nonspecifically in the glomerulus, 
alternatively, the HIV proteins could be initially deposited in the glomerulus (planted 
antigens) and subsequently be detected by the antibody in situ formation of immune 
complexes (Weiner et al, 2003). 
Although we can be exceptionally patient with HIV infection and the coexistence of lupus 
with renal involvement, and it would be important to make a diagnosis difference between 
the two entities. In patients with both HIV infection and a diagnosis of SLE, three patterns of 
disease occurrence have been described: HIV following SLE diagnosis, SLE following HIV 
infection, and simultaneous diagnosis of HIV and SLE. Since the appearance of an 
autoimmune disorder in patients with a pre-existing immunodeficiency would not be 
expected, at least from a mechanistic standpoint, we will focus our review on patients with 
existing HIV who developed signs and symptoms consistent with a new diagnosis of lupus. 
SLE and HIV infection are two diseases whose clinical and serologic presentations may 
occasionally mimic one another, but with pathogenic mechanisms that theoretically are 
mutually exclusive. The seemingly paradoxical coexistence of these two immune disorders 
offers intriguing insights into the complex cellular and humoral immune networks that 
govern autoimmune phenomena and self tolerance. 
Finally, the clinical management of the HIV positive lupus patient represents a therapeutic 
challenge for the physician due to the delicate equilibrium that needs to be achieved 
between SLE remission and HIV control (Gindea et al, 2010). 
2.3 Other nephropathies in patients with HIV infection 
2.3.1 Thrombotic microangiopathy 
Thrombotic microangiopathy (TMA) is a known complication of HIV infection (Connolly et 
al, 1995; Alpers, 2003). Published reports of the incidence of TMA evaluated during the pre-
HAART era vary considerably, depending on the type of study performed, diagnostic 
criteria used to evaluate patients, and stage of HIV disease (Connolly et al, 1995). It is likely 
that this under-diagnosed entity, as shown in autopsy studies (Gadallah et al, 1996) and 
patients with progressive deterioration of renal function, the presence of MAT in renal 
biopsy exceeded the incidence of HIVAN (Peraldi et al, 1999). 
Endothelial cell injury appears to be the primary event causing platelet activation and 
deposition in the microvasculature. On these microthrombi mechanical destruction would 
occur, anemia, schistocytes, elevated LDH and Coombs test negative. Direct cytopathic 
roles of HIV as well as other factors such as malignancy, drugs, and infectious agents 
have been implicated in the pathogenesis of HIV-TMA. It is known that various HIV 
proteins can directly damage endothelial cells, inducing apoptosis therein (Alpers, 2003). 
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In experimental animals infected with HIV often develops MAT, so it is suspected that 
HIV itself plays a key role in endothelial damage (Eitner et al, 1999). It is also the 
possibility that anticardiolipin antibodies/antiphospholipid frequently detected in HIV 
patients (Boue et al, 1990) have pathogenic importance. In the primary antiphospholipid 
syndrome or lupus erythematosus associated with MAT may be triggered. Although not 
able to demonstrate that HIV-infected patients with anticardiolipin antibodies are at 
higher risk for MAT, it is an intriguing association. In idiopathic MAT has been achieved 
in many cases to elucidate the molecular basis of the disorder, especially those with 
family history: gaps ADAMS-13 and other enzymes that degrade the von Willebrand 
factor in type forms PTT and alterations of the complement system in the SHU. There is 
no evidence that these disorders occur in the MAT of patients infected with HIV. 
Although the majority of patients present in a more advanced stage of HIV disease, TMA 
can be the initial presenting symptom of HIV infection.  
Clinical features are those of idiopathic TMA (Eitner et al, 1999), and the diagnosis should 
be suspected in any patient with new onset thrombocytopenia and microangiopathic 
haemolytic anaemia. Most patients are male and young and progressive deterioration of 
renal function is associated with the typical hematological findings MAT: schistocytes 
anemia with peripheral blood, thrombocytopenia, elevated LDH. Although most cases 
present a clear and rapidly progressive deterioration of renal function, similar to pictures of 
hemolytic uremic syndrome (HUS), others can have predominant neurologic manifestations, 
as in thrombotic thrombocytopenic purpura (TTP). 
Kidney biopsy shows changes similar to idiopathic MAT: platelet-fibrin thrombi in 
preglomerular arterioles and the glomerular capillaries, arterioles with endothelial edema 
imaging in "onion skin" and mesangiolysis with widening of subendothelial space. When 
there are extrarenal manifestations (neurological, cardiac) vascular lesions are similar in the 
vessels of the affected organs. 
Therapy with plasma exchange or infusion appears to be efficacious. A rapid diagnosis and 
institution of plasmapheresis is crucial for a favorable outcome. The long term prognosis of 
HIV-TMA is unfavorable and may depend on the stage of HIV infection. The recent data 
after the use of highly active retroviral treatment, however, are unavailable and current 
prognosis is therefore uncertain.  
2.3.2 Malignant hypertension 
Malignant hypertension is defined by the presence of unacceptably high blood pressure 
with grade III hypertensive retinopathy (hemorrhages and exudates) or IV (papilledema 
more vascular lesions). As we noted earlier, is a casual presentation of idiopathic IgA 
nephropathy, but its impact on the rest of idiopathic GN is rare. By contrast, preliminary 
studies indicate incidence of MHT special not only in IgA nephropathy patients with HIV, 
in which may be the most frequent presentation of this entity, but in other glomerular 
diseases associated with HIV (Morales et al, 2008). On the other hand, entities such as 
membranoproliferative GN, membranous and focal glomerulosclerosis, in which the MHT 
is a rare complication, there are a significant number of cases when associated with HIV 
infection. In our experience, malignant nephrosclerosis (arteriolar fibrinoid necrosis with 
intimal thickening and luminal narrowing; see Figure 3) was detected in six cases (three of 
them with IgAN, one with C-FSG, one with NC-FSG and one with MGN). 
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Fig. 3. Renal biopsy of patient 1 (Table 1), showing a glomerulus with mesangial 
proliferation (the immunofluorescence showed predominant deposits of IgA) and vascular 
lesions of malignant nephrosclerosis (fibrinoid necrosis) in the afferent arteriole. 
(hematoxylin;eosin; x400). 
The typical symptoms of MHT (markedly increased BP, blurred vision due to retinal 
haemorrhages and severe headache). To interpret this catastrophic prognosis in HIV 
patients with GN and MHT, we speculate that the development of MHT has an irreversible 
detrimental influence on glomerular diseases already having a rather poor prognosis by 
themselves, see Figure 4.  
On the other hand, the development of chronic renal failure could likely exacerbate the 
appearance of infectious and cardiovascular complications in these HIV-infected patients 
because both patients with chronic renal failure and HIV infection are particularly prone to 
the appearance of such complications (Grinspoon & Carr, 2005; Kamin & Grinspoon, 2005; 
Gupta et al, 2005). Other possible pathogenic pathways to explain this particular propensity 
of HIV patients with glomerular diseases to MHT could rely on the already known higher 
incidence of thrombotic microangiopathy (TMA) among HIV patients (Alpers, 2003). Both 
TMA and MHT could be interpreted as clinical manifestations of a systemic endothelial 
injury, due to a direct toxic effect of HIV, other infectious agents (particularly HCV and 
HBV) or other factors (such as drug addictions) linked to the environment of HIV infection. 
On the other hand, the presence of antiphospholipid antibodies is also more common 
among HIV patients, and these autoantibodies could play a role in endothelial vascular 
damage (Alpers, 2003; Galrao et al, 2007).  
 

























Fig. 4. Probability of renal survival (absence of chronic dialysis) in HIV patients with or 
without malignant hypertension. 
In addition, considering the dismal prognosis of our patients in spite of HAART treatment 
and a satisfactory control of blood pressure, early detection and treatment of hypertension 
in HIV patients with glomerular diseases are mandatory. 
2.3.3 Amyloidosis 
In autopsy series of patients infected with HIV, as well as reviews of renal biopsies, 
amyloidosis is a relatively common finding (Lanjewar et al, 1999; Joseph et al, 2000). This is 
a secondary amyloidosis, type AA. Many studies have been suggested that frequent chronic 
infections may be responsible for this complication. However, it is possible that HIV 
infection itself plays a pathogenic role. Described a high level of SAA, acute phase reactant 
which is the precursor of AA amyloid in patients infected with HIV (Husebekk et al, 1986) 
and experimental models have shown that a significant proportion of animals infected 
develop amyloidosis (King et al, 1983). 
As is common in amyloidosis, massive proteinuria and nephrotic syndrome were the most 
common renal manifestations in the cases described. There are no studies about specific 
therapeutic options in these patients, apart from trying to eradicate the underlying 
infectious process. 
2.3.4 Hypertensive and diabetic nephropathy 
Metabolic complications of HAART (dyslipidemia, changes in body fat, insulin resistance, 
diabetes mellitus) and the aging of the infected population suggest that kidney damage 
secondary to diabetes and hypertension may have increasing importance in patients 
infected HIV (Masia-Canuto et al, 2006).  
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In some series of renal biopsies of patients with HIV infection has been reported the 
presence of diabetic nephropathy in 6% of cases, hypertensive nephropathy in 4% (Szczech 
et al, 2004).The recommended treatment is similar to that used in the uninfected population 
and should include strict control of blood pressure and the early use of BSRAA to try to 
reduce proteinuria. 
3. Tubular and interstitial renal disease 
Patients infected with HIV can present a wide variety of tubular and interstitial renal 




 Acute tubular necrosis 
 Interstitial nephritis associated with drugs 
 Renal failure and Fanconi syndrome (certain reverse transcriptase inhibitors) 
 Allergic interstitial nephritis 
 Cristal-induced nephropathy (certain protease inhibitors) 
 Interstitial nephritis associated with infections (cytomegalovirus, tuberculosis, hongos, 
Salmonella, Legionella, etc) 
 Kaposi sarcoma and Lymphoma infiltrative 
 Rhabdomyolysis 
 
Table 4. Tubular and interstitial renal disease 
The recommendations for the treatment of these nephropathies consist of drug withdrawal 
or correction of the precipitating cause, corrections, electrolyte, and in interstitial nephritis 
immunoallergic the administration of a short course of corticosteroids. 
4. Conclusion  
In conclusion, due to the wide range of kidney damage in people with HIV infection, it is 
difficult to predict the renal histology according to clinical criteria, so renal biopsy is 
mandatory for histologic diagnosis. In addition, the course and prognosis of these patients 
has changed radically since the introduction of antiretroviral therapy, with higher survival, 
so early diagnosis is essential and the establishment of an alternative therapy to prevent 
progression of renal disease. 
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Henoch-Schönlein  
Purpura Nephritis in Childhood 
Marco Zaffanello 
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Italy 
1. Introduction 
Henoch-Schönlein purpura is one of the most common causes of systemic vasculitis. 
Henoch–Schönlein purpura typically affects children between the age of 3 and 10 years. The 
aetiology is unknown. Diagnosis includes palpable purpura (essential) in the presence of 
diffuse abdominal pain, acute arthritis/arthralgia, renal involvement characterized by 
haematuria and/or proteinuria (Ozen et al., 2006) and skin biopsy showing predominant 
IgA deposition in the walls of cutaneous vessels.  
In the majority of cases it is a self-limiting disease. Therefore, up to 40% of children with 
Henoch–Schönlein purpura require hospitalization for management of acute disease 
manifestations which may include nephritis, hypertension, severe pain, gastrointestinal 
bleeding or arthritis. Purpura occurs in all cases, joint pains and arthritis in 80% of cases, 
and abdominal pain in 62% of cases.  
The purpura typically appears on the legs and buttocks (Fig.1), but may also be seen on the 
arms, face and trunk. The abdominal pain is colicky, and may be accompanied by nausea, 
vomiting, constipation or diarrhea. There may be blood or mucus in the stools. Sometime 
finding includes a gastrointestinal haemorrhage, occurring in 33% of cases, due to 
intussusceptions (Saulsbury, 1999). The joints involved tend to be the ankles, knees, and 
elbows but arthritis in the hands and feet is possible; the arthritis is non-erosive and hence 
causes no permanent deformity. Problems in other organs, such as the central nervous 
system (brain and spinal cord) and lungs may occur, but much less commonly than the skin, 
bowel and kidneys (Saulsbury, 2001) 
 
 
Fig. 1. Henoch-Schönlein purpura in a 8 years old female child 
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Paediatric patients may develop glomerulonephritis within 4 to 6 weeks of the initial 
purpura presentation (Saulsbury, 2007). Renal involvement in Henoch-Schönlein purpura is 
transitory in most cases. Therefore, the long-term prognosis in Henoch-Schönlein purpura 
depends on the severity of renal involvement and can be poor when complicated by severe 
nephritis and chronic renal failure.   
2. Pathogenesis 
Henoch-Schönlein purpura nephritis is a systemic immune-complex mediated disease 
according to the clinical or histological pattern of recurrences of Henoch-Schönlein purpura 
nephritis in some patients after transplantation (Soler et al., 2005). The histological hallmark 
of Henoch-Schönlein purpura is severe inflammation of small vessels, particularly post-
capillary venules, with neutrophils, resulting in fibrinoid necrosis of vessel walls and 
extravasation of erythrocytes (Saulsbury, 1999). The clinical features are a consequence of 
general vasculitis due to IgA1 deposition in vessels and the renal measangium (Saulsbury, 
1999). Therefore, the pathogenetic mechanisms are still not fully understood.  
2.1 IgA immune complexes 
Similarly to IgA nephropathy, deposits of IgA-binding M proteins of group A streptococci 
were found on Henoch-Schönlein purpura kidneys. All Henoch-Schönlein purpura patients 
have IgA1-circulating immune complexes of small molecular mass. Therefore, only those 
with nephritis have large-molecular-mass IgA1-IgG-containing circulating immune 
complexes (Levinsky & Barratt, 1979). Large-molecular mass IgA-IgG complexes in the 
circulation are the major factor responsible for the formation of the nephritogenic immune 
complexes in patients with Henoch-Schönlein purpura nephritis. 
Some children with Henoch-Schönlein purpura nephritis subsequently have an episode or 
recurrent episodes of macroscopic hematuria, associated with upper respiratory tract 
infection without the other clinical features of Henoch-Schönlein purpura nephritis (Waldo, 
1988). Thus, these children’s clinical phenotype changes to that of IgA nephropathy. As the 
renal histologic and immunofluorescence microscopy findings in Henoch-Schönlein 
purpura nephritis are indistinguishable from those seen in patients with IgA nephropathy 
(Evans et al., 1973), it has long been ever speculated that Henoch-Schönlein purpura 
nephritis and IgA nephropathy have common pathogenetic mechanisms representing 
different ends of a continuous spectrum of disease (Waldo, 1988).  
Henoch-Schönlein purpura nephritis is similar to IgA nephropathy since IgA1, but not IgA2, 
is found in the circulating immune complexes and in mesangial immune deposits (Novak et 
al., 2007). IgA1-containing immune complexes are excreted in elevated amounts in the urine 
in patients with IgA nephropathy and Henoch-Schönlein purpura nephritis and may 
provide a specific marker for disease activity and/or severity in these patients (Suzuki et al., 
2008). IgA-binding M proteins may encounter circulatory IgA forming a complex with IgA-
Fc that could deposit in renal tissues (Schmitt et al., 2010).  
Reduced galactosylation of IgA1 O-glycans has been reported in patients with Henoch-
Schönlein purpura nephritis (Allen et al., 1998). Glycosylation defects are due to complex 
changes in expression of specific glycosyltransferases with reduced expression of β1,3-
galactosyltransferase and elevated expression of GalNAc-specific α2,6-sialyltransferase in 
patients with both IgA nephropathy and Henoch-Schönlein purpura nephritis, but not in 
patients with Henoch-Schönlein purpura without nephritis or healthy controls (Suzuki, 
 
Henoch-Schönlein Purpura Nephritis in Childhood 
 
211 
Moldoveanu et al., 2008). Due to their size, Galactose-deficient IgA1 containing immune 
complexes are less efficiently taken up by the asialoglycoprotein receptor in the liver and 
catabolised and their amounts increase in the circulation (Moura et al., 2004). Galactose-
deficient IgA1 leads to the formation of the circulating immune complexes.  These 
complexes may then deposit in the renal mesangium and incite, likely due to the binding to 
mesangial cells, to cellular activation (Lau et al., 2010). Consequently, mesangial cells start to 
proliferate and overproduce extracellular matrix components, cytokines and chemokines 
(Davin & Weening, 2003) leading to glomerular injury contributing to the pathogenesis of 
Henoch-Schönlein purpura nephritis.  
Glomerular depositions of other components, including kappa and lambda light chains, are 
also variably demonstrated in Henoch-Schönlein purpura nephritis. In patients with IgA 
nephropathy, lambda light chains were found predominantly over kappa light chains (Lai et 
al., 1996). 
2.2 Complement 
Complement activation appears to play an important role in the pathogenesis of IgA 
nephropathy and Henoch-Schönlein purpura nephritis, as glomerular complement 
activation may initiate the inflammatory cascade and enhance glomerular injury (Wyatt et 
al., 1987). Therefore, hypocomplementemia has been reported in some patients with 
Henoch-Schönlein purpura nephritis, and it is usually transient and not related to the 
severity of the diseases (Motoyama & Litaka, 2005). 
3. Incidence 
The estimated annual incidence of Henoch-Schönlein purpura in children is 10–20 per 
100,000 children (Rostoker, 2001). The annual incidence of Henoch-Schönlein purpura in 
Asian children [4.9 per 100,000] and African children [6.2 per 100,000] was significantly 
lower than Caucasian children [17.8 per 100,000].  
In childhood Henoch-Schönlein purpura, the male:female ratio ranges from 1.2−1.6 (Yang et 
al., 2005).  
Renal involvement occurs less frequently in children than adulthood (Yang et al.,  
2005; Pillebout et al., 2002). The incidence of nephritis in patients with Henoch-Schönlein 
purpura has been reported to be 15-62% with an estimated annual incidence of 20.4 per 
100,000 children (Gardner-Medwin et al., 2002; Shenoy, Bradbury, et al. 2007; Bogdanovic, 
2009).  
The overall incidence of Henoch-Schönlein purpura nephritis and the severity of Henoch-
Schönlein purpura nephritis in patients between 1987 and 1997 were similar to those in 
children between 1998 and 2008 and the number of patients with severe Henoch-Schönlein 
purpura nephritis has not decreased (Kawasaki et al., 2010). The overall incidence of 
Henoch-Schönlein purpura nephritis is rather stable over time.  
It could be estimated that 1–2% of all Henoch-Schönlein purpura nephritis patients will 
ultimately develop chronic kidney disease (Stewart et al., 1988; Narchi, 2005). A variable 
percentage of children (0−19%) with Henoch-Schönlein purpura nephritis may progress to 
renal failure or end stage renal disease (Ronkainen et al., 2002; Coppo et al., 1997; Goldstein 
et al., 1992; Kawasaki et al., 2003; Pillebout et al., 2002). In children with Henoch-Schönlein 
purpura nephritis followed up at tertiary centres the risk for progression to chronic kidney 
disease or end-stage renal disease is predicted to be 5–18% at 5 years, 10–20% at 10 years 
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Paediatric patients may develop glomerulonephritis within 4 to 6 weeks of the initial 
purpura presentation (Saulsbury, 2007). Renal involvement in Henoch-Schönlein purpura is 
transitory in most cases. Therefore, the long-term prognosis in Henoch-Schönlein purpura 
depends on the severity of renal involvement and can be poor when complicated by severe 
nephritis and chronic renal failure.   
2. Pathogenesis 
Henoch-Schönlein purpura nephritis is a systemic immune-complex mediated disease 
according to the clinical or histological pattern of recurrences of Henoch-Schönlein purpura 
nephritis in some patients after transplantation (Soler et al., 2005). The histological hallmark 
of Henoch-Schönlein purpura is severe inflammation of small vessels, particularly post-
capillary venules, with neutrophils, resulting in fibrinoid necrosis of vessel walls and 
extravasation of erythrocytes (Saulsbury, 1999). The clinical features are a consequence of 
general vasculitis due to IgA1 deposition in vessels and the renal measangium (Saulsbury, 
1999). Therefore, the pathogenetic mechanisms are still not fully understood.  
2.1 IgA immune complexes 
Similarly to IgA nephropathy, deposits of IgA-binding M proteins of group A streptococci 
were found on Henoch-Schönlein purpura kidneys. All Henoch-Schönlein purpura patients 
have IgA1-circulating immune complexes of small molecular mass. Therefore, only those 
with nephritis have large-molecular-mass IgA1-IgG-containing circulating immune 
complexes (Levinsky & Barratt, 1979). Large-molecular mass IgA-IgG complexes in the 
circulation are the major factor responsible for the formation of the nephritogenic immune 
complexes in patients with Henoch-Schönlein purpura nephritis. 
Some children with Henoch-Schönlein purpura nephritis subsequently have an episode or 
recurrent episodes of macroscopic hematuria, associated with upper respiratory tract 
infection without the other clinical features of Henoch-Schönlein purpura nephritis (Waldo, 
1988). Thus, these children’s clinical phenotype changes to that of IgA nephropathy. As the 
renal histologic and immunofluorescence microscopy findings in Henoch-Schönlein 
purpura nephritis are indistinguishable from those seen in patients with IgA nephropathy 
(Evans et al., 1973), it has long been ever speculated that Henoch-Schönlein purpura 
nephritis and IgA nephropathy have common pathogenetic mechanisms representing 
different ends of a continuous spectrum of disease (Waldo, 1988).  
Henoch-Schönlein purpura nephritis is similar to IgA nephropathy since IgA1, but not IgA2, 
is found in the circulating immune complexes and in mesangial immune deposits (Novak et 
al., 2007). IgA1-containing immune complexes are excreted in elevated amounts in the urine 
in patients with IgA nephropathy and Henoch-Schönlein purpura nephritis and may 
provide a specific marker for disease activity and/or severity in these patients (Suzuki et al., 
2008). IgA-binding M proteins may encounter circulatory IgA forming a complex with IgA-
Fc that could deposit in renal tissues (Schmitt et al., 2010).  
Reduced galactosylation of IgA1 O-glycans has been reported in patients with Henoch-
Schönlein purpura nephritis (Allen et al., 1998). Glycosylation defects are due to complex 
changes in expression of specific glycosyltransferases with reduced expression of β1,3-
galactosyltransferase and elevated expression of GalNAc-specific α2,6-sialyltransferase in 
patients with both IgA nephropathy and Henoch-Schönlein purpura nephritis, but not in 
patients with Henoch-Schönlein purpura without nephritis or healthy controls (Suzuki, 
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Moldoveanu et al., 2008). Due to their size, Galactose-deficient IgA1 containing immune 
complexes are less efficiently taken up by the asialoglycoprotein receptor in the liver and 
catabolised and their amounts increase in the circulation (Moura et al., 2004). Galactose-
deficient IgA1 leads to the formation of the circulating immune complexes.  These 
complexes may then deposit in the renal mesangium and incite, likely due to the binding to 
mesangial cells, to cellular activation (Lau et al., 2010). Consequently, mesangial cells start to 
proliferate and overproduce extracellular matrix components, cytokines and chemokines 
(Davin & Weening, 2003) leading to glomerular injury contributing to the pathogenesis of 
Henoch-Schönlein purpura nephritis.  
Glomerular depositions of other components, including kappa and lambda light chains, are 
also variably demonstrated in Henoch-Schönlein purpura nephritis. In patients with IgA 
nephropathy, lambda light chains were found predominantly over kappa light chains (Lai et 
al., 1996). 
2.2 Complement 
Complement activation appears to play an important role in the pathogenesis of IgA 
nephropathy and Henoch-Schönlein purpura nephritis, as glomerular complement 
activation may initiate the inflammatory cascade and enhance glomerular injury (Wyatt et 
al., 1987). Therefore, hypocomplementemia has been reported in some patients with 
Henoch-Schönlein purpura nephritis, and it is usually transient and not related to the 
severity of the diseases (Motoyama & Litaka, 2005). 
3. Incidence 
The estimated annual incidence of Henoch-Schönlein purpura in children is 10–20 per 
100,000 children (Rostoker, 2001). The annual incidence of Henoch-Schönlein purpura in 
Asian children [4.9 per 100,000] and African children [6.2 per 100,000] was significantly 
lower than Caucasian children [17.8 per 100,000].  
In childhood Henoch-Schönlein purpura, the male:female ratio ranges from 1.2−1.6 (Yang et 
al., 2005).  
Renal involvement occurs less frequently in children than adulthood (Yang et al.,  
2005; Pillebout et al., 2002). The incidence of nephritis in patients with Henoch-Schönlein 
purpura has been reported to be 15-62% with an estimated annual incidence of 20.4 per 
100,000 children (Gardner-Medwin et al., 2002; Shenoy, Bradbury, et al. 2007; Bogdanovic, 
2009).  
The overall incidence of Henoch-Schönlein purpura nephritis and the severity of Henoch-
Schönlein purpura nephritis in patients between 1987 and 1997 were similar to those in 
children between 1998 and 2008 and the number of patients with severe Henoch-Schönlein 
purpura nephritis has not decreased (Kawasaki et al., 2010). The overall incidence of 
Henoch-Schönlein purpura nephritis is rather stable over time.  
It could be estimated that 1–2% of all Henoch-Schönlein purpura nephritis patients will 
ultimately develop chronic kidney disease (Stewart et al., 1988; Narchi, 2005). A variable 
percentage of children (0−19%) with Henoch-Schönlein purpura nephritis may progress to 
renal failure or end stage renal disease (Ronkainen et al., 2002; Coppo et al., 1997; Goldstein 
et al., 1992; Kawasaki et al., 2003; Pillebout et al., 2002). In children with Henoch-Schönlein 
purpura nephritis followed up at tertiary centres the risk for progression to chronic kidney 
disease or end-stage renal disease is predicted to be 5–18% at 5 years, 10–20% at 10 years 
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and 20–32% at 20 years from the diagnosis (Goldstein et al., 1992; Coppo et al., 1997; Kaku et 
al., 1998; Bogdanovic, 2009).  
4. Clinical patterns 
The average duration of Henoch-Schönlein purpura symptoms is 4 weeks. The majority of 
patients experience resolution of symptoms within 2 to 3 months. Approximately 30% of 
patients have one or more recurrences after the resolution of initial symptoms (Saulsbury, 
1999; Trapani et al., 2005). Therefore, purpura lasting longer than 1 month or relapsing 
disease are associated with the development of nephritis(Rigante et al., 2005; Shin, Park, et 
al., 2006). Patients showing abdominal pain as the initial symptom had a higher probability 
of developing nephrotic syndrome. Persistent rash was a poor prognostic factor for Henoch-
Schönlein purpura nephritis (Hung et al., 2009).  
Renal signs are manifested in the majority of Henoch-Schönlein purpura patients from 3 
days to 17 months after onset of the disease (Kaku et al., 1998), occurring more frequently 
within the first 3 months (Sano et al., 2002). In few cases the renal disease may develop even 
years after the initial presentation (Mollica et al., 1992). While abnormalities on urinalysis 
may continue for a long time, only 1% of all Henoch-Schönlein purpura patients develop 
chronic kidney disease (Saulsbury, 2001).  
Nephritis is the one feature of Henoch-Schönlein purpura that may have chronic 
consequences. The long-term prognosis is largely dependent on the severity of nephritis 
(Narchi, 2005; Mir et al., 2007). Renal manifestations of the disease ranged from mild, benign 
involvement, intermittent haematuria and proteinuria, to rapidly progressive or crescentic 
nephritis. Of the 40% of patients who develop kidney involvement, almost all have evidence 
(visible or on urinalysis) of blood in the urine. More than half also have proteinuria, which 
in one eighth is severe enough to cause nephrotic syndrome (Saulsbury, 2001). From a 
retrospective study, nephritis occurred in 46% of the Henoch-Schönlein purpura patients, 
consisting of isolated haematuria in 14%, isolated proteinuria in 9%, both haematuria and 
proteinuria in 56%, nephrotic-range proteinuria in 20% and nephrotic-nephritic syndrome in 
1% (Jauhola et al., 2010).  
Renal involvement is in most cases mild and self-limited in children. Henoch-Schönlein 
purpura nephritis in children had a lower risk of progression to renal insufficiency than 
adults. Gross hematuria and lower extremity edema were less frequent in the children than 
adults (Hung et al., 2009).  Morbidity is low in patients with Henoch-Schönlein purpura 
who have hematuria and mild proteinuria at onset, while it is higher among those with 
more severe renal disease, as in a nephritic, nephrotic or a nephritic/nephrotic signs (Coppo 
et al., 2006; Ronkainen et al., 2002; Narchi, 2005; Goldstein et al., 1992). The main clinical 
signs of rapidly progressive Henoch-Schönlein purpura nephritis at presentation were 
edema, hypertension, gross hematuria, and oliguria (Oner, 1995). End-stage renal disease 
was associated with nephritic and/or nephrotic syndrome at presentation in nearly all 
children with Henoch-Schönlein purpura nephritis (Soylemezoglu et al., 2009). The highly 
variable clinical course of Henoch-Schönlein purpura nephritis has been related to the 
marked variability in histopathologic presentation at renal biopsy, with glomeruli ranging 
from histologically normal to diffuse proliferative and crescentic lesions (Assadi, 2009). 
4.1 Classification 
Five categories of Henoch-Schönlein purpura nephritis were identified according to renal 
manifestations at disease onset (Falkner et al., 2004): (A) micro/macroscopic hematuria or 
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persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol);  
(B) persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol) 
and micro- or macroscopic hematuria; (C) nephritic syndrome (moderate proteinuria and 
urine albumin/creatinine ratio ≥ 200–400 mg/mmol), decreased glomerular filtration rate, 
hematuria and/or hypertension, or nephrotic syndrome (urinary albumin excretion  
> 40 mg/hour/m2 body surface area or urine albumin/creatinine ratio ≥ 400 mg/mmol, 
serum albumin < 25 g/L; (D) acute progressive glomerular nephritis; (E) chronic glomerular 
nephritis. Classes A and B were considered as mild renal disease, and classes C to E as 
severe disease (Meadow et al., 1972).  
Another clinical evaluation categorized the patients according to four stages. Stage (A) is 
considered normal: the patient was normal on physical examination, with normal urine and 
renal function; stage (B) had minor urinary abnormalities: the patient was normal on 
physical examination, with microscopic hematuria or proteinuria of less than 20 mg/m2/h; 
stage (C) had persistent nephropathy: the patient had proteinuria of 20 mg/m2/h or greater 
or hypertension and a 24-h creatinine clearance of 60 ml/ min/1.73 m2 or greater; stage (D) 
had renal insufficiency: the patient had a 24-h creatinine clearance of less than 60 
ml/min/1.73 m2, including dialysis/transplant or death (Kawasaki et al., 2010).  
4.2 Serum IgA  
Although serum IgA levels are higher in children with Henoch-Schönlein purpura / 
Henoch-Schönlein purpura nephritis than in controls, this serum abnormality does not 
constitute a sensitive diagnostic marker of Henoch-Schönlein purpura with or without 
nephritis. In particular, over 40% children with Henoch-Schönlein purpura had elevated 
serum IgA levels at presentation. Therefore, the difference in serum IgA levels between 
patients with and without nephritis was not statistically significant. 
4.3 Renal biopsy  
Renal involvement can be severe but may resolve completely. Therefore, some children will 
develop long-term sequelae. The renal biopsy is helpful in determining the need for 
treatment with immunosuppression in the acute phase (McCarthy & Tizard, 2010).  
The criteria for renal biopsy were defined as follows: (1) the patients had proteinuria of 20 
mg/m2/hour or greater and haematuria or (2) the patients had proteinuria of less than 20 
mg/m2/hour and recurrent macrohematuria (Kawasaki et al., 2010). According to another 
recent review a renal biopsy has been recommended in the following situations: (1) acute renal 
impairment/nephritic syndrome at presentation; (2) nephrotic syndrome with normal renal 
function persisting at 4 weeks; (3) nephrotic range proteinuria (urine protein/creatinine ratio, 
>250 mg/mmol) at 4–6 weeks (if not improving spontaneously); (4) persistent proteinuria-
urine protein/creatinine ratio >100 mg/mmol for more than 3 months. Consider biopsy 
particularly if the diagnosis is not clear (McCarthy & Tizard, 2010). 
Renal involvement in Henoch-Schönlein purpura is quantified by means of a kidney biopsy 
(Fig. 2), which may demonstrate positive mesangial staining and positive anti-IgA antisera on 
immunofluorescence, with glomerular changes graded chiefly according to the Henoch-
Schönlein purpura nephritis classification described in the International Study of Kidney 
Disease in Children (Rai et al., 1999; Sheno, Bradbury, et al. 2007; Ronkainen et al., 2006). The 
grading of renal histology has been considered as an important marker of outcome (Farine et 
al., 1986). The classification provided by the Study of Kidney Disease in Children included 
grade I: minimal alterations; grade II: mesangial proliferation; grade III: focal or diffuse 
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and 20–32% at 20 years from the diagnosis (Goldstein et al., 1992; Coppo et al., 1997; Kaku et 
al., 1998; Bogdanovic, 2009).  
4. Clinical patterns 
The average duration of Henoch-Schönlein purpura symptoms is 4 weeks. The majority of 
patients experience resolution of symptoms within 2 to 3 months. Approximately 30% of 
patients have one or more recurrences after the resolution of initial symptoms (Saulsbury, 
1999; Trapani et al., 2005). Therefore, purpura lasting longer than 1 month or relapsing 
disease are associated with the development of nephritis(Rigante et al., 2005; Shin, Park, et 
al., 2006). Patients showing abdominal pain as the initial symptom had a higher probability 
of developing nephrotic syndrome. Persistent rash was a poor prognostic factor for Henoch-
Schönlein purpura nephritis (Hung et al., 2009).  
Renal signs are manifested in the majority of Henoch-Schönlein purpura patients from 3 
days to 17 months after onset of the disease (Kaku et al., 1998), occurring more frequently 
within the first 3 months (Sano et al., 2002). In few cases the renal disease may develop even 
years after the initial presentation (Mollica et al., 1992). While abnormalities on urinalysis 
may continue for a long time, only 1% of all Henoch-Schönlein purpura patients develop 
chronic kidney disease (Saulsbury, 2001).  
Nephritis is the one feature of Henoch-Schönlein purpura that may have chronic 
consequences. The long-term prognosis is largely dependent on the severity of nephritis 
(Narchi, 2005; Mir et al., 2007). Renal manifestations of the disease ranged from mild, benign 
involvement, intermittent haematuria and proteinuria, to rapidly progressive or crescentic 
nephritis. Of the 40% of patients who develop kidney involvement, almost all have evidence 
(visible or on urinalysis) of blood in the urine. More than half also have proteinuria, which 
in one eighth is severe enough to cause nephrotic syndrome (Saulsbury, 2001). From a 
retrospective study, nephritis occurred in 46% of the Henoch-Schönlein purpura patients, 
consisting of isolated haematuria in 14%, isolated proteinuria in 9%, both haematuria and 
proteinuria in 56%, nephrotic-range proteinuria in 20% and nephrotic-nephritic syndrome in 
1% (Jauhola et al., 2010).  
Renal involvement is in most cases mild and self-limited in children. Henoch-Schönlein 
purpura nephritis in children had a lower risk of progression to renal insufficiency than 
adults. Gross hematuria and lower extremity edema were less frequent in the children than 
adults (Hung et al., 2009).  Morbidity is low in patients with Henoch-Schönlein purpura 
who have hematuria and mild proteinuria at onset, while it is higher among those with 
more severe renal disease, as in a nephritic, nephrotic or a nephritic/nephrotic signs (Coppo 
et al., 2006; Ronkainen et al., 2002; Narchi, 2005; Goldstein et al., 1992). The main clinical 
signs of rapidly progressive Henoch-Schönlein purpura nephritis at presentation were 
edema, hypertension, gross hematuria, and oliguria (Oner, 1995). End-stage renal disease 
was associated with nephritic and/or nephrotic syndrome at presentation in nearly all 
children with Henoch-Schönlein purpura nephritis (Soylemezoglu et al., 2009). The highly 
variable clinical course of Henoch-Schönlein purpura nephritis has been related to the 
marked variability in histopathologic presentation at renal biopsy, with glomeruli ranging 
from histologically normal to diffuse proliferative and crescentic lesions (Assadi, 2009). 
4.1 Classification 
Five categories of Henoch-Schönlein purpura nephritis were identified according to renal 
manifestations at disease onset (Falkner et al., 2004): (A) micro/macroscopic hematuria or 
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persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol);  
(B) persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol) 
and micro- or macroscopic hematuria; (C) nephritic syndrome (moderate proteinuria and 
urine albumin/creatinine ratio ≥ 200–400 mg/mmol), decreased glomerular filtration rate, 
hematuria and/or hypertension, or nephrotic syndrome (urinary albumin excretion  
> 40 mg/hour/m2 body surface area or urine albumin/creatinine ratio ≥ 400 mg/mmol, 
serum albumin < 25 g/L; (D) acute progressive glomerular nephritis; (E) chronic glomerular 
nephritis. Classes A and B were considered as mild renal disease, and classes C to E as 
severe disease (Meadow et al., 1972).  
Another clinical evaluation categorized the patients according to four stages. Stage (A) is 
considered normal: the patient was normal on physical examination, with normal urine and 
renal function; stage (B) had minor urinary abnormalities: the patient was normal on 
physical examination, with microscopic hematuria or proteinuria of less than 20 mg/m2/h; 
stage (C) had persistent nephropathy: the patient had proteinuria of 20 mg/m2/h or greater 
or hypertension and a 24-h creatinine clearance of 60 ml/ min/1.73 m2 or greater; stage (D) 
had renal insufficiency: the patient had a 24-h creatinine clearance of less than 60 
ml/min/1.73 m2, including dialysis/transplant or death (Kawasaki et al., 2010).  
4.2 Serum IgA  
Although serum IgA levels are higher in children with Henoch-Schönlein purpura / 
Henoch-Schönlein purpura nephritis than in controls, this serum abnormality does not 
constitute a sensitive diagnostic marker of Henoch-Schönlein purpura with or without 
nephritis. In particular, over 40% children with Henoch-Schönlein purpura had elevated 
serum IgA levels at presentation. Therefore, the difference in serum IgA levels between 
patients with and without nephritis was not statistically significant. 
4.3 Renal biopsy  
Renal involvement can be severe but may resolve completely. Therefore, some children will 
develop long-term sequelae. The renal biopsy is helpful in determining the need for 
treatment with immunosuppression in the acute phase (McCarthy & Tizard, 2010).  
The criteria for renal biopsy were defined as follows: (1) the patients had proteinuria of 20 
mg/m2/hour or greater and haematuria or (2) the patients had proteinuria of less than 20 
mg/m2/hour and recurrent macrohematuria (Kawasaki et al., 2010). According to another 
recent review a renal biopsy has been recommended in the following situations: (1) acute renal 
impairment/nephritic syndrome at presentation; (2) nephrotic syndrome with normal renal 
function persisting at 4 weeks; (3) nephrotic range proteinuria (urine protein/creatinine ratio, 
>250 mg/mmol) at 4–6 weeks (if not improving spontaneously); (4) persistent proteinuria-
urine protein/creatinine ratio >100 mg/mmol for more than 3 months. Consider biopsy 
particularly if the diagnosis is not clear (McCarthy & Tizard, 2010). 
Renal involvement in Henoch-Schönlein purpura is quantified by means of a kidney biopsy 
(Fig. 2), which may demonstrate positive mesangial staining and positive anti-IgA antisera on 
immunofluorescence, with glomerular changes graded chiefly according to the Henoch-
Schönlein purpura nephritis classification described in the International Study of Kidney 
Disease in Children (Rai et al., 1999; Sheno, Bradbury, et al. 2007; Ronkainen et al., 2006). The 
grading of renal histology has been considered as an important marker of outcome (Farine et 
al., 1986). The classification provided by the Study of Kidney Disease in Children included 
grade I: minimal alterations; grade II: mesangial proliferation; grade III: focal or diffuse 
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proliferation or sclerosis with <50% crescents; grade IV: focal or diffuse mesangial proliferation 
or sclerosis with 50–75% crescents; grade V: focal or diffuse mesangial proliferation or sclerosis 





Fig. 2. Methenamine-silver stain of a glomerular of a patient with Henoch-Schönlein 
purpura nephritis showing diffuse mesangial and focal endocapillary proliferation (panel 
A). The immunofluorescence studies showed intense IgA positivity (3+) (panel B); 
complement C3 staining was also mildly positive (1+).  
5. Risk factors 
5.1 Renal involvement in Henoch-Schönlein purpura 
Some authors attempted to identify prognostic factors for a child with Henoch-Schönlein 
purpura to develop nephritis by using univariate and multivariate analysis models. The 
independent risk factors for Henoch-Schönlein purpura nephritis were persistent purpura, 
severe abdominal symptoms and age above 4 or 7 or 10 years. Other independent risk 
factors were relapse or decreased serum factor XIII activity (Kaku et al., 1998; Sano et al., 
2002; Rigante et al., 2005; Shin, Park, et al., 2006; Ronkainen et al., 2006). Persistent purpura, 
severe abdominal symptoms and an older age were confirmed as the most significant risk 
factors for later nephropathy (Bogdanovic, 2009). A prospective study showed that age over 
8 years at onset (OR 2.7), abdominal pain (OR 2.1) and a recurrence of Henoch-Schönlein 
purpura disease (OR 3.1) were independent risk factors for developing nephritis(Jauhola et 
al., 2010). 
5.2 Long-term renal impairment 
Severe renal involvement at onset of Henoch-Schönlein purpura is in general predictive of a 
poor renal outcome. The independent predictors of a poor renal outcome were severe initial 
 
Henoch-Schönlein Purpura Nephritis in Childhood 
 
215 
presentations with renal failure, nephritic, nephrotic syndrome or mixed syndrome and the 
percentage of glomeruli with crescents (Mir et al., 2007). Some few children with mild renal 
symptoms at onset have a poor long-term outcome. Thus, long-term follow-up is mandatory 
also for these patients (Algoet & Proesmans, 2003; Goldstein et al., 1992). 
6. Follow-up 
A clinical pathway was recommended if there is evidence of haematuria, proteinuria, renal 
impairment or hypertension in patients with Henoch-Schönlein purpura (Tizard & Hamilton-
Ayres, 2008). Prospectively and systematically collected data suggested that weekly urine 
dipstick tests should be continued for 2 months from the onset of Henoch-Schönlein purpura. 
Beyond that point frequent routine follow-up is neither cost-effective nor necessary in patients 
with no urine abnormalities during follow-up. However, the length of follow-up time should 
be increased at least up to 6 months individually in the case of Henoch-Schönlein purpura 
recurrence and in those developing nephritis (Jauhola et al., 2010). 
7. Prevention of Henoch-Schönlein purpura nephritis 
Intervention to shorten the duration of Henoch-Schönlein purpura and prevent relapses 
may be helpful in preventing the development of nephritis. However, no therapy has yet 
been shown to decrease the duration of Henoch-Schönlein purpura, prevent recurrences, or 
prevent the development of nephritis (Saulsbury, 2009). 
Studies reported on patients with Henoch-Schönlein purpura lacking clinical signs of 
nephropathy at admission were treated with prednisone at doses ranging from 1.0 to  
2.5 mg/kg/day over a period of 7–21 days. Early prednisone treatment did not succeed in 
reducing the risk of further renal complication from Henoch-Schönlein purpura. Although 
prednisone is effective in alleviating the abdominal pain and joint pain associated with 
Henoch-Schönlein purpura, it did not short the duration of the disease, prevented the 
recurrences, or prevented the development of nephritis (Ronkainen et al., 2006). The 
relatively small subgroup of Henoch-Schönlein purpura patients who may benefit from 
corticosteroids included those who present with renal involvement and probably those with 
severe abdominal symptoms requiring medical attention (Mollica et al., 1992; Saulsbury, 
1999; Narchi, 2005).  
In general, the prophylactic treatment with prednisone at 2 mg/kg/day in Henoch-
Schönlein purpura must be considered of value if (1) there is a quicker resolution of 
abdominal pain, considering the cost and potential damage from prolonged treatment; (2) 
the treatment performed during the acute phase reduce the rates of abdominal surgery for 
exploration or actual intestinal injury; (3) the avoidance of several late-onset medical 
conditions, including hypertension, preeclampsia, and persistent nail-fold capillary changes, 
suggesting a chronic vasculitis (Gibson et al., 2008). Such measure at this time has not been 
demonstrated. However, 2– 4 weeks of prednisone administration at doses ranging from 1.0 
to 2.5 mg/kg per day over a period of 7–21 days or intravenous methylprednisolone 
prophylaxis (5 mg/kg four to six times per day for 3–5 days) failed to prevent renal 
involvement in Henoch-Schönlein purpura after 0.5–1 years (Zaffanello et al., 2009).  
Dapsone, an antileprotic drug, has been used at 1–2 mg/kg/day daily in a few patients with 
prolonged in Henoch-Schönlein purpura, improving the time of purpuric rush, but it has 
not been studied in a rigorous fashion in children with nephritis (Iqbal & Evans, 2005).  
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proliferation or sclerosis with <50% crescents; grade IV: focal or diffuse mesangial proliferation 
or sclerosis with 50–75% crescents; grade V: focal or diffuse mesangial proliferation or sclerosis 





Fig. 2. Methenamine-silver stain of a glomerular of a patient with Henoch-Schönlein 
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The clinical course of patients in a report suggested that colchicines, an ancient anti-
inflammatory drug, may be effective treatment at dosages of 1.2 mg/day in children with 
prolonged Henoch-Schönlein purpura possibly preventing the development of nephritis 
(Saulsbury, 2009). Therefore, at the current time insufficient data are available to support a 
recommendation for prophylaxis. 
8. Conventional treatment 
Conventional therapies were defined as drugs or procedures that act as immune 
modulators. 
8.1 Treatment of mild form of Henoch-Schönlein purpura nephritis 
Patients with mild renal symptoms have showed lower proportion of poor outcome than 
those with severe renal symptoms. In particular, patients with isolated hematuria showed a 
good prognosis, but 18% of patients with mild proteinuria at onset showed a poor outcome 
(Edström Halling et al., 2010). For this reason patients would be followed until full clinical 
resolution of renal symptoms. Since the level of proteinuria at onset does not seem to be a 
reliable predictor of outcome, the persistence of mild proteinuria in the long-term follow-up 
(one year) may require renal biopsy. Finally, the treatment of mild clinical form must be 
weighed according to International Study of Kidney Disease in Children grading score  
(see 8.2. and 8.3. sections).  
8.2 Treatment of moderately severe Henoch-Schönlein purpura nephritis 
Patients affected by moderately-severe proteinurias were treated with prednisone, 
intravenous gamma globulins and tonsillectomy, while pulse methylprednisolon and 
cyclophosphamide were introduced according to the degree of severity of renal histology.  
Three Henoch-Schönlein purpura nephritis patients treated by means of intravenous  
(2 g/kg/month) and intramuscular gamma globulins (0.35 ml/kg every 15 days) showed 
improved degrees of proteinuria and acuity index at renal biopsy (Rostoker et al., 1994; 
Rostoker et al., 1995). The administration of the angiotensin converting enzyme inhibitor 
(enalapril 10 mg/day) combined with fish oil led to a significant reduction in protein 
excretion rate after a few weeks of treatment in case series (Dixit et al., 2004). Additionally, 
tonsillectomy proved to be effective in five patients affected by Henoch-Schönlein purpura 
nephritis (Sanai &  Kudoh, 1996) as well as in 16 children with Henoch-Schönlein purpura 
nephritis in combination with intravenous pulse methylprednisolon at a dose of  
1 gram/1.73 m2 of body surface area (three to four cycles), prednisone (2 mg/kg/day) and 
cyclophosphamide (2 mg/kg/day) (Inoue et al., 2007).  
Data obtained from the literature are insufficient to support the use of specific treatments, such 
as intravenous gamma globulins and angiotensin converting enzyme inhibitors, in moderate-
severe Henoch-Schönlein purpura nephritis, based on case series (Zaffanello et al., 2009).  
8.3 Treatment of rapidly progressive or crescentic Henoch-Schönlein purpura 
nephritis 
Predictors of treatment with immunosuppression drugs were higher albuminurias and 
urine immunoglobulin G, and lower glomerular filtration rate at onset and a higher 
International Study of Kidney Disease in Children grading score in the biopsy. 
Unfortunately, no significant difference in outcome was found between the treated and 
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untreated patients with crescents. Neither was there any significant difference in glomerular 
filtration rate between treated and untreated patients (Edström Halling et al., 2010). 
Several studies have reported that patients with severe Henoch-Schönlein purpura nephritis 
may benefit from an intravenous pulse of methylprednisolone (Kawasaki et al., 2003; 
Niaudet & Habib, 1998; Edström Halling et al., 2010), cyclosporine A (Ronkainen et al., 
2003), cyclophosphamide (Kawasaki et al., 2004; Tarshish et al., 2004; Shenoy et al., 2007; 
Kawasaki et al., 2004; Edström Halling et al., 2010), urokinase pulse therapy (Kawasaki et 
al., 2003; Zaffanello et al., 2007), azathioprine (Zaffanello et al., 2007; Foster et al., 2000), and 
plasma exchange therapy (Scharer et al., 1999). All severe cases almost received angiotensin 
converting enzyme inhibitors and/or angiotensin II receptor blockers combined with 
immunosuppressant drugs (Edström Halling et al., 2010).  
Some protocols of treatment for Henoch-Schönlein purpura nephritis included the 
prescription of a single specific immunosuppressive treatment; other included two or 
multiple immunosuppressive drugs.  
8.3.1 Steroids 
Steroids included prednisolone or methylprednisolone at 30 mg/kg/day for 3 consecutive 
days or dexamethasone at 5 mg/kg/day (Kawasaki et al., 2003; Niaudet &  Habib, 1998). 
Fifty-six patients with renal lesions graded as IIIb or higher were treated with 
intravenous/oral steroids, along with dipyridamole and anticoagulant warfarin. The acuity 
index decreased at second biopsy, whereas the chronicity index did not differ significantly 
(Kawasaki et al., 2003).  
8.3.2 Cyclosporine A 
Single treatment included cyclosporine A performed for 6 months - 2 years (Ronkainen et 
al., 2003).  
Cyclosporine A, at the initial dose of 4–8 mg/kg/day, with blood level kept at 150–200 μg/L, 
and at the maintenance dose of 1–5 mg/kg/day, with blood level kept at 80–100 μg/L, proved 
to be effective in some case series with biopsy-proven steroid-resistant Henoch-Schönlein 
purpura nephritis. In particular, the treatment was effective in reducing the nephrotic 
proteinuria range after an average of 2 months in seven patients. Stable remission after a mean 
follow-up of 6 years was achieved in four subjects (Ronkainen et al., 2003). Treatment with 
cyclosporine A was effective in one patient with renal crescents following the failure of pulse 
steroid, oral prednisone and an 8 months course of azathioprine at 2 mg/kg/day (Shin et al., 
2006). In seven patients, treatment with pulse or oral prednisone and cyclosporine A with or 
without angiotensin converting enzyme inhibitor cilazapril displayed a marked efficacy in 
reversing nephrotic-range proteinuria and reducing histological grading post-treatment (Shin 
et al., 2005). In another study involving a group of 82 children with varying degrees of renal 
manifestation and histology (Mir et al., 2007), the majority received steroid treatment while 
only a few were treated with angiotensin converting enzyme inhibitor or cyclophosphamide in 
combination with steroids. Despite treatment, the long-term prognosis worsened markedly in 
those children manifesting severe clinical presentation. 
8.3.3 Cyclophosphamide 
Single treatments included cyclophosphamide performed for 8-12 weeks (Tarshish et al., 
2004; Zaffanello et al., 2007).  
A case series of patients with biopsy-proven Henoch-Schönlein purpura nephritis displayed 
varying degrees of response to cyclophosphamide at 2-2.5 mg/kg/day. Several patients in 
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untreated patients with crescents. Neither was there any significant difference in glomerular 
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whom the initial renal biopsy had revealed ≥80% crescentic glomeruli received 
cyclophosphamide in combination with pulse of methylprednisolone and/or long-term oral 
prednisone. The combined treatment was effective in aiding clinical recovery, maintaining 
normal renal function and reducing grade histology. Unfortunately, the lack of control 
patients and the small number of patients treated or short follow-up period hamper the 
drawing of firm conclusions (Zaffanello et al., 2007; Zaffanello et al., 2009).  
Long-term outcome of patients treated with daily cyclophosphamide expressed as end-stage 
renal disease did not differ with controls (Tarshish et al., 2004), indicating failure at level II 
of evidence. In a retrospective investigation, 21 children with crescents in 40% of glomeruli 
who were treated with an association of azathioprine at 1-2 mg/kg/day and steroids 
displayed an effective clinical outcome. Unfortunately, the considerable variability of the 
histological patterns complicated any interpretation of the results obtained (Bergstein et al., 
1998; Foster et al., 2000). Moreover, nine patients with severe histologically graded lesions 
were prescribed aggressive therapy with azathioprine and steroids, leading to marked 
clinical improvement. Regrettably, histological outcome was not reported, thus hindering 
the drawing of sustainable conclusions (Singh et al., 2002). Lastly, ten children treated with 
steroids and azathioprine were compared to ten patients receiving steroids alone. The initial 
biopsy revealed histological lesions comparable to those observed at follow-up, although 
mesangial IgA depositions were reduced in the majority of patients (Shin et al., 2005). 
However, the small number of patients studied led to difficulties in interpreting results. 
8.3.4 Mycophenolate mofetil 
Mycophenolate mofetil at 900-1,200 mg/m2/day was tested in patients with vasculitis and 
connective tissue disease involving the kidney, one of whom was affected by Henoch-
Schönlein purpura nephritis. This drug was administered subsequent to the failure of 
treatment with steroids and azathioprine (Filler et al., 2003). However, two patients featuring a 
prolonged course of nephritis were first prescribed steroids and azathioprine with the 
subsequent addition of mycophenolate mofetil (Algoet & Proesmans, 2003). Once again, due to 
the exceedingly low number of patients treated, no firm conclusions could be drawn.  
8.3.5 Single or combined treatment 
Other protocols were performed with double immunosuppressant therapy, including steroid–
cyclophosphamide (Oner et al., 1995; Iijima et al., 1998; Flynn et al., 2001; Tanaka et al., 2003; 
Kawasaki et al., 2004; Mir et al., 2007), steroid combined with azathioprine for 8-15 months 
(Bergstein et al., 1998; Foster et al., 2000; Singh et al., 2002; Shin et al., 2005; Zaffanello et al., 
2007), and steroid– cyclosporine A or steroid – (angiotensin converting enzyme inhibitors) – 
cyclosporine A (Shin et al., 2005; Shin et al., 2006; Shin et al., 2007).  
Triple immunosuppressant therapy was carried out using steroid– cyclophosphamide – 
azathioprine (Shenoy et al., 2007) and steroid– azathioprine –mycophenolate mofetil (Algoet 
et al., 2003; Zaffanello et al, 2007).  
8.3.6 Evidence based treatment 
The majority of reports provide scarce support to the various treatment options identified in 
cases of severe childhood Henoch-Schönlein purpura nephritis (Zaffanello et al., 2009). As 
the Henoch-Schönlein purpura nephritis and IgA nephropathy have identical pathogenesis 
and renal lesions, for which current evidence supports the use of immunosuppressive drugs 
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in patients with severe disease (Samuels et al., 2003; Cheng et al., 2009), the treatment 
protocols with proven significant benefit in IgA nephropathy should be used in children 
having Henoch-Schönlein purpura nephritis of comparable severity (Bogdanovic, 2009). A 
recent, single-centre, retrospective review looking at treatment of severe Henoch-Schönlein 
purpura nephropathy and IgA nephropathy demonstrated that therapy with differing 
combinations of steroids, cyclophosphamide, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers produced a good outcome in 54% of children with severe 
(>stage III) histological changes on initial renal biopsy (Edström Halling et al., 2009). For this 
reason, many physicians prescribe similar treatments in Henoch-Schönlein purpura patients 
with nephritis, despite the lack of disease-specific data, although IgA nephritis lesions 
however, tend to have a less severe inflammatory component and clinical trials on IgA 
nephropathy often include adult patients, while Henoch-Schönlein purpura nephropathy is 
primarily a disease that develops in children (Zaffanello et al., 2010).  
Moreover, several patients with moderately severe Henoch-Schönlein purpura nephritis 
(histological grade I–III and serum albumin >2.5 g/dl) were treated with angiotensin-
converting enzyme inhibitors and/or angiotensin receptor blockers. Patients with Henoch-
Schönlein purpura nephritis exceeding grade III or serum albumin ≤ 2.5 g/dl received 
combination therapy comprising prednisolone at 2 mg/kg/day, given in three divided 
doses (maximum dose, 80 mg/day) for the first 4 weeks, followed by prednisolone at  
2 mg/kg given as a single dose every other morning for 8 weeks, immunosuppressant 
azathioprine at 2 mg/kg/day as a single dose (maximum dose 100 mg) or mizoribine at  
5 mg/kg/day as a single dose (maximum dose 300 mg) maintained for 6 months, and 
warfarin at 1 mg/day given as a single dose each morning. The warfarin dose was then 
adjusted to give a thrombo-test result of 20–50%, and dipyridamole started at 3 mg/kg/day 
given in three divided doses, increased to 6 mg/kg/day (maximum dose, 300 mg/day) 
maintained for 8 weeks if the patient experienced no adverse effects, such as headache. The 
resolution of proteinuria, without renal dysfunction, was 50% at 5.2 months, 80% at  
8.5 months, and 90% at 11.1 months (Ninchoji et al., 2011). 
8.4 Plasma exchange 
Patients featuring rapid progression of Henoch-Schönlein purpura nephritis, despite the 
treatment with immunosuppressive medications (steroids, azatioprine and 
cyclophosphamide), were treated with plasma exchange. Among these children, 36% 
developed end-stage renal disease between 1 and 7 years after the initiation of treatment 
(Gianviti et al., 1996). The other children showed a reduction of glomerular filtration rate and 
crescents > 50% of glomeruli and continued plasma exchange treatment (Hattori et al., 1999).  
A case series of eight children with a rapidly progressive course of disease treated with plasma 
exchange, the beneficial effects produced were only transient, and, despite repeated plasma 
exchange, the subjects progressed to end-stage renal disease after 1–4 years (Scharer et al., 
1999). In case series study, children with extensive crescent formation underwent plasma 
exchange followed by multiple drug therapy, including steroids, pulse urokinase and 
cyclophosphamide. The patients manifested a decrease in acuity index and percentage of 
glomeruli with crescents, whereas the chronicity index remained unchanged (Kawasaki et al., 
2004). Plasma exchange was recently performed in patients with a histology grading of at least 
III at renal biopsy. At follow-up, only one child treated later in the course of the disease 
underwent a kidney transplant. At the end of the study, the investigators reported that the 
early performing of plasma exchange may delay the rate of progression of cellular crescents to 
the fibrotic stage and end-stage renal disease (Shenoy et al., 2007).  
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whom the initial renal biopsy had revealed ≥80% crescentic glomeruli received 
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drawing of firm conclusions (Zaffanello et al., 2007; Zaffanello et al., 2009).  
Long-term outcome of patients treated with daily cyclophosphamide expressed as end-stage 
renal disease did not differ with controls (Tarshish et al., 2004), indicating failure at level II 
of evidence. In a retrospective investigation, 21 children with crescents in 40% of glomeruli 
who were treated with an association of azathioprine at 1-2 mg/kg/day and steroids 
displayed an effective clinical outcome. Unfortunately, the considerable variability of the 
histological patterns complicated any interpretation of the results obtained (Bergstein et al., 
1998; Foster et al., 2000). Moreover, nine patients with severe histologically graded lesions 
were prescribed aggressive therapy with azathioprine and steroids, leading to marked 
clinical improvement. Regrettably, histological outcome was not reported, thus hindering 
the drawing of sustainable conclusions (Singh et al., 2002). Lastly, ten children treated with 
steroids and azathioprine were compared to ten patients receiving steroids alone. The initial 
biopsy revealed histological lesions comparable to those observed at follow-up, although 
mesangial IgA depositions were reduced in the majority of patients (Shin et al., 2005). 
However, the small number of patients studied led to difficulties in interpreting results. 
8.3.4 Mycophenolate mofetil 
Mycophenolate mofetil at 900-1,200 mg/m2/day was tested in patients with vasculitis and 
connective tissue disease involving the kidney, one of whom was affected by Henoch-
Schönlein purpura nephritis. This drug was administered subsequent to the failure of 
treatment with steroids and azathioprine (Filler et al., 2003). However, two patients featuring a 
prolonged course of nephritis were first prescribed steroids and azathioprine with the 
subsequent addition of mycophenolate mofetil (Algoet & Proesmans, 2003). Once again, due to 
the exceedingly low number of patients treated, no firm conclusions could be drawn.  
8.3.5 Single or combined treatment 
Other protocols were performed with double immunosuppressant therapy, including steroid–
cyclophosphamide (Oner et al., 1995; Iijima et al., 1998; Flynn et al., 2001; Tanaka et al., 2003; 
Kawasaki et al., 2004; Mir et al., 2007), steroid combined with azathioprine for 8-15 months 
(Bergstein et al., 1998; Foster et al., 2000; Singh et al., 2002; Shin et al., 2005; Zaffanello et al., 
2007), and steroid– cyclosporine A or steroid – (angiotensin converting enzyme inhibitors) – 
cyclosporine A (Shin et al., 2005; Shin et al., 2006; Shin et al., 2007).  
Triple immunosuppressant therapy was carried out using steroid– cyclophosphamide – 
azathioprine (Shenoy et al., 2007) and steroid– azathioprine –mycophenolate mofetil (Algoet 
et al., 2003; Zaffanello et al, 2007).  
8.3.6 Evidence based treatment 
The majority of reports provide scarce support to the various treatment options identified in 
cases of severe childhood Henoch-Schönlein purpura nephritis (Zaffanello et al., 2009). As 
the Henoch-Schönlein purpura nephritis and IgA nephropathy have identical pathogenesis 
and renal lesions, for which current evidence supports the use of immunosuppressive drugs 
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in patients with severe disease (Samuels et al., 2003; Cheng et al., 2009), the treatment 
protocols with proven significant benefit in IgA nephropathy should be used in children 
having Henoch-Schönlein purpura nephritis of comparable severity (Bogdanovic, 2009). A 
recent, single-centre, retrospective review looking at treatment of severe Henoch-Schönlein 
purpura nephropathy and IgA nephropathy demonstrated that therapy with differing 
combinations of steroids, cyclophosphamide, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers produced a good outcome in 54% of children with severe 
(>stage III) histological changes on initial renal biopsy (Edström Halling et al., 2009). For this 
reason, many physicians prescribe similar treatments in Henoch-Schönlein purpura patients 
with nephritis, despite the lack of disease-specific data, although IgA nephritis lesions 
however, tend to have a less severe inflammatory component and clinical trials on IgA 
nephropathy often include adult patients, while Henoch-Schönlein purpura nephropathy is 
primarily a disease that develops in children (Zaffanello et al., 2010).  
Moreover, several patients with moderately severe Henoch-Schönlein purpura nephritis 
(histological grade I–III and serum albumin >2.5 g/dl) were treated with angiotensin-
converting enzyme inhibitors and/or angiotensin receptor blockers. Patients with Henoch-
Schönlein purpura nephritis exceeding grade III or serum albumin ≤ 2.5 g/dl received 
combination therapy comprising prednisolone at 2 mg/kg/day, given in three divided 
doses (maximum dose, 80 mg/day) for the first 4 weeks, followed by prednisolone at  
2 mg/kg given as a single dose every other morning for 8 weeks, immunosuppressant 
azathioprine at 2 mg/kg/day as a single dose (maximum dose 100 mg) or mizoribine at  
5 mg/kg/day as a single dose (maximum dose 300 mg) maintained for 6 months, and 
warfarin at 1 mg/day given as a single dose each morning. The warfarin dose was then 
adjusted to give a thrombo-test result of 20–50%, and dipyridamole started at 3 mg/kg/day 
given in three divided doses, increased to 6 mg/kg/day (maximum dose, 300 mg/day) 
maintained for 8 weeks if the patient experienced no adverse effects, such as headache. The 
resolution of proteinuria, without renal dysfunction, was 50% at 5.2 months, 80% at  
8.5 months, and 90% at 11.1 months (Ninchoji et al., 2011). 
8.4 Plasma exchange 
Patients featuring rapid progression of Henoch-Schönlein purpura nephritis, despite the 
treatment with immunosuppressive medications (steroids, azatioprine and 
cyclophosphamide), were treated with plasma exchange. Among these children, 36% 
developed end-stage renal disease between 1 and 7 years after the initiation of treatment 
(Gianviti et al., 1996). The other children showed a reduction of glomerular filtration rate and 
crescents > 50% of glomeruli and continued plasma exchange treatment (Hattori et al., 1999).  
A case series of eight children with a rapidly progressive course of disease treated with plasma 
exchange, the beneficial effects produced were only transient, and, despite repeated plasma 
exchange, the subjects progressed to end-stage renal disease after 1–4 years (Scharer et al., 
1999). In case series study, children with extensive crescent formation underwent plasma 
exchange followed by multiple drug therapy, including steroids, pulse urokinase and 
cyclophosphamide. The patients manifested a decrease in acuity index and percentage of 
glomeruli with crescents, whereas the chronicity index remained unchanged (Kawasaki et al., 
2004). Plasma exchange was recently performed in patients with a histology grading of at least 
III at renal biopsy. At follow-up, only one child treated later in the course of the disease 
underwent a kidney transplant. At the end of the study, the investigators reported that the 
early performing of plasma exchange may delay the rate of progression of cellular crescents to 
the fibrotic stage and end-stage renal disease (Shenoy et al., 2007).  
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Plasma exchange in patients with Henoch-Schönlein purpura nephritis, either alone or in 
combination with immunosuppressant, cannot currently be recommended due to the 
paucity of data available (Zaffanello & Fanos, 2009). 
8.5 Adjuvant treatment 
Adjuvant therapies were defined as any secondary treatment used in addition to the 
primary or conventional treatments that increased the likelihood of cure (eg, intravenous 
immunoglobulins, anticoagulants, enzymes and vitamins). Results on moderate urinary 
abnormalities and severe Henoch-Schönlein purpura nephritis are reported separately 
because the renal implications, clinical monitoring, and conventional treatment modalities 
differ in terms of outcome measures (Zaffanello et al., 2009). 
8.5.1 Moderate urinary abnormalities 
Adjuvant treatment in children with isolated proteinuria with or without nephrotic 
syndrome has been reviewed (Zaffanello et al., 2009). 
Two studies (Rostoker et al., 1995; de Almeida et al., 2007) reported the usefulness of  
3 months treatment with intravenous immunoglobulins (2 g/kg/month) followed by 
intramuscular immunoglobulins (0.35 mL/kg) twice a month for 8 months in treating 
nephritis with significant proteinuria. Both the severity of proteinuria and the acuity index 
significantly improved in the majority of these patients with renal histology of stage III and 
normal renal function. In patients with severe gastrointestinal involvement who did not 
respond to methylprednisolone, were administered intravenous immunoglobulins at 2 g/kg 
in a single dose (Rostoker et al., 1998; Aries et al., 2005). Finally, the efficacy of intravenous 
immunoglobulins (2 g/kg, infused over 10–12 hours) in inhibiting the progression of the 
disease has been tested although only in unstructured case series.  
Intravenous administration of Factor XIII concentrate from 30 to 50 U/kg for 3 days was 
associated with significant improvements in the severity of proteinuria and hematuria 
compared with non-treated group (Erdoğan et al., 2003).   
In children aged 3 to 15 years with Henoch-Schönlein purpura nephritis, tocopherol  
300 mg/day was to be administered for 6-17 weeks (Kaku et al., 1998). Oxidative damage 
and worsening of the clinical course were observed despite significant increases in mean 
plasma vitamin E concentration. In 5 children with biopsy-proven Henoch-Schönlein 
purpura nephritis, treatment with an angiotensin-converting enzyme inhibitor (enalapril) 
for hypertension and adjuvant treatment with fish oil 1 g twice a day as an antioxidant was 
associated with significantly decreased severity of proteinuria, decreased blood pressure, 
and stable serum creatinine concentration and glomerular filtration rate. The limitation of 
this study was the small sample size and the confounding antiproteinuric effect of the 
angiotensin-converting enzyme inhibitor (Dixit et al., 2004; Chiurchiu et al., 2005).  
A systematic review reported no clear benefit of the use of dipyridamole (3-6 mg/kg/day 
for 8 weeks) and heparin (adjusted to maintain activated partial thromboplastin time 
between 60 and 80 seconds for 4 weeks) in treating Henoch-Schönlein purpura nephritis, 
with limitations being the small number of studies, small sample size, and poor 
methodology of the studies (Chartapisak et al., 2009).   
8.5.2 Severe Henoch-Schönlein purpura nephritis   
Adjuvant treatments of severe Henoch-Schönlein purpura nephritis with crescent 
formations in children have been studies from a systematic review (Zaffanello et al., 2009).  
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The patients with severe Henoch-Schönlein purpura described in these articles had 
nephrotic syndrome, Henoch-Schönlein purpura nephritis, rapidly progressive 
glomerulonephritis, and/or kidney failure. Histology of kidney biopsies found a significant 
proportion with crescent formations (International Study of Kidney Disease in Children 
grade IV–V). These patients were at high risk for kidney failure despite aggressive treatment 
with cocktails that included adjuvant anticoagulants or antiplatelet agents such as heparin 
(Iijima et al., 1998), warfarin (Kaku et al., 1998; Iijima et al., 1998; Kawasaki et al., 2004) 
dipyridamole (Oner et al., 1995; Kaku et al., 1998; Iijima et al., 1998; Mir et al., 2007) and 
acetylsalicylic acid (Mir et al., 2007). Treatments associated conventional with adjuvant 
therapy including three days intravenous pulse of methylprednisolone and/or long-term 
oral prednisolone administration for 6 months (Oner et al., 1995; Kawasaki et al, 2003; 
Kawasaki et al., 2004; Mir et al., 2007). Intravenous steroids were used alone (Kawasaki et 
al., 2003) or in combination with (or to replace) cyclophosphamide(Oner et al., 1995), or 
comparable steroid pulse therapy was used with cyclophosphamide (Kawasaki et al., 2004; 
Mir et al., 2007) and Cyclosporine A (Mir et al., 2007). Oral steroid therapy was used alone 
or in combination with cyclophosphamide (Iijima et al., 1998; Tanaka et al., 2003; Shekelle et 
al., 1999). 
In  a case series of 12 children aged 6 to 14 years with Henoch-Schönlein purpura, quadruple 
therapy with cyclophosphamide for 2 months, intravenous pulse methylprednisolone for 3 
days, oral prednisone for 3 months, and adjuvant oral dipyridamole for 6 months, 
glomerular filtration rate normalized in 11 patients and 7 patients had complete remission 
(Oner et al., 1995). In a case series of 14 children followed up for a mean (standard 
deviation) of 7.5 (0.9) years, combination treatment consisted of prednisone for 12 weeks, 
cyclophosphamide for 8 weeks, and adjuvant intravenous heparin  for 4 weeks followed by 
warfarin 1 mg/day for 4 weeks, and dipyridamole for 8 weeks . The histologic abnormalities 
of the kidney significantly improved in the meantime (Iijima et al., 1998).  
In 2 clinical trials, cyclosporine A was used for the treatment of severe Henoch-Schönlein 
purpura nephritis in children, either alone (Ronkainen J, 2003) or in combination with steroids 
and adjuvant dipyridamole (Mir et al., 2007). In particular, a retrospective, nonrandomized 
study in 82 children, prednisone or pulse methylprednisolone and cyclophosphamide and 
cyclosporine were given; asetil salicylic acid or dipyridamole were given as adjuvant therapy, 
although their dosing were not reported as well. In 35% of nephrotic patients and 62% of 
nephritic patients showed complete remission after 6 months and long-term course (Mir et al., 
2007). In a case series of 13 patients with renal histology grade IIIb or IVb, prednisone was 
administered for 26 weeks and cyclophosphamide was administered for 8 weeks (Tanaka et 
al., 2003). Adjuvant therapy was dipyridamole 5 mg/kg/day (maximum, 300 mg/day).  
At study end, acuity index was significantly decreased, chronologic index was unchanged, 
and renal histology grade was improved significantly (Tanaka et al., 2003).  
In a controlled study, 26 in 37 children with severe Henoch-Schönlein purpura nephritis, 
triple therapy with oral cyclophosphamide for 12 weeks, pulse methylprednisolone for 3 
days, and intravenous pulse urokinase at 5000 U/kg/day (maximum, 180,000 U) for 7 
consecutive days was effective. Thus, after 6 months, severity of proteinuria and mesangial 
IgA deposition were significantly reduced (Kawasaki et al., 2003; Kawasaki et al., 2004). 
Observations were reported in retrospective case series, and the literature lacks reports of 
substantial clinical trials. Because the literature search did not find any well-structured 
studies reporting benefits of the use of antiplatelet agents or heparin in children with 
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Henoch-Schönlein purpura nephritis, the use of such therapy is not recommended at this 
time since lack of evidence from well structured clinical trials (Zaffanello et al., 2009). 
9. Prognosis 
9.1 Prognostic factors and clinical findings 
Age at onset has not been shown to be a predictor of poor outcome (Ronkainen et al., 2002; 
Coppo et al., 1997; Counahan et al., 1977; Edström Halling et al., 2010). In the long-term, the 
morbidities of Henoch-Schönlein purpura are predominantly attributed to the intensity of 
renal involvement at presentation. Anymore, the majority of patients that first manifest 
nephropathy during childhood will not reach end stage renal disease before adulthood 
(Wyatt & Hogg, 2001). 
Female had a markedly greater risk of a poor long-term outcome (Edström Halling et al., 
2010).  
Patients with isolated hematuria showed a good prognosis (Narchi, 2005), with some 
exceptions (Goldstein et al, 1992). Most children with Henoch-Schönlein purpura nephritis 
who present only with hematuria and/or low-grade proteinuria at onset have good 
probabilities of recovery (Mir et al., 2007). Only patients showing normal urinalysis for 6 
months may be discharged from follow-up. In view of the possibility of late deterioration in 
those with mild renal involvement, long-term albeit annual follow-up was recommended 
(Narchi, 2005). It has been calculated that 18% of patients with mild proteinuria at onset 
progress towards poor outcome (Ronkainen et al., 2002; Butani & Morgenstern, 2007; 
Edström Halling et al., 2010).  
Of children who at onset displayed mild symptoms, 72% achieved a complete recovery, 
compared to 47% of those with severe symptoms. Of children who had mild symptoms at 
onset, 15% had a poor outcome compared to 41% of those with severe symptoms (Edström 
Halling et al., 2010). 
Henoch-Schönlein purpura nephritis patients with nephritic/nephritic syndrome and 
massive proteinuria (Niaudet & Habib, 1998) are considered to have severe disease 
(Kawasaki et al., 2003; Niaudet & Habib, 1998). Therefore, no significant difference in 
outcome was found between patients with nephrotic versus non-nephrotic proteinuria at 
onset. Of patients with nephrotic or nephritic-nephrotic features, 68% had a good outcome 
and specifically 59% of them achieved complete recovery. Level of urinary 
albumins/creatinine ratio at 1 year above or below 144 mg/mmol discriminated between 
poor and good outcome with a sensitivity of 95% and specificity of 40%, positive predictive 
value 82%, negative predictive value 73% (Edström Halling et al., 2010). 
Patients with a poor outcome had lower Glomerular Filtration Rate than patients with a 
good outcome. An initial renal insufficiency was a predictor of poor renal outcome in 
Henoch-Schönlein purpura nephritis (Edström Halling et al., 2010). 
There was no difference in outcome between patients who were normotensive and those 
who were hypertensive at the first investigation (Edström Halling et al., 2010).  
9.2 Prognostic factors and biopsy findings 
International Study of Kidney Disease in Children grading score and proteinuria at the 1-
year follow-up were the best discriminators of a good and poor outcome (Edström Halling 
et al., 2010). 
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Kawasaki (Kawasaki et al., 2003) classified Henoch-Schönlein purpura nephritis patients 
with International Study of Kidney Disease in Children grade IIIb or higher as having 
severe disease. Shenoy (Shenoy et al., 2007) concluded that most children with Henoch-
Schönlein purpura nephritis grade IIIb or higher on initial biopsy had persistent renal 
abnormalities at long-term follow-up. The risks for long-term renal impairment are highest 
in children who present and/or with more than 50% of glomeruli (grade IV or above) 
occupied by large crescents or sclerosing lesions (Bogdanovic, 2009) because they showed 
higher probabilities for development of progressive renal disease, renal failure, or end-stage 
renal disease after long-term follow-up (Iijima et al., 1998; Kawasaki et al., 2004; Niaudet & 
Habib, 1998).  
Patients with segmental glomerulosclerosis had a poorer outcome than those without 
segmental glomerulosclerosis. The comparison of patients with crescents to those without or 
those with global glomerulosclerosis to those without revealed no difference in outcome. 
Patients with poor outcome had a higher degree of mesangial matrix expansion, mesangial 
proliferation, interstitial inflammation and interstitial fibrosis than did those with a good 
outcome. Crescents were not a factor of poor prognosis, but the majority of the patients with 
crescents were treated, which may have improved the course of the disease (Edström 
Halling et al., 2010). 
10. Conclusion 
At this time, randomized controlled trials are needed to demonstrate whether the present 
management with conventional and adjuvant treatments improve truly renal survival of 
patients with Henoch-Schönlein purpura nephritis. Anymore, the choice of the treatment 
must depend on both the histological and clinical severity of the Henoch-Schönlein purpura 
nephritis. In particular, recommendations include a combination therapy for clinically and 
histologically severe Henoch-Schönlein purpura nephritis, which is unnecessary for 
moderate Henoch-Schönlein purpura nephritis.  
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(Kawasaki et al., 2003; Niaudet & Habib, 1998). Therefore, no significant difference in 
outcome was found between patients with nephrotic versus non-nephrotic proteinuria at 
onset. Of patients with nephrotic or nephritic-nephrotic features, 68% had a good outcome 
and specifically 59% of them achieved complete recovery. Level of urinary 
albumins/creatinine ratio at 1 year above or below 144 mg/mmol discriminated between 
poor and good outcome with a sensitivity of 95% and specificity of 40%, positive predictive 
value 82%, negative predictive value 73% (Edström Halling et al., 2010). 
Patients with a poor outcome had lower Glomerular Filtration Rate than patients with a 
good outcome. An initial renal insufficiency was a predictor of poor renal outcome in 
Henoch-Schönlein purpura nephritis (Edström Halling et al., 2010). 
There was no difference in outcome between patients who were normotensive and those 
who were hypertensive at the first investigation (Edström Halling et al., 2010).  
9.2 Prognostic factors and biopsy findings 
International Study of Kidney Disease in Children grading score and proteinuria at the 1-
year follow-up were the best discriminators of a good and poor outcome (Edström Halling 
et al., 2010). 
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Kawasaki (Kawasaki et al., 2003) classified Henoch-Schönlein purpura nephritis patients 
with International Study of Kidney Disease in Children grade IIIb or higher as having 
severe disease. Shenoy (Shenoy et al., 2007) concluded that most children with Henoch-
Schönlein purpura nephritis grade IIIb or higher on initial biopsy had persistent renal 
abnormalities at long-term follow-up. The risks for long-term renal impairment are highest 
in children who present and/or with more than 50% of glomeruli (grade IV or above) 
occupied by large crescents or sclerosing lesions (Bogdanovic, 2009) because they showed 
higher probabilities for development of progressive renal disease, renal failure, or end-stage 
renal disease after long-term follow-up (Iijima et al., 1998; Kawasaki et al., 2004; Niaudet & 
Habib, 1998).  
Patients with segmental glomerulosclerosis had a poorer outcome than those without 
segmental glomerulosclerosis. The comparison of patients with crescents to those without or 
those with global glomerulosclerosis to those without revealed no difference in outcome. 
Patients with poor outcome had a higher degree of mesangial matrix expansion, mesangial 
proliferation, interstitial inflammation and interstitial fibrosis than did those with a good 
outcome. Crescents were not a factor of poor prognosis, but the majority of the patients with 
crescents were treated, which may have improved the course of the disease (Edström 
Halling et al., 2010). 
10. Conclusion 
At this time, randomized controlled trials are needed to demonstrate whether the present 
management with conventional and adjuvant treatments improve truly renal survival of 
patients with Henoch-Schönlein purpura nephritis. Anymore, the choice of the treatment 
must depend on both the histological and clinical severity of the Henoch-Schönlein purpura 
nephritis. In particular, recommendations include a combination therapy for clinically and 
histologically severe Henoch-Schönlein purpura nephritis, which is unnecessary for 
moderate Henoch-Schönlein purpura nephritis.  
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1. Introduction  
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown 
etiology.  The onset of SLE is believed to be triggered by ill-defined environmental factors in 
genetically susceptible individuals (Mok, 2003a).  Although the exact pathogenetic 
mechanisms have yet to be elucidated, recent works have revealed a myriad of 
immunological abnormalities in patients with SLE. These include aberrant apoptosis and 
defective clearance of apoptotic materials such as nuclear autoantigens and nucleosomes, 
and immune complexes by macrophages and the complement system (Katsiari, 2010), 
increased maturation of myeloid dendritic cells which drive the development of the 
proinflammatory Th17 cells (Fransen, 2010), and defective functions of the regulatory T cells 
(Tregs) leading to hyperactivity of the helper T cells and autoreactive B cells causing 
production of autoantibodies (Tucci, 2010). 
Of the numerous clinical manifestations of SLE, renal disease is one of the commonest and 
most serious.  Lupus renal disease appears to be more prevalent in certain ethnic groups 
such as the African and Hispanic Americans, as well as the Asians (Mok, 2005a). Renal 
involvement in SLE adversely affects its ultimate prognosis as reflected by the rates of 
patient survival and renal survival (survival without the need for renal replacement 
therapy), and is a major determinant for morbidity and impairment of quality of life (Mok, 
1999).  
The glomerulus is the commonest site of kidney involvement by lupus. However, the renal 
interstitium and tubules, as well as the vessels may also be affected (Cross, 2005). The 
presentation of renal disease in SLE is variable, ranging from no symptoms, trace 
proteinuria or urinary sediments to frank nephrotic syndrome, chronic renal insufficiency, 
and nephritic syndrome with rapid progression leading to acute renal failure. Early 
recognition of renal disease and close monitoring of renal parameters for progress after 
treatment is an essential part of the management. Conventional serological markers and 
clinical renal parameters for active lupus nephritis are not sensitive or specific enough, and 
novel biomarkers for early detection of renal disease and prediction of renal prognosis are 
under ongoing evaluation. It is believed that a combination of conventional parameters with 
one or more serological or urine biomarkers may yield better sensitivity and specificity for 
predicting renal activity or flare of nephritis in patients with SLE. This may help to abate the 
need for more invasive investigations such as renal biopsy in the assessment of renal activity 
and allow early institution of therapy (Mok, 2010a). 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
230 
Stewart, M., Savage, J.M., Bell, B., McCord, B. (1988). Long term renal prognosis of Henoch-
Scho¨ nlein purpura in an unselected childhood population. European Journal of 
Pediatrics, Vol.147, pp.113–5, ISSN 03406199. 
Suzuki, H., Moldoveanu, Z., Hall, S., Brown, R., Vu, H.L., Novak, L., Julian, B.A., Tomana, 
M., Wyatt, R.J., Edberg, J.C., Alarcón, G.S., Kimberly, R.P., Tomino, Y., Mestecky, J., 
Novak, J. (2008). IgA1-secreting cell lines from patients with IgA nephropathy 
produce aberrantly glycosylated IgA1. The Journal of Clinical Investigation, 2008 
Vol.118, No.2, pp.629-39. ISSN 00219738. 
Suzuki, H., Suzuki Y., Narita, I., Aizawa, M., Kihara, M., Yamanaka, T., Kanou, T., 
Tsukaguchi, H., Novak, J., Horikoshi, S., Tomino, Y. (2008). Toll-like receptor 9 
affects severity of IgA nephropathy. Journal of the American Society of Nephrology, 
Vol.19, No.12, pp. 2384-2395, ISSN 10466673. 
Tanaka, H., Suzuki, K., Nakahata, T., Ito, E., Waga, S. (2003). Early treatment with oral 
immunosuppressants in severe proteinuric purpura nephritis. Pediatric Nephrology, 
Vol.18, pp.347–350, ISSN 0931041X. 
Tarshish, P., Bernstein, J., Edelmann, C.M., Jr. (2004). Henoch-Schonlein purpura nephritis: 
course of disease and efficacy of cyclophosphamide. Pediatric Nephrology, Vol.19, 
pp.51-56, ISSN 0931041X. 
Tizard, E.J., Hamilton-Ayres, M.J. (2008). Henoch Schonlein purpura. Archives of Disease in 
Childhood  Educ Pract Ed, Vol. 93, No.1, pp.1-8, ISSN 17430585. 
Trapani, S., Micheli, A., Grisolia, F., Resti, M., Chiappini, E., Falcini, F., De Martino, M. 
(2005). Henoch-Schonlein purpura in childhood: epidemiological and clinical 
lanalysis of 150 cases over a 5-year period and review of literature. Seminars in 
Arthritis and Rheumatism, Vol.35, pp.143-153, ISSN 00490172. 
Waldo, F.B. (1988). Is Henoch-Schönlein purpura the systemic form of IgA nephropathy? 
American Journal of Kidney Diseases, Vol.12, pp.373–377, ISSN 02726386. 
Wyatt, R.J., Hogg, R.J. (2001). Evidence-based assessment of treatment options for children 
with IgA nephropathies. Pediatric Nephrology, Vol.16, pp.156–167, ISSN 0931041X. 
Wyatt. R.J., Kanayama, Y., Julian, B.A., Negoro, N., Sugimoto, S., Hudson, E.C., Curd, J.G. 
(1987). Complement activation in IgA nephropathy. Kidney International, Vol.31, 
pp.1019–1023, ISSN 00852538. 
Yang, Y.H., Hung, C.F., Hsu, C.R., Wang, L.C., Chuang, Y.H., Lin, Y.T., Chiang, B.L. (2005). 
A nationwide survey on epidemiological characteristics of childhood Henoch-
Schönlein purpura in Taiwan. Rheumatology, Vol.44, pp.618−22, ISSN 14620324. 
Zaffanello, M., Brugnara, M., Franchini, M. (2007). Therapy for children with henoch-
schonlein purpura nephritis: a systematic review. ScientificWorldJournal, Vol.7, 
pp.20-30, ISSN 1537-744X. 
Zaffanello, M., Brugnara, M., Franchini, M., Fanos, V. (2009). Adjuvant Treatments in 
Henoch-Schönlein Purpura Nephritis in Children: a systematic review. Current 
Therapeutic Research - Clinical and Experimental, Vol.70, No.3, pp. 254-265, ISSN 
0011393X.  
Zaffanello, M., Emma, F., Weiss, P.F., Hastings, M.C., Eison, T.M. (2010). Commentaries on 
‘Interventions for preventing and treating kidney disease in Henoch-Schonlein 
Purpura’. Evidence-Based Child Health, Vol.5, pp.703–708, ISSN. 
Zaffanello, M., Fanos, V. (2009). Treatment-based literature of Henoch–Schönlein purpura. 
Pediatric Nephrology, Vol.24, pp.1901–1911, ISSN 0931041X. 
14 
Lupus Glomerulonephritis 
Chi Chiu Mok  
Department of Medicine, Tuen Mun Hospital and Center for Assessment and  
Treatment of Rheumatic Diseases, Pok Oi Hospital, Hong Kong,  
SAR China 
1. Introduction  
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown 
etiology.  The onset of SLE is believed to be triggered by ill-defined environmental factors in 
genetically susceptible individuals (Mok, 2003a).  Although the exact pathogenetic 
mechanisms have yet to be elucidated, recent works have revealed a myriad of 
immunological abnormalities in patients with SLE. These include aberrant apoptosis and 
defective clearance of apoptotic materials such as nuclear autoantigens and nucleosomes, 
and immune complexes by macrophages and the complement system (Katsiari, 2010), 
increased maturation of myeloid dendritic cells which drive the development of the 
proinflammatory Th17 cells (Fransen, 2010), and defective functions of the regulatory T cells 
(Tregs) leading to hyperactivity of the helper T cells and autoreactive B cells causing 
production of autoantibodies (Tucci, 2010). 
Of the numerous clinical manifestations of SLE, renal disease is one of the commonest and 
most serious.  Lupus renal disease appears to be more prevalent in certain ethnic groups 
such as the African and Hispanic Americans, as well as the Asians (Mok, 2005a). Renal 
involvement in SLE adversely affects its ultimate prognosis as reflected by the rates of 
patient survival and renal survival (survival without the need for renal replacement 
therapy), and is a major determinant for morbidity and impairment of quality of life (Mok, 
1999).  
The glomerulus is the commonest site of kidney involvement by lupus. However, the renal 
interstitium and tubules, as well as the vessels may also be affected (Cross, 2005). The 
presentation of renal disease in SLE is variable, ranging from no symptoms, trace 
proteinuria or urinary sediments to frank nephrotic syndrome, chronic renal insufficiency, 
and nephritic syndrome with rapid progression leading to acute renal failure. Early 
recognition of renal disease and close monitoring of renal parameters for progress after 
treatment is an essential part of the management. Conventional serological markers and 
clinical renal parameters for active lupus nephritis are not sensitive or specific enough, and 
novel biomarkers for early detection of renal disease and prediction of renal prognosis are 
under ongoing evaluation. It is believed that a combination of conventional parameters with 
one or more serological or urine biomarkers may yield better sensitivity and specificity for 
predicting renal activity or flare of nephritis in patients with SLE. This may help to abate the 
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Therapy of lupus nephritis should target at symptomatic control, preservation of renal 
function, reduction of renal flares, prevention of treatment-related complications, and 
ultimately reduction in mortality (Mok, 2003b). The treatment schedule of lupus nephritis 
is now divided into an induction phase and a maintenance phase. Induction treatment 
aims at controlling inflammation and minimizing glomerular injury, whereas 
maintenance therapy is to reduce the risk of renal flares and renal function decline in the 
long-run. A combination of glucocorticoids with a non-glucocorticoid immunosuppressive 
agent has been shown to be more effective than glucocorticoid monotherapy in reducing 
the risk of progression into end stage renal failure in lupus nephritis (Austin, 1986). Of the 
many non-glucocorticoid immunomodulating agents, mycophenolate mofetil (MMF)  
has emerged to be the first-line treatment of lupus nephritis around the world because 
studies have shown that it is associated with fewer adverse effects than 
cyclophosphamide, particularly on the ovarian functions (Ginzler, 2005). Recent evidence 
also reveals that maintenance therapy with MMF is more effective than azathioprine in 
reducing the composite endpoint of renal flare and deterioration of renal function 
(Wolfsy, 2010). 
In this chapter, the prevalence, presentation and significance of renal involvement in 
patients with SLE is discussed. An update on the current therapies of lupus nephritis is 
also presented based on the results of recent randomized controlled trials. Finally, 
promising biomarkers for the detection and monitoring of lupus nephritis is briefly 
reviewed. 
2. Prevalence of renal disease in SLE 
Lupus renal disease appears to be more prevalent in certain ethnic groups such as the 
African and Hispanic Americans, as well as the Asians (Mok, 2005a; Dooley, 1997). In a 
comparative study of the clinical manifestations of SLE in three ethnic groups, it was 
reported that renal disease, as defined by the American College of Rheumatology (ACR) 
criteria, namely persistent daily proteinuria of more than 500mg, presence of cellular casts 
or biopsy evidence of lupus nephritis, occurred in 45% of African American, 42% of Chinese 
and 30% of Caucasian patients, respectively (Mok, 2005a).  Another multi-ethnic US cohort 
of SLE patients reported that renal disease occurred in 51% of Africans and 43% of 
Hispanics but only in 14% of Caucasians (Bastian, 2002). In a prospective study of 216 
Chinese patients with new onset SLE, 31% patients had active renal disease at the time of 
initial presentation (Mok, 2004). Of 148 patients without overt renal disease at SLE onset, 
33% developed active renal disease after a median of 14 months. The overall cumulative 
incidence of renal disease as defined according to the ACR renal criteria in this cohort of 
patients was 60% at 5 years post-SLE diagnosis (Mok, 2004). The actual incidence of renal 
disease might have been underestimated as the renal definition does not include subtle renal 
involvement such as proteinuria of less than 500mg/day or microscopic hematuria, or both. 
These studies illustrate that lupus renal involvement is more common in the Africans, 
Hispanics and Chinese than the Caucasians. 
3. Clinical presentation of lupus renal disease 
The presentation of renal disease in SLE is variable, ranging from no symptoms (detected by 





sediments (microscopic hematuria, pyuria or cellular casts), to more serious proteinuria 
(nephrotic syndrome), and acute nephritic syndrome with rapid progression to acute renal 
failure. Occasionally, patients may present with chronic renal failure, isolated renal 
insufficiency and hypertension as the initial manifestation.  
The wide range of presentations of lupus nephritis does not necessarily correlate with the 
histological findings from renal biopsy. “Silent” lupus nephritis has long been recognized in 
the literature. A retrospective study of 21 SLE patients with low level of proteinuria 
(<1gm/day) who underwent renal biopsy showed that proliferative lupus nephritis was 
present in 57% patients (Christopher-Stine, 2007). This emphasizes the frequent discordance 
of the histological severity with clinical presentation, and the need for renal biopsy, 
especially for new onset renal disease as evidenced by abnormal urinalysis and/or renal 
function impairment. 
4. Renal biopsy 
Renal biopsy is the gold standard of confirming the diagnosis of lupus glomerulonephritis. 
The finding of positive staining for immunoglobulin G, A and M, together with C1q, C3 and 
C4, constitutes the “full house” staining pattern for lupus nephritis. In addition to 
establishment of the diagnosis of lupus renal disease and confirming renal flares, renal 
biopsy also provides information on the histological classes of lupus nephritis, and the 
degree of inflammation and damage in the kidneys so as to guide therapeutic decision. 
Renal biopsy should be considered in SLE patients with new onset of proteinuria of more 
than 1g/day with and without active urinary sediments, especially in the presence of active 
lupus serology or impaired renal function. Some experts recommend renal biopsy at a lower 
threshold of proteinuria (eg. 500mg/day). 
Patients with lupus nephritis that is refractory to treatment should be evaluated for other 
possible causes for the persistence of proteinuria or deterioration in renal function such as 
the nephrotoxic side effects of medications (eg. the calcineurin inhibitors and non-
steroidal anti-inflammatory drugs), renal vein thrombosis, infections, overdiuresis and 
poorly controlled hypertension. Treatment compliance should be checked. A repeat renal 
biopsy should be considered in patients with persistently active serological markers 
because it provides information on the following: (1) histological transformation of the 
classes of lupus nephritis; (2) the degree of residual activity in the kidneys; and (3) the 
extent of chronic irreversible changes and its progression since the initiation  
of immunosuppressive treatment. These data may help to guide further treatment 
decisions. 
5. Histological classification of lupus glomerulonephritis 
The histological classification of lupus nephritis has undergone several modifications. The 
first WHO classification was formulated in 1974 and was last revised in 1995. According to 
this system, lupus glomerulonephritis was classified according to the extent and pattern of 
immune deposits and inflammation, which were detected by immunohistochemistry on 
light microscopy. There were 5 histological subtypes of lupus nephritis (class I to V) in the 
1974 WHO classification (McCluskey, 1975).  The differentiation of class III and class IV 
disease was based on the percentage of glomeruli affected by proliferative lesions (>50% 
was classified as Class IV). No qualitative differences between class III and class IV lesions 
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were described. Tubulointerstitial and vascular lesions were not included in the 
classification. 
The WHO classification was revised in 1982 (Churg, 1982). Class I disease was subdivided 
into 2 subclasses based on the presence and absence of immune deposits on 
immunofluorescence or electron microscopy. Class III was denoted focal segemental 
glomerulonephritis and Class IV was referred to diffuse proliferative glomerulonephritis. 
There were no description on the percentage of involvement of glomeruli for the 
differentiation between class III and class IV disease. Class III and IV disease was 
subdivided into active, chronic, or mixed types of glomerular injury. Class V was denoted 
membranous glomerulonephritis, which was subdivided into 4 subclasses: pure 
membranous nephropathy without or with mesangial hypercellularity (Va and Vb, 
respectively), membranous nephropathy with segmental endocapillary proliferation and/or 
necrosis (Vc) and membranous nephropathy with diffuse endocapillary proliferation 
and/or necrosis (Vd). Class VI was introduced to denote advanced sclerosing 
glomerulonephritis.  
The WHO system was further revised in 1995 (Churg, 1995), with the emphasis of segmental 
glomerular capillary wall necrosis to be the defining feature of class III lesions, regardless of 
the percentage of glomeruli affected. For membranous lupus nephropathy, as the long-term 
prognosis is dependent on the proliferative than membranous component, the 1995 WHO 
classification removed Vc and Vd to be included into class III and class IV lupus nephritis, 
respectively. Class V retained only the subclasses Va and Vb, under the category “diffuse 
membranous glomerulonephritis”. 
The histological classification system was modified once again in 2003 by the International 
Society of Nephrology and the Renal Pathology Society (Weening, 2004) (Table 1). One of 
the reasons was the demonstration of the poor outcome of diffuse segmental necrotizing 
glomerulonephritis involving over 50% of glomeruli, (a “severe” form of class III disease), 
as compared to class IV lupus nephritis. Class III disease referred to focal lupus nephritis, 
which was defined as involvement of less than 50% of glomeruli by segmental 
endocapillary proliferative lesions, with or without capillary wall necrosis and crescents, 
and subendothelial deposits. Class IV disease was denoted diffuse lupus nephritis which 
involved more than 50% of the glomeruli.  This class is subdivided into diffuse segmental 
lupus nephritis (class IVS) when >50% of the involved glomeruli showed segmental 
lesions, and diffuse global lupus nephritis (class IVG) when >50% of the glomeruli having 
global lesions.  The proportion of glomeruli with active and chronic lesions, fibrinoid 
necrosis or crescents, tubulointerstitial and vascular pathology should be separated 
reported.  
Class V, or membranous lupus nephritis, was defined as global or segmental continuous 
granular subepithelial immune deposits, often in the presence of concomitant mesangial 
immune deposits and hypercellularity. The distinction between pure membranous 
nephropathy and membranous nephropathy superimposed on mesangial changes was 
eliminated. When a diffusely distributed membranous lesion is associated with an active 
lesion of class III or IV, both diagnoses are reported (‘V+III’ or ‘V+IV’). Finally, minimal 
change nephropathy (class I) was renamed minimal mesangial lupus nephritis, which was 
characterized by normal light microscopy of the glomeruli with accumulation of mesangial 
immune complexes identified by immunofluorescence and/or electron microscopy. A 
complete lack of renal abnormalities by light microscopy, immunofluorescence, and electron 
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6. Prognosis of lupus renal disease 
Renal involvement of SLE carries significant morbidity and mortality. The renal survival 
(survival without dialysis) rates of lupus nephritis in the 1990’s range from 83-92% in 5 years 
and 74-84% in 10 years (Mok, 1999; Donadio, 1995; Bono, 1999; Neumann, 1995). The risks of 
end stage renal failure were particularly high in patients with diffuse proliferative 
glomerulonephritis, with figures ranging from 11-33% in 5 years (Mok, 1999; Dooley, 1997, 
Donadio, 1995; Neumann, 1995; Bakir, 1994; Nossent, 2000; Korbet, 2000). The prognosis of 
lupus nephritis depends on a large number of demographic, racial, genetic, histopathological, 
immunological and time-dependent factors (Mok, 2005b). Renal disease that fails to remit with 
conventional immunosuppressive therapies is a major risk factor for subsequent deterioration 
of renal function and poor outcome (Mok, 1999; Korbet, 2000; Mok, 2006b). Other unfavorable 
prognostic factors for lupus neprhitis include younger age, male sex, histological cellular 
crescents, fibrinoid necrosis, subendothelial deposits, glomerular scarring, tubular atrophy and 
interstitial fibrosis, impaired renal function at presentation, persistent hypertension, 
hypocomplementemia, low hematocrit, as well as delay in treatment due to problems of access 
to health care and poor compliance (Mok, 2005b). 
A recent hospital registry study of 5686 patients with SLE showed that there was a loss in 
life expectancy of 20 years in female and 27 years in male patients, respectively (Mok, 2011). 
Among 514 lupus deaths, direct complications of renal disease accounted for 9% of all cases 
(Mok, 2011). This reiterates that the prognosis of renal disease in SLE has yet to be improved 
by novel therapies in the future. 
7. Current treatment of lupus glomerulonephritis 
The immunosuppressive therapy of lupus nephritis is divided into an induction phase 
which targets at reducing inflammation and glomerular injury and a maintenance phase 
that aims to reduce the long-term risk of renal flares and renal function decline. Adjunctive 
therapies such as vigorous control of blood pressure to less than 120/80mmHg may retard 
the deterioration of renal function. The early use of renal protection agents such as the 
angiotensin converting enzyme inhibitors (ACEIs) and the angiotensin II receptor 
antagonists is mandatory. Hyperlipidemia should also be aggressively controlled to offer 
protection against accelerated vascular disease, especially in the membranous type of lupus 
nephritis. Calcium and vitamin D should be adequately supplemented to reduce the risk of 
aggravation of disease activity related to vitamin D deficiency, and to protect against loss in 
bone mineral density. Low-dose aspirin should be considered in patients with histological 
evidence of antiphospholipid syndrome nephropathy, although there is still no published 
evidence that this will protect against renal function decline. Anticoagulation may be 
considered in patients with persistent nephrotic range of proteinuria and the presence of the 
antiphospholipid antibodies.  
8. Induction therapy for lupus nephritis 
Milder form of lupus nephritis (ISN/RPS Class I, II) is usually manageable with 
corticosteroids (Mok, 2010b). Azathioprine (AZA) can be added as a corticosteroid sparing 
agent and for the treatment of concomitant extra-renal manifestations. Mild class V disease 
can be treated with ACEIs. Proliferative lupus nephritis (class III and IV or mixed III/V and 





function) disease requires more aggressive induction regimens consisting of corticosteroids 
and a non-corticosteroid immunosuppressive agent. 
The standard therapy for severe proliferative lupus nephritis has been a combination of high-
dose glucocorticoid and cyclophosphamide (CYC). From the series of randomized controlled 
trial conducted by the National Institute of Health (NIH), it was demonstrated that prednisone 
combined with intravenous (IV) pulse CYC offered better long-term protection against renal 
function decline than prednisone alone (Austin, 1986; Gourley, 1996; Illei, 2001). However, the 
use of CYC is associated with a number of untoward side effects, which include infection, 
ovarian and bladder toxicities, leukopenia, increased risk of cervical intraepithelial neoplasia 
and malignancy. Some of these toxicities are dose dependent, with a higher risk related to a 
higher cumulative dose (Mok, 1998). IV pulse CYC has gained popularity over continuous 
daily oral CYC because it is associated with less toxicity on the bladder and the gonads. 
Whether oral CYC is more efficacious than IV pulse CYC in lupus nephritis remains 
controversial because of the lack of large controlled trials (Austin, 1986; Mok, 2001). A recent 
analysis of a large cohort of patients with diffuse proliferative lupus nephritis showed a trend 
of better efficacy of oral CYC than IV pulse CYC in preserving renal function after a mean 
follow-up of 8.8 years (Mok, 2006b). In a multivariate model, the cumulative dose of CYC 
delivered instead of the route of CYC was an independent factor for a complete renal 
response. This suggests that the higher potency of the oral CYC regimen is probably related to 
the higher cumulative dose delivered instead of the route of administration per se. However, 
ovarian toxicity leading to premature menopause was more frequent in users of oral CYC. 
Although the optimal route of CYC and duration of therapy in lupus nephritis remains to be 
defined, recent evidence supports the use of a shorter course and lower dose of CYC to 
minimize toxicities (Mok, 2001; Mok, 2002; Houssiau, 2010a). Houssiau et al. (2010a) 
compared the efficacy and toxicity of two less intensive intravenous pulse CYC regimens for 
the initial treatment of lupus nephritis.  Eighty-four patients (predominantly Caucasians) 
were randomized to receive either 8 intravenous pulses of CYC (0.5g/m2 to a maximum of 
1.5gm) or 6 biweekly low dose pulses of CYC (500mg each). In both regimens, CYC was 
later substituted with AZA for long-term maintenance. Patients who participated in the 
study had milder renal disease compared to other lupus nephritis trials, as reflected by a 
lower proportion of patients having class IV disease, nephrotic syndrome and renal function 
impairment. After 10 years, rates of mortality, sustained doubling of serum creatinine and 
end stage renal disease did not differ between the two groups (36). The incidence of 
cardiovascular events and was also similar. Cancers, however, were numerically more 
common in patients who had received the low-dose regimen. Thus, for less serious lupus 
nephritis, a low-dose CYC regimen, followed by AZA is a viable strategy if there are no 
alternatives to CYC for initial treatment. 
Nevertheless, CYC remains the treatment of choice for high-risk patients with proliferative 
lupus nephritis such as those with impaired or rapidly deteriorating renal function, 
histological cellular crescents or a combination of high activity and chronicity scores (Tang, 
2009). The course of CYC should be limited to less than 6 months, with subsequent replacement 
by another immunosuppressive agent, to reduce the incidence of toxicities (Mok, 2002). 
9. Recent controlled trials for induction therapy of severe lupus nephritis 
Six randomized controlled trials comparing the efficacy and adverse effects of different 
treatment protocols for the induction therapy of severe lupus nephritis have recently been 
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presented (Appel, 2009; Grootscholten, 2006, Bao, 2008; Chen, 2011; Mok, 2008; Furie, 2009). 
These are briefly summarized in Table 2. 
In the largest lupus nephritis controlled trial to-date, called the Aspreva Lupus Management 
Study (ALMS), 370 patients with histologically ISN/RPS class III, IV or V lupus nephritis 
were randomized to receive either monthly IV pulse CYC (0.5-1.0g/m2) or MMF (target 
3g/day) on top of high-dose prednisone (60mg/day initially and then tapered) (Appel, 
2009). Two-third of the participants had class IV disease. Asians and Hispanics comprised 
33% and 35% of the participants, respectively. Three hundred and six (83%) patients 
completed the 24-week protocol. Clinical response, defined by a decrease in urine 
protein/creatinine ratio (P/Cr) to <3 in patients with baseline nephrotic range P/Cr 3, or 
by 50% in patients with subnephrotic baseline P/Cr (<3), and stabilization (25%) or 
improvement in serum creatinine at 24 wk as adjudicated by a blinded clinical endpoints 
committee, was not significantly different between the CYC (53%) and MMF (56%) group. 
Subgroup analyses revealed that MMF was associated with a significantly higher response 
rate than CYC (60% vs 39%; p=0.03) in the non-Caucaisan non-Asians, which were mainly 
Hispanics. The rates of adverse events and serious adverse events were not significantly 
different between the two groups. Specifically, nausea, vomiting and alopecia were 
numerically more frequent in the CYC group, whereas diarrhea was more commonly 
reported in the MMF group. The induction phase of the ALMS study did not allow 
comparison of long-term side effects such as sustained amenorrhea and malignancies. There 
were 9 and 5 deaths in the MMF and CYC group, respectively. Of the 9 deaths in the MMF 
group, 7 were Asians (mainly Chinese), suggesting that Asian patients tolerated high-dose 
prednisone and MMF (3g/day) less well.  
A controlled trial comparing the efficacy of CYC and azathioprine (AZA) in lupus nephritis 
was reported by Grootscholten et al. (2006). In this study, 87 patients with proliferative 
lupus nephritis (class III and IV) were randomized to receive either oral prednisone 
combined with intravenous pulse CYC (750mg/m2 monthly for 6 months and then quarterly 
for another 7 doses) or intravenous pulse methylprednisolone (1 gram daily for 3 days for 9 
pulses) together with AZA (2mg/kg/day). At the end of the third year, both groups of 
patients received AZA for long-term maintenance (2mg/kg/day). The dosage of AZA was 
reduced to 1mg/kg/day after 4 years of treatment. This cohort of patients consisted mainly 
of Caucasian patients (76%) who had serious renal disease as evidenced by a high 
proportion of patients having hypertension (57%), nephrotic syndrome (53%) and impaired 
creatinine clearance (56%) at presentation. In the first 2 years, no significant difference in the 
rates of complete and partial renal remission could be demonstrated between the two 
regimens. After a median follow-up of more than 5 years, significantly more patients in the 
AZA arm relapsed and there was a trend of higher incidence of doubling of serum 
creatinine in the AZA-treated patients. Interestingly, the incidence of herpes zoster infection 
was lower in the CYC than AZA arm during the first two years of treatment. 
Although this was a randomized controlled trial, the number of patients assigned to the two 
treatment arms was unequal (50 patients in the CYC arm vs 37 patients in the AZA group). 
The corticosteroid regimens of the two treatment arms were also different, which 
confounded a proper interpretation of whether CYC was more effective than AZA by its 
own.  However, taking the observation that relapse of nephritis and renal function decline 
was more common in AZA-treated patients despite the use of a more intensive 
corticosteroid regimen, it was not unreasonable to conclude for the superiority of CYC over 
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Bao et al. (2008) studied 40 patients with mixed proliferative and membranous lupus nephritis 
(ISN/RPS IV+V) by randomizing them to receive either IV pulse CYC (0.5-1g.m2 monthly) 
(N=20) or low-dose combination of MMF (500mg BD) and tacrolimus (Tac) (2mg BD) (N=20), 
on top of high-dose prednisolone (0.6-0.8mg/kg/day) after 3 daily pulses of 
methylprednisolone (0.5g). The mean creatinine clearance at recruitment was 97.6ml/min and 
85% patients had normal serum creatinine level. At 6 months, the rate of complete response, 
defined as daily proteinuria <0.4g/day with normal urinary sediments and stabilization of 
serum creatinine (<15% increase), was significantly higher in the MMF / Tac group (50%) than 
the CYC group (5%). The corresponding rates at 9 months of treatment were 65% and 15%, 
respectively. Leukopenia, gastrointestinal upset, upper respiratory tract infection, alopecia and 
irregular menses were more common in the CYC than MMF/Tac group of patients. 
A randomized controlled trial comparing the short-term efficacy of IV pulse CYC with 
tacrolimus (Tac) in lupus nephritis were recently presented (Chen, 2011). In this study, 81 
patients with class III, IV or V lupus nephritis were randomized to receive IV pulse CYC 
(0.5-1g.m2 monthly) (N=39) or Tac (0.05mg/kg/day titrating to a level of >5ng/mL) (N=42) 
in combination with high-dose prednisolone (1mg/kg/day). The study population 
consisted of moderate to high-risk patients as shown by a high proportion of class IV 
disease (77%) and impaired renal function (11%) at presentation. At 6 months, the rate of 
complete remission, which was defined as proteinuria <0.3g/day, stabilization of serum 
creatinine and normalization of urinary sediments, was not significantly different between 
the CYC and Tac group of patients (38% vs 52%, p=0.2). Regarding adverse events, 
gastrointestinal upset and leucopenia were significantly more frequent in the CYC group 
but the rate of infection was similar between the CYC- and Tac-treated patients. Transient 
increase in serum creatinine was reported in 8% of patients receiving Tac. 
Our group has conducted a controlled trial comparing the efficacy of MMF (2g/day, 
titrating to 3g/day if response suboptimal at 3 months) with Tac (0.1mg/kg/day in first 2 
months with tapering to 0.06mg/kg/day) in combination of high-dose prednisolone 
(0.6mg/kg/day for 6 weeks and taper) for lupus nephritis (Mok, 2008). Up to March 2011, 
130 patients with ISN/RPS class III, IV or V lupus nephritis were recruited. Our preliminary 
analysis showed that the clinical complete and partial response rates were not significantly 
different between the two treatment arms at month 6. The rate of infection, in particular 
herpes zoster reactivation, was higher in MMF than Tac-treated patients, whereas alopecia, 
tremor and reversible increase in serum creatinine was more frequent in the Tac group of 
patients. Dose-related neurological and metabolic adverse effects of Tac, and the possibility 
of early renal relapse upon completion of the induction phase and substitution of Tac have 
to be carefully monitored. 
The LUNAR study is a phase III randomized, double-blind, placebo-controlled multicenter 
study to evaluate the efficacy and safety of rituximab in patients with active proliferative 
lupus nephritis (Furie, 2009). Patients with ISN/RPS Class III or IV lupus nephritis and 
urine protein to creatinine (UP/Cr) ratio >1 were randomized to receive rituximab (1000mg) 
or placebo infusion on days 1, 15, 168 (week 24) and 182 (week 26), on top of corticosteroid 
and MMF (>2g/day). Seventy-two patients were recruited in each treatment arm. Two-third 
of the patients had class IV nephritis and the mean UP/Cr at entry was 4.0±2.8. At week 52, 
no statistically significant differences in the primary and secondary endpoints were 
observed between the rituximab and placebo groups of patients, although there were 
numerically more responders in the rituximab group (57% vs 46% in the placebo group). 





placebo than the Whites. Rituximab had a greater effect than placebo on anti-dsDNA and 
complement levels at week 52. Serious adverse events and infection rates were similar 
between the two groups but two deaths occurred in the rituximab-treated patients. 
Taken the evidence from these recent studies together, it appears that MMF should be used 
as the first line treatment in combination with corticosteroids for severe lupus nephritis 
because of its stronger evidence (largest sample size) compared to other agents and lower 
incidence of toxicities compared to conventional CYC. Although Tac has similar efficacy 
with either CYC or MMF, it has been tried in a smaller population of patients and 
disadvantages such as transient and long-term nephrotoxicity, as well as higher relapse rate 
upon substitution with another immunosuppressive agent are of concern. However, Tac is a 
definite option when patients are contraindicated for or intolerant to MMF. Moreover, Tac is 
indicated as salvage therapy for refractory lupus nephritis. Tac is preferred to cyclosporin A 
for the lower incidence of cosmetic side effects. The initial results of the B cell depleting 
agents such as rituximab are disappointing. Although evidence does not support an 
additional benefit of rituximab on top of MMF treatment for lupus nephritis, rituximab is an 
option to be considered in recalcitrant lupus nephritis, as evidenced by a number of 
uncontrolled case series (Jonsdottir, 2010; Melander, 2009; Vigna-Perez, 2006).  
10. Maintenance therapy for lupus nephritis 
There are no randomized controlled trials with the main objective of delineating whether 
maintenance therapy of lupus nephritis is effective or not. However, some indirect evidence 
suggests that maintenance therapy is probably necessary in severe lupus nephritis. In a 
long-term follow-up of 145 patients who participated in the NIH lupus nephritis studies, 
renal flares occurred in 45% of the patients when immunosuppression was completely 
stopped (Illei, 2002). A recent retrospective review of 32 patients with predominantly diffuse 
proliferative lupus nephritis described a relapse of lupus activity in 53% of patients after 
immunosuppression was discontinued (Moroni, 2006). In our experience with 212 patients 
with diffuse proliferative lupus nephritis (Mok, 2006b), despite maintenance treatment was 
given to 73% of patients, more than one-third of patients still had renal flares which might 
be serious. The use of maintenance therapy for more than 3 years was independently 
associated with an increased likelihood of having the composite outcome of doubling of 
serum creatinine, end stage renal failure or death (hazard ratio 4.62 [1.35-15.8]; p=0.02).  
In a 2006 retrospective review of 32 patients with proliferative lupus nephritis in whom 
immunosuppressive therapy was stopped for a median of 203 months, clinical remission 
persisted in 47% of patients (Moroni, 2006). Patients who experienced sustained remission had 
received a longer total median duration of immunosuppressive treatment since renal biopsy 
than those who did not experience remission (median 57 months vs 30 months; p<0.01). This 
finding, coupled with the observation that maintenance treatment for less than 3 years after 
successful cyclophosphamide induction was a predictor of poor renal outcome in proliferative 
lupus nephritis (Mok, 2006b), suggests that maintenance immunosuppressive therapy should 
be continued for at least 3 years after a complete clinical response is achieved. 
Four recent randomized controlled trials compare the efficacy of different immunosuppressive 
agents in maintaining remission in lupus nephritis (summarized in Table 3). Contreras et al. 
(2004) randomized 59 patients with lupus nephritis (mainly African and Hispanic Americans; 
78% had class IV disease) to receive one of the three treatment arms after induction with 4-7 
pulses of intravenous CYC: (1) MMF (0.5-3g/day); (2) quarterly pulse CYC; (3) AZA (1-
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3mg/kg/day). Long-term observation showed that either MMF or AZA was superior to CYC 
in the prevention of the composite outcome of renal failure and death. MMF was more 
efficacious than pulse CYC in the prevention of renal flares. Moreover, maintenance treatment 
with CYC was associated with more side effects such as nausea, vomiting and infection. 
Although the sample size is small, this study shows that maintenance treatment of lupus 
nephritis with either AZA or MMF is safe and effective. However, whether MMF is more cost-
effective than AZA is not clear because significant difference in all outcomes is not apparent 
between MMF- and AZA-treated patients. Moroni et al. (2006) studied 69 patients (mainly 
Caucasians) with lupus nephritis and compared the efficacy of cyclosporin A (CSA) with AZA 
for maintenance therapy. After initial induction treatment with pulse methylprednisolone, 
prednisone and oral CYC (91.523.8 mg/day for a median of 3 months), patients were 
randomized to receive either cyclosporin A (Neoral; 4.0 to 2.5-3.0mg/kg/day) (N=36) or AZA 
(2mg/kg/day) (N=33) for maintenance. At 4 years of follow-up, flare occurred in 24% of AZA-
treated and 19% of CSA-treated patients, respectively (no significant difference). Minor 
infections and leucopenia were more commonly reported with AZA treatment whilst 
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In the MAINTAIN study conducted by Houssiau et al. (2010b), 105 patients with class III, 
IV, Vc and Vd lupus nephritis were randomized to receive either MMF (2g/day) (N=53) or 
AZA (2mg/kg/day) (N=52) after an initial induction regimen that consisted of IV pulse 
methylprednisolone, high-dose prednisone and IV pulse CYC (500mg 2-weekly for 6 doses). 
Participants were mainly Caucasians and 10% of patients had impaired renal function at 
study entry. After a mean follow-up of 53 (15-65) months, 24 (23%) patients withdrew from 
the study mainly because of pregnancy wish (in the MMF group) and adverse effects. 
Frequency of renal and extra-renal flares, doubling of serum creatinine and incidence of 
infections occurred at similar frequency in the two arms. However, drug-related cytopenias 
were more common with AZA. 
Results of the maintenance phase of the ALMS study was released in the 9th International 
Lupus Congress at Vancouver in 2010 (Wofsy 2010). Two hundred and twenty-seven 
patients who had completed the induction phase of the ALMS (IV pulse CYC or MMF 
3g/day) were randomized to receive either MMF (2g/day) (N=116) or AZA (2mg/kg/day) 
(N=111) for maintenance treatment. The mean daily doses received by the patients were 
1.870.43g and 12048mg, respectively, for MMF and AZA. After a mean follow-up of 2.1 
years, the rate of treatment failure, defined as renal flare, doubling of serum creatinine or 
end stage renal disease, need for rescue therapy or death, was significantly less common in 
MMF than AZA-treated patients. The results were similar in patients induced by CYC or 
MMF at recruitment. 
Taken these studies together, it appears that MMF is the preferred agent for long-term 
maintenance therapy for lupus nephritis. However, the cost-effectiveness of this approach 
has to be evaluated in future analysis. AZA and CSA are alternative options for patients 
who are intolerant to MMF or plan for pregnancy. The long-term use of the calcineurin 
inhibitors such as Tac and CSA is not encouraged because of the increased risk of 
nephrotoxicity, hyperlipidemia and atherosclerosis. 
11. Membranous lupus nephropathy 
Membranous lupus nephropathy (MLN), defined as global or segmental continuous 
granular subepithelial immune deposits, often in the presence of mesangial immune 
deposits and mesangial hypercellularity, comprises only one-fifth of all cases of 
histologically confirmed lupus nephritis (Mok, 2009). Reported rates of patient survival and 
end-stage renal disease in MLN vary considerably, because of substantial heterogeneity 
among the published studies. The risk of progression of MLN to renal failure is generally 
reduced in the absence of proliferative lesions, but patients are nevertheless at risk of 
thromboembolic complications.  
The optimal therapy for MLN remains elusive because of the paucity of clinical trials. Mixed 
membranous and proliferative lupus nephritis should be treated in the same way as pure 
proliferative lupus nephritis. If MLN is not accompanied by proliferative lesions but is 
associated with clinically relevant proteinuria, renal insufficiency or failure to respond to 
supportive therapies, immunosuppressive treatment is indicated. In addition, 
cardiovascular protection and blockade of the renin-angiotensin system should be instituted 
early in all patients. 
Austin et al. (2009) randomized 42 patients (71% Blacks or Hispanics) with MLN to receive one 
of the following regimens: (1) alternate day prednisone (1mg/kg/day for 8 weeks and taper to 
0.25mg/kg/day throughout); (2) similar prednisone regimen plus IV pulse CYC (0.5-1.0g/m2 
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In the MAINTAIN study conducted by Houssiau et al. (2010b), 105 patients with class III, 
IV, Vc and Vd lupus nephritis were randomized to receive either MMF (2g/day) (N=53) or 
AZA (2mg/kg/day) (N=52) after an initial induction regimen that consisted of IV pulse 
methylprednisolone, high-dose prednisone and IV pulse CYC (500mg 2-weekly for 6 doses). 
Participants were mainly Caucasians and 10% of patients had impaired renal function at 
study entry. After a mean follow-up of 53 (15-65) months, 24 (23%) patients withdrew from 
the study mainly because of pregnancy wish (in the MMF group) and adverse effects. 
Frequency of renal and extra-renal flares, doubling of serum creatinine and incidence of 
infections occurred at similar frequency in the two arms. However, drug-related cytopenias 
were more common with AZA. 
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patients who had completed the induction phase of the ALMS (IV pulse CYC or MMF 
3g/day) were randomized to receive either MMF (2g/day) (N=116) or AZA (2mg/kg/day) 
(N=111) for maintenance treatment. The mean daily doses received by the patients were 
1.870.43g and 12048mg, respectively, for MMF and AZA. After a mean follow-up of 2.1 
years, the rate of treatment failure, defined as renal flare, doubling of serum creatinine or 
end stage renal disease, need for rescue therapy or death, was significantly less common in 
MMF than AZA-treated patients. The results were similar in patients induced by CYC or 
MMF at recruitment. 
Taken these studies together, it appears that MMF is the preferred agent for long-term 
maintenance therapy for lupus nephritis. However, the cost-effectiveness of this approach 
has to be evaluated in future analysis. AZA and CSA are alternative options for patients 
who are intolerant to MMF or plan for pregnancy. The long-term use of the calcineurin 
inhibitors such as Tac and CSA is not encouraged because of the increased risk of 
nephrotoxicity, hyperlipidemia and atherosclerosis. 
11. Membranous lupus nephropathy 
Membranous lupus nephropathy (MLN), defined as global or segmental continuous 
granular subepithelial immune deposits, often in the presence of mesangial immune 
deposits and mesangial hypercellularity, comprises only one-fifth of all cases of 
histologically confirmed lupus nephritis (Mok, 2009). Reported rates of patient survival and 
end-stage renal disease in MLN vary considerably, because of substantial heterogeneity 
among the published studies. The risk of progression of MLN to renal failure is generally 
reduced in the absence of proliferative lesions, but patients are nevertheless at risk of 
thromboembolic complications.  
The optimal therapy for MLN remains elusive because of the paucity of clinical trials. Mixed 
membranous and proliferative lupus nephritis should be treated in the same way as pure 
proliferative lupus nephritis. If MLN is not accompanied by proliferative lesions but is 
associated with clinically relevant proteinuria, renal insufficiency or failure to respond to 
supportive therapies, immunosuppressive treatment is indicated. In addition, 
cardiovascular protection and blockade of the renin-angiotensin system should be instituted 
early in all patients. 
Austin et al. (2009) randomized 42 patients (71% Blacks or Hispanics) with MLN to receive one 
of the following regimens: (1) alternate day prednisone (1mg/kg/day for 8 weeks and taper to 
0.25mg/kg/day throughout); (2) similar prednisone regimen plus IV pulse CYC (0.5-1.0g/m2 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
244 
every two months); or (3) similar prednisone regimen plus CSA (5mg/kg/day). At 12 months, 
the cumulative probability of complete (<0.3g/day proteinuria) or partial (<2.0g/day 
proteinuria or improvement by 50% from baseline) remission was highest with CSA (83%), 
followed by IV pulse CYC (60%) and prednisone alone (27%).  The response rates of either 
CSA or CYC were significantly better than prednisone alone. However, relapse of nephrotic 
syndrome was significantly more common after discontinuation of treatment with CSA than 
IV pulse CYC. Adverse effects during the 12-month period included insulin-requiring diabetes 
(one with prednisone and two with CsA), pneumonia (one with prednisone and two with 
CsA), and localized herpes zoster (two with IVCY). 
A recent pooled analysis of 65 patients with pure membranous lupus nephritis recruited for 
two randomized controlled trials and completed 24 weeks of treatment (Ginzler, 2005; 
Appel, 2009) showed that there were no differences in the measured end points, response 
rate, mortality and withdrawal rate between MMF and IV pulse CYC (Radhakrishnan, 
2010). There was also no difference in the change in proteinuria or partial response rate 
between MMF and CYC in those patients presenting with nephritic syndrome.  
Therefore, similar to the proliferative types of lupus nephritis, more serious MLN should be 
treated with a combination of glucocorticoids and non-glucocorticoid immunosuppressive 
agent. A number of uncontrolled series have reported efficacy of various regimens for MLN 
such as AZA, tacrolimus and MMF in combination with glucocorticoids (Mok, 2009). Taken 
these together, possible options for MLN include MMF, IV pulse CYC, CSA, AZA and 
tacrolimus. Many specialists will start with MMF or AZA for their lower incidence of 
adverse effects, reserving other agents for salvage therapy when the clinical response is not 
optimal. Controlled trials comparing existing immunosuppressive agents and experimental 
modalities such as rituximab, infliximab and sirolimus should be undertaken in the future 
(Jonsdottir, 2011). 
12. Refractory lupus nephritis 
There is no international consensus on the definitions of remission and treatment 
refractoriness in lupus nephritis. In the absence of reliable and readily available biomarkers 
for ongoing activity / inflammation in the kidneys and histological / immunological data 
from routine post-therapy renal biopsy, true remission of lupus nephritis is difficult to 
define. Despite the discrepancies in the clinical criteria used, up to 20% of patients with 
lupus nephritis are reported to be resistant to initial immunosuppressive therapy (Mok, 
2006a). They are more likely to be patients with multiple unfavorable prognostic factors 
such as the African ethnicity, delayed institution of CYC, poor treatment compliance, 
impaired serum creatinine, severe nephrotic syndrome, arterial hypertension at 
presentation, and the presence of active crescents and a higher degree of chronicity in renal 
histology (Mok, 2005b).  
Using the similar renal response criteria as suggested by the NIH investigators (Boumpas, 
1998), we reported that 14% of a cohort of 212 patients with diffuse proliferative lupus 
nephritis did not respond to either continuous oral or intermittent pulse CYC therapy at the 
end of the induction courses (Mok, 2006b). The failure to respond to immunosuppressive 
treatment in the first year is associated with increased risk of renal function decline and the 
development of end stage renal disease (Mok, 1999). 
Controlled trials in refractory lupus nephritis are unavailable. Open-labeled studies have 





the biological agents such as MMF, calcineurin inhibitors (CSA and tacrolimus), 
leflunomide, intravenous immunoglobulin, immunoadsorption and rituximab in the 
treatment of CYC-refractory lupus nephritis. More aggressive CYC regimens such as daily 
oral CYC and the immunoablative CYC protocol have been used in lupus nephritis, but at 
the expense of more toxicities (Petri, 2010). Novel biological agents that are undergoing 
clinical trials in renal and non-renal lupus include epratuzumab, ocrelizumab, belimumab, 
abatacept and atacicept (summarized in Table 4) (Mok, 2010c). 
 
B cell depletion 
Fludarabine, rituximab, epratuzumab, ocrelizumab, belimumab, atacicept 
B cell tolerization 
Abetimus sodium 
Blockade of the co-stimulatory pathways 
Abatacept (CTLA4-Ig) 
Neutralization of cytokines 
IL-10, TNF, IL-6, type I interferons 
Anti-complement 
anti-C5b (eculizumab) 
Table 4. Biological therapies for renal and non-renal lupus 
13. Biomarkers for lupus nephritis 
Current laboratory markers for lupus nephritis such as proteinuria, urine protein-to-
creatinine ratio, creatinine clearance, anti-dsDNA and complement levels are unsatisfactory. 
They lack sensitivity and specificity for differentiating renal activity and damage in lupus 
nephritis. Significant kidney damage can occur before renal function is impaired and first 
detection by laboratory parameters. Persistent proteinuria may not necessarily indicate 
ongoing inflammation in the kidneys; and may be contributed by pre-existing chronic 
lesions or recent damage in the kidneys during the course of the disease. Flares of nephritis 
can occur without any observable and recent increase in the degree of proteinuria. Renal 
biopsy is the gold standard for providing information on the histological classes of lupus 
nephritis and the relative degree of activity and chronicity in the glomeruli. However, it is 
invasive and serial biopsies are impractical in the monitoring of lupus nephritis. Thus, novel 
biomarkers that are able to discriminate lupus renal activity and its severity, predict renal 
flares, monitor treatment response and disease progress, and stratify prognosis are 
necessary. 
A biomarker refers to a biologic, biochemical or molecular event that can be assayed 
qualitatively and quantitatively by laboratory techniques. An ideal biomarker for lupus 
nephritis should possess the following properties: (1) Good correlation with renal activity as 
reflected by the degree of proteinuria and urine sediments; (2) Sensitive to change so that it 
can be used for serial monitoring of disease activity in the kidneys and defining treatment 
response and clinical remission; (3) Ability to predict renal activity / flares before an 
obvious change in conventional clinical parameters occurs so that early treatment / 
preventive strategies can be considered; (4) Specific to nephritis among patients with SLE; 
and (5) Specific to SLE for aiding early diagnosis of lupus nephritis. In addition, a useful 
biomarker should be easy to assay, simple to interpret and readily available in most 
laboratories with a reasonable cost. 
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(one with prednisone and two with CsA), pneumonia (one with prednisone and two with 
CsA), and localized herpes zoster (two with IVCY). 
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Appel, 2009) showed that there were no differences in the measured end points, response 
rate, mortality and withdrawal rate between MMF and IV pulse CYC (Radhakrishnan, 
2010). There was also no difference in the change in proteinuria or partial response rate 
between MMF and CYC in those patients presenting with nephritic syndrome.  
Therefore, similar to the proliferative types of lupus nephritis, more serious MLN should be 
treated with a combination of glucocorticoids and non-glucocorticoid immunosuppressive 
agent. A number of uncontrolled series have reported efficacy of various regimens for MLN 
such as AZA, tacrolimus and MMF in combination with glucocorticoids (Mok, 2009). Taken 
these together, possible options for MLN include MMF, IV pulse CYC, CSA, AZA and 
tacrolimus. Many specialists will start with MMF or AZA for their lower incidence of 
adverse effects, reserving other agents for salvage therapy when the clinical response is not 
optimal. Controlled trials comparing existing immunosuppressive agents and experimental 
modalities such as rituximab, infliximab and sirolimus should be undertaken in the future 
(Jonsdottir, 2011). 
12. Refractory lupus nephritis 
There is no international consensus on the definitions of remission and treatment 
refractoriness in lupus nephritis. In the absence of reliable and readily available biomarkers 
for ongoing activity / inflammation in the kidneys and histological / immunological data 
from routine post-therapy renal biopsy, true remission of lupus nephritis is difficult to 
define. Despite the discrepancies in the clinical criteria used, up to 20% of patients with 
lupus nephritis are reported to be resistant to initial immunosuppressive therapy (Mok, 
2006a). They are more likely to be patients with multiple unfavorable prognostic factors 
such as the African ethnicity, delayed institution of CYC, poor treatment compliance, 
impaired serum creatinine, severe nephrotic syndrome, arterial hypertension at 
presentation, and the presence of active crescents and a higher degree of chronicity in renal 
histology (Mok, 2005b).  
Using the similar renal response criteria as suggested by the NIH investigators (Boumpas, 
1998), we reported that 14% of a cohort of 212 patients with diffuse proliferative lupus 
nephritis did not respond to either continuous oral or intermittent pulse CYC therapy at the 
end of the induction courses (Mok, 2006b). The failure to respond to immunosuppressive 
treatment in the first year is associated with increased risk of renal function decline and the 
development of end stage renal disease (Mok, 1999). 
Controlled trials in refractory lupus nephritis are unavailable. Open-labeled studies have 





the biological agents such as MMF, calcineurin inhibitors (CSA and tacrolimus), 
leflunomide, intravenous immunoglobulin, immunoadsorption and rituximab in the 
treatment of CYC-refractory lupus nephritis. More aggressive CYC regimens such as daily 
oral CYC and the immunoablative CYC protocol have been used in lupus nephritis, but at 
the expense of more toxicities (Petri, 2010). Novel biological agents that are undergoing 
clinical trials in renal and non-renal lupus include epratuzumab, ocrelizumab, belimumab, 
abatacept and atacicept (summarized in Table 4) (Mok, 2010c). 
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IL-10, TNF, IL-6, type I interferons 
Anti-complement 
anti-C5b (eculizumab) 
Table 4. Biological therapies for renal and non-renal lupus 
13. Biomarkers for lupus nephritis 
Current laboratory markers for lupus nephritis such as proteinuria, urine protein-to-
creatinine ratio, creatinine clearance, anti-dsDNA and complement levels are unsatisfactory. 
They lack sensitivity and specificity for differentiating renal activity and damage in lupus 
nephritis. Significant kidney damage can occur before renal function is impaired and first 
detection by laboratory parameters. Persistent proteinuria may not necessarily indicate 
ongoing inflammation in the kidneys; and may be contributed by pre-existing chronic 
lesions or recent damage in the kidneys during the course of the disease. Flares of nephritis 
can occur without any observable and recent increase in the degree of proteinuria. Renal 
biopsy is the gold standard for providing information on the histological classes of lupus 
nephritis and the relative degree of activity and chronicity in the glomeruli. However, it is 
invasive and serial biopsies are impractical in the monitoring of lupus nephritis. Thus, novel 
biomarkers that are able to discriminate lupus renal activity and its severity, predict renal 
flares, monitor treatment response and disease progress, and stratify prognosis are 
necessary. 
A biomarker refers to a biologic, biochemical or molecular event that can be assayed 
qualitatively and quantitatively by laboratory techniques. An ideal biomarker for lupus 
nephritis should possess the following properties: (1) Good correlation with renal activity as 
reflected by the degree of proteinuria and urine sediments; (2) Sensitive to change so that it 
can be used for serial monitoring of disease activity in the kidneys and defining treatment 
response and clinical remission; (3) Ability to predict renal activity / flares before an 
obvious change in conventional clinical parameters occurs so that early treatment / 
preventive strategies can be considered; (4) Specific to nephritis among patients with SLE; 
and (5) Specific to SLE for aiding early diagnosis of lupus nephritis. In addition, a useful 
biomarker should be easy to assay, simple to interpret and readily available in most 
laboratories with a reasonable cost. 
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Hitherto, quite a number of serum and urine biomarkers have been studied in lupus 
nephritis (summarized in Table 5). Many of these markers have only been tested in cross-
sectional studies with small sample size, and none has been rigorously validated in large-
scale longitudinal cohorts of patients with different ethnic background. It is unlikely at this 
juncture that a candidate biomarker stand-alone can replace conventional clinical 
parameters to monitor disease progress and detect early renal flares. Urine biomarkers 
appear to be more encouraging than serum biomarkers possibly because they are the direct 
products or consequences of kidney inflammation or injury. Future directions in SLE 
biomarker research should focus on a combination of novel markers with conventional 
clinical parameters to enhance the sensitivity and specificity for the prediction of renal flares 
and prognosis in lupus nephritis (Mok, 2010a). 
 
Urinary monocyte chemoattractant protein-1 (uMCP-1)
Plasma and urine neutrophil gelatinase–associated lipocalin (NGAL) 








Serum and urine IL-12 
Peripheral blood leukocyte chemokine transcriptional levels 
Serum apoCIII 
Serum ICAM-1 
Anti-endothelial cell antibody 
Urine osteoprotegerin (OPG) 
FOXP3 mRNA expression in urinary sediments 
Urine endothelin-1 
Urine CXCR3+CD4+T cells 
Urine VCAM-1, P-selectin, TNFR-1 and CXCL16 
Urine TGF-1 
TGF and MCP-1 mRNA expression in urine sediments 
Chemokine and growth factor mRNA level in urinary sediments 
Serum nitrate and nitrite level 
Anti-ribosomal P antibody 
Urine glycoprotein panel
Table 5. Novel biomarkers for lupus nephritis 
14. Conclusions 
Renal involvement is a major determinant of the prognosis of SLE. Lupus renal disease is 
more frequent in certain ethnic groups such as the Africans, Hispanics and Asians. Of the 
various histological types of lupus nephritis, diffuse proliferative lupus nephritis carries the 
worst prognosis. Treatment of lupus nephritis should target at disease remission, prevention 





treatment of lupus nephritis is immunosuppression using a combination of high-dose 
glucocorticoid and a non-glucocorticoid immunosuppressive agent. Mycophenolate mofetil 
combined with prednisone has emerged to be the standard regimen. Intravenous pulse or 
daily oral cyclophosphamide is reserved for more serious or refractory cases of lupus 
nephritis. The evidence for calcineurin inhibitors in lupus nephritis is less strong and these 
agents are reserved for patients intolerant or recalcitrant to standard therapies. B cell 
modulation is emerging as novel therapeutic modalities for lupus nephritis. While further 
evidence from controlled trials is eagerly awaited, the current use of B cell modulating 
agents is confined to recalcitrant lupus renal disease. Conventional markers for activity of 
lupus nephritis are neither sensitive nor specific. Novel biomarkers are being studied for 
earlier detection of renal flares and better prognostic stratification so that intervention can 
be instituted early to minimize damage to renal function.  
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1. Introduction 
Anti–glomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder 
characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic 
formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis.  
In 1919, an autopsy of an 18-year-old male patient, who had developed hemoptysis and 
acute renal failure after experiencing flu-like symptoms, revealed massive alveolar 
hemorrhage, glomerulonephritis with fibrinous exudates in Bowman’s capsule and 
necrotizing vasculitis in the spleen and gut (Goodpasture, 1919). Stanton and Tange 
reported 9 cases with alveolar hemorrhage and RPGN as Goodpasture’s syndrome (Stanton 
& Tange, 1958). Anti-GBM disease was defined as the presence of serum autoantibodies to 
the noncollagenous domain of the alpha 3 chain of type IV collagen or a linear binding of 
IgG to glomerular capillary walls as detected by direct immunofluorescence in patients with 
RPGN. Anti-GBM disease was divided into two types: anti-GBM disease without alveolar 
hemorrhage was regarded as renal-limited anti-GBM disease, and that with alveolar 
hemorrhage was defined as Goodpasture’s syndrome.  
This review focuses on anti-GBM disease by comparing international differences in 
prevalence, clinical features, treatments and outcomes in order to improve the prognosis of 
anti-GBM disease.  
2. Prevalence 
Anti-GBM disease is relatively rare, with an estimated annual incidence of about  
0.5-1.0/million population (Table 1). It has been estimated to cause 0.2-2.4% of biopsy-
proven glomerulonephritis cases in Europe, but less than 0.2% in Asia. It causes about 10% 
of RPGN (or necrotizing and/or crescentic glomerulonephritis) in Europe, more than 10% of 
RPGN in the United States, and less than 10% in Asia. In Japan, to improve the prognosis of 
patients with RPGN, a nation-wide survey of patients with RPGN in 365 hospitals between 
1989 and 2000 was conducted, and clinical characteristics including initial symptoms, 
laboratory findings and histological findings were investigated along with treatment 
methods and outcomes (Hirayama et al., 2008). Among patients with RPGN, 6.6% had anti-
GBM disease. In comparison with foreign countries, this Japanese rate of anti-GBM disease 
in RPGN was lower.  
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GN 2nd GN RPGN 
Rychlík et al. 2004 Czech 0.17 0.31 * 1.2 *  
Heaf et al. 1999 Denmark 0.6   12.8 + 
Andrassy et al. 1991 Germany 0.55   7.9 
Daly et al. 1996 Ireland  2.4 *   
Schena et al. 1997 Italy 0.1 0.20 * 1.5 *  
Grcevska et al. 1995 Macedonia    3.6 + 
Naumovic et al. 2009 Serbia 0.02 0.18 * 0.74 *  
Rivera et al. 2002 Spain    14.6 + 
Saxena et al. 1991 Sweden    13.4 + 
Williams et al. 1988 United Kingdom 1.12(0.2 – 4.0)    
Angangco et al. 1994 United Kingdom  0.81 *  11.2 + 
Parfrey et al. 1985 Canada    11.5 + 
Wilson and Dixon 1973 United States  7.0 *   
Jennette 1993 United States    14.6 + 
Briganti et al. 2001 Australia 0.99 0.8 *   
NZGS 1989 New Zealand  5.9 *   
Date et al. 1987 India  0.04 *   
Sumethkul et al. 1999 Thai  0.10 *  3.3 + 
Tang et al. 2003 China  0.15 *  8.7 + 
Li, FK. et al. 2004 China(HongKong) 0.6    
Li, LS. et al. 2004 China  0.21 * 0.86 *  
Hirayama et al. 2008 Japan    6.6 
The incidence of patients with anti-GBM disease is expressed as the number per 1 million population per year. 
The frequencies of patients with anti–GBM disease in glomerulonephritis, secondary glomerulonephritis or 
rapidly progressive glomerulonephritis are expressed as percentages. *Biopsy-proven glomerulonephritis. 
Blanks are unavailable data. Abbreviations: yr, years; GN, glomerulonephritis; 2nd GN, secondary 
glomerulonephritis; RPGN, rapidly progressive glomerulonephritis (including +necrotizing and/or crescentic 
glomerulonephritis); NZGS, The New Zealand Glomerulonephritis Study.  
Table 1. Prevalence of anti–GBM disease in various countries.  
All age groups are affected, but the peak incidence of anti-GBM disease is in the third 
decade in young men, with a second peak in the sixth and seventh decades affecting men 
and women equally (Figure 1). Alveolar hemorrhage is more common in younger men, 
while isolated renal disease is more frequent in the elderly, with a near-equal gender 
distribution. In that survey (Hirayama et al., 2008), the mean age at onset of renal-limited 
anti-GBM disease was 52.6±17.0 years. There was only one peak incidence of anti-GBM 
disease, and this peak occurred in the fifth and sixth decades. The gender distribution was 
nearly equal in renal-limited anti-GBM disease (male: female = 1: 0.94).  
 














< 20 20-29 30-39 40-49 50-59 60-69 > 70
Herody et al. (1993, France) Daly et al. (1996, Ireland)
Savage et al. (1985, United Kingdom) Williams et al. (1988, United Kingdom)
Levy et al. (2001, United Kingdom) Briggs et al. (1979, United States)
Johnson et al. (1985, United States) NZGS (1989, New Zealand)
Li et al. (2004, China) Cui et al. (2005, China)









< 20 20-29 30-39 40-49 50-59 60-69 > 70
Shah et al. (2002, various) Herody et al. (1993, France)
Savage et al. (1986, United Kingdom) Levy et al. (2001, United Kingdom)
Briggs et al. (1979, United States) Johnson et al. (1985, United States)
Teague et al. (1978, New Zealand) Simpson et al. (1982, New Zealand)
Li et al. (2004, China) Hirayama et al. (2008, Japan)
 
Fig. 1. Investigations of age distribution in anti-GBM disease (upper) and Goodpasture’s 
syndrome (lower). 
The histograms show the number of patients with anti-GBM disease classified by patient 
age at the onset of the disease. Abbreviations: GN, glomerulonephritis; Biopsy, biopsy-
proven glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; NZGS, The 
New Zealand Glomerulonephritis Study; N.A., not available. 
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Fig. 1. Investigations of age distribution in anti-GBM disease (upper) and Goodpasture’s 
syndrome (lower). 
The histograms show the number of patients with anti-GBM disease classified by patient 
age at the onset of the disease. Abbreviations: GN, glomerulonephritis; Biopsy, biopsy-
proven glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; NZGS, The 
New Zealand Glomerulonephritis Study; N.A., not available. 
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Alveolar hemorrhage is observed in 35-62% of patients with anti-GBM disease in Europe, 
the United States, and China, and it is more common in younger patients and in men, 
whereas renal-limited anti-GBM disease is more common in older patients and in women. In 
Japan, alveolar hemorrhage of patients with anti-GBM disease was less frequent (23.4%) and 
the age at onset of Goodpasture’s syndrome was lower (49.4±14.4 years), but it was more 
common in females (male: female = 1: 1.75).  
This disease appears to be more common in Caucasians and very rare in those of African 
origin (Pusey, 2003; Ooi et al., 2008). There is apparently a higher incidence of onset of 
Goodpasture’s disease in the spring and summer, as well as localized clustering of the 
disease, perhaps suggesting an infectious relationship (Pusey, 2003). Anecdotal associations 
with urinary tract infections and lithotripsy, which may subclinically affect the glomerular 
basement membrane, have also been reported (Pusey, 2003; Ooi et al., 2008).  
3. Pathogenesis 
In 1934, Masugi reported nephrotoxic glomerulonephritis induced by anti-kidney serum in 
an experimental model (Masugi, 1934), after which a linear binding of IgG to glomerular 
capillary walls was detected by direct immunofluorescence (Ortega & Mellors, 1956). In 
1964, a linear immunostaining of IgG was observed in 2 patients with Goodpasture’s 
syndrome (Scheer & Grossman, 1964), and in another study the kidney serum of patients 
with Goodpasture’s syndrome and of patients with crescentic glomerulonephritis without 
alveolar hemorrhage contained antibodies that reacted with the GBM of humans and 
animals (Lerner et al., 1967). Those authors also demonstrated that those anti-GBM 
antibodies caused glomerulonephritis when injected into animals.  
3.1 Structure of GBM 
GBM, which exists between endothelial cells and podocytes, consists of type IV collagen, 
heparansulphate proteoglycan, laminine and fibronectin. Type IV collagen, which consists 
of 3 of 6 alpha-chains (α1 to α6) encoded by three pairs of genes on chromosomes 2, 13 and 
X, and its molecules were trimeric (α1α1α2, α3α4α5 and α5α5α6). This basement membrane, 
found in kidney, lung, cochlea and eye, comprises the surface on which epithelial cells rest. 
In kidneys, α3α4α5 molecules were found in the GBM, particularly the epithelial side; 
α1α1α2 molecules were in the mesangium, the endothelial side of the GBM, tubular 
basement membranes and Bowman’s capsule; and α5α5α6 molecules were in tubular 
basement membranes and Bowman’s capsule. Each alpha-chain was made by one long 
collagenous domain and two terminal noncollagenous globular domains: the C-terminal 
noncollagenous (NC1) domain and the N-terminal domain (the 7S domain). Mature GBM is 
a lattice-like structure comprised in part by heterotrimers of α3, 4 and 5 chains, which form 
a triple helix with short NC1 and 7S domains (Sado et al., 1998). The NC1 domain of the α3 
chain of a tissue-specific type IV collagen [α3(IV)NC1] monomer is structured into the 
collagen IV network through the association of α3, α4 and α5 chains to form a triple helical 
protomer and through the oligomerization of these protomers via end-to-end associations 
and intertwining of triple helixes (Hudson et al., 2003).  
3.2 Anti-GBM antibodies 
The target of the anti-GBM antibodies was identified as α3(IV)NC1 (Saus et al., 1988). The 
two conformational epitopes of anti-GBM antibodies have been defined as EA and EB 
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(Kalluri et al., 1996; Borza et al., 2000). The EA epitope is 17-31 amino acids on the  
N-terminal side, and the EB epitope is 127-141 amino acids on the C-terminal side (Netzer et 
al., 1999). Alterations of the amino acid sequence translated by the COL4A3 gene, which 
encodes α3(IV)NC1, are not major factors, because no mutation of the COL4A3 gene was 
found (Persson et al., 2004). It was suggested that EA and EB, as cryptic B-cell epitopes, were 
enclosed in the quaternary structure of the hexamers created by sulfilimine crosslinks 
between the trimers of adjacent NC1 chains (Vanacore et al., 2008, 2009). Recently, in 
patients with Goodpasture’s disease, elevated autoantibody titers to α3(IV)NC1 and 
α5(IV)NC1 monomers at diagnosis were associated with the eventual loss of renal function 
(Pedchenko et al., 2010). In that study, these anti-GBM antibodies bound to specific epitopes 
that encompassed region EA in the α5(IV)NC1 monomer and regions EA and EB in the 
α3(IV)NC1 monomer, but did not bind to the native crosslinked α345(IV)NC1 hexamer. 
Thus, it is a dissociation of the NC1 hexamers that expose the pathogenic epitopes on the α3 
and α5 chains, precipitating the production of anti-GBM antibodies (Pedchenko et al., 2010). 
It was suggested that the autoantibody itself may subsequently alter antigen conformation 
and expose further epitopes, causing an epitope-spreading phenomenon (Salant, 2010).  
3.3 Crescent formations 
The anti-GBM antibody bound to GBM ligates Fc receptors, leading to the activation of 
monocytes, neutrophils, eosinophils, basophils and macrophages. These release chemokines 
that attract a further influx of neutrophils into glomeruli, causing severe tissue injury, 
including the disruption of the GBM. Renal injury in anti-GBM disease is amplified by the 
activation of complements and protease after the binding (Sheerin et al., 1997; Baricos et al., 
1991). The release of reactive oxygen species by neutrophils is also probably an important 
pathogenic mechanism of tissue injury.  
The histogenesis and origin of cellular crescents, which are cap-like multilayered 
accumulations of proliferating cells, have remained controversial. Although early 
ultrastructural studies suggested that crescents are formed by proliferating epithelial cells 
(Morita et al., 1973; Min et al., 1974), subsequent histochemical studies with antibodies 
against leukocytes identified the presence of monocytes-macrophages in cellular crescents 
(Atkins et al., 1976; Thomson et al., 1979). It was demonstrated that epithelial cells 
predominated in crescents of patients during the early phases of disease; later phases were 
characterized by rupture of the basement membrane of Bowman’s capsule and subsequent 
infiltration of cellular crescents, predominantly by macrophages (Boucher et al., 1987). The 
composition of cellular crescents may change during the progression of disease after the 
inciting glomerular injury (Ophascharoensuk et al., 1998).  
The main stimulus to the migration of macrophages and neutrophils is probably the 
exudation of fibrin in Bowman’s space caused by the disruption of the GBM and Bowman’s 
capsule (Tipping et al., 1988). Several possible causes of acute renal injury in anti-GBM 
disease were identified, including the functional roles of a number of macrophage 
proinflammatory mediators, such as IL-1 (Lan et al., 1993), TNF-alpha (Lan et al., 1997; Le 
Hir et al., 1998) and matrix metalloproteinase (Kaneko et al., 2003). In epithelial crescent 
formation in the glomerulus, thrombin generated by coagulation (He et al., 1991) and 
growth-factor cytokines (IL-1 and IL-2) released by monocytes and platelets (Adler et al., 
1990) stimulate the migration of epithelial cells. Moreover, interleukin-12 (Kitching et al., 
1999) and interferon-γ (Timoshanko et al., 2002) are also involved.  
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3.4 Environmental and genetic factors 
Environmental factors are thought to play a role in triggering the disease. In the first case of 
Goodpasture’s syndrome, intercurrent infection amplifies the intensity of inflammatory 
responses and can aggravate disease and so make it clinically apparent. There are a number 
of case reports of clusters of patients with anti-GBM disease (Perez et al., 1974), which may 
implicate an infective agent; however, no clear viral association has been identified. Group 
A type 12 streptococcal cell membrane shares some cross-reactivity with the human 
glomerular basement membrane, generating another hypothesis: that infection may initiate 
anti-GBM antibody production (Blue & Lange, 1975).  
Goodpasture’s syndrome has been noted to occur more frequently in smokers (Salama et al., 
2001). Lazor et al. (2007) reported that 89% of their patients with Goodpasture’s syndrome 
were active smokers. In another study, alveolar hemorrhage was present in 100% of patients 
who smoked and in only 20% of nonsmokers with Goodpasture’s disease (Donaghy & Rees, 
1983). No significant difference in circulating anti-GBM antibody titers was found between 
smokers and nonsmokers, suggesting that cigarette smoking may increase the permeability 
of lung capillaries and thus expose alveolar basement membranes to circulating anti-GBM 
antibodies (Donaghy & Rees, 1983; Klasa et al., 1988). Other inhaled substances may also be 
associated with anti-GBM disease, including cocaine (García-Rostan y Pérez et al., 1997; 
Lazor et al., 2007), hard metals such as inert tungsten carbide and cobalt (Lechleitner et al., 
1993), smoke inhalation (Klasa et al., 1988) and possibly volatile hydrocarbon solvents 
(Beirne & Brennan, 1972; Bombassei & Kaplan, 1992). In particular, hydrocarbon exposure 
may influence the development of alveolar hemorrhage (Churchill et al., 1983; Bonzel et al., 
1987). Another environmental factor, alemtuzumab, which is a humanized anti-CD52 
monoclonal antibody, recently was identified as a cause of anti-GBM disease (Clatworthy et 
al., 2008).  
Genetic factors appear to play a role in susceptibility to anti-GBM disease. As a genetic 
factor of anti-GBM disease, the human leukocyte antigen (HLA) complexes are known to 
influence susceptibility to anti-GBM disease. A strong association with HLA-DR2 specificity 
has been confirmed (Rees et al., 1978). In HLA genotyping, DRB1*1501 (the serologically 
defined HLA-DR2 gene) and DRB1*1502 (HLA-DR15 gene) allele at the DRB1 locus is 
associated with anti-GBM disease in Caucasians (Fisher et al., 1997), Chinese (Yang et al., 
2009) and Japanese (Kitagawa et al., 2008). The strongest association was with HLA 
DRB1*1501 but, when the effect of this gene was excluded, subsequent analysis revealed an 
increased frequency of DRB1*04 and DRB1*03 and a decreased frequency of DRB1*07 and 
DRB1*01 (Phelps & Rees, 1999). Other genetic influences of anti-GBM disease have been 
identified, including the immunoglobulin heavy chain Gm locus that encodes the constant 
region of the IgG heavy chain (Rees et al., 1984), polymorphisms of FCGR genes that encode 
the Fc receptor for IgG (FcγR) (Zhou et al., 2010a, 2010b) and kallikrein genes (Liu et al., 
2009).  
4. Clinical symptoms 
General malaise (fatigue), weight loss, fever, arthralgia or myalgia may be the initial features 
of anti-GBM disease in a pattern similar to but much less prominent than that in systemic 
vasculitis. Symptoms relating to anemia may also occur even in the absence of significant 
hemoptysis.  
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Authors Year Nation 
symptoms








Shah et al. * 2002 Various 15% 28% 26% 65% 7% 17% (8/54) (15/54) (14/54) (35/54) (4/54) (9/54) 
Lazor et al. 2007 France & Switzerland 
64% 43% 79% 75% 36% 18% 
(18/28) (12/28) (22/28) (21/28) (10/28) (5/28) 
Merkel et al. 1994 Germany 40% 28% 14% 51% 20% N.A. (14/35) (10/35) (5/35) (18/35) (7/35) 
Daly et al. 1996 Ireland N.A. N.A. N.A. 25% 35% 50% (10/40) (14/40) (20/40) 
Williams et al. 1988 United Kingdom N.A. N.A. 
10% 10% 10% 60% 
(1/10) (1/10) (1/10) (6/10) 
Proskey et al. * 1970 United States 
51% 22% 57% 82% 12% N.A. (29/56) (12/56) (32/56) (46/56) (7/56) 
Wilson et al. 1973 United States
34% 14% 32% 46% 42% 10% 
(17/50) (7/50) (16/50) (23/50) (21/50) (5/50) 
Briggs et al. 1979 United States
22% 11% 44% 50% 56% N.A. (4/18) (2/18) (8/18) (9/18) (10/18) 
Walker et al. 1985 Australia N.A. N.A. N.A. 62% N.A. 62% (13/21) (13/21) 
Teague et al. * 1978 New Zealand
68% 26% 78% 86% 43% N.A. (19/28) (7/27) (21/27) (25/29) (12/28) 









Cui et al. 2005 China N.A. N.A. N.A. 59% 27% 52% (57/97) (26/97) (50/97) 
Hirayama et al. 2008 Japan 53% 57% 6% 15% 19% 28% (25/47) (27/47) (3/47) (7/47) (9/47) (13/47) 
The frequencies of patients with each symptom are expressed as percentages. *All investigated patients 
had Goodpasture’s syndrome. Abbreviations: N.A., not available. 
Table 2. Investigations of clinical symptoms in anti-GBM disease at the initial presentation.  
The principal clinical features relate to the development of renal failure due to RPGN or 
alveolar hemorrhage (Table 2). Hemoptysis is the predominant symptom of alveolar 
hemorrhage. Alveolar hemorrhage may cause severe impairment of oxygenation, so 
intensive care and artificial ventilation are sometimes needed. The mild lung symptoms are 
only dry cough and shortness of breath. Although one-third to two-thirds of patients with 
anti-GBM disease demonstrate alveolar hemorrhage in general, in our survey, 23.4% (11/47) 
of patients with anti-GBM disease suffered from alveolar hemorrhage (Hirayama et al., 
2008). A minority of patients exhibited macrohematuria. Anirua or oliguria was seen in 17-
62% of patients at presentation, and these findings suggested a poorer prognosis (Levy et al., 
2001; Hudson et al., 2003).  
5. Laboratory examinations 
In general, all patients with anti-GBM disease had microscopic hematuria on urinalysis. 
Proteinuria is modest, but can be heavier when the disease has a more subacute course. In 
our survey (Hirayama et al., 2008), the mean 24-hour excretion of urinary protein in renal-
limited anti-GBM disease was 2.1±3.0 g and that of Goodpasture’s syndrome was 3.7±3.2 
g.  
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Briggs et al. 1979 United States
22% 11% 44% 50% 56% N.A. (4/18) (2/18) (8/18) (9/18) (10/18) 
Walker et al. 1985 Australia N.A. N.A. N.A. 62% N.A. 62% (13/21) (13/21) 
Teague et al. * 1978 New Zealand
68% 26% 78% 86% 43% N.A. (19/28) (7/27) (21/27) (25/29) (12/28) 









Cui et al. 2005 China N.A. N.A. N.A. 59% 27% 52% (57/97) (26/97) (50/97) 
Hirayama et al. 2008 Japan 53% 57% 6% 15% 19% 28% (25/47) (27/47) (3/47) (7/47) (9/47) (13/47) 
The frequencies of patients with each symptom are expressed as percentages. *All investigated patients 
had Goodpasture’s syndrome. Abbreviations: N.A., not available. 
Table 2. Investigations of clinical symptoms in anti-GBM disease at the initial presentation.  
The principal clinical features relate to the development of renal failure due to RPGN or 
alveolar hemorrhage (Table 2). Hemoptysis is the predominant symptom of alveolar 
hemorrhage. Alveolar hemorrhage may cause severe impairment of oxygenation, so 
intensive care and artificial ventilation are sometimes needed. The mild lung symptoms are 
only dry cough and shortness of breath. Although one-third to two-thirds of patients with 
anti-GBM disease demonstrate alveolar hemorrhage in general, in our survey, 23.4% (11/47) 
of patients with anti-GBM disease suffered from alveolar hemorrhage (Hirayama et al., 
2008). A minority of patients exhibited macrohematuria. Anirua or oliguria was seen in 17-
62% of patients at presentation, and these findings suggested a poorer prognosis (Levy et al., 
2001; Hudson et al., 2003).  
5. Laboratory examinations 
In general, all patients with anti-GBM disease had microscopic hematuria on urinalysis. 
Proteinuria is modest, but can be heavier when the disease has a more subacute course. In 
our survey (Hirayama et al., 2008), the mean 24-hour excretion of urinary protein in renal-
limited anti-GBM disease was 2.1±3.0 g and that of Goodpasture’s syndrome was 3.7±3.2 
g.  
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Shah et al. 2002 Various N.A. 6.62 35% (27/78) (N.A.)
Herody et al. 1993 France N.A. N.A. 55% (16/29) 
Lazor et al. 2007 France & Switzerland 
1.2 1.27 41% 
(0 – 35.0) (0.61 – 21.47) (11/28) 
Andrassy et al. 1991 Germany 6.4 12.8 67% (0 – 15.3) (6.1 – 16.5) (2/3) 
Merkel et al. 1994 Germany N.A. 11.41 ± 5.64 71% (0.2 – 3.5) (0.19 – 22.96) (20/28) 
Daly et al. 1996 Ireland N.A. 5.1 ± 6.8 50% (N.A.) (20/40) 
Segelmark et al. 2003 Sweden N.A. 8.94 46% (5.44 – 12.34) (36/79) 
Savage et al. 1986 United Kingdom N.A. N.A. 64% (69/108) 
Williams et al. 1988 United Kingdom N.A. 11.80 ± 4.67 70% (1.60 – 18.37) (7/10) 
Levy et al. 2001 United Kingdom N.A. 3.59 55% (0.6 – 10.9) (39/71) 
Briggs et al. 1979 United States 2.6 ± 0.5 5.94 ± 7.11 33% (1.9 – 3.5) (0.8 – 30.0) (6/18) 
Johnson et al. 1985 United States 4.3 ± 5.2 4.87 ± 6.93 12% (0 – 22.0) (0.9 - 25.0) (2/17) 
Jennette  2003 United States 1.67 ± 3.35 9.7 ± 7.2 N.A. (0.20- 16.20) (0.8 - 50)
Walker et al. 1985 Australia 1.4 6.56 45% (0.4 – 5.4) (1.24 – 32.35) (10/22) 
Simpson et al. 1982 New Zealand N.A. 5.37 ± 5.22 10% (0.68 – 19.80) (2/20) 
Teague et al. 1978 New Zealand N.A. N.A. 14% (4/29) 
Li et al. 2004 China(Hong Kong) N.A. 
6.96 ± 6.41 50% 
(1.19 – 22.09) (5/10) 
Cui et al. 2005 China N.A. N.A. 71% (69/97) 
Hirayama et al 2008 Japan 2.4 ± 3.0 7.29 ± 4.19 60% (0.1 – 12.2) (1.00 – 16.80) (28/47) 
Amounts of urinary protein and serum creatinine levels are expressed as means ± standard deviation or 
medians with ranges. Frequency of end-stage renal failure at presentation is expressed as a percentage. 
To convert serum creatinine in mg/dL to μmol/L, multiply by 88.4. Abbreviations: ESRD, end-stage 
renal disease; N.A., not available. 
Table 3. Investigations of renal findings in anti-GBM disease at the initial presentation.  
Unfortunately, most patients with anti-GBM disease had renal failure at the time of 
diagnosis, and the number of patients needing dialysis was not a few (Table 3). In our 
survey (Hirayama et al., 2008), the mean serum creatinine (s-Cr) level in renal-limited anti-
GBM disease was 7.07±4.21 mg/dl, while that in Goodpasture’s syndrome was 7.99±4.31 
mg/dl. Hemodialysis therapy had already been initiated in 59.6% (28/47) of the anti-GBM 
disease patients before the start of immunosuppressive treatments.  
Anemia was observed in most patients with anti-GBM disease, and the mean hemoglobin 
concentration in renal-limited anti-GBM disease was 8.8±1.7 g/dl, while that in 
Goodpasture’s syndrome was 7.5±1.1 g/dl. The mean erythrocyte sedimentation rate (ESR) 
in renal-limited anti-GBM disease was 105±44 mm/h, and that in Goodpasture’s syndrome 
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was 82±45 mm/h. The mean serum C-reactive protein (CRP) level in renal-limited anti-GBM 
disease was 8.5±7.2 mg/dl, and that in Goodpasture’s syndrome was 8.2±8.1 mg/dl. In 
comparison with other forms of RPGN, such as micropolyangiitis (MPA) and Wegener’s 
granulomatosis (WG), there was no difference in inflammation markers such as leukocyte 
count, ESR and serum CRP. However, in patients with anti-GBM disease, the mean level of 
s-Cr at the time of diagnosis was higher than that in patients with MPA (4.54±3.13 mg/dl) or 
WG (3.84±3.24 mg/dl). Therefore, early diagnosis of anti-GBM disease is very important.  
Although obvert hemoptysis may not be immediately present in patients with Goodpasture’s 
syndrome and alveolar hemorrhage may not be immediately obvious in radiological 
examinations, an elevated alveolo-arterial oxygen difference (AaPO2) can be a sensitive 
indicator of alveolar hemorrhage. An elevated red blood cell count in bronchoalveolar lavages, 
as detected by bronchoscopy, is useful information for the diagnosis of alveolar hemorrhage, 
but lung biopsy does not contribute to this diagnosis (Lazor et al., 2007).  
The diagnosis of anti-GBM disease is dependent on the detection of anti-GBM antibodies in 
either the circulation or the kidney tissue. These serum antibodies are usually detected using 
an enzyme-linked immunosorbent assay or radioimmunoassay method. The antibodies 
have not been reported to occur in the absence of disease, and false negatives are rare when 
appropriate checks are performed. In our survey (Hirayama et al., 2008), 91.5% (43/47) of 
patients with anti-GBM disease were diagnosed via the detection of serum anti-GBM 
antibodies.  
In serological examinations, other autoantibodies were not usually detected. However, in 
our survey (Hirayama et al., 2008), anti-nuclear antibodies were detected in 11.8% of renal-
limited anti-GBM disease and in 27.3% of patients with Goodpasture’s syndrome. Anti-
DNA antibody was not detected in renal-limited anti-GBM disease, but it was detected in 
22.2% of patients with Goodpasture’s syndrome. Moreover, anti-neutrophil cytoplasmic 
antibodies (ANCA) were detected in 12.8% (5/39) of patients with anti-GBM disease; a 
perinuclear pattern was detected in all five anti-GBM disease patients with ANCA, and a 
cytoplasmic pattern was detected in one. Anti-GBM antibody and ANCA coexisted in 15 - 
50% of cases of anti-GBM disease described in the previous literature (Jayne et al., 1990; 
Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005; Levy et al., 2004). Other studies 
revealed that patients with double-positive antibodies were predominantly MPO-ANCA, 
older and male (Jayne et al., 1990; Bosch et al., 1991; Yang et al., 2005; Rutgers et al., 2005). In 
our survey (Hirayama et al., 2008), the age at onset of patients with double-positive 
antibodies was higher (mean age, 52.6 years), but female-dominant (male : female = 1 : 4). 
The prognosis of patients with double-positive antibodies varied; the renal and patient 
survival rates of patients with double-positive antibodies were reported to be either better 
(Jayne et al., 1990; Bosch et al., 1991), not significantly different (Yang et al., 2005), or worse 
(Rutgers et al., 2005; Levy et al., 2004) than those of patients with anti-GBM antibody alone. 
In our survey (Hirayama et al., 2008), the prognosis of patients with double-positive 
antibodies was poor; two died and the remaining three required maintenance hemodialysis. 
Alveolar hemorrhage was observed in two of five patients with double-positive antibodies, 
and three of them had interstitial pneumonitis.  
6. Imaging examinations 
Kidneys were usually normal-sized or enlarged due to inflammation. In our survey 
(Hirayama et al., 2008), ultrasonography showed that 61.0% of patients with anti-GBM 
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disease had kidneys of normal size, while atrophic kidneys were observed in 12.2% of 
patients and enlarged kidneys were observed in 26.8%. There were no specific 
morphological abnormalities on any type of renal imaging examinations.  
In cases with Goodpasture’s syndrome, shadows usually involve the central lung fields with 
peripheral and upper-lobe sparing on chest radiography or computed tomography  




Fig. 2. Chest computed tomography in a patient with Goodpasture’s syndrome. 
Symmetrical shadows involved the central lung fields with peripheral sparing. Bilateral 
pleural effusions due to hypervolemia in acute kidney injury were also observed.  
7. Pathological findings 
A renal biopsy is essential in suspected anti-GBM disease both to confirm the diagnosis and 
to assess the renal prognosis. Glomerular fibrinoid necrosis and crescent formation with 
linear staining of the glomerular capillary walls for IgG are the histological hallmarks of 
anti-GBM disease.  
7.1 Light microscopic findings 
The histological pattern of disease starts with mesangial expansion and hypercellularity. It 
progresses to focal and segmental glomerulonephritis with infiltration by inflammatory 
cells, accompanied by segmental necrosis with prominent breaks in the GBM. Later, 
glomeruli develop an extensive crescent formation composed of parietal epithelial cells and 
macrophages in association with the destruction of the GBM (Figure 3). The crescents are 
usually at the same stage of evolution.  
 




Fig. 3. Periodic acid-Schiff methenamine silver (PAM)−stained glomerulus in a patient with 
anti-GBM disease. 
The disruption of the capillary walls, segmental necrosis and cellular crescent formation are 
observed. Rupture of the basement membrane of Bowman’s capsule and periglomerular 
infiltration of inflammatory cells are also observed. Interstitial edema with infiltration of 
inflammatory cells is revealed.  
Various degrees of crescent formation are observed in more than 90% of patients with anti-
GBM disease. In Europe, the United States and Asian-Pacific, including Japan, the mean 
percentage of glomeruli showing crescent formation ranged from 40% to 100%, and about 
70% to 100% of patients with anti-GBM disease had more than 50% crescentic glomeruli 
(Figure 4). Anti-GBM disease is pathologically the most severe form of glomerulonephritis 
(Holdsworth et al., 1985; Jennette, 2003, Hirayama et al., 2008).  
Although tubules are usually normal, epithelial flattening is revealed in the severe acute 
phase. In the chronic phase, tubules in the area of severe injury undergo atrophy and some 
disappear. Acute tubulitis sometimes occurs if there is a linear staining of tubular basement 
membranes for IgG. Interstitial edema with infiltration of inflammatory cells is predominant 
in the acute phase, whereas interstitial fibrosis is revealed in the chronic phase. Interstitial 
infiltrates are composed of neutrophils, eosinophils, lymphocytes, monocytes and 
macrophages. If Bowman’s capsules are disrupted, inflammatory cells infiltrate around 
glomeruli and have a granulomatous appearance. Acute inflammation of renal vessels, 
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except for glomerular capillaries, is not typical for anti-GBM disease, unless the case has 
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Fig. 4. Previous investigations of crescent formation in anti-GBM disease and ANCA-
associated vasculitis. 
Each bar shows the frequency of patients with 50% or more crescents in anti-GBM disease 
(purple) and ANCA-associated vasculitis (blue). The numbers show the mean percentage of 
glomeruli showing crescent formation in anti-GBM disease. Abbreviations: UK, United 
Kingdom; USA, United States; NZ, New Zealand. 
7.2 Immunofluorescence findings 
The immunohistologic feature of anti-GBM disease is linear staining of the glomerular 
capillary walls for IgG (Figure 5). IgG1 is the predominant IgG subclass in staining of the 
glomerular capillary walls (Bowman et al., 1987; Segelmark et al., 1990). Linear staining for 
IgM and IgA is less common, but rare cases with anti-GBM disease have linear staining only 
for IgA and circulating IgA-class anti-GBM antibodies in the absence of IgG-class anti-GBM 
antibodies in the serum or staining in glomeruli (Border et al., 1979; Gris et al., 1991; Borza et 
al., 2005). Granular or discontinuous linear staining for C3 is observed in most cases with 
anti-GBM disease, but glomerular staining for C3 is negative for some cases (Wilson and 
Dixon, 1973). Irregular staining for fibrin is observed in portions of glomerular necrosis and 
cellular crescents.  
Linear staining of tubular basement membranes for IgG sometimes occurs (Lehman et al., 
1975; Andres et al., 1978).  
 




Fig. 5. Direct immunofluorescence for IgG in a patient with anti-GBM disease. 
Linear staining for IgG along glomerular capillary walls is observed, but staining for IgG at 
the part of the cellular crescent is not.  
7.3 Electroscopic findings 
The rupture of GBM with variable degrees of endothelial swelling and lucent expansion of 
the subendothelial zone is common urtrasturactural findings in the acute phase of anti-GBM 
disease. Rupture of Bowman’s capsule, focal effacement of epithelial foot processes and 
accumulation of epithelial cells and macrophages in Bowman’s spaces are also observed. 
Occasionally, neutrophils are identified in capillaries, especially at sites where GBM is 
disrupted. Those findings are also observed in pauci-immune crescentic glomerulonephritis, 
but electron-dense deposits are absent, unlike the case with immune complex-type 
crescentic glomerulonephritis.  
8. Treatments 
As the pathogenesis of anti-GBM disease became clear, treatment regimens were designed 
to remove the circulating pathogenic anti-GBM antibodies by therapeutic plasma exchange, 
attenuate the pathogenic antibody-mediated glomerular inflammatory responses by 
administration of corticosteroids and suppress further production of these pathogenic 
antibodies by the use of immunosuppressive agents.  
8.1 Therapeutic plasmapheresis 
To remove the circulating pathogenic anti-GBM antibodies, therapeutic plasma exchange is 
recommended as the initial treatment. The effectiveness of therapeutic plasmapheresis for 
improving renal function has been reported. In the most commonly used regimens, plasma 
exchange of 4 L of plasma for 5% human albumin was performed daily for 14 days or until 
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1975; Andres et al., 1978).  
 




Fig. 5. Direct immunofluorescence for IgG in a patient with anti-GBM disease. 
Linear staining for IgG along glomerular capillary walls is observed, but staining for IgG at 
the part of the cellular crescent is not.  
7.3 Electroscopic findings 
The rupture of GBM with variable degrees of endothelial swelling and lucent expansion of 
the subendothelial zone is common urtrasturactural findings in the acute phase of anti-GBM 
disease. Rupture of Bowman’s capsule, focal effacement of epithelial foot processes and 
accumulation of epithelial cells and macrophages in Bowman’s spaces are also observed. 
Occasionally, neutrophils are identified in capillaries, especially at sites where GBM is 
disrupted. Those findings are also observed in pauci-immune crescentic glomerulonephritis, 
but electron-dense deposits are absent, unlike the case with immune complex-type 
crescentic glomerulonephritis.  
8. Treatments 
As the pathogenesis of anti-GBM disease became clear, treatment regimens were designed 
to remove the circulating pathogenic anti-GBM antibodies by therapeutic plasma exchange, 
attenuate the pathogenic antibody-mediated glomerular inflammatory responses by 
administration of corticosteroids and suppress further production of these pathogenic 
antibodies by the use of immunosuppressive agents.  
8.1 Therapeutic plasmapheresis 
To remove the circulating pathogenic anti-GBM antibodies, therapeutic plasma exchange is 
recommended as the initial treatment. The effectiveness of therapeutic plasmapheresis for 
improving renal function has been reported. In the most commonly used regimens, plasma 
exchange of 4 L of plasma for 5% human albumin was performed daily for 14 days or until 
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the circulating anti-GBM antibodies were no longer detected (Lockwood et al., 1976). In the 
presence of alveolar hemorrhage, 300-400 ml of fresh-frozen plasma was given at the end of 
each treatment.  
To reduce the replacement of plasma,  anti-GBM antibody removal has been modified. 
Immunoadsorption to remove circulating IgG immunoglobulins without the need for 
protein substitution during daily treatments may also be beneficial in Goodpasture’s 
disease. Anecdotal case reports suggest that it may be an alternative to plasmapheresis in 
patients with severe renal failure (Laczika et al., 2000). There was a case report of 
Goodpasture’s syndrome that we treated with double filtration plasmapheresis combined 
with immunosuppression therapy (Nagasu et al., 2009). In that therapy, the removal 
efficiency for the anti-GBM antibody was 24 to 60% for each procedure.  
8.2 Corticosteroids 
To attenuate the pathogenic antibody-mediated glomerular inflammatory responses, 
corticosteroid is also a key element of this treatment. According to the most commonly used 
regimens, oral dosing of prednisolone at 1 mg/kg/day ideal body weight (maximum 80 mg 
daily) continues for at least 2 weeks, after which the dose is reduced every second week to 
30 mg by 8 weeks. After that, the dosages of prednisolone are tapered to 2.5-5.0 mg/week 
and maintained at 7.5-10 mg/kg/day. Oral corticosteroids have generally been continued 
for at least 6 months. Intravenous administration of methylprednisolone 10 mg/kg (500-
1000 mg) once daily for 1-3 days has been advocated for patients with severe alveolar 
hemorrhage or very rapid deterioration of renal function (Johnson et al., 1985).  
8.3 Immunosuppressive agents 
To further suppress the production of pathogenic anti-GBM antibodies, a combination of 
immunosuppressive agents is usually given. Among these immunosuppressive agents, 
cyclophosphamide is usually administered. According to the most commonly used 
regimens, the oral dose is 2-3 mg/kg/day (this is rounded down to the nearest 50 mg; 
reduced to 2 mg/kg/day in patients over 55 years) for 3 months. This administration is 
stopped if white blood cell counts fall below 4,000/μL. In such cases the agent is restarted at 
a lower dose once the white blood cell counts return above 4,000/μL. Intravenous 
cyclophosphamide (IVCY) is not usually administered, but it may be useful for a refractory 
case of the standard therapy (Baumgartner et al., 1995).  
Although azathioprine is sometimes used as maintenance therapy, it alone does not provide 
adequate immunosuppression to modify the disease.  
8.4 Therapeutic options for refractory diseases 
There is very little study on the treatment of refractory anti-GBM disease. Cyclosporine is 
controversial; at 6 mg/kg/day it was effective for an anti-GBM disease patient treated with 
corticosteroid, cyclophosphamide and plasma exchange (Querin et al., 1992), whereas it was 
not useful (Pepys et al., 1982). Small numbers of case reports of successful outcomes with 
mycophenolic acid or mycophenolate mofetil in patients unresponsive to or intolerant of 
standard therapy have been published (Garcia-Canton et al., 2000; Kiykim et al., 2010; Malho 
et al., 2010). Rituximab, a chimeric monoclonal anti-CD20 antibody, was effective for a case of 
relapsed anti-GBM disease that was resistant to standard treatment (Arzoo et al., 2002). In that 
case, rituximab (375 mg/m2) was administered once a week for 6 consecutive weeks; the 
symptoms completely resolved and anti-GBM antibody titers were decreased from 51 U/mL 
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to the undetectable range. However, these treatments cannot yet be recommended as a first-
line therapy because no randomized controlled trials have been carried out.  
9. Prognosis 
Most patients without treatment died shortly after diagnosis of anti-GBM disease; the 
survival rate at 12 months was 4%, and the renal survival rate was 2% (Benoit et al., 1963). 
Although mortality has improved by the introduction of intense immunosuppression, renal 
survival remains very poor because of the delayed diagnosis of anti-GBM disease or delayed 
initiation of induction therapies.  
9.1 Outcomes 
The prognosis for patients with anti-GBM disease is poor; the survival rate at 6-12 months 
was 67-94%, but the renal survival rate was 15-58% in Europe, the United States, China and 
Japan (Table 4).  
 
Authors Year Nation Treatment N AH (%) 
1-year survival 
(%) 
Patient  Renal  
Herody et al. 1993 France OCS+CYC+AZA 29 50 93 41 
Lazor et al. 2007 France & Switzerland OCS+CYC+PE 24 100 100 58 
Merkel et al. 1994 Germany OCS+CYC+PE 35 57 89 29 
Daly et al. 1996 Ireland IS+PE 40 67 98 20 
Segelmark et al. 2003 Sweden OCS+CYC+PE 79 24 66 25 
Peters et al. 1982 United Kingdom IS+PE 41 56 76 39 
Savage et al. 1986 United Kingdom IS+PE 108 52 78 20 
Levy et al. 2001 United Kingdom OCS+CYC+PE 71 62 77 53 
Proskey et al. 1970 United States IS 56 100 77 23 
Wilson et al. 1973 United States IS 53 60 53 13 
Beirne et al. 1977 United States IS 29 54 42 17 
Briggs et al. 1979 United States IS(+PE) 18 61 84 22 
Johnson et al 1985 United States OCS+CYC 9 78 89 22 OCS+CYC+PE 8 100 100 75 
Walker et al. 1985 Australia IS+PE 22 62 59 45 
Teague et al. 1978 New Zealand IS+PE 29 100 64 31 
Simpson et al. 1982 New Zealand 
no treatment 8 100 63 25 
OCS+AZA 4 100 100 50 
OCS+CYC+PE 8 100 100 63 
Li et al. 2004 China (Hong Kong) IS+PE 10 40 70 15 
Cui et al. 2005 China IS+PE 97 58 92 22 
Hirayama et al 2008 Japan OCS+CYC 21 14 86 24 OCS+CYC+PE 22 36 68 14 
Abbreviations: N, number of patients; AH, alveolar hemorrhage; IS, immunosuppressants (including 
methylprednisolone pulse therapy, oral corticosteroids, cyclophosphamide or azathioprine);  
PE, plasma exchange; OCS, oral corticosteroids; CYC, cyclophosphamide; AZA, azathioprine. 
Table 4. Investigations of treatments for anti–GBM antibody disease. 
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the circulating anti-GBM antibodies were no longer detected (Lockwood et al., 1976). In the 
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Immunoadsorption to remove circulating IgG immunoglobulins without the need for 
protein substitution during daily treatments may also be beneficial in Goodpasture’s 
disease. Anecdotal case reports suggest that it may be an alternative to plasmapheresis in 
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Goodpasture’s syndrome that we treated with double filtration plasmapheresis combined 
with immunosuppression therapy (Nagasu et al., 2009). In that therapy, the removal 
efficiency for the anti-GBM antibody was 24 to 60% for each procedure.  
8.2 Corticosteroids 
To attenuate the pathogenic antibody-mediated glomerular inflammatory responses, 
corticosteroid is also a key element of this treatment. According to the most commonly used 
regimens, oral dosing of prednisolone at 1 mg/kg/day ideal body weight (maximum 80 mg 
daily) continues for at least 2 weeks, after which the dose is reduced every second week to 
30 mg by 8 weeks. After that, the dosages of prednisolone are tapered to 2.5-5.0 mg/week 
and maintained at 7.5-10 mg/kg/day. Oral corticosteroids have generally been continued 
for at least 6 months. Intravenous administration of methylprednisolone 10 mg/kg (500-
1000 mg) once daily for 1-3 days has been advocated for patients with severe alveolar 
hemorrhage or very rapid deterioration of renal function (Johnson et al., 1985).  
8.3 Immunosuppressive agents 
To further suppress the production of pathogenic anti-GBM antibodies, a combination of 
immunosuppressive agents is usually given. Among these immunosuppressive agents, 
cyclophosphamide is usually administered. According to the most commonly used 
regimens, the oral dose is 2-3 mg/kg/day (this is rounded down to the nearest 50 mg; 
reduced to 2 mg/kg/day in patients over 55 years) for 3 months. This administration is 
stopped if white blood cell counts fall below 4,000/μL. In such cases the agent is restarted at 
a lower dose once the white blood cell counts return above 4,000/μL. Intravenous 
cyclophosphamide (IVCY) is not usually administered, but it may be useful for a refractory 
case of the standard therapy (Baumgartner et al., 1995).  
Although azathioprine is sometimes used as maintenance therapy, it alone does not provide 
adequate immunosuppression to modify the disease.  
8.4 Therapeutic options for refractory diseases 
There is very little study on the treatment of refractory anti-GBM disease. Cyclosporine is 
controversial; at 6 mg/kg/day it was effective for an anti-GBM disease patient treated with 
corticosteroid, cyclophosphamide and plasma exchange (Querin et al., 1992), whereas it was 
not useful (Pepys et al., 1982). Small numbers of case reports of successful outcomes with 
mycophenolic acid or mycophenolate mofetil in patients unresponsive to or intolerant of 
standard therapy have been published (Garcia-Canton et al., 2000; Kiykim et al., 2010; Malho 
et al., 2010). Rituximab, a chimeric monoclonal anti-CD20 antibody, was effective for a case of 
relapsed anti-GBM disease that was resistant to standard treatment (Arzoo et al., 2002). In that 
case, rituximab (375 mg/m2) was administered once a week for 6 consecutive weeks; the 
symptoms completely resolved and anti-GBM antibody titers were decreased from 51 U/mL 
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to the undetectable range. However, these treatments cannot yet be recommended as a first-
line therapy because no randomized controlled trials have been carried out.  
9. Prognosis 
Most patients without treatment died shortly after diagnosis of anti-GBM disease; the 
survival rate at 12 months was 4%, and the renal survival rate was 2% (Benoit et al., 1963). 
Although mortality has improved by the introduction of intense immunosuppression, renal 
survival remains very poor because of the delayed diagnosis of anti-GBM disease or delayed 
initiation of induction therapies.  
9.1 Outcomes 
The prognosis for patients with anti-GBM disease is poor; the survival rate at 6-12 months 
was 67-94%, but the renal survival rate was 15-58% in Europe, the United States, China and 
Japan (Table 4).  
 
Authors Year Nation Treatment N AH (%) 
1-year survival 
(%) 
Patient  Renal  
Herody et al. 1993 France OCS+CYC+AZA 29 50 93 41 
Lazor et al. 2007 France & Switzerland OCS+CYC+PE 24 100 100 58 
Merkel et al. 1994 Germany OCS+CYC+PE 35 57 89 29 
Daly et al. 1996 Ireland IS+PE 40 67 98 20 
Segelmark et al. 2003 Sweden OCS+CYC+PE 79 24 66 25 
Peters et al. 1982 United Kingdom IS+PE 41 56 76 39 
Savage et al. 1986 United Kingdom IS+PE 108 52 78 20 
Levy et al. 2001 United Kingdom OCS+CYC+PE 71 62 77 53 
Proskey et al. 1970 United States IS 56 100 77 23 
Wilson et al. 1973 United States IS 53 60 53 13 
Beirne et al. 1977 United States IS 29 54 42 17 
Briggs et al. 1979 United States IS(+PE) 18 61 84 22 
Johnson et al 1985 United States OCS+CYC 9 78 89 22 OCS+CYC+PE 8 100 100 75 
Walker et al. 1985 Australia IS+PE 22 62 59 45 
Teague et al. 1978 New Zealand IS+PE 29 100 64 31 
Simpson et al. 1982 New Zealand 
no treatment 8 100 63 25 
OCS+AZA 4 100 100 50 
OCS+CYC+PE 8 100 100 63 
Li et al. 2004 China (Hong Kong) IS+PE 10 40 70 15 
Cui et al. 2005 China IS+PE 97 58 92 22 
Hirayama et al 2008 Japan OCS+CYC 21 14 86 24 OCS+CYC+PE 22 36 68 14 
Abbreviations: N, number of patients; AH, alveolar hemorrhage; IS, immunosuppressants (including 
methylprednisolone pulse therapy, oral corticosteroids, cyclophosphamide or azathioprine);  
PE, plasma exchange; OCS, oral corticosteroids; CYC, cyclophosphamide; AZA, azathioprine. 
Table 4. Investigations of treatments for anti–GBM antibody disease. 
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Renal function improves in 15-75% of patients with anti-GBM disease through the 
combination of plasma exchange with corticosteroids and immunosuppressive agents, 
whereas the renal survival rates of anti-GBM disease patients treated with 
immunosuppressive agents alone ranged from 2-22%. Improvement of renal function is 
usually evident within days of the start of plasma exchange. However, it should be 
emphasized that this regimen has never been properly assessed by a prospective 
randomized controlled trial because of the rarity and acuteness of the condition. The only 
reported randomized controlled trial was very small and used lower doses of both plasma 
exchange and cyclophosphamide than those that are generally used in practice.  
Although the effectiveness of treatment using therapeutic plasma exchange combined with 
immunosuppressive agents to improve renal function has been reported, only half of 
patients with anti-GBM disease had been treated with plasma exchange in our survey 
(Hirayama et al., 2008). Therefore, there was no significant difference in the renal survival 
rates between anti-GBM antibody disease patients treated with and without plasma 
exchange (P = 0.683 by the Log-rank Mantel-Cox test). Moreover, there was no significant 
difference in mortality between anti-GBM antibody disease patients treated with and 
without plasma exchange (P = 0.109).  
9.2 Predictors of survival 
The best predictors of renal survival are s-Cr at the initiation of treatment and the mean 
percentage of crescent formations. Renal function improves coincidentally with the 
introduction of plasma exchange in about 80-95% of patients with s-Cr levels less than or 
equal to 5.7-6.8 mg/dL (500-600 μmol/L), but in far fewer of those with higher s-Cr levels or 
those who require dialysis. Unfortunately, most patients with anti-GBM disease had renal 
failure at the time of diagnosis, and the mean percentage of crescent formation was high in 
anti-GBM disease patients. Therefore, in most patients with anti-GBM disease, the diagnosis 
may have been made too late to improve renal function by combination therapy.  
9.3 Relapse/recurrence 
Relapses of anti-GBM disease are rarely observed, in contrast to most other autoimmune 
kidney diseases. The anti-GBM antibodies seem to disappear spontaneously after 12-18 
months (Levy et al., 1996). However, several reports demonstrated recurring cases with anti-
GBM disease (Adler et al., 1981; Hind et al., 1984; Klasa et al., 1988; Levy et al., 1996). In our 
survey (Hirayama et al., 2008), relapse or recurrence was also rare in patients with anti-GBM 
disease (13.9%) in comparison with patients with ANCA-associated vasculitis, such as WG 
(29.4%) and MPA (29.3%). Therefore, remission induction therapy is more important in anti-
GBM disease. The mean time to recurrence is estimated to be 4.3 years (range, 1-10 years), 
and that late recurrence may occur with a frequency of 2-14%. During relapses, circulating 
anti-GBM antibodies often reappear. The combination of plasmapheresis and 
immunosuppressive agents as re-remission induction therapy is also successful in relapsing 
cases (Levy et al., 1996).  
10. Conclusion 
Anti-GBM disease is a rare but well-characterized glomerulonephritis. It occurs across all 
racial groups but is most common in Caucasians. Although the effectiveness of treatment 
using therapeutic plasma exchange combined with immunosuppressive agents to improve 
 
Anti-Glomerular Basement Membrane Disease 
 
267 
renal function has been reported, the prognosis for patients with this disease is poor. To 
improve the prognosis, it may be necessary to detect this disease in earlier stages and to 
treat it without delay.  
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1. Introduction 
Patients with severe autoimmune lupus glomerulonephritis that is resistant to 
immunosuppressive therapy need alternative treatment. Recently, bone marrow 
transplantation (BMT) has been proposed as a potential therapy for refractory 
autoimmune disease. BMT involves the administration of hematopoietic stem cells, which 
are self- renewing and capable of giving rise to all mature hematopoietic cell types and 
possibly some non-hematopoietic cell types. The etiologic and pathogenic bases of many 
autoimmune diseases ultimately reside in the self-renewing hematopoietic stem cell 
population. Therefore, the effects of BMT as a treatment for and/or preventive measure 
against these autoimmune diseases have been investigated extensively (Sykes&Nicolic, 
2005). Studies in animal models have shown that the transfer of hematopoietic stem cells 
can reverse the autoimmune state. The induction of fully allogeneic bone marrow  
(BM) chimerism, however, is fraught with difficulties. Each of the various methods of 
inducing fully allogeneic BM chimerism through hematopoietic cell transplantation (HCT) 
requires a different set of conditions, such as host T cell depletion, donor myeloablation, 
major histocompatibility complex (MHC) fully matched donor BM, or lethal dose of total 
body irradiation (TBI). Meeting these conditions is usually a burden on the recipient. 
Moreover, fully allogeneic BM chimerism is always associated with risks of graft versus 
host disease (GVHD) and immunodeficiency, which make it less practical for clinical 
application. 
Accordingly, the induction of mixed allogeneic BM chimerism has been proposed as a 
treatment for autoimmune disease. Mixed chimerism refers to a state in which allogeneic 
donor hematopoietic cells coexist with recipient cells in host bone marrow.  
In this paper, the advantages of inducing mixed BM chimerism are summarized and a 
process for inducing peripheral/central tolerance is introduced. Several mechanistic 
pathways which are thought to be involved in reversing the autoimmune state are then 
described. Based on our original data, we propose one possible mechanism in which newly 
developed donor T cells, which have been positively selected in the host thymus and 
restricted host MHC, are able to regulate auto-reactive B cells through T cell receptor 
(TCR)/MHC interaction. Finally, we discuss the potential risks associated with fully MHC-
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1. Introduction 
Patients with severe autoimmune lupus glomerulonephritis that is resistant to 
immunosuppressive therapy need alternative treatment. Recently, bone marrow 
transplantation (BMT) has been proposed as a potential therapy for refractory 
autoimmune disease. BMT involves the administration of hematopoietic stem cells, which 
are self- renewing and capable of giving rise to all mature hematopoietic cell types and 
possibly some non-hematopoietic cell types. The etiologic and pathogenic bases of many 
autoimmune diseases ultimately reside in the self-renewing hematopoietic stem cell 
population. Therefore, the effects of BMT as a treatment for and/or preventive measure 
against these autoimmune diseases have been investigated extensively (Sykes&Nicolic, 
2005). Studies in animal models have shown that the transfer of hematopoietic stem cells 
can reverse the autoimmune state. The induction of fully allogeneic bone marrow  
(BM) chimerism, however, is fraught with difficulties. Each of the various methods of 
inducing fully allogeneic BM chimerism through hematopoietic cell transplantation (HCT) 
requires a different set of conditions, such as host T cell depletion, donor myeloablation, 
major histocompatibility complex (MHC) fully matched donor BM, or lethal dose of total 
body irradiation (TBI). Meeting these conditions is usually a burden on the recipient. 
Moreover, fully allogeneic BM chimerism is always associated with risks of graft versus 
host disease (GVHD) and immunodeficiency, which make it less practical for clinical 
application. 
Accordingly, the induction of mixed allogeneic BM chimerism has been proposed as a 
treatment for autoimmune disease. Mixed chimerism refers to a state in which allogeneic 
donor hematopoietic cells coexist with recipient cells in host bone marrow.  
In this paper, the advantages of inducing mixed BM chimerism are summarized and a 
process for inducing peripheral/central tolerance is introduced. Several mechanistic 
pathways which are thought to be involved in reversing the autoimmune state are then 
described. Based on our original data, we propose one possible mechanism in which newly 
developed donor T cells, which have been positively selected in the host thymus and 
restricted host MHC, are able to regulate auto-reactive B cells through T cell receptor 
(TCR)/MHC interaction. Finally, we discuss the potential risks associated with fully MHC-
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mismatched allogeneic mixed chimerism. This information will help to determine the role 
that HCT can play in the treatment of autoimmune glomerulonephritis. 
2. Bone marrow mixed chimerism 
2.1 What is the advantage of mixed chimerism? 
Mixed chimerism refers to a state in which allogeneic donor hematopoietic cells coexist with 
recipient cells in host bone marrow, whereas fully allogeneic chimerism refers to a state in 
which donor hematopoietic cells completely replace recipient cells.  
It is known that fully allogeneic chimeras transplanted from a donor with fully mismatched 
MHC usually reject donor BM, or experience severe GVHD. Even if donor BM cells were 
safely engrafted in host BM, the resulting fully MHC-mismatched chimeras would develop 
immunodeficiency. In fully allogeneic chimeras, all mature T cells are supposed to be 
restricted to the host MHC type, irrespective of their own genetic background. This occurs 
because thymocytes, the precursors of mature T cells, are positively selected for weak 
reactivity to the self-peptide/MHC complex in the host thymus; this positive selection is 
mediated only by thymic cortical epithelial cells and not by bone marrow-derived cells. 
Therefore, in the periphery, all TCRs have certain affinity to host MHC molecules but not to 
donor MHC molecules. Thus, if the donor MHC is fully mismatched with the host MHC, 
there are no peripheral T cells which can interact with peripheral B cells differentiated from 
donor hematopoietic stem cells which generate donor-type MHC. This is the cause of 
deficiency in humoral immunity in fully MHC-mismatched allogeneic chimerism (Janeway 
et al., 2001). 
In mixed chimerism, on the other hand, TCR/MHC interactions are at least partially 
maintained, because B cells differentiated from recipient hematopoietic stem cells are still 
being generated. Moreover, during intrathymic development, thymocytes that have high 
affinity to self MHC molecules are deleted from the repertoire in a process known as 
negative selection. Thymocytes from both the recipient and the donor mature on the 
thymic epithelium expressing MHC molecules with the recipient haplotype. Nevertheless, 
the repertoire of T cells, which react with high affinity to MHC molecules with the donor 
haplotype, eliminated in mixed chimera. This implies that bone marrow-derived cells 
must be able to induce negative selection. Actually, negative selection in the thymus  
can be mediated by several different cells. The most important of these are the BM-
derived dendritic cells and macrophages. In mixed chimera, the dendritic cells and 
macrophages differentiated from both donor and host hematopoietic stem cells are 
located in the thymus, where they eliminate T cells with strong reactivity to self-peptides 
on both donor and host MHC; thus donor- and host-specific tolerance to each other is 
established.  
To summarize, mixed chimerism offers several advantages over full chimerism as a means 
of treating autoimmune disease:  
1. Mixed chimeras exhibit superior immune-competence across complete MHC barriers. 
Mixed chimeras possess certain populations of antigen presenting cells (APCs) and B 
cells which express host-type MHC molecules in the periphery, whereas mixed 
chimeras exhibit normal humoral and cellular immune responses. 
2. In mixed chimeras, dendritic cells and macrophages differentiated from both the recipient 
and the donor hematopoietic stem cells locate to the thymus where they delete both  
host-reactive and donor-reactive T cells through negative selection, resulting in a 
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peripheral T cell repertoire that is tolerant toward both donor and host cells. Therefore, 
GVHD, one of the most important complications of allogeneic BMT, is not seen in mixed 
chimeras. 
3. Mixed chimerism can be achieved through non-myeloablative regimens, which are 
generally less toxic than the myeloablative regimens necessary to induce full BM 
chimerism (this point will be discussed in detail in the next section). 
2.2 How is mixed chimerism induced? 
As explained above, once specific tolerance is established, the state of mixed chimerism is 
thought to be stable. The difficulty in establishing stable mixed chimerism lies in blocking 
the first attack of host peripheral T cells on donor bone marrow stem cells until “tolerized” T 
cells are renewed in the host thymus. Because host T cells play a dominant role in the 
rejection of allografts, several methods of deleting host T cells through the injection of 
various lymphocyte-deleting antibodies along with either total body irradiation or 
immunosuppressive drugs have been attempted (Tomita et al, 1996. Nikolic et al, 2000). 
These regimens enabled BM engraftment but were a burden on recipients and frequently 
made them susceptible to infection. The toxicity of the necessary conditioning regimens has 
precluded the use of this approach in clinical transplantation.  
Another method of inducing allogeneic tolerance involves the temporary inhibition of co-
stimulatory interaction between APCs and T cells by injecting blocking antibodies. This 
method works because T cell activation without proper co-stimulation can induce a state of 
antigen-specific non-responsiveness (Fig.1). 
 
 
Fig. 1. Activation of naïve T cells requires co-stimulation. Binding of the peptide/MHC 
complex by the TCR and the CD4 or CD8 co-receptor transmits the first signal to the T cell. 
Activation of naïve T cells requires a second signal, namely, the ligation of B7 molecules 
(B7.1/B7.2) and CD28, which stimulates the clonal expansion of naïve T cells. Binding of 
CD40L by CD40 plays a central role effector function in the full differentiation of T cells. 
This ligation also activates APCs to express B7 molecules (left). Stimulation of CTLA4 with 
anti-CTLA4 Ab and/or Blocking CD40/CD40L by MR1 induces antigen-specific T cell 
tolerance (right). 
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mismatched allogeneic mixed chimerism. This information will help to determine the role 
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host-reactive and donor-reactive T cells through negative selection, resulting in a 
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Recently, Takeuchi et al. have shown that administration of MHC-mismatched donor 
bone marrow to mice receiving 3Gy TBI one day before BMT and a single injection of 
Hamster- anti-mouse CD40L monoclonal antibody (MR1, hybridoma) intraperitoneally 
(i.p.) with BMT permitted the induction of permanent mixed chimerism and tolerance 
without T cell depletion (Y. Takeuchi et al., 2004). This regimen is quite simple and less 
toxic than the alternatives, because 3Gy TBI is nonlethal and does not require MHC 
matching. Therefore we have adopted this regimen for treatment of autoimmune disease 
in systemic lupus erythematosus (SLE) model mice (”BXSB”mice) and investigated the 
effect of induction of fully MHC-mismatched bone marrow mixed chimerism (E. Takeuchi 
& Y. Takeuchi, 2007). 
3. Treatment of autoimmune glomerulonephritis in BXSB lupus mice 
3.1 BM mixed chimerism can be induced in BXSB mice 
BXSB mice spontaneously develop autoimmune disease with features similar to human 
SLE. The disease is associated with auto-antibodies to self-antigens (Ags) including 
double strand (ds) DNA, single strand (ss) DNA, anti-platelet antibodies (Abs) and  
anti-erythrocyte Abs, with accompanying splenomegaly and lymphadenopathy. Immune 
complex-mediated nephropathy is the hallmark disease associated with the BXSB 
genotype. Histopathological changes are evident by 10 weeks of age, leading to end-stage 
renal disease and 70% mortality by 40 weeks of age. We sought to determine whether  
the simple regimen described above was also effective for the induction of long-term 
mixed chimerism in BXSB mice. Twenty million normal bone marrow cells from MHC-
matched (B6/GFP: H-2b) or -mismatched (BALB/c: H-2d) donors were injected with 2.0mg 
MR1 (i.p.) to seven-week old BXSB mice (H-2b) that had received a nonlethal dose of 4Gy 
TBI one day prior to BMT. We increased the TBI dose for BXSB mice from 3 to 4Gy 
because BXSB mice are more resistant to engraftment than normal recipients are. This 
regimen allowed the induction of multi-lineage mixed chimerism in 70-90% of host BXSB 
mice. 
As shown in Table 1 and Fig.2, long-term stable chimerism was observed in MHC- 





Table 1. The percentage of donor cells among PBL of chimeric mice. (n=9)  
To confirm the establishment of donor-specific tolerance, chimeric BXSB mice also received 
skin grafts from a BM donor and a third party (C3H/HeN, H-2k) one day after BMT. All 
chimeric BXSB mice accepted the donor skin, but rejected the third-party skin grafts within 
20 days (Fig.3), indicating that chimeric BXSB mice acquired donor-specific tolerance 
without immune-deficiencies (E. Takeuchi, 2011). 
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Fig. 2. An example of chimerism in peripheral blood lymphocytes (PBL).  
The percentage of BALB/c (H-2Dd) donor cells present among PBL of various lineages was 
analyzed through two-color FACS. These data were obtained 24 weeks after BMT. 
 
 
Fig. 3. Donor-specific skin graft tolerance. Donor and third-party skin was grafted 1 day 
post-BMT. Chimeric mice receiving MHC-mismatched BALB/c BM (◆BMT: n=9) accepted 
BALB/c skin grafts permanently, while third-party skin was rejected. Mice treated with TBI 
and anti-CD40L Ab (△: n=5) and mice receiving no treatment (●:n=5) rejected both donor 
and third-party skin. 
These results indicate that, with regard to reciprocal tolerant between donor and host, T 
cells in stable mixed chimeric mice do not reject additional tissue grafts transplanted from 
the same donor. In lupus patients who suffer from renal disorders, and who are treated by 
means of kidney transplantation, the induction of specific immunologic tolerance to donor 
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antigens would prevent both chronic graft rejection and the side effects associated with 
chronic, nonspecific immunosuppressive therapy.  
3.2 Induction of mixed chimerism suppressed lupus nephritis in BXSB mice 
Even when transplanted kidneys are engrafted stably, when pre-existing lupus goes 
untreated, renal disorder will eventually recur. It is also known, however, that the induction 
of mixed chimerism reverses the autoimmune state. To evaluate the effect of inducing MHC-
matched or MHC-mismatched mixed chimerism, individual kidneys were harvested from 
experimental mice and tissue sections were stained with periodic acid-Schiff (PAS) for 
histopathologic examination. None of the donor mouse strains were prone to autoimmune 
disease (Fig.4A). In both the fully MHC-matched and the fully MHC-mismatched chimeric 
mice groups, lupus glomerulonephritis was significantly ameliorated compared with that in 
untreated BXSB mice, as revealed by pathological analysis conducted more than 40 weeks 
after BMT (Figs.4D and E).  
 
 
Fig. 4. Kidney sections stained with PAS (left panel) and IF with anti-mouse complement C3 
(right panel). Kidneys were harvested from normal control mice or 47-50-week-old (40-43 
weeks after BMT) BXSB mice with or without the indicated treatments. C57BL/6 control 
mice (A and G), untreated BXSB mice (B and H), irradiated BXSB mice (C and I), BALB/c 
BMT chimeric mice (D and J), GFP/B6 BMT chimeric mice (E and K), BALB/cGFP/B6 F1 
BMT chimeric mice (F and L). 
Both untreated (Fig.4B) and irradiated BXSB mice (Fig.4C) exhibited severe 
glomerulonephritis with PAS-positive deposits. BXSB mice that had received TBI+MR1 
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exhibited histopathology similar to BXSB mice that had received only TBI (data not shown). 
For semiquantitative histologic analyses, more than 30 glomeruli from each kidney section 
were examined. Glomerulonephritis was scored on a scale of 0-4, based on the intensity and 
extent of histopathological changes [0; no glomerular lesions. 1; minimal thickening of the 
mesangium. 2; noticeable increase in both mesangeal and glomerular capillary cellularity. 3; 
same as 2 with the addition of superimposed inflammatory exudates and capsular 
adhesions. 4; obliteration of the glomerular architecture (>70% of glomeruli)]. Mean renal 
scores of both MHC-matched and –mismatched chimeric mice were significantly better than 
those of untreated or irradiated control BXSB mice (BALB/c BMT: 0.970.74, GFP/B6 BMT: 
0.070.26 vs. untreated BXSB: 2.960.72, TBI: 1.850.77, TBI+MR1: 2.473.4, >30 glomeruli 
from each kidney section in three mice of each group were evaluated. p<0.05). We also 
evaluated immune-complex mediated glomerulonephritis through immunofluorescence (IF) 
staining with anti-mouse complement C3 in 30 glomeruli per renal section (Fig.4. right 
panels). Untreated mice and irradiated mice exhibited the peripheral loop pattern (Figs. 4H 
and I), while almost all glomeruli in the sections from chimeric mice showed negative 
staining (Figs. 4J and K). Because the cause of death in BXSB mice is most often renal failure, 
the improvement of their glomerulonephritis may have contributed to the prolongation of 
their life-spans. These results indicate that the induction of mixed chimerism significantly 
inhibited the development of lupus-like disease.  
It should be noted, however, that the induction of mixed chimerism in BXSB mice could 
not completely eliminate auto-reactive host lymphocytes because our regimen retains 
certain stem cells and lymphocytes belonging to the host. This naturally leads to the 
question of how donor cells reverse the host autoimmune state, which is discussed in the 
next section. 
4. How does BM chimerism reverse the autoimmune state? 
4.1 Hypothesis 
We and several other groups have shown that the induction of bone marrow mixed 
chimerism is an effective treatment for and/or means of prevention against the 
development of autoimmune disease. Previous studies have debated the mechanisms that 
may be responsible for the reversal of the autoimmune state in BM chimerism, but the 
mechanism of the exclusion of self-reactive lymphocytes has not yet been conclusively 
identified. Preceding studies have argued about the mechanisms underlying the reversal of 
the autoimmune state in BM chimerism. In several studies which reversed destructive 
autoimmune type І diabetes (NOD mice with induced mixed chimerism), the suppression of 
autoimmune disease was attributed to reciprocal clonal deletion or to anergy induction of T 
lymphocytes of recipient and donor origin (Mathieu et al., 1997. Nikolic et al., 2004). Other 
mechanisms have also been proposed, including induction of peripheral anergy, a change in 
the Th1/Th2 profile, correction of abnormal secretion of cytokines and positive selection of 
regulatory T cells in the thymus. Among proposed hypotheses, we have focused on the role 
of cognate TCR/MHC interactions in the pathogenesis of autoimmune disease in BXSB mice 
(E. Takeuchi et al., 2011) 
4.2 The induction of MHC-mismatched chimerism does not suppress anti-DNA Abs 
During the development of their lupus-like autoimmune disease, BXSB mice are known to 
produce auto-antibodies to self-antigens including dsDNA. We measured serum anti-
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exhibited histopathology similar to BXSB mice that had received only TBI (data not shown). 
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dsDNA antibody (anti-DNA Ab) levels by means of ELISA to evaluate whether auto-
reactive Abs were eliminated by the induction of mixed chimerism. Actually, the anti-DNA 
Ab levels in both MHC-matched and MHC-mismatched chimeric mice were lower than 
those in untreated or irradiated BXSB mice. Meanwhile, anti-DNA Ab levels in fully MHC-
matched mixed chimeric mice (GFP/B6 BMT) were not statistically different from those in 
normal control B6 mice, but those in fully MHC-mismatched mixed chimeric mice (BALB/c 
BMT) were significantly higher than those in normal controls. This tendency was even more 
pronounced when anti-DNA IgM levels in the above groups were compared. There were no 
significant differences in anti-DNA IgM levels between MHC-mismatched chimeric mice 
and untreated or TBI+MR1 mice, even though total anti-DNA levels were much lower in 
chimeric mice than in other groups.  
These data indicated that anti-DNA Ab producing cells were still present in the BXSB 
chimeric mice, though they stopped switching iso-types from IgM to IgG in MHC-
mismatched chimera. Only in MHC-matched chimeric mice could the expansion of anti-
DNA Ab production be suppressed down to a normal level; the induction of fully MHC-
mismatched chimerism did not completely suppress or eliminate anti-DNA-producing B 
cells.  
4.3 Selective suppression of auto-reactive antibodies in chimeric mice 
In order to distinguish the contributions of donor-type and host-type B cells to anti-dsDNA 
antibody production, we determined IgM allotypes [IgMa: BALB/c (donor), IgMb: BXSB 
(host)] in the serum of fully MHC-mismatched (BALB/c→BXSB) chimeric mice 20 weeks 
after BMT. At this point, the percentage of allogeneic donor B cells in the chimeric mice was 
51.011.8%, indicating that allogeneic donor and host B cells had contributed equally to the 
immune response. Surprisingly, however, we found that the majority of the anti-DNA IgM 
was IgMa (allogeneic donor-type), whereas IgMb (host-type) anti-DNA antibody production 
was suppressed (Fig. 5A).  
 
 
Fig. 5. The ratio of host-type IgM to donor-type IgM. (A) Serum anti-DNA IgM in BALB/c 
BMT BXSB was measured in each sample by means of ELISA. The percentages of anti-DNA 
IgMa (donor-type IgM: dark bar) and IgMb (host-type IgM: light bar) add up to the total 
anti-DNA IgM. (B) Total IgM in each BALB/c BM- transplanted BXSB mouse was measured 
individually. The percentages of serum IgMa (donor-type IgM: dark bar) and IgMb (host-
type IgM: light bar) add up to the total IgM. 
The majority of the total serum IgM, on the other hand, was host-type IgMb (Fig. 5B), 
suggesting that the production of “normal” serum Ig is dependent on host MHC-restricted T 
cells. Total serum IgM levels in fully MHC-mismatched chimeric mice were not significantly 
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different from those in other groups (data not shown). These results indicated that normal B 
cells derived from donor BALB/c mice, rather than genetically lupus-prone host-type B 
cells, were responsible for anti-DNA antibody production in these chimeric BXSB mice. 
Thus the regulation of auto-antibody production appears to be under MHC-restriction of the 
host type. Additionally, to confirm which set of B cells (donor-type or host-type) could react 
with foreign antigens, sheep red blood cells (SRBC) were administered intraperitoneally to 
five BALB/c chimeric BXSB mice. Three days after immunization, serum anti-SRBC Ab was 
detected through flow cytometry. All chimeric mice produced antibodies that were reactive 
with SRBC. As expected, almost all of the detected anti-SRBC Ab was IgMb (host-type), not 
IgMa (allogeneic donor-type) (data not shown). In mixed chimeras, all peripheral T cells are 
supposed to be restricted to host MHC, because of positive selection in the host thymus. T 
cells in fully MHC-mismatched chimeric mice should therefore be capable of cognate 
interaction with host-type B cells but not with donor-type B cells. Accordingly, only host-
type B cells were activated by antigens through cognate interaction with helper T cells. 
Donor-type B cells remained “silent” because they could not interact properly with T cells. 
Interestingly, however, our results indicated the possibility that not only “proper” activation 
against foreign antigens, but also suppression of auto-reactive antibody production were 
regulated through TCR/MHC cognate interactions. 
4.4 Do T cells survey auto-reactive antibody production? 
Based on these data, we drew the following conclusions: 1. Allogeneic BM chimerism 
ameliorates autoimmune disease, but fully MHC-mismatched chimerism fails to suppress 
the production of anti-DNA antibodies. 2. In MHC-mismatched mixed chimeras, anti-
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cells can recognize only host B cells but not donor B cells. To tie theses conclusions 
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different from those in other groups (data not shown). These results indicated that normal B 
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T cell precursors derived from BM differentiate to mature T cells in the host thymus. 
Through a process known as positive selection, all T cell populations can interact with self-
MHC with proper affinity. Since these processes are performed by MHC molecules 
expressed on thymic epithelial cells, the TCR repertoire in mixed chimera is restricted to 
host MHC. We and others speculate that under genetically normal conditions, T cell-
mediated trimming of autoantibody production may occur through cognate interactions 
between TCR and MHC+peptide presented on B cells (Rathmell et al., 1995, Shinohara et al., 
1997). In the case of the BXSB mouse, it is known that T cells have certain defects which 
might play an important role in the pathogenesis of autoimmunity (Wofsy, 1986). We also 
speculate that the pivotal defect of BXSB may be a genetic defect in this surveillance 
function of T cells (Fig.6A). In the case of fully MHC-matched chimerism, T cells derived 
from donor BM can take this place of defective host T cells. Auto-reactive B cells derived 
from both donor and host BM can be regulated or trimmed by donor T cells through 
TCR/MHC interactions (Fig.6B). In MHC-mismatched chimerism, immature T cells are 
positively selected on the basis of their weak reactivity with self-peptides presented 
exclusively on H-2b MHC molecules, since thymic epithelial cells express only host MHC. 
Therefore, in the periphery, all T cells recognize antigens presented by APCs on H-2b MHC 
molecules (BXSB: host type MHC). Yet, B cells expressing H-2d MHC (BALB/c: donor type 
MHC) are still generated from donor BM stem cells as this process is genetically determined. 
T cells developing in the BXSB thymus should be incapable of cognate interactions with 
these “wrong” MHC molecules expressed on donor B cells. We speculate that the failure of 
cognate interaction with T cells might be the reason why auto-reactive antibody levels rose 
in MHC fully-mismatched chimeric mice (Fig.6C). 
The present study did not address the question of how anti-self B cells were initially 
triggered. We also induced fully MHC-mismatched BM chimerism in normal B6 mice 
(BALB/c→B6) as opposed to lupus BXSB mice. The anti-DNA Ab levels seen in 
BALB/c→B6 chimeric mice were slightly higher than those in normal B6 mice, but, much 
lower than those seen in BALB/c→BXSB chimeric mice (data not shown). This means that 
the induction of fully MHC-mismatched chimerism in normal mice may carry a risk of 
autoantibody production, though uncertain factors in host BXSB mice drives a non-
physiological priming of B cells. 
4.5 BMT from haplo-identical donor effectively suppressed auto-antibody production 
If there is indeed a host-type MHC restriction in the suppression of auto-reactive antibody 
production, BMT from a donor with partially identical MHC that is sufficient to maintain 
cognate interaction should be equally as effective as BMT from a fully MHC-matched 
GFP/B6 mouse. To test this hypothesis, BM cells taken from BALB/c (H-2d)  GFP/B6  
(H-2b) F1 mice with haplo-identical MHC (H-2b/d) were transplanted to BXSB (H-2b) mice. 
In this case, all B cells, even those differentiated from donor BM, contained at least one  
H-2b allele. As shown in Figs.4F and L, lupus glomerulonephritis in F1 chimeric mice was 
alleviated to a degree comparable to that seen in MHC-matched GFP/B6 chimeric mice. 
Serum anti-DNA Ab in F1 chimeric mouse group was decreased to level comparable to 
that seen in fully MHC-matched GFP/B6 chimeric mice (data not shown).  
The survival rates in both the GFP/B6 chimeric mouse group and the F1 chimeric mouse 
group, which were higher than that in the BALB/c chimeric mouse group, indicated that 
BMT from F1 mice is also effective as a treatment for lupus-like disease in BXSB mice (B6 
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BMT: 100%, F1 BMT: 80%, vs BALB/c BMT: 70%, TBI+MR1: 60%, TBI: 20%, untreated: 20% 
survival, 50weeks after BMT). These results suggest that the maintenance of TCR/MHC 
cognate interaction with all B cells is important in regulating auto-reactive Ab production, 
and that reconstitution of the T cell surveillance system may reverse the autoimmune state 
of lupus-like disease in the BXSB mouse. Moreover, our results indicate one possibility for 
clinical application: BMT between parent and child, both parent→child and child→parent, 
may be able to reverse the autoimmune state of SLE effectively. 
5. Clinical application and unknown risks of mixed chimerism 
This paper has demonstrated that the maintenance of TCR/MHC interaction with all B cells 
is important in regulating auto-reactive Ab production. However, we and several other 
groups have reported that the induction of fully MHC-mismatched chimerism is certainly 
effective as a treatment for autoimmunity. How does the induction of fully MHC-
mismatched mixed chimerism suppress autoimmune disease? One answer to this question 
is demonstrated by the results of an immunohistochemical experiment in which we staind 
for several isotypes of immunoglobulin.  
As depicted in Table 2, linear staining patterns with IgG and/or IgM were definitely 
observed on the glomeruli of kidney sections taken from MHC-mismatched chimeric mice; 
the same sections were negative for C3 depositions, however. Linear staining with both IgG 
and C3 was observed on the glomeruli taken from untreated mice. 
 
 
Table 2. Immunofluorescence staining with several isotype Ig of glomeruli. 
This indicates that antibodies deposited in fully MHC-mismatched chimeric mice, mainly 
IgM, did not activate the complements effectively. As a result, lupus glomerulonephritis is 
milder in chimeric mice than in untreated mice. We presume that class-switching from IgM 
to other isotypes does not occur on donor anti-dsDNA IgM-producing B cells, since 
TCR/MHC cognate interactions were disrupted.  
Given that T cells could neither activate nor suppress B cells, B cells are expected to be 
inactive or “silent”. In fact, we have confirmed that, when fully MHC-mismatched 
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T cell precursors derived from BM differentiate to mature T cells in the host thymus. 
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MHC with proper affinity. Since these processes are performed by MHC molecules 
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1997). In the case of the BXSB mouse, it is known that T cells have certain defects which 
might play an important role in the pathogenesis of autoimmunity (Wofsy, 1986). We also 
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function of T cells (Fig.6A). In the case of fully MHC-matched chimerism, T cells derived 
from donor BM can take this place of defective host T cells. Auto-reactive B cells derived 
from both donor and host BM can be regulated or trimmed by donor T cells through 
TCR/MHC interactions (Fig.6B). In MHC-mismatched chimerism, immature T cells are 
positively selected on the basis of their weak reactivity with self-peptides presented 
exclusively on H-2b MHC molecules, since thymic epithelial cells express only host MHC. 
Therefore, in the periphery, all T cells recognize antigens presented by APCs on H-2b MHC 
molecules (BXSB: host type MHC). Yet, B cells expressing H-2d MHC (BALB/c: donor type 
MHC) are still generated from donor BM stem cells as this process is genetically determined. 
T cells developing in the BXSB thymus should be incapable of cognate interactions with 
these “wrong” MHC molecules expressed on donor B cells. We speculate that the failure of 
cognate interaction with T cells might be the reason why auto-reactive antibody levels rose 
in MHC fully-mismatched chimeric mice (Fig.6C). 
The present study did not address the question of how anti-self B cells were initially 
triggered. We also induced fully MHC-mismatched BM chimerism in normal B6 mice 
(BALB/c→B6) as opposed to lupus BXSB mice. The anti-DNA Ab levels seen in 
BALB/c→B6 chimeric mice were slightly higher than those in normal B6 mice, but, much 
lower than those seen in BALB/c→BXSB chimeric mice (data not shown). This means that 
the induction of fully MHC-mismatched chimerism in normal mice may carry a risk of 
autoantibody production, though uncertain factors in host BXSB mice drives a non-
physiological priming of B cells. 
4.5 BMT from haplo-identical donor effectively suppressed auto-antibody production 
If there is indeed a host-type MHC restriction in the suppression of auto-reactive antibody 
production, BMT from a donor with partially identical MHC that is sufficient to maintain 
cognate interaction should be equally as effective as BMT from a fully MHC-matched 
GFP/B6 mouse. To test this hypothesis, BM cells taken from BALB/c (H-2d)  GFP/B6  
(H-2b) F1 mice with haplo-identical MHC (H-2b/d) were transplanted to BXSB (H-2b) mice. 
In this case, all B cells, even those differentiated from donor BM, contained at least one  
H-2b allele. As shown in Figs.4F and L, lupus glomerulonephritis in F1 chimeric mice was 
alleviated to a degree comparable to that seen in MHC-matched GFP/B6 chimeric mice. 
Serum anti-DNA Ab in F1 chimeric mouse group was decreased to level comparable to 
that seen in fully MHC-matched GFP/B6 chimeric mice (data not shown).  
The survival rates in both the GFP/B6 chimeric mouse group and the F1 chimeric mouse 
group, which were higher than that in the BALB/c chimeric mouse group, indicated that 
BMT from F1 mice is also effective as a treatment for lupus-like disease in BXSB mice (B6 
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BMT: 100%, F1 BMT: 80%, vs BALB/c BMT: 70%, TBI+MR1: 60%, TBI: 20%, untreated: 20% 
survival, 50weeks after BMT). These results suggest that the maintenance of TCR/MHC 
cognate interaction with all B cells is important in regulating auto-reactive Ab production, 
and that reconstitution of the T cell surveillance system may reverse the autoimmune state 
of lupus-like disease in the BXSB mouse. Moreover, our results indicate one possibility for 
clinical application: BMT between parent and child, both parent→child and child→parent, 
may be able to reverse the autoimmune state of SLE effectively. 
5. Clinical application and unknown risks of mixed chimerism 
This paper has demonstrated that the maintenance of TCR/MHC interaction with all B cells 
is important in regulating auto-reactive Ab production. However, we and several other 
groups have reported that the induction of fully MHC-mismatched chimerism is certainly 
effective as a treatment for autoimmunity. How does the induction of fully MHC-
mismatched mixed chimerism suppress autoimmune disease? One answer to this question 
is demonstrated by the results of an immunohistochemical experiment in which we staind 
for several isotypes of immunoglobulin.  
As depicted in Table 2, linear staining patterns with IgG and/or IgM were definitely 
observed on the glomeruli of kidney sections taken from MHC-mismatched chimeric mice; 
the same sections were negative for C3 depositions, however. Linear staining with both IgG 
and C3 was observed on the glomeruli taken from untreated mice. 
 
 
Table 2. Immunofluorescence staining with several isotype Ig of glomeruli. 
This indicates that antibodies deposited in fully MHC-mismatched chimeric mice, mainly 
IgM, did not activate the complements effectively. As a result, lupus glomerulonephritis is 
milder in chimeric mice than in untreated mice. We presume that class-switching from IgM 
to other isotypes does not occur on donor anti-dsDNA IgM-producing B cells, since 
TCR/MHC cognate interactions were disrupted.  
Given that T cells could neither activate nor suppress B cells, B cells are expected to be 
inactive or “silent”. In fact, we have confirmed that, when fully MHC-mismatched 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
288 
chimeric mice are immunized with foreign antigen (sheep red blood cells, SRBC), antigen-
specific antibodies (anti-SRBC IgM) are mainly produced by host B cells (as mentioned in 
4.3). In rare cases, however, especially when immunization with the same antigen is 
repeated several times, donor B cells accidentally respond and produce specific 
antibodies. A T cell that is specific for one peptide on an MHC molecule may cross-react 
with peptides presented by other allogeneic MHC molecules. By these accidental 
interactions, donor B cells are activated and start to produce specific antibodies. During 
activation and proliferation, B cells undergo variable-region somatic hypermutation and 
change their antigen affinity, resulting in the generation of variant immunoglobulins, 
some of which are thought to bind to the original foreign antigen with higher affinity. 
However, the potential disadvantage of this process is that some of the antibodies could 
be auto-reactive. 
To test this hypothesis, we induced an auto-cross-reactive antibody (Ab) by introducing a 
foreign antigen with a homolog to an auto-antigen into a BXSB lupus mouse strain of mixed 
chimerism with several combinations of donor BM. The titer of auto-cross reactive foreign 
Ab plateaued at low levels in normal mice and MHC-matched/haplo-identical chimeric 
mice, but rose higher in BXSB and fully MHC-mismatched chimeric mice (unpublished 
data). These results indicate that the induction of fully MHC-mismatched chimerism may 
carry a risk of secondary auto-antibody production. 
Under normal conditions, these auto-reactive B cells may be anergic. In lupus patients, 
however, non-physiological factors may prime auto-reactive B cells. For example, it has been 
reported that circulating B cell activating factor (BAFF) is elevated in the serum of human 
patients with lupus, and that the overexpression of BAFF in mice promotes TLR-induced 
production of auto-antibodies through a T cell independent process (Groom et al., 2007). 
Under autoimmune conditions, normal B cell may have the potential to run off the rails. The 
maintenance of TCR/MHC interaction may be a “rein” by which immune-response is 
controlled in chimeras. 
Because several mechanisms have been suggested as drivers of autoimmune disease, further 
study is necessary to identify each mechanism’s role. Nevertheless, our results showing the 
specific suppression of auto-reactive antibody production suggest the existence of a 
surveillance system that trims auto-reactive B cells after priming. The reconstitution of this 
surveillance system through the induction of BM mixed chimerism can be an effective 
treatment for lupus disease. Moreover, the induction of BM mixed chimerism with haplo-
identical donor BM, which maintains cognate T/B interaction with both donor and host 
cells, can be equally effective as fully MHC-matched donor BM. These results may support 
the clinical application of BMT as a treatment for lupus disease. 
6. Conclusions 
Induction of BM mixed chimerism can be useful for treatment of refractory lupus 
glomerulonephritis. Elucidation the mechanism through which mixed chimerism reverses 
the autoimmune state is necessary for clinical application.  
In this paper, we suggested the existence of T cell surveillance system through TCR/MHC 
interaction. Through TCR/MHC interaction, T cell-mediated trimming of auto-antibody 
production may occur under normal condition. The induction of bone marrow mixed 
chimerism may reverse the auto-immune state through reconstruction of the T cell 
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surveillance system and the maintenance of TCR/MHC interaction with all B cells is 
important in regulating auto-antibody production. 
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chimeric mice are immunized with foreign antigen (sheep red blood cells, SRBC), antigen-
specific antibodies (anti-SRBC IgM) are mainly produced by host B cells (as mentioned in 
4.3). In rare cases, however, especially when immunization with the same antigen is 
repeated several times, donor B cells accidentally respond and produce specific 
antibodies. A T cell that is specific for one peptide on an MHC molecule may cross-react 
with peptides presented by other allogeneic MHC molecules. By these accidental 
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1. Introduction  
The pulmonary-renal syndrome involves the combination of diffuse alveolar hemorrhage 
and a rapid progressive glomerulonephritis (RPGN). It is usually a systemic vasculitis that 
can led through a vast vasculitic process to life-threatening injury to the involved organs 
lung and kidney [Niles 1996, Salant 1987, Boyce 1986, Gallagher 2002 & De Groot 2005].  
In the differential diagnosis other diseases of acute renal and lung injury with alveolar 
hemorrhage without RPGN have to be discussed.  
2. Pulmonary-renal syndrome  
The diffuse alveolar hemorrhage is defined by the triad of hemoptysis, diffuse alveolar infiltrates 
and low hematocrit. However, the clinical presentation is variable (slight cough, progressive 
dyspnea, manifest hemoptysis) and these symptoms don`t have to occur simultaneously 
[Hauber 2007]. Slowly protracted courses through to fulminant organ failure are described.  
A rapid-progressive glomerulonephritis (RPGN) is manifested by a rapidly progressive renal 
function loss (a few days to few weeks) and the presence of a nephritic sediment with 
deformed erythrocytes of a glomerular origin and possibly red cell casts.  
2.1 Pathophysiology  
The underlying cause of a pulmonary-renal syndrome is usually a systemic vasculitis of the 
small pulmonary and renal vessels. These vasculitides have a heterogeneous pathogenesis - 
there are three different pathophysiological mechanisms of injury [Niles 1996, Salant 1987 & 
De Groot 2005]:  
1. mediated by anti-neutrophil-cytoplasmic antibodies (ANCA),  
2. immune-complex mediated vasculitis of small vessels or 
3. by antibodies against the glomerular basement membrane (Goodpasture  Syndrome).  
In the kidney a RPGN is caused by damage of the capillaries and basal membranes with 
leakage of erythrocytes, followed by an influx of macrophages, fibrinogen and the formation 
of extracapillary cell proliferation (so called crescents) [Salant 1987].  
In the lungs, a diffuse alveolar hemorrhage is caused by a pulmonary capillaritis [Hauber 2007]. 
In the case of ANCA-associated systemic vasculitis the detection of ANCA is possible in ~ 
80% of patients. Besides the correlation of ANCA titers with disease activity, there is 
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evidence of a pathogenetic role of ANCA. Myeloperoxidase (MPO) and proteinase 3 (Pr3) 
are detected in the cytoplasm of non-stimulated neutrophils. It is assumed that cytokines 
(e.g. TNF, interleukins) raise the expression of Pr3 and MPO on the cell surface of 
granulocytes and thus a reaction of these antigens with ANCA is possible. This process 
leads to activation of granulocytes and release of adhesion molecules to the interaction of 
leukocytes with vascular endothelial cells. Finally cell necrosis and apoptosis contribute to 
vascular inflammation process [Bosch 2006].  
2.2 Diagnosis  
2.2.1 Basic steps  
As with any systemic vasculitis the diagnosis of pulmonary-renal syndrome is made in three 
steps:  
1. Adequate evaluation and networking of existing and past patient's symptoms.  
2. Establishing the diagnosis by laboratory, technical and biopsy examinations.  
3. Differential diagnosis of vasculitis.  
2.2.2 Imaging  
The value of imaging refers to the extent of pulmonary capillaritis resulting in diffuse alveolar 
hemorrhage: in a conventional X-ray or in a computer tomography of the chest confluent or 
mixed interstitial-alveolar infiltrates are found (Fig. 1).  
 
 
Fig. 1. Diffuse alveolar hemorrhage in chest x-ray in Wegener's granulomatosis. 
In a RPGN sonographically enlarged kidneys presents with a wide  parenchym area. 
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2.2.3 Serology  
Antibodies against the glomerular basement membrane (GBM) can be found typically in the 
rare Goodpasture's syndrome (Tab. 1).  
The above briefly described heterogeneous pathogenesis of small vessels vasculitis results in 
the immunological classification considering serological / immunological parameters such 
as anti-neutrophil-cytoplasmic antibodies (ANCA) by immunfluorescence-optical findings 
(perinuclear or cytoplasmtic fluorescence) or ELISA against the target antigen proteinase 3 
or myeloperoxidase (Tab. 1) [Bosch 2006]. In addition, the eosinophils, IgE and the extended 
autoimmunserology: anti-nuclear factor (ANA), anti-ds-DNA, C3, C4 and cryoglobulins can 
be determined.  
 
Disease Proteinase-3-Antibody 







Granulomatosis 70 % 20 % 10 % <10% 
Microscopic 
Polyangiitis 30 % 60 % 10 % <10% 
Churg-Strauss-
Syndrome 10 % 60 % 30 % <10% 
Goodpasture 
Syndrome <10% <30% 70% 95% 
Table 1. ANCA-Sensitivity.  
The rapid availability of these antibodies has improved the time to establish an early 
diagnosis, which is prognostically relevant [Saxena 1995].  
2.2.4 Renal biopsy  
The diagnosis of RPGN is done by renal biopsy: in light microscopy there is a 
glomerulonephritis with crescent formation in the Bowman's capsule compartment 
(extracapillary proliferation) in more than 50% of the glomeruli. The further work is carried 
out by immunohistochemistry and electron microscopy.  
In immunohistology, the type of immunoglobulins and the deposition pattern (capillary, 
mesangial, granular, linear along the glomerular basement membrane) differ. Only in 
Goodpasture syndrome, linear deposits are found along the glomerular basement 
membrane. In case of an ANCA triggered form immune deposits are missing (pauci-
immune RPGN). In contrast, in immune-complex vaculitis there can be found a different 
picture, usually with granular deposition of IgG, IgM, IgA or complement.  
2.2.5 Bronchoscopy 
The diagnosis of diffuse alveolar hemorrhage includes the clinical picture and a brochoscopy 
with a bronchoalveolar lavage and the microscopic detection of siderophages. Especially in 
the case of diffuse infiltrates in imaging without hemopytsis a bronchoscopy can be helpful 
and a definite diagnosis can be established [Hauber 2007].  
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3. Differential diagnosis of the pulmonary-renal syndrome  
As already stated the pulmonary-renal syndrome is usally caused by a systemic small 
vessels vasculitis (Tab. 2), these can be categorized [Niles 1996, Salant 1987, De Groot 2005, 
Jennette 1994 & Falk 1997]:  
- morphological criteria (size of the infesting vessels, presence or absence of granulomas),  
- etiological criteria (idiopathic or secondary forms) and  
- immunological criteria (ANCA-associated vasculitis, immune-complex vasculitis or 
caused by anti-basement antibodies). 
3.1 ANCA-associated small vessel vasculitis 
The Chapel Hill Consensus Conference classification defines [Jennette 1994]:  
1. Wegener's granulomatosis,  
2. microscopic polyangiitis and  
3. Churg-Strauss syndrome.  
Renal involvement is present in many systemic diseases, especially in the small vessel 
vasculitis – pointed out by Gallo in the New England Journal of Medicine: "The kidney is 
often a window on systemic disease" [Gallo 1991].  
The suspicion of a pulmonary-renal syndrome in an ANCA-associated systemic vasculitis 
can often be taken from a careful history and thorough clinical examination with detection 
of other vasculitic signs (eye inflammation, intractable rhinitis / sinusitis, skin rashes, 
arthralgia, myalgia or polyneuropathy) (Fig. 2). 
 
 
Fig. 2. General symptoms and signs of organ involvement in systemic small vessels 
vasculitis. 
 




 WG MP CSS GP SLE 
Clinical presentation
Vasculitic general 
symptoms + + + - + 
Granulomatous 
inflammation + - + - - 
Eye involvement + (+) (+) - (+) 
Recurrent asthma 
bronchiale - - + - - 
Pulmonary-renal 
syndrome possible + + (+) + (+) 
Skin (purpura, necrosis) + + + - + 
Gastrointestinal 
symptoms (+) (+) (+) - (+) 
 WG MP CSS GP SLE 




80 - 90 %
~ 70 % 
~ 20 %
80 - 90 % 
~ 30 % 
~ 60 %
50 - 70 %
~ 10 % 
~ 60 %
< 30 % - 
Eosinophilia - - + - - 
Reduced complement 
levels - - - - + 
Anti-ds-DNA - - - - + 
Anti-GBM-Ab - - - 95% - 
Histology/Immunohistology
Leucocytoclastic
vasculitis + + + - + 
Granulomatous 
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WG = Wegener's Granulomatosis. MP = microscopic polyangiitis. CSS = Churg-Strauss syndrome.  
GP = Goodpasture's Syndrome SLE = systemic lupus erythematosus. ANCA = antineutrophil 
cytoplasmic antibodies. PR-3 = proteinase-3. MPO = myeloperoxidase. IC = immune complex.  
GBM = Glomerular basement membrane. ds = double strand. 
Table 2. The most important differential diagnoses of pulmonary-renal syndrome with 
clinical features, laboratory and histological findings. 
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3.1.1 Wegener's granulomatosis  
Wegener's granulomatosis is a necrotizing vasculitis of the small and medium-sized vessels, 
associated with granulomas inflammation of the upper and lower respiratory tract and the 
frequent finding of glomerulonephritis. In active disease in about 90% of cases c-ANCA are 
directed against proteinase 3 (Tab. 1 and 2). Figure 3 shows the predominant symptoms in 
image and Figure 4 in number (at onset and during disease) [Hoffmann 1992].  
 
 
      a bloody rhinitis               b aphthae                           c / d  vasculitic skin involvement  
Fig. 3. Wegener's granulomatosis. 
 
 
Fig. 4. Organ involvement in Wegener's granulomatosis. 
3.1.2 Microscopic polyangiitis  
Microscopic polyangiitis is characterized by a necrotizing vasculitis of small vessels with 
minimal or missing immune deposits and an inflammation of the pulmonary capillaries. 
Typically, there are p-ANCA directed against myeloperoxidase (Tab. 1 and 2) [Jennette 1994 & 
Falk 1997]. Wegener`s granulomatosis and Microscopic polyangiitis shows comparable organ 
involvement, but the symptoms of the upper respiratory tract are usally milder in Microscopic 
polyangiitis, because there is no granulomatous inflammation. Compared to Wegener's 
granulomatosis disease recurrence is rare in patients with Microscopic polyangiitis.  
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3.1.3 Churg-Strauss syndrome  
The Churg-Strauss syndrome is characterized by recurrent asthma attacks and allergic rhinitis, 
an intermittently or permanently detectable eosinophilia (> 1500/mm3) and necrotizing 
granulomas and / or necrotizing arteritis with a Wegner's granulomatosis-like presentation. 
The serological diagnosis is less clear: c-ANCA or anti-PR3-Ab detected only rarely, p-ANCA 
and anti-MPO-Ab can be detected in up to 60% of cases (Tab. 1 and 2) [Hoffmann 1992].  
The Churg-Strauss syndrome can be distinguished clinically (asthma attacks, eosinophilia) 
from Wegener`s granulomatosis or Microscopic polyangiits. Renal involvement is seen in 
approximately 25% of patients. 
3.2 Goodpasture syndrome  
The Goodpasture's syndrome is a rare disease with an incidence of 0.1-1 per million per year 
and affects mainly caucasian males. It is characterized by hemoptysis and / or radiological 
evidence of pulmonary infiltrates and a RPGN, which usually develops after hemoptysis. 
There is the very reliable detection of anti-GBM antibody, the identified antigen is the C-
terminal end of the alpha-3-chain of type IV collagen. The immunohistological workup of 
the renal biopsy shows linear IgG deposits in the glomerular basement membranes (Tab. 1 
and 2) [Goodpasture 1919, Salama 2001, Pusey 2003 & Hudson 2003].  
Compared to the ANCA-associated small vessel vasculitidies (Wegener`s Granulomatosis,  
Microscopic polyangiitis and Churg-Strauss syndrome) there are no other, general vasculitic 
symptoms in patients with Goodpasture syndrome. 
3.3 Immune-complex vasculitis of small vessels  
Immune-complex vasculitidies like 
1. systemic lupus erythematosus,  
2. cryoglobulinemic vasculitis and  
3. Purpura Schoenlein-Hennoch [Markus 1989]  
are important differential diagnostic considerations of the pulmonary-renal syndrome.  
They can be distinguished by the previously described extended-serological diagnostic 
workup.  
3.4 Further differential diagnoses  
If this diagnostic workup is unremarkable, there are several more differential diagnosis:  
1. antiphospholipid syndrome with vasculitis and / or pulmonary embolism  
2. mixed connective tissue diseases (systemic sclerosis, polymyositis)  
3. thrombotic thrombozypenic purpura. 
4. infectious diseases involving kidney and lung (e.g Hanta-virus, cytomegalie-virus, 
Legionella, Mycoplasma, Leptospirosis, tuberculosis, sepsis)  
Moreover, a primary renal disease can lead to a pulmonary disease and mimic the image of 
a pulmonary-renal syndrome:  
1. acute renal failure with pulmonary edema and uremic hemoptysis  
2. thromboembolism in nephrotic syndrome: renal vein thrombosis and/ or pulmonary 
embolism  
3. immunosuppression in renal disease and a pneumonia.  
Conversely, a primary pulmonary disease can lead to renal disease and can mimic the image 
of pulmonary-renal syndrome:  
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1. Infection of the respiratory tract with prerenal renal failure and / or postinfectious 
glomerulonephritis or hematuria in IgA nephropathy  
2. Lung cancer with immune-complex nephritis.  
4. Conclusions 
Since early treatment with the mentioned diseases is critical, the diagnosis has to be 
established quickly - the fast antibody-diagnostic and diagnostic imaging have a central role.  
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Rapidly progressive glomerulonephritis (RPGN) is one of the nephrology emergencies 
which needs special attention. RPGN is a clinical description which determines by 
symptoms and signs of glomerulonephritis (GN); edema, hypertension and gross 
hematuria, and evidence of acute renal failure(severe decrease in glomerular filtration rate 
presents as oliguria or anuria, and increased serum levels of BUN and creatinine). Definite 
diagnosis of the disorder is based on kidney biopsy's findings. Early diagnosis and 
appropriate treatment plays a critical role in renal saving and preventing permanent 
glomerular damage. 
This chapter will focus on clinical manifestations, therapeutic protocols and prognostic 
factors in patients with different subtypes of RPGN. 
Rapidly progressive glomerulonephritis (RPGN) is dened as a syndrome with abrupt or 
insidious onset of hematuria, proteinuria, anemia, and rapidly progressing acute renal 
failure(ARF), and special findings on light microscopy examination of kidney biopsy's 
specimen; crescentic lesions which usually involved most glomerular architectures 
(Hirayama, et al., 2008; Rutgersetal., 2004). It also characterized by rapid loss of renal 
function (GFR<50% within 3 months)with histological findings of crescent lesions which 
usually involves>50 % of glomeruli (Couser, 1988). 
RPGN can be primary or secondary. Secondary forms occur in any form of severe 
glomerulonephritis including membranoproliferative GN, IgA nephropathy, post infectious 
GN, and systemic lupus erythematous (SLE). Primary RPGN is an autoimmune disease 
which is divided into three immunopathologic categories:(Rutgerset al., 2004; Haas .& 
Eustace, 2004): 
Type 1 RPGN: glomerulonephritis with antibodies directed against the glomerular basement 
membrane (GBM) (anti -GBM mediated GN) 
Type II RPGN: immune-complex induced glomerulonephritis 
Type III RPGN: Antineutrophil cytoplasmic antibody associated glomerulonephritis 
(ANCA-associated glomerulonephritis or pauci-immune GN) 
RPGN type 1 and 2 are responsible for 10 -20 %  and 40 %  of all cases respectively. RPGN 
type 2 can be found in different forms of systemic disease such as post infectious 
GN(PSGN), Ig-A nephropathy, Henoch–Schönlein purpura (HSP), SLE, membranous 
GN(MGN) or membrano- proliferative GN(MPGN). A few cases of idiopathic immune -
complex-mediated RPGN have been reported (Jindal, 1999). 
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1. Infection of the respiratory tract with prerenal renal failure and / or postinfectious 
glomerulonephritis or hematuria in IgA nephropathy  
2. Lung cancer with immune-complex nephritis.  
4. Conclusions 
Since early treatment with the mentioned diseases is critical, the diagnosis has to be 
established quickly - the fast antibody-diagnostic and diagnostic imaging have a central role.  
5. Acknowledgment 
This work was supported by the Robert-Bosch Foundation. 
6. References  
Niles JL et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated 
condition. Arch Intern Med 1996; 156: 440-445. 
Salant, DJ. Immunopathogenesis of crescentic glomerulonephritis and lung purpura. Kidney 
Int 1987; 32: 408-425. 
Boyce NW, Holdsworth SR. Pulmonary manifestations of the clinical syndrome of acute 
glomerulonephritis and lung hemorrhage. Am J Kidney Dis 1986; 8: 31-36. 
Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: A 4-year, single-center 
experience. Am J Kidney Dis 2002; 39: 42-47. 
De Groot K, Schnabel A. Internist (Berl). 2005; 46: 769-781. 
Hauber HP, Zabel P. Lunge und Autoimmunerkrankungen – Klinik und Diagnostik. Dtsch 
Med Wochenschr 2007; 132: 1633-1638. 
Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-418. 
Saxena et al., Circulating autoantibodies as serological markers in the differential diagnosis of 
pulmonary renal syndrome. J Intern Med 1995; 238: 143-152. 
Jennette JC et al. Nomenclature of systemic vasculitides: Proposal of an international 
consensus conference. Arthritis Rheum 1994; 37, 187-192.  
Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997; 314-322. 
Gallo G. Renal complications of B-cell dyscrasias. N Engl J Med 1991; 324: 1889- 1990. 
Hoffmann GS et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 
1992;116: 488-498.  
Masi AT et al. The American College of Rheumatology 1990 criteria for the classification of the 
Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 
33: 1094-1100. 
Goodpasture EW. The significance of certain pulmonary lesions in relation to the aetiology of 
pneumonia. Am J Med Sci 1919; 158: 863-870. 
Salama AD et al. Goodpastures`s disease. Lancet 2001; 358: 917-920. 
Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003; 64: 1535-1550. 
Hudson BG et al. Alport`s syndrome, Goodpasture`s syndrome, and type IV collagen. N Engl J 
Med 2003; 348: 2543-2556. 
Markus HS, Clark JV. Pulmonary hemorrhage in Henoch-Schönlein purpura. Thorax 1989; 44: 
525-526. 
18 
RPGN - Clinical Features,  
Treatment and Prognosis 
Mitra Naseri 
Mashhad University of Medical Sciences,  
Islamic Republic of Iran 
1. Introduction  
Rapidly progressive glomerulonephritis (RPGN) is one of the nephrology emergencies 
which needs special attention. RPGN is a clinical description which determines by 
symptoms and signs of glomerulonephritis (GN); edema, hypertension and gross 
hematuria, and evidence of acute renal failure(severe decrease in glomerular filtration rate 
presents as oliguria or anuria, and increased serum levels of BUN and creatinine). Definite 
diagnosis of the disorder is based on kidney biopsy's findings. Early diagnosis and 
appropriate treatment plays a critical role in renal saving and preventing permanent 
glomerular damage. 
This chapter will focus on clinical manifestations, therapeutic protocols and prognostic 
factors in patients with different subtypes of RPGN. 
Rapidly progressive glomerulonephritis (RPGN) is dened as a syndrome with abrupt or 
insidious onset of hematuria, proteinuria, anemia, and rapidly progressing acute renal 
failure(ARF), and special findings on light microscopy examination of kidney biopsy's 
specimen; crescentic lesions which usually involved most glomerular architectures 
(Hirayama, et al., 2008; Rutgersetal., 2004). It also characterized by rapid loss of renal 
function (GFR<50% within 3 months)with histological findings of crescent lesions which 
usually involves>50 % of glomeruli (Couser, 1988). 
RPGN can be primary or secondary. Secondary forms occur in any form of severe 
glomerulonephritis including membranoproliferative GN, IgA nephropathy, post infectious 
GN, and systemic lupus erythematous (SLE). Primary RPGN is an autoimmune disease 
which is divided into three immunopathologic categories:(Rutgerset al., 2004; Haas .& 
Eustace, 2004): 
Type 1 RPGN: glomerulonephritis with antibodies directed against the glomerular basement 
membrane (GBM) (anti -GBM mediated GN) 
Type II RPGN: immune-complex induced glomerulonephritis 
Type III RPGN: Antineutrophil cytoplasmic antibody associated glomerulonephritis 
(ANCA-associated glomerulonephritis or pauci-immune GN) 
RPGN type 1 and 2 are responsible for 10 -20 %  and 40 %  of all cases respectively. RPGN 
type 2 can be found in different forms of systemic disease such as post infectious 
GN(PSGN), Ig-A nephropathy, Henoch–Schönlein purpura (HSP), SLE, membranous 
GN(MGN) or membrano- proliferative GN(MPGN). A few cases of idiopathic immune -
complex-mediated RPGN have been reported (Jindal, 1999). 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
300 
Interestingly different forms of RPGN share similar clinical features including hematuria, 
proteinuria, edema, hypertension and symptoms of ARF .patients with Anti –GBM anti - 
body or pauci-immune RPGN (ANCA -associated vasculitis) may have pulmonary 
hemorrhage and hemoptysis (Jindal, 1999). In pauci-immune RPGN the initial symptoms 
are non-specific; often fatigue, fever, night sweats and artheralgias are first clinical 
manifestations (Jindal, 1999). 
2. Histopathology characteristics of RPGN and laboratory findings 
Variable clinical manifestations and non-specific histologic changes complicate diagnosis 
and classification of vasculitis .To confirm the diagnosis light microscopy and immuno - 
fluorescence examinations of kidney biopsy shouldbe accompanied by appropriate serologic 
tests, includingANCA (Vizjak et al., 2003). 
2.1 Light microscopy findings 
Histopathologically, RPGN is characterized by avasculitis which involves glomerular 
capillaries, and results in formation of cellular crescents within most glomeruli (Hricik et al., 
1998). The hallmark histologic lesions are crescents; a morphologic expression of severe 
glomerular injury. In severe glomerular injury rupture of the glomerular capillaries allows 
inflammatory mediators to spill into Bowman's space, resulting in epithelial cell proliferation 
and invasion of monocyte and macrophage to Bowman's space (Couser, 1988; Jennette & Falk, 
1998; Jennette &Thomas, 2001). Crescents are divided into cellular, fibro cellular or fibrous 
types. Halmarks of irreversible glomerular or tubulointerstitial injuries are glomerular 
sclerosis, fibrous or fibro cellular crescents, and interstitial fibrosis.The lesions usually are seen 
in various stages of activity or resolution.Necrotizing inflammation in small cortical arteries is 
reported in 10   % of biopsy specimens .Inflammation of medullary vasa rectae with papillary 
necrosis is another finding that may be found(Lionakiet al., 2007). 
In acute pauci -immune glomerulonephritis(RPGN type III  ) fibrinoid necrosis accompanies 
crescents. These lesions occur at the same frequency irrespective of the presence or absence 
of associated vasculitis (DAgati et al., 1986). Acute lesions range from focal segmental 
fibrinoid necrosis affecting less than 10 %of glomeruli to severe diffuse necrotizing and 
crescentic glomerulonephritis that may injure all glomeruli.Periglomerular granulomatous 
inflammation may occur, but is not specific for pauci -immune glomerulonephritis 
(Lionakiet al., 2007). 
3. Histopathology characteristics on immunoflurecent microscopy 
Anti-GBM glomerulonephritis characterized by linear staining for IgG and usually C3 along 
the glomerular capillary. Immune complex-mediated glomerulonephritis, which is found in 
severe forms of various types of glomerulonephritis such as PSGN, IgA nephropathy, and 
lupus nephritis, characterized by granular glomerular staining for one or more immuno- 
globulins and/or complement components, and pauci-immune glomerulonephritis 
characterized by mild or absent glomerular tuft staining for immunoglobulins and/or 
complement (Rutgerset al., 2004  .)  
Anti-neutrophil cytoplasmic antibodies(ANCAs) associated glomerulonephritis are usually 
pauci immune; however, immunofluorescence microscopy often reveals a low level of 
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staining (less than +2, in the 0–4 scale (Harriset al., 1998). Figure 1 presents histologic 
findings in light and immunoflurecent microscopy. 
3.1 Electron microscopy findings 
On electron microscopy examination absence of electron-dense immune complex deposits 
(type I RPGN), multiple electron-dense deposits (type II RPGN), and few or no electron -





Fig. 1. Histopathologic findings in light and immunoflurecent microscopy (Lionakiet al., 2007) 
a/left; light microscopic demonstration of ANCA -associated necrotizing GN (with a crescent), 
arrows; (alveolar capillaritis with intra -alveolar hemorrhage); arrow; middle (and pulmonary 
necrotizing granulomatous inflammation with a multinucleated giant cell) arrow; right 
b/middle; Immunofluorescence microscopy can separate crescentic glomerulonephritis into anti -
GBM with linear IgG staining, ( left) immune complex with granular staining, (right); or pauci -
immune categories with little or no immunoglobulin staining  
4. Anti-neutrophil cytoplasmic and anti-GBM antibodies 
Anti -neutrophil cytoplasmic antibodies(ANCAs )are characteristic markers of small vessel 
vasculitides; Wegener’sgranulomatosis(WG), Microscopic polyangiitis(MPA), Churg -Strauss 
Syndrome(CSS), and idiopathic pauci -immune necrotizing glomerulonephritis for them the 
term ANCA associated vasculitides(AAV) has long being used(Jennette et al., 1989). 
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Fig. 2. Electron microscopy findings (Haas, M. &Eustace, 2004) 
C: Electron microscopy showing multiple sub-epithelial electron-dense deposits, some 
appearing partially resorbed, with extension of the glomerular basement membrane (GBM) 
around the deposits (uranyl acetate and lead citrate stain, original magnification ×6300)  
F: Electron microscopy showing a large subepithelial deposit in a “notch” area (arrow), as 
well as mesangial deposits (uranylacetate and lead citrate stain, original 
magnification×3800). 
The standard approach for detection of ANCA is indirect immunofluorescence (IIF) 
technique followed by antigen-specific quantitative assays .Myeloperoxidase (MPO) and 
proteinase3 (PR3) are major ANCA antigens (Falk .&Jennette, 1988; Goldschmeding et al., 
1989; Niles et al., 1989). 
In patients with RPGN, there are two major sub classes of ANCA, namely perinuclear  
(p - ANCA) and cytoplasmic (c - ANCA) (Guillevinet al., 1999  .) The main epitope of p -ANCA 
is myeloperoxidase(MPO), and that of c-ANCA is proteinase-3 (PR3) (Asarodet al., 2000). 
MPO-ANCAis a useful serum marker for MPA and idiopathic pauci -immune crescentic GN, 
and PR3-ANCA is regarded as a serum marker for Wegener’s granulomatosis and MPA  
(Asarodet al., 2000). Majority (approximately80- 85%) of cases of pauci-immune crescentic 
glomerulonephritis are ANCA positive(Haueret al., 2002;Jennette, 2003). Greater than 95% 
of cytoplasmic ANCA are PR3-ANCA and >95 %of perinuclear ANCA are MPO -ANCA 
(Lionakiet al., 2007). The c and p-ANCAs are mostly directed against the azurophilic 
granule proteins proteinase 3 (PR3)and myeloperoxidase (MPO), respectively .Detection of c 
and especially p-ANCAs are not equivalent to the presence of PR3-and MPO-ANCA. It is 
recommended to detect ANCA by an antigen-specific ELISA (Savigeet al., 2000; Cohen 
Tervaert et al., 1991). 
Anti-GBM antibodies which are directed to the non-collagenous part ofthe α 3 chain of type 
IV collagen, can also be evaluated byboth IIF and ELISA(Rutgerset al., 2004) .The ANCA -
GBM dot-blot is a qualitative assay that uses nitrocellulose strips on which purified antigens 
are blotted at preset spots .MPO and PR3 antigens that are used in these tests are produced 
from human leukocytes .The GBM-ANCA dot-blot assay has been revealed reactivities that 
had not been detected by ELISA(Table 1) (Rutgers et al., 2004). 
 




Table 1. Characteristics of the GBM-ANCA Dot-Blot Assay (Rutgerset al., 2004) 
5. RPGN, Pulmonary–renal syndrome (PRS), and ANCA-associated vasculitis 
(AAVs) 
The ANCA-associated vasculitis(WG, MPA, and CSS) are a group of rare autoimmune 
conditions characterized by the development of necrotizing vasculitis .They share a number 
of clinical features and are therefore treated using similar treatment protocols. 
The AAVs are rare with an annual incidence of 20/million in Europe, with WG as the most 
common and CSS the least frequent (Ntatsaki et al., 2010).In far-east, MPA is more common 
than WG .It's thought that they arise from interaction between an environmental factor and 
a genetically predisposing agent(Ntatsaki et al., 2011). 
Pulmonary–renal syndrome (PRS) is defined as combination of diffuse alveolar hemorrhage 
(DAH) and glomerulonephritis(Savageet al., 1997;Seo& Stone, 2004;Jennette& Falk, 2003). 
This syndrome is caused by different diseases, including various forms of primary systemic 
vasculitis especially WG and MPA, ANCA-associated systemic vasculitis(AAV), Good 
pasture's syndrome, SLE, and infection-associated or drug induced glomerulonephritis 
(Westmanm et al., 1997;Brusselle, 2007). 
Immunologic injuries or non-immunologic mechanisms are involved in pathogenesis of 
PRS .Immunologic mechanisms such as production of anti-GBM antibodies, ANCA, 
immune complexes mediated injuries and non-immunologic mechanisms such as 
thrombotic microangiopathy(Rondeauet al., 1989 ) have been suggested .Pulmonary 
involvement in the majority of cases is the result of small-vessel vasculitis that involves 
arterioles, venules and alveolar capillaries (necrotic pulmonary capillaritis). These lesions 
are clinically expressed with DAH(Levy. &Winearls, 1994). In the majority of cases the 
underlying renal pathology is a form of focal proliferative glomerulonephritis  (Jayne et al., 
2000), with fibrinoid necrosis, as well as micro vascular thrombi, and extensive crescent 
formation accompanies glomerular tuft disease (Walters et al., 2010). 
According to results of ANCA pulmonary renal syndrome can be categorized into two sub -
groups: 
1. ANCA-positive Pulmonary–renal syndrome 
2. ANCA-negative Pulmonary–renal syndrome 
Circulating ANCAs are detected in the majority of pulmonary–renal syndromes( The 
Wegener's Granulomatosis Etanercept Trial [WGET] Research Group2005; Dickersinet al., 
1994.)Three major systemic vasculitis syndromes are associated with positive ANCAs 
consists of Wegener’s granulomatosis, microscopic polyangiitis and Churg–Strauss 
syndrome (The Wegener's Granulomatosis Etanercept Trial[ WGET]Research Group, 2005), 
and idiopathic pulmonary–renal syndrome(Bolton&turgill, 1989). 
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Majority of cases of pulmonary-renal syndromes are related to ANCA associated vasculitis 
(Brusselle, 2007).Pulmonary–renal syndrome in ANCA-negative systemic vasculitis is very 
rare and has been reported in Behçet’s disease, HSP, IgA nephropathy and in mixed cryo  –
globulinaemia and rarely in thrombotic thrombocytopenic purpura(TTP)(Naseri & 
Zabolinejad, 2008). 
ANCA-positive Pulmonary–renal syndrome :More than 80 %of patients with necrotizing 
pauci immune small -vessel vasculitis have circulating ANCA (Jennette .&Falk, 1997). The 
main clinicopathological expressions of AAV are WG, MPA, CSS and renal -limited 
vasculitis (RLV). The highest incidence is for WG in northern Europe (Haugebergm etal., 
1998; Watts et al., 2000, 2008; Laneet al., 2000; Reinhold-Keller et al., 2005), while the 
incidence of MPA/RLV is higher in Japan (Fujimotoet al., 2006). 
Wegener's granulomatosis (WG  ): Friedrich Wegener in 1939 was the firsti nvestigator to 
recognize a group of diseases characterized by extra vascular necrotizing granulomatous 
inflammation of the respiratory tract with vasculitis and/or glomerulonephritis (Schultz 
&Tozman, 1995). In 1983, Fauci et al reported details of 85 patients with Wegener's 
granulomatosis followed over a 21-year period. Their diagnosis was based on upper and 
lower respiratory tract complications, renal disease, and variable involvement of other 
organs with disseminated vasculitis .Tissue biopsies confirmed the characteristic clinical 
findings (Fauciet al., 1983).Pathologically Wegener’s granulomatosis was characterized by 
small-vessel necrotizing vasculitis and granulomatous inflammation involving mostly the 
upper and lower respiratory tracts and the kidneys (Sugimoto et al., 2007). 
Diffuse alveolar hemorrhage is the most serious complication in small-vessel vasculitis. 
Respiratory symptoms including cough and hemoptysis.CXR or chest CT-scan may reveal 
diffuse lung infiltrate.Clinical manifestations, pathologic and serologic findings play 
important role in the diagnosis of WG. 75 - 90 %of patients with active disease have PR3 -
ANCAs (Langford, 2005;, Ozaki, 2007). The role of PR3-ANCA in the pathogenesis of the 
disease is not clear, but in vitro evidence suggests that PR3 -ANCA can directly or indirectly 
damage endothelial cells (Preston et al., 2002).With the recognition of association between 
ANCAs and Wegener’sgranulomatosis, the concept of Wegener’s granulomatosishas been 
modified and recently a less restrictive definition has been proposed, termed ‘‘Wegener’s 
vasculitis.’’ This term includes ANCA-positive patients with clinical presentations of WG 
such as sinusitis, pulmonary infiltrates, nephritis, and documented necrotizing vasculitis, 
but without biopsy-proven granulomatousin flammation. Both classic Wegener’s 
granulomatosis and Wegner's vasculitis are different manifestations of the same disease 
process.The term ‘‘Wegener’ssyndrome "is a more generic term suggested by the working 
classification of ANCA-associated vasculitides(Tervaert, &Stegeman, 2003). 
Diagnostic criteria have been reported by the research group of intractable vasculitis, 
ministry ofHealth, Labor, and Welfare {MHLW  } of Japan for definite diagnosis of AAV 
including WG (Table 2) (Ozaki, 2007).Necrotizing granulomatous lesions commonly affect 
the ear, nose and throat (E), lung (L), and kidney(K).Systemic symptoms in WG are 
classified as the following : 
1. E Symptoms: nasal symptoms; purulent rhinorrhea, epistaxis, and a saddle nose, eye 
symptoms; ophthalmic pain, visual disturbance, and exophthalmia, ear symptoms; 
otalgia and otitis media, and throat symptoms; pharyngeal ulcer, hoarseness, and 
laryngeal obstruction. 
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2. lung (L)symptoms: bloody sputa, cough, and dyspnea  





Table 2. Diagnostic criteria for Wegener’s granulomatosis (Ozaki, 2007) 
Biopsies of the nasal mucosa, lung, and kidney reveal necrotizing granulomatous vasculitis 
and necrotizing crescentic glomerulonephritis without immune deposits(Ozaki, 2007). WG 
with E, L, and K involvement is classified as the generalized form, while when there is no 
kidney involvement, E only, L only, or E  +L, the term of limited form is used. The 
therapeutic strategies are different for each forms (Ozaki, 2007). 
Microscopic polyangiitis (MPA) 
Renal and pulmonary symptoms are characteristic in MPA, and interstitial pneumonitis  
and pulmonary hemorrhage are common clinical features .MPO -ANCA is positive in  
50-75% of patients and biopsy of the lung and kidney reveals necrotizing vasculitis of 
arterioles, capillaries, and venules with few immune deposits necrotizing and crescentic 
GN (Ozaki; 2007). Granulomatous inflammation and asthma are not seen in MPA (Jennette 
&Falk, 1997).  
Table 3 presents diagnostic criteria for microscopic polyangiitis(Ozaki, 2007). 
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Allergic granulomatous angiitis (AGA) or Churg-Strauss syndrome(CSS) 
Churg and Strauss was firstly described allergic granulomatous angiitis(Churg, & Strauss, 
1951). The disease is characterized by presence of asthma, eosinophilia, and necrotizing 
granulomatous inflammation .Clinical manifestations of small-vessel vasculitis; palpable 
purpura of the lower extremities, mononeuritis multiplex, abdominal pain, and gastro  - 
intestinal bleeding develop several years after the onset of asthma.Positive MPO-ANCA are 
seen and skin biopsy shows necrotizing vasculitis of small vessels with massive eosinophilic 
infiltration and extravascular granulomatosis(Ozaki, 2007). Table 4 presents diagnostic 
criteria for CSS(Ozaki, 2007). 
 
 
Table 3. Diagnostic criteria for microscopic polyangiitis(Ozaki, 2007) 
SLE and AAV 
Systemic lupus erythromatosis is an autoimmune disorder .Variety of autoantibodies are 
present in SLE patients including ANCA which have been reported in 3 -69 %of 
cases(Molnaretal., 2002;Edgar et al., 1995; Pradhan et al., 2004).Some studies(Chinet al., 2000; 
Nishiyaet al., 1997) have reported p -ANCA in 37.3 -42 %of patients with lupus nephritis, 
mainly those who have diffuse proliferative GN(DPGN), and minority of patients without 
renal involvement. In Pradhan et al's study predominant ANCA pattern was p-ANCAwhile 
c-ANCApattern was not found in any patient(Pradhan et al., 2004).Their study revealed that 
ANCA can be used as a serological marker to differentiate vasculitides in lupus nephritis 
cases from SLE without nephritis. 
 










Table 5. Correlation of organ involvement with ANCA serology and other autoantibodies in 
SLE patients(Pradhan et al., 2004) 
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Atypical or X-ANCA has been reported among SLE patients by Savige et al, This antibody 
showing specificities tocathepsin G and lactoferrin (Savige et al., 1996). Table 5 shows 
correlation of organ involvement with ANCA serology and other autoantibodies in SLE 
patients (Pradhan et al., 2004 ). 
6. Treatment of RPGN 
Untreated RPGN typically progresses to end -stage renal disease over a period of weeks to a 
few months. Early diagnosis and initiation of appropriate therapy is essential to minimize 
the degree of irreversible renal injuries. The therapy of most patients involves pulse methyl   -
prednisolone followed by daily oral prednisone, oral or intravenous (IV) cyclophosphamide, 
and in some cases plasmapheresis. Empiric therapywith IV methylprednisolone should be 
begun in patients with severe disease with adding of plasmapheresisespecially if the patient 
has hemoptysis (Appel et al., 2010), If a renal biopsy performs soon after initiating empiric 
therapy the histological abnormalities will not alter. 
6.1 Treatment of ANCA associated vasculitis (AAV) 
Pauci-immune crescentic glomerulonephritis is a severe form of glomerular inflammation, 
which if left untreated, usually progresses to end-stage renal failure in weeks or months, 
AAV is responsible for 80 %of cases(Sakaiet al., 2002).The evidence based studies for the 
management of the AAV is well established and the strategy of induction, consolidation and 
maintenance therapy is accepted. Guidelines have been designed by both the British Society 
for Rheumatology (Lapraiket al., 2007) and European league against rheumatism 
(Mukhtyaret al., 2009) on the management of the AAVs. The AAVs are conventionally 
treated with a strategy of remission induction followed by maintenance therapy using 
glucocorticoids combined with cyclophosphamide during induction and azathioprine 
(AZA) for maintenance (Ntatsaki et al., 2011). Current standard treatment is combination of 
cyclophosphamide and steroids, but the optimal doses, routes of administration, and 
duration of therapy remain poorly defined (Hotta, et al., 2005). As immunosuppressive 
therapies increases the risk of infection, therefore one of the most important aspect of 
successful treatment srategies should be sufficient attenuation of inflammation without 
serious immunosuppression which leading to life-threatening infection. 
Corticosteroids 
For the induction of remission corticosteroid regimen is recommended which includea daily 
intravenous pulse of methylprednisolone (15 mg /kg)for 3 days, followed by oral prednisone 
(1mg/kg/day) for 3 weeks, which then tapered progressively (Pagnouxet al., 2008). In pauci-
immuneRPGN and MPA usefulness of combination of methylprednisolone pulse therapy 
for 3 days, oral corticosteroid of 1mg/kg/day for 1 month, and cyclophos -phamide of  
2 mg  / kg/day for 6 to 12 months has been confirmed in several studies (Salama, et al., 2002;  
J indal, 1999; Hoffman, 1997; Guillevin et al., 1991). 
Cyclophosphamide(CYC) 
Different therapeutic agents have been used in treatment of AAV.Standard therapy for AAV 
is treatment with combination of cyclophosphamide and prednisolone(Pagnouxet al., 2008). 
After induction with daily oral or pulse intravenous cyclophosphamide therapy, relapse 
rates of 15  % at 12 months(Haubitzet al .,  1998), and 38  % at 30 months(Guillevinet al., 1997) 
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have been reported.In long-time follow-up 50 %of patients experience relapse within 5 years 
(Hoffman et al., 1992).Treatment with cyclophosphamide is effective, but also very toxic 
(Hoffmanet al., 1992).Repeated treatment with cyclophosphamide increases adverse effects. 
To avoid cyclophosphamide - related toxicity, alternative induction treatments are needed 
(Stassen et al., 2007). 
Mycophenolate mofetil (MMF)  : MMF is considered as a potent immuno suppressive drug 
with favorable side effects, so it has been considered as an alternative to cyclophosphamide 
treatment in patients with AAV (Stassen et al., 2007;Pesavento et al., 1999; Haidinger et al., 
2000; Joy et al., 2005;Koukoulaki, & Jayne, 2006). MMF is a drug which usually is well 
tolerated. In patients with auto-immune diseases such as SLE, MMF is effective in inducing 
remission with short-term efficacy which is comparable with cyclophosphamide (Chanet al., 
2000, 2005; Ong et al., 2005; Ginzler etal., 2005). Induction treatment with MMF and oral 
steroids consisted of oral MMF 1000 mg twice daily and oral prednisolone 1 mg/kg once 
daily (maximum 60 mg). If patients are still in remission after 1 year, MMF is tapered by  
500 mg every 3 months and Prednisolone is tapered after 6 weeks by 10 mg every2 weeks 
until a dose of 30 mg was reached, and by 5 mg every2 weeks until 10 mg. Next, the dose is 
reduced2.5 mg every month (Stassen et al., 2007). Stassen et al reported that combination of 
oral steroids and MMF induced complete and partial remission in 78% and 19 %of patients 
respectively(Stassen et al., 2007), Therefore they suggested oral steroids with MMF in 
patients with relapses of AAV intolerant to cyclophosphamide therapy.Bone marrow 
suppression is an uncommon side effect of MMF treatment which can result in anemia, 
leucocytopenia or thrombocytopenia in a number of patients .Fortunately this side effect 
responds to temporary dose reduction in nearly all patients( Stassen et al., 2007). 
Methotrexate(MTX) 
For remission maintenance in patients who are intolerant of AZA or relapse while taking it 
other alternative agents such as MTX or MMF have been recommended (Ntatsaki et al., 
2011). Methotrexate is an alternative drug for cyclophosphamide which is currently studied 
(De Grootet al., 2005; Sneller et al., 1995; Stoneet al., 1999). According to one randomized (De 
Groot et al., 2005) and two uncontrolled studies (Sneller et al., 1995; Stoneet al., 1999) MTX 
effectively induced remission in 90 %and 71–74 %of patients respectively, but relapses 
occurred more frequently than when cyclophosphamide was used (70%vs. 47%)(De Groot et 
al., 2005). MTX is excreted by kidney, therefore should be used with caution in those with 
renal impairment (Ntatsaki et al., 2011; M etzler et al., 2007). 
Groot et al conducted an unblended, randomized, controlled trial study todetermine 
whether MTX could replace treatment with cyclophosphamide and oral corticosteroids(De 
Grootet al., 2005).They found that MTX can replacecyclophosphamide for initial treatment 
of early AAV, but it was less effective for induction of remission in patients with extensive 
disease or those with pulmonaryinvolvement .In addition the relapse was more common in 
patients who treated with MTX than those who received cyclophosphamide.Patients were 
randomized to receive either MTX 7.5 mg/week increasing to 20 mg/week at 8 weeks or LEF 
loading dose 100 mg/day for 3 days, followed by20 mg /day until Week 4, then 30 mg/day 
for 2 years .Their study showed no differences in efficacy or safety between two treatments. 
Pagnoux et al(Pagnouxet al 2008)compared AZA with MTX in maintaining remission in WG 
and MPA patients who had achieved remission with intravenous pulse of cyclophos - 
phamide. They found no significant difference in adverse events and relapses rates either 
during the 12-month treatment phase or subsequent follow-up between two groups. 
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ANCAs can induce cytokine-primed neutrophils undergo degranulation and respiratory 
bursts during which they release toxic oxygen species and lytic enzymes (Falk et al., 1990). 
Anti-idiotype antibodies with inhibitory effects on ANCA in vitro have been found in a 
pooled human gamma globulin preparation (Pall et al., 1994.)Evidence showed that IVIG 
acts in different phases of theimmune response including neutralization of circulating 
pathogenic antibodies, Fc receptor modulation, blockade or suppression of antibody -
dependent cell toxicity, natural killer cell function, auto antibodyproduction and 
complement activation, and acceleration of neutrophil apoptosis (Kazatchkine & Kaver i, 
2001; Tsujimoto et al., 2002). 
Beneficial effect of high-dose intravenous immunoglobulin in ANCA–associated vasculitis 
has been approved by different studies (Ito-Iharaet al., 2006; Tuso et al., 1992; Jayneet al., 
1993; Richteret al., 1995). Ito et al evaluated IVIG monotherapy (400 mg/kg/day for 5 days)in 
AAV patients. Their study showed that IVIG decreased the leukocyte count, C- reactive 
protein level, Birmingham Vasculitis Activity Score and improved the systemic symptoms 
(Ito-Iharaet al., 2006). Other studies suggested that IVIG induces remission in 40–82% of 
patients (Richter et al., 1995; Jayne et al., 1991; Levy et al., 1999; Jayne et al., 2000). IVIG 
appears to have an important place in the management of ANCA-RPGN, but it's indications 
have not been determined. Because IVIG is an expensive drug additional studies on its cost-
effectiveness and rational introduction into clinical practice are needed(Hotta et al., 2005). 
Anti-B-cell therapy(Rituximab) 
Beneficial effects of Rituximab which is a monoclonal antibody against anti-CD20 have been 
reported in several case series(Gottenberg et al., 2005; Omdal et al., 2005; Speckset al., 2001), 
and uncontrolled studies( Eriksson, 2005; Keogh et al., 2005a, 2005b; Smith et al., 2006).The 
main problem of treatment with rituximab is that relapses commonly occurred after 6–9 
months(Keogh et al., 2005a, 2005b; Smith et al., 2006). 
Apheresis therapies 
Results of clinical trial of apheresis therapies, either plasmapheresis or cytapheresis in AAV 
are disappointing. These studies showed no benefit(Glöckner et al., 1988; Cole et al., 1992; 
Zäuneret al., 2002), benefits just in dialysis dependent patients(Pusey et al., 1991)or benefits 
on preserving the renal function (Furutaet al., 1998; Hasegawaet al., 2005). 
Pusey et al .Found that plasma exchange is of added benefit in dialysis -dependent patients 
because in patients who were initially dialysis-dependent, renal function was more likely to 
have recovered when treated with plasma exchange plus drugs rather than drugs alone 
(Pusey et al., 1991).Report from the European community group suggested that adding 
plasma exchange to immuno suppressive therapy was not beneficial if there was severe 
tubular atrophy and fewer than 33 %of the glomeruli were normal(De Lind van 
Wijngaarden et al., 1998). 
In contrast to AAV in anti-GBM RPGN, the beneficial effect of plasma exchange has been 
well established .It might be attributable to the direct role of anti-GBM antibody in the 
pathogenesis of anti-GBM antibody RPGN, while in AAV no direct role for ANCA have 
been established (Hotta et al., 2005). The main advantage of Apheresis therapies is that no 
severe infectious episodes have been noted (Nagaseet al., 1998; Sawadaet al., 2003). Japan 
nation wide survey of RPGN (Yamagataet al., 2004) recommends cytapheresis in patients 
with aggressive forms of RPGN (rapid deterioration of renal function like the PR3-ANCA-
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associated RPGN, or pulmonary renal syndrome complicated by severe inflammation, or 
relapses with high MPO-ANCA titer). 
Anti-TNF-alpha 
 Insights into the role of Th1 cytokines in the pathogenesis of WG have led to trial therapies 
with antagonists of tumor necrosis factor -alpha (TNFα)and inhibitors of monocyte function, 
such as interleukin -10(Kamesh et al., 2002) .Etanercept  ( Enbrel ;soluble receptors), infliximab 
(Remicade;human -mouse chimeric antibody against TNF), and adalimumab (Humila; human 
anti -TNF antibody)are biological antagonists of TNF(Ozaki, 2007).Etanercept have been 
reported ineffective in maintaining remission and a higher rate of malignancy have been noted 
in patients who have received the drug (Wegener's granulomatosis etanercept trial [WGET] 
research group, 2005).In an open label study, infliximab was added to standard immuno 
suppressive therapy in 16 patients with acute AAV at first presentation or relapse and in 16 
with persistent disease despite multiple immuno suppressive regimens, 88% of patients 
achieved remission within a mean of 6.4 weeks(Boothet al., 2004) . 
Anti-T cell antibodies :Different studies have been reported that active systemic vasculitis 
is mediated in part by T cell-induced injury .This finding has led to the evaluation of anti-T 
cell antibodies in patients with Wegener's granulomatosis who are resistant to cytotoxic 
therapy (Lockwoodet al., 1993; Hagenet al., 1995; Schmittet al., 2004). 
In one study, the administration of a combination of two humanized monoclonal antibodies 
led to long-lasting remission in four patients with different forms of refractory vasculitis  
( Lockwoodet al., 1993).In other study 15 patients with refractory disease received anti-
thymocyte globulin(ATG)which resulted in a partial or complete remission in 9 and 4 
patients, respectively (Schmittet al., 2004).The role of these experimental therapies remains 
to be determined. 
Intravenous azathioprine  
High dose intravenous azathioprine has been tested for treating a variety of immune-
mediated diseases .In one report, four patients with WG who had not responded to oral 
cyclophosphamide were treated with monthly infusions of azathioprine) (Benensonetal., 
2005).Two reached remission of disease, one of whom developed renal involvement during 
relapse, which responded to retreatment. 
15-Deoxyspergualin  
15 -deoxyspergualin (gusperimus), a drug with anti -proliferative effect on antigen -
stimulated B cells, has been evaluated in a small number of patients who didn't respond 
to cyclophosphamide or had contraindications to the use of cyclophosphamide .The 
administration of 15 -deoxyspergual in 20 patients resulted in complete or partial 
remission in six and eight respectively(Bircket al., 2003).All patient experienced transient 
leucopenia with each treatment cycle. In another study seven patients treated with 15 -
deoxyspergualin and glucocorticoids, all reached complete or partial remission .The main 
problem was that to maintain remission prolonged treatment up to 4 years was 
required(Schmittet al., 2005).In addition serial monitoring of white blood count is 
required to avoid excessive leucopenia.  
Radiation therapy  
Radiation therapy has been evaluated in patients with WG and air way involvement (
Eagletonet al., 1979; Neviani et al., 2002).The use of ionizing radiation for non-malignant 
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In contrast to AAV in anti-GBM RPGN, the beneficial effect of plasma exchange has been 
well established .It might be attributable to the direct role of anti-GBM antibody in the 
pathogenesis of anti-GBM antibody RPGN, while in AAV no direct role for ANCA have 
been established (Hotta et al., 2005). The main advantage of Apheresis therapies is that no 
severe infectious episodes have been noted (Nagaseet al., 1998; Sawadaet al., 2003). Japan 
nation wide survey of RPGN (Yamagataet al., 2004) recommends cytapheresis in patients 
with aggressive forms of RPGN (rapid deterioration of renal function like the PR3-ANCA-
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associated RPGN, or pulmonary renal syndrome complicated by severe inflammation, or 
relapses with high MPO-ANCA titer). 
Anti-TNF-alpha 
 Insights into the role of Th1 cytokines in the pathogenesis of WG have led to trial therapies 
with antagonists of tumor necrosis factor -alpha (TNFα)and inhibitors of monocyte function, 
such as interleukin -10(Kamesh et al., 2002) .Etanercept  ( Enbrel ;soluble receptors), infliximab 
(Remicade;human -mouse chimeric antibody against TNF), and adalimumab (Humila; human 
anti -TNF antibody)are biological antagonists of TNF(Ozaki, 2007).Etanercept have been 
reported ineffective in maintaining remission and a higher rate of malignancy have been noted 
in patients who have received the drug (Wegener's granulomatosis etanercept trial [WGET] 
research group, 2005).In an open label study, infliximab was added to standard immuno 
suppressive therapy in 16 patients with acute AAV at first presentation or relapse and in 16 
with persistent disease despite multiple immuno suppressive regimens, 88% of patients 
achieved remission within a mean of 6.4 weeks(Boothet al., 2004) . 
Anti-T cell antibodies :Different studies have been reported that active systemic vasculitis 
is mediated in part by T cell-induced injury .This finding has led to the evaluation of anti-T 
cell antibodies in patients with Wegener's granulomatosis who are resistant to cytotoxic 
therapy (Lockwoodet al., 1993; Hagenet al., 1995; Schmittet al., 2004). 
In one study, the administration of a combination of two humanized monoclonal antibodies 
led to long-lasting remission in four patients with different forms of refractory vasculitis  
( Lockwoodet al., 1993).In other study 15 patients with refractory disease received anti-
thymocyte globulin(ATG)which resulted in a partial or complete remission in 9 and 4 
patients, respectively (Schmittet al., 2004).The role of these experimental therapies remains 
to be determined. 
Intravenous azathioprine  
High dose intravenous azathioprine has been tested for treating a variety of immune-
mediated diseases .In one report, four patients with WG who had not responded to oral 
cyclophosphamide were treated with monthly infusions of azathioprine) (Benensonetal., 
2005).Two reached remission of disease, one of whom developed renal involvement during 
relapse, which responded to retreatment. 
15-Deoxyspergualin  
15 -deoxyspergualin (gusperimus), a drug with anti -proliferative effect on antigen -
stimulated B cells, has been evaluated in a small number of patients who didn't respond 
to cyclophosphamide or had contraindications to the use of cyclophosphamide .The 
administration of 15 -deoxyspergual in 20 patients resulted in complete or partial 
remission in six and eight respectively(Bircket al., 2003).All patient experienced transient 
leucopenia with each treatment cycle. In another study seven patients treated with 15 -
deoxyspergualin and glucocorticoids, all reached complete or partial remission .The main 
problem was that to maintain remission prolonged treatment up to 4 years was 
required(Schmittet al., 2005).In addition serial monitoring of white blood count is 
required to avoid excessive leucopenia.  
Radiation therapy  
Radiation therapy has been evaluated in patients with WG and air way involvement (
Eagletonet al., 1979; Neviani et al., 2002).The use of ionizing radiation for non-malignant 
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disease is controversial .Current data do not support its use in systemic disorder like 
Wegener's granulomatosis (Stone et al., 2010). 
Stem cell transplantation: High-dose, myeloablative chemotherapy with stem cell 
transplantation has been used for the treatment of refractory severe vasculitis. There are few 
case reports of successful treatment in patients with WG (Kötteret al., 2005). More studies 
are required to determine the role of stem cell transplantation in the management of 
resistant AAV. 
Prophylaxis against Pneumocystis carinii pneumonia(PCP) 
Opportunistic infections especially Pneumocystis carinii pneumonia are potentially fatal 
complications of immuno suppressive therapy in RPGN and AAV .The estimated incidence 
of PCP is approximately 6 percent(Ognibeneet al., 1995).Different approaches to prophylaxis 
against PCP infection during initial immunosuppressive therapy have been suggested: 
trimethoprim-sulfamethoxazole one single strength (80 mg/400 mg)tablet daily or one 
double strength tablet (160 mg/800 mg)three times per week or Atovaquone in patients who 
are allergic to sulfonamides or do not tolerate trimethoprim-sulfamethoxazole.During 
treatment with methotrexate and glucocorticoids, the addition of trimethoprim -
sulfamethoxazole increases the risk of pancytopenia, therefore Atovaquone is suggested for 
prophylaxis in such patients..It has been recommended to continue PCP prophylaxis in 
maintenance immuno suppressive therapy phase until the CD4-positive T cell count exceeds 
300/microL(Mansharamaniet al., 2000).patients who have received trimethoprim-
sulfamethoxazole for prophylaxis during induction, should continue the prophylaxis when 
azathioprine is used and switch to atovaquone when methotrexate is replaced for 
maintenance therapy. 
Some patients have low CD4 -positive T cell counts for prolonged periods after the cessation 
of cyclophosphamide and require prolonged PCP prophylaxis; in addition glucocorticoids 
should be tapered to the lowest possible dose .If patients develop neutropenia when receive 
prophylaxis, the drug should be switched to atovaquone (Stoneet al., 2010). 
Management of RPGN and AAV in pregnancy: As with active disease in non-pregnant 
patients, prednisone alone is relatively ineffective, and to induce remission combined 
therapy with cyclophosphamide is needed.The major challenges of treatment during 
pregnancy are potentially serious adverse effects which can occur with both MMF and 
cyclophosphamide. In addition, insufficient data about the safety of rituximab is available. 
High risk of skeletal and palatal defects, as well as malformations of the limbs and eyes has 
been noted in case of fetal cyclophosphamide exposure during the first trimester.Although 
fetal risk is much smaller during the second and third trimesters, pancytopenia and 
impaired fetal growth can occur .MMF fetal exposure increases the risk of miscarriage and 
congenital malformation such as cleft lip and palate .As a result, some consider MMF to be 
contraindicated in pregnancy.The safer immuno suppressive drugs that have been effective 
in WG and MPA include glucocorticoids, azathioprine, cyclosporine and tacrolimus. 
Alternatives that could be considered include cyclophosphamide or rituximab in the second 
or third trimester once organogenesis is complete(Stoneet al., 2010). 
6.1.1 Prognosis of RPGN and ANCA associated vasculitis 
RPGN If left untreated typically progresses to end-stage renal disease over a period of 
weeks to a few months .Patients with fewer crescents may present slowly progressive 
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course(Baldwin et al., 1987) .Despite various immuno suppressive therapy protocols 
mortality of ANCA positive RPGN is still high, and the major cause of death is infectious 
complications(Booth et al., 2003; De Lind van Wijngaardenet al 1998).Outcome of AAV 
depends on patient 's age, degree of renal impairement at presentation and presence of 
pulmonary involvement. During the first 6 months of treatment mortality is very high as a 
result of aggressive course of the disease and toxic effects of early immuno suppressive 
treatments(Sakai et al 2002;Boothet al., 2003). Although the introduction of steroids and 
cyclophosphamide pulse therapy have improved the overall mortality of AAV, the 2-year 
mortality rate is still high ( 20   % in 2-year follow-up)(Booth et al., 2003;Hogan et al., 
1996;Falk et al 2000;Franssen et al 2000). Serum creatinine, dialysis dependency, and 
percentage of non-crescentic glomeruli at diagnosis have been considered as the best 
predictors of disease outcome(Bajema et al., 1999; Levy et al., 2001; Slotet al2003.و).The 
prognosis for patients with anti-GBM antibody disease is poor(Hirayama, et al., 2008), and 
renal survival and mortality rates of 20.9%and 23.3 % at 6 months after onset have been 
reported respectively. Early diagnosis and starting treatment without delay might improve 
the prognosis(Hirayama, et al., 2008.)A large nationwide survey of RPGN in Japan showed 
that mortality correlates with age, severity of renal dysfunction, presence of pulmonary 
involvement, and high C-reactive protein level( Sakaiet al., 2002). The mortality rate of 
Japanese patients was higher than in European or American patients because of the high 
incidence of lethal infection (Hotta et al., 2005). 
Japan Nationwide Survey of RPGN noted that 6 -month renal and patients' survival for PR3-
ANCA -associated RPGN were 88.2 %and 92.3% respectively, while for MPO -ANCA they were 
69.9 %and 74.2 %respectively(Yamagata et al., 2005).patients' survival is very low in MPA if 
the disease presents as pulmonary renalsyndrome (Gallagheret al., 2002 Lauque et al., 2000; 
Niles et al., 1996).Introduction of immuno suppressive agents considerably has improved the 
outcome of AAV over the past 30 years .WG and MPA if left untreated have a rapidly 
progressive and usually fatal course(Ntatsaki et al., 2011). Walton reported a mean survival of 
5 months in patients with WG, and mortality rate of 82 %  and 89 %in 1 and 2 year follow -up 
respectively (Walton, 1958).Standard treatments significantly have improved prognosis in WG 
and MPA, and some studies have reported 5 -year survival rates of 81 % for MPA and 87   % for 
WG  (Eriksson et al., 2009).in European Vasculitis Study, there was 11.1 %mortality at 1 year  (
Littleet al., 2010.)High age at presentation, severe renal involvement (high serum 
creatininelevel at presentation), pulmonary involvement, high ESR and high scores of disease 
activity and damage were poor prognostic factors (Holle et al., 2011). 
Suzuki et al 's study confirmed that ANCA-associated vasculitis is the most serious 
etiologies of  RPGN( Suzukiet al., 2010).In nationwide survey byYamagata and Koyama 
(Koyamaet al., 2009; Yamagata et al., 2005), and Suzuki's study main causes of patients' 
death were infectious complications, including DIC which was mainly linked to pneumonia 
by opportunistic pathogens( Pneumocystis carinii, Candida albicans, and cytomegalovirus). 
Researchers hope they will find new immuno suppressive drugs with highest efficacy, 
lowest side effects and high safety during pregnancy to improve patients' survival and 
quality of life .It's a dream that undoubetly will be achieved in next years.  
7. Conclusion 
RPGN is a nephrology emergency which needs special attention.If the disease left untreated 
typically progresses to end-stage renal disease over a period of weeks to a few 
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disease is controversial .Current data do not support its use in systemic disorder like 
Wegener's granulomatosis (Stone et al., 2010). 
Stem cell transplantation: High-dose, myeloablative chemotherapy with stem cell 
transplantation has been used for the treatment of refractory severe vasculitis. There are few 
case reports of successful treatment in patients with WG (Kötteret al., 2005). More studies 
are required to determine the role of stem cell transplantation in the management of 
resistant AAV. 
Prophylaxis against Pneumocystis carinii pneumonia(PCP) 
Opportunistic infections especially Pneumocystis carinii pneumonia are potentially fatal 
complications of immuno suppressive therapy in RPGN and AAV .The estimated incidence 
of PCP is approximately 6 percent(Ognibeneet al., 1995).Different approaches to prophylaxis 
against PCP infection during initial immunosuppressive therapy have been suggested: 
trimethoprim-sulfamethoxazole one single strength (80 mg/400 mg)tablet daily or one 
double strength tablet (160 mg/800 mg)three times per week or Atovaquone in patients who 
are allergic to sulfonamides or do not tolerate trimethoprim-sulfamethoxazole.During 
treatment with methotrexate and glucocorticoids, the addition of trimethoprim -
sulfamethoxazole increases the risk of pancytopenia, therefore Atovaquone is suggested for 
prophylaxis in such patients..It has been recommended to continue PCP prophylaxis in 
maintenance immuno suppressive therapy phase until the CD4-positive T cell count exceeds 
300/microL(Mansharamaniet al., 2000).patients who have received trimethoprim-
sulfamethoxazole for prophylaxis during induction, should continue the prophylaxis when 
azathioprine is used and switch to atovaquone when methotrexate is replaced for 
maintenance therapy. 
Some patients have low CD4 -positive T cell counts for prolonged periods after the cessation 
of cyclophosphamide and require prolonged PCP prophylaxis; in addition glucocorticoids 
should be tapered to the lowest possible dose .If patients develop neutropenia when receive 
prophylaxis, the drug should be switched to atovaquone (Stoneet al., 2010). 
Management of RPGN and AAV in pregnancy: As with active disease in non-pregnant 
patients, prednisone alone is relatively ineffective, and to induce remission combined 
therapy with cyclophosphamide is needed.The major challenges of treatment during 
pregnancy are potentially serious adverse effects which can occur with both MMF and 
cyclophosphamide. In addition, insufficient data about the safety of rituximab is available. 
High risk of skeletal and palatal defects, as well as malformations of the limbs and eyes has 
been noted in case of fetal cyclophosphamide exposure during the first trimester.Although 
fetal risk is much smaller during the second and third trimesters, pancytopenia and 
impaired fetal growth can occur .MMF fetal exposure increases the risk of miscarriage and 
congenital malformation such as cleft lip and palate .As a result, some consider MMF to be 
contraindicated in pregnancy.The safer immuno suppressive drugs that have been effective 
in WG and MPA include glucocorticoids, azathioprine, cyclosporine and tacrolimus. 
Alternatives that could be considered include cyclophosphamide or rituximab in the second 
or third trimester once organogenesis is complete(Stoneet al., 2010). 
6.1.1 Prognosis of RPGN and ANCA associated vasculitis 
RPGN If left untreated typically progresses to end-stage renal disease over a period of 
weeks to a few months .Patients with fewer crescents may present slowly progressive 
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course(Baldwin et al., 1987) .Despite various immuno suppressive therapy protocols 
mortality of ANCA positive RPGN is still high, and the major cause of death is infectious 
complications(Booth et al., 2003; De Lind van Wijngaardenet al 1998).Outcome of AAV 
depends on patient 's age, degree of renal impairement at presentation and presence of 
pulmonary involvement. During the first 6 months of treatment mortality is very high as a 
result of aggressive course of the disease and toxic effects of early immuno suppressive 
treatments(Sakai et al 2002;Boothet al., 2003). Although the introduction of steroids and 
cyclophosphamide pulse therapy have improved the overall mortality of AAV, the 2-year 
mortality rate is still high ( 20   % in 2-year follow-up)(Booth et al., 2003;Hogan et al., 
1996;Falk et al 2000;Franssen et al 2000). Serum creatinine, dialysis dependency, and 
percentage of non-crescentic glomeruli at diagnosis have been considered as the best 
predictors of disease outcome(Bajema et al., 1999; Levy et al., 2001; Slotet al2003.و).The 
prognosis for patients with anti-GBM antibody disease is poor(Hirayama, et al., 2008), and 
renal survival and mortality rates of 20.9%and 23.3 % at 6 months after onset have been 
reported respectively. Early diagnosis and starting treatment without delay might improve 
the prognosis(Hirayama, et al., 2008.)A large nationwide survey of RPGN in Japan showed 
that mortality correlates with age, severity of renal dysfunction, presence of pulmonary 
involvement, and high C-reactive protein level( Sakaiet al., 2002). The mortality rate of 
Japanese patients was higher than in European or American patients because of the high 
incidence of lethal infection (Hotta et al., 2005). 
Japan Nationwide Survey of RPGN noted that 6 -month renal and patients' survival for PR3-
ANCA -associated RPGN were 88.2 %and 92.3% respectively, while for MPO -ANCA they were 
69.9 %and 74.2 %respectively(Yamagata et al., 2005).patients' survival is very low in MPA if 
the disease presents as pulmonary renalsyndrome (Gallagheret al., 2002 Lauque et al., 2000; 
Niles et al., 1996).Introduction of immuno suppressive agents considerably has improved the 
outcome of AAV over the past 30 years .WG and MPA if left untreated have a rapidly 
progressive and usually fatal course(Ntatsaki et al., 2011). Walton reported a mean survival of 
5 months in patients with WG, and mortality rate of 82 %  and 89 %in 1 and 2 year follow -up 
respectively (Walton, 1958).Standard treatments significantly have improved prognosis in WG 
and MPA, and some studies have reported 5 -year survival rates of 81 % for MPA and 87   % for 
WG  (Eriksson et al., 2009).in European Vasculitis Study, there was 11.1 %mortality at 1 year  (
Littleet al., 2010.)High age at presentation, severe renal involvement (high serum 
creatininelevel at presentation), pulmonary involvement, high ESR and high scores of disease 
activity and damage were poor prognostic factors (Holle et al., 2011). 
Suzuki et al 's study confirmed that ANCA-associated vasculitis is the most serious 
etiologies of  RPGN( Suzukiet al., 2010).In nationwide survey byYamagata and Koyama 
(Koyamaet al., 2009; Yamagata et al., 2005), and Suzuki's study main causes of patients' 
death were infectious complications, including DIC which was mainly linked to pneumonia 
by opportunistic pathogens( Pneumocystis carinii, Candida albicans, and cytomegalovirus). 
Researchers hope they will find new immuno suppressive drugs with highest efficacy, 
lowest side effects and high safety during pregnancy to improve patients' survival and 
quality of life .It's a dream that undoubetly will be achieved in next years.  
7. Conclusion 
RPGN is a nephrology emergency which needs special attention.If the disease left untreated 
typically progresses to end-stage renal disease over a period of weeks to a few 
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months.When there is a strong clinical suspecsion special immuno suppressive treatment 
should be started as soon as possible (preferably after kidney biopsy) .Despite various 
immuno suppressive therapy protocols mortality of ANCA positive RPGN patients is still 
high, also prognosis of anti-GBM antibody disease is poor.acctually treatment of RPGN and 
AAV are serious challenges in nephrology medicine which needs more clinical trial studies 
in larger groups of patients. 
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1. Introduction 
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in 
adults. In the United States, almost half of patients entering ESRD programs were diabetic, 
and most of them (≥80%) had type 2 diabetes. This is due to the facts that 1) diabetes, 
particularly type 2, is increasing in prevalence; 2) diabetes patients now live longer; and 3) 
patients with diabetic ESRD are now being accepted for treatment in ESRD programs where 
formerly they had been excluded. The annual cost of caring for these patients, in the United 
States alone, exceeds $10 billion. The mortality rate of patients with diabetic nephropathy is 
high, and a marked increase in cardiovascular risk accounts for more than half of the 
increased mortality among these patients.  
The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin 
excretion (microalbuminuria), a stage termed as incipient nephropathy at which renal 
histology may be relatively normal or may reveal glomerulosclerosis. Diabetes can cause a 
variety of pathological abnormalities: isolated glomerular basement membrane thickening, 
mesangial expansion, nodular intercapillary and/or diffuse glomeruloscelorsis or even 
advanced diabetic sclerosis. While glomerulopathy is quite the hallmark of diabetic 
nephropathy, the frequency and functional significance of interstitial lesions in diabetic 
kidney is now well recognized. Furthermore, the occurrence of non-diabetic glomerulopathy 
or vasculitis alone or superimposed on diabetic nephropathy is increasingly being 
documented in literature. The pathogenesis is incompletely understood and is very 
vigorously being investigated.  
Once overt diabetic nephropathy (proteinuria) is present, ESRD can be postponed, but in 
most instances not prevented, by effective antihypertensive treatment and careful glycemic 
control. Treatment options currently are limited to obvious pathogenic factors while several 
innovative therapies are under evaluation. Therefore, in the last decades, there has been 
intensive research into pathophysiologic mechanisms of early diabetic renal injury, 
predictors of diabetic nephropathy risk, and early intervention strategies 
2. Epidemiology 
Type 1 diabetes — The epidemiology of diabetic nephropathy has been best studied in 
patients with type 1 disease, since the time of clinical onset is usually known. About 0.5% of 
 19 
Diabetic Glomerulopathy 
Mahmoud Barazi1, Harneet Kaur2 and Sharma Prabhakar1 
1Department of Internal Medicine,  
Texas Tech University Health Science Center, Lubbock, TX 
2Department of Internal Medicine,  
New York Medical College, Valhalla, NY 
USA 
1. Introduction 
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in 
adults. In the United States, almost half of patients entering ESRD programs were diabetic, 
and most of them (≥80%) had type 2 diabetes. This is due to the facts that 1) diabetes, 
particularly type 2, is increasing in prevalence; 2) diabetes patients now live longer; and 3) 
patients with diabetic ESRD are now being accepted for treatment in ESRD programs where 
formerly they had been excluded. The annual cost of caring for these patients, in the United 
States alone, exceeds $10 billion. The mortality rate of patients with diabetic nephropathy is 
high, and a marked increase in cardiovascular risk accounts for more than half of the 
increased mortality among these patients.  
The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin 
excretion (microalbuminuria), a stage termed as incipient nephropathy at which renal 
histology may be relatively normal or may reveal glomerulosclerosis. Diabetes can cause a 
variety of pathological abnormalities: isolated glomerular basement membrane thickening, 
mesangial expansion, nodular intercapillary and/or diffuse glomeruloscelorsis or even 
advanced diabetic sclerosis. While glomerulopathy is quite the hallmark of diabetic 
nephropathy, the frequency and functional significance of interstitial lesions in diabetic 
kidney is now well recognized. Furthermore, the occurrence of non-diabetic glomerulopathy 
or vasculitis alone or superimposed on diabetic nephropathy is increasingly being 
documented in literature. The pathogenesis is incompletely understood and is very 
vigorously being investigated.  
Once overt diabetic nephropathy (proteinuria) is present, ESRD can be postponed, but in 
most instances not prevented, by effective antihypertensive treatment and careful glycemic 
control. Treatment options currently are limited to obvious pathogenic factors while several 
innovative therapies are under evaluation. Therefore, in the last decades, there has been 
intensive research into pathophysiologic mechanisms of early diabetic renal injury, 
predictors of diabetic nephropathy risk, and early intervention strategies 
2. Epidemiology 
Type 1 diabetes — The epidemiology of diabetic nephropathy has been best studied in 
patients with type 1 disease, since the time of clinical onset is usually known. About 0.5% of 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
328 
the population in the United States and Central Europe has type 1 diabetes. The prevalence 
is higher in the northern Scandinavian countries and lower in southern Europe and Japan. 
Approximately 20 to 30 percent will have microalbuminuria after a mean duration of 
diabetes of 15 years (Orchard TJ 1990). Less than half of these patients will progress to overt 
nephropathy; microalbuminuria may regress or remain stable in a substantial proportion, 
probably related to glycemic and blood pressure control. 
Prior to the current period of intensive monitoring and treatment, it was suggested that 25 
to 45 percent of diabetic patients will develop clinically evident disease (the minimal 
criterion for which is a persistently positive urine dipstick for protein) (Parving HH, 1998). 
After so-called macroalbuminuria or clinical grade proteinuria (>300 mg albuminuria per 
day) develops, the majority of patients will progress to end-stage renal failure. 
 
 
Fig. 1. Estimated cumulative incidences of proliferative retinopathy or worse (A), 





The overall incidence of end-stage renal disease (ESRD) was also substantial, with reported 
rates of 4 to 17 percent at 20 years from time of initial diagnosis and approximately 16 
percent at 30 years (Nathan DM 2009). A strong predictor of the development of ESRD was 
the level of glycemic control during the first two decades of IDDM. The risk of ESRD in the 
group with the poorest glycemic control was almost threefold higher than in the middle 
group, and fourfold higher than the group with the best glycemic control. 
In comparison to these findings, subsequent studies have found that the renal prognosis of 
type 1 diabetes, including the rate of progression to ESRD, has dramatically improved over 
the last several decades. In addition to the importance of glycemic control, more aggressive 
blood pressure reduction and the use of angiotensin converting enzyme inhibitors have 
been shown to reduce the rate of progression of, though not prevent, diabetic nephropathy 
(Krolewski M 1996). 
Type 2 diabetes is about nine times more prevalent than type 1 diabetes, accounting in part 
for the greater contribution of type 2 diabetic patients to ESRD incidence. In Caucasians, the 
prevalence of progressive renal disease has generally been lower in type 2 diabetes than in 
type 1 disease (Cowie CC, 1989). However, this observation may not apply to all groups with 
type 2 diabetes, some of whom have had a more ominous renal prognosis. Studies in type 2 
diabetic patients from Western Europe and in Pima Indians from Arizona showed rates of 
progression to nephropathy similar to those of type 1 diabetic patients. The risk of developing 
ESRD is much higher in black than in white American patients with type 2 diabetes.  
As previously described, however, the use of modern therapies lowers the incidence of ESRD, 
even in groups at extremely high risk such as the Pima Indians. In a subsequent study, for 
example, the incidence of diabetic ESRD was noted to have declined significantly from the 
period 1991-1994 to the period 1999-2002 (32 to 15 cases per 1000 patient-years, respectively). 
 
 
Fig. 2. Cumulative incidence of ESRD according to duration of IDDM and according to 
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the population in the United States and Central Europe has type 1 diabetes. The prevalence 
is higher in the northern Scandinavian countries and lower in southern Europe and Japan. 
Approximately 20 to 30 percent will have microalbuminuria after a mean duration of 
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After so-called macroalbuminuria or clinical grade proteinuria (>300 mg albuminuria per 
day) develops, the majority of patients will progress to end-stage renal failure. 
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Data suggest that the renal risk is currently equivalent in the two types of diabetes. Evidence 
in support of this hypothesis includes the observations in one report that the time to 
proteinuria from the onset of diabetes and the time to ESRD from the onset of proteinuria 
were similar in type 1 and type 2 disease (Ritz E, 1999). 
 
 
Fig. 3. Cumulative prevalence of persistent proteinuria among patients with type 1 or type 2 
diabetes according to the duration of diabetes (Panel A), and cumulative prevalence of renal 
failure among patients with type 1 or type 2 diabetes according to the duration of 
proteinuria (Panel B). 
Glycemic control, systemic blood pressure levels, and genetic factors seem to be very 
important in determining diabetic nephropathy risk. Other factors such as lipid levels, 
smoking habits, and vitamin D intake may also have a role in modulating this risk. 
As with type 1 diabetes, some patients with microalbuminuria due to type 2 diabetes, 
particularly those with good glycemic control, experience regression of microalbuminuria 





3. Natural history and clinical course 
The course of renal involvement in type 1 diabetes can be divided in five stages. Stage I, 
present at diagnosis, is that of renal hypertrophy-hyperfunction. At this stage, patients at 
risk and not at risk of diabetic nephropathy cannot be clearly separated. A 25 to 50 percent 
elevation in the glomerular filtration rate (GFR) is seen early in the course in up to one-half 
of patients with type 1 diabetes mellitus, an abnormality that is exaggerated after ingestion 
of a protein load.  
 
 
Fig. 4. The five stages of renal involvement in type 1 diabetes 
This increase in GFR could be explained by a relative increase in glomerular capillary 
pressure and/or ultrafiltration coefficient. Glomerular hypertrophy and increased renal size 
typically accompany the rise in GFR. In an inception cohort study of adult-onset type 1 
diabetic subjects, a greater albumin excretion rate within the normal range, male gender, 
higher mean blood pressure and hemoglobin A1c, and shorter stature were independent 
predictors of development of microalbuminuria over 18 years of follow-up.  
Hyperfiltration also occurs early in the course of type 2 diabetes (Vora JP, 1992). The degree 
of hyperfiltration and the course of the GFR in type 2 diabetes mellitus was evaluated in 
more detail in a study of 194 Pima Indians of the Gila River Indian Community in Arizona 
who have the world’s highest incidence of Non-Insulin-Dependent Diabetes Mellitus 
(NIDDM) (Nelson RG, 1996). The following results were noted: 
 In 31 patients with a normal glucose tolerance test, the mean GFR was 123 mL/min 
 In 29 patients with impaired glucose tolerance, the mean GFR was 135 mL/min 
 In 30 patients with newly diagnosed type 2 disease, the mean GFR was 143 mL/min 
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 In 70 patients with overt diabetes for more than five years and either normal albumin 
excretion or microalbuminuria, the mean GFR was 153 mL/min; in 34 similar patients 
with overt proteinuria, the mean GFR was 124 mL/min 
 
 
Fig. 5. Glomerular filtration rate and effective renal plasma flow in non-insulin dependent 
diabetics (NIDDMs) (N= 110) and normal subjects (N = 32). 
After four year follow-up, the GFR rose 14 percent in patients with impaired glucose 
tolerance, 18 percent in newly diagnosed patients, was stable in those with 
microalbuminuria, and fell 35 percent in those with overt proteinuria. This pattern is 
consistent with the hypothesis that hyperfiltration causes progressive glomerular damage. 
However, the base-line glomerular filtration rate in the diabetic subjects predicted neither 
increasing urinary albumin excretion nor declining glomerular filtration during four years 
of follow-up, suggesting that hyperfiltration itself is not the principal factor in the 
development or progression of nephropathy. Higher urinary albumin excretion at base line, 
however, did predict increasing albuminuria and, in subjects with macroalbuminuria, 
declines in the GFR; these findings suggest that enhanced protein flux across the glomerular 
capillary wall contributes to progressive glomerular damage. Proteinuria also predicts the 
progression of renal disease in patients with nondiabetic renal disease. 
Studies in experimental animals indicate that dilatation of the afferent (precapillary) 
glomerular arteriole plays an important role in the hyperfiltration response, by raising both 
the intraglomerular pressure and renal blood flow. (Bank N, 1991) A role for hormones is 
suggested by the ability of a chronic infusion of a somatostatin analogue octreotide to 
partially reverse both the early hyperfiltration and the increase in renal size in type 1 





insulin-like growth factor I (IGF-1), which is produced in part within the kidney. Although 
the pathogenetic role of IGF-1 is unproven, it is of interest that infusion of this hormone in 
normal subjects can replicate the findings seen in diabetics — renal vasodilatation and an 
elevation in GFR. Similar hemodynamic changes plus renal hypertrophy can be induced by 
IGF-I in experimental animals.  
 
 
Fig. 6. Changes in the Mean Glomerular Filtration Rate and Median Urinary Albumin-to-
Creatinine Ratio from Base Line to the End of Follow-up in Subjects with Impaired Glucose 
Tolerance (IGT), Newly Diagnosed Non-Insulin-Dependent Diabetes Mellitus  
(New NIDDM), NIDDM and Normal Urinary Albumin Excretion (Normoalbuminuria), 
NIDDM and Microalbuminuria, and NIDDM and Macroalbuminuria. 
Each arrow connects the value at the base-line examination and the value at the end of 
follow-up. The dashed line indicates the time of diagnosis, and the shaded area the 25th 
through 75th percentiles of values in subjects with normal glucose tolerance. Albumin was 
measured in milligrams per liter and creatinine in grams per liter. 
Several other factors directly related to hyperglycemia also may be important, including the 
intracellular accumulation of sorbitol and the formation of glycosylated proteins (Passariello 
N, 1993). The enzyme aldose reductase converts intracellular glucose to sorbitol, which then 
accumulates within the cells. Studies in hyperfiltering humans with type 1 diabetes have 
shown that the chronic administration of an aldose reductase inhibitor (tolrestat) lowers the 
GFR toward normal. 
Stage II is defined by the presence of detectable glomerular lesions in patients with normal 
albumin excretion rates and normal blood pressure levels. Normoalbuminuric patients with 
more severe glomerular lesions might be at increased risk of progression. Patients can 
remain in stage 2 for the remainder of their lives. However, those in whom nephropathy is 
destined to progress further will at this stage exhibit a loss of the normal nocturnal blood 
pressure decline (i.e., night/day ratios >0.9 and non-dipping) as an early diabetic 
nephropathy indicator that often precedes the development of persistent microalbuminuria. 
Microalbuminuria, typically occurring in 2 to 5 percent of patients per year, defines stage 
III. Patients with microalbuminuria are referred to as having incipient nephropathy. 
Microalbuminuria (a sign of endothelial dysfunction that is not necessarily confined to the 
kidney) may be present earlier, particularly during adolescence and in patients with poor 
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glycemic control and high-normal blood pressure levels. Compared with normoalbuminuric 
patients, patients with persistent microalbuminuria have threefold to fourfold greater risk of 
progression to proteinuria and ESRD. Current studies indicate that between 20% and 45% of 
microalbuminuric type 1 diabetic patients will progress to proteinuria after about 10 years of 
follow-up, whereas 20% to 25% will return to normoalbuminuric levels (Hovind P, 2004) 
and the rest will remain microalbuminuric. At this stage, glomerular lesions are generally 
more severe than in the previous stages, and blood pressure tends to be increasing, often 
into the hypertensive range. Other laboratory abnormalities, such as increased levels of 
cholesterol, triglycerides, fibrinogen, Von Willebrand’s factor, and prorenin, can be detected 
in some patients. Diabetic retinopathy, lower extremity amputation, coronary heart disease, 
and stroke are also more frequent in this group.  
The normal rate of albumin excretion is less than 20 mg/day (15 µg/min); persistent 
albumin excretion between 30 and 300 mg/day (20 to 200 µg/min) is called 
microalbuminuria and, in patients with type 1 diabetes, persistent microalbuminuria may be 
indicative of early diabetic nephropathy unless there is some coexistent renal disease. 
It was initially thought that microalbuminuria precedes the loss of glomerular filtration rate 
(GFR) in patients with type 1 diabetes. However, some patients with normoalbuminuria or 
microalbuminuria have significant reductions in GFR prior to the development of 
macroalbuminuria. Loss of renal function, which was defined as an estimated decrease in 
GFR of more than 3.3 percent per year, occurred in 9 percent of patients with 
normoalbuminuria and 16 percent with regression of microalbuminuria. Loss of renal 
function occurred much more frequently (32 and 68 percent) in patients with stable or 
progressive microalbuminuria, respectively. 
Patients with newly diagnosed type 2 diabetes in which 6.5 percent had microalbuminuria 
and 0.7 percent had macroalbuminuria at the time of diagnosis. The rate of 
microalbuminuria at the time of diagnosis of type 2 diabetes may be higher in older patients. 
There are at least two possible explanations for the presence of microalbuminuria at the time 
of diagnosis of type 2 diabetes: the patients had previously undiagnosed diabetes or some 
other disease was responsible for the microalbuminuria. Forty to 50 percent of patients with 
type 2 diabetes who have microalbuminuria eventually die of cardiovascular disease; this is 
three times as high a rate of death from cardiac causes as among patients who have diabetes 
but have no evidence of renal disease. 
As with type 1 diabetes, some patients with microalbuminuria and type 2 diabetes regress to 
normoalbuminuria. At six years, regression occurred in 51 percent, while progression to 
macroalbuminuria occurred in 28 percent. Several factors (short duration of microalbuminuria, 
better glycemic and blood pressure control, and the use of ACE inhibitors or angiotensin II 
receptor blockers) were independently associated with remission. 
Stage IV occurs after 10 to 20 years of diabetes and is characterized by the presence of 
dipstick-positive proteinuria: proteinuria of greater than 300 mg/d. Hypertension is present 
in about 75% of these patients, and reduced GFR and dyslipidemia are also common. 
Retinopathy and peripheral and autonomic neuropathy are present in most patients. In 
addition, the risk for cardiovascular events is extremely high, and asymptomatic myocardial 
ischemia is frequent. Without therapeutic interventions, GFR declines by about 1.2 
mL/min/month in proteinuric type 1 diabetic patients. In type 2 diabetic patients, Once 
macroalbuminuria is present, creatinine clearance declines at a rate that varies widely from 
patient to patient; the average reduction is 10 to 12 ml per minute per year in untreated 
patients. Hypertension and proteinuria may accelerate the decline in the glomerular 





Progression to ESRD (stage V) occurs 5 to 15 years after the development of proteinuria. 
Renal replacement therapy—either dialysis or transplantation is required at this stage. 
4. Pathogenesis 
Diabetic nephropathy occurs as a result of a complex yet incompletely understood interaction 
between hemodynamic and metabolic factors (Cooper, M., 2001). Hemodynamic factors that 
contribute to the development of diabetic nephropathy include increased systemic and 
intraglomerular pressure, as well as activation of vasoactive humoral pathways including the 
renin angiotensin system and endothelin (G.M. Hargrove, 2000). These hemodynamic 
pathways activate intracellular second messengers such as protein kinase C (PKC), Mitogen-
activated protein (MAP kinase) (M. Haneda, 1997), nuclear transcription factors such as NF-kB 
and various growth factors such as the prosclerotic cytokine, TGF-β and the permeability 
enhancing growth factor, vascular endothelial growth factor, VEGF.  
Glucose dependent pathways are also activated within the diabetic kidney and result in 
enhanced oxidative stress, renal polyol formation (Dunlop ME, 2000) and the accumulation 
of advanced glycation end products (AGEs). In combination, these pathways ultimately lead 
to increased renal albumin permeability and extracellular matrix accumulation, resulting in 
increasing proteinuria, glomerulosclerosis and ultimately tubulointerstitial fibrosis. 
5. Hemodynamic pathways 
Glomerular hyperperfusion and hyperfiltration are the early signs resulting from decreased 
resistance in both the afferent and efferent arterioles of the glomerulus. Afferent arteriole 
seems to have a greater decrease in resistance than the efferent, which in fact may have 
increased resistance. Many factors have been reported to be involved in this faulty 
autoregulation, including nitric oxide, prostanoids, vascular endothelial growth factor 
(VEGF), TGF-β1, and the renin angiotensin system, specifically angiotensin II. These early 
hemodynamic changes predispose to albumin leakage from the glomerular capillaries and 
overproduction of mesangial cell matrix, as well as thickening of the glomerular basement 
membrane and injury to podocytes (Ziyadeh, F 2008). In addition, increased mechanical 
strain from these hemodynamic changes can induce localized release of certain cytokines 
and growth factors (Wolf, G.F.N, 2007) 
 
 
Fig. 7. Interaction of hemodynamic and metabolic pathway, cytokines and intracellular 
signaling molecules mediating diabetic nephropathy 
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The action of vasoactive hormones, such as angiotensin II and endothelin are mediator of 
renal hemodynamic changes. Glomerular hypertension and hyperfiltration contribute to the 
development of diabetic nephropathy because use of renin–angiotensin blockers preserves 
kidney function and morphology. Blockade of the renin-angiotensin–aldosterone system 
antagonizes the profibrotic effects of angiotensin II by reducing its stimulation of TGF-β1 
(Hilker, KF, 2005). Support that such profibrotic effects underlie diabetic nephropathy has 
also been provided by study of an animal model of diabetic nephropathy (Nagai Y, 2005). 
Transient blockade of the renin–angiotensin system (for 7 weeks) in prediabetic rats reduced 
proteinuria and improved glomerular structure. Additionally, the administration of an 
angiotensin converting-enzyme inhibitor to patients with type 1 diabetes and nephropathy 
appears to reduce serum concentrations of TGF-β1. A correlation exists between decreased 
levels of TGF-β1 in serum and urine and renal protection, as determined by changes in the 
glomerular filtration rate. 
5.1 Renin-angiotensin system in diabetic nephropathy 
The renin-angiotensin system (RAS) has been extensively studied in diabetes. Earlier studies 
centered on the systemic RAS, and the data obtained have been conflicting, with 
stimulation, suppression, and no change in the system being reported (Wolf, G, 2007). The 
factors that influence the systemic RAS in addition to the different stages of disease and 
species studied may explain many of these divergent findings. However in various diabetic 
models, increased renal renin content relative to plasma renin levels has generally been 
found, thus suggesting impaired renal renin release into the circulation. In clinical diabetic 
nephropathy, there is decreased plasma rennin activity that may be due to nonenzymatic 
glycation of prorenin with decreased conversion to active renin. Thus, diabetic nephropathy 
has traditionally been considered a “low renin” state. However, plasma renin activity may 
not accurately reflect activity of the RAS in the kidney. 
Another problem has been the difficulty of accurate measurement of plasma angiotensin-II 
(Ang II), which is an important issue because discordance can exist between plasma renin 
and Ang II levels. More recently, the intrarenal RAS has been the focus of extensive study. 
Abundant evidence indicates the existence of local tissue RASs that are regulated 
independent of plasma RAS (Ballerma, B.J., 1984). It was reported that glomerular Ang II 
receptors decrease in the diabetic rat 3 to 4 weeks after induction of the disease. 
Downregulation of glomerular Ang II receptors implies that intra- renal Ang II generation 
may be increased. The density of Ang II receptors in the proximal tubules was reported to 
be reduced in diabetic rats and was accompanied by decreased mRNA expression for the 
AT1 receptor (Cheng, H.F, 1994). Recently, AT1 receptor density has also been shown to be 
decreased in mesangial cells when incubated in high-glucose media (Amiri F, G, 1999). ACE 
activity in whole kidney is low in diabetes. 
However, this is probably due primarily to mesangial RAS. Staining for ACE has been 
found to be enhanced in glomeruli and vasculature of diabetic rats and in patients with 
diabetic nephropathy (Mizuiri, S., 1998). These data suggest that the term “intrarenal” RAS 
is oversimplistic, in as much as the vascular RAS (vessels and glomeruli) appears to be 
regulated differently from the tubulointerstitial RAS. Angiotensin receptor blockers (ARBs) 
enhance the renal vasodilation in patients with diabetes (despite the presence of low plasma 
rennin activity), again supporting the concept that the renal vascular RAS is activated in 
several intrarenal compartments including the glomeruli by several orders of magnitude 





independently of the systemic RAS and also is consistent with the finding that in most renal 
cell culture studies, effects of Ang II are observed at substantially higher concentrations 
(about 0.01-1.0 mmol/L) than those found in the systemic circulation. 
5.2 Vaso-active hormones 
Endothelium is an interior covering of blood vessels. There are various biological functions 
of endothelium and it regulates vascular tone and maintains free flow of blood in vessels 
(Escandon, J.C, 2001). The luminal surface of every blood vessel, forms a physical and 
metabolic barrier to circulating elements. The endothelium is an important endocrine organ 
and releases a number of vasoactive hormones, including endothelin (ET-1) (Ulker, 2003), 
endothelium-derived hyperpolarizing factor (EDHF: nitric oxide and prostacyclin). 
Endothelin-1 is a potent vasoconstrictor, Endothelium-derived hyperpolarizing factor is still 
a controversial subject of vascular biology. Endothelial cells of every blood vessel release 
nitric oxide and prostacyclin and they form a particular partnership in the regulation of 
vascular and platelet function. 
5.3 Nitric Oxide 
Nitric Oxide (NO), originally identified as “endothelial derived relaxing factor,” is a 
ubiquitously utilized signaling molecule that regulates a wide variety of organ and cellular 
functions, including renal hemodynamics and salt and water regulation. NO is generated 
enzymatically from the amino acid L-arginine by one of three specific nitric oxide synthases: 
“neuronal”(NOS1 or nNOS), “endothelial” (NOS3 or eNOS), or “inducible” (NOS2 or 
iNOS). Many, but not all, of the intracellular signaling pathways activated by NO are 
mediated by activation of guanylate cyclase, which increases intracellular levels of cyclic 
guanosine monophosphate. 
All three NOS isoforms are present in the mammalian kidney, with both distinct and 
overlapping patterns of distribution. In normal kidney, NOS1 is highly expressed in the 
macula densa and glomerular parietal epithelium, as well as in the medulla in the collecting 
ducts and thin ascending limb. NOS2 is expressed in the endothelium of glomerular 
capillaries and afferent and efferent arterioles, renal arteries, and descending vasa recta, as 
well as in proximal tubule and medullary thick ascending limb. NOS3 is also expressed in 
tubules, including S3 segments of the proximal tubule, medullary thick ascending limb, and 
collecting duct, in addition to arcuate arteries and vasa recta bundles (Kone, BC, 1997). Both 
in vivo and in vitro studies have provided conflicting results regarding NOS expression and 
NO production in diabetes. Most but not all studies in cultured renal cells have determined 
decreased NO production in response to hyperglycemia (Komers R, 2003).  
It has been established for a long time that the principal risk factors that affect the 
development and progression of diabetic nephropathy includes uncontrolled 
hyperglycemia, hypertension (systemic and glomerular) and activation of RAAS. All these 
three factors have been shown to modulate intra renal NO generation either directly or 
through signaling pathways. The role of NO in affecting the renal structure and function is 
very complicated and depends on several factors including the stage of diabetic renal 
disease, isoforms of NOS involved, structures in the kidney, and influence of other factors in 
diabetic milieu. The complex metabolic milieu in diabetes triggers several 
pathophysiological mechanisms that simultaneously stimulate and suppress intrarenal NO 
production. The net effect on renal NO levels depends on the mechanisms that prevail in a 
given stage of the disease process.  
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production. The net effect on renal NO levels depends on the mechanisms that prevail in a 
given stage of the disease process.  
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5.3.1 Dual role of Nitric Oxide in diabetic nephropathy 
The currently available evidence enables us to reasonably conclude that early diabetic 
nephropathy is associated with increased renal NO production mediated primarily by 
constitutively released NO through eNOS or NOS III activation. There is some contribution 
to this augmented NO production through nNOS (NOS I) derived enhanced synthesis, 
particularly from macula densa region of the kidney. Together the increased intrarenal NO 
generation contributes to the development of glomerular hyperfiltration and 
microalbuminuria that characterize early diabetic nephropathy.  
On the other hand, advanced diabetic nephropathy with severe proteinuria, hypertension 
and renal failure is associated with a state of progressive NO deficiency. As the duration of 
diabetic state increases, factors that suppress NO bioavailability prevail. Many factors 
including activation of protein kinase C, activation of TGF-beta, NO quenching by advanced 
glycosylation end products (AGE) contribute to the NO deficient state – either directly or by 
inhibiting and/or by post translational modification of activity of NOS isoforms. Other 
inhibitors of NOS enzyme such as asymmetric dimethylarginine (ADMA) accumulate in 
diabetic nephropathy and may contribute to progression of DN and such association has 
also been observed in other microvascular complications such as retinopathy. Most of these 
changes are mediated by endothelial and partly inducible NOS in the chronic advanced 
stage of DN. Progressive loss of renal parenchyma also contributes partially to the NO 
deficiency since kidney is a major source of L-arginine, the sole precursor of NO. These 
changes and the factors affecting them are discussed well in a review (Prabhakar 2005) and 
schematically represented in the figure below. 
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In a recent study, the natural history of renal manifestations have been described in ZSF1 rats, 
a recently developed rodent model of type 2 diabetes who developed obesity and 
hyperglycemia by 20 weeks of age on a high-carbohydrate diet. They also developed systolic 
and diastolic hypertension, hypercholesterolemia, profound hypertriglyceridemia, proteinuria, 
and renal failure. Renal histology demonstrated changes consistent with early diabetic 
nephropathy, including arteriolar thickening, tubular dilation and atrophy, glomerular 
basement membrane thickening, and mesangial expansion. Furthermore, renal nitric oxide 
production was decreased, and homogenates from renal cortices demonstrated reduced 
expression of renal endothelial and inducible nitric oxide synthases. These changes were 
associated with increased urinary levels and renal expression of 8-hydroxydeoxyguanosine, an 
indicator of mitochondrial oxidative stress, as well as with increased renal peroxynitrite 
formation. Administration of either insulin or the antioxidant alpha-lipoic acid decreased 
proteinuria and oxidative stress, but only the former slowed progression of renal failure 
(Prabhakar 2007). 
5.4 Prostacyclin 
The first step in prostacyclin synthesis is the liberation of arachidonic acid from membrane-
bound lipids via the enzymatic actions of phospholipase A2 (PLA2). In endothelial cells, 
phospholipase A2 activation is a calcium-dependent step. Once liberated, arachidonic acid is 
available for metabolism by cyclooxygenase (COX). Cyclooxygenase is present in two 
isoforms: COX-1 and COX-2. Cyclo-oxygenase-1, like NOSI or NOSIII, is constitutively 
expressed, while COX-2, like NOSII, is induced at sites of inflammation and/or by PAMPs. 
In healthy endothelial cells, COX-1 is the predominate isoform. Cyclooxygenase has two 
enzymatic activities: firstly, an oxygenase step forms prostaglandin (PG) G2; and secondly, a 
peroxidase step, which forms PGH2 from PGG2. Prostaglandin H2 is the substrate for a 
range of downstream prostaglandin synthase enzymes, including prostacyclin synthetase 
(PGIS), the actions of which result in the formation of prostacyclin. Endothelial cells are 
enriched in cyclooxygenase-1(COX-1) and PGIS, which is why, when phospholipase A2 is 
activated, prostacyclin is the predominant metabolite made. It is important to note that in 
platelets, which also express predominantly COX-1, thromboxane is the principal product 
made. This is because platelets express mainly thromboxane synthase with negligible levels 
of PGIS. 
5.5 Endothelin1 
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelium 
from big ET-1 (Xu 1994) via specific cleavage by endothelium converting enzyme (ECE). ET-
1 produces its actions by acting on endothelin ETA and ETB receptors (Haynes, 1993). ETA 
receptor predominates in vascular smooth muscle cells and mediates vasoconstriction in 
both large and small blood vessels where as ETB receptors on endothelial cells mediate 
vasodilation through the production of nitric oxide and prostacyclin (Verhaar, MC, 1998). 
ET-1 is involved in the pathogenesis of cardiovascular disorders such as hypertension and 
heart failure including diabetic nephropathy (Benigni 1998). Diabetes mellitus induces the 
renal overexpression of ET-1 in the glomeruli and tubular epithelial cells leading to 
progression of diabetic nephropathy. It was shown that diabetes-induced elevated level of 
renal ET-1 might induce glomerular hyperperfusion and damage tubulointerstitium in rats. 
The diabetes-induced elevated level of renal ET-1 was noted to accelerate the progression of 
diabetic nephropathy in rats31. It has been documented that ET-1 activates a variety of 
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In a recent study, the natural history of renal manifestations have been described in ZSF1 rats, 
a recently developed rodent model of type 2 diabetes who developed obesity and 
hyperglycemia by 20 weeks of age on a high-carbohydrate diet. They also developed systolic 
and diastolic hypertension, hypercholesterolemia, profound hypertriglyceridemia, proteinuria, 
and renal failure. Renal histology demonstrated changes consistent with early diabetic 
nephropathy, including arteriolar thickening, tubular dilation and atrophy, glomerular 
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production was decreased, and homogenates from renal cortices demonstrated reduced 
expression of renal endothelial and inducible nitric oxide synthases. These changes were 
associated with increased urinary levels and renal expression of 8-hydroxydeoxyguanosine, an 
indicator of mitochondrial oxidative stress, as well as with increased renal peroxynitrite 
formation. Administration of either insulin or the antioxidant alpha-lipoic acid decreased 
proteinuria and oxidative stress, but only the former slowed progression of renal failure 
(Prabhakar 2007). 
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bound lipids via the enzymatic actions of phospholipase A2 (PLA2). In endothelial cells, 
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available for metabolism by cyclooxygenase (COX). Cyclooxygenase is present in two 
isoforms: COX-1 and COX-2. Cyclo-oxygenase-1, like NOSI or NOSIII, is constitutively 
expressed, while COX-2, like NOSII, is induced at sites of inflammation and/or by PAMPs. 
In healthy endothelial cells, COX-1 is the predominate isoform. Cyclooxygenase has two 
enzymatic activities: firstly, an oxygenase step forms prostaglandin (PG) G2; and secondly, a 
peroxidase step, which forms PGH2 from PGG2. Prostaglandin H2 is the substrate for a 
range of downstream prostaglandin synthase enzymes, including prostacyclin synthetase 
(PGIS), the actions of which result in the formation of prostacyclin. Endothelial cells are 
enriched in cyclooxygenase-1(COX-1) and PGIS, which is why, when phospholipase A2 is 
activated, prostacyclin is the predominant metabolite made. It is important to note that in 
platelets, which also express predominantly COX-1, thromboxane is the principal product 
made. This is because platelets express mainly thromboxane synthase with negligible levels 
of PGIS. 
5.5 Endothelin1 
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelium 
from big ET-1 (Xu 1994) via specific cleavage by endothelium converting enzyme (ECE). ET-
1 produces its actions by acting on endothelin ETA and ETB receptors (Haynes, 1993). ETA 
receptor predominates in vascular smooth muscle cells and mediates vasoconstriction in 
both large and small blood vessels where as ETB receptors on endothelial cells mediate 
vasodilation through the production of nitric oxide and prostacyclin (Verhaar, MC, 1998). 
ET-1 is involved in the pathogenesis of cardiovascular disorders such as hypertension and 
heart failure including diabetic nephropathy (Benigni 1998). Diabetes mellitus induces the 
renal overexpression of ET-1 in the glomeruli and tubular epithelial cells leading to 
progression of diabetic nephropathy. It was shown that diabetes-induced elevated level of 
renal ET-1 might induce glomerular hyperperfusion and damage tubulointerstitium in rats. 
The diabetes-induced elevated level of renal ET-1 was noted to accelerate the progression of 
diabetic nephropathy in rats31. It has been documented that ET-1 activates a variety of 
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signaling systems to induce contraction, hypertrophy, proliferation, and extracellular matrix 
accumulation in mesangial cells (Sorokin, 2003). The detrimental role of ET-1 in 
pathogenesis of diabetic nephropathy has been confirmed by the fact that diabetes induced 
elevated level of renal ET-1 is associated with an expansion of mesangial cells and collagen 
deposition in the glomeruli of diabetic mice. It has been recently demonstrated that ET-1 
mediated activation of ETA receptor induced the renal TGF-β production and inflammation 
in diabetic rats (Sasser, 2007). Treatment with CPU0213, a dual ETA/ETB receptor 
antagonist has been found to improve the renal function in rats with diabetic nephropathy 
by suppressing Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
suggesting that ET-1 contributes to the pathogenesis of diabetic nephropathy via 
upregulation of NADPH oxidase mediated ROS production in renal cells (Xu, M., 2009). 
Thus under pathological conditions, prevention of endothelin-mediated various signaling 
pathways may provide an alternative approach to treat diabetic nephropathy. 
5.6 Urotensin 
Urotensin II (UII) is an 11-amino acid vasoactive peptide, recently identified as the ligand 
for a novel G protein-coupled receptor, GPR-14 (renamed urotensin receptor [UT]). In 
addition to its potentvasoconstrictive actions, UII also has trophic and profibrotic effects, 
leading to its implication in the pathogenesis of heart failure. However, it has been noted 
that elevated plasma levels of UII in association with renal impairment and diabetes and 
diabetic nephropathy. Urotensin-II, an endogenous vasoconstrictor, has been suggested to 
be involved in the pathogenesis of vascular endothelial dysfunction (VED) (Maguire, J.J., 
2002). Urotensin-II increases the activity of NADPH oxidase and plasminogen activator 
inhibitor-1 (PAI-1) and cause decrease in endothelium dependent relaxation (Watanabe, T., 
2006). The overexpression of urotensin-II in endothelial cells cause VED by increasing the 
expression of type 1 collagen and formation of ROS. 
6. Metabolic pathway 
Advanced glycosylation end products or AGEs are a chemically heterogeneous group of 
compounds formed as a result of the ‘‘Maillard reaction’’ when reducing sugars react non-
enzymatically with amine residues, predominantly lysine and arginine, on proteins, lipids 
and nucleic acids. While the initial stage of the reaction leading to the formation of 
reversible glycosylation proteins termed Schiff bases is rapid and glucose dependent, a 
much slower reaction over a period of days results in the formation of the more stable 
Amadori product. These early glycosylation products accumulate predominantly on long 
lived proteins such as vessel wall collagen and crystallines (Brownlee, 2001), undergoing a 
series of in vivo rearrangements to form irreversible, complex compounds and cross-links, 
termed AGEs.  
Once AGE related cross‐links form on proteins, they become resistant to proteolytic 
degradation (Thomas, 2005). As well as their non-receptor mediated effects; AGES can exert 
their biological effects through receptor-mediated mechanisms, the most important of which 
is the receptor for advanced glycation end products (RAGE). RAGE is a signal transduction 
receptor that belongs to the immunoglobin superfamily and is expressed on a number of cell 
types including monocytes/macrophages, endothelial cells, renal mesangial cells and 
podocytes (Yan, S.F., 2004). Binding of AGEs to the RAGE receptor activates a number of 





renal disease. These include enhanced cytosolic reactive species formation, stimulation of 
intracellular molecules such as PKC and NF-kB and the activation and expression of a 
number of growth factors and cytokines such as TGF-β and VEGF (Wendt, T., 2003). Indeed, 
strategies to inhibit the formation of AGEs have been shown to ameliorate diabetic 
nephropathy. 
In the initial study by Soulis-Liparota et al. aminoguanidine, an inhibitor of AGE formation, 
which acts by scavenging intermediates in the advanced glycation pathway attenuated the 
rise in albuminuria observed in diabetic rodents, while preventing increases in collagen 
related fluorescence in isolated glomeruli and renal tubules (Soulis-Liparota, T. 1991). 
Similar results have been obtained with alagebrium, a putative AGE cross-link breaker. In 
an experimental study, both aminoguanidine and alagebrium attenuated the albuminuria 
observed in diabetic rodents (Forbes, J.M., 2003). Furthermore, alagebrium was also 
beneficial when used as part of a delayed intervention protocol, suggesting that it may be 
useful in both preventing and retarding diabetic nephropathy (Ziayadeh, F.N., 1991).  
A subsequent study confirmed and extended these findings. The early (weeks 16–32) and 
late (weeks 24–32) administration of alagebrium was again shown to reduce albuminuria in 
a type 1 diabetic rodent model. As a number of previous groups had demonstrated increases 
in collagen and other extracellular matrix components in experimental diabetic 
nephropathy, this study also sought to determine the mechanisms surrounding the 
improvements in microalbuminuria in diabetic rodent kidneys. The compound was shown 
to reduce diabetes induced increases in the gene expression of TGF-β1, connective tissue 
growth factor (CTGF) and collagen IV. Early treatment with alagebrium was also associated 
with significant structural improvement in the kidney including a reduction in the 
glomerulosclerotic index and tubulointerstitial area, in conjunction with a reduction in AGE 
peptide fluorescence in serum and the kidney. Furthermore, a reduction in renal 
accumulation of the specific AGE, carboxymethylysine (CML) and decreased RAGE 
immunostaining was also seen, providing further evidence that accumulation of AGEs is 
implicated in renal extracellular matrix accumulation in diabetes.  
In the setting of diabetes mellitus and long-term hyperglycemia, nonenzymatic modification 
of proteins (or lipids) by glucose, or its metabolic products, results in their stable 
modification and altered function. This process is thought to underlie a major pathogenic 
pathway leading to tissue injury in diabetes. A major pathway for AGE formation involves 
triose phosphate intermediaries derived from metabolism of glucose. Triose phosphates 
build up as intracellular glucose increases and can nonenzymatically form the early 
glycosylation product methyglyoxal by spontaneous decomposition (Degenhardt 1998 and 
Frye 1998). Amine-catalyzed sugar fragmentation reactions then modify protein lysine 
residues directly, forming N- (epsilon) - (carboxymethyl) lysine (CML), a major product of 
oxidative modification of glycated proteins. Alternatively, reaction of terminal amino 
groups (e.g., on lysine) with glucose itself may form from early glycation products (i.e., 
Amadori products) that rearrange to produce stable moieties that possess distinctive 
chemical crosslinking and biologic properties, designated AGEs (Cohen 2003 and Vlassara 
1981). Other glucosederived Amadori products and fructose are thought to be potential 
precursors of 3-deoxyglucosone (3-DG) in vivo. Fructose generated by the aldose reductase 
pathway is converted into fructose-3- phosphate by the action of 3-phosphokinase (3- PK). 
This leads to the generation of 3-deoxyglucosone, a central precursor in the generation of an 
array of AGEs, in particular, CML-adducts and others (3-Deoxyglucosone, 1999) 3-DG can 
further react with proteins to form pyrrolines or pentosidine.  
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antagonist has been found to improve the renal function in rats with diabetic nephropathy 
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suggesting that ET-1 contributes to the pathogenesis of diabetic nephropathy via 
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Urotensin II (UII) is an 11-amino acid vasoactive peptide, recently identified as the ligand 
for a novel G protein-coupled receptor, GPR-14 (renamed urotensin receptor [UT]). In 
addition to its potentvasoconstrictive actions, UII also has trophic and profibrotic effects, 
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renal disease. These include enhanced cytosolic reactive species formation, stimulation of 
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AGEs have been suggested to represent a general marker of oxidative stress and long‐term 
damage to proteins in aging, atherosclerosis, and diabetes (Wendt T.M., 2003). Renal CML-
AGE is increased in diabetes. Immunolocalization of CML in skin, lung, heart, kidney, 
intestine, intervertebral discs, and particularly in arteries provide evidence for age-
dependent increases in CML accumulation in distinct locations, and acceleration of this 
process in diabetes (Schleicher, E.D., 1997). Immunostaining and immunoblots of diabetic 
human kidneys show increased CML in diabetic glomeruli, especially in the mesangial 
matrix and capillary walls (Nathan, D.M., 2005). 
6.1 Oxidative stress 
Generally, large amount of reactive oxygen species are generated with in nephron by 
metabolic activity that is counter balanced by a large number of antioxidant enzymes and 
free radical scavenging systems. Peroxidation of cell membrane lipids, oxidation of proteins, 
renal vasoconstriction and damage to DNA are the negative biological effects of reactive 
oxygen species. Unfortunately, hyperglycemia tips the balance towards production of 
reactive oxygen species, most of which seem to be generated in the mitochondria 
(Nishikawa, T. 2007). The metabolism of glucose through destructive alternate pathways, 
such as via PKC activation and advanced glycation end‐product formation, in the setting of 
hyperglycemia also seems partly dependent on reactive oxygen species. Oxidative stress 
specifically induced by hyperglycemia even before diabetes becomes clinically apparent. 
DNA damage marker induced by reactive oxygen species is higher in patients with severe 
nephropathy (i.e. proteinuria versus microalbuminuria). Diabetic nephropathy is linked 
with severe oxidative stress. This pathway may be responsible for the decreased 
bioavailability of nitric oxide in the kidney (Prabhakar 2007). 
6.2 Reactive oxygen species 
Diabetic nephropathy is characterized by excessive deposition of extracellular matrix (ECM) 
in the kidney, leading to glomerular mesangial expansion and tubulointerstitial fibrosis. 
Clinical studies have demonstrated that high blood glucose is the main cause of initiation 
and progression of diabetic vascular complications including nephropathy. High reactive 
oxygen species (ROS) induced by glucose upregulates TGF-β1 and extra cellular matrix 
protein (ECM) expression in the glomerular mesangial cells. Hyperglycemia induced ROS 
generation and ROS-activated signal transduction cascade and transcription factors and 
overexpression of genes and proteins in glomerular mesangial and tubular epithelial cells 
lead to ECM accumulation in diabetic kidney. 
6.3 Nephrin 
Podocytes (specialized visceral epithelial cells) are important for the maintenance of the 
dynamic functional barrier (Mundel 2002). Nephrin, a protein found in these cells, is crucial 
for maintaining the integrity of the intact filtration barrier. The renal expression of nephrin 
might be impaired in diabetic nephropathy. Patients with diabetic nephropathy have 
markedly reduced renal nephrin expression and fewer electron‐dense slit diaphragms 
compared with patients without diabetes and minimal nephropathic changes or controls 
(Benigni. 2004). Furthermore, nephrin excretion is raised 17-30% in patients with diabetes 
(with and without albuminuria) compared with that in individuals without diabetes.  
Thus, nephrin excretion could be an early finding of podocyte injury, even before the onset 





aldosterone system might help protect nephrin expression. In a study of patients with type 2 
diabetes, treatment with an angiotensin-converting-enzyme inhibitor for 2 years maintained 
nephrin expression at control levels compared with that in untreated patients with diabetes. 
By contrast, the expression of two other important podocyte and slit diaphragm proteins, 
podocin and CD2AP, was similar in the three groups. Comparable decreases in renal 
nephrin expression were reported in other studies of diabetic nephropathy. 
6.4 Vitamin D 
Vitamin D has a role beyond the regulation of calcium metabolism. There is evidence that 
the vitamin D system is also involved in regulation of the immune system, cell growth, and 
differentiation. Vitamin D binds to its nuclear receptor, and later to the vitamin D response 
element of target genes, to regulate gene transcription. It also interacts with pathways that 
are germane to the development and progression of diabetic complications, including the 
renin–angiotensin system (RAS), hypertension, inflammation, and albuminuria. Three 
recent randomized trials have shown that the vitamin D analogue—19-nor-1-α-
dihydroxyvitamin D2 (paricalcitol) can reduce proteinuria in patients with chronic kidney 
disease, including those with diabetes.  
 
 
ACE=angiotensin-converting enzyme.  
AT1=type 1 angiotensin receptor. 
PRR=(pro)renin receptor.  
ACE2=angiotensin-converting enzyme 2. TACE=tumor necrosis factor α converting enzyme. mas-
1=receptor for angiotensin 1–7. 
Fig. 9. Interactions between vitamin D and key elements of the renin–angiotensin system 
Vitamin D is a negative regulator of RAS (Li YC, 2002). In experimental chronic kidney 
disease, paricalcitol reduces the renal expression of renin, the (pro)renin–receptor, 
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angiotensinogen, and the type 1 angiotensin receptor (Freundlich M, 2008). Vitamin D also 
inhibits tumor necrosis factor α converting enzyme (TACE) (Dusso A, 2010), which 
regulates the shedding of angiotensin-converting enzyme 2 (ACE2), itself the major enzyme 
that metabolizes angiotensin II in the proximal tubule. Diabetes is associated with reduced 
ACE2 expression; therefore inhibition of TACE expression might improve the balance of 
RAS in the kidney, and might have additional renoprotective effects by inhibition of the 
TACE-dependent release of other pathogenic mediators. 
Vitamin D has several anti-inflammatory actions, including effects on prostaglandin 
synthesis, inhibition of nuclear factor κB signaling, and innate immunity, all of which have 
been implicated in diabetic chronic kidney disease. Vitamin D deficiency is associated with 
raised concentrations of C-reactive protein. In previous studies, paricalcitol reduced C-
reactive protein concentrations in patients with chronic kidney disease, which paralleled the 
decline in albuminuria 
Patients with diabetes have increased rates of vitamin D deficiency (Tanaka H, 2009) 
especially in those with chronic kidney disease in whom the urinary loss of protein-
associated vitamin D magnifies reduced activation of vitamin D by the proximal tubule, and 
reduced expression of the vitamin D receptor. For these patients, it seems rational to replace 
vitamin D. Selective analogues that restore vitamin D receptor signaling without risking 
hypercalcemia or hyperphosphatemia might have particular advantages, because of the 
aberrant calcification of diabetic vessels. Of note, vitamin D replacement reduced 
proteinuria in about half of diabetic patients with stage 3 or 4 chronic kidney disease in a 
placebo-controlled trial (Teng M 2003) 
7. Histopathology 
The pathogenesis of diabetic nephropathy is complex, and renal pathological lesions are 
diverse. Most likely, there are many pathogenic pathways, which through composite, 
interactive routes lead to the histological damage that we see in renal biopsies of patients 
with diabetic nephropathy (Elisabeth J.J, 2011). Though the number of patients with type 2 
diabetes in a worldwide context is increasing and is predicted to be 438 million in 2030, 
paradoxically, diabetic nephropathy is probably becoming the renal disease per se for which 
the least renal biopsies are performed. In many centers, clinical parameters in the absence of 
a renal biopsy will diagnose the patient with diabetic nephropathy. Only if unusual signs or 
symptoms are present, such as sudden onset nephrotic syndrome, will a renal biopsy be 
performed, mostly with the aim to exclude other causes than diabetic nephropathy for the 
patient’s clinical presentation. This means that in relation to diabetic nephropathy, co-
morbidity is often seen by the pathologist in the renal biopsy, and cases in which diabetic 
nephropathy alone is present become less frequent. In many recent publications, the 
diagnosis of diabetic nephropathy was based on clinical symptoms, which, in many studies, 
also formed the gold standard on the evaluation of intervention therapies meant to prevent, 
slow down, or even reverse the processes causing diabetic nephropathy. 
7.1 Histopathological classification system 
Up to 2010, the terminology for histopathological lesions in diabetic nephropathy was variable. 
The new classification launched in 2010 (Thijs W, 2010) distinguishes four classes, essentially 
characterized by the absence of histological lesions (class I), mesangial changes (class II), 






Table 1. Histological classification of Diabetic glomerulopathy 
7.1.1 Class I: Glomerular basement membrane thickening 
The biopsy specimen shows no or only mild, nonspecific changes by light microscopy that 
do not meet the criteria of classes II through IV. By direct measurements with EM the 
glomerular basement membrane (GBM) on average is thicker than 430 nm in males 9 years 
and older and thicker than 395 nm in females. These cutoff levels are based on a deviation 
from normal GBM thickness plus 2 standard deviations as recently determined. Light 
microscopic changes in the GBM and epithelial foot process effacement by EM have no 
influence on the classification.  
Class I incorporates cases with certain degree of chronic and other reactive changes (e.g., 
changes of arterionephrosclerosis, ischemic type changes, or interstitial fibrosis). Diagnosing 
DN in cases without characteristic light microscopic glomerular lesions may be difficult, 
especially when a thicker GBM is also seen with aging or hypertension. The presence of 
arteriolar hyalinosis may be helpful in these cases, although it is not a prerequisite. 
GBM thickening is a characteristic early change in type 1 and type 2 DN and increases with 
duration of disease. GBM thickening is a consequence of extracellular matrix accumulation, 
with increased deposition of normal extracellular matrix components such as collagen types 
IV and VI, laminin, and fibronectin. Such accumulations result from increased production of 
these proteins, their decreased degradation, or a combination of the two. GBM thickening 
may already be present in type 1 diabetes patients who are normoalbuminuric. GBM 
thickening has even been described as a “prediabetic” lesion: In patients with proteinuria 
and isolated GBM thickening but without overt diabetes, 20% were positive on a blood test 
for diabetes at the time of biopsy, whereas 44% were diagnosed with diabetes at 6 months, 
and 70% at 2 years after the biopsy was taken. Long-term glucose control and urinary 
albumin excretion (UAE) correlate strongly with basement membrane thickness. 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
344 
angiotensinogen, and the type 1 angiotensin receptor (Freundlich M, 2008). Vitamin D also 
inhibits tumor necrosis factor α converting enzyme (TACE) (Dusso A, 2010), which 
regulates the shedding of angiotensin-converting enzyme 2 (ACE2), itself the major enzyme 
that metabolizes angiotensin II in the proximal tubule. Diabetes is associated with reduced 
ACE2 expression; therefore inhibition of TACE expression might improve the balance of 
RAS in the kidney, and might have additional renoprotective effects by inhibition of the 
TACE-dependent release of other pathogenic mediators. 
Vitamin D has several anti-inflammatory actions, including effects on prostaglandin 
synthesis, inhibition of nuclear factor κB signaling, and innate immunity, all of which have 
been implicated in diabetic chronic kidney disease. Vitamin D deficiency is associated with 
raised concentrations of C-reactive protein. In previous studies, paricalcitol reduced C-
reactive protein concentrations in patients with chronic kidney disease, which paralleled the 
decline in albuminuria 
Patients with diabetes have increased rates of vitamin D deficiency (Tanaka H, 2009) 
especially in those with chronic kidney disease in whom the urinary loss of protein-
associated vitamin D magnifies reduced activation of vitamin D by the proximal tubule, and 
reduced expression of the vitamin D receptor. For these patients, it seems rational to replace 
vitamin D. Selective analogues that restore vitamin D receptor signaling without risking 
hypercalcemia or hyperphosphatemia might have particular advantages, because of the 
aberrant calcification of diabetic vessels. Of note, vitamin D replacement reduced 
proteinuria in about half of diabetic patients with stage 3 or 4 chronic kidney disease in a 
placebo-controlled trial (Teng M 2003) 
7. Histopathology 
The pathogenesis of diabetic nephropathy is complex, and renal pathological lesions are 
diverse. Most likely, there are many pathogenic pathways, which through composite, 
interactive routes lead to the histological damage that we see in renal biopsies of patients 
with diabetic nephropathy (Elisabeth J.J, 2011). Though the number of patients with type 2 
diabetes in a worldwide context is increasing and is predicted to be 438 million in 2030, 
paradoxically, diabetic nephropathy is probably becoming the renal disease per se for which 
the least renal biopsies are performed. In many centers, clinical parameters in the absence of 
a renal biopsy will diagnose the patient with diabetic nephropathy. Only if unusual signs or 
symptoms are present, such as sudden onset nephrotic syndrome, will a renal biopsy be 
performed, mostly with the aim to exclude other causes than diabetic nephropathy for the 
patient’s clinical presentation. This means that in relation to diabetic nephropathy, co-
morbidity is often seen by the pathologist in the renal biopsy, and cases in which diabetic 
nephropathy alone is present become less frequent. In many recent publications, the 
diagnosis of diabetic nephropathy was based on clinical symptoms, which, in many studies, 
also formed the gold standard on the evaluation of intervention therapies meant to prevent, 
slow down, or even reverse the processes causing diabetic nephropathy. 
7.1 Histopathological classification system 
Up to 2010, the terminology for histopathological lesions in diabetic nephropathy was variable. 
The new classification launched in 2010 (Thijs W, 2010) distinguishes four classes, essentially 
characterized by the absence of histological lesions (class I), mesangial changes (class II), 






Table 1. Histological classification of Diabetic glomerulopathy 
7.1.1 Class I: Glomerular basement membrane thickening 
The biopsy specimen shows no or only mild, nonspecific changes by light microscopy that 
do not meet the criteria of classes II through IV. By direct measurements with EM the 
glomerular basement membrane (GBM) on average is thicker than 430 nm in males 9 years 
and older and thicker than 395 nm in females. These cutoff levels are based on a deviation 
from normal GBM thickness plus 2 standard deviations as recently determined. Light 
microscopic changes in the GBM and epithelial foot process effacement by EM have no 
influence on the classification.  
Class I incorporates cases with certain degree of chronic and other reactive changes (e.g., 
changes of arterionephrosclerosis, ischemic type changes, or interstitial fibrosis). Diagnosing 
DN in cases without characteristic light microscopic glomerular lesions may be difficult, 
especially when a thicker GBM is also seen with aging or hypertension. The presence of 
arteriolar hyalinosis may be helpful in these cases, although it is not a prerequisite. 
GBM thickening is a characteristic early change in type 1 and type 2 DN and increases with 
duration of disease. GBM thickening is a consequence of extracellular matrix accumulation, 
with increased deposition of normal extracellular matrix components such as collagen types 
IV and VI, laminin, and fibronectin. Such accumulations result from increased production of 
these proteins, their decreased degradation, or a combination of the two. GBM thickening 
may already be present in type 1 diabetes patients who are normoalbuminuric. GBM 
thickening has even been described as a “prediabetic” lesion: In patients with proteinuria 
and isolated GBM thickening but without overt diabetes, 20% were positive on a blood test 
for diabetes at the time of biopsy, whereas 44% were diagnosed with diabetes at 6 months, 
and 70% at 2 years after the biopsy was taken. Long-term glucose control and urinary 
albumin excretion (UAE) correlate strongly with basement membrane thickness. 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
346 
7.1.2 Class II: Mesangial expansion, mild (IIa) or severe (IIb) 
Class II encompasses those patients classified with mild or severe mesangial expansion but 
not meeting inclusion criteria for class III or IV and is analogous to the previously used term 
“diffuse diabetic glomerulosclerosis.” Mesangial expansion is defined as an increase in 
extracellular material in the mesangium such that the width of the interspace exceeds two 
mesangial cell nuclei in at least two glomerular lobules. The difference between mild and 
severe mesangial expansion is based on whether the expanded mesangial area is smaller or 
larger than the mean area of a capillary lumen. If severe mesangial expansion is seen in 
more than 25% of the total mesangium observed throughout the biopsy, the biopsy is 
classified as IIb. If this is not the case, but at least mild mesangial expansion is seen in more 
than 25% of the total mesangium, the biopsy is classified as IIa. 
Expansion of cellular and matrix components in the mesangium is a hallmark of type 1 and 
type 2 DN. It can be detected in some patients within a few years after the onset of type 1 
diabetes. When the mesangium expands, it restricts and distorts glomerular capillaries and 
diminishes the capillary filtration surface.  
Various indices have been proposed to describe the amount of mesangial expansion in 
DN. Mauer et al. define mesangial expansion by mesangial fractional volume or volume 
density (Vv), defined as the fraction or percentage of the cross-sectional area of the 
glomerular tuft made up by mesangium, expressed in the formula: Vv (mes/glom). Using 
this formula, many correlations have been made between mesangial expansion and 
clinical parameters of DN, particularly showing highly inverse correlations exist between 
Vv (mes/glom) and GFR. There is also a relationship between Vv (mes/glom) and UAE 
and blood pressure.  
Another index to express mesangial expansion is the so-called “index of mesangial 
expansion” (IME) for DN. The IME is determined by a semiquantitative estimate of the 
width of mesangial zones in each glomerulus: grade 0 is normal, 1 is twice normal thickness, 
2 is three times normal thickness, and so forth; half grades can also be assigned. The mean of 
the grades for each glomerulus for IME can thus be determined from a single biopsy. The 
IME closely correlates with the Vv (mes/glom).  
In other classifications, mesangial expansion is defined in more practical ways, such as in 
the new classification for IgA nephropathy in which it is defined as an increase in the 
extracellular material in the mesangium such that the width of the interspace exceeds two 
mesangial cell nuclei in at least two glomerular lobules. 
7.1.3 Class III: Nodular sclerosis (Kimmelstiel–Wilson lesions) 
If at least one convincing Kimmelstiel–Wilson lesion is found and the biopsy specimen does 
not have more than 50% global glomerulosclerosis it is classified as class III. Kimmelstiel–
Wilson lesions appear in type 1 and type 2 diabetes (only one-third of microalbuminuric 
type 2 diabetic patients had them) as focal, lobular, round to oval mesangial lesions with an 
acellular, hyaline/matrix core, rounded peripherally by sparse, crescent-shaped mesangial 
nuclei. Compared to type 1 diabetes, type 2 diabetes  
Paul Kimmelstiel and Clifford Wilson first described nodular lesions in glomeruli from eight 
maturity-onset diabetes patients in 1936. According to Cameron, they barely noted the 
association with diabetes, and it was Arthur Allen who clarified the association in 105 
patients with diabetes in 1941. Nodular sclerotic lesions may also occur in the absence of DN 







Fig. 10. Representative examples of the morphologic lesions in DN: 
(A) Glomerulus showing only mild ischemic changes, with splitting of Bowman’s capsule. 
No clear mesangial alteration.  
(B) EM of this glomerulus: the mean width of the GBM was 671 nm (mean taken over 55 
random measurements). EM provides the evidence for classifying the biopsy with only mild 
light microscopic changes into class I.  
(C, D) Class II glomeruli with mild and moderate mesangial expansion, respectively. In 
panel C, the mesangial expansion does not exceed the mean area of a capillary lumen (IIa), 
whereas in panel D it does (IIb).  
(E, F) In panel F is a class III Kimmelstiel–Wilson lesion. The lesion in panel E is not a 
convincing Kimmelstiel–Wilson lesion, therefore (on the basis of the findings in this 
glomerulus) the finding is consistent with class IIb. For the purpose of the classification, at 
least one convincing Kimmelstiel–Wilson (as in panel F) needs to be present.  
In panel H, signs of class IV DN consist of hyalinosis of the glomerular vascular pole and a 
remnant of a Kimmelstiel–Wilson lesion on the opposite site of the pole.  
Panel G is an example of glomerulosclerosis that does not reveal its cause (glomerulus from 
the same biopsy as panel H).  
For the purpose of the classification, signs of DN should be histopathologically or clinically 
present to classify a biopsy with global glomerulosclerosis in > 50% of glomeruli as class IV 
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Fig. 10. Representative examples of the morphologic lesions in DN: 
(A) Glomerulus showing only mild ischemic changes, with splitting of Bowman’s capsule. 
No clear mesangial alteration.  
(B) EM of this glomerulus: the mean width of the GBM was 671 nm (mean taken over 55 
random measurements). EM provides the evidence for classifying the biopsy with only mild 
light microscopic changes into class I.  
(C, D) Class II glomeruli with mild and moderate mesangial expansion, respectively. In 
panel C, the mesangial expansion does not exceed the mean area of a capillary lumen (IIa), 
whereas in panel D it does (IIb).  
(E, F) In panel F is a class III Kimmelstiel–Wilson lesion. The lesion in panel E is not a 
convincing Kimmelstiel–Wilson lesion, therefore (on the basis of the findings in this 
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In panel H, signs of class IV DN consist of hyalinosis of the glomerular vascular pole and a 
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For the purpose of the classification, signs of DN should be histopathologically or clinically 
present to classify a biopsy with global glomerulosclerosis in > 50% of glomeruli as class IV 
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It is claimed that in the initial stage of developing nodular sclerotic lesions in DN, two 
important processes take place: lytic changes in the mesangial area called mesangiolysis and 
detachment of endothelial cells from the GBM. Exactly how these two processes relate 
remains uncertain. Paueksakon et al. detected fragmented red blood cells in Kimmelstiel–
Wilson lesions, which supports the theory that microvascular injury contributes to the 
pathogenesis of these lesions. Dissociation of endothelial cells may disrupt the connections 
between the mesangial area and the GBM. This process precedes expansion of the 
Kimmelstiel–Wilson lesion. These lesions consist of an accumulation of mesangial matrix 
with collagen fibrils, small lipid particles, and cellular debris. 
A completely developed Kimmelstiel–Wilson lesion destroys the normal structure of 
glomerular tuft with a decrease in mesangial cells, especially in the central area. In 1992, a 
graphic method of analysis of the position of Kimmelstiel–Wilson lesions demonstrated the 
nodules were distributed in a horseshoe-shaped area corresponding to the peripheral or 
intralobular mesangium, excluding the possibility of hyperfiltration as being their main 
cause of development. 
The presence of at least one Kimmelstiel–Wilson lesion associates with longer duration of 
diabetes and less favorable clinical parameters. In a study of 36 patients with type 2 
diabetes, patients with Kimmelstiel–Wilson lesions had more severe overall retinopathy and 
higher serum creatinine concentrations than those with mesangial lesions alone. In a study 
of 124 Chinese patients with type 2 diabetes, patients with at least one Kimmelstiel–Wilson 
lesion had relatively long duration of diabetes mellitus, a poor prognosis, and frequent 
evidence of diabetic retinopathy. Kimmelstiel–Wilson lesions are often found in 
combination with mesangial expansion. The occurrence of Kimmelstiel– Wilson lesions is 
widely considered transitional from an early or moderately advanced stage to a 
progressively more advanced stage of disease. 
7.1.4 Class IV: Advanced diabetic glomerulosclerosis 
Class IV implies advanced DN with more than 50% global glomerulosclerosis in which there 
is clinical or pathologic evidence that the sclerosis is attributable to DN. Glomerulosclerosis 
in DN is the end point of multifactorial mechanisms that lead to excessive accumulation of 
extracellular matrix proteins such as collagen types I, III, and IV and fibronectin in the 
mesangial space, which through stages of mesangial expansion and development of 
Kimmelstiel–Wilson lesions finally result in glomerulosclerosis. The clustering of sclerotic 
lesions in columns perpendicular to the kidney surface suggests that vascular factors 
relating to the interlobular arteries also contribute.  
8. Tubulointerstitial lesions, vascular lesions and nondiabetic glomerular 
lesions 
8.1 Tubular lesions 
Concomitant tubular basement membrane thickening of nonatrophic tubules is apparent 
from the development of class II glomerular diabetic lesions and becomes more conspicuous 
in class III and IV, which is best seen in PAS or silver stains. Interstitial fibrosis and tubular 
atrophy (IFTA) follow glomerular changes in type 1 DN that ultimately lead to ESRD. A 
score of 0 is assigned when the biopsy specimen shows no IFTA, a score of 1 is assigned 





50% of the biopsy has IFTA, and finally, a score of 3 is assigned when at least 50% IFTA is 
present, which is similar to the scoring in the recently published classification of IgA 
nephropathy. 
Presence of mononuclear cells in the interstitium is a widely recognized finding in DN. 
Inflammatory interstitial infiltrates comprise T lymphocytes and macrophages. A score of 0 
is assigned if interstitial infiltrates are absent, 1 if they only occur around atrophic tubules, 
and 2 if the inflammatory infiltrate is also in other areas than around atrophic tubules. 
8.2 Vascular lesions 
According to Stout et al., hyalinosis of the efferent arteriole is relatively specific for DN, but 
hyalinosis of the afferent arteriole occurs in numerous other settings. Chronic cyclosporine 
nephropathy is a typical example in which arteriolar hyalinosis occurs outside DN. Tracy et 
al. also report the presence of arteriolar hyalinosis in kidneys of young patients with 
coronary heart disease. Efferent arteriolar hyalinosis is an important lesion by which DN is 
distinguished from hypertensive nephropathy. However, most studies relate arteriolar 
hyalinosis to clinical parameters, not distinguishing between efferent and afferent arterioles, 
showing clear correlations with UAE and disease progression.  
In addition to characteristic arteriolar hyalinosis, relatively nonspecific arteriosclerosis may 
be present in the biopsy specimen. Bohle and colleagues found increases in vascular disease 
associate with more severe glomerular disease. Osterby et al. use a so-called “matrix to 
media ratio” to investigate the role of arteriosclerosis and find this ratio is increased in 
patients with microalbuminuria, suggesting that arteriolar matrix accumulation occurs early 
in the course of DN. By assessing the most severely affected artery in the biopsy and assign 
a score of 0 if no intimal thickening is present, 1 if intimal thickening is less than the 
thickness of the media, and 2 if intimal thickening is more than the thickness of the media. 
Isolated or significant medial thickness may be associated with concurrent hypertension. 
9. Other glomerular lesions 
In 1994, Stout et al. defined “insudative lesions” as consisting of intramural accumulations 
of presumably imbibed plasma proteins and lipids within renal arterioles, glomerular 
capillaries, Bowman’s capsule, or proximal convoluted tubules. Insudative lesions in 
Bowman’s capsule are called capsular drop lesions, and in afferent and efferent arterioles 
they are called hyalinized afferent and efferent arterioles. In glomerular capillaries they are 
called fibrin cap lesions, although this term is considered obsolete and moreover is 
amisnomer because the lesion does not contain fibrin; we prefer the term hyalinosis for 
these lesions. 
Capsular drops are mainly located between the parietal epithelium and Bowman’s capsule 
of the glomerulus. Capsular drops are prevalent in advanced DN and associate with disease 
progression. The common belief, reviewed by Alsaad et al., is that capsular drops are 
specific but not entirely pathognomonic of DN. Stout et al. report a prevalence of capsular 
drops in 5.3% of biopsies without diabetes. However, finding a capsular drop in a biopsy 
can help distinguish DN from other causes of glomerulosclerosis.  
By light microscopy, glomerular hyalinosis describes the same staining characteristics as the 
capsular drop lesion but it occupies the capillary lumen instead of being attached to 
Bowman’s capsule. This lesion is not a specific finding in DN, because similar lesions are 
recognized in focal glomerulosclerosis, arterionephrosclerosis, and lupus nephritis. 
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Table 2. Interstitial and vascular lesions of DN 
Finally, there is increasing recognition of abnormalities in the glomerulotubular junctions 
with focal adhesions called “tip lesions” and atrophic tubules with no observable 
glomerular opening (so-called “atubular glomeruli”). These lesions are typically found in 
more advanced stages of nephropathy associated with overt proteinuria. 
One of the important questions that need to be validated is whether the new classification 
system, which makes no distinction between patients with type 1 and type 2 diabetes, is 
helpful for clinicians. Type 2 diabetes has more heterogenous clinical course with more 
heterogenous lesions. Type 2 diabetes also has different response towards treatments, and 
different relationship between diabetic nephropathy and retinopathy. In a study that 
published by Osterby R, Gall MA, Schmitz A, et al in 1993, virtually all patients with type 1 
diabetes with overt nephropathy have retinopathy, whereas less than 50% of patients with 
type 2 diabetes and diabetic nephropathy have diabetic retinopathy. These figures may have 
been altered somewhat in the course of time. In 2010, Pedro et al. studied the prevalence and 
relationship between diabetic nephropathy and retinopathy in a population-based 
transversal study in northeastern Spain including 8187 type 2 and 488 type 1 diabetes 
patients. They distinguished between patients with microalbuminuria and those with overt 
nephropathy. The relationship between microalbuminuria and diabetic retinopathy was 
different between the types of diabetes, but the relationship between overt nephropathy and 
diabetic retinopathy was similar in both types. Overt nephropathy, in this study, was a risk 
factor for diabetic retinopathy in both types. 
10. Biomarker studies 
A number of studies reported on biomarkers in either plasma or urine for diabetic 
nephropathy, particularly in relation to type 2 diabetes. A group from Denmark reported on 
transthyretin, apolipoprotein A1, apolipoprotein C1, and cystatin C as promising 
biomarkers for diabetic nephropathy in the plasma of patients with type 1 diabetes 
(Overgaard AJ 2010). Proteomic analysis of plasma from a cross-sectional cohort of 123 type 





macroalbuminuric, gave rise to 290 peaks clusters. Independent component analysis 
identified 16 candidate peaks that contributed significantly in their respective components 
with high stability and ability to separate the groups. Four of the peaks were identified as 
transthyretin, apolipoprotein A1, apolipoprotein C1, and cystatin.  
Soluble CD40 ligand derived from platelets and mediating atherothrombosis, was shown to 
be elevated in type 1 diabetes patients with diabetic nephropathy in comparison with 
controls. The study was a prospective, observational follow-up study of 443 type 1 diabetes 
patients with diabetic nephropathy and a control group of 421 patients with longstanding 
type 1 diabetes and persistent normoalbuminuria. High levels of sCD40L did not predict 
development of end-stage renal disease (P = 0.85) nor rate of decline in glomerular filtration 
rate (GFR) (Lajer M 2010). 
There were several studies on biomarkers in type 2 diabetes giving rise to a number of 
new markers. A group from China reported an independent association between plasma 
levels of osteopontin and the presence and severity of diabetic nephropathy in type 2 
diabetes (Yan X 2010). In another study on type 2 diabetes, plasma levels of 
methylglyoxal, a side-product of many metabolic pathways, was found to be higher in 
patients with diabetic nephropathy than in those without and, furthermore, were shown 
to correlate with the urinary albumin: creatinine ratio (Lu J 2011). Fibroblast growth factor 
23 (FGF-23), previously reported as a marker for outcome in chronic kidney disease in 
general, was found to be predictive of renal outcome in type 2 diabetes patients with 
macroalbuminuric nephropathy (Alkhalaf A, 2010). At baseline, serum FGF- 23 showed a 
significant association with serum creatinine and proteinuria. FGF-23 was an independent 
predictor of the primary outcome in this study, defined as death, doubling of serum 
creatinine, and/or dialysis need. The moderate consistency observed between biomarkers 
reported in different studies is puzzling, which is probably due to different technologies 
used and the lack of statistical power in some studies resulting in the reporting of 
artifacts. Also the distinction between those patients with and without diabetic 
nephropathy in most of these studies is not proven by biopsy. 
It is evident that a huge amount of effort is being put into how to identify diabetic 
nephropathy in patients with diabetes without being invasive, that is, without taking a renal 
biopsy, both in clinical practice and clinical research studies. A drawback in most of these 
biomarker studies pursuing this aim is that no renal biopsy was taken to determine the 
presence and severity of diabetic nephropathy in the diabetic patients in the first place. 
Virtually all studies rely on clinical parameters, mostly expressed as the amount of 
albuminuria, for the diagnosis of diabetic nephropathy. How reliable is this? Chronic renal 
insufficiency and/or proteinuria especially in type 2 diabetes may stem from chronic renal 
disease other than classic diabetic nephropathy. In a recent retrospective study of 69 patients 
with type 2 diabetes with renal biopsies, 52% had non diabetes-related nephropathy (Mou S, 
2010). Selection bias most likely plays a role in these data, as renal biopsies are typically 
performed in these patients if co-morbidity is suspected. It remains, however, most likely 
that some of the patients included in the biomarker studies were unrightfully given the 
diagnosis of diabetic nephropathy, and it is uncertain how important this contamination of 
the data is for the study outcomes. Only one marker study in 2010 was found that did 
incorporate renal biopsy findings and interestingly, in this study, a classification model was 
able to reliably differentiate diabetic nephropathy from nondiabetic chronic kidney disease 
(Papale M 2010). Among the best predictors of this classification model were ubiquitin and b 
2-microglobulin. 
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There are probably also a considerable proportion of patients without albuminuria who are 
at the beginning stages of diabetic nephropathy. These patients are unrightfully diagnosed 
as not having diabetic nephropathy. Interesting in this light was the 2010 study by Nielsen 
et al., which evaluated the new marker of tubulointerstitial damage kidney injury molecule 
1 (KIM-1) in type 1 diabetes patients with either normoalbuminuria, microalbuminuria, or 
macroalbuminuria in comparison with normal controls. Urine KIM1 was elevated in all type 
1 diabetes patients in comparison with the normal controls and irrespective of the presence 
of albuminuria. Thus, normoalbuminuric patients with type 1 diabetes also had elevated 
urine KIM1. It was therefore concluded that tubular damage may be present at an early 
stage in all patients, the so-called ‘tubular phase’ of diabetic nephropathy. Whether or not 
this means that in fact all patients with type 1 diabetes have a latent form of diabetic 
nephropathy remained undiscussed, but that would be an interesting hypothesis. Another 
study that investigated urinary changes in non-overt diabetic nephropathy in type 2 
diabetes came from Japan (Araki S,2010). This study included 254 patients with type 2 
diabetes of whom 185 were normoalbuminuric and 69 had microalbuminuria. At baseline, 
urinary type IV collagen levels. were higher in patients with microalbuminuria. During a 
follow-up study with a median duration of 8 years, the level of urinary type IV collagen 
inversely correlated with the annual decline in estimated GFR, whereas overt proteinuria 
did not appear in a majority of patients. Two studies from Malaysia gave similar results, 
with type IV collagen levels correlating with the amount of urinary albumin in 30 type 2 
diabetes patients at baseline Sthaneshwar P, 2010), but also with subsequent GFR change 
(Katavetin P 2010). Also in New Zealand, urinary collagen IV was studied in diabetes: spot 
urine samples from 457 unselected patients attending a hospital diabetes clinic were 
analyzed for albumin, creatinine, and a number of biomarkers including collagen IV 
(Cawood TJ, 2010). The proportion of patients with abnormal collagen IV increased from 26, 
58, and 65%, respectively, across the normoalbuminuria, microalbuminuria, and 
macroalbuminuria groups. The authors conclude that longitudinal studies are now required 
to assess whether these biomarkers can detect early renal disease with greater specificity 
and sensitivity than the albumin: creatinine ratio. Including histopathological findings in 
these types of studies would certainly make a great contribution to our better understanding 
of the mechanism leading to diabetic nephropathy. 
11. Treatment 
Interventions that have been found useful in preventing or retarding the progression of DN 
include  
 Strict glycemic control 
 Strict blood pressure control 
 Cessation of smoking 
 Control of hyperlipidemia and  
 Restriction of protein intake.  
12. Strict glycemic control  
Hyperglycemia is an important risk factor for development of microalbuminuria, 
progression of established microalbuminuria to macroalbuminuria and impaired glomerular 





sex, long duration of diabetes, smoking, obesity, elevated blood pressure, and genetic 
predisposition. (de Boer IH 2011) 
Studies have shown that strict glycemic control delays the development of 
microalbuminuria, stabilizes or reduces protein excretion in patients with microalbuminuria 
and overt proteinuria, and slows the rate of progression to chronic renal failure. The 
Diabetes Control and Complications Trial (DCCT) compared conventional with intensive 
glycemic management in 1,441 type-I diabetic patients. This study proved that intensive 
treatment reduced the risks of retinopathy, nephropathy, and neuropathy by 35% to 90% 
compared with conventional treatment. The absolute risks of retinopathy and nephropathy 
were proportional to the mean glycosylated hemoglobin (HbA1c) level over the follow-up 
period preceding each event. Intensive treatment was most effective when begun early, 
before complications were detectable. These risk reductions were achieved at a median 
HbA1c level difference of 9.1% for conventional treatment versus 7.3% for intensive 
treatment. ((The DCCT/EDIC Research Group 2000, The DCCT/EDIC Research Group 
2002)) In the combined cohorts, intensive treatment reduced the development of 
microalbuminuria and clinical albuminuria by 39% and 56%, respectively. The benefits of 
intensive therapy were also long-lasting and persisted beyond the period of shortest 
intervention. (The DCCT/EDIC Research Group 2000, The DCCT/EDIC Research Group 
2002) Thus, intensive treatment should be started as soon as possible safely after the onset of 
type 1 diabetes mellitus and maintained thereafter, aiming for a practicable target HbA1c 
level of 7.0% or less. (Writing Team for the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Research Group 2002). 
These findings suggest that hyperglycemia has long-term chronic effects on the underlying 
pathophysiology of microvascular complications. It takes time for improvements in control to 
negate the long lasting effects of prior prolonged hyperglycemia, and once the biological 
effects of prolonged improved control are manifest, the benefits are long lasting. However, 
using the current intensive treatment regimen led to a 3-fold increase in severe hypoglycemic 
events and to excess weight gain in the DCCT. (DCCT/EDIC research group 2002) 
Efforts need to be made to eliminate preventable severe hypoglycemic episodes that result 
from unsafe patient behavior and decisions, and to avoid inordinate weight gain. Irregular 
food intake, failure to check blood glucose before planned or unplanned vigorous exercise 
or before operating a motor vehicle, and excess alcohol ingestion have been identified as risk 
factors for hypoglycemia and serious complications and must be scrupulously avoided. 
Mealtime bolus doses of rapid acting insulin must be based on the pre-injection blood 
glucose level, the anticipated amount of carbohydrate intake and upcoming exercise. 
Thorough diabetes education and its regular reinforcement should be provided by diabetes 
nurse and dietitian educators. These professionals can negotiate individualized care plans 
with patients, give them training in self-management, and provide stimulation, motivation, 
and positive reinforcement for good self-care behavior, such as frequent self blood glucose 
monitoring and regular eating habits. While these measures can interfere with patients’ 
lifestyles, they are the current price that must be paid to delay or reduce the risk of 
microvascular complications. (DCCT/EDIC research group 2002) 
13. Blood pressure control  
Long term and aggressive antihypertensive treatment induces a progressive reduction in the 
rate of decline in kidney function. Thus, this modality of treatment can postpone renal 
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insufficiency in patients with DN. Both systolic and diastolic hypertension markedly 
accelerate the progression of DN, and aggressive antihypertensive management has been 
shown to decrease the rate of fall of glomerular filtration rate, increase the median life 
expectancy, and reduce the need for dialysis and transplantation.  
The primary goal of therapy for non-pregnant patients with DM older than 18 years is to 
achieve a blood pressure less than 130/80 mmHg for patients with proteinuria <1 g/day, and 
less than 125/75 mmHg for patients with >1 g/day of proteinuria. Angiotensin converting 
enzyme (ACE) inhibitors and ARBs are recommended as first-line antihypertensive therapy 
for patients with type-I and type-2 DM. Other agents that can be used include Beta blockers, 
calcium channel blockers, and diuretics. (American Diabetes Association 2003, Ayodele OE 
2004).  
Persistent clinical proteinuria is closely associated with the presence of hypertension in 
IDDM patients. In NIDDM patients the risk of developing clinical proteinuria is increased 
more than twofold in patients with blood pressure > 165/95 mm Hg compared to those with 
lower blood pressure after adjusting for age, sex and duration of diabetes. Moreover, in both 
insulin-dependent and non-insulin-dependent diabetes, the age adjusted total mortality rate 
is greatly increased in those patients with proteinuria or hypertension (Earle K 1994). 
Prospective studies have shown that normoalbuminuric patients who progress to 
microalbuminuria have higher blood pressures (albeit within the normal range) than those 
who persistently remain normoalbuminuric. Parents of insulin-dependent diabetic patients 
with nephropathy have a higher prevalence of hypertension and cardiovascular disease 
compared to patients without nephropathy (Earle K 1994). 
ACE Inhibition versus Angiotensin II (Ang II) receptor type 1 blockade in the Renin-
Angiotensin System (RAS). RAS is one of the most important physiological regulators of 
renal function. ACE inhibitors selectively dilate efferent arterioles. This decreases the arterial 
pressure and in turn reduces glomerular capillary pressure. In addition, Ang II causes 
mesangial cell growth and matrix production. Numerous animal studies and clinical trials 
have shown that ACE inhibitors significantly reduce the loss of kidney function in DN. They 
prevent progression of microalbuminuria to overt proteinuria and several studies evaluated 
the effect of ACE inhibitor on development and progression of DN.  
The landmark study by Lewis et al. [1993], examined the effect of captopril on the 
progression of DN in patients with type 1 DM (Lewis, EJ 1993). This was measured as the 
rate of decline in creatinine clearance and the combined end points of dialysis, 
transplantation, and death. Treatment with captopril was associated with 48% risk reduction 
for doubling the serum creatinine as compared to placebo. The results of this study were 
subsequently confirmed by North American Microalbuminuria Study Group and EUCLID 
study group (EUCLID Study Group 1997, Laffel LM 1995). They extended the observation 
by showing a protective effect of ACE inhibitors in patients with a variety of renal diseases, 
including glomerulopathies, interstitial nephritis, nephrosclerosis, and DN. The exception 
was polycystic kidney disease. Importantly, the protective effect of ACE inhibition was 
independent of the severity of renal insufficiency. (Lewis, EJ 1993, Brown N 1998) 
The MICRO-HOPE (Heart Outcomes Prevention Evaluation) studied the benefit of ramipril 
in type 2 diabetics. The diabetes sub-study of the Heart Outcomes Prevention Evaluation 
study showed ramipril reduced the risk of overt nephropathy by 24%. Moreover, ramipril 
reduced urinary albumin excretion at 1 year and at the end of the study. Thus, ACE 
inhibitors have also been shown to be renoprotective in patients with type 2 DM. (Heart 





Two studies, Irbesartan in Patients with Diabetes and Microalbuminuria (IRMA-2) and 
Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study examined the effect of 
ARB’s in diabetic patients with microalbuminuria, but without overt DN (Parving HH 2001, 
Barnett A 2006). It is well known that, in patients with type 2 DM presence of 
microalbuminuria increases the risk of developing DN 10 to 20 times. IRMA-2 study showed 
that irbesartan significantly reduced the rate of progression of microalbuminuria to overt 
DN in patients with type 2 diabetes. Furthermore, the study discovered that irbesartan was 
associated with significantly more common restoration of normoalbuminuria as compared 
to standard therapy. All these effects were achieved independent of the systemic blood 
pressure. The more recent DETAIL study compared the renoprotective effects of ACE 
inhibitor enalapril and ARB telmisartan. In this head-to-head comparison the authors 
showed that both treatments were equally effective in preventing the progression of renal 
dysfunction, measured as decline in the GFR. Reduction of Endpoints in NIDDM with 
Angiotensin II Antagonist Losartan (RENAAL) study (Brenner BM 2001) showed that 
treatment with losartan was associated with a 25% decrease in the risk for doubling serum 
creatinine level. The risk of developing ESRD was also reduced by 28%.  
Other individual factors may better define the impact of ACE inhibitors on the progression 
of renal insufficiency. In particular, Rigat et al described an insertion (I) and deletion (D) 
polymorphism in the ACE gene that correlates with ACE activity. ACE levels are highest in 
patients who are homozygous for the ACE D allele and lowest in patients homozygous for 
the ACE I allele (Rigat B 1990). They are intermediate in those who are heterozygous. 
Yoshida et al (Yoshida H 1995) later reported a greater reduction in proteinuria in response 
to ACE inhibition in patients with IgA nephropathy who were homozygous for the D allele. 
In contrast to this, other investigators have suggested a worse response to therapy in 
patients who carry the D allele (Parving HH 1996). Obviously, large-scale studies are needed 
to define the impact of genetic factors on the renal protective effects of ACE inhibition.  
There are studies suggesting that dual blockade of renin-angiotensin system using a 
combination of ACE inhibitor and an ARB in patients with nephropathy is superior to the 
use of either drug alone. (Ayodele OE 2004, Mogensen CE 2000, Rosner MH 2003).  
The antiproteinuric effects of inhibitors of the renin angiotensin system are increased by 
sodium restriction and by concomitant administration of diuretics or non-dihydropyridine 
calcium channel blockers. (American Diabetes Association 2002, Ayodele OE 2004, Arauz-
Pacheco C 2002). 
In the United Kingdom Prospective Diabetes Study, atenolol showed beneficial effects 
comparable to captopril on diabetes-related mortality and microvascular complications in 
patients with type-2 diabetes. (United Kingdom Prospective Diabetes Group 1998) Beta-
blockers have been shown to reduce mortality following myocardial infarction, and the 
absolute benefit of a given relative reduction is greater in diabetics compared to 
nondiabetics due to higher mortality from myocardial infarction in patients with diabetes. 
(Ayodele OE 2004) The nondihydropyridine calcium channel blockers have been shown to 
lower protein excretion in patients with diabetes. (Bakris GL 1990 and 1997) Their 
antiproteinuric effect may be due to reduction in intraglomerular pressure, reduction in 
glomerular hypertrophy, and improved glomerular size. The dihydropyridine calcium 
channel blockers have a variable effect on protein excretion ranging from increased 
protein excretion to no effect to a fall in protein excretion in various studies. (Melbourne 
Diabetic Nephropathy Study Group 1991, Vellussi M 1996, Salako BL 2002, Rosssing P, 
1997) 
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14. Protein restriction  
The role of dietary protein restriction in CKD is best described as controversial. However, 
restriction of protein (0.6 g/kg body weight per day) and phosphorus (0.5 to 1 g per day) were 
shown to reduce the decline in GFR, lower blood pressure, and stabilize renal function 
compared with higher intakes. This was suggested by a randomized trial involving patients 
with type-I DM and overt DN. In addition, another study showed that restriction of protein 
intake to 0.8 g/kg body weight per day reduced the rate of progression to ESRD in patients 
with type-I diabetes. The National Kidney Foundation recommends that patients with GFR <29 
mL/min per m2 should have a daily protein intake of 0.6 g/kg body weight. More recently, a 4-
year randomized controlled trial in 82 patients with type 1 diabetes with progressive DN 
showed that a moderately low–protein diet (0.9 g · kg−1 · day−1) reduced the risk of ESRD or 
death by 76%, although no effect on GFR decline was observed (Hansen HP, 2002) 
A prospective, randomized controlled trial in patients with type 1 diabetes suffering from 
progressive diabetic nephropathy demonstrated beneficial effect of moderate restriction in 
dietary protein on the development of ESRD or death. The beneficial effect of protein 
restriction appeared within the first year, and persisted with continued treatment, as also 
has been demonstrated in non-diabetic nephropathies suggesting that type 1 diabetic 
patients with progressive diabetic nephropathy are highly sensitive to dietary protein 
restriction (Hansen HP, 2002). 
The mechanisms by which a low-protein diet may reduce progression of DN are still 
unknown, but might be related to improved lipid profile and/or glomerular 
hemodynamics. (Jorge L, 2005) Since diabetic patients have other restrictions to the diet, this 
may reduce compliance to an additional low-protein diet, although better compliance can be 
obtained by applying much more intensive dietary counseling (Hansen HP, 2002) 
15. Cessation of smoking 
Smoking has been shown in many previous studies to effect diabetic complications. 
Cessation of smoking alone may reduce the risk of progression by 30% in patients with type-
2 diabetes. (Ritz E, 2000) Recent studies demonstrated that smokers have increased systolic 
blood pressures and proteinuria amongst diabetics with nephropathy (Sawicki, PT 1996) 
More recent work by Chihuran et al has shown that renal function declines faster in smokers 
than nonsmokers with type 2 DN undergoing treatment to improve blood pressure 
including ACE inhibitors. Also, loss of renal function is slower in those who stopped 
smoking. Cigarette smoking remains a risk factor for renal function decline in type 2 DN 
despite currently recommended therapy (Chihuran T, 2002)  
16. Hyperlipidemia 
There is suggestion that elevation in lipid levels may contribute to the development of 
glomerulosclerosis in chronic renal failure. (Ravid M, 1995, Krolewski AS, 1994) Studies have 
shown that lipid lowering may have a beneficial effect on renal function. (Lam KSL, 1995) A 
meta-analysis of 13 controlled trials involving a total of 362 subjects, 253 of whom had 
diabetes, showed that statins decreased proteinuria and preserved GFR in patients with 
chronic renal disease. (Fried LF, 2001) Adequately powered randomized controlled trials will 
be needed to determine the role of lipid lowering therapy in retarding the rate of decline in 





17. Renal replacement therapy 
The renal replacement modalities available for patients with ESRD from diabetes include 
peritoneal dialysis, hemodialysis, and renal transplantation. Various studies have shown 
similar survival in hemodialysis and peritoneal dialysis, though patients are more likely to 
persist with hemodialysis than with peritoneal dialysis. Both hemo- and peritoneal dialysis 
limit social life, leisure, and sexual activity.(Hostetter TH, 1981) Patients with diabetes may 
manifest uremic symptoms at a relatively less-advanced degree of renal insufficiency than 
their nondiabetic counterparts. (Hostetter TH, 1982) 
18. Emerging therapies 
Extensive research is currently underway in this field and some new pathogenic mediators 
for DN have been discovered. These include 
 Renin  
 Advanced Glycosylation end-products [AGE]  
 Protein Kinase C [PKC]  
 Transforming growth factor – Beta 1 [TGF-1]  
 Nitric Oxide [NO]  
 Vascular endothelial growth factor [VEGF]  
 Oxidative stress  
18.1 Direct renin inhibitor – Aliskiren  
Blockade of RAS is a key therapeutic strategy in slowing progression of DN. Interruption of 
the RAS may also be accomplished by blocking the activity of renin. Aliskiren is a direct 
renin inhibitor and thus, decreases angiotensin II and aldosterone levels. Aliskiren is a 
potent antihypertensive and anti proteinuric.  
18.2 Advanced Glycosylation end-products [AGEs]  
The formation of AGEs and their cross-linked products is a phenomenon of normal aging; 
however, it is accelerated in the DM. AGE–cross-linked products accumulate in patients 
with DM and have been implicated in the pathologic process of diabetic complications. 
Several anti-AGE agents have been tested and shown to be renoprotective in experimental 
diabetic animal models. (Thomas MC, 2005)  
Aminoguanidine is the prototype of an AGE formation inhibitor which acts by scavenging 
intermediates in the advanced glycation catalytic process.  
ALT-946 is a more potent and selective AGE formation inhibitor than aminoguanidine. It 
has minimal effects on NO synthesis and appears to have fewer toxic effects, although it has 
not been studied in as much detail.  
Pyridoxamine (PYR) - Pyridoxamine is one of the three natural forms of pyridoxine (vitamin 
B6). It scavenges pathogenic reactive carbonyl species and inhibits the formation of AGEs 
from Amadori compounds. (Voziyan PA, 2002, Chetyrkin SV, 2008)  
18.3 Thiamine  
Experimental studies have suggested that thiamine and benfothiamine (S-benzoylthiamine 
monophosphate), a vitamin B1 derivative, can also prevent or decrease kidney injury. These 
drugs decrease formation of AGE compounds and protein kinase C (PKC) activity in DN.  
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AGE Breakers - This group of compounds decreases AGE accumulation by breaking the 
glycation cross-links.  
AGE Receptor Antagonists - AGEs mediate their effects both directly and indirectly through 
receptor-dependent mechanisms. They bind to the transmembrane receptor for AGE 
(RAGE) and prevent the development of diabetic microvascular complications. (Bierhaus A 
2005, Wendt T, 2003) Thus, RAGE is a potential target to prevent AGE effects.  
18.4 Pentoxifylline  
Pentoxifylline (PTF) is a methylxanthine derivative with hemorheological properties that 
has favorable effects on microcirculatory blood flow. In vivo, it also functions as a 
phosphodiesterase inhibitor. (Navarro J.F., 1999)  
18.5 Protein Kinase C inhibitors  
Recent studies have identified that activation of PKC initiated by hyperglycemia is 
associated with many vascular abnormalities in retinal, renal, and cardiovascular tissues. 
The blocking of PKC-beta isoforms has been shown to decrease albuminuria, structural 
injury, and TGF-beta expression in animal models of DM. (Koya D, 2000) Ruboxistaurin is 
one such PKC beta inhibitor. 
18.6 Glycosaminoglycans  
Glycosaminoglycans are important determinants of GBM permeability. An emerging body 
of evidence supports the notion that glomerular capillary wall and mesangial alterations in 
DN involve pathobiochemical alterations of glycoproteins in these structures. Heparin and 
sulodexide are examples of this class of drugs. 
18.7 Endothelin receptor antagonists  
DN is associated with enhanced renal synthesis of endothelins. A number of preclinical reports 
suggested that endothelin might be an appropriate target to decrease DM-related albuminuria. 
(Turgut F, 2010) Avosentan (SPP301) is a new orally available endothelin 1 antagonist.  
18.8 Antifibrotic agents and growth factor inhibitors  
Characteristic morphologic lesions of DN include glomerular hypertrophy, thickening of the 
basement membrane, and mesangial expansion. This leads to glomerulosclerosis, 
tubulointerstitial fibrosis, and, eventually, loss of kidney parenchyma. Several growth factors 
which are normally expressed in the kidney have been implicated in the pathogenesis of DN.  
TGF-β Inhibitors - Pirfenidone (PFD) is a low molecular weight synthetic molecule that 
exerts dramatic antifibrotic properties in cell culture and various animal models of fibrosis. 
SMP-534, another antifibrotic agent is also being studied. Several AGE inhibitors also 
decrease TGF-β levels. (Turgut F,2010, Sugaru E., 2006)  
CTGF Inhibitors - Connective tissue growth factor (CTGF/CCN2) has been associated with 
fibrosis in various tissues including the kidney. It is up-regulated in most models of DN. 
Clinical trials evaluating anti-CTGF ab (FG3019) are underway. 
18.9 Nitric Oxide (NO) modulation  
Abnormalities of renal NO generation have been linked to pathogenesis of renal disease in 
diabetes. NO and / or NO Synthase are targets for drug development for treatment and/or 





18.10 Vascular endothelial growth factor (VEGF) inhibitors  
VEGF is a main regulator of blood vessel growth and plays an important role in promoting 
endothelial survival and maintaining the microvasculature. Loss of capillaries is strongly 
associated with the progression of CKD to ESRD (Doi K, 2010).  
19. Alternative and complementary therapies for diabetic nephropathy 
19.1 Exercise and Yoga 
The American Diabetes Association recommends a minimum of 30 minutes of moderate-
intensity aerobic physical activity 5 days per week, or vigorous-intensity aerobic physical 
activity for 20 minutes 3 times per week is recommended for healthy adults aged 18 to 65. 
Currently, there is no clinical evidence to suggest that vigorous exercise increases the rate of 
progression of diabetic nephropathy. In fact, some studies have shown that aerobic exercise 
actually decreased urine protein excretion (Gordon LA, 2008). Additionally, it has been 
demonstrated that resistance training may have a beneficial effect on muscle mass, 
nutritional status, functional capacity, and glomerular filtration rate. Therefore, the 
American Diabetes Association feels that there is no need to restrict exercise in patients with 
diabetic nephropathy. A more recent study that examined the effects of Yoga and 
conventional exercise showed findings that suggest better glycemic and blood pressure 
control obtained in type 2 diabetic patients after Hatha yoga than conventional PT exercises 
(Gordon LA, 2008).  
19.2 Life style modifications  
Obesity is often associated with diabetes mellitus and also with nephropathy independent 
of diabetes (often focal sclerosis). However the impact of weight loss in diabetic subjects 
with nephropathy on renal function and proteinuria remains as a subject of intense 
investigation. Short term studies recently reported that weight reduction using dietary 
therapy for 4 weeks resulted in significant reduction in systolic pressure, proteinuria, and 
serum creatinine in obese patients with diabetic nephropathy. (A Saiki, 2005). Longer 
studies involving larger group of patients need to be evaluated to validate such conclusions. 
19.3 Herbal and Food derivatives  
19.3.1 Curcumin  
Curcumin is the active component in Tumeric Rhizomes (Curcuma Long Linn). Curcumin 
has been shown to possess anti-inflammatory, anti-oxidant and antifibrotic properties in 
many tissues, in vivo and in vitro studies. Tikoo et al have shown that curcumin treatment 
prevented the development of DN by significantly lowering blood urea nitrogen and 
plasma creatinine/body weight ratio in diabetic animals. (Tikoo K, 2008) Various biological 
actions of curcumin are mediated by inhibiting cell proliferation (Sikora E, 1997), oxidative 
stress and inflammation (Sharma C, 2006). Several other investigators have also shown that 
the anti-inflammatory property of curcumin can significantly improve kidney function in 
animals with chronic renal failure.  
19.3.2 Cinnamon 
Cinnamon has been known for its antidiabetic effects for some time now. Mishra et al have 
investigated its effects on nephropathy in diabetes in rodent models of type I diabetes. 
Histological studies of the kidney proved the protective effect of cinnamon oil by reducing 
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the glomerular expansion, eradicating hyaline casts, and decreasing the tubular dilatations. 
(Mishra A, 2010). The authors concluded that the volatile oil from cinnamon contains more 
than 98 % cinnamaldehyde and that it confers dose-dependent, significant protection against 
alloxan-induced renal damage. While the mechanism of its action remains unclear, it is 
believed to be mostly due to its antidiabetic and antioxidant effects leading to reduced 
formation of AGEs.  
20. Conclusions  
During the last 3 decades, considerable progress has been made in delaying the progression of 
CKD even as the frequency of DN continues to increase. This is a truly a reflection of the 
advances made in understanding the pathogenesis. As reviewed in this chapter many 
pathogenic cytokines and growth factors have emerged in the recent years that either initiate or 
contribute to the progressive renal injury in diabetes. Current treatment options are still 
suboptimal. However with the rapid strides being made in the field, several new therapeutic 
targets are being recognized and effective treatment strategies being developed. 
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1. Introduction 
We evaluated the incidences of metabolic syndrome (MS) and its components in the urban 
residents of southern China, analyzed their relationship to insulin resistance (IR), meanwhile 
compared the different of MS diagnostic criteria between Chinese Diabetes Society (CDS) and 
International Diabetes Federation (IDF) in clinic practice in the southern urban residents of 
China. The total incidence of MS was 8.7% according to the diagnostic criteria of CDS, but up 
to 19.8% according to the diagnostic criteria of IDF. The total incidences of hypertension, 
abdominal obesity and diabetes were 22.1%, 39.2% and 6.7%, respectively. The incidence of IR 
was 5.0% according the value of HOMA-IR. By means of binary logistic regression analysis, 
impaired fasting glucose, diabetes, obesity, abdominal obesity, elevated triglyceride and high 
sensitivity C reactive protein were independent risks of insulin resistance, but gender, 
hypertension, elevated low density lipoprotein and total cholesterol were not independent 
risks of insulin resistance. It is suggested by the data of our present screening in the residents 
of southern China that the incidence of MS according to the diagnostic criteria of CDS was 
lower than that according to the diagnostic criteria of IDF. Some residents with MS main 
presentation of abdominal obesity would be missed diagnosis by the criteria base on BMI. In 
the components of MS, hypertension, abdominal obesity and lower high density lipoprotein 
were more common than others. IR was associated to most of the components of MS and may 
be one of the main pathogenic factors. 
By means of cross-section epidemiological analysis, we investigated the relationship of 
glycometabolic disorder and IR with chronic kidney diseases (CKD). The prevalence of CKD 
was 12.6% in the community population, with 11.2% in the youth group, 19.4% in the 
middle age group and 17.7% in the elder group. And there were a significantly difference 
between the three age groups (P<0.01). The awareness rates and treatment rates of CKD 
were very low in all of the three groups. In the whole screened population there was a 
higher CKD prevalence in IR residents when compared to non-IR residents, 36.9% versus 
12.6% (P<0.01). Among population with only impair FBG but not diabetes, CKD prevalence 
in those residents with IR was higher than those without IR, 33.3% versus 16.0% (P<0.05). 
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By means of cross-section epidemiological analysis, we investigated the relationship of 
glycometabolic disorder and IR with chronic kidney diseases (CKD). The prevalence of CKD 
was 12.6% in the community population, with 11.2% in the youth group, 19.4% in the 
middle age group and 17.7% in the elder group. And there were a significantly difference 
between the three age groups (P<0.01). The awareness rates and treatment rates of CKD 
were very low in all of the three groups. In the whole screened population there was a 
higher CKD prevalence in IR residents when compared to non-IR residents, 36.9% versus 
12.6% (P<0.01). Among population with only impair FBG but not diabetes, CKD prevalence 
in those residents with IR was higher than those without IR, 33.3% versus 16.0% (P<0.05). 
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Even among population with normal FBG, CKD prevalence in those residents with IR was 
higher than whose without IR, 39.1% versus 12.0% (P<0.01). It was observed in different age 
group that the prevalence of albuminuria and the mean albuminuria level were higher in 
the residents with IR when compared to the residents without IR. No difference existed 
between either the prevalence of decreasing eGFR or the mean level of eGFR in residents 
with IR and without IR in the middle age group and the old group, but not in the youth 
group in which. The mean level of eGFR was significantly higher in the residents with IR 
when compared to the residents without IR (P<0.01). It is indicated in our data that CKD is 
common and the awareness rate and treatment rate are very low in this investigated 
community population. IR might be associated with the increasing prevalence of CKD, 
especially with the increased prevalence of microalbuminuria, even in the population with 
normal FBG. Furthermore IR might also be associated with elevated eGFR in population at 
the early stage of diabetes but without CKD, while associated with decreased eGFR in those 
with CKD. It is suggested that IR might be a risk factor of CKD and also a prevention and 
treatment target of CKD in community residents. 
We also explored the incidences of hyperuricemia (HUA) in the urban residents and the 
related risk factors. The total incidence of HUA was 23.5% in the cohort residents, and was 
28.4% in the males and 19.7% in the females (P<0.01). The serum uric acid level was positively 
related to body weight (or BMI), waist circumference and the age (for females) when 
controling with serum creatinine (P<0.01). Alcohol consumption and smoke influences 
significantly on the serum uric acid level, and highest uric acid levels were in the residents 
frequently drunk and smoked in the past. More common prevalence of HUA was in the 
patients with chronic kidney disease and hypertension, and the serum uric acid levels were 
similar in these patients. There was no significant difference of the incidences of HUA between 
the patients with diabetes and non diabetes. It is suggested by our present investigation that 
the incidence of HUA is increasing in the residents of inland city of China, and that the change 
of their lifestyle with lose weight, prevention of obesity, avoid smoke and restriction of alcohol 
would be the most effective measures to change the high prevalence of HUA. 
2. Pathogenesis of metabolic syndrome associated kidney damage 
2.1 Insulin resistance and pathogenesis of metabolic syndrome-associated kidney 
damage 
Insulin resistance and metabolic renal damage is closely related. So the metabolic syndrome 
were screened for kidney damage, assessment is very necessary. Regarding to the 
pathogenesis of insulin resistance and to improve the treatment based on will also be a 
metabolic control of renal damage in a new direction for the future. 
2.1.1 Insulin resistance leads to kidney damage 
The metabolic syndrome (MS) was defined as the presence of 3 or more of the following risk 
factors: elevated blood pressure, insulin resistance, low high-density lipoprotein cholesterol 
level, high triglyceride level, elevated glucose level, and abdominal obesity. MS disease risk 
factors in order to gather more focus is characterized by heart, kidney blood vessels and 
other target organs. The impact is clear. Now the increasing number of researches show that 
compared with simple hypertension, metabolic syndrome is more easily lead to kidney 
damage. Some studies further confirmed that the large vessels and kidney of metabolic 
syndrome patients damaged obvious. MS can cause kidney damage, and the kidney disease 
affects MS as well. This shows the relationship between MS and kidney disease is very close. 
 
Metabolic Syndrome Associated Kidney Damage 
 
371 
So people consensus that MS is started for obesity as the common factor. And insulin 
resistance is the central link of MS. This can be inferred that the relationship between insulin 
resistance and metabolic renal damage is close.  
Insulin resistance refers to the uptake of insulin to promote peripheral tissue, the use of 
glucose output and inhibit the biological effects of glycogen decreased, with the changes in 
the compensatory ability of the body showed hyperinsulinemia and (or) high blood sugar 
status. The kidney damage mechanisms caused by high blood sugar is including that: ① 
polyol pathway activation; ② protein non-enzymatic glycation (advanced glycation end 
products formation); ③ activation of protein kinase C. The renal injury is caused by these 
lesions and GBM thickening. In addition, the recent study found, MS appears 
hyperinsulinemia is also often high viremia of amylin, amylin is a high-fiber protein, mainly 
deposited in the glomerular mesangial area widened, K-W nodules, blood vessel walls and 
renal interstitial, which become one of the causes of injury about glomerular and interstitial. 
In vitro experiments showed that amylin may be higher in mesangial cells through 
induction of apoptosis and increased permeability in endothelial cells kidney damage, but 
the exact mechanism is still not very clear.[1, 2]  
Now that insulin resistance occurs most often in patients with metabolic syndrome, is the 
central link in the pathogenesis and pathogenic basis. It not only prompts a new-onset diabetes 
mellitus, cardiovascular events and all-cause mortality in high-risk, but also the renal damage 
and failure are independent risk factors.[3-6] The primary kidney disease before there is often 
severely impaired renal function also showed insulin resistance.[4] Therefore, insulin 
resistance and renal damage can reinforce each other, so to clear the relationship  between 
insulin resistance and metabolic  renal damage is useful that in the prevention and treatment 
of kidney disease is especially prominent role in the process. This article is the review on the 
causes of pathogenesis why insulin resistance leads to metabolic kidney damage. 
2.1.2 Insulin resistance and pathogenesis of metabolic syndrome-associated kidney 
damage 
Insulin resistance is the central link of metabolic syndrome. The U.S. NHANES Ш data 
shows that the prevalence of metabolic syndrome has reached 23.7% for the adults who over 
20 years ’old.[3] The study showed that In type 2 diabetes, more severe insulin resistance is 
independently associated with microalbuminuria.[5, 6] Animal experiments confirmed that 
clinical diabetes mellitus in the event of hyperinsulinemia stage before changes of structure 
and function in kidney have been.[7] Such early renal damage has its own characteristics 
and pathogenesis, which are different from diabetic nephropathy. Insulin resistance 
mechanisms lead to kidney damage mainly in the following areas. 
Insulin-like growth factor (IGF) axis is involved in diabetic renal disease 
Insulin-like growth factor I (IGF-I) is a potent mitogenic polypeptide under the regulation of 
growth hormone (GH). Evidence of significant involvement of the GH/IGF system in diabetic 
nephropathy and other nephropathies has been provided by several studies. Kidney tissue 
expresses receptors not only for IGF-I but also for GH, which suggests that although most of 
the biologic effects of GH are mediated by IGF-I, GH may also act independently of IGF-I. IGF-
I may have pathogenic roles in diabetic nephropathy and other nephropathies. Serum IGF-I 
levels are reduced in hyperglycemic diabetic subjects, despite elevated GH levels. This 
phenomenon has been explained by inhibition of hepatic IGF-I synthesis, resulting from 
decreases in hepatic GHR expression and binding. The metabolic consequences of these 
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were screened for kidney damage, assessment is very necessary. Regarding to the 
pathogenesis of insulin resistance and to improve the treatment based on will also be a 
metabolic control of renal damage in a new direction for the future. 
2.1.1 Insulin resistance leads to kidney damage 
The metabolic syndrome (MS) was defined as the presence of 3 or more of the following risk 
factors: elevated blood pressure, insulin resistance, low high-density lipoprotein cholesterol 
level, high triglyceride level, elevated glucose level, and abdominal obesity. MS disease risk 
factors in order to gather more focus is characterized by heart, kidney blood vessels and 
other target organs. The impact is clear. Now the increasing number of researches show that 
compared with simple hypertension, metabolic syndrome is more easily lead to kidney 
damage. Some studies further confirmed that the large vessels and kidney of metabolic 
syndrome patients damaged obvious. MS can cause kidney damage, and the kidney disease 
affects MS as well. This shows the relationship between MS and kidney disease is very close. 
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So people consensus that MS is started for obesity as the common factor. And insulin 
resistance is the central link of MS. This can be inferred that the relationship between insulin 
resistance and metabolic renal damage is close.  
Insulin resistance refers to the uptake of insulin to promote peripheral tissue, the use of 
glucose output and inhibit the biological effects of glycogen decreased, with the changes in 
the compensatory ability of the body showed hyperinsulinemia and (or) high blood sugar 
status. The kidney damage mechanisms caused by high blood sugar is including that: ① 
polyol pathway activation; ② protein non-enzymatic glycation (advanced glycation end 
products formation); ③ activation of protein kinase C. The renal injury is caused by these 
lesions and GBM thickening. In addition, the recent study found, MS appears 
hyperinsulinemia is also often high viremia of amylin, amylin is a high-fiber protein, mainly 
deposited in the glomerular mesangial area widened, K-W nodules, blood vessel walls and 
renal interstitial, which become one of the causes of injury about glomerular and interstitial. 
In vitro experiments showed that amylin may be higher in mesangial cells through 
induction of apoptosis and increased permeability in endothelial cells kidney damage, but 
the exact mechanism is still not very clear.[1, 2]  
Now that insulin resistance occurs most often in patients with metabolic syndrome, is the 
central link in the pathogenesis and pathogenic basis. It not only prompts a new-onset diabetes 
mellitus, cardiovascular events and all-cause mortality in high-risk, but also the renal damage 
and failure are independent risk factors.[3-6] The primary kidney disease before there is often 
severely impaired renal function also showed insulin resistance.[4] Therefore, insulin 
resistance and renal damage can reinforce each other, so to clear the relationship  between 
insulin resistance and metabolic  renal damage is useful that in the prevention and treatment 
of kidney disease is especially prominent role in the process. This article is the review on the 
causes of pathogenesis why insulin resistance leads to metabolic kidney damage. 
2.1.2 Insulin resistance and pathogenesis of metabolic syndrome-associated kidney 
damage 
Insulin resistance is the central link of metabolic syndrome. The U.S. NHANES Ш data 
shows that the prevalence of metabolic syndrome has reached 23.7% for the adults who over 
20 years ’old.[3] The study showed that In type 2 diabetes, more severe insulin resistance is 
independently associated with microalbuminuria.[5, 6] Animal experiments confirmed that 
clinical diabetes mellitus in the event of hyperinsulinemia stage before changes of structure 
and function in kidney have been.[7] Such early renal damage has its own characteristics 
and pathogenesis, which are different from diabetic nephropathy. Insulin resistance 
mechanisms lead to kidney damage mainly in the following areas. 
Insulin-like growth factor (IGF) axis is involved in diabetic renal disease 
Insulin-like growth factor I (IGF-I) is a potent mitogenic polypeptide under the regulation of 
growth hormone (GH). Evidence of significant involvement of the GH/IGF system in diabetic 
nephropathy and other nephropathies has been provided by several studies. Kidney tissue 
expresses receptors not only for IGF-I but also for GH, which suggests that although most of 
the biologic effects of GH are mediated by IGF-I, GH may also act independently of IGF-I. IGF-
I may have pathogenic roles in diabetic nephropathy and other nephropathies. Serum IGF-I 
levels are reduced in hyperglycemic diabetic subjects, despite elevated GH levels. This 
phenomenon has been explained by inhibition of hepatic IGF-I synthesis, resulting from 
decreases in hepatic GHR expression and binding. The metabolic consequences of these 
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alterations produce a "vicious cycle," wherein the hyperglycemia/insulinopenia induce 
decreases in serum IGF-I levels, which in turn induce GH hypersecretion, making optimal 
metabolic control more difficult to achieve.[8] People speculate that the mechanism underlying 
the renal effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and 
IGFBP-1) protein accumulation. They also speculate that the mechanism underlying the renal 
effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and IGFBP-1) 
protein accumulation. This study demonstrates that the GH/IGF axis plays a central role in the 
pathogenesis of early diabetic renal changes, and it suggests specific GHR blockade as a new 
concept in the treatment of diabetic kidney disease.[9] 
Insulin resistance increase renal damage through the rennin-angiotensin system 
Angiotensin II (Ang II) and insulin are implicated in the mesangial cell hypertrophy and 
excessive accumulation of mesangial matrix seen in glomerulosclerosis. Therefore, the 
effects of Ang II with and without insulin on mRNA levels of several important extracellular 
matrix genes and transforming growth factor beta-1 (TGF-beta 1) were examined. The 
results of the studies suggest that insulin, itself, significantly increases TGF-beta 1 and 
extracellular matrix gene expression in rat mesangial cells. Ang II alone has modest effects, 
while Ang II and insulin have additive effects. To explain the mechanism of these additive 
effects, we investigated the action of Ang II on insulin signaling and the effect of insulin on 
Ang II AT1 receptor mRNA expression. Ang II did not enhance insulin-induced insulin 
receptor substrate-1 (IRS-1) phosphorylation or phosphatidylinositol 3 (PI-3) kinase activity, 
but did enhance insulin-induced mitogen activated protein (MAP) kinase activity.[10] 
Insulin increased message levels of AT1 receptor by twofold. These results suggest that 
enhancement of MAP kinase activity and AT1 receptor regulation by insulin may contribute 
to the additive effects of insulin and Ang II in mesangial cells. 
The direct impact of insulin resistance on kidney 
Insulin major role in the tubules, but the specific sites of action are not yet entirely clear.It has a 
strong role in preserving sodium and dose dependent, while the presence of insulin to counter, 
this is still Paul sodium. Therefore, insulin resistance and hyperinsulinemia that occurs when 
the sodium sensitivity of blood pressure increase in glomerular pressure increased, resulting in 
microalbuminuria. A study was performed by Vedovato M to measure the effect of Na+ intake 
on blood pressure and albuminuria, in relation with insulin sensitivity and kidney 
haemodynamics, in Type 2 diabetic patients with and without microalbuminuria. They found 
that high salt intake increases blood pressure and albuminuria in Type 2 diabetic patients with 
microalbuminuria. These responses are associated with insulin resistance and increased 
glomerular pressure. Insulin resistance could contribute to greater salt sensitivity, increased 
glomerular pressure and albuminuria.[11] 
Insulin resistance increase the renal damage by the plasminogen activator inhibitor 1  
The insulin resistance syndrome typically features glucose intolerance and elevated fasting 
insulin and triglyceride levels. Elevated levels of PAI-1 and tPA antigens associated with 
glucose intolerance, hyperinsulinemia, and hypertriglyceridemia support inclusion of 
impaired fibrinolysis as an additional feature of the insulin resistance syndrome. Elevated 
fibrinolytic factors are also correlated with elevated markers of inflammation and 
endothelial dysfunction, which has been hypothesized to cause insulin resistance and 
thereby be the common pathogenic mechanism underlying atherosclerosis, insulin 
resistance, and glucose intolerance.[12] Hagiwara H’s study proved that renal PAI-1 gene 
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expression is up-regulated in both type 1 and type 2 diabetic rats, and changes in gene 
expressions of fibrinolytic factors may play important roles in the development and 
pathogenesis of diabetic nephropathy.[13] In addition, TGF-β, angiotensin П and thrombin 
could stimulate the synthesis of PAI-1, the process by inhibiting fibrinolysis and plasmin-
mediated matrix metalloproteinase activity, so that less matrix degradation, resulting in 
renal fibrosis. 
Insulin resistance increases the rates of renal damage by endothelin (ET) -1 
Endothelin-1, released from the vascular endothelium after cleavage from big endothelin-1, 
is a potent paracrine vasoconstrictor peptide. Small studies suggest that the circulating level 
of endothelin-1 is elevated in subjects with cardiovascular risk factors. High endothelin-1 
level may better reflect endothelin-1 generation. It is indicated by studies that endothelin-1 
level is not related to blood pressure, but higher in healthy young men with insulin 
resistance and obesity.[14] It was discovered in a diabetic mouse model treated with A-type 
ET receptor antagonist that glomerular TGF-β and collagen I, II, IV production were 
decreased. 
Insulin resistance increase the renal damage through oxidative stress 
Insulin-stimulated (or inhibited) pathways retain normal sensitivity to the hormone, 
hyperinsulinemia could, by its effects on antioxidative enzymes and on free radical 
generators, enhance oxidative stress. Other effects of insulin involve the inhibition of 
proteasome and the stimulation of polyunsaturated fatty acid (PUFA) synthesis and of nitric 
oxide (NO).[15] Prabhakar SS attempted to review the existing literature, discuss the 
controversies, and reach some general conclusions as to the role of NO production in the 
diabetic kidney. He found that genetic polymorphisms of the NOS enzyme also may play a 
role in the NO abnormalities that contribute to the development and progression of diabetic 
nephropathy.[16] 
Insulin resistance increases renal damage through nitric oxide 
The results of study performed by Steinberg HO argued that insulin effect on the 
endothelium is mediated by its own receptor and insulin signaling pathways, resulting in 
the increased release of nitric oxide. The vascular actions of insulin are impaired in insulin-
resistant conditions such as obesity, Type II (non-insulin-dependent) diabetes mellitus and 
hypertension, which could contribute to the excessive rate of cardiovascular disease in these 
groups. Insulin-resistant state in obesity and Type II diabetes shows a multitude of 
metabolic abnormalities that could cause vascular dysfunction. Non-esterified fatty acid 
level increased long before hyperglycaemia becomes present.[17] Under the circumstance of 
insulin resistance, endothelial dysfunction leads to vascular complications in the central 
link, which results in microalbuminuria. 
2.2 Hypertension and pathogenesis of metabolic syndrome-associated nephropathy 
The abnormality of kidney structure and function caused by hypertension is called 
hypertensive renal damage. Arteriolar nephrosclerosis is the most characteristic pattern in 
hypertensive renal damage, including benign arteriolar nephrosclerosis and malignant 
arteriolar nephrosclerosis. The former caused by benign hypertension, the latter caused by 
malignant hypertension. Sustained hypertension can cause renal arteriolosclerosis for 5-10 
years (tunica intimal thickening of arcuate artery and interlobular arteries, hyaline of 
afferent artery), wall thickening, lumens narrowing, and secondary ischemic renal 
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alterations produce a "vicious cycle," wherein the hyperglycemia/insulinopenia induce 
decreases in serum IGF-I levels, which in turn induce GH hypersecretion, making optimal 
metabolic control more difficult to achieve.[8] People speculate that the mechanism underlying 
the renal effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and 
IGFBP-1) protein accumulation. They also speculate that the mechanism underlying the renal 
effects of this GHR antagonist involves renal GHR inhibition of renal IGF-I (and IGFBP-1) 
protein accumulation. This study demonstrates that the GH/IGF axis plays a central role in the 
pathogenesis of early diabetic renal changes, and it suggests specific GHR blockade as a new 
concept in the treatment of diabetic kidney disease.[9] 
Insulin resistance increase renal damage through the rennin-angiotensin system 
Angiotensin II (Ang II) and insulin are implicated in the mesangial cell hypertrophy and 
excessive accumulation of mesangial matrix seen in glomerulosclerosis. Therefore, the 
effects of Ang II with and without insulin on mRNA levels of several important extracellular 
matrix genes and transforming growth factor beta-1 (TGF-beta 1) were examined. The 
results of the studies suggest that insulin, itself, significantly increases TGF-beta 1 and 
extracellular matrix gene expression in rat mesangial cells. Ang II alone has modest effects, 
while Ang II and insulin have additive effects. To explain the mechanism of these additive 
effects, we investigated the action of Ang II on insulin signaling and the effect of insulin on 
Ang II AT1 receptor mRNA expression. Ang II did not enhance insulin-induced insulin 
receptor substrate-1 (IRS-1) phosphorylation or phosphatidylinositol 3 (PI-3) kinase activity, 
but did enhance insulin-induced mitogen activated protein (MAP) kinase activity.[10] 
Insulin increased message levels of AT1 receptor by twofold. These results suggest that 
enhancement of MAP kinase activity and AT1 receptor regulation by insulin may contribute 
to the additive effects of insulin and Ang II in mesangial cells. 
The direct impact of insulin resistance on kidney 
Insulin major role in the tubules, but the specific sites of action are not yet entirely clear.It has a 
strong role in preserving sodium and dose dependent, while the presence of insulin to counter, 
this is still Paul sodium. Therefore, insulin resistance and hyperinsulinemia that occurs when 
the sodium sensitivity of blood pressure increase in glomerular pressure increased, resulting in 
microalbuminuria. A study was performed by Vedovato M to measure the effect of Na+ intake 
on blood pressure and albuminuria, in relation with insulin sensitivity and kidney 
haemodynamics, in Type 2 diabetic patients with and without microalbuminuria. They found 
that high salt intake increases blood pressure and albuminuria in Type 2 diabetic patients with 
microalbuminuria. These responses are associated with insulin resistance and increased 
glomerular pressure. Insulin resistance could contribute to greater salt sensitivity, increased 
glomerular pressure and albuminuria.[11] 
Insulin resistance increase the renal damage by the plasminogen activator inhibitor 1  
The insulin resistance syndrome typically features glucose intolerance and elevated fasting 
insulin and triglyceride levels. Elevated levels of PAI-1 and tPA antigens associated with 
glucose intolerance, hyperinsulinemia, and hypertriglyceridemia support inclusion of 
impaired fibrinolysis as an additional feature of the insulin resistance syndrome. Elevated 
fibrinolytic factors are also correlated with elevated markers of inflammation and 
endothelial dysfunction, which has been hypothesized to cause insulin resistance and 
thereby be the common pathogenic mechanism underlying atherosclerosis, insulin 
resistance, and glucose intolerance.[12] Hagiwara H’s study proved that renal PAI-1 gene 
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expression is up-regulated in both type 1 and type 2 diabetic rats, and changes in gene 
expressions of fibrinolytic factors may play important roles in the development and 
pathogenesis of diabetic nephropathy.[13] In addition, TGF-β, angiotensin П and thrombin 
could stimulate the synthesis of PAI-1, the process by inhibiting fibrinolysis and plasmin-
mediated matrix metalloproteinase activity, so that less matrix degradation, resulting in 
renal fibrosis. 
Insulin resistance increases the rates of renal damage by endothelin (ET) -1 
Endothelin-1, released from the vascular endothelium after cleavage from big endothelin-1, 
is a potent paracrine vasoconstrictor peptide. Small studies suggest that the circulating level 
of endothelin-1 is elevated in subjects with cardiovascular risk factors. High endothelin-1 
level may better reflect endothelin-1 generation. It is indicated by studies that endothelin-1 
level is not related to blood pressure, but higher in healthy young men with insulin 
resistance and obesity.[14] It was discovered in a diabetic mouse model treated with A-type 
ET receptor antagonist that glomerular TGF-β and collagen I, II, IV production were 
decreased. 
Insulin resistance increase the renal damage through oxidative stress 
Insulin-stimulated (or inhibited) pathways retain normal sensitivity to the hormone, 
hyperinsulinemia could, by its effects on antioxidative enzymes and on free radical 
generators, enhance oxidative stress. Other effects of insulin involve the inhibition of 
proteasome and the stimulation of polyunsaturated fatty acid (PUFA) synthesis and of nitric 
oxide (NO).[15] Prabhakar SS attempted to review the existing literature, discuss the 
controversies, and reach some general conclusions as to the role of NO production in the 
diabetic kidney. He found that genetic polymorphisms of the NOS enzyme also may play a 
role in the NO abnormalities that contribute to the development and progression of diabetic 
nephropathy.[16] 
Insulin resistance increases renal damage through nitric oxide 
The results of study performed by Steinberg HO argued that insulin effect on the 
endothelium is mediated by its own receptor and insulin signaling pathways, resulting in 
the increased release of nitric oxide. The vascular actions of insulin are impaired in insulin-
resistant conditions such as obesity, Type II (non-insulin-dependent) diabetes mellitus and 
hypertension, which could contribute to the excessive rate of cardiovascular disease in these 
groups. Insulin-resistant state in obesity and Type II diabetes shows a multitude of 
metabolic abnormalities that could cause vascular dysfunction. Non-esterified fatty acid 
level increased long before hyperglycaemia becomes present.[17] Under the circumstance of 
insulin resistance, endothelial dysfunction leads to vascular complications in the central 
link, which results in microalbuminuria. 
2.2 Hypertension and pathogenesis of metabolic syndrome-associated nephropathy 
The abnormality of kidney structure and function caused by hypertension is called 
hypertensive renal damage. Arteriolar nephrosclerosis is the most characteristic pattern in 
hypertensive renal damage, including benign arteriolar nephrosclerosis and malignant 
arteriolar nephrosclerosis. The former caused by benign hypertension, the latter caused by 
malignant hypertension. Sustained hypertension can cause renal arteriolosclerosis for 5-10 
years (tunica intimal thickening of arcuate artery and interlobular arteries, hyaline of 
afferent artery), wall thickening, lumens narrowing, and secondary ischemic renal 
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parenchyma ischemic lesions, including glomerular ischemic shrinkage, sclerosis, tubular 
atrophy, interstitial infiltration of inflammatory cells and fibrosis, which lead to benign 
arteriolar nephrosclerosis. Malignant arteriolar nephrosclerosis is an accelerated 
hypertension or malignant hypertension-induced renal damage. 
2.2.1 Pathogenesis of benign arteriolar nephrosclerosis  
Factor of hemodynamics 
Due to normal autoregulatory mechanism of renal vessels, renal blood flow (RBF) can be 
kept relatively stable, which can protect the kidney from blood pressure fluctuation. Renal 
arteriolar constrictive response occurs in the presence of hypertension, which increase renal 
vascular resistance and decrease renal blood flow (RBF). The degree of contraction of 
efferent arteries is more significant than afferent arteries in early stage. Glomerular filtration 
rate (GFR) can still be maintained within the normal range. With the progress of 
hypertension, there is renal arteriosclerosis, compliance decreasing, arterial wall thickening, 
lumens stenosis, and RBF further decline, GFR falling, which lead to ischemic renal lesions. 
Impairment of kidney tubules secondary to ischemia is more sensitive than glomeruli. 
Furthermore, renal tubular load does not reduce for maintaining normal GFR, thus more 
likely to increase renal tubular injury secondary to glomerular hyperperfusion.[18] 
However, benign arteriolar nephrosclerosis has obvious individual differences. There is not 
observed renal arteriolar sclerosis in some glomerulosclerosis secondary to hypertension. 
Hypertensive renal injury is not completely ischemic lesions. In addition to ischemic 
hypoperfusion nephron, the recent view is that most hypertensive renal damage is 
characterized by hypertransfusion compensatory nephron. The existence of glomerular 
hyperperfusion, high pressure and high filtration promote renal parenchyma lesions, 
especially is the major pathogenesis of glomerulosclerosis.[19].  
Under hypertension state, renal vascular sensitivity to Ang II was significantly enhanced.  
Renal vascular resistance increased in the patients with hypertension who are injected low 
dose Ang II, and did not significantly change in normal people. The mechanism of 
proteinuria occurence is currently considered that increased RAS activity lead to podocyte 
fracture membrane damage and basilar membrane permeability increasing. High intra-
glomerular pressure and high shear stress-induced endothelial cell injury and dysfunction, 
activated local lesions, increased Ang II and aldosterone, induced renal vascular remodeling 
and renal arteriosclerosis.[20] 
Non-hemodynamic factors 
In hypertension state, vascular endothelium bear high pressure and shear stress, cause 
endothelial cell injury, injured endothelial cell can lease cytokines, such as transforming 
growth factor β (TGF-β), plasminogen activator inhibitor (PAI).[21] Hypertension can 
directly cause renin-angiotensin-aldosterone system activation and oxidative stress. These 
factors can cause together kidney damage, matrixfibrosis and tissue hardening.[22, 23] 
Clinically nephroangiosclcrosis may occur before significant elevation of blood pressure, 
such as unilateral nephrectomy or early type 1 diabetes mellitus (TIDM). Glomerular 
capillary blood flow is still significantly increased. Therefore, the renal capillary pressure 
overload, it can lead to nephrosclerosis. high pressure and high shear in glomerular cause 
endothelial cell dysfunction, which could lead to increase in some active factors such as 
angiotensin II (Ang II), endothelin-1(ET-1), thromboxane A2 (TXA2), TGF-β2 and platelet-
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derived growth factor (PDGF) factors, leading to vasoconstriction, mesangial cell 
proliferation and collagen deposition, promoting ECM synthesis and secretion. The high 
pressure in glomeruli can also lead to glomerular visceral epithelial cell injury, increasing 
permeability of the basement membrane, causing proteinuria, eventually leading to 
glomerulosclerosis, nephron loss. Therefore, the patients with essential hypertension have 
low perfusion of ischemic nephron and high perfusion nephron, the latter is more 
characteristic pattern.  
In addition, reactive oxygen species, salt intake, lithium-sodium counter-transport 
abnormalities, racial and genetic backgrounds, metabolic disorders, age, gender, body mass 
index, smoking is also influencing factors. 
In summary, hypertensive renal damage is secondary to vascular lesions caused by high 
arterial pressure. The main mechanism of hypertensive renal damage is hemodynamics 
abnormalities in glomerular, and cytokines, vasoactive substances and the ECM are 
involved in the disease process. 
2.2.2 Pathogenesis of malignant arteriolar nephrosclerosis 
The direct vascular injury of elevated blood pressure  
When blood pressure is significant elevated, renal artery and glomerular capillary stress and 
shear stress can be changed, which induce endothelial cells to secrete varied adhesion 
molecules, promoting inflammatory cell adhesion to endothelial cells, leading to endothelial 
cell damage.[24] Vascular endothelial cell damage lead to increased permeability, plasma 
protein and fibrinogen deposition in the vessel wall, induce vascular fibrinoid necrosis and 
tunica intimal damage. Finally, it appears vascular lumen narrowed and renal ischemia. But 
some patients with severe and persistent hypertension, whose vascular injury can not 
become malignant state. It indicates that in addition to intravascular pressure, there are 
other factors involved in vascular damage.     
Activation of renin-angiotensin-aldosterone system (RAAS) and endothelin  
Malignant hypertension often accompanied with activation of RAAS, It should be noted that 
the activation of RAAS may be primary or secondary. Activation of RAAS can promote 
intermittent vasoconstriction, activate platelets, release thromboxane and platelet derived 
growth factor (PDGF), stimulate myointimal cell migration and proliferation, cause vascular 
lumen narrowed, increased level of blood pressure and renal ischemia. When the systolic 
pressure is over 180-190mmHg critical level, it can occur naturally natriuretic and diuretic 
phenomenon, the decline in blood volume can further activate the RAAS.[25] In addition, 
elevated angiotensin can  promote inflammatory cells adhesion to endothelial cell, induce 
apoptosis of endothelial cells, damage the integrity of blood vessels, induce fibrinoid 
necrosis of arteriole by "vascular toxicity".[26] Endothelin is of powerful vasoconstrictor 
function, it can cause sustained elevation of blood pressure. Animal model of malignant 
hypertension has been confirmed to plasma endothelin and endothelin-mRNA expression in 
renal tissue increased.[27]  
Microvascular coagulation and thrombosis 
Hypertension damage vascular endothelial, which active directly coagulation system, lead 
to platelet aggregation and fibrin deposition in vascular lumen. When red blood cells pass 
through the damaged vascular lumen, it prone to result in damage and lead to 
microvascular coagulation. Meanwhile, both platelet aggregation and adhesion of 
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parenchyma ischemic lesions, including glomerular ischemic shrinkage, sclerosis, tubular 
atrophy, interstitial infiltration of inflammatory cells and fibrosis, which lead to benign 
arteriolar nephrosclerosis. Malignant arteriolar nephrosclerosis is an accelerated 
hypertension or malignant hypertension-induced renal damage. 
2.2.1 Pathogenesis of benign arteriolar nephrosclerosis  
Factor of hemodynamics 
Due to normal autoregulatory mechanism of renal vessels, renal blood flow (RBF) can be 
kept relatively stable, which can protect the kidney from blood pressure fluctuation. Renal 
arteriolar constrictive response occurs in the presence of hypertension, which increase renal 
vascular resistance and decrease renal blood flow (RBF). The degree of contraction of 
efferent arteries is more significant than afferent arteries in early stage. Glomerular filtration 
rate (GFR) can still be maintained within the normal range. With the progress of 
hypertension, there is renal arteriosclerosis, compliance decreasing, arterial wall thickening, 
lumens stenosis, and RBF further decline, GFR falling, which lead to ischemic renal lesions. 
Impairment of kidney tubules secondary to ischemia is more sensitive than glomeruli. 
Furthermore, renal tubular load does not reduce for maintaining normal GFR, thus more 
likely to increase renal tubular injury secondary to glomerular hyperperfusion.[18] 
However, benign arteriolar nephrosclerosis has obvious individual differences. There is not 
observed renal arteriolar sclerosis in some glomerulosclerosis secondary to hypertension. 
Hypertensive renal injury is not completely ischemic lesions. In addition to ischemic 
hypoperfusion nephron, the recent view is that most hypertensive renal damage is 
characterized by hypertransfusion compensatory nephron. The existence of glomerular 
hyperperfusion, high pressure and high filtration promote renal parenchyma lesions, 
especially is the major pathogenesis of glomerulosclerosis.[19].  
Under hypertension state, renal vascular sensitivity to Ang II was significantly enhanced.  
Renal vascular resistance increased in the patients with hypertension who are injected low 
dose Ang II, and did not significantly change in normal people. The mechanism of 
proteinuria occurence is currently considered that increased RAS activity lead to podocyte 
fracture membrane damage and basilar membrane permeability increasing. High intra-
glomerular pressure and high shear stress-induced endothelial cell injury and dysfunction, 
activated local lesions, increased Ang II and aldosterone, induced renal vascular remodeling 
and renal arteriosclerosis.[20] 
Non-hemodynamic factors 
In hypertension state, vascular endothelium bear high pressure and shear stress, cause 
endothelial cell injury, injured endothelial cell can lease cytokines, such as transforming 
growth factor β (TGF-β), plasminogen activator inhibitor (PAI).[21] Hypertension can 
directly cause renin-angiotensin-aldosterone system activation and oxidative stress. These 
factors can cause together kidney damage, matrixfibrosis and tissue hardening.[22, 23] 
Clinically nephroangiosclcrosis may occur before significant elevation of blood pressure, 
such as unilateral nephrectomy or early type 1 diabetes mellitus (TIDM). Glomerular 
capillary blood flow is still significantly increased. Therefore, the renal capillary pressure 
overload, it can lead to nephrosclerosis. high pressure and high shear in glomerular cause 
endothelial cell dysfunction, which could lead to increase in some active factors such as 
angiotensin II (Ang II), endothelin-1(ET-1), thromboxane A2 (TXA2), TGF-β2 and platelet-
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derived growth factor (PDGF) factors, leading to vasoconstriction, mesangial cell 
proliferation and collagen deposition, promoting ECM synthesis and secretion. The high 
pressure in glomeruli can also lead to glomerular visceral epithelial cell injury, increasing 
permeability of the basement membrane, causing proteinuria, eventually leading to 
glomerulosclerosis, nephron loss. Therefore, the patients with essential hypertension have 
low perfusion of ischemic nephron and high perfusion nephron, the latter is more 
characteristic pattern.  
In addition, reactive oxygen species, salt intake, lithium-sodium counter-transport 
abnormalities, racial and genetic backgrounds, metabolic disorders, age, gender, body mass 
index, smoking is also influencing factors. 
In summary, hypertensive renal damage is secondary to vascular lesions caused by high 
arterial pressure. The main mechanism of hypertensive renal damage is hemodynamics 
abnormalities in glomerular, and cytokines, vasoactive substances and the ECM are 
involved in the disease process. 
2.2.2 Pathogenesis of malignant arteriolar nephrosclerosis 
The direct vascular injury of elevated blood pressure  
When blood pressure is significant elevated, renal artery and glomerular capillary stress and 
shear stress can be changed, which induce endothelial cells to secrete varied adhesion 
molecules, promoting inflammatory cell adhesion to endothelial cells, leading to endothelial 
cell damage.[24] Vascular endothelial cell damage lead to increased permeability, plasma 
protein and fibrinogen deposition in the vessel wall, induce vascular fibrinoid necrosis and 
tunica intimal damage. Finally, it appears vascular lumen narrowed and renal ischemia. But 
some patients with severe and persistent hypertension, whose vascular injury can not 
become malignant state. It indicates that in addition to intravascular pressure, there are 
other factors involved in vascular damage.     
Activation of renin-angiotensin-aldosterone system (RAAS) and endothelin  
Malignant hypertension often accompanied with activation of RAAS, It should be noted that 
the activation of RAAS may be primary or secondary. Activation of RAAS can promote 
intermittent vasoconstriction, activate platelets, release thromboxane and platelet derived 
growth factor (PDGF), stimulate myointimal cell migration and proliferation, cause vascular 
lumen narrowed, increased level of blood pressure and renal ischemia. When the systolic 
pressure is over 180-190mmHg critical level, it can occur naturally natriuretic and diuretic 
phenomenon, the decline in blood volume can further activate the RAAS.[25] In addition, 
elevated angiotensin can  promote inflammatory cells adhesion to endothelial cell, induce 
apoptosis of endothelial cells, damage the integrity of blood vessels, induce fibrinoid 
necrosis of arteriole by "vascular toxicity".[26] Endothelin is of powerful vasoconstrictor 
function, it can cause sustained elevation of blood pressure. Animal model of malignant 
hypertension has been confirmed to plasma endothelin and endothelin-mRNA expression in 
renal tissue increased.[27]  
Microvascular coagulation and thrombosis 
Hypertension damage vascular endothelial, which active directly coagulation system, lead 
to platelet aggregation and fibrin deposition in vascular lumen. When red blood cells pass 
through the damaged vascular lumen, it prone to result in damage and lead to 
microvascular coagulation. Meanwhile, both platelet aggregation and adhesion of 
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leukocytes on vessel wall lead to turbulence, promoting to form platelet micro-
thrombus.[28] 
Genetic factors 
It is reported that HLAB15, DR3, BW35 and CW4 are significantly associated with the 
incidence of malignant hypertension.[29, 30]  
2.3 Lipid metabolic disorders and pathogenesis of metabolic syndrome-associated 
nephropathy 
Lipid metabolism and kidney disease are closely related. As early as 1982, Moorhead[31] 
proposed that lipid accumulation can lead to chronic renal injury, it is not only a lot of 
primary or secondary renal diseases with common clinical manifestations, but also the 
progress of the diseases.[32] Hyperlipidemia, in addition to proteinuria and hypertension, 
promotes CKD progression outside the third most important factor. In polycystic kidney 
disease, obesity, diabetes and hypertension in animal models, hypercholesterolemia were 
found to accelerate the progress of kidney diseases, and high-fat diet can induce kidney 
macrophages and foam cell formation leaching, resulting in glomerular sclerosis.[33] In 
obese Zucker rats, lowering serum triglycerides improves glomerular sclerosis.[34] These 
results suggest that lipid metabolism is closely related with renal dysfunction, and a series 
of clinical studies have also been to the same conclusion. Samuelsson et al[35] found 
triglyceride-rich lipoproteins containing Apo-B in patients with CKD are closely related to 
the progress of the disease; Muntner et al[36] found in 12 728 subjects with normal renal 
function that low HDL cholesterol and hypertriglyceridemia in individuals with impaired 
renal function appeared more dangerous. 
2.3.1 Mesangial cell function 
Regulation of glomerular filtration of mesangial cells to produce matrix components, 
involved in the development of many glomerular diseases. Mesangial cell surface LDL, 
oxidized HDL and very low density lipoprotein act through receptor pathway and the 
corresponding lipoproteins. LDL can bind to mesangial cells and mesangial cell function can 
offset.[37] LDL stimulates mesangial cells and had a "phase effect", ie, low concentration of 
LDL stimulates cell proliferation, and high concentrations inhibits cell proliferation as toxic 
cells effect. The effect of LDL promoting mesangial cell proliferation may be related to 
arachidonic acid metabolism. Mesangial cells cytochrome P450 monooxygenase system 
produces epoxide metabolic pathways, it can promote cell proliferation, LDL oxidation and 
the formation of more toxic OX-LDL in a dose dependent manner, which can further 
increase mesangial cell injury. The mesangial cells and macrophages form foam cells and 
release cytokines and growth factors, such as transforming growth factor β, tumor necrosis 
factor, platelet derived growth factor and interleukin-1 and so on. These cytokines can 
stimulate the LDL receptor gene transcription and expression of epithelial cells, mesangial 
cells and macrophages, and promote the deposition of lipid in kidney cells and induced 
renal injury.[38] Mesangial cells themselves can be oxidized by LDL. OX-LDL can induce 
apoptosis of mesangial cells. 
2.3.2 Mesangial matrix 
Glomerular mesangial matrix includes type IV collagen, fibronectin and laminin. LDL and 
LDL oxidation in vitro can stimulate the increase of extracellular matrix components. LDL 
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can be activated in mesangial cells by LDL protein kinase C, which promotes transforming 
growth factor-β synthesis in the cells, and TGF-β can stimulate the cells to produce tissue 
inhibitor of matrix metalloproteinases, inhibiting matrix degradation and leading to the 
increase of mesangial matrix.[39] It has been confirmed by in vitro experiments that lipids 
increased the expression of TGF-β mRNA in mesangial cells and epithelial cells. 
2.3.3 Endothelial cells 
Endothelial cells with LDL receptor, VLDL receptor and LDL receptor related protein. 
Lipoprotein receptors and related, or non-receptor pathway, causing cell proliferation, 
lipoprotein lipase and lipoprotein receptors can enhance and strengthen its effect in 
promoting cell proliferation. OX-LDL and Lp of endothelial dysfunction caused mainly by 
interfering with the vasodilators nitric oxide synthesis and direct inactivation; and increased 
thromboxane A2 and endothelin production, damage vascular endothelial NO dependent 
relaxation response, cause renal ball efferent arteries, increasing the pressure in the 
glomerular endothelial cells to further damage, the release of cytokines, to promote cell 
proliferation, glomerular sclerosis. In addition, the lipoprotein receptor pathway through 
the endothelial cells directly mediated endothelial cell injury, while activation of coagulation 
and fibrinolytic system activation and inhibition of platelet function, leading to fibrin 
deposition and thrombosis, increased glomerular injury. 
2.3.4 Glomerular epithelial cells 
Glomerular epithelial cell surface LDL, VLDL receptor and lipoprotein receptor related 
protein, which contains both apoB and apoE, respectively, with the lipoproteins, the 
annexation of the metabolism of cells. apoE with high affinity receptors, the degree of 
cellular cholesterol esterification increased, and inhibition of cholesterol synthesis, therefore, 
glomerular epithelial cellsith more and VLDL, thus not explain the clinical 
hypercholesterolemia, only lipoprotein formed an exception. Can also cause the deposition 
of lipids in the glomeruli, glomerulosclerosis occurring phenomenon. 
2.3.5 Tubulo-interstitium 
Tubular injury showed increased tubulointerstitial matrix proteins and fibrosis. Proximal 
tubular epithelial cells present LDL, very low density lipoprotein receptor, hyperlipidemia 
lipid deposition in the renal tubules, tubular epithelial cells by phagocytosis, the formation 
of foam cells, while LDL, OX-LDL for the expression and FN mRNA secretion, further 
stimulate tubulointerstitial synthesis, promoting fibrosis. 
2.3.6 OX-LDL renal toxicity 
OX-LDL can promote renal cell proliferation, apoptosis and phenotypic transformation, 
involved in the glomerulosclerosis process from cell to cell is too small too many states the 
state of the process of cell loss.[40] OX-LDL also has the monocyte chemotactic activity of 
macrophages can express clear the OX-LDL receptor, OX-LDL uptake by macrophages 
stimulated macrophages after the synthesis of growth factors, cytokines and other related 
matrix protein synthesis in the media. Extraordinary receptor exists in glomerular mesangial 
cells and epithelial cells. In the case of lipid metabolism, the oxidation of LDL can be 
modified first intake, OX-LDL accumulation in the kidney and stimulate the kidney cells to 
secrete TGF-β1 and other cytokines to promote renal fibrosis, leading to monocyte-
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leukocytes on vessel wall lead to turbulence, promoting to form platelet micro-
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macrophage in the local infiltration. Moreover, the activation of macrophages and can 
promote LDL oxidation, secretion of TGF-β and PDGF-AD, caused by extracellular matrix 
and mesangial expansion, creating a vicious cycle.[41] Focal segmental glomerulosclerosis in 
animal models and human glomerular diseases, a number of chronic renal biopsy tissues 
were detected by OX-LDL deposition, and the extent of OX-LDL deposition and renal 
dysfunction and protein was positively correlated with urine. 
2.4 Hyperuricemia and pathogenesis of metabolic syndrome-associated nephropathy 
Hyperuricemia is highly prevalent in MS patients. A few studies showed that 
hyperuricemia was associated closely with progression of kidney disease.[42] About 20% to 
60% of patients with gout have mild or moderate renal failure. The histological lesion 
named "gouty nephropathy" includes glomerulosclerosis, interstitial fibrosis, and renal 
arteriolosclerosis, often with focal interstitial urate crystal deposition. 
The precipitation of uric acid in the renal medulla with formation of characteristic tophi was 
believed to activate an inammatory response resulting in renal interstitial fibrosis, a loss of 
nephrons, and ultimately to irreversible chronic renal failure. When pH<5.5 in vivo or 
dehydration, urate can deposit in the renal tubules and interstitium which cause urate 
nephropathy. It also can form kidney stone in distal tubule and collecting duct and induce 
obstruction. Emmerson[43] found that some interstitial deposits of urate and uric acid in the 
kidney derived from intra-tubular deposits which react with the tubular epithelium and 
pass into the interstitium; loss of tubular integrity may not be a prerequisite for crystal 
migration. Toblli[44] confirmed that urate crystals deposit in renal tubular cells, evoke 
complement, platelet, inflammatory cell and macrophages by classical pathway or 
alternative pathway, induce the expression of cytokine and transforming growth factor beta 
increased; stimulate fibroblast to be fibrocyte, activate cross linkage of collagen and 
ultimately lead to renal fibrosis or renal failure.  
However, it is difficult to ascribe the generalized renal damage in gout to the deposition of 
urate crystals, for they are often only focally present. 
Recent studies have reported that mild hyperuricemia in normal rats induced by the uricase 
inhibitor, oxonic acid (OA), results in systemic hypertension, renal vasoconstriction, 
glomerular hypertension and hypertrophy, and tubulointerstitial injury independent of 
intra-renal crystal formation.[45-47] It has also been found that hyperuricemia can accelerate 
renal disease in the remnant kidney model and accelerate experimental cyclosporine 
nephropathy.[48,49] The main pathophysiological mechanism by which uric acid causes 
these conditions involves the  inhibition of endothelial nitric oxide bioavailability and direct 
actions on endothelial cells and vascular smooth muscle cells.[50,51] The importance of 
these pathways is suggested by a recent prospective study in which lowering uric acid in 
individuals with hyperuricemia and renal dysfunction was associated with improved BP 
control and slower progression of renal disease.[52]  
There are a lot of clinical evidences that hyperuricemia may induce endothelial dysfunction, as 
lowering uric acid with allopurinol can improve endothelial function as measured by brachial 
artery vasodilatation.[53] Interestingly, while both uric acid and nitric oxide (NO) exhibit 
circadian variation, serum uric acid peaks around 6 a.m. when the level of NO is lowest.[54] 
This relationship can be accounted for by the finding that uric acid also inhibits endothelial cell 
dependent vasodilatation of rat aortic rings[55] and NO production in endothelial cells.[56] 
Furthermore, uric acid blunts endothelial cell proliferation in response to serum. [56] The 
mechanism by which uric acid inhibits NO levels is complex. It may involve scavenging by 
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oxidants, which can be induced by NADPH oxidase under hyperuricemia.[57] A reduced NO 
bioavailability could also be due in part to inhibition secondary to CRP production.[56] 
In addition, the activation of RAS plays an important role in the exacerbation of renal injury 
caused by uric acid, which has been shown to be an important mediator of progression of 
renal disease, not only by its hemodynamic effects to increase systemic and glomerular 
pressure, but also by its direct fibrogenic effect in kidney and vessels. The increase of renin 
expression is observed in hyperuricemic rats. The relationship between serum uric acid and 
plasma renin activity has been described in humans.[58] Blocking the renin angiotensin 
system can ameliorate hypertension and renal injury in hyperuricemic rats.[45] 
Furthermore, studies in humans suggest that uric acid acts on blood pressure and renal 
injury in part via the renin angiotensin system.[59] All of above discoveries suggest that the 
roles of uric acid may also be mediated by the activation of the renin angiotensin system. 
Hyperuricemia also alters glomerular hemodynamics.[47] Hyperuricemia induces cortical 
renal vasoconstriction in rats as evidenced by a significant increase of afferent and efferent 
arteriolar resistances. A decrease in glomerular plasma flow and the ultrafiltration 
coefficient resulted in a 35% decrease in single nephron GFR whereas glomerular pressure 
was increased. These changes were restored by allopurinol treatment. Aberrant renal 
autoregulation appears to be responsible for the glomerular hypertension observed with 
experimental hyperuricemia. Under normal conditions, an increase in mean systemic 
arterial pressure causes a reflex vasoconstriction of the afferent arteriole, thus preventing the 
transmission of the increased pressure to the glomerular circulation. However, in the event 
that the afferent arteriolar vasoconstriction is insufficient, the transmission of increased 
pressure to the glomeruli results in glomerular hypertension.[47] While renal 
vasoconstriction occurs in experimental hyperuricemia, it may be insufficient for the degree 
of systemic hypertension, therefore glomerular pressures are increased. This may be due to 
the disease of the afferent arteriole that occurs in the hyperuricemic rats, as evidenced by an 
increase in the media to lumen ratio. Again, the observation that allopurinol was able to 
prevent arteriolar hypertrophy leading to a normal renal autoregulatory response indicates 
a potential role of uric acid on this process.[47] 
2.5 Obesity and pathogenesis of metabolic syndrome-associated nephropathy 
The metabolic syndrome is a cluster of the most dangerous heart attack risk factors: diabetes 
and prediabetes, abdominal obesity, high cholesterol and high blood pressure.[60] Abdominal 
obesity is the form of obesity most strongly associated with metabolic syndrome. Obesity and 
metabolic syndrome has been found to be independent risk factors for CKD.[3, 61, 62] Treating 
obesity might stabilize renal function or reverse early hemodynamic abnormalities and 
glomerular dysfunction.[63, 64] Since the first description of an association between massive 
obesity and nephrotic proteinuria in 1974, a specific histopathologic pattern characterized by 
glomerulomegaly, in many cases accompanied by focal segmental glomerulosclerosis, has 
been described repeatedly in obese patients without any other defined primary or secondary 
glomerular diseases (including diabetic nephropathy, hypertensive nephrosclerosis, and 
secondary focal segmental glomerulosclerosis) and now is referred to as "obesity-related 
glomerulopathy".[65, 66] Overweight, obesity, and the metabolic syndrome have recently 
emerged as strong independent risk factors for chronic kidney disease (CKD) and ESRD. The 
multivariate analysis made by Chen et al[3] showed that the risk for being affected by CKD 
was more than twice as high in patients with an increased waist circumference than in those 
without, suggesting that obesity may be an independent risk factor for CKD. 
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Obesity with the features of the metabolic syndrome causes renal dysfunction,[67] 
increase glomerular filtration rate (GFR), renal blood flow (RBF), and filtration fraction 
(FF) in experimental and clinical observations.[64, 68, 69] Obesity also increases the risk 
factor for diabetes and hypertension. Iseki[70] indicate that obesity, including metabolic 
syndrome, is a potential treatable cause of CKD and ESRD. In a large cohort of >320,000 
patients who were followed at Kaiser Permanente, Hsu et al[62, 71] found that a higher 
BMI was a strong independent risk factor for ESRD even after adjustment for other major 
risk factors that are associated with ESRD, including smoking, baseline hypertension, and 
diabetes.  
Hyperlipidemia, hyperinsulinemia, hyperleptinemia, hyperuricemia and hypercoagulability, 
together in obese patients may directly or indirectly affect renal structure and function, caused 
kidney damage. 
The pathogenesis of ORG may be implicated:  
1. Renal hemodynamic alterations: Studies in animals and in humans have shown that 
obesity is associated with elevated GFR and increased renal blood flow.[68, 71] This likely 
occurs because of afferent arteriolar dilation as a result of proximal salt reabsorption, 
coupled with efferent renal arteriolar vasoconstriction as a result of elevated Ang II. In 
addition, Ang II may have a role in the regulation of adipokine production in adipose 
tissue and may increase insulin resistance in the setting of obesity.[72, 73]  
2. Sympathetic stimulation: Obesity-related there is widespread increased sympathetic 
nerve activity, its causes and obese patients with baroreceptor dysfunction and 
vasomotor centers less on the incoming inhibitory signals.[74]  
3. Leptin: Wolf[75] studies have shown that Leptin levels in obese patients was 
significantly higher, it was upregulated in glomerular endothelial cells and mesangial 
cells. Increased TGF-β1 and its receptor mRNA expression promote glomerular 
endothelial cells and mesangial cell proliferation. 
4. Inflammation: The results of several studies have suggested that adipose tissue, 
especially visceral adipose tissue, is a major source of cytokine secretion in the 
metabolic syndrome, and that inflammatory cells, especially mature bone marrow–
derived macrophages, invade adipose tissue early in obesity.[76, 77] Inflammation was 
linked to obesity and the metabolic syndrome in patients with CKD. Ramkumar et 
al[78] found a strong association between inflammation as defined by a CRP level >3 
mg/dl and a high BMI in patients with CKD.  
5. Changes in fatty acid composition in kidney, causing kidney reduced the release of 
vasoactive substances, increased the pressure of glomerular capillary. Hall et al[79] 
show that the mechanisms responsible for increased sodium reabsorption and altered 
pressure natriuresis in obesity include activation of the renin-angiotension and 
sympathetic nervous systems, and physical compression of the kidneys due to 
accumulation of intra-renal fat and extracellular matrix.  
2.6 Diabetes and pathogenesis of metabolic syndrome-associated nephropathy 
Diabetic nephropathy is the most important long-term complication of diabetes mellitus and 
a major cause of end-stage renal disease. The condition is associated with excess 
cardiovascular morbidity and mortality, as well as other diabetic microvascular 
complications.[80] The etiopathogenesis of diabetic nephropathy appears to involve both 
genetic and environmental factors leading to disease in a subgroup of patients. Improved 
knowledge of the natural history and pathophysiology of the condition have enabled 
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2.6.1 Historical background 
DN has the characteristic of obvious family accumulation, but the incidence of the disease in 
different races is very different. Diabetic nephropathy is a serious problem resulted from 
microvascular complications of diabetes mellitus. Thus, genetic factors determining 
susceptibility plays an important role in DN, which was shown by studies about 
angiotensinogen (AGT) gene, angiotensin converting enzyme (ACE) gene, aloes reeducates 
(AR) gene, Glut21 gene, endothelial cells Nitric oxide synthase (eNOS) gene, cell receptor β-
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show that the mechanisms responsible for increased sodium reabsorption and altered 
pressure natriuresis in obesity include activation of the renin-angiotension and 
sympathetic nervous systems, and physical compression of the kidneys due to 
accumulation of intra-renal fat and extracellular matrix.  
2.6 Diabetes and pathogenesis of metabolic syndrome-associated nephropathy 
Diabetic nephropathy is the most important long-term complication of diabetes mellitus and 
a major cause of end-stage renal disease. The condition is associated with excess 
cardiovascular morbidity and mortality, as well as other diabetic microvascular 
complications.[80] The etiopathogenesis of diabetic nephropathy appears to involve both 
genetic and environmental factors leading to disease in a subgroup of patients. Improved 
knowledge of the natural history and pathophysiology of the condition have enabled 
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2.6.1 Historical background 
DN has the characteristic of obvious family accumulation, but the incidence of the disease in 
different races is very different. Diabetic nephropathy is a serious problem resulted from 
microvascular complications of diabetes mellitus. Thus, genetic factors determining 
susceptibility plays an important role in DN, which was shown by studies about 
angiotensinogen (AGT) gene, angiotensin converting enzyme (ACE) gene, aloes reeducates 
(AR) gene, Glut21 gene, endothelial cells Nitric oxide synthase (eNOS) gene, cell receptor β-
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chain of fixed area (TCRβ) genes. Correlation between gene polymorphism and the 
occurrence and development of DN has also been discovered.[82] 
2.6.2 Chronic hyperglycemia 
Hyperglycemia can activate intracellular key catalytic glucose into sorbitol AR. With high 
glucose increased AR activity, polyol metabolism in kidney is active, so that excessive 
accumulation of sorbitol and fructose. Sorbitol polarity is strong, thus can not freely through 
the membrane, while fructose has little further metabolism. It results in fructose 
accumulation and the increase of intracellular osmotic pressure and therefore cell edema. 
While the level of intracellular inositol is decreased, glutathione, NADH / NAD + ratio 
increased, Na2K2ATP activity decreased, which results in tissue hypoxia and endothelial 
cell damage, contributing to the occurrence and development of DN.[83] Some studies 
suggest that AR gene polymorphism is related to AR mRNA levels in peripheral blood 
mononuclear cells and diabetic micro-vascular complications. High glucose can lead to non-
enzymatic glycosylation reaction, formation of advanced glycation end products (AGEs) in 
many organs. AGEs bind the AGE receptor (RAGE) of vascular endothelial cells, 
macrophages, vascular smooth muscle cells, mesangial cells and other cells. RAGE, as a 
signal transduction receptor, activates mitogen-activated protein kinase pathway (MAPK) 
and nuclear factor (NF) -κB signaling pathway (cell proliferation and inflammatory 
response), Ras pathway (stress and apoptosis), Rac/Cdc-42 pathway (cell growth and 
movement), Jak / Stat pathway (regulation of gene expression), raising the expression of a 
variety of growth factors, such as platelet derived growth factor and transforming growth 
factor, basic fibroblast growth factor, and adhesion molecules, such as intercellular adhesion 
molecules-1 and vascular cell adhesion molecule.[84] 
Reactive oxygen species (ROS), including superoxide radicals, hydrogen peroxide, hydroxyl 
radicals, and lipid peroxidation, are of in vivo biological activity of inducing aerobic 
metabolism. Studies demonstrated that increased oxidative stress existed in diabetes. High 
glucose increased the generation of ROS by inhibiting the activity of the three glycerol 
phosphate dehydrogenase, leading to the development of microvascular complications 
mediated by diabetes-related signaling pathways, such as PKC pathway, polyol pathway, 
hexosamine pathway and AGEs formation. High glucose can also increase the the gene 
transcription of adhesion molecules and inflammatory NF-κB. Increased levels of ROS can 
also increase peroxynitrite synthesis and nitrotyrosine formation, leading to DNA damage, 
prompting the development of diabetic microvascular complications.[85] 
PKC activation in diabetes is a common pathway of vascular injury. PKC family, has more 
than ten isozymes and plays, mainly PKC-β, a role in vascular injury in diabetes. PKC can be 
activated through a variety of ways. Hyperglycemia within the tissue cells can increase PKC 
activation, increase NADH / NAD + ratio, increase oxidative stress.[86] PKC inhibited 
endothelial nitric oxide synthase (eNOS) activity, decreasing NO level and NO-mediated 
inhibition of cyclic guanosine monophosphate (cGMP) generation, leading to vasomotor 
dysfunction.[87] PKC stimulated platelet aggregation and increased the content and activity 
of PAI-1, promoting the hypercoagulability of patients with diabetes. PKC promoted 
vascular endothelial growth factor (VEGF) expression, promoting angiogenesis, increasing 
vascular permeability.[88] PKC regulated the expression of transforming growth factor 
(TGF)-β and increased the expression of fibronectin and collagen type IV, leading to 
extracellular matrix expansion. Researches had shown that TGF-β promoted local 
extracellular matrix deposition. 
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2.6.3 Microvascular disorders 
Homodynamic changes in early diabetic micro-vascular disorders characterized by 
increased pressure, is generally reversible. High glucose increased the plasma osmolality, 
increasing blood volume and renal blood flow. Diabetes changed the ratio between the 
resistance of glomerular arterioles, resulting in glomerular capillary hyperperfusion and 
high pressure, the mesangial matrix expansion and basement membrane thickening, and 
therefore leading to focal glomerular sclerosis.[89] Meanwhile, the capillary endothelial cell 
was damaged, the normal filtration barrier was damaged, protein filtration was increased, 
which result in the loss of glomerular function. 
Microvascular disorders in DN is the pathological basis of clinical manifestations, the most 
prominent is the basement membrane thickening and the damage of glomerular filtration 
barrier function. The pathogenesis includes continuing glomerular hyperperfusion and 
hyperfiltration, increased collagen synthesis. Sustained high glucose leads to the non-
enzymatic glycation of basement membrane protein components. Another major 
pathological feature of DN is increased mesangial matrix. Mesangial expansion is mainly 
resulted from the following factors: glomerular hemodynamic abnormalities, increased 
capillary pressure. High filtration can stimulate the increase of mesangial matrix, the 
damage of glomerular filtration barrier. The leakage and accumulation of macromolecules in 
the membrane system stimulate mesangial cell proliferation and promote matrix 
production. High blood glucose activates protein kinase C in mesangial cell and the increase 
in mesangial matrix protein synthesis. Cellular growth factors are the important factors 
playing roles in increasing mesangial matrix. The most important of which is TGF-β. High 
blood glucose, glomerular capillary pressure and angiotensin (Ang) - II can promote the 
synthesis of extracellular matrix of mesangial and tubular epithelial cell. In addition 
endothelin (ET) also stimulate the proliferation of mesangial cells and the secretion of 
matrix. NO had inhibitory effect on mesangial cells. NO level is increased in early stage of 
diabetic nephropathy, which results in glomerular hyperperfusion and hyperfiltration. And 
it is reduced in the late stage due to endothelial cell damage, which leds to the increasing of 
mesangial matrix, playing a role in accelerating glomerular injury.[90] 
In diabetes, blood flow slows down and micro-thrombosis is easy to form, mainly due to 
abnormal endothelial cell and platelet function. The increase in serum of von Willebrand factor 
(vWF) is considered a sign of vascular endothelial cell injury. vWF is synthesized by 
endothelial cells, mediates platelet adhesion to endothelium, promote thrombosis. Overseas 
studies suggest that vWF is an independent risk factor for microvascular disease in 
diabetes.[91] In addition endothelial dysfunction is also reflected by the decreased activity of 
tissue plasminogen activator (t-PA) or the incresed activity of plasminogen activator inhibitor 
(PAI) which result in decreased fibrinolytic activity. Decreased prostacyclin-2 (PGI-2) synthesis 
reduced platelet inhibition. Increased release of ET can promote platelet aggregation. Plasma β 
platelet globulin (β-TG) and platelet factor 4 (PF4) levels reflect platelet activation. Increased 
thromboxane (TXA) -2 synthesis promote platelet aggregation and thrombosis. Many studies 
shown that increased platelet aggregation plays a very important role in the development of 
microangiopathy in type-2 diabetes mellitus, in addition to long-term hyperglycaemia. 
2.7 Metabolic syndrome in pathogenesis of allograft renal damage 
The metabolic syndrome (MS) is a cluster of interrelated common clinical entities, which 
include obesity, insulin resistance, glucose intolerance, hypertension and dyslipidaemia. 
Insulin resistance is their common pathophysiological basis. Metabolic syndrome 
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chain of fixed area (TCRβ) genes. Correlation between gene polymorphism and the 
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accumulation of sorbitol and fructose. Sorbitol polarity is strong, thus can not freely through 
the membrane, while fructose has little further metabolism. It results in fructose 
accumulation and the increase of intracellular osmotic pressure and therefore cell edema. 
While the level of intracellular inositol is decreased, glutathione, NADH / NAD + ratio 
increased, Na2K2ATP activity decreased, which results in tissue hypoxia and endothelial 
cell damage, contributing to the occurrence and development of DN.[83] Some studies 
suggest that AR gene polymorphism is related to AR mRNA levels in peripheral blood 
mononuclear cells and diabetic micro-vascular complications. High glucose can lead to non-
enzymatic glycosylation reaction, formation of advanced glycation end products (AGEs) in 
many organs. AGEs bind the AGE receptor (RAGE) of vascular endothelial cells, 
macrophages, vascular smooth muscle cells, mesangial cells and other cells. RAGE, as a 
signal transduction receptor, activates mitogen-activated protein kinase pathway (MAPK) 
and nuclear factor (NF) -κB signaling pathway (cell proliferation and inflammatory 
response), Ras pathway (stress and apoptosis), Rac/Cdc-42 pathway (cell growth and 
movement), Jak / Stat pathway (regulation of gene expression), raising the expression of a 
variety of growth factors, such as platelet derived growth factor and transforming growth 
factor, basic fibroblast growth factor, and adhesion molecules, such as intercellular adhesion 
molecules-1 and vascular cell adhesion molecule.[84] 
Reactive oxygen species (ROS), including superoxide radicals, hydrogen peroxide, hydroxyl 
radicals, and lipid peroxidation, are of in vivo biological activity of inducing aerobic 
metabolism. Studies demonstrated that increased oxidative stress existed in diabetes. High 
glucose increased the generation of ROS by inhibiting the activity of the three glycerol 
phosphate dehydrogenase, leading to the development of microvascular complications 
mediated by diabetes-related signaling pathways, such as PKC pathway, polyol pathway, 
hexosamine pathway and AGEs formation. High glucose can also increase the the gene 
transcription of adhesion molecules and inflammatory NF-κB. Increased levels of ROS can 
also increase peroxynitrite synthesis and nitrotyrosine formation, leading to DNA damage, 
prompting the development of diabetic microvascular complications.[85] 
PKC activation in diabetes is a common pathway of vascular injury. PKC family, has more 
than ten isozymes and plays, mainly PKC-β, a role in vascular injury in diabetes. PKC can be 
activated through a variety of ways. Hyperglycemia within the tissue cells can increase PKC 
activation, increase NADH / NAD + ratio, increase oxidative stress.[86] PKC inhibited 
endothelial nitric oxide synthase (eNOS) activity, decreasing NO level and NO-mediated 
inhibition of cyclic guanosine monophosphate (cGMP) generation, leading to vasomotor 
dysfunction.[87] PKC stimulated platelet aggregation and increased the content and activity 
of PAI-1, promoting the hypercoagulability of patients with diabetes. PKC promoted 
vascular endothelial growth factor (VEGF) expression, promoting angiogenesis, increasing 
vascular permeability.[88] PKC regulated the expression of transforming growth factor 
(TGF)-β and increased the expression of fibronectin and collagen type IV, leading to 
extracellular matrix expansion. Researches had shown that TGF-β promoted local 
extracellular matrix deposition. 
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2.6.3 Microvascular disorders 
Homodynamic changes in early diabetic micro-vascular disorders characterized by 
increased pressure, is generally reversible. High glucose increased the plasma osmolality, 
increasing blood volume and renal blood flow. Diabetes changed the ratio between the 
resistance of glomerular arterioles, resulting in glomerular capillary hyperperfusion and 
high pressure, the mesangial matrix expansion and basement membrane thickening, and 
therefore leading to focal glomerular sclerosis.[89] Meanwhile, the capillary endothelial cell 
was damaged, the normal filtration barrier was damaged, protein filtration was increased, 
which result in the loss of glomerular function. 
Microvascular disorders in DN is the pathological basis of clinical manifestations, the most 
prominent is the basement membrane thickening and the damage of glomerular filtration 
barrier function. The pathogenesis includes continuing glomerular hyperperfusion and 
hyperfiltration, increased collagen synthesis. Sustained high glucose leads to the non-
enzymatic glycation of basement membrane protein components. Another major 
pathological feature of DN is increased mesangial matrix. Mesangial expansion is mainly 
resulted from the following factors: glomerular hemodynamic abnormalities, increased 
capillary pressure. High filtration can stimulate the increase of mesangial matrix, the 
damage of glomerular filtration barrier. The leakage and accumulation of macromolecules in 
the membrane system stimulate mesangial cell proliferation and promote matrix 
production. High blood glucose activates protein kinase C in mesangial cell and the increase 
in mesangial matrix protein synthesis. Cellular growth factors are the important factors 
playing roles in increasing mesangial matrix. The most important of which is TGF-β. High 
blood glucose, glomerular capillary pressure and angiotensin (Ang) - II can promote the 
synthesis of extracellular matrix of mesangial and tubular epithelial cell. In addition 
endothelin (ET) also stimulate the proliferation of mesangial cells and the secretion of 
matrix. NO had inhibitory effect on mesangial cells. NO level is increased in early stage of 
diabetic nephropathy, which results in glomerular hyperperfusion and hyperfiltration. And 
it is reduced in the late stage due to endothelial cell damage, which leds to the increasing of 
mesangial matrix, playing a role in accelerating glomerular injury.[90] 
In diabetes, blood flow slows down and micro-thrombosis is easy to form, mainly due to 
abnormal endothelial cell and platelet function. The increase in serum of von Willebrand factor 
(vWF) is considered a sign of vascular endothelial cell injury. vWF is synthesized by 
endothelial cells, mediates platelet adhesion to endothelium, promote thrombosis. Overseas 
studies suggest that vWF is an independent risk factor for microvascular disease in 
diabetes.[91] In addition endothelial dysfunction is also reflected by the decreased activity of 
tissue plasminogen activator (t-PA) or the incresed activity of plasminogen activator inhibitor 
(PAI) which result in decreased fibrinolytic activity. Decreased prostacyclin-2 (PGI-2) synthesis 
reduced platelet inhibition. Increased release of ET can promote platelet aggregation. Plasma β 
platelet globulin (β-TG) and platelet factor 4 (PF4) levels reflect platelet activation. Increased 
thromboxane (TXA) -2 synthesis promote platelet aggregation and thrombosis. Many studies 
shown that increased platelet aggregation plays a very important role in the development of 
microangiopathy in type-2 diabetes mellitus, in addition to long-term hyperglycaemia. 
2.7 Metabolic syndrome in pathogenesis of allograft renal damage 
The metabolic syndrome (MS) is a cluster of interrelated common clinical entities, which 
include obesity, insulin resistance, glucose intolerance, hypertension and dyslipidaemia. 
Insulin resistance is their common pathophysiological basis. Metabolic syndrome 
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significantly increases the risk for cardiovascular disease and chronic kidney disease.[92] 
Recently it has been found that MS is also common in renal transplant recipients. How is 
kidney transplantation complicated with metabolic syndrome? 
2.7.1 Immunosuppressive therapies 
Immunosuppressive therapies induce post-transplantation diabetes 
Post-transplantation diabetes is believed to be multi-factorial, probably involving β-cell 
toxicity and increased insulin resistance. In addition to other risk factors, studies suggest 
that immunosuppressive regimens may account for a large degree of the increased risk for 
the development of post-transplantation diabetes. 
Corticosteroids and Calmodulin inhibitors (cyclosporine and tacrolimus) are widely used in 
kidney transplant recipients. They have long been recognized to potently affect glucose 
tolerance by a prevalent increase of peripheral insulin resistance. 
Increasing daily prednisolone dose was independently associated with insulin resistance as 
glucocorticoids promote gluconeogenesis in the liver, inhibit glucose uptake, diminish 
glycogen synthesis in skeletal muscle cells and also may attenuate insulin secretion from 
pancreatic beta-cells. Several mechanisms displayed in vitro studies on murine β-cell or 
human cell lines incubated with dexamethasone, have been proposed: insulin secretion 
inhibition by increased expression of a2-adrenergic receptors, decreased cAMP levels, 
decreased Glut2 protein at the β-cell plasma membrane, down regulation of glucokinase 
mRNA, increased voltage-gated K+channel activity, β-cell apoptosis through the activation 
of the calcineurin phosphatase and the corticosteroid receptor.[93-96] 
Calcineurin inhibitors, tacrolimus and cyclosporine cause reversible toxicity to islet cells and 
may directly affect the transcriptional regulation of insulin expression. Furthermore, both 
calcineurin inhibitors impair insulin gene transcription regulation through the inhibition of 
calcineurin signalisation. Other mechanisms have been proposed: closing of the ATP-
sensitive potassium channel, interference with mitochondrial function of pancreatic β-cell, 
impairment of glucose-stimulated insulin secretion downstream of the rise in intracellular 
Ca2+ at insulin exocytosis, reduced ATP production and glycolysis derived from reduced 
glucokinase activity, decreased islet cell viability by a down regulation of anti-apoptotic 
factors and accumulation of pro-apoptotic mediators in cultures of freshly isolated human 
islets. Tacrolimus is more diabetogenic than cyclosporine.[97-99] At the first, it can be due to 
the steroid mimetic effect of tacrolimus. Tacrolimus binds to FK506-binding protein (FKBP), 
predominantly FKBP-12. Another immunophilin, FKBP-52 is associated with the 
cytoplasmic glucocorticoid (GC) receptor complex. When cells are exposed to 
glucocorticoids, the steroid binds to the GC receptor and liberates it from the complex. By 
binding to FKBP-52 in the GC receptor complex, tacrolimus may alter the affinity of 
interactions and either cause a release of the GC receptor at lower steroid concentrations, a 
steroid-sparing effect, or it may free the GC receptor I absence of steroids . Second, 
tacrolimus increases the bioavailability of steroids. 
Immunosuppressive therapies induce obesity 
Prednisone can induce overweight or obesity in transplant recipients, espically abdominal 
obesity, the abdominal fat which is sensitive to catecholamine can induce insulin resistance 
through elevating the level of low density lipoprotein and very low density lipoprotein, 
inhibiting the activity of phosphofructokinase, blocking glycolysis and glucose uptake. 
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2.7.2 Virus infection 
Cytomegalovirus is one of the most important pathogenic microorganism after renal 
transplantation, Cytomegalovirus infection can infect insulin secretion, induce insulin 
resistance and  impair the function of pancreatic β-cell, and it is independent infector of 
post-transplant diabetes mellitus（PTDM).[100] Cytomegalovirus infection increases the 
activity of tumor necrosis factor(TNF), TNF can affect the function of islet B cell and 
decrease the organism’s sensitivity to insulin, that will promote insulin resistance in renal 
transplant recipients. 
Patients with HCV infection were found to have a 8.3-fold higher risk of appearing PTDM 
compared with HCV(-) patient.[101] Patients with HCV disease have increased peripheral 
insulin resistance and are hyperinsulinemic, similar to those with type 2 DM. It also is 
postulated that patients with HCV have decreased β-cell responsiveness, possibly caused by 
direct viral effects. Other explanations include an autoimmune pathogenesis because HCV 
has been associated with several autoimmune diseases, including cryoglobulinemia, 
Hashimoto’s thyroiditis, and Sjogren’s syndrome. This would suggest antibody-mediated 
destruction of pancreatic β-cells. A potential role of viruses in the cause of type 1 DM has 
been suggested, as well as a role for enteroviruses. A greater prevalence of PTDM in 
patients with HCV therefore likely is caused by a combination of increased peripheral 
insulin resistance and either a direct viral- or immune-mediated effect of HCV on pancreatic 
β-cells that results in relative insulin deficiency. 
2.7.3 Polycystic kidney disease 
Insulin resistance with compensatory hyperinsulinaemia has been reported in adult 
polycystic kidney disease patients. It is reported that post-transplant diabetes mellitus 
(PTDM) occured in 10 adult polycystic kidney disease (APKD) patients and four controls 
(34.6% vs 15.3%; P<0.005).[102] It has been shown that increased membrane fluidity and 
abnormal erythrocyte Na/Li counter-transport, both abnormalities associated with insulin 
resistance, are present in APKD patient.[103, 104] 
3. Diagnosis 
Till now there is no formal denomination of metabolic syndrome associated kidney diseases 
which are often diagnosed as obesity-associated glomerulonephropathy, diabetic 
nephropathy, hypertension-associated kidney damage, lipid disorder associated kidney 
damage and hyperuricemia-associated kidney damage.  
The diagnosis of metabolic syndrome associated renal disease is generally two levels criterion 
(Table 3-1). The first level is for large sample epidemiological screening, which is base on the 
diagnosis of MS and CKD, and often including MS complicated with CKD or CKD 
complicated with MS. The second is for clinical evaluation and treatment, which base on the 
diagnosis of MS and the clinical presentation and renal pathology of obesity-associated 
glomerulonephropathy, diabetic nephropathy, hypertension related renal damage lipid 
disorder associated kidney damage and hyperuricemia-associated kidney damage. Renal 
biopsy might be necessary for the investigation and clinical diagnosis of metabolic syndrome 
associated kidney diseases under some circumstances, and the pathological evaluation should 
be made with not only light microscope, but also immunofluorescence and electron 
microscope. The definite diagnosis of metabolic syndrome associated kidney diseases should 
exclude other primary or secondary kidney diseases. In clinical practice, metabolic syndrome 
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significantly increases the risk for cardiovascular disease and chronic kidney disease.[92] 
Recently it has been found that MS is also common in renal transplant recipients. How is 
kidney transplantation complicated with metabolic syndrome? 
2.7.1 Immunosuppressive therapies 
Immunosuppressive therapies induce post-transplantation diabetes 
Post-transplantation diabetes is believed to be multi-factorial, probably involving β-cell 
toxicity and increased insulin resistance. In addition to other risk factors, studies suggest 
that immunosuppressive regimens may account for a large degree of the increased risk for 
the development of post-transplantation diabetes. 
Corticosteroids and Calmodulin inhibitors (cyclosporine and tacrolimus) are widely used in 
kidney transplant recipients. They have long been recognized to potently affect glucose 
tolerance by a prevalent increase of peripheral insulin resistance. 
Increasing daily prednisolone dose was independently associated with insulin resistance as 
glucocorticoids promote gluconeogenesis in the liver, inhibit glucose uptake, diminish 
glycogen synthesis in skeletal muscle cells and also may attenuate insulin secretion from 
pancreatic beta-cells. Several mechanisms displayed in vitro studies on murine β-cell or 
human cell lines incubated with dexamethasone, have been proposed: insulin secretion 
inhibition by increased expression of a2-adrenergic receptors, decreased cAMP levels, 
decreased Glut2 protein at the β-cell plasma membrane, down regulation of glucokinase 
mRNA, increased voltage-gated K+channel activity, β-cell apoptosis through the activation 
of the calcineurin phosphatase and the corticosteroid receptor.[93-96] 
Calcineurin inhibitors, tacrolimus and cyclosporine cause reversible toxicity to islet cells and 
may directly affect the transcriptional regulation of insulin expression. Furthermore, both 
calcineurin inhibitors impair insulin gene transcription regulation through the inhibition of 
calcineurin signalisation. Other mechanisms have been proposed: closing of the ATP-
sensitive potassium channel, interference with mitochondrial function of pancreatic β-cell, 
impairment of glucose-stimulated insulin secretion downstream of the rise in intracellular 
Ca2+ at insulin exocytosis, reduced ATP production and glycolysis derived from reduced 
glucokinase activity, decreased islet cell viability by a down regulation of anti-apoptotic 
factors and accumulation of pro-apoptotic mediators in cultures of freshly isolated human 
islets. Tacrolimus is more diabetogenic than cyclosporine.[97-99] At the first, it can be due to 
the steroid mimetic effect of tacrolimus. Tacrolimus binds to FK506-binding protein (FKBP), 
predominantly FKBP-12. Another immunophilin, FKBP-52 is associated with the 
cytoplasmic glucocorticoid (GC) receptor complex. When cells are exposed to 
glucocorticoids, the steroid binds to the GC receptor and liberates it from the complex. By 
binding to FKBP-52 in the GC receptor complex, tacrolimus may alter the affinity of 
interactions and either cause a release of the GC receptor at lower steroid concentrations, a 
steroid-sparing effect, or it may free the GC receptor I absence of steroids . Second, 
tacrolimus increases the bioavailability of steroids. 
Immunosuppressive therapies induce obesity 
Prednisone can induce overweight or obesity in transplant recipients, espically abdominal 
obesity, the abdominal fat which is sensitive to catecholamine can induce insulin resistance 
through elevating the level of low density lipoprotein and very low density lipoprotein, 
inhibiting the activity of phosphofructokinase, blocking glycolysis and glucose uptake. 
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2.7.2 Virus infection 
Cytomegalovirus is one of the most important pathogenic microorganism after renal 
transplantation, Cytomegalovirus infection can infect insulin secretion, induce insulin 
resistance and  impair the function of pancreatic β-cell, and it is independent infector of 
post-transplant diabetes mellitus（PTDM).[100] Cytomegalovirus infection increases the 
activity of tumor necrosis factor(TNF), TNF can affect the function of islet B cell and 
decrease the organism’s sensitivity to insulin, that will promote insulin resistance in renal 
transplant recipients. 
Patients with HCV infection were found to have a 8.3-fold higher risk of appearing PTDM 
compared with HCV(-) patient.[101] Patients with HCV disease have increased peripheral 
insulin resistance and are hyperinsulinemic, similar to those with type 2 DM. It also is 
postulated that patients with HCV have decreased β-cell responsiveness, possibly caused by 
direct viral effects. Other explanations include an autoimmune pathogenesis because HCV 
has been associated with several autoimmune diseases, including cryoglobulinemia, 
Hashimoto’s thyroiditis, and Sjogren’s syndrome. This would suggest antibody-mediated 
destruction of pancreatic β-cells. A potential role of viruses in the cause of type 1 DM has 
been suggested, as well as a role for enteroviruses. A greater prevalence of PTDM in 
patients with HCV therefore likely is caused by a combination of increased peripheral 
insulin resistance and either a direct viral- or immune-mediated effect of HCV on pancreatic 
β-cells that results in relative insulin deficiency. 
2.7.3 Polycystic kidney disease 
Insulin resistance with compensatory hyperinsulinaemia has been reported in adult 
polycystic kidney disease patients. It is reported that post-transplant diabetes mellitus 
(PTDM) occured in 10 adult polycystic kidney disease (APKD) patients and four controls 
(34.6% vs 15.3%; P<0.005).[102] It has been shown that increased membrane fluidity and 
abnormal erythrocyte Na/Li counter-transport, both abnormalities associated with insulin 
resistance, are present in APKD patient.[103, 104] 
3. Diagnosis 
Till now there is no formal denomination of metabolic syndrome associated kidney diseases 
which are often diagnosed as obesity-associated glomerulonephropathy, diabetic 
nephropathy, hypertension-associated kidney damage, lipid disorder associated kidney 
damage and hyperuricemia-associated kidney damage.  
The diagnosis of metabolic syndrome associated renal disease is generally two levels criterion 
(Table 3-1). The first level is for large sample epidemiological screening, which is base on the 
diagnosis of MS and CKD, and often including MS complicated with CKD or CKD 
complicated with MS. The second is for clinical evaluation and treatment, which base on the 
diagnosis of MS and the clinical presentation and renal pathology of obesity-associated 
glomerulonephropathy, diabetic nephropathy, hypertension related renal damage lipid 
disorder associated kidney damage and hyperuricemia-associated kidney damage. Renal 
biopsy might be necessary for the investigation and clinical diagnosis of metabolic syndrome 
associated kidney diseases under some circumstances, and the pathological evaluation should 
be made with not only light microscope, but also immunofluorescence and electron 
microscope. The definite diagnosis of metabolic syndrome associated kidney diseases should 
exclude other primary or secondary kidney diseases. In clinical practice, metabolic syndrome 
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associated kidney diseases are often accompanied with other primary or secondary kidney 
diseases. Post-transplant metabolic syndrome associated kidney diseases are often 
complicated with acute or chronic rejection in renal allograft. 
 
Level 1 Metabolic syndrome complicated with chronic kidney disease 
1. Consistent with the diagnosis criterion of metabolic syndrome (necessary). 
2. Consistent with the chronic kidney disease (necessary). 
 
Level 2 Metabolic syndrome associated kidney disease 
1. Consistent with the diagnosis criterion of metabolic syndrome (necessary). 
2. One of the following diagnosis criterions. 
i. The obesity patient with the renal pathological character of obesity- associated 
glomerulonephropathy. 
ii. The diabetes patient with the renal pathological character of diabetic 
nephropathy. 
iii. The hypertension patient with the renal pathological character of 
hypertension related renal damage. 
iv. The patients with hyperuricemian and the renal pathological character of uric 
acid nephropathy 
Table 3.1. The diagnosis of metabolic syndrome associated renal disease: two levels of 
criterion 
3.1 Diagnosis of MS 
A diagnosis of metabolic syndrome associated kidney diseases must be based on the 
diagnosis of metabolic syndrome which is not only composed of central obesity, diabetes or 
prediabetes, hypertension, lipid metabolic disorder, etc., but also insulin resistance as its 
critical pathophysiological basis. the American Heart Association (AHA) along with the 
National Heart, Lung and Blood Institute issued an up-to-date version on the diagnosis of 
the metabolic syndrome.[105] The International Diabetes Federation (IDF) also provided a 
working definition for the syndrome (Table 3-2).[106]  
 
Clinical diagnosis criteria Categorical cut points 
Insulin resistance None 
Body weight 
Increased WC (population specific) 
plus any 2 of the following 
Lipid 
TG ≥150 mg/dL (1.7 mmol/L)or on TG Rx 
HDL-C <40 mg/dL (1.03 mmol/L)in men or <50 mg/dL (1.3 
mmol/L) in women or on HDL-C Rx 
Blood pressure 
≥130 mm Hg systolic or ≥85 mm Hg diastolic or on 
hypertension Rx 
Glucose ≥100 mg/dL(5.6 mmol/L), includes diabetes 
Table 3.2. Criteria for Clinical Diagnosis of Metabolic Syndrome (IDF, 2005) 
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The present AHA/NHLBI statement, in contrast to IDF, maintains the ATP III criteria except 
for minor modifications (Table 3-3).  
 
Measure (any 3 of 5 constitute 
diagnosis of metabolic syndrome) Categorical cut points 
Elevated waist circumference ≥102 cm (≥40 inches) in men, ≥88 cm (≥35 inches) in women 
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) Or On drug treatment for elevated triglycerides 
Reduced HDL-C <40 mg/dL (1.03 mmol/L) in men<50 mg/dL (1.3 mmol/L) in women Or On drug treatment for reduced HDL-C 
Elevated blood pressure 
≥130 mm Hg systolic blood pressure, Or ≥85 mm Hg 
diastolic blood pressure Or On antihypertensive drug 
treatment in a patient with a history of hypertension 
Elevated fasting glucose ≥100 mg/dL (5.6 mmol/L) or On drug treatment for elevated glucose 
Table 3.3. Criteria for Clinical Diagnosis of Metabolic Syndrome (AHA/NHLBI) 
It is suggested by the data of our recent community-based screening that the incidence of MS 
according to the diagnostic criteria of CDS was lower than that according to the diagnostic 
criteria of IDF. Some residents with MS mainly presentation of abdominal obesity would be 
missed diagnosis by the criteria base on BMI. In the components of MS, hypertension, 
abdominal obesity and lower high density lipoprotein were more common than others. 
3.2 Diagnosis of CKD 
The early evidences of metabolic syndrome associated kidney diseases might exist before 
the occurrence of clinical diabetes or hypertension, and it should include elevated or 
decreased GFR, microalbuminuria or even smaller proteins occurring in the urine before 
microalbuminuria, the presentation of renal pathological disorders existing before the 
clinical manifestation.  
According the K/DOQI definition and classification, CKD is defined as kidney damage or 
glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months or more, irrespective of 
cause. Kidney damage in many kidney diseases can be ascertained by the presence of 
albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine 
specimens. GFR can be estimated from calibrated serum creatinine and estimating 
equations.[107]  
There are many methods to determine GFR have been used, such as measuring GFR using 
exogenous markers, or endogenous markers, using exogenous marker is extremely 
inconvenience and is not used in clinical and epidemic practice. The often used endogenous 
markers are serum creatinine (SCr), usually calculated as creatinine clearance (CCr), and 
serum cystatin C. Most studies have shown that serum cystatin C levels correlate better with 
GFR than does serum creatinine alone, especially at higher levels of GFR. In practice, 
combining use of multiple indexes, such as SCr, age gender and race to evaluate GFR will be 
more accurate. So there many equations have been used to estimate GFR. The two most 
commonly used equations to estimate GFR are serum creatinine based: Cockcroft-Gault 
(CG) and the Modification of Diet in Renal Disease (MDRD) equations. A recent study 
involving a pooled analysis of individuals with chronic kidney disease proposed an 
 
An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
386 
associated kidney diseases are often accompanied with other primary or secondary kidney 
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The present AHA/NHLBI statement, in contrast to IDF, maintains the ATP III criteria except 
for minor modifications (Table 3-3).  
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estimation equation that included serum cystatin C in addition to serum creatinine, age, sex, 
and race. Studies concluded this equation provided the most accurate estimates. 
The CG equation is as follows: 
CCr(ml/min) ={[140 – Age(yr)] × Weight(kg)}/SCr(mg/dl) ×72×(0.85, if female) 
The six variable MDRD equation is as follows: 
GFR= 170 ×(SCr)-0.999 × (Age)-0.176 × 0.762(if female) × 1.18(if black) ×(BUN)-0.170× (Alb)0.318 
where BUN is blood urea nitrogen and Alb is albumin. 
The abbreviated version or four variable version of the MDRD equation (ml/min per 1.73 
m2) is as follows: 
GFR = 186 × (SCr) 1.154 × (Age) 0.203 × 0.742(if female) × 1.212(if black) 
The equation base on SCr and serum CysC is as follow: 
eGFR = 177.6 ×( SCr)-0.65 × (CysC)-0.57  ×(Age)-0.20 × 0.82(if female) × 1.11 (if black) 
3.3 Renal pathological changes in metabolic syndrome 
There is a small sample retrospective design.[108] The histopathologic presentation of patients 
with metabolic syndrome compared with controls had a greater prevalence of tubular 
atrophy, interstitial fibrosis, and arterial sclerosis, suggesting microvascular disease. Patients 
with metabolic syndrome had greater global and segmental glomerulosclerosis. Glomerular 
volume and cross-sectional surface area were not different. The combined end point of 
tubular atrophy greater than 5%, interstitial fibrosis greater than 5%, and presence of arterial 
sclerosis was more prevalent in patients with metabolic syndrome than controls.  
4. Prevention and treatment 
Aggressive multitargeted management of the metabolic syndrome can also improve cardio 
vascular and renal outcomes and is highly recommended by the American Heart 
Association. Although no study has evaluated whether multiple interventions can reduce 
the incidence or progression of CKD in patients with the metabolic syndrome.[109]  
4.1 Lifestyle changes 
Lifestyle interventions are the first line therapies recommended for treatment of the 
metabolic syndrome. The essential and important measurements include weight reduction, 
regular exercise, and a low-calorie, low-fat diet. Yet few data are available to indicate that 
such lifestyle interventions can prevent or reverse renal damage.[109]  
4.2 Medication treatment 
If lifestyle change is not sufficient, then drug therapies for abnormalities in the individual 
risk factors may be indicated. Such as medicine for treatment of diabetes, hypertension, lipid 
disorder and hyperuricemia. 
4.2.1 Treatment of elevated blood glucose 
In metabolic syndrome patients with IFG (or IGT if assessed), weight reduction, increased 
physical activity, or both will delay (or prevent) the onset of type 2 diabetes mellitus. 
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Intensive glucose control to lower the glycated hemoglobin value to 6.5% yielded a 10% 
relative reduction in the combined outcome of major macrovascular and microvascular 
events, primarily as a consequence of a 21% relative reduction in nephropathy. 
Oral Antihyperglycemic Agents:[110] Metformin, thiazolidinediones and acarbose will lower 
risk for type 2 diabetes mellitus in people with IFG or IGT. The nonsulfonylurea insulin 
secretagogues repaglinide and nateglinide can be used in renal failure without dose 
adjustments. Metformin is contraindicated in renal failure because of the associated risk for 
lactic acidosis. It can be used at low dosages up to a creatinine clearance of 30 to 60 ml/min 
and should be avoided with clearances<30 ml/min. Although the metabolism of 
thiazolidinediones is unaffected by renal failure, they must be used with caution in this context 
because of their volume retaining effect with a risk for heart failure. The sulfonylureas 
(glyburide, gliclazide, glipizide, glibenclamide, tolbutamide, and chlorpropamide) have 
increased potency to prolong sulfonylurea induced hypoglycemia as the renal function 
decreases and are contraindicated in severe renal failure. α-Glucosidase inhibitors (acarbose 
and miglitol) are also contraindicated in renal failure. 
Insulin therapy: Insulin therapy maybe benefits in glycaemic control, but not improves 
insulin resistance and metabolic syndrome. Insulin analogues, whose main objective is to 
stimulate physiologic insulin secretion, has opened new therapeutic possibilities in diabetic 
CRF patients.[111] Although only a few studies have evaluated the clinical efficacy and safety 
profile of insulin analogues in CRF patients, preliminary results appear hopeful. There is 
another concern of insulin injection for long term might be unfavourable, as ectogenous 
insulin may inhibit endogenous insulin secretion and results in the lack of the co-secretion 
of other beneficial substances such as C-peptide which is just now known to be potential in 
the treatment of diabetic nephropathy.[112]  
4.2.2 Treatment of elevated blood pressure 
In the presence of diabetes or chronic kidney disease, the blood pressure goal is <130/80 
mm Hg.  Mild elevations of blood pressure often can be effectively controlled with lifestyle 
therapies. Some investigators support angiotensin-converting enzyme (ACE) inhibitors as 
first-line therapy for hypertension in the metabolic syndrome, especially when either type 2 
diabetes mellitus or chronic renal disease is present. ARBs may be used in those who cannot 
tolerate ACE inhibitors or as an alternative to ACE inhibitors. 
4.2.3 Treatment of dyslipidemia 
According to ATP III, as long as LDL-C remains above goal level, LDL-C is the primary 
target of therapy even in the metabolic syndrome. Other lipid risk factors are secondary. The 
LDL-C goals depend on estimates of absolute risk. 
The main effects of Statin therapy are reduction of LDL-cholesterol, triglyceride and 
systemic inflammation, possible improvement of endothelial function and inhibition of renal 
endothelin 1-mediated proteinuria. The goal level of LDL-cholesterol: <1.80 mmol/l in very 
high-risk patients and <2.60 mmol/l in high-risk patients.[109]  
Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and reduced 
HDL-C. The main effects of fibrates therapy are decrease of triglycerides, increase of HDL, 
increase of insulin sensitivity, anti-inflammatory and antihypertensive action, and also 
reduction of mesangium-induced glomerular matrix deposition.[109]  
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4.3 New treatment 
Islets transplantation or stem cell transplantation has shown very exciting future in more 
effectively controlling blood glucose and preventing and treating diabetes-associated organ 
damage. More early intervention and prevention targets have been found for metabolic 
syndrome associated kidney diseases. 
4.3.1 Islets transplantation 
Pancreas or Islets transplantation is indicated to treatment of type 1 diabetes which insulin 
is insufficient for normal glucose metabolism. After long term (more than five years) of 
normoglycemia, diabetic nephropathy will be reversed.[81] It is not clear that pancreas or 
Islets transplantation will be benefit to improve of type 2 diabetes. In fact, insulin resistance 
will be more serious after transplantation due to the use of immunosuppressive agent.[113] 
Our small sample of patients with type 2 diabetes and ESRD receive combined 
transplantation of islets and kidney shown reversion of the peripheral nerves and vascular 
diseases, and maybe a protection of renal graft from damage of hyperglycosemia. 
Islet transplantation is an effective therapy for insulin-dependent diabetes mellitus, based 
on the research data which indicated that islet transplantation could not only retrieve the 
glycometabolism disorders but also prevent and reverse diabetes-associated 
microangiopathy. According to the registration data of the International Organ 
Transplantation Center, there had been up to 1300 patients received islet transplantation by 
the end of 2006. More than 40 institutes have developed islet transplantation for totally 550 
cases of diabetic patients, since the Edmonton Islet Transplantation Protocol was available in 
2000. The growth rate increased markedly compared to the era before 2000. 
The islets isolated from donor’s pancreatic tissue, by means of enzyme digestion and 
centrifugal purification, are injected into recipients’ liver through portal vein. The 
transplanted islets locate in hepatic sinus, adjusting the synthesis of hepatic glycogen and 
reversing the disorders of glycometabolism through secreting insulin. Autogeneic islet 
transplantation is limited in patients received entire or partial resection of pancreas due to 
chronic pancreatitis and tumor. Allogeneic islet transplantation needs immunosuppressants 
and therefore is mainly suit for kidney transplant recipients with type I diabetes-associated 
renal failure. Along with the development of new immunosuppressants, the indications of 
islet transplantation are increasing. In recent years islet transplantation along has been 
applied in patients with “friable” type I diabetes with refractory severe hypoglycemia while 
without renal failure, and considered for patients with type II diabetes and complete lost of 
islets’ function. 
A four year cooperative study was carried out in 9 islet transplantation centers of USA, 
Canada and Europe and 36 cases of type I diabetes received islet transplantation according 
to coincident Edmondon Protocol. It was shown by the data that 16 cases were insulin-
independent one year after transplantation (16/36, 44%) and, among them, 5 cases were still 
insulin-independent after 2 years follow-up (5/16, 31%). The study proved the efficacy of 
Edmondon Protocol in significantly increasing the success rate of islet transplantation. 
Besides, it is indicated by the success of Edmondon islet transplantation protocol that islet 
transplantation along is also fit to patients with type I diabetes while it is not always needed 
to be performed together with renal transplantation. In recent years some islet transplant 
recipients without renal failure were only administered short-term of immunosuppressive 
treatment (Daclizum administered on day 1 and day 3) and good efficacy achieved, which 
suggests that islet transplantation along may be do not need long-term immunosuppression 
therapy. 
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The surgical operation of islet transplantation is simple, but the isolation and the 
purification of islets belong to high-tech range. The skill and experience of operators are 
extremely important. Different operators have markedly different isolation results even they 
use the same pancreas from the same donor and apply the same isolation procedure. How 
to get enough functional islets from donor’s pancreas is the key technique for islet 
transplantation. Islet transplantation is a program needs multi-department and multi-
subject cooperation. A cooperation network should include endocrinologists, surgeons, 
transplantation center, net-serving staff, official administrators, transplant immunologists, 
transportation department. In addition, the qualities of a lot of procedures during 
transplantation can influence the result of islet transplantation, including patient selection, 
tissue matching, reservation and transportation, islet isolation and purification, islet 
implantation, blood glucose controlling during islet transplantation, immunosuppressant 
administration, and function evaluation after transplantation. The determination of islet cell 
auto-antibodies in recipients’ blood after transplantation is important for the prognosis of 
long-term islet transplantation efficacy. We should further investigate the relationship 
between the production of islet cell auto-antibodies and the survival of transplanted islets, 
and make sure if the auto-antibodies is the main factor resulting in the damage of 
transplanted islets. Islet cell auto-antigens can be produced with gene recombination and 
immune absorption column can be prepare with the auto-antigens and used to in time 
eliminate the auto-antibodies in patients’ blood, reducing islet damage induced by the 
antibodies and increase the long-term survival of transplanted islets. 
4.3.2 Stem cell transplantation 
Stem cell transplantation has shown effective in treatment of type 1 diabetes shown beta cell 
function increased,[114] and also in treatment of type 2 diabetes with significant increase of 
serum adiponectin and glucose tolerance.[115] Data from studies of NOD/SCID mice with 
diabetes shown that mesenchymal stem cells (MSCs) administration can prevent and treat 
diabetic nephropathy, prevent the pathological changes in the glomeruli and enhances their 
regeneration resulting in improved kidney function in diabetic animals.[116]  
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This former “age constraint” on the natural history of CF is paralleled by other major 
developments, such as an expansion of the number of organ systems, which we now know 
are involved in this disease. We now know that this disease affects more than the 
pulmonary and gastrointestinal systems.  
With the aging of the CF population, it has come to light that CF patients suffer from an 
increased risk of Diabetes Mellitus (Fischman & Nookala, 2008; Stecenko & Moran, 2010), 
Osteoporosis (Haworth, 2010), and malignancies (Hernandez-Jimenez et al., 2008). There is 
also a growing body of literature suggesting that as a result of treating other conditions 
associated with CF and as a result of the inflammatory and immunologic milieu associated 
with Cystic Fibrosis, these patients also suffer from renal disease (Stephens & Ridden, 2002; 
Katz et al., 1988) (Figure 2). In this chapter, we will discuss our current understanding of 
Cystic Fibrosis and review potential associations to renal disease with special attention to 






Source: Cystic Fibrosis Foundation Patient Registry Annual Data Reports, 1996-2006 
Fig. 2. Prevalence of Cystic Fibrosis Patients Requiring Dialysis for Renal Failure 
2. Background - Cystic Fibrosis 
2.1 Genetics 
Cystic Fibrosis is the most common, lethal, autosomal recessive disorder seen among the 
Caucasian population. For this reason, its disease prevalence throughout much of the world 
is 1 in 2,000 to 1 in 3200 individuals. Among non-Caucasian populations, and those not 
living in North America or Western Europe, the prevalence is approximately 1 in 4,000 to  
 




Legend: ABPA = Allergic Bronchopulmonary Aspergillosis,  
CFRD = Cystic Fibrosis-Related Diabetes Mellitus 
Fig. 3. Common Signs and Symptoms of Cystic Fibrosis, by Stages of Life 
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1 in 20,000 (Figure 4) (Sullivan & Freedman, 2009). Although we have known for decades of 
the association between salty sweat, obstructive lung disease, and pancreatic insufficiency, 
which comprise the hallmark symptoms of CF, and it was postulated as early as 1949 that a 
gene defect was the cause of CF, it was not until 1989 that the gene defect was localized to 
chromosome 7 (Rowe et. al., 2005). Since that time, more than fifteen hundred mutations 





Source: Cystic Fibrosis Foundation Patient Registry Annual Data Report 2009 
Fig. 4. Racial Demographics of Cystic Fibrosis Patients in North America 
This specific gene encodes a protein called the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR), which is found on many different types of cells. CFTR 
plays numerous regulatory roles throughout the body. The role most commonly 
associated with CFTR is that of chloride channel. However, the CFTR protein also plays a 
role in the inhibition of sodium transport, the regulation of ATP channels, and the 
inhibition of calcium-activated chloride channels. We now know that there are multiple 
types of CFTR gene mutations. They range in effect from complete lack of protein 
production (Class I Mutation), and defective protein processing and trafficking to the cell 
surface (Class II), to reduced production of normal-functioning CFTR protein (Class V) 
(Sullivan & Freedman, 2009) (Table 1). The F508del mutation, which accounts for two-
thirds of Cystic Fibrosis in Northern Europe and North America, is a class II mutation, 
resulting in production of a defective CFTR protein. 
 









I Protein not produced No Severe 
II 
Protein trafficking defect with CFTR 
degraded in ER/GolB; 
 
CFTR does not reach cell membrane
No Severe 
III 
Defective protein regulation; 
 
CFTR reaches cell membrane but not 
activated by ATP or cyclic AMP
No Severe 
IV Reduced Cl transport through apical membrane CFTR Yes Mild 
V Splicing defect with reduced production of functioning CFTR Yes Mild 
VI CFTR reaches cell membrane, but more rapid CFTR turnover Yes Presumably Mild 
Legend: CFTR = Cystic Fibrosis Transmembrane Regulator Protein, ER = Endoplasmic Reticulum,  
GolB = Golgi Body, ATP = Adenosine Triphosphate, AMP = Adenosine Monophosphate, Cl = Chloride ion 
Table 1. CFTR Mutation Classes 
Since Cystic Fibrosis is an autosomal recessive genetic trait, full expression of this disease 
requires that a defective gene be present on each chromosome. However, having one 
abnormal gene typically conveys a milder level of morbidity. As the level of CFTR metabolic 
regulatory function decreases below fifty percent, the chance of the individual developing 
sino-pulmonary conditions such as sinusitis, nasal polyps, or asthma increases. Men with the 
cystic fibrosis trait may experience infertility due to Congenital Bilateral Absence of the Vas 
Deferens (CBAVD). Despite the fact that it takes the presence of only one abnormal CFTR gene 
and fifty percent CFTR function for sino-pulmonary and genitourinary symptoms to occur; it 
typically takes CFTR function at levels less than five-percent of normal, usually seen with two 
mutations, before a patient’s sweat chloride excretion rises to levels diagnostic of CF. 
Furthermore, it takes CFTR protein function to be decreased by ninety-nine percent for 
pancreatic insufficiency to occur (Strasbaugh & Davis, 2007). Moreover, despite our efforts to 
characterize the association between genetic defect and phenotypic disease, neither sweat 
chloride level nor pulmonary function test values correlate with number or type of CFTR 
mutation. In two studies looking at this association, a mutation known to lead to Cystic 
Fibrosis could be found in only three out of five patients (Groman et. al., 2005; Groman et al., 
2002). However, it is interesting that a 2009 study of urinary protein excretion with regard to 
Cystic Fibrosis did find an apparent association between level of renal protein excretion and 
genotype, suggesting that although we cannot directly correlate gastrointestinal or pulmonary 
phenotype with a patient’s genotype, we may be able to correlate renal phenotype with CF 
genotype (Cemlyn-Jones & Gamboa, 2009). 
2.2 Pathophysiology 
The pathophysiology of Cystic Fibrosis results from abnormalities localized to the CFTR 
gene site resulting in an abnormality in CFTR protein production or processing. Either 
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typically takes CFTR function at levels less than five-percent of normal, usually seen with two 
mutations, before a patient’s sweat chloride excretion rises to levels diagnostic of CF. 
Furthermore, it takes CFTR protein function to be decreased by ninety-nine percent for 
pancreatic insufficiency to occur (Strasbaugh & Davis, 2007). Moreover, despite our efforts to 
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through this absence of CFTR protein, or through the production of abnormally functioning 
protein, an electrolyte imbalance occurs on luminal surfaces in multiple organ systems. The 
common result is the production of thick, tenacious secretions, which have impaired 
immunologic function and result in dysregulation of the patient’s inflammatory response, 
leading to an imbalance between pro-inflammatory and anti-inflammatory chemokines. In 
addition, there has been some evidence to suggest that the abnormal CFTR protein may 
facilitate protein binding of bacteria, leading to CF-related lung disease involving such 
bacterial pathogens as Pseudomonas aeruginosa and Staphylococcus aureus (Sullivan & 
Freedman, 2009; Rowe, 2005).  
2.3 Diagnosis 
The diagnosis of Cystic Fibrosis is typically made based on a combination of clinical 
symptoms consistent with the disease along with confirmatory testing. Since 1959, the 
diagnostic standard for Cystic Fibrosis has been the measurement of sweat chloride levels, 
as stimulated through a process using Pilocarpine Iontophoresis. In children younger than 
six months of age, a normal concentration of sweat chloride is considered to be less than 30 
mmol/liter. In patients older than six months, the normal range would be less than 41 
mmol/liter. Regardless of age, any repeatable sweat chloride level greater than 59 
mmol/liter is consistent with the diagnosis of Cystic Fibrosis, particularly if accompanied by 
symptoms of sino-pulmonary disease, a gastrointestinal malady such as fat-soluble vitamin 
deficiency, malnutrition, or intestinal obstruction, metabolic alkalosis, dehydration, or acute 
salt depletion (Figure 2) (Farrell et al., 2008).  
Consistent with the phenotypic pancreatic insufficiency seen in 90-95% of Cystic Fibrosis 
patients, pancreatic enzyme levels may be measured to help confirm the diagnosis. As of 
2010, fourteen European countries and all states in the United States have a process in place 
for screening newborns for this disease. Most of these testing programs, at least to some 
degree, rely on measuring levels of Immunoreactive Trypsinogen, a pancreatic enzyme 
found to be elevated in the first six weeks of life in infants with CF (Barto & Flume, 2010). 
In the situation where the sweat chloride analysis is indeterminate or the symptomatic 
phenotype is subtle, genetic testing is often employed. If the patient is found to have two 
mutations known to be consistent with the cystic fibrosis phenotype, then the diagnosis can 
be made. If one mutation is found, and it is unclear if the patient has a second, less well-
characterized mutation, then the patient is considered to have a possible diagnosis of Cystic 
Fibrosis. As noted previously, genetic testing may still be performed in the circumstance of 
confirmed disease, since the patient’s specific mutations may have prognostic significance. 
Furthermore, as we attain a greater understanding of the myriad of ways that defective 
CFTR genes may lead to inadequate or defective protein production and function, we will 
be able to tailor our therapeutic regimens more effectively to the patient’s genetic 
circumstance, in order to modulate or restore CFTR function (Ashlock et al., 2009). 
2.4 Clinical manifestations 
To date, it has been impossible to draw a direct link between the degree of genotypic 
abnormality and a particular patient’s morbidity. However, there are some common clinical 
patterns and associations seen in cystic fibrosis patients. Based on these clinical findings, an 
all-encompassing definition of Cystic Fibrosis would be “a chronic and progressive, multi-
system disease leading to sino-pulmonary disease, with probable exocrine pancreatic 
insufficiency, malnutrition, and gastrointestinal obstructive symptoms”. Patients with 
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Cystic Fibrosis typically have some degree of obstructive lung disease and present with a 
distinguishing factor of early colonization and subsequent infection from organisms not 
typically seen except in immunosuppressed or severely bronchiectatic individuals, such as 
Pseudomonas aeruginosa, Burkholderia cepacia, or Stenotrophomonas maltophilia. 
As a consequence of pancreatic insufficiency and associated malnutrition, many Cystic 
Fibrosis patients are deficient in fat soluble vitamins and suffer from a chronic, negative 
protein balance. Mouse studies have shown that the presence of CFTR gene defects leads to 
a heightened risk of Osteoporosis and subsequent bone fracture (Haworth, 2010). Along 
with this fracture risk, CF patients have an increased risk of kidney stones. One autopsy 
study of thirty-eight CF patients found that thirty-five had evidence of nephrocalcinosis, 
including one still-born and two neonatal infants (Katz et al., 1988). This predilection seems 
to be multifactorial and results from the interplay of 1) impaired vitamin D absorption 
leading to impaired calcium absorption, 2) chronic disease characterized by increased 
metabolic tempo, 3) immobility, 4) increased osteoclast activity, 5) inadequate caloric intake 
due to increase work-of-breathing, 6) an imbalance between protein anabolism and 
catabolism, and 7) loss of oxalate-degrading bacteria due to frequent, and often chronic 
antibiotic use (Stephens & Rigden, 2002). Furthermore, Andrieux et al., in their 2010 study, 
found that 75% of children in their study population had hypocitraturia and 70% had 
hyperoxaluria, both of which are risk factors for nephrolithiasis (Andrieux et al., 2010). 
One interesting aspect of the renal expression of CFTR is that cystic fibrosis patients often 
have greater antibiotic excretion than their non-CF counterparts. This necessitates the use of 
higher-than-typical antibiotic doses. The classic example of this occurs with the use of 
aminoglycoside antibiotics for treatment of pseudomonal infections, where Tobramycin is 
dosed at 10 mg/kg, sometimes in conjunction with inhaled Tobramycin, instead of the usual 
5-7 mg/kg (Barto & Flume, 2010, Bergman et al., 2007). Indeed, in one study of renal failure 
in children with Cystic Fibrosis, twenty of twenty-four cases of acute renal failure were 
associated with recent or concomitant aminoglycoside administration (Bertenshaw et al., 
2007). As a result of this uncertain pharmacokinetic and pharmacodynamic profile 
encountered with cystic fibrosis patients, monitoring drug levels is critical to insure that 
therapeutic doses are being achieved for efficacy.  
3. Renal disease and the CF patient 
3.1 A broad picture of renal disease in Cystic Fibrosis 
Since Dorothy Anderson first generated the term, “Cystic Fibrosis,” in 1938, we have 
known that kidney disease may be part of this malady (Abramowsky & Swinehart, 1982). 
However, the natural history of CF-related renal disease has been elucidated in few 
studies. In Abromowksy and Swinehart’s 1982 study, they found that all thirty-four of the 
patients studied had some form of glomerulopathy, with nineteen having 
glomerulosclerosis. Twenty-five had what was described as a “Mesangiopathy,”and 
twenty-six had tubulointerstitial disease. In this study, the authors concluded that a 
number of factors had led to the myriad of renal lesions observed: 1) lung disease with 
resultant cyanosis, 2) liver disease, 3) Cystic Fibrosis-Related Diabetes Mellitus, 4) the 
effects of nephrotoxic medications, and 5) an altered immune response. Of note, the 
authors report that sixteen of thirty-four patients studied had complement-3 (C3) deposits 
in their kidneys while thirteen had evidence of immunoglobulin–M deposits (IgM) 
(Abramowsky & Swinehart, 1982). 
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A more contemporary, 2010 study investigating renal disease in Cystic Fibrosis followed 112 
children, starting in the first year of life. This study revealed the presence of 
microalbuminuria in fifty-eight percent of patients. This finding was attributed to the 
presence of chronic inflammation as a result of the malfunctioning or absent CFTR protein, 
repeated infections, and the nephrotoxicity of many medications commonly used in the 
treatment of CF (Andrieux et al., 2010). Furthermore, a 2009 study following five hundred 
ten adults with CF, median age of thirty-one years, found that 13 developed renal disease 
severe enough to warrant renal biopsy, with eight different types of nephropathies found on 
histologic analysis. Twelve of these thirteen patients were found to have glomerular lesions. 
In this study, the main types of renal disease found were AA amyloidosis and diabetic 
nephropathy (Yahiaoui et al., 2009).  
In literature reviewed for their 2002 article on renal disease in Cystic Fibrosis, Stephens and 
Rigden report that IgA Nephropathy appeared to be the most common form of 
glomerulonephritis described in CF patients, though the occurrence of this condition appeared 
rare (Stephens & Rigden, 2002). With respect to all renal disease in CF patients, the most 
common renal pathology found has been nephrocalcinosis. Drug-related nephrotoxicity also 
continues to be a common cause of renal morbidity among CF patients. Among the various 
agents responsible medication-induced renal disease, aminoglycosides continue to play a 
prominent role. As a result of the pharmacodynamic and pharmacokinetic eccentricities of the 
cystic fibrosis patient, Acute Tubular Necrosis (ATN) remains a constant concern when 
treating pulmonary exacerbations in this patient population. This risk of ATN is amplified by 
pulmonary biofilm formation and the need to use a combination of intravenous, oral, and 
inhaled antibiotics to effect a decrease in pathogen levels, and potentially facilitate bacterial 
eradication. It is for this reason that current Cystic Fibrosis Foundation guidelines recommend 
once-daily dosing of aminoglycosides to optimize treatment benefit, yet minimize risk of renal 
injury (Flume et al., 2009). Furthermore, a 2010 review of aminoglycoside toxicity in cystic 
fibrosis patients suggested that use of once-daily Tobramycin, particularly when dosed in the 
morning, may be superior to use of gentamicin in preventing aminoglycoside-induced renal 
injury (Prayle & Smyth, 2010). 
3.2 Measurement of renal function in CF patients 
Discussion of renal disease in CF patients is complicated by the fact that conventional 
methods of measuring renal function may not be accurate in this population (Prayle & 
Smyth, 2010). In Andrieux’s 2008 study of renal disease in children with CF, his team 
observed that there was no correlation between a calculated Glomerular Filtration Rate 
(GFR), using the Schwartz Formula’s manipulation of serum creatinine (SCr) values, and a 
urine creatinine-based (UCr) standard.  
Schwartz Formula:  
GFR(mL/min/1.73 m2) = ((k)(Height in cm)/(SCr in mg/dL)) where  
K = Constant as follows: 
 0.33 in premature infant 
 0.45 in term infants to 1 year-old 
 0.55 in children older than one, up to 13 years old 
 0.55 in adolescent females 
 0.65 in adolescent males  
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In one-third of children studied, the Schwartz Formula’s serum-creatinine derived approach 
overestimated renal function (Andrieux et al., 2010). Furthermore, Yahiaoui’s 2009 study 
investigating renal disease in thirteen adults with Cystic Fibrosis concluded that one of the 
reasons that renal disease is considered uncommon in CF patients is that measurements of SCr 
and calculations of GFR, using either the Cockcroft-Gault or MDRD equations, fail to 
adequately and reliably reflect a CF patient’s true level of kidney function (Yahiaoui et al., 2009).  
To explain this apparent inadequacy in SCr-based evaluation of renal function observed in 
the CF population, it has been suggested that decreases in muscle mass seen among CF 
patients, and typically related to their underlying disease state, leads to decreased 
production of SCr. This would hinder the proportional rise in SCr levels in response to renal 
insufficiency, which has been observed in other studied populations. Recognizing this 
challenge of accurately measuring renal function in CF patients, methods that more directly 
measure kidney function have been proposed including methods using UCr collection, 
typically over twenty-four hours, or using plasma levels of an inert tracer which is only 
excreted via the kidneys (Prayle & Smyth, 2010). 
In recognizing the fallacies of SCr-based formulae, the difficulties of collecting urine accurately 
over an extended period of time, and the invasiveness of nuclear tracer-based measurements 
of renal function, Beringer and colleagues studied levels of the biomarker Cystatin C (Cys C) 
as a potential method of estimating GFR. Their study showed that measurement of Cystatin C 
clearance was a suitable alternative to measurement of SCr or calculated GFR in following a 
CF patient’s renal function. Furthermore, Cys C levels were not affected by age, gender, 
muscle mass, diet, or level of physical activity. Moreover, the authors make specific mention of 
using this method to follow CFRD patients for evidence of renal disease (Beringer et al., 2009). 
Unfortunately, at this time, Cys C levels have not become widely employed. 
3.3 Cystic Fibrosis-Related Diabetes Mellitus and Renal Disease 
Since Cystic Fibrosis-Related Diabetes Mellitus (CFRD) is becoming an increasingly common 
complication in the natural history of Cystic Fibrosis, and can lead to significant renal 
pathology, we discuss this type of renal disease as an independent section. By the time CF 
patients reach their thirtieth birthday, 45-50% will have developed CFRD, with an associated 
increase in morbidity and mortality. This complication of Cystic Fibrosis was formerly the 
most dreaded of sequelae, as it was associated with a six-fold increase in mortality, 
particularly among women (Fischman & Nookala, 2008). However, through aggressive efforts 
to increase screening for evidence of impaired glucose intolerance and overt diabetes, as well 
as through early use of oral diabetic medications and insulin, the mortality disparity associated 
with CFRD has all but disappeared (Stecenko & Moran, 2010) (Table 2).  
As with other forms of Diabetes Mellitus, CFRD may lead to microvascular changes in such 
structures as the Eyes, Kidneys, Stomach, and Nerves. A 2007 study of the microvascular 
complications of CFRD suggested that CFRD-related nephropathy occurred less commonly 
than renal complications seen in association with other forms of Diabetes Mellitus 
(Schwarzenberg et al., 2007). The results found in Schwarzenberg’s study appear to be 
consistent with our current understanding of CFRD, which suggests that the increased 
mortality risk that CFRD conveys is due to accelerated progression of the patient’s 
underlying lung disease, not due to vascular complications (Stecenko & Moran, 2010). 
Moreover, the microalbuminuria that we typically associate with microvascular damage to 
the kidney was only seen among CF patients who had fasting hyperglycemia 
(Schwarzenberg et al., 2007) (Table 3).  
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Characteristic CFRD DM I DM II 
Age at Onset 18-21 years < 20 years >40 years 
Prevalence 
22% of CFFR 
population (2% of 
children, 19% of 
adolescents, 45-50% 
over age 30a) 
7% of US population 
7% of US population  
(NB: > 15% of population 
> 50 years) 








Unchanged Increased Slightly Increased Dramatically 
Ketoacidosis No Yes No 
Microvascular 
Complications Yes Yes Yes 
Macrovascular 
Complications Extremely Rare
 Yes Yes 
Nutritional 
Support 
High calorie diet: (120-
150%) of RDA 
Fat: 40% of dietary 
intake (No restrictions 
on type) 
Protein: 10-20% of 
calories, not reduced for 
nephropathy 
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Legend: CFFR = North American Cystic Fibrosis Foundation Registry; DM I = Diabetes Mellitus Type I; 
DM II = Diabetes Mellitus Type II ; RDA = recommended daily allowance; SOC = standard of care;  
SC = subcutaneously administered. 
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It is interesting that a subsequent 2008 study comparing microvascular changes found in CF 
patients to a matched cohort of patients with Type I Diabetes Mellitus (DM1) found that while 
retinopathy occurred more frequently in DM1, renal disease as measured through 
microalbuminuria occurred with greater frequency in patients with CFRD. The authors of this 
study explained this discrepancy in microvascular findings by speculating that other factors, 
such as deficient CFTR function, chronic inflammation, repeated exposure to nephrotoxic 
agents, or genetic predispositions may be the cause (van den Berg et al., 2008). While the 
results of these two studies may appear to be conflicting, a closer analysis reveals that van den 
Berg’s study methodology does not distinguish patients with fasting hyperglycemia from 
those without; thus, if van den Berg’s CFRD population had a preponderance of patients with 
fasting hyperglycemia, then the results of these two studies may be consistent. 
Within the last decade, case reports have emerged suggesting that Nodular 
Glomerulosclerosis (NGS) in cystic fibrosis patients may mimic the findings of Diabetic 
Nephropathy (DN) (Westall et al., 2004). Since the histopathology of these cases appears to 
be misleadingly reminiscent of that seen in Diabetic Nephropathy, we have chosen to 
discuss these cases in conjunction with our discussion of CFRD-related renal disease. In 
their case report, Westall’s team reports that all three patients had pathologic findings 
thought consistent with DN, including Kimmelstiel-Wilson Nodules, without any evidence 
of impaired glucose tolerance. The authors speculate that the Focal and Nodular 
Glomerulosclerosis observed (e.g. the Kimmelstiel-Wilson nodules) may be an idiopathic 
occurrence, may be the result of CFTR deficiency or abnormal function, or may be the result 
of accumulation of toxic molecules. The authors explain that these toxic molecules are 
generated as the by-product of an inflammatory process or as a result of oxidative stress. 
Furthermore, they conjectured that these pathologic findings may be the consequence of 
undetected episodes of hyperglycemia, which would eventually become more persistent.  
In an accompanying editorial to Westall’s case series, Krous discusses the implications of 
Westall’s work. In his commentary, Krous does raise the question of whether we should be 
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routinely screening cystic fibrosis patients for proteinuria, since renal pathology similar to 
DN has been described, even without evidence of hyperglycemia. Krous also calls for 
further investigation of the specific pathologic process that leads to the NGS seen in both CF 
and Diabetes Mellitus. In the end, the only answer that Krous leaves us with is that it may 
be prudent to screen CF patients for proteinuria (Krous HF, 2004). 
3.4 Glomeulonephritis 
3.4.1 An introduction to glomerular disease in Cystic Fibrosis 
Despite the fact that renal pathology among cystic fibrosis patients was described from the 
time that CF’s constellation of symptoms was first delineated, there still remains relatively 
little written on renal involvement in CF. There are many explanations as to why this may 
be the case: lack of a clear CF renal disease phenotype, difficulty measuring renal 
impairment due to inadequacy of SCr-based renal function tests, and, possibly, reluctance of 
cystic fibrosis center care teams to pursue the presence of renal pathology with potentially 
intrusive, and possibly invasive testing (Yahiaoui et al., 2009). However, with the aging of 
this patient population, an increasing number of case reports have suggested that renal 
disease is part of the CF phenotype. In 1972, Openheimer described the presence of 
glomerular pathology in autopsied CF patients (Openheimer, 1972). Abramowsky’s 1982 
study showed that a majority of patients studied not only had evidence of glomerular 
involvement, but also immunoflourescence findings of immunoglobulin and complement 
deposition in glomeruli, with localization to the mesangial regions and capillary loops 
(Abramowsky & Swineheart, 1982). A more contemporary study of thirteen adults with CF 
and renal disease, who underwent a renal biopsy, revealed that twelve had glomerular 
lesions (Yahiaoui et al., 2009). Thus, it is clear that, beyond a CF patient’s very real risk of 
experiencing a renal injury as a result of a medication adverse drug reaction or toxicity, 
Cystic Fibrosis, itself, may be associated with renal pathology. In this section we will discuss 
the types of glomerular lesions that have been observed and current theories on the 
development of glomerular pathology in Cystic Fibrosis. 
3.4.2 IgA Nephropathy 
In Stephens and Rigden’s review of renal disease in Cystic Fibrosis, they report that among 
the glomerulonephritides, IgA Nephropathy is the most frequently reported (Stephens & 
Rigden, 2002). In a 1999 case series reported by Stirati and colleagues, four out of the five CF 
patients who underwent a renal biopsy for proteinuria had findings consistent with IgA 
Nephropathy. It should be noted that the authors do admit that since IgA Nephropathy is a 
common type of GN in young adults, and the patients in their study ranged in age from 
twenty-two to thirty years, their findings may be a chance occurrence.  
However, another plausible explanation for this association, put forth by the authors is that 
recurrent bacterial infections result in a robust immune response leading to increased levels 
of circulating immunoglobulins and immune complexes. These immune-mediating 
molecules may deposit in the kidney and lead to the histopathology and morbidity observed 
(Stirati et al., 1999). Interestingly, in Abromowsky and Swinehart’s 1982 study, the 
explanation of chronic bacterial infection leading to a high level of immune activity resulting 
in glomerular pathology was also raised. Abramowsky and Swinehart conjectured that the 
proximate cause was chronic pseudomonas aeruginosa infection. However, contemporary 
immunologic investigations using pseudomonas antiserum did not reveal any antigens in 
the studied glomeruli.  
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If chronic pseudomonal infection is not the nidus for this robust immune response, then 
what is? The answer may actually lie in staphylococcal infection. Staphylococcus 
epidermitis bacteremia and staphylococcus aureus-asssociated endocardititis have long 
been known to cause glomerulonephritis. Furthermore, histopathology of staphylococcal-
associated GN typically reveals glomerular immune complex deposits containing 
complement, particularly C3, and immunoglobulins, typically IgG and IgM. These 
findings are consistent with those described in CF-related Glomerulonephritis, and have 
even greater significance in light of the fact that staphylococcus remains a common 
colonizing pathogen (Figure 5), and a major cause of lung infection early in a CF patient’s 
life, typically causing pneumonia before pseudomonas aeruginosa infections become 
common. Moreover, idiopathic IgA Nephropathy is known to occur within a few days of 
the patient experiencing an upper respiratory infection. Thus, there appears to be a viable 
association between staphylococcal colonization and IgA Nephropathy in cystic fibrosis 
patients (Satoskar et al., 2006). 
 
 
Source: Cystic Fibrosis Foundation Patient Registry Annual Data Reports, 1986-2009 
Fig. 5. Prevalence of Staphylococcus Aureus Infection/Colonization Among Cystic Fibrosis 
Patients 
In a 2006 case series by Satoskar and colleagues, they report eight cases of staphylococcus 
infection-associated mesangial and/or intracapillary proliferative glomerulonephritis (GN) 
associated with IgA-laden immune complex deposition. In this study, seven of the eight 
patients described had infections other than endocarditis, and the eighth suffered from an 
epidural abscess which resulted in endocarditis (Satoskar et al., 2006). The reason why 
staphylococcal infections may lead to GN remains unclear. One theory proposed by 
Satoskar suggests that staphylococcus enterotoxins may behave as superantigens that bind 
Major Histocompatibility Complex Class II (MHC II) molecules on Antigen-Presenting Cells 
(APC). This complex of MHC II and enterotoxin then binds to T-cell receptors, resulting in 
widespread T-cell activation and a surge of cytokine release. These cytokines, in turn, 
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activate B-cells, which then produce IgA and IgG molecules. These immunoglobulins are 
then released, resulting in immune complex formation, and eventual deposition in the 
Kidney. Further elaborating on this mechanism of glomerular pathology, Koyoma’s group 
described a specific staphylococcus aureus envelope antigen as a proximate cause for 
superantigen formation (Koyoma et al., 2004). Thus, research studying the association 
between staphylococcal skin and wound infections, as well as idiopathic IgA Nephropathy, 
may shed some light on the pathologic association between IgA Nephropathy and Cystic 
Fibrosis. 
3.4.3 Membranoproliferative Glomerulonephritis 
The occurrence of Membranoproliferative Glomerulonephritis (MPGN) in cystic fibrosis 
patients is not a new finding. Ambrowsky and Swinehart’s 1982 autopsy study of thirty-
four Cystic Fibrosis patients showed on eighteen patients who had evidence of immune 
complex deposition in the Kidney, and, of those, sixteen had evidence of mesangial 
proliferation with two also having evidence of membranoproliferative histopathology. 
Thus, this autopsy study would suggest that MPGN is a major cause of renal disease in 
the CF patient.  
However, more contemporary reviews of the subject do not find nor discuss MPGN in the 
CF patient (Stephens & Rigden, 2002; Yahiaoui et al., 2009). Indeed, the only recent report 
of this association was published by Soriano and colleagues in 2008 (Soriano et al., 2008). 
In this paper, the authors discuss multiple, plausible explanations for the natural history 
of renal disease in CF. One mechanism proposed, the Factor H Deficiency Model, is based 
on the observation that genetic knockout mice who are deficient in alternate complement 
pathway Factor H not only develop MPGN, but also experience higher mortality with 
pseudomonas aeruginosa infections than factor H sufficient mice. Furthermore, factor H 
deficiency has been found to lead to aberrant activation of Complement Factor C3 and 
higher serum levels of various chemokines and cytokines (Soriano et al., 2008). This 
pathologic explanation is supported by the work of Wisnieski’s group, who reported in 
1985 that mortality among their cohort of one hundred thirty-nine patients was highly 
associated with decreased alternate complement pathway function and the presence of 
circulating immune complexes (Wisnieski et al., 1985).  
Separate from the immunologic explanation proposed above, a plausible link between 
Cystic Fibrosis and Membranoproliferative Glomerulonephritis lies in the function of Toll-
like Receptors (TLR), which are part of the Innate Immune System. This family of receptor 
proteins is responsible for recognizing recurring structures on pathogens, including single-
stranded DNA, lipopolysaccharides, and RNA molecules. Upon recognition of a structure 
known to be associated with a pathogen, the TLR initiates inflammatory and immune 
responses whose end result is meant to be destruction of the pathogen. By modulating 
immune responses, including regulating helper T-cell immunologic responses, aberrant TLR 
function is conjectured to lead to kidney inflammation and glomerulonephritis (Smith & 
Alpers, 2005). A 2004 study by Muir and colleagues showed that TLR-2 expression was up-
regulated in the lungs of CF patients (Muir et al., 2004). Moreover, in 2006, Shuto and 
colleagues suggested that this TLR-2 up-regulation and prolonged activation was critical to 
the pathogenesis of CF lung disease (Shuto et al., 2006). Separate from the Factor H 
Deficiency or the TLR models for the development of glomerulonephritis in cystic fibrosis 
patients, the presence of staphylococcal superantigens has been conjectured to lead to 
MPGN in CF patients (Soriano et al., 2008). 
 




To date, there has been very little written on the treatment of glomerulonephritis in CF 
patients. One available case series details the diagnosis and treatment of two adult patients. 
In this article, it is reported that one of the patients experienced an improvement in his renal 
disease to the point where he could safely forgo hemodialysis after undergoing a double-
lung transplant and starting his anti-rejection regimen (Soriano et al., 2008). This would 
suggest that the conventional immunosuppressant therapy typically employed in the 
treatment of glomerulonephritis would be appropriate in this population as well. However, 
given the known pharmacokinetic and pharmacodynamic intricacies of the CF patient, 
further study is warranted. 
4. Conclusion  
Cystic Fibrosis is a disease in evolution. Through wide-spread newborn screening programs, 
patients are diagnosed earlier. Through an aggressive, world-wide therapy development 
network, new and revolutionary treatments for the manifestations of Cystic Fibrosis are 
shepherded from the lab bench to the patient’s home. As we develop a better understanding 
of how genetic mutation translates into phenotypic dysfunction and symptoms, we will be 
able to regulate and modify protein function to ameliorate the symptoms of Cystic Fibrosis. 
However, with these revolutionary changes to how patients experience the morbidity of 
Cystic Fibrosis, and with the aging of the CF population, new manifestations of CF may 
emerge. Kidney disease, particularly glomerulonephritis, may be one of the more plausible 
morbidities to afflict CF patients with growing regularity in the future. Thus, we must stay 
ever vigilant, and not become complacent that we have a complete understanding of this 
disease process. Cystic Fibrosis is no longer a disease of children. We must, therefore, 
continue to broaden our understanding of what it means to be an adult with Cystic Fibrosis. 
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ever vigilant, and not become complacent that we have a complete understanding of this 
disease process. Cystic Fibrosis is no longer a disease of children. We must, therefore, 
continue to broaden our understanding of what it means to be an adult with Cystic Fibrosis. 
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1. Introduction 
The type IV collagen nephropathies comprise a spectrum of abnormalities predominantly 
affecting the glomerular basement membrane (GBM) in the kidney, but also involving other 
organs such as the ear and eye. Type IV collagen nephropathies result from genetic 
mutations causing loss or deficiency of type IV collagen synthesis, and have been associated 
with Alport syndrome at one end of the spectrum, where individuals who are the most 
severely affected experience end-stage renal failure (ESRF) in their early teen-age years 
together with hearing loss and vision abnormalities. At the other end of the spectrum type 
IV collagen nephropathies are associated with mild defects, such as thin basement 
membrane nephropathy (TBMN) or benign familial hematuria where individuals may 
experience mild kidney abnormalities involving episodic hematuria but retain relatively 
normal renal function and show no extra-renal abnormalities. There are six different type IV 
collagen genes located on multiple chromosomes, and three of these genes (COL4A3, 
COL4A4, and COL4A5) are associated with X-linked, autosomal recessive or autosomal 
dominant  inheritance patterns of Alport syndrome. In addition the type IV collagen genes 
are associated with the TBMN phenotype, involving heterozygous mutations of the COL4A3 
and COL4A4 genes, with an autosomal dominant pattern of inheritance. The main focus of 
this chapter is the mild forms of Alport syndrome, and so in the following pages we review 
mild presentations of Alport syndrome, and illustrate this with a unique New Zealand family 
segregating mild X-linked Alport syndrome, some of whom display features of TBMN. 
2. Synthesis and distribution of type IV collagen  
The type IV collagen family is comprised of six homologous -chains designated 1(IV)–
6(IV) encoded for by the COL4A1-6 genes respectively, the corresponding genes of which 
are located pairwise on chromosomes 13q34, 2q36-37 and Xq22. Each -chain has three 
domains composed of a short 7S domain at the amino terminus, a long collagenous domain 
of approximately 1400 residues of Gly-Xaa-Yaa repeats and a noncollagenous (NC1) domain 
of about 230 residues at the carboxyl terminus (Figure 1). Three  chains assemble into 
triple-helical molecules called protomers that then assemble into supramolecular networks 
by the association of four protomers at the N-terminus, forming a 7S tetramer, and the 
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1. Introduction 
The type IV collagen nephropathies comprise a spectrum of abnormalities predominantly 
affecting the glomerular basement membrane (GBM) in the kidney, but also involving other 
organs such as the ear and eye. Type IV collagen nephropathies result from genetic 
mutations causing loss or deficiency of type IV collagen synthesis, and have been associated 
with Alport syndrome at one end of the spectrum, where individuals who are the most 
severely affected experience end-stage renal failure (ESRF) in their early teen-age years 
together with hearing loss and vision abnormalities. At the other end of the spectrum type 
IV collagen nephropathies are associated with mild defects, such as thin basement 
membrane nephropathy (TBMN) or benign familial hematuria where individuals may 
experience mild kidney abnormalities involving episodic hematuria but retain relatively 
normal renal function and show no extra-renal abnormalities. There are six different type IV 
collagen genes located on multiple chromosomes, and three of these genes (COL4A3, 
COL4A4, and COL4A5) are associated with X-linked, autosomal recessive or autosomal 
dominant  inheritance patterns of Alport syndrome. In addition the type IV collagen genes 
are associated with the TBMN phenotype, involving heterozygous mutations of the COL4A3 
and COL4A4 genes, with an autosomal dominant pattern of inheritance. The main focus of 
this chapter is the mild forms of Alport syndrome, and so in the following pages we review 
mild presentations of Alport syndrome, and illustrate this with a unique New Zealand family 
segregating mild X-linked Alport syndrome, some of whom display features of TBMN. 
2. Synthesis and distribution of type IV collagen  
The type IV collagen family is comprised of six homologous -chains designated 1(IV)–
6(IV) encoded for by the COL4A1-6 genes respectively, the corresponding genes of which 
are located pairwise on chromosomes 13q34, 2q36-37 and Xq22. Each -chain has three 
domains composed of a short 7S domain at the amino terminus, a long collagenous domain 
of approximately 1400 residues of Gly-Xaa-Yaa repeats and a noncollagenous (NC1) domain 
of about 230 residues at the carboxyl terminus (Figure 1). Three  chains assemble into 
triple-helical molecules called protomers that then assemble into supramolecular networks 
by the association of four protomers at the N-terminus, forming a 7S tetramer, and the 
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dimerization of two protomers at the C-terminus, forming an NC1 hexamer (Timpl et al., 
1981). Interruptions in the Gly-Xaa-Yaa amino acid sequence at multiple sites along the 
collagenous domain give rise to flexibility, allowing for looping and supercoiling of 
protomers into networks (Hudson 2004, Miner 2003, Zhou & Reeders 1996). 
 
 
Fig. 1. A schematic drawing showing an example of 3-, 4-, and 5(IV)-chains and 
3.4.5(IV) protomer formation. D: domain 
To date, only three different types of collagen protomer have been identified; 1.1.2(IV), 
3.4.5(IV) and 5.5.6(IV) (Hudson 2004). The protomer 1.1.2(IV) is ubiquitously 
present in most basement membranes (Hudson et al., 1993, Borza et al., 2001, Boutaud et al., 
2000, Timpl et al., 1981). In contrast, 3.4.5(IV) and 5.5.6(IV) show restricted tissue 
distribution. In the kidney the 1.1.2(IV)-1.1.2(IV) network predominates during early 
nephrogenesis in the GBM, the Bowman’s capsular basement membrane, and tubular 
basement membrane. As the kidney becomes mature during the 2nd trimester of fetal 
development, the 3.4.5(IV)-3.4.5(IV) network gradually becomes dominant and 
replaces the 1.1.2(IV)-1.1.2(IV) network in the GBM and in tubular basement 
membranes while the 1.1.2(IV)-5.5.6(IV) and the 1.1.2(IV)-1.1.2(IV) networks 
are distributed in the Bowman's capsular basement membrane and in tubular basement 
membranes (Harvey et al., 1998, Milner 2003). The protomer 3.4.5(IV) is also expressed in 
the lung, testis, cochlea and eye while the 5.5.6(IV) network is present in skin, smooth 
muscle and esophagus (Cosgrove et al., 1998, Hudson et al., 2003, Kalluri et al., 1997). 
Alterations in any of the COL4A3, COL4A4 and COL4A5 genes may cause Alport syndrome.  
3. Alport syndrome 
Alport syndrome is a hereditary disorder with considerable genetic and clinical heterogeneity 
characterized by hematuria, proteinuria (1-2 gm of protein per day) and progressive renal 
failure and is frequently associated with diagnostic ocular abnormalities and high tone 
sensorineural deafness. Ocular abnormalities include lenticonus of the anterior lens capsule, 
retinopathy and cataracts. Other extra-renal manifestations include mental retardation or 
leiomyomatosis in rare cases (Alport 1927, Flinter et al., 1988, Hudson et al., 2003).  
3.1 Genetics 
In approximately 85% of patients with Alport syndrome there is X-linked inheritance of 
mutations in the COL4A5 gene encoding the 5(IV) collagen chain on chromosome Xq22. 
COL4A5 is a large gene comprising 51 exons. As many as 588 mutations have been described 
to date and are spread throughout the gene without any identified mutational hot spots. The 
types of mutations that involve COL4A5 consist of missense, deletion, splice site, nonsense, 
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The remaining 15% of Alport syndrome patients show autosomal inheritance; of these 14% 
are recessive and 1% are dominant, which are caused by mutations either in the COL4A3 or 
COL4A4 genes on chromosome 2q36-37 encoding the 3(IV) or 4(IV) proteins. 
Heterozygous mutations of COL4A3 or COL4A4 could result in a less severe phenotype than 
that of homozygous or compound mutations in these genes (Jefferson et al., 1997). The 
authors also noted that heterogygous mutations of these genes could result in thin basement 
membrane nephropathy (TBMN) which typically does not result in renal failure. The 
authors postulated that mutations in the COL4A3 or COL4A4 gene can cause a spectrum of 
disease, ranging from TBMN/benign familial hematuria to autosomal dominant and 
recessive forms of Alport syndrome.  
3.2 Pathogenesis 
Ultrafiltration of plasma in the renal glomeruli is the major function of the kidney 
(Voskarides et al., 2008). The primary filtration barrier of the glomerular capillary consists of 
three layers: the fenestrated endothelial cells, the intervening GBM, and the epithelial 
podocyte foot processes. The foot processes are connected to each other by the slit 
diaphragm, and together these constitute an important component of the filtration barrier; 
the loss of podocyte foot processes results in massive proteinuria. The GBM is a special kind 
of acellular extracellular matrix, having properties of a viscous gel. The filtration barrier 
behaves as a selective sieve restricting the passage of macromolecules on the basis of their 
size, shape, and charge. Deterioration of the integrity of the GBM results in mild proteinuria. 
The major constituent of GBM is type IV collagen, which together with laminin, nidogen, 
and sulfated proteoglycans maintains the filtration barrier and provides the substrata and 
signals necessary for proper renal cell function (Hudson & Tryggvason 2003). 
Mutations present in Alport syndrome that produce post-translational defects in 3(IV), 
4(IV), or 5(IV) chains may result in incorrect folding or assembly of monomers. Such 
defective monomers are rapidly degraded. The mutations, therefore, arrest the normal 
developmental maturation during the fetal 2nd trimester period when the 1.1.2(IV) 
network is largely replaced by the 3.4.5(IV) network in the GBM. This maturation may 
be related to oxidative and physical stress in GBM (Kalluri et al., 2000) and perhaps also in 
the cochlea (Huang et al., 2000) and the lens capsule (Reddan et al., 1996). In the kidney, as 
plasma traverses glomerular capillaries, the protein content, including the levels of serum 
proteases, increases. The embryonic 1.1.2(IV) network is more susceptible to 
endoproteolysis than the more heavily cross-linked 3.4.5(IV) network (Kalluri et al 
1997). It seems, then, that GBM that is more exposed to proteases or oxidants needs the 
protection of a resistant collagen IV network. Over time, patients with Alport syndrome 
probably become more sensitive to proteolysis, which may explain why their glomerular 
membranes thicken unevenly, split, and ultimately deteriorate (Kalluri et al., 1997, Kalluri et 
al., 2000). Immunohistochemical studies show that mutations in the COL4A5 gene, which 
cause the X-linked form of Alport syndrome, frequently result in the loss of all three of the 
3(IV), 4(IV) and 5(IV) chains in the GBM (Naito et al., 1996, Naito et al., 2003, Yoshioka 
et al., 1994). Thus, the absence of a functionally normal 5(IV) chain can disrupt assembly of 
the triple-helical protomer, and frequently leads to loss of the entire 3.4.5(IV) network in 
the GBM. 
Mutations involving the NC1 domain of COL4A5 result in no or severely reduced 
3.4.5(IV) protomer formation within cells and/or in failure of secretion from cells 
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The remaining 15% of Alport syndrome patients show autosomal inheritance; of these 14% 
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(Kobayashi  T et al., 2008, Kobayashi & Uchiyama 2010). In the normal process of formation 
of the type IV collagen network, the NC1 domain plays an important role in forming 
protomers as three chains specifically interact with each other. Additionally, in forming 
NC1 hexamers, two protomers dimerize at the C-terminus. Defective monomers or 
protomers of type IV collagen networks may be degraded rapidly. 
4. Genotype-phenotype correlation in X-linked Alport syndrome 
Approximately six hundred mutations in COL4A5 have been reported, 588 of which are 
causally linked with X-linked Alport syndrome (Arup Laboratories 2011). Considerable 
allelic heterogeneity is observed by the high number of mutations and the associated 
phenotypic variability. Clinically the natural history of the nephropathy and other extra-
renal lesions are quite variable. A number of researchers have attempted to link genotypes 
in Alport syndrome to phenotypes (Bekheirnia et al., 2010, Gross et al., 2002, Jais et al., 2000). 
Gross and colleagues have proposed a classification linking phenotype and genotype into 
three categories (Gross et al., 2002).  
 Type S (severe); genotypic alterations in COL4A5 include major gene rearrangements, 
premature stop codons, frameshift mutations, and donor splice site alterations. Also 
includes mutations involving the NC1 domain. The phenotype is characterised by early 
onset of ESRF at about 20 years of age and significant extra-renal manifestations 
including 80% with sensorineural deafness and 40% with ocular lesions. 
 Type MS (moderately severe). The genotype in this group is characterised by non-
glycine-XY missense alterations, in-frame deletions/insertions, acceptor splice site 
changes and glycine-XY substitutions involving exons 21-47. This type is associated 
with ESRF appearing in the mid-twenties with about 65% of individuals having hearing 
loss and 30% ocular defects. 
 Type M (moderate). The genotype is glycine-XY substitutions involving exons 1-20. The 
phenotype appears to be milder with a later onset of ESRF at about 30 years of age, 
including a significant number of individuals with sensorineural deafness (70%) and 
ocular lesions (30%). 
Bekheirnia and colleagues have confirmed previous reports (Gross et al., 2002, Jais et al., 
2000) in that there is a strong genotype-phenotype correlation in X-linked Alport 
syndrome (Bekheirnia et al., 2010). The authors conclude that missense mutations are 
associated with the best prognosis with an average age at onset of ESRF of 37 yr, followed 
by splice site mutations at 28 yr, truncating mutations at 25 yr and small deletions at 22 
yr. The authors also point out a strong relationship between mutation position and age 
onset of ESRF, with younger ages at onset of ESRF associated with the 5' end of the gene. 
Affected males with splice mutations or truncating mutations showed two-fold greater 
odds of developing eye problems and hearing loss than those with missense mutations. 
Mutations associated with hearing loss and ocular changes are located closer to the 5' end 
of the gene.  
5. Mild forms of Alport syndrome 
While many affected males of X-linked Alport syndrome show moderate to severe forms 
of nephropathy and extra-renal abnormalities between the second and third decades, it is 
also well known that there are occasional milder cases where ESRF may be delayed until 
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the fifth or sixth decade along with variable age occurrence of deafness (Bekheirnia et al., 
2010, Kobayashi et al., 2008, Smeets et al., 1992). Of the six hundred or so COL4A5 
mutations that have been reported to date (Arup Laboratories 2011), 588 mutations were 
pathogenic for X-linked Alport syndrome, whereas 12/600 mutations were benign (silent). 
A total of 81/588 mutations (13.8%) were associated with a mild form of Alport syndrome 
where the age of onset of ESRF was over 30 yr old. These 81 mutations of a mild form are 
shown in Figure 2 and consist of 66 mutations within exons (red column) and 15 
mutations within introns (blue column), widely distributed over the COL4A5 gene. It 
appears that mutations involved in a mild form of Alport syndrome are widely 
distributed within 51 exons of the COL4A5 gene with a tendency for more mutations 
between Exon 25 to 51. 
 
 
Fig. 2. Distribution and frequency of mutations in exons (red column) and introns (blue 
column) within the COL4A5 gene causally relating to X-linked Alport syndrome (Arup 
Laboratories 2011). 
6. A unique mild form of Alport syndrome in New Zealand families 
We previously described a novel Cys1638Tyr alteration in the NC1 domain of COL4A5 
identified in a large New Zealand family (Fig 3) with a hereditary nephropathy (Wilson et 
al., 2007). This family was identified when two sisters (IV26 and IV28) presented to the clinic 
to be considered as potential live kidney donors for their sons (V29 and V35, respectively) 
who had ESRF (see Tables 1 and 2). Both women were found to have significant proteinuria 
and hypertension and so it was decided to carry out renal biopsies. Following the results of 
the biopsies each family member was then evaluated for the presence of renal disease as 
indicated in Table 1, and only three male members of the extensive pedigree were found to 
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exhibit ESRF. Extra-renal manifestations such as sensorineural deafness or ocular changes 
were not observed in any family member. Further renal biopsies were carried out on 
additional family members, so that renal biopsies now totalled eight members of the family. 
The biopsies from a 39 year-old male with proteinuria of 1.1 g/24h and normal auditory and 
eye examination (V42) showed mild increase of mesangial matrix and mild periglomerular 
Bowman capsular fibrosis (Fig 4A). There were occasional areas showing focal interstitial 
accumulation of foam cells (Fig 4B), interstitial fibrosis (Fig 4C) and thick-wall hyalinized 
vessels surrounded by scattered aggregates of lymphocytes (Fig 4D).  
 
 
Fig. 3. Family pedigree. A simplified pedigree of the family showing males (squares) and 
females (circles) depicted by generation (I-V) is shown. While the disease appears severe in this 
pedigree, the extended pedigree was published previously (Wilson et al., 2007), and only 
32/155 members of the extended pedigree are shown in this diagram. Some of the individuals 
indicated in Tables 1 and 2 are represented in this pedigree and are identified in each case by 
their corresponding number. Black symbols indicate individuals with biopsy-confirmed GN. 
Black dots inside the symbols indicate obligate carriers. Grey symbols indicate individuals who 
were not biopsied, with  clinical manifestations of renal disease and therefore presumed GN. 
Open symbols indicate individuals without clinical signs of renal disease. X chromosome region 
markers (Xq21.33-Xq23) informative for linkage analysis are indicated on the right, and shown 
below the symbols are the genotypes for each individual that are associated with the relevant 
marker. The boxed region indicates a common haplotype inherited from the father or the mother, 
corresponding to genotypes of the 3 markers that segregate with the disease. The genomic region 
of chromosome X corresponding to this haplotype contained the COL4A5 gene locus. 
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Table 1. Renal disease identified prior to mutation screening in the New Zealand family 
Electron microscopy of a renal biopsy from (V42), of which histology is shown in Fig 4, 
demonstrated a classical basket weave pattern or splitting of the basement membrane 
characteristic of Alport syndrome (Fig 5A and 5B). However, a diagnosis of Alport 
syndrome was not necessarily an obvious diagnosis in this family, since the disease in all 
three males was relatively mild and there was a lack of extra-renal manifestations in any of 
the family members, raising some doubts as to whether this was Alport syndrome prior to 
carrying out genetic analysis. 
To determine the genetic cause of the disease in this family, genomic DNA was isolated 
from whole blood of each of the family members, and used in linkage analysis with genetic 
markers spanning chromosome X carried out as described in Wilson et al (2007). Strong 
evidence for linkage to markers DXS6789, DXS8096, DXS1210, adjacent to the COL4A5 (and 
COL4A6) genes located on chromosome X was obtained, indicating that this corresponded 
to a collagen nephropathy in the family, and that it was most likely due to a mutation in 
COL4A5. 
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Table 2. Renal disease or carrier status identified after mutation screening in the NZ family 
 





Fig. 4. Histological findings of the kidney of a patient, 39 yr old male with hematuria, 
proteinuria 1.1 g/24h and normal auditory and eye examination. (A) Glomerulus from 
kidney biopsy of this patient showing mild periglomerular fibrosis and mild mesangial 
matrix increase. Tubular atrophy is seen at the right upper corner. (B) Focal accumulations 
of foam cells in the interstitium. (C) Multiple focal areas of interstitial fibrosis associated 
with atrophic tubules. (D) Sclerosed vessels surrounded by lymphocytes.  
Eventually the mutation, comprising a c.4913G>A nucleotide substitution in exon 50 of 
COL4A5, was identified by PCR amplification and sequenced following analysis using a 
series of primer pairs corresponding to each of the 51 exons making up the COL4A5 
transcript (Genbank accession number NM_000495) as well as the entire promoter region 
between COL4A5 and COL4A6. Therefore, this analysis conclusively showed that the disease 
in this family was a mild form of Alport syndrome. 
Since it is known that most cases of Alport syndrome result in loss of the synthesis or 
secretion of the collagen protein and/or protomer, which can be detected by the absence of 
the collagen staining by immunohistochemistry, in order to further understand whether the 
pathogenesis of this disease in the New Zealand family was due to the loss of synthesis of 
COL4A5, immunohistochemical studies of the 1 to 5 type IV collagens in kidney biopsies 
from affected and carrier individuals were carried out. This analysis showed that in affected 
men (V31, V35 and V42) and carriers (IV26 and IV28) the GBMs were positive for  to 5 
type IV collagens, as exemplified in Fig 6 (3, 4 and 5). These findings were considerably 
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syndrome was generally found to result in the loss of all three of the 3(IV), 4(IV) and 




Fig. 5. Electron microscopy of glomerular basement membranes of the same patient (V42) of 
Figure 4. (A) Characteristic splitting or basket weave appearance of GBM (arrows) and 
abnormal podocyte foot processes. (original magnification x9,700). (B) Higher magnification of a 
basket weave appearance. (original magnification x13,500). Note, the ultra-structural changes in 
the glomerular basement membrane of patients with Alport syndrome were variably associated 
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Fig. 6. Immunohistochemistry using monoclonal antibodies against V collagen in a kidney 
biopsy shows 3, 4 and 5 positivity in the GBM.  
Unlike most other reports of Alport syndrome, and inconsistent with the disease severity 
and multi-organ involvement that is generally associated with NC1 mutations, the major 
manifestation of the renal abnormality in the New Zealand family was proteinuria, which 
occurred in six of the nine male members who carried the COL4A5 mutation. Only three of 
the nine males in the family who inherited the mutation presented with glomerulonephritis 
and ESRF.  
The NC1 domain plays an important role in the selection of  chains for assembly into 
heterotrimers. In general, substitution and missense mutations in the NC1 domain, as in 
other regions of COL4A5, lead to hematuria, proteinuria, ESRF and sensorineural hearing 
loss with an overwhelming predominance in males (Barker et al., 1996, Barker et al., 1997, 
Gross et al., 2002, Hertz et al., 2001, Inoue et al., 1999, Knebelmann et al., 1996, Nakanishi et 
al., 1994, Netzer et al., 1996, Zhou et al., 1991). A previous study classified X-linked Alport 
syndrome patients caused by mutations involving the NC1 domain into Type S (severe) 
phenotype (Gross et al., 2002). Mutations involving other cysteine residues in the NC1 
domain have also been reported and include C1486S (Zhou et al., 1991), C1567R 
(Knebelmann et al., 1996) and C1586R (Hertz et al., 2001) and others (see Figure 7).  
Using the proposed classification suggested by Gross and colleagues, the New Zealand 
family would be placed in ‘type S’ on the basis of the mutant genotype involving the NC1 
domain. However, none of the family members had a phenotype as severe as reported 
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disease in the affected male members of the New Zealand family was relatively late. The 
lack of extra-renal manifestations in the males is also contrary to previous reports 
correlating NC1 mutations with 'type S' Alport syndrome.  
Therefore, while NC1 domain mutations in COL4A5 are thought to be associated with 
severe forms of Alport syndrome, the pattern of disease in this family was comparatively 
mild, and only 27% of the affected or presumed obligate mutant males in the family 
developed end-stage renal disease. Indeed, considerable variability and phenotypic 
heterogeneity in the extent of renal disease was observed in the affected males and carrier 
females. For example, one family member, a 72 year-old male (IV39) shown in Table 2, was 
later found to carry the sequence alteration, and was initially apparently phenotypically 
unaffected, but then further investigation revealed proteinuria (1.6g/24h) and hypertension. 
This man was not biopsied. Furthermore, the presentation of ESRF in one female carrier in 
this study (III2) leads to the conclusion that female carriers were also affected. Skewed 
inactivation of the X chromosome could account for this, although other genetic or 
environmental factors, such as hypertension, could also be contributing factors to the 
variability in disease progression. This amount of phenotypic variation between males and 
females is unusual in Alport syndrome, and even more unusual is the fact that none of the 
family members exhibited the full spectrum of renal, auditory and ocular abnormalities 
typifying Alport syndrome. The inheritance pattern was clearly consistent with an X-linked 
dominant mode, albeit with reduced penetrance, as the linkage analysis, together with the 
scan of the entire COL4A5 gene for the mutation, clearly identified that the NC1 domain 
mutation identified in COL4A5 was the causative mutation in this family.  
The Cys1638Tyr alteration in the New Zealand family is predicted to affect the 10th 
conserved cysteine residue among 12 cysteine residues in the NC1 domain, thus disrupting 
the disulfide bond linking the C-terminal ’-’ hairpin (Fig 7). In the kidney GBM the ’ 
to ’ disulfide-bridge could be involved in inter-molecular rather than intra-molecular 
interactions. For example, inter-protomer disulfide cross-links, or interactions with other 
molecules, such as integrins could involve formation of disulfide linkages to the cysteine 
residues at positions 66, 72, 177 or 183 in the N-terminal or C-terminal - sheets in the 
type IV collagen NC1 domain. 
During protomer assembly the NC1 domains of the 3(IV),4(IV) and 5(IV) chains 
specifically interact to select chains for triple-helix formation. In Alport syndrome, NC1 
domain cysteine substitutions (see Figure 7) are thought to affect the folding of the 
monomeric NC1 domain, preventing its participation in trimer assembly. The NC1 domain 
is also important for network assembly, whereby the NC1 trimers of two protomers 
specifically interact forming a NC1 hexamer. Variants that result in a loss of, or a defect in 
any of the 3(IV), 4(IV), or 5(IV) chains result in incorrect folding or assembly of the 
entire protomer leading to a complete absence of the 3.4.5(IV) network from the GBM. 
However in kidney biopsies from affected patients in this family the 3(IV), 4(IV) and 
5(IV) collagens were still present in the GBM, implying that the p.Cys1638Tyr alteration 
must still allow for the correct assembly of the triple helical protomer. It is possible, 
however, that an organ-specific defect in protomer function rather than assembly could 
explain the lack of sensorineural hearing loss or ocular defects in this family, although it 
remains to be determined whether the p.Cys1638Tyr variant could indeed disrupt the 
dimerization of two protomers at the C-terminus, thus affecting network assembly. 
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Further to the New Zealand family, there have been 7 other mutations involving cysteine 
residues in the NC1 domain (Bekheirnia et al., 2010, Gross et al., 2002, Hertz et al., 2001, 
Inoue et al., 1999, Knebelman et al., 1996, Wang et al., 2005., Wilson et al., 1997, Zhou et al., 
1991) affecting males and females (Figure 7). These mutations are shown together with 
information of age at the time of diagnosis. From refs 2, 3, 6, 7 and 8 patients were detected 
during the ages of 6–16 yrs while one was at 31 yrs old. From refs 3 and 2 two males showed 
ESRF at 14 and 16 yr old, respectively. When clinical information was available, all of the 
affected individuals appeared to show hearing loss, except for three individuals who had 
mutations involving C226 (Wang et al, 2005), C177 (Bekheirnia et al., 2010) and C183 
(Wilson et al., 2007). The latter report is our own New Zealand family described here. 
Patients with other mutations of the NC1 domain either lacked a5(IV) in the GBM, or  were 
clinically more severe than the patients with the C177 and C183 mutations, both of which, 
interestingly involved mutations in the same disulfide linkage.  
 
 
Fig. 7. Depiction of NC1 domain showing locations of cysteine sequence alterations, and the 
clinical details of patients. Shown are the positions of the beta sheet domains (1-6, 1’-6’), 
and alpha helix (1, 1’) and cysteine residues arranged linearly, and their disulfide 
linkages. Cysteine residue missense mutations of the NC1 domain that have been previously 
reported are shown (^), together with the cysteine mutation in the New Zealand family ( 
under cysteine 183; amino acid numbering in this figure is from the start of the NC1 domain, 
which is one amino acid longer than in our previous report (Wilson et al, 1997). ND, not 
determined. +, characteristic is present. -, characteristic is absent. M, male, F, female. Refs; 1 
(Zhou et al., 1991); 2 (Knebelmann et al., 1996); 3 (Hertz et al., 2001); 4 (Bekheirnia et al., 
2010); 5 (Wilson et al., 1997); 6 (Gross et al., 2002), 7 (Inoue et al., 1999); 8 (Wang et al., 2005). 
Kobayashi and colleagues constructed a plasmid containing mutations corresponding to a 
variety of missense or deletion mutations of the NC1 domain of COL4A5, which were grown 
in a kidney cell line. The results showed that mutations render the collagen chain defective 
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in terms of heterotrimer formation between the 3, 4 and 5 collagen chains, and/or the 
secretion of the heterotrimer from cells (Kobayashi et al., 2008). After our publication, these 
researchers further constructed a plasmid containing the mutation corresponding to 
Cys1638Tyr into the 5(IV) chain. The results of this experiment showed that heterotrimer 
formation in the cells and secretion of the 5(IV) chain in the monomeric form from the cells 
were markedly decreased compared to cells containing the wild-type chain. However, the 
heterotrimer that was formed from the mutant chain was still secreted from the cells. They 
concluded that the residual ability of the mutant chain to form and be secreted may have led 
to the unique mild phenotype formed in the Alport syndrome family with the Cys1638Tyr 
mutation (Kobayashi & Uchiyama 2010).  
7. Renal lesions in carrier women of X-linked Alport Syndrome and Thin 
Basement Membrane Nephropathy 
Thin basement membrane nephropathy (TBMN) is the most common cause of inherited 
renal disease and its incidence has been reported to be as high as 1% of the world 
population (Kashtan 2005, Tazon et al., 2003, Wang & Savige 2005). It is defined as diffuse 
thinning of the GBM characterised by persistent glomerular hematuria, minimal proteinuria, 
and normal renal function. Genetic studies of TBMN have helped to establish that many 
patients with benign familial hematuria are actually the carriers of autosomal recessive 
Alport syndrome, carrying mutations only in the one allele of COL4A3 or COL4A4 
(Voskarides et al., 2008). A novel missense mutation of COL4A3 in a Chinese Han 
consanguineous family was identified and the underlying pathogenic role in the 
homozygous form was investigated in autosomal recessive Alport syndrome and in the 
hetrozygous form in TBMN within the identical family (Hou et al., 2007). These studies 
showed that while TBMN manifest as a dominant disorder in the family with the COL4A3 
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was approximately 150 nm, and much thinner than the normal GBM (300-400 nm). Another 
carrier woman also showed focal areas of severely thin GBM (Fig 9B). In addition there were 
occasional regional areas of thick segments of GBM (Fig 9C). It is notable that the typical 
basket weave appearance or splitting was not present in the females. One message to take 
from these studies is that electron microscopic examination of the kidneys in carrier women 
with clinical symptoms should be mandatory because the light microscopic observations on 
their own often provide unremarkable findings or only subtle changes and may not show a 
full range of pathology. 
Although TBMN has been regarded as a benign condition with an excellent prognosis, as 
high as 38% of COL4A3/COL4A4 heterozygous mutant carriers, of all ages, develop chronic 
renal failure and 19.5% progress to ESRF (Voskarides et al., 2008). These authors emphasize 
a strong association between TBMN and focal segmental glomerulosclerosis (FSGS). Several 
studies report that TBMN predisposes to premature glomerular obsolescence and that this 
may then lead to late onset renal insufficiency followed by ESRF (Nieuhof et al., 1997, 
Nogueira et al., 2000). Other studies suggest that there may be other factors that predispose 
transition from TBMN to FSGS (Sue et al., 2004). These factors could be due to involvement 
of modifier genes such as podocyte specific genes or environmental factors.  
These findings concur with a previous report (Jais et al., 2003) in that hematuria was 
observed in 95% of 323 female carriers of X-linked Alport syndrome. Proteinuria, hearing 
loss, and ocular defects also developed in 75%, 28%, and 15%, respectively. Moreover, the 
probability of developing ESRF or deafness before the age of 40 yr was 12% and 10%, 
respectively, in females versus 90% and 80%, respectively in men. In their study 
ultrastructural change of the GBM were found in 26 of 28 carriers and consisted of typically 
thick and split or alternatively thick and thin GBM in 19 patients. When taken together, our 
results and those of Jais et al (2003) suggest that TBMN may frequently develop in carrier 
women with a heterozygous COL4A5 mutation.  
8. Conclusions  
In conclusion, mild forms of Alport syndrome may occur in association with certain 
mutations in the collagenous domain of the collagen proteins. In addition, we showed a 
p.Cys1638Tyr mutation occurring within the NC1 domain of COL4A5 in a New Zealand 
family was associated with a mild form of Alport syndrome. Mild forms of Alport 
syndrome also occur in females with COL4A5 mutations, in whom there is considerable 
phenotypic variation. In particular, it appears that electron microscopy carried out in female 
carriers of COL4A5 mutations reveals much more about the health of their kidneys than 
does routine light microscopy alone. The abnormalities present in the kidneys of female 
carriers suggest that with appropriate management of diet and hypertension this could 
prevent the onset of renal disease in these women. Additional investigations of the 
pathogenic role of COL4A5 mutations in female members of Alport families, and of the role 
of the NC1 domain in the New Zealand family, will further help to better understand the 
role of collagens in the structure and function of the filtration barrier in the GBM. 
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1. Introduction 
Worldwide research has shown that racial differences occur with regard to the histological 
subtypes, response to treatment and outcome of idiopathic nephrotic syndrome (INS) in 
children (Bhimma et al. 2006:1847; Bhimma, R. 2009:15; Ingulli &Tejani 2001:393). Several 
reasons have been suggested to explain these differences such as a higher prevalence of 
infections, lower socio-economic status and inequalities in access to health care resources, 
genetics, and environmental factors but none of these have been substantiated by data. 
Results from the International Study of Kidney Disease in Children (International Study of 
Kidney Disease in Children ISKDC 1978:159) showed that the majority of children with INS 
have minimal change nephrotic syndrome (MCNS) which responds to corticosteroid 
treatment and that a kidney biopsy is not indicated. Based on these findings empiric 
corticosteroid treatment was recommended, without performing a kidney biopsy. The study 
population consisted of predominantly white children from North America, Europe and 
Asia. These recommendations have been implemented worldwide as standard of care for 
the past 40 years despite the lack of prospective renal biopsy studies to substantiate this 
recommendation and which may not be applicable to other settings with a predominance of 
black patients. An increasing incidence of focal segmental glomerulosclerosis (FSGS) in 
children and adults with INS has been reported recently (Borges et al. 2007:1309; Filler et al. 
2003 :1107; Srivastava et al. 1991:13). Studies reporting the outcome of INS associated with 
FSGS are variable, which is not surprising, as differences in the population mix, aetiology, 
pathogenesis and duration of disease are often not taken into consideration. This begs the 
question whether the recommendation of the International Study of Kidney Disease in 
Children for the management of INS should still be adhered to. Or should it be revised 
taking into consideration different racial groups? On the other hand, in the light of the rising 
incidence of FSGS, it may be prudent to withdraw the recommendation. 
Paediatric nephrologists from developing countries, and specifically Africa, need to formulate 
guidelines specific to their patients with INS. To this end, relevant clinical characteristics such 
as the antenatal and family history, birth weight, feeding and nutrition, growth and onset of 
disease should be documented and analysed in their reports. Low birth weight (LBW) which 
has been shown to be associated with decreased glomerular endowment (Manalich et al. 
2007:770, Vehaskari , VM. 2007:490) and subsequent increased risk for the development of 
chronic kidney disease (CKD), is a case in point, since it is more common in impoverished 
population groups living in Africa. However, most publications describing the influence of 
LBW on CKD come from developed countries. (Teeninga et al. 2008:1615)  
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Limited resources are often the stumbling block for clinicians in developing countries. For 
the standard care of a child with INS the minimum investigations necessary in the work-up 
include urine biochemistry, urine microscopy and investigations to exclude infectious and 
immune disorders. A kidney biopsy is recommended for all children and should include 
light microscopy, immuno-histochemistry or immunofluorescent studies and electron 
microscopy. These investigations are costly, but essential to make a definitive diagnosis. 
Without a specific diagnosis of the underlying pathology and the associated complications it 
will not be possible to make reliable recommendations for targeted treatment in a child with 
INS in a developing country. 
2. Aim 
The aim of the study is to describe the clinical characteristics, histological subtypes, response 
to treatment and outcome of children with INS treated at the paediatric renal unit of the 
Steve Biko Academic Hospital (SBAH). This is a level 3 South African hospital, affiliated to 
the University of Pretoria and the referral centre for the surrounding multiracial population 
of roughly 5 million children under the age of 14 years. 
3. Methods 
A retrospective audit was performed of consecutive children admitted with a clinical diagnosis 
of INS. The latter was defined as ≥2+ proteinuria on a urine dipstick test, hypoalbuminaemia 
of <25 g/L and oedema. Children who had macroscopic haematuria (red or brownish 
discolouration of urine) substantiated by >2+ blood on a urine dipstick test and hypertension 
in addition to the criteria for INS, were also included and were categorised as nephritic-
nephrotic. Hypertension was diagnosed according to the 4th Report of the National High Blood 
Pressure Education Program Working Group on High Blood Pressure in Children and 
Adolescents. (The Fourth Report of the National High Blood Pressure Education Program 
Working Group on High Blood Pressure in Children and Adolescents. 2004:555).  
The racial groups were documented as black, white, Indian, and mixed. The Indian and 
white racial groups were pooled and categorised as white. The black and mixed racial 
groups were similarly pooled and categorised as black. This grouping was done because of 
known similarities in clinical presentation, response to treatment and outcome in the 
respective groups. (Bhimma et al.1997:429). 
The clinical characteristics analysed were age at presentation, gender, anthropometry 
(height/length for age and weight for age), and blood pressure.  
The following investigations were analysed: urine dipstick tests, urine protein:creatinine 
ratio (mg/mg), s-albumin and s-cholesterol, s-creatinine and estimated glomerular filtration 
rate (eGFR) in ml/min/1.73m2. eGFR was calculated using a modified Schwartz formula 
(Schwartz. et al. 1987:571), i.e.: [40 x height (cm)/s-creatinine (µmol/L)]. Kidney function at 
presentation was categorised according to the National Kidney Foundation Kidney Disease 
Outcomes (K/DOQI clinical practice guidelines 2002:S1). Investigations to rule out 
secondary nephrotic syndrome include: the third and fourth components of complement 
(C3 and C4), immunologic tests for systemic lupus erythematosus (antinuclear antibodies 
and anti-double-stranded DNA antibodies), antistreptolysin O and anti DNase B titers, 
hepatitis B and C serology, cytomegalovirus (CMV) antibodies and HIV enzyme-linked 
immunosorbent assay (ELISA). 
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The indications for a kidney biopsy were: a family history of kidney disease, congenital and 
infantile nephrotic syndrome, children with clinical features suggestive of nephrotic 
syndrome (NS) other than MCNS, children who failed to respond to an 8-week course of 
corticosteroids, prior to the administration of cyclophosphamide, children with persisting 
elevated s-creatinine levels and all black children.  
4. Treatment  
The mainstay of treatment was corticosteroids with the aim to achieve and maintain 
remission rather than adhering to a standardised protocol. For this reason a higher dose and 
a longer course were used (daily dose versus alternate day treatment) compared to the 
ISKDC guidelines (International Study of Kidney Disease in Children 1978:159). The 
primary contraindications for corticosteroid treatment were children with CNS, secondary 
NS (e.g. hepatitis B associated nephropathy, Henoch-Schőnlein purpura), children with 
CKD Stage 3 or more associated with stunting and wasting, cardiomegaly, anaemia and 
bone mineral disease and presumably immune-compromised children.  
Second line immunosuppressive therapy was initiated in a selective group of children, 
influenced by compliance and socio-economic factors, and only after parental consent had 
been obtained. Indications for second line immunosuppressive therapy included children 
with steroid dependent or frequently relapsing NS, those who developed secondary steroid 
resistance and a selective group of children with partial response. Exclusion criteria for 
cyclophosphamide treatment included children with underlying chronic infections, e.g. 
untreated Mycobacterium tuberculosis or HIV infection and those at increased risk of 
developing acute or chronic infections due to poor nutritional status.  
4.1.1 Corticosteroid treatment 
Prednisone was administered as a single daily dose at 2 mg/kg/day and tapered to 1 
mg/kg/day after 4 weeks in children who responded and achieved remission. Further 
tapering was only initiated after another 4 weeks and treatment stopped after a total of 20 
weeks. For those who had not responded to corticosteroid treatment at a dose of 2 
mg/kg/day by the 4th week – which occurred commonly in the event of black children - 
this high dose was continued for a maximum of 8 weeks when the dose was tapered 
according to the response of the child.  
Response to treatment was classified as: remission, partial response and steroid resistant. 
Remission was defined as no or trace proteinuria on dipstick test for three consecutive days 
or urine protein:creatinine ratio of <0.2 mg/mg. Relapse was defined as proteinuria of ≥ 2+ 
on dipstick test for three consecutive days or urine protein:creatinine ratio of ≥ 2.0 mg/mg. 
Partial response was defined as  2+ proteinuria on urine dipstick or urine 
protein:creatinine ratio < 2.0 mg/mg after a maximum of 8 weeks of high dose steroid 
treatment (2 mg/kg/day). Steroid resistance was defined as persistent proteinuria ≥2+ and 
urine protein:creatinine ratio ≥ 2.0 mg/mg after a maximum of 8 weeks of high dose steroid 
treatment (2 mg/kg/day). Steroid dependence was defined as relapse when the dose of 
corticosteroid treatment was decreased or within two weeks after stopping it. Frequent 
relapse was defined as ≥2 relapses per 12-month period. 
4.1.2 Cyclophosphamide treatment  
The total course of oral cyclophosphamide for an individual child was calculated as  
168 mg/kg over 8 or 12 weeks administered as 3 mg/kg/day for 8 weeks or 2 mg/kg/day 
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Outcomes (K/DOQI clinical practice guidelines 2002:S1). Investigations to rule out 
secondary nephrotic syndrome include: the third and fourth components of complement 
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The indications for a kidney biopsy were: a family history of kidney disease, congenital and 
infantile nephrotic syndrome, children with clinical features suggestive of nephrotic 
syndrome (NS) other than MCNS, children who failed to respond to an 8-week course of 
corticosteroids, prior to the administration of cyclophosphamide, children with persisting 
elevated s-creatinine levels and all black children.  
4. Treatment  
The mainstay of treatment was corticosteroids with the aim to achieve and maintain 
remission rather than adhering to a standardised protocol. For this reason a higher dose and 
a longer course were used (daily dose versus alternate day treatment) compared to the 
ISKDC guidelines (International Study of Kidney Disease in Children 1978:159). The 
primary contraindications for corticosteroid treatment were children with CNS, secondary 
NS (e.g. hepatitis B associated nephropathy, Henoch-Schőnlein purpura), children with 
CKD Stage 3 or more associated with stunting and wasting, cardiomegaly, anaemia and 
bone mineral disease and presumably immune-compromised children.  
Second line immunosuppressive therapy was initiated in a selective group of children, 
influenced by compliance and socio-economic factors, and only after parental consent had 
been obtained. Indications for second line immunosuppressive therapy included children 
with steroid dependent or frequently relapsing NS, those who developed secondary steroid 
resistance and a selective group of children with partial response. Exclusion criteria for 
cyclophosphamide treatment included children with underlying chronic infections, e.g. 
untreated Mycobacterium tuberculosis or HIV infection and those at increased risk of 
developing acute or chronic infections due to poor nutritional status.  
4.1.1 Corticosteroid treatment 
Prednisone was administered as a single daily dose at 2 mg/kg/day and tapered to 1 
mg/kg/day after 4 weeks in children who responded and achieved remission. Further 
tapering was only initiated after another 4 weeks and treatment stopped after a total of 20 
weeks. For those who had not responded to corticosteroid treatment at a dose of 2 
mg/kg/day by the 4th week – which occurred commonly in the event of black children - 
this high dose was continued for a maximum of 8 weeks when the dose was tapered 
according to the response of the child.  
Response to treatment was classified as: remission, partial response and steroid resistant. 
Remission was defined as no or trace proteinuria on dipstick test for three consecutive days 
or urine protein:creatinine ratio of <0.2 mg/mg. Relapse was defined as proteinuria of ≥ 2+ 
on dipstick test for three consecutive days or urine protein:creatinine ratio of ≥ 2.0 mg/mg. 
Partial response was defined as  2+ proteinuria on urine dipstick or urine 
protein:creatinine ratio < 2.0 mg/mg after a maximum of 8 weeks of high dose steroid 
treatment (2 mg/kg/day). Steroid resistance was defined as persistent proteinuria ≥2+ and 
urine protein:creatinine ratio ≥ 2.0 mg/mg after a maximum of 8 weeks of high dose steroid 
treatment (2 mg/kg/day). Steroid dependence was defined as relapse when the dose of 
corticosteroid treatment was decreased or within two weeks after stopping it. Frequent 
relapse was defined as ≥2 relapses per 12-month period. 
4.1.2 Cyclophosphamide treatment  
The total course of oral cyclophosphamide for an individual child was calculated as  
168 mg/kg over 8 or 12 weeks administered as 3 mg/kg/day for 8 weeks or 2 mg/kg/day 
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for 12 weeks (=168 mg/kg). Cyclophosphamide tablets are sugar coated and contain 50 mg 
cyclophosphamide/tablet. It cannot be crushed or divided. The dose to be taken per 7-day 
week was therefore calculated for each patient and was limited to a maximum dose of  
3 mg/kg/day. Tablets were administered for fewer than seven days per week for smaller 
patients weighing less than 25 kg who required <50 mg/day (i.e. no treatment on weekend 
days).  
A kidney biopsy was performed in all children before cyclophosphamide treatment was 
initiated. No child received a second course of cyclophosphamide.  
4.1.3 Intravenous methylprednisolone pulse treatment 
A course of intravenous methylprednisolone was administered in three scenarios, i.e. 
children with anasarca and who were resistant to their first course of oral corticosteroid 
treatment, children who became steroid dependent or developed frequent relapses after 
having had a course of cyclophosphamide treatment and children with partial response to 
oral corticosteroid and cyclophosphamide treatment. Selection of patients for this form of 
treatment was further influenced by their ability or willingness to frequently return to the 
hospital and by the absence of recurrent infections.  
Intravenous corticosteroid treatment consisted of methylprednisolone 30 mg/kg/dose 
(maximum dose of 1000 mg) administered according to established guidelines (Mendoza et 
al 1990:303), but excluding cyclophosphamide treatment (Table 1).  
It was discontinued when a patient experienced unacceptable adverse effects, e.g. 
progressive fluid retention or volume overload, with worsening hypertension or when 
proteinuria remained unchanged after 6 to 8 weeks.  
 






30 mg/kg thrice weekly 
30 mg/kg per week 
30 mg/kg per 2 weeks 
30 mg/kg per 4 weeks 







2 mg/kg/day b 
1.5mg/kg/day tapered slowly 
1 mg/kg/day tapered slowly 
0.5mg/kg/day tapered slowly 
a = Maximum dose 1000 mg 
b = Maximum dose 60 mg 
Table 1. Intravenous methylprednisolone (M-P) pulse regimen 
4.1.4 Adjunctive treatment  
Adjunctive treatment included diuretics for symptomatic management of oedema, 
antihypertensive drugs, multivitamin and folic acid supplementation, alpha-calcidol for 
children on high-dose corticosteroid treatment and with persisting nephrotic-range 
proteinuria. Treatment with an angiotensin converting enzyme inhibitor (ACE-inhibitor) 
was given for its antiproteinuric effect to alleviate persistent proteinuria and as an 
antihypertensive drug if needed. Other antihypertensive drugs used included a β-blocker 
(atenolol), calcium antagonist (amlodipine), α-blocker (prazosin) and a vasodilator 
(hydralazine). Angiotensin receptor blockers were not prescribed because of 
unavailability. 
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Diuretics of all classes, namely furosemide, hydrochlorothiazide and spironolactone were 
used in combinations if needed for children with diuretic-resistant NS. Hydroxy-
methylglutharyl coenzyme A reductase inhibitors (statins) were selectively prescribed to 
children older than 5 years with persistent NS associated with an elevated total cholesterol 
level of >10 mmol/L. All children received a diet containing reduced salt and saturated fat. 
Protein intake was not restricted.  
5. Ethical approval 
The study was approved by the University of Pretoria Research Ethics Committee and 
permission was obtained from the chief executive officer of the hospital to access hospital files.  
6. Statistical analysis 
Categorical data was reported as proportions and quantitative data as means (standard 
deviations) and medians (range).  
Frequencies of variables within groups were compared using the two-sided Fisher exact test 
and a p-value <0.05 was regarded as significant. Renal and patient survival in the two 
population groups were assessed using Kaplan Meier non parametric life table survival 
analysis.  
7. Results  
Over a period of 23 years (1986 – 2009) 358 children with a clinical diagnosis of NS were 
admitted and comprised the study group. Of these 278/358 (77.7%) were black and 80/358 
(22.3%) white. The median age was 58 months (range 0.5 – 144 months) and the male: female 
ratio 1.3:1.  
The age at presentation was categorised in 4 groups as depicted in table 2. Twenty seven 
children were  12 months of age at the time of presentation, of whom 15/27 (4%) presented 
within the first 3 months of life and were diagnosed with CNS. An additional ten children 
were also diagnosed with CNS but were referred later, when they were older than 3 months. 
Fifty percent (179/358) of the children were in the age group >12-72 months.  
 
Age category (months) Number % 
   
0-3 15 4.2 
>3-12 12 3.3 
>12 - 72 179 50.0 
>72 152 42.5 
Total 358 100% 
Table 2. Age Categories of Children at Presentation  
Stunting (height/length for age z-score > -2SD) was present in 88/358 (24.6%) children. 
Microscopic haematuria was present in 52/109 (47.7%) and macroscopic haematuria in 
34/109(9.5%) children with MCNS.  
A constellation of clinical and laboratory features including, age >12 months to 72 months, 
normal blood pressure, absence of haematuria, normal renal function and normal levels of 
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serum C3 have been quoted as suggestive of MCNS with an expected good prognosis 
(International Study of Kidney Disease in Children 1978:159). In this study 67% of the 
children with MCNS fulfilled the criteria for the diagnosis, apart from not having a normal 
blood pressure. This finding has been described by others (Habib et al 1971) which 
questions the validity of the criteria for diagnosing MCNS.  
Hypertension was present in 227/358 (63.4%) children at presentation of whom 171/227 
(47.8%) required treatment with antihypertensive drugs for at least 6 weeks. Diuretics were 
used for symptomatic management of oedema and were often used as a first line 
antihypertensive drug in children considered to have volume overload. Of those with 
persistent hypertension 146/171 (85.4%) received an ACE-inhibitor as the preferred 
antihypertensive drug. Overall 213/358 (59.5%) received an ACE-inhibitor for its anti-
proteinuric effect. Renal function and s-potassium were monitored in all children who were 
treated with an ACE-inhibitor. No child experienced an allergic response or developed 
significant coughing with this treatment. An acute increase in s-creatinine levels occurred in 
some patients, usually in association with volume contraction, which was reversible in all 
cases with fluid resuscitation.  
The mean s-albumin level at the time of presentation was 13.2  5.2 g/L. Some patients had 
below detectable s-albumin levels and for these the lowest value documented was an 
arbitrary level of 10g/L for the purpose of statistical analysis. This means that the true mean 
level was in fact lower. The mean s-cholesterol at the time of presentation was 11.4  7.3 
mmol/L. As already stated above, statins were only prescribed to a limited number of older 
children with persistent hypercholesterolaemia. The main reason why younger children 
with similar high cholesterol levels were not treated with statins is the lack of long-term 
safety information on the effects of these drugs on the developing brain, immune functions, 
hormones and energy metabolism.  
Kidney function was monitored using change in eGFR over time. Despite its limited 
accuracy, especially in children with poor muscle bulk, it was the only feasible test which 
could be done at regular intervals at follow-up visits. The results of eGFR at the time of 






eGFR at presentation 
n = 358 
eGFR last follow up 
n = 358 







1 ≥90 189 (68.0%) 55 (68.8%) 178 (64.0%) 66 (82.5%) 
2 60-89 42 (15.1%) 20 (25.0%) 29 (10.4%) 10 (12.5) 
3 30-59 27 (9.7%) 4 (5.0%) 18(6.5%) 1 (1.3%) 
4 + 5 <29 20 (7.1%) 1(1.3%) 53(19.0%)* 3 (3.8%) 
eGFR = Estimated glomerular filtration rate  
*One black child with CKD stage 5 who had a successful kidney transplant is included in the number of 
black children with stage 4 and 5 CKD. 
Table 3. eGFR at the Time of Presentation and During Follow Up in the Two Race Groups 
Significantly more black compared to white children had stage 4 or 5 CKD on presentation, 
7.1% vs. 1.3% respectively (p=0.03), or had developed stage 4 or 5 CKD at the time of last 
follow up, 19.0% vs. 3.8% respectively (p= 0.000). 
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A secondary cause for NS was identified in 26 (7.2%) children including Henoch-
Schőnlein purpura, systemic lupus erythematosus, chronic hepatitis B infection, HIV 
infection and IgA glomerulonephritis. Ten children (2.8%) had chronic hepatitis B 
associated nephropathy. None of them were given any immunosuppressive treatment, 
interferon or other specific antiviral treatment. In eleven children a genetic cause of NS 
was suspected.  
CNS was diagnosed in 25/358 (7%) children, none of whom had a syndromic form of CNS. 
Investigations for mutations of NPHS1, NPHS2 and WT1 were not done in any of the 
children with CNS or suspected familial NS because of unavailability.  
Kidney biopsies were performed in 318/358 (89%) children. The main histological diagnoses 
are depicted in table IV. Eighteen children had inconclusive histology which was reported 
as “FSGS cannot be excluded.” In these cases there was a chronic inflammatory cell infiltrate 
in the interstitium, interstitial fibrosis and tubulo-interstitial atrophy suggestive of FSGS but 
the biopsy sample did not have glomeruli with focal sclerosis. If this group of children is 
added to the group with definite FSGS, the frequency of FSGS increases to 98/318 (31%). 
Eleven children (10 black, 1 white) were diagnosed with immune complex 
glomerulonephritis (ICGN), based on the presence of immune deposits in the basement 
membrane on electron microscopy examination and another 26 (25 black, 1 white) had 
ICGN with secondary glomerular sclerosis. 
 




 (%)  p-value 
     
MCNS  42(66) 67(26.4) 109 (34.2) <0.001* 
Focal segmental glomerulosclerosis (FSGS) 9 (14)  71(28) 80 (25) 0.01* 
MCNS – FSGS ** 7(11) 11 (4.3)  18 (5.7) 0.048* 
Immune complex glomerulonephritis (ICGN) 1(1.6) 10 (4) 11(3.4) 0.31 
ICGN and secondary FSGS 1 (1.6)  25( 9.8)   26 (8.2) 0.02* 
Membranous nephropathy (MN)  0 (0) 14 (5.5) 14 (4.4) 0.04* 
Mesangiocapillary glomerulonephritis 1 (1.6) 12 (5)   13 (4) 0.22 
Congenital nephrotic syndrome (CNS)  0 (0) 25 (9.8) 25 (8) 0.02* 
Other  3 (4.7) 19 (7.5) 22 (7)  
     
Total *** 64(100) 254 (100) 318 (100)  
*Statistically significant 
**MCNS-FSGS: Histology was reported as “FSGS cannot be excluded” and was therefore inconclusive 
but very suggestive of FSGS due to the presence of a chronic inflammatory cell infiltrate in the 
interstitium, interstitial fibrosis and tubular atrophy on the biopsy.  
***Includes all children who had kidney biopsies, including the children with congenital nephrotic 
syndrome. 
Table 4. Main Histological Subtypes of Nephrotic Syndrome (n = 318) 
In table 5. the frequencies of all the histological subtypes excluding CNS are depicted, which 
is in line with the procedure followed by the ISKDC. CNS is considered a distinct form of 
NS with a unique etio-pathogenesis and a high frequency of underlying genetic mutations 
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A secondary cause for NS was identified in 26 (7.2%) children including Henoch-
Schőnlein purpura, systemic lupus erythematosus, chronic hepatitis B infection, HIV 
infection and IgA glomerulonephritis. Ten children (2.8%) had chronic hepatitis B 
associated nephropathy. None of them were given any immunosuppressive treatment, 
interferon or other specific antiviral treatment. In eleven children a genetic cause of NS 
was suspected.  
CNS was diagnosed in 25/358 (7%) children, none of whom had a syndromic form of CNS. 
Investigations for mutations of NPHS1, NPHS2 and WT1 were not done in any of the 
children with CNS or suspected familial NS because of unavailability.  
Kidney biopsies were performed in 318/358 (89%) children. The main histological diagnoses 
are depicted in table IV. Eighteen children had inconclusive histology which was reported 
as “FSGS cannot be excluded.” In these cases there was a chronic inflammatory cell infiltrate 
in the interstitium, interstitial fibrosis and tubulo-interstitial atrophy suggestive of FSGS but 
the biopsy sample did not have glomeruli with focal sclerosis. If this group of children is 
added to the group with definite FSGS, the frequency of FSGS increases to 98/318 (31%). 
Eleven children (10 black, 1 white) were diagnosed with immune complex 
glomerulonephritis (ICGN), based on the presence of immune deposits in the basement 
membrane on electron microscopy examination and another 26 (25 black, 1 white) had 
ICGN with secondary glomerular sclerosis. 
 




 (%)  p-value 
     
MCNS  42(66) 67(26.4) 109 (34.2) <0.001* 
Focal segmental glomerulosclerosis (FSGS) 9 (14)  71(28) 80 (25) 0.01* 
MCNS – FSGS ** 7(11) 11 (4.3)  18 (5.7) 0.048* 
Immune complex glomerulonephritis (ICGN) 1(1.6) 10 (4) 11(3.4) 0.31 
ICGN and secondary FSGS 1 (1.6)  25( 9.8)   26 (8.2) 0.02* 
Membranous nephropathy (MN)  0 (0) 14 (5.5) 14 (4.4) 0.04* 
Mesangiocapillary glomerulonephritis 1 (1.6) 12 (5)   13 (4) 0.22 
Congenital nephrotic syndrome (CNS)  0 (0) 25 (9.8) 25 (8) 0.02* 
Other  3 (4.7) 19 (7.5) 22 (7)  
     
Total *** 64(100) 254 (100) 318 (100)  
*Statistically significant 
**MCNS-FSGS: Histology was reported as “FSGS cannot be excluded” and was therefore inconclusive 
but very suggestive of FSGS due to the presence of a chronic inflammatory cell infiltrate in the 
interstitium, interstitial fibrosis and tubular atrophy on the biopsy.  
***Includes all children who had kidney biopsies, including the children with congenital nephrotic 
syndrome. 
Table 4. Main Histological Subtypes of Nephrotic Syndrome (n = 318) 
In table 5. the frequencies of all the histological subtypes excluding CNS are depicted, which 
is in line with the procedure followed by the ISKDC. CNS is considered a distinct form of 
NS with a unique etio-pathogenesis and a high frequency of underlying genetic mutations 
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and is therefore usually not analysed with other forms of INS. Kidney biopsies were done in 
318 children (64 white and 254 black). After exclusion of the 25 children with CNS, all of 
whom were black, the frequencies of the histopathological subtypes of only the remaining 
229 black children changed.  
 




 (%)  p-value 
     
MCNS 42(65.6) 67(29.3) 109 (37.2) <0.000* 
Focal segmental glomerulosclerosis (FSGS) 9 (14.0)  71(31.0) 80 (27.3) 0.004* 
MCNS – FSGS ** 7(10.9) 11 (4.8)  18 (6.1) 0.07 
Immune complex glomerulonephritis (ICGN) 1(1.6) 10 (4.4) 11(3.7) 0.26 
ICGN and secondary FSGS 1 (1.6)  25( 11.0)   26 (8.9) 0.01* 
Membranous nephropathy 0 (0) 14 (6.1) 14 (4.8) 0.03* 
Mesangiocapillary glomerulonephritis 1 (1.6) 12 (5.2)   13 (4.4) 0.18 
Other  3 (4.7) 19 (8.3) 22 (7.5)  
     
***Total  64 (100) 229 (100) 293 (100)  
*Statistically significant  
**MCNS-FSGS: Histology was reported as “FSGS cannot be excluded” and was therefore inconclusive 
but very suggestive of FSGS due to the presence of chronic inflammatory cell infiltrate in the 
interstitium, interstitial fibrosis and tubular atrophy on the biopsy.  
***All children who had kidney biopsies, but excluding the children with congenital nephrotic 
syndrome. 
Table 5. Histological Subtypes of Nephrotic Syndrome Excluding Children with Congenital 
Nephrotic Syndrome (n=293) 
The incidences of the four major histological subtypes (MCNS, FSGS, membranous 
nephropathy, mesangiocapillary glomerulonephritis were significantly higher in the black 
children (Table 5). 
7.1 Results of treatment  
Remission with oral corticosteroid treatment was achieved in 33/41(81%) white vs 
33/59(56%) black children (p=0.02) who had MCNS. The response rate of the black children 
is similar to the 60% response rate in black children reported previously from Kalafong 
Hospital (Prinsloo JG. 1986:375) but lower than the 78% response rate reported a decade 
later in children from the Chris-Hani Baragwanath Hospital (Johannesburg), both tertiary 
hospitals in South Africa (Thomson 1997:402). Oral corticosteroid treatment resulted in 
remission in 3/9 white children and 8/40 black children with FSGS (p=0.6). In the combined 
group of children with FSGS and MCNS-FSGS 9/13 (69.2%) white children vs 4/14 (28.5%) 
(p<0.05) black children went into remission with this treatment. Twenty five children who 
failed to respond to oral corticosteroid treatment were treated with a course of intravenous 
methylprednisolone of whom only 4 (one white and 3 black children) went into complete 
remission. This form of treatment was abandoned because of its poor efficacy, high toxicity 
and cost and the disruptive effect it had on school attendance. Hundred children were 
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treated with cyclophosphamide, 46 were white and 54 black. The response rate to this 
treatment was statistically significantly different in the white and black children. Sustained 
remission was achieved in 37/46 (80%) white and in 23/54 (43%) black children (P=0.002; 
95% CI 2.2 – 13.7). The ISKDC reported no benefit of orally administered cyclophosphamide 
and prednisone compared to prednisone alone for the treatment of steroid resistant NS 
(Tarshish, P et al. 1996: 590). Their report and the poor response of children with steroid 
resistant NS in this study prompted discontinuation of cyclophosphamide treatment in 
children with steroid resistant NS since 2007. No patient experienced side effects of 
cyclophosphamide treatment, but they were all monitored at least every 10 to 14 days 
throughout the duration of the treatment. Several children who had been in contact with 
chicken pox were given human varicella-zoster immune globulin and/or acyclovir 
prophylactically, but none developed serious chicken pox.  
7.2 Morbidity and mortality 
Acute reversible renal failure occurred in 35/358 (9.8%) children and thrombotic 
complications, other than strokes in 9/358 (2.5%). Six children (1.7%) developed strokes, one 
of whom developed bilateral sequential middle cerebral artery thromboses a few months 
apart. She was one of a family of 3 children who all had steroid resistant NS. At the time that 
she developed the first stroke she was not dehydrated, but had a mild lower respiratory 
tract infection, iron deficiency anaemia and a thrombocytosis, which are known risk factors 
for thrombo-embolic complications in children with nephrotic syndrome.  
Fourty eight percent of all children experienced acute invasive bacterial infections, including 
pneumonia, peritonitis and septicaemia. In those with steroid sensitive NS acute bacterial 
infections occurred during relapses. The frequency of infection was inversely related to age 
and was particularly high in children younger than 3 months. Of these children 87% 
developed serious infections compared to 39% of children older than 6 years. Streptococcus 
pneumoniae was the predominant causal organism, followed by Escherichia coli and other 
gram negative organisms. Twenty six children (7.3%) developed peritonitis of whom three 
demised due to pneumococcal septicaemic shock. Pneumococcal infections occurred in 7/80 
(8.7%) white children vs 19/278 (6.8%) black children (p=0.6). Until recently pneumococcal 
polysaccharide vaccine was given to all children younger than 5 years at the time of their 
first presentation, despite its limited efficacy in children younger than 2 years. Since 2009 the 
pneumococcal conjugate vaccine is available in South Africa which is used for revaccination 
of this group of children. Long term prophylactic penicillin was not used.  
Chronic hepatitis B infection (positive HBsAg and/or HBeAg) occurred in 10/358 (2.8%) 
children, all of whom were black. Hepatitis B vaccine was included in the routine 
immunization schedule of children in South Africa since 1991 and since that time no child 
was diagnosed with hepatitis B related NS. No child had hepatitis C related NS. 
Investigations to rule out CMV infection were only done in children with CNS and in those 
with atypical clinical features of NS, including anaemia, hepatosplenomegaly, skin rash or 
positive central nervous system signs. In most cases only CMV IgM and IgG were done, 
which were often both positive due to unexplained reasons at the time, because the test for 
CMV viral load was not available. Should a CMV infection be diagnosed it is not necessarily 
proof of the causality of the NS.  
All children were screened for underlying Mycobacerium tuberculosis infection with a chest 
X-ray, gastric aspirates or induced sputum cultures and Mantoux test (skin prick test with 
intradermal injection of purified protein derivative of Mycobacterium tuberculosis). Because 
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and is therefore usually not analysed with other forms of INS. Kidney biopsies were done in 
318 children (64 white and 254 black). After exclusion of the 25 children with CNS, all of 
whom were black, the frequencies of the histopathological subtypes of only the remaining 
229 black children changed.  
 




 (%)  p-value 
     
MCNS 42(65.6) 67(29.3) 109 (37.2) <0.000* 
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children uncommonly have sputum positive tuberculosis, several of our patients received 
empiric anti-tuberculous treatment for 6 months when the diagnosis could not be 
unequivocally excluded. A high prevalence of tuberculosis associated with a deleterious 
effect on renal function was reported in black children with FSGS. (Kala et al.1993:392). It 
has been postulated that immune responses mediated by infections with Mycobacterium 
tuberculosis and HI-virus may contribute to glomerulosclerosis. Mycobacterium 
tuberculosis infection was present in too few patients in this study to draw any conclusion.  
Investigations for HIV infection were only done in children who had clinical features 
suggestive of the disease and whose parents had given consent to testing. It is therefore not 
possible to report on the true incidence of NS associated with HIV infection. Patients with HIV 
infection had a variety of histological lesions, including, immune complex glomerulonephritis, 
immunotactoid and fibrillary glomerulonephritis and FSGS. No patient had HIV collapsing 
glomerulopathy which has been reported as one of the commonest histological lesions in black 
adult patients with HIV infection. Recently HIV- associated kidney disease has been reported 
to have become the most common form of kidney disease in children seen in the renal unit at 
one of the academic hospitals in South Africa. (Bhimma R, 2009:15) 
Only one infant with CNS had congenital syphilis and treatment with penicillin did not 
result in cure of the disease. Chronic “quartan malarial nephropathy” or other parasitic 
related forms of NS did not occur.  
7.3 Outcome 
At presentation 21/358 children had CKD stage 4 or 5. Of the black children 20/278 (7.2%) 
had CKD stage 4 or 5 compared to 1/80(1.3%) white children (p=0.03). Over the period of 
follow up more black children (53/278) (19%) developed stage 4 or 5 CKD compared to 
white children (3/80)(3.8%)(p= 0.000). Kaplan-Meier estimation of renal survival depicting 
the difference in renal survival in black and white children  is demonstrated in Fig1. One 
black child was successfully transplanted during the follow up period and had normal renal 
function at last follow up. Persistent nephrotic range proteinuria is associated with a rapid 
progression to end-stage kidney disease. Several children in this study had long standing 
suboptimal management of nephrotic range proteinuria when presenting to the SBAH 
which contributed to a more rapid progression to end stage kidney disease. 
Forty three patients died during the follow up period. Three (3.7%) white children died of 
whom 2 succumbed to complications of renal failure (renal deaths) and one died due to 
pneumococcal septicaemia (non renal death). Forty black children died during the follow up 
period, mostly due to end stage renal failure. In the black children infectious related deaths 
occurred mostly in the children with congenital NS. Black children had a significantly 
higher mortality compared to white children (40/268 vs. 3/80) (p<0.001). Kaplan-Meier 
patient survival estimate depicting the difference in patient survival for black and white 
children  is demonstrated in Fig 2. 
8. Discussion  
This study population differs in several aspects from those reported from developed 
countries. The majority of patients are black with an inherent risk of CKD due to a genetic 
predisposition aggravated by poor socio-economic circumstances and chronic infections. 
Poor prognostic indicators namely stunting, profound hypoalbuminaemia, long standing 
nephrotic-range proteinuria, hypertension and impaired kidney function are common at 
presentation against a background of tuberculosis and HIV infection. 
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The results of this audit confirm that significant racial differences exist in the clinical 
presentation, histological subtypes, response to treatment and outcome in South African 
children with NS. Similar findings have been reported by other study groups in South 
Africa (Bhimma et al. 2006: 1847; Bhimma R, 1997: 429), from other countries in Africa (Yao 
Doe, J. et al. 2006: 672; Olowu et al. 2010:200) and also from elsewhere in the world (Ingulli, 
E. & Tejani, A. 2001:393). In their study on idiopathic FSGS in children Ingulli et al. (Ingulli, 
E. & Tejani, A. 2001:393) reported that the rate of FSGS was higher (32.2% vs. 20%), and 
progress to end stage kidney disease was more common (78% vs. 33%) in black and 
Hispanic compared to white children. Olowu et al. (Olowu et al. 2010:200) reported an 
incidence of 18.5 % MCNS and 25.9% FSGS in their study of black Nigerian children with 
INS. Ethnic differences in the incidences of FSGS have now been well established. Over the 
past 10 years there have been several reports of an increasing incidence of FSGS in children 
(Borges et al. 2007:1309; Filler et al. 2003: 1107)   
In this study 77% of the children were black and 23% were white. There was a significant 
difference in the incidences of the main histological subtypes (MCNS, FSGS, immune 
complex glomerulonephritis, secondary FSGS and membranous nephropathy) between 
black and white children. The incidence of MCNS was 65.6% and 29.3% (p<0.000) and of 
FSGS, 14% and 31% (p=0.004) in white and black children respectively.  
The first course of corticosteroid treatment was often longer or more intense than that 
recommended by the ISKDC (International Study of Kidney Disease in Children: 1978:13) 
because of delayed achievement of remission or only partial response after the first four 
weeks. Corticosteroid treatment was also often given daily rather than on alternate days 
because parents failed to understand alternate day dosing schemes. White children with 
MCNS had a better response to oral corticosteroid treatment compared to black children 
with MCNS (80% vs 56%; p=0.02). Remission with oral corticosteroid treatment was 
achieved in more white children with FSGS compared to black children with FSGS, 
although this difference did not reach statistical significance (33% vs 20 %; p=0.6). Response 
rates in both race groups in this study were much lower compared to the 93.1% response 
rate reported by the ISKDC (International Study of Kidney Disease in Children: 1978:13). 
After 2000 we stopped using high dose intravenous methylprednisolone for the treatment of 
steroid resistant NS in our patients for several reasons. It is too costly, it places a heavy 
burden on the family and child, and only 4 of 25 children (16%) went into remission with 
this treatment. This very poor response rate compared to that of Mendoza et al (Mendoza, 
S.A. et al. 1990:303), who reported complete remission in 52% of their patients, can possibly 
be explained by the fact that we omitted an alkylating agent in our treatment regimen. 
Adhikari et al (Adhikari et al. 1997:423) reported a dismal outcome in 12 South African 
children with FSGS who were treated with a combination of intravenous 
methylprednisolone and an alkylating agent. Although they considered this treatment as 
“promising,” their patients developed serious side effects including alopecia, cataracts, 
leukopaenia, systemic candidiasis, gram negative septicaemia, and one child demised of a 
serious infection which was undoubtedly caused by the severe immune suppression 
associated with the treatment. 
Infections remain a serious risk to all children during a relapse of NS, which is practically 
always for those with steroid resistant NS. This risk is intensified in those living in poor 
socio-economic circumstances. Forty eight percent of our patients experienced acute 
invasive bacterial infections and three succumbed to documented pneumococcal 
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septicaemia. Management of the children with CNS was particularly challenging, due to 
their serious immune compromised state and high frequency of recurring infections. All 
children with CNS were black and screening for a possible infectious cause was not very 
fruitful. Genetic studies were not undertaken in any of our patients as we do not have access 
to genetic laboratory services. Kidney biopsy revealed idiopathic FSGS or secondary 
glomerular sclerosis in 15/25 children with CNS. A very dense chronic inflammatory cell 
infiltrate was present in all cases. Children with CNS were not treated with corticosteroids 
or other immunosuppressive drugs. Most of them remained in hospital for long periods or 
required frequent admissions for treatment of bacterial infections or gastroenteritis. An ACE 
inhibitor was not prescribed to any child less than 3 months old and was usually only given 
to children older than 12 months.  
Because of the lower incidence of MCNS in black children in South Africa first reported in 
1979, (Bhimma et al. 1997:429; Lewin, et al. 1979: 88) it has been our practice to biopsy all 
black children at the time of their first presentation. For the same reason paediatric 
nephrologists elsewhere in Africa have also advocated pre-treatment renal biopsies in their 
patients. Olowu et al. (Olowu et al. 2010:200] reported that only 18.5% of the black children 
with INS in their study of Nigerian patients had MCNS.  
Most centres in developed countries are still following the ISKDC recommendation 
regarding biopsies despite worldwide reports of an increasing incidence of FSGS in both 
children and adults. Filler et al (Filler et al. 2003 :1107) reported a declining incidence of 
MCNS from 81.1% to 64% and an increasing incidence of FSGS from 10.8 to 24.7% of FSGS 
in their childhood population in Ontario, over two time periods 1985-1993 and 1993-2002. 
The incidence of MCNS in the first period did not differ significantly from that reported 
by the ISKDC (International Study of Kidney Disease in Children 1978: 13) and although 
not specifically reported, the inference is made that the majority of their patients 
responded to corticosteroid therapy. The incidence of FSGS in their patients has more 
than doubled over 17 years while the population under study remained stable. Race is not 
mentioned in their study. Despite an alarming increase in the incidence of FSGS in their 
patients, they argue that empirical steroid treatment with a cut-off point at 28 days is  
still justifiable. During the second period of their study the incidence of MCNS is similar 
to the incidence of MCNS in white children in our study, 64.7% vs. 65.6 % and the 
incidence of FSGS slightly less than that of FSGS in black patients in our study 24.7%  
vs. 31%.  
Already in 1997 Thomson et al. (Thomson, P.D. 1997:508), performing pre-treatment 
biopsies in all their black patients, reported an incidence of FSGS in 31.3% which is identical 
to the 31% incidence of FSGS in black patients in this study. It appears that there has not 
been an increase in the incidence of FSGS in black children in Gauteng Province in South 
Africa over this period.  
It can be expected that the HIV epidemic has contributed to the incidence of CKD in South 
Africa in general, but its possible role in the development of FSGS, or its contribution to an 
increase in the incidence of FSGS, is uncertain. Local multi-centre prospective research 
studies in patients with HIV-associated nephropathy will be necessary to explore this 
question.  
Primary FSGS is a spectrum of podocytopathies caused by a variety of contributing 
etiologies, including genetics, infections, environment, including the intra-uterine 
environment, drugs and toxins. It is an aggressive disease, more so in black children 
compared to white children. The rationale of performing a kidney biopsy at presentation is 
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It can be expected that the HIV epidemic has contributed to the incidence of CKD in South 
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increase in the incidence of FSGS, is uncertain. Local multi-centre prospective research 
studies in patients with HIV-associated nephropathy will be necessary to explore this 
question.  
Primary FSGS is a spectrum of podocytopathies caused by a variety of contributing 
etiologies, including genetics, infections, environment, including the intra-uterine 
environment, drugs and toxins. It is an aggressive disease, more so in black children 
compared to white children. The rationale of performing a kidney biopsy at presentation is 
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that it confirms the histological subtype and may give clues to the stage and type of initial 
injury. It has been suggested that the different variants of FSG may respond differently to 
treatment (Valeri. et al. 1996: 1734). Immuno-histochemistry and electron microscopy may 
also help in differentiating primary and secondary forms of FSGS. It is well known that 
patients with extensive involvement of glomeruli, advanced tubulo-interstitial fibrosis and 
tubular atrophy are less likely to respond to corticosteroid treatment compared to those with 
no interstitial involvement. It is questionable whether it is justifiable to expose such a patient 
who may also happen to be malnourished and have poor social circumstances to aggressive 
immune suppression for a disease which may not have an immunological background. The 
possible departure of many of our black patients from a hostile intra uterine environment 
resulting in low birth weight and low glomerular endowment is an aspect which has not 
been investigated systematically.  
9. Conclusions 
Compared to the ISKDC report black children have a lower incidence of MCNS and a higher 
incidence of FSGS. Black children also have a more aggressive form of FSGS which responds 
poorly to corticosteroid and other immuno-suppressive treatment. More black children 
develop CKD stage 4 and 5 compared to white children and black children have a higher 
mortality compared to white children. The results of this study and similar evidence from 
the rest of Africa suggest that the ISKDC recommendation of empiric corticosteroid 
treatment in children with INS should not be followed in the management of black children 
with INS. We suggest that a kidney biopsy should be done at presentation to allow a 
definitive diagnosis and targeted treatment from the outset.  
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1. Introduction 
Although the expanding prevalence of lifestyle-related diseases such as diabetes mellitus and 
hypertension which ultimately cause renal dysfunction, glomerulonephritis still remains as 
one of the major causes of end-stage renal failure in most countries all over the world. In 
addition to the immunological therapy using corticosteroids and immunosuppressants, 
management of non-immunological risk factors such as hypertension, obesity and disorders of 
glucose and lipid metabolism greatly affect the prognosis of renal function in the treatment of 
patients with glomerulonephritis. Especially, hypertension is a pivotal risk factor for the 
progression of renal injuries and the adequate blood pressure control is a matter of primary 
importance in order to prevent the development of renal dysfunction.  
In this chapter, the importance of blood pressure control is stressed referring the evidence 
thus far, and current topics and future prospects are discussed as to the matters such as 
target blood pressure levels and choices of antihypertensive agents. 
2. Target blood pressure 
Generally, hypertension is diagnosed when the systolic blood pressure is higher than 
140mmHg and/or the diastolic blood pressure is higher than 90mmHg. However, this is an 
arbitrary definition and the linear relation between the blood pressure level and the risk of 
renal dysfunction can be extended even in the normotensive range in epidemiological 
studies. Figure 1 shows the relations of blood pressure level categories and the risk of 
developing end-stage renal failure in 17-year follow-up study of Okinawa prefecture 
residents in Japan (1). Naturally, hypertension increases the risk of renal failure with 
elevating grade of blood pressure levels. Moreover, blood pressure levels lower than 
140/90mmHg but higher than 130/85mmHg, namely the high-normal blood pressure, 
offers a significant risk for future development of renal failure.  
As for the target blood pressure level in the treatment of glomerulonephritis patients, Figure 
2 depicts the outcomes of Modification of Diet in Renal Disease (MDRD) study (2) in which 
the blood pressure control level less than 125/75mmHg brought about slower GFR 
reduction than the level less than 140/90mmHg in subjects with nondiabetic renal diseases 
especially when the proteinuria was prominent. Similarly, Figure 3 plots the annual 
decrease rates of GFR against achieved blood pressure levels in hypertensive subjects with 
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renal diseases (3). In patients whose hypertension was not treated, GFR decreased by more 
than 10mL/min per year. When the blood pressure was lowered to 140/90mmHg, the rate 
of annual GFR decline was reduced by half. However, considering that the physiological 
annual GFR decline with aging is about 1mL/min, the annual GFR decline in 140/90mmHg 
subjects is faster than the natural rate. As compared with this, strict blood pressure lowering 
to 130/85mmHg or 130/80mmHg yielded retardation of GFR decline to a nearly 
physiological level in subjects with renal diseases.  
 
 
Fig. 1. Relationship between the incidence of end-stage renal failure and the blood pressure 
level (1). The incidence of end-stage renal failure is increased not only in hypertensive 
subjects but also in subjects with high-normal blood pressure ranging  
130-139/85-89 mmHg as compared with lower normal blood pressure subjects.  
 
 
Fig. 2. The annual decrease in glomerular filtration rate (GFR) in nondiabetic renal disease 
patients of The Modification of Diet in Renal Disease(MDRD) Study. (2) 
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Thus, it is suggested that the blood pressure should be lowered below the high-normal level 
in glomerulonephritis patients in order to maximally slow the progression of renal 
dysfunction. Therefore, the American, European and Japanese guidelines for the 
management of hypertension recommend the target blood pressure level of less than 
130/80mmHg in patients with chronic kidney disease (CKD) (4-6).  
 
 
Fig. 3. Relationship between the annual decrease in glomerular filtration rate (GFR) and the 
achieved mean blood pressure level in studies treated hypertensive patients with renal 
diseases (3). The GFR decline rate was suppressed to the level near to the physiological 
decrease with aging in patients whose blood pressure was lowered under 130/85mmHg.  
3. Glomerular hypertension and hyperfiltration 
According to the hyperfiltration theory proposed by Hostteter and Brenner (7,8), increases 
in glomerular capillary pressure, referred to as glomerular hypertension, play an important 
role in the development and the progression of glomerular injuries ultimately resulting in 
glomerular sclerosis and the loss of its nephron. As indicated in Figure 4, not only high 
blood pressure but also increased salt intake and decreased urinary sodium excretion 
resulting in body fluid volume expansion raise intraglomerular capillary pressure and cause 
glomerular hypertension. In addition, the increases in protein intake and glomerular 
efferent arteriolar resistance are also the factors that contribute to the elevation of 
intraglomerular capillary pressure. Long-lasting of sustained glomerular hypertension 
impairs glomerular capillary endothelium and allows filtration of plasma protein molecules, 
followed by widening of mesangial area, obstruction of capillary lumen, hyalinosis of 
glomerular tuft and finally resulting in glomerular sclerosis, abolition of blood flow and 
filtration function. The loss of glomeruli brings about the atrophy of following renal tubules 
and nephrons themselves. Once a certain proportion of nephrons fall into atrophy, the 
intraglomerular capillary pressure and the single nephron filtration glomerular filtration 
rate of remaining glomeruli increase in order to compensate the reduced renal blood flow 
and maintain the glomerular filtration rate, which consequently promote further 
development of glomerular hypertension.  
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Fig. 4. Relations of factors contributing to the increase in intraglomerular capillary pressure 
and progression of glomerular sclerosis.  
In order to stop the progression of this vicious cycle, comprehensive control of factors 
influencing the intraglomerular capillary pressure elevation such as arterial hypertension 
and intakes of salt and protein is needed. As mentioned concerning the target blood 
pressure, strict blood pressure control is important in patients with glomerulonephritis. In 
controlling the blood pressure, it should be kept in mind that reduction of intraglomerular 
capillary pressure as well as systemic arterial pressure is essential in order to achieve 
maximally effective inhibition of glomerular injuries and renal dysfunction. With regard to 
the hemodynamic aspect of renal microcirculation, intraglomerular capillary pressure is 
regulated by the balance between vascular resistances of afferent and efferent glomerular 
arterioles as depicted in Figure 5. A number of neural and humoral factors are known to 
affect the contraction and dilation of glomerular arterioles. Among them, the renin-
angiotensin-aldosterone (RAA) system indicated in Figure 6 is assumed to play a pivotal 
role in the regulation of glomerular hemodynamics. Especially, angiotensin II, a peptide 
exhibiting prominent bioactivities in the RAA system, induce strong contraction of efferent 
rather than afferent glomerular arterioles. In addition, angiotensin II facilitates mesangial 
cell proliferation, increases oxidative stress by activating NAD(P)H oxidase, and induce 
proinflammatory transcription factor NF-B (9,10). These versatile effects of angiotensin II 
also contribute to the progression of renal tissue injuries.  
On the other hand, angiotensin II stimulates the adrenal cortex to secrete aldosterone, a 
major mineralocorticoid, which facilitates renal tubular reabsorption of sodium resulting in 
blood and body fluid volume expansion and blood pressure elevation. Besides this well-
known effect, aldosterone has been shown to promote renal tissue fibrosis and production 
of extracellular matrices such as collagen (9-11). Moreover, aldosterone injures endothelial, 
 
Blood Pressure Control in Patients with Glomerulonephritis 459 
epithelial and mesangial cells of glomeruli. In addition, aldosterone, like angiotensin II, 
constricts the efferent arterioles preferably to the afferent arteriole and increase the 
intraglomerular capillary pressure and filtration of plasma protein molecules. Thus, 
aldosterone is also assumed to be a factor exerting detrimental effects to the progression of 
glomerular diseases.  
 
 
Fig. 5. The structure of glomeruli and factors relating to the hemodynamics and hydrauric 
pressure of glomeruli and glomerular arterioles.  
 
 
Fig. 6. Outlines of the renin-angiotensin-aldosterone system and the biological actions 
elicited by its components.  
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aldosterone is also assumed to be a factor exerting detrimental effects to the progression of 
glomerular diseases.  
 
 
Fig. 5. The structure of glomeruli and factors relating to the hemodynamics and hydrauric 
pressure of glomeruli and glomerular arterioles.  
 
 
Fig. 6. Outlines of the renin-angiotensin-aldosterone system and the biological actions 
elicited by its components.  
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Several other hormones and autacoids are known to elicit dilation or contraction of the 
glomerular arterioles. Atrial natriuretic peptide (ANP), produced by the heart, dilates the 
afferent arteriole and preserves renal and glomerular blood flow in the state of heart failure 
(12). This action is supposed to work also in glomerulonephritis patients with reduced renal 
function because the plasma ANP level is increased by body fluid volume increase and 
reduced clearance in the kidney. Vascular endothelium produces vasoactive substances such 
as nitric oxide (NO) and endothelin (ET). NO preferentially dilates and ET preferentially 
contract the afferent arterioles (13,14). NO is supposed to participate in the mechanism of 
increased glomerular filtration in the early stage of diabetic nephropathy, however, the NO 
synthase inhibition has been shown to increase intraglomerular capillary pressure in 
experimental glomerulonephritis (15,16). The pathophysiological implication of ET in the 
glomerular circulation is not well understood.  The kidney has abundant ability to produce 
prostaglandins (PG) from arachidonic acid and PGE2 which facilitates natriuresis and dilates 
the afferent arterioles is the major PG produced in the kidney. As compared with this, PGI2 
produced by vascular endothelium dilates both the afferent and the efferent arterioles (17). 
Nonsteroidal anti-inflammatory drugs such as indomethacin, which inhibit cyclooxygenase 
and PG production, can cause renal dysfunction as the adverse effect. The inflammatory 
process in the pathogenesis of glomerulonephritis is supposed to stimulate PG production in 
the kidney. This possibly increases glomerular and renal blood flow on one hand, however, 
may rather increase intraglomerular pressure on the other hand by preferentially dilating the 
afferent arterioles. However, it has been reported that the long-term administration of PGI2 
analogue mitigated the progression of renal dysfunction without increasing intraglomerular 
capillary pressure in patients with chronic glomerulonephritis (18).  
Taken these together into consideration, it is suggested that the enhancement of RAA system is 
harmful to the glomeruli and the kidney via the nocuous actions of angiotensin II and 
aldosterone. Reductions in renal function generally cause an increase in body fluid volume 
which inhibits plasma renin activity and concentrations of angiotensin II and aldosterone. 
Therefore, the circulating components of RAA system is supposed to be rather suppressed in 
patients with advanced glomerulonephritis. However, the renal and cardiovascular cells have 
been shown to produce components of RAA system such as renin, angiotensin converting 
enzyme (ACE) and aldosterone. In addition, angiotensinogen produced by the liver is 
abundant in plasma. Therefore, it is thought that angiotensin II and aldosterone are locally 
produced in the renal and cardiovascular systems and their concentrations in the tissues may 
be higher than in plasma. And, it is possible that the renal tissue RAA system is rather 
enhanced and contributes to the progression of renal injuries in patients with advanced 
glomerulonephritis although the circulating components of RAA system are suppressed.  
4. Inhibitors of renin-angiotensin-aldosterone system in antihypertensive 
drug therapy for patients with glomerulonephritis 
The precedent sections stressed the importance of strict blood pressure control and the 
implications of RAA system in the management of renal diseases in order to prevent the 
progression of renal dysfunction efficiently and effectively. In this context, inhibitors of 
RAA system such as ACE inhibitors and angiotensin II receptor antagonists (ARB) are 
supposed to provide renoprotective effects in addition to their hypotensive effects by 
inhibiting the detrimental actions of angiotensin II and aldosterone. Especially, these 
inhibitors of RAA system preferentially dilate the efferent arterioles as compared to the 
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afferent arterioles and thereby lower intraglomerular capillary pressure effectively (Figure 
5). Anderson et al. (19) have shown that an ACE inhibitor lowers intraglomerular capillary 
pressure, reduces proteinuria and inhibits the progression of glomerular sclerosis more 
prominently than other antihypertensive drugs in rats with reduced renal mass in which the 
circulating RAA system is thought to be suppressed.  
In human, it is a distinctive feature that the intraglomerular capillary pressure is elevated and 
the GFR is increased at the early stage of diabetic nephropathy. This glomerular hypertension 
facilitates the progression of diabetic nephropathy stages, namely, microalbuminuria, overt 
proteinuria, a GFR reduction, a serum creatinine increase and end-stage renal failure. Taguma 
et al. (20) have first reported that an ACE inhibitor reduces proteinuria in patients with diabetic 
nephropathy, and it is suggested that the suppression of angiotensin II generation brings about 
alleviation of glomerular hypertension and reduce hydrauric transcapillary filtration pressure of 
protein. After that, Lewis et al. (21) performed the multi-center collaborative prospective study 
evaluating the renoprotective effects of an ACE inhibitor in patients with type 1 diabetes 
mellitus presenting overt proteinuria and demonstrated that captopril inhibited the serum 
creatinine increase and the incidence of end-stage renal failure. As well as ACE inhibitors, 
multiple lines of later clinical studies have indicated that ARB are effective in retarding the 
progression of nephropathy at each stage in patients with type 2 diabetes (22-24).  
With regard to the non-diabetic renal disease such as glomerulonephritis, the ACE Inhibition 
in Progressive Renal Insufficiency (AIPRI) study (25) and Ramipril Efficacy in Nephropathy 
(REIN) study (26) showed that ACE inhibitors delay the progression of renal insufficiency in 
European patients with non-diabetic renal disease. Furthermore, African American Study of 
Kidney Disease and Hypertension (AASK) (27) suggested that ACE inhibitors slow renal 
disease progression in African American patients with hypertensive renal disease. Also as for 
the Asian population, we have reported that an ACE inhibitor and an ARB are effective in 
reducing proteinuria and slowing the deterioration of renal function in Japanese patients with 
chronic glomerulonephritis (28,29). Namely, an ACE inhibitor, benazepril, or an ARB, 
valsartan, inhibited the increase in serum creatinine and reduced proteinuria by 30-40% as 
compared with placebo (Figure 7,8). In addition, there is another study reported that an ACE 
inhibitor improved renal outcomes in Chinese patients with advanced stage of non-diabetic 
renal disease whose serum creatinine ranged 3.1 to 5.0mg/dL (30).  
 
 
Fig. 7. Changes in serum creatinine concentrations and urinary protein excretions in 
glomerulonephritis patients given the ACE inhibitor or the placebo (28).  
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afferent arterioles and thereby lower intraglomerular capillary pressure effectively (Figure 
5). Anderson et al. (19) have shown that an ACE inhibitor lowers intraglomerular capillary 
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Fig. 7. Changes in serum creatinine concentrations and urinary protein excretions in 
glomerulonephritis patients given the ACE inhibitor or the placebo (28).  
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Fig. 8. Changes in serum creatinine concentrations and urinary protein excretions in 
glomerulonephritis patients given the angiotensin II receptor blocker (ARB) or the placebo (29). 
As compared with ACE inhibitors and ARB, clinical evidence of other inhibitors of RAA 
system, such as renin inhibitors and aldosterone blockers seems less abundant regarding 
their renoprotecitve effects in patients with glomerulonephritis. In the cascade of RAA 
system indicated in Figure 6, conversion of angiotensinogen to angiotensin I by the 
enzymatic action of renin is assumed to be a rate-limiting step. Therefore, renin inhibitors 
such as aliskiren are thought to be theoretically effective in suppressing the activity of RAA 
system. Aliskiren, alone or in combination with ARB, has been shown to reduce 
albuminuria and proteinuria in patients with diabetic nephropathy (31,32), however, its 
efficacy in patients with glomerulonephritis is to be studied.  
ACE inhibitors are widely used in the treatment of hypertension and renal disease. They 
reduce plasma levels of angiotensin II and aldosterone. However, it has been shown that the 
plasma aldosterone concentration rather increases in a certain portion of patients after 
month of long-term administration and this phenomenon is recognized as aldosterone 
breakthrough. Sato et al. (33) have reported that the long-term ACE inhibitor treatment 
failed to reduce albuminuria in patients with diabetic nephropathy who had developed 
aldosterone breakthrough, however, the albuminuria significantly reduced after adding 
spironolactone, an aldosterone blocker. Although spironolactone can cause adverse effects 
by its partially estrogenic actions such as gynecomastia and menstrual disorder which 
sometimes hamper the continuation of administration, eplerenone, a newly developed 
aldosterone blocker, is much more specific to the mineralocorticoid receptor and almost free 
from such estrogenic side effects. There is paucity of clinical evidence as to the effects of 
aldosterone blockers in glomerulonephritis patients, however, the use of an aldosterone 
blocker in addition to an ACE inhibitor or an ARB would be expected to exhibit protective 
effects against the progressions of glomerular injuries and renal dysfunction.  
5. Calcium channel blockers in antihypertensive drug therapy for patients 
with glomerulonephritis 
Although the guidelines for hypertension management recommend strict blood pressure 
control in order to prevent organ injuries and cardiovascular diseases, the target blood 
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pressure is generally achieved only in less than a half of hypertensive patients under 
treatment. In terms of lowering blood pressure, the hypotensive effect of CCB, directly 
dilating vascular smooth muscle, is consistently reliable in various conditions including 
glomerulonephritis patients. Therefore, the addition of CCB to RAA system inhibitors is 
expected to bring about effective blood pressure reduction with few chances to cause 
impeding adverse effects.  
Ca channels residing in the plasma membrane of cells are composed five subunits; 1, 2, , 
 and . Among them, the 1 subunit conforming Ca2+ ion pathway has isoforms of L, N, 
P/Q, R and T. There are three isoforms of 1 subunit, L, N and T in the cardiovascular 
tissues, and Table 1 shows their distributions, functions and pharmacological blockers. 
Dihydropyridine (DHP) CCB, which are generally used as hypertensive drugs, blocks the L-
type Ca channels existing in the arterial smooth muscle. With regard to the glomerular 
arterioles, because the afferent but not the efferent arterioles have the L-type channels, DHP 
CCB generally preferentially dilate the afferent arterioles. Therefore, it is supposed that the 
reduction in intraglomerular capillary pressure may not be so prominent as compared with 
the reduction in systemic arterial pressure. In this respect, the N-type and the T-type 
channels exist both in the afferent and the efferent arterioles and the blockers of these Ca 
channels are assumed to dilate both glomerular arterioles. This property is expected to 
contribute to the reduction in intraglomerular capillary pressure. Indeed, the N-type CCB, 
cilnidipine, and the T-type CCB such as efonidipine and azelnidipine have been shown to 
reduce proteinuria significantly in patients with glomerulonephritis as compared with L-
type CCB (Figure 9), suggesting these CCB are effective in alleviating glomerular 
hypertension (34-36).  
 
 
Fig. 9. The glomerular filtration rate (GFR) and the urinary excretions of protein in 
glomerulonephritis patients given the L-type Ca channel blocker (CCB), amlodipine,  
or the L- and T-type CCB, efonidipine (35).  
As listed in Table 1, T-type Ca channels exist also in the adrenal and the in vitro experiments 
using cultured adrenal cells have shown that the T-type CCB suppress the expression of 
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aldosterone synthase gene (CYP11B2) and production of aldosterone (37,38). In harmony with 
this, clinical studies in healthy subjects and hypertensive patients have shown that the acute or 
the chronic administrations of T-type CCB lower plasma aldosterone levels (39,40). We have 
compared the effects of L- and T-type CCB efonidipine and L-type CCB amlodipine in patients 
with glomerulonephritis and observed that efonidipine reduces plasma aldosterone 
concentration as compared with amlodipine while the plasma angiotensin II concentrations 
were comparable (Figure 10)(35). It is mentioned in the previous section of this chapter that 
aldosterone is supposed to promote the progression of glomerular injuries and the aldosterone 
blocker can reduce albuminuria. Considering that the mechanism of aldosterone suppression 
by T-type CCB is different from those by ACE inhibitors, ARB and aldosterone blockers, this 
property of T-type CCB would be expected to provide an additive benefit, when combined 
with the RAA system inhibitors, against the progression of renal dysfunction in the 
antihypertensive treatment of glomerulonephritis patients.  
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Table 1. Subtypes of Ca channel and their locations, functions and blockers. 
 
 
Fig. 10. The plasma concentrations of angiotensin II and aldosterone in glomerulonephritis 
patients given the L-type Ca channel blocker (CCB), amlodipine, or the L- and T-type CCB, 
efonidipine (35). 
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6. Summary and conclusions 
Strict blood pressure control over 24 hours is of primary importance in preventing 
progression of renal injuries and deterioration of renal function in patients with glomerular 
diseases. In addition, it is important to lower not only systemic blood pressure but also 
intraglomerular capillary pressure in order to protect glomeruli from sclerosis because the 
increase in intraglomerular capillary pressure, glomerular hypertension, causes filtration of 
albuminuria and proteinuria which are dose-dependently related to the progression of renal 
injuries. Therefore, the antihypertensive therapy in patients with glomerulonephritis should 
aim not only the normalization of blood pressure but also the reduction of proteinuria and 
albuminuria. In order to lower intraglomerular capillary pressure, inhibitors of RAA system 
such as ACE inhibitors and ARB are effective as antihypertensive drugs because angiotensin 
II greatly contribute to the contraction of the efferent arterioles of glomeruli. In addition, 
interests are attracted as to the usefulness aldosterone receptor blockers and renin inhibitors 
as novel agents protecting the kidney. CCB are potent hypotensive agents, however, they 
rather dilate the afferent arterioles and may not be so effective as RAA system inhibitors in 
lowering intraglomerular capillary pressure. In this respect, some dihydropyridine CCB 
which block not only L-type Ca channel but also N- or T-type Ca channel have been shown 
to dilate efferent arterioles in addition to dilating afferent arterioles and are expected to be 
beneficial to protect glomeruli as well as lowering blood pressure effectively. 
Prognosis of renal function in glomerulonephritis may be largely dependent on the nature 
of its pathohistological diagnosis and the therapeutic effects of immunosuppressive agents. 
In addition to these, efforts to lessen and minimize risk factors for renal injuries should be 
continuously made in order to inhibit the deterioration of renal function. Such efforts would 
be expected to contribute to inhibit not only the development of renal failure but also the 
incidence of cardiovascular diseases and to improve the prognosis of glomerulonephritis 
patients. Among the various risk factors for real injuries hypertension has great influence 
and the adequate blood pressure control is  a pivotally important issue.  
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aldosterone synthase gene (CYP11B2) and production of aldosterone (37,38). In harmony with 
this, clinical studies in healthy subjects and hypertensive patients have shown that the acute or 
the chronic administrations of T-type CCB lower plasma aldosterone levels (39,40). We have 
compared the effects of L- and T-type CCB efonidipine and L-type CCB amlodipine in patients 
with glomerulonephritis and observed that efonidipine reduces plasma aldosterone 
concentration as compared with amlodipine while the plasma angiotensin II concentrations 
were comparable (Figure 10)(35). It is mentioned in the previous section of this chapter that 
aldosterone is supposed to promote the progression of glomerular injuries and the aldosterone 
blocker can reduce albuminuria. Considering that the mechanism of aldosterone suppression 
by T-type CCB is different from those by ACE inhibitors, ARB and aldosterone blockers, this 
property of T-type CCB would be expected to provide an additive benefit, when combined 
with the RAA system inhibitors, against the progression of renal dysfunction in the 
antihypertensive treatment of glomerulonephritis patients.  
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